nct_id,title,primary_drug,all_drug_names,drug_count,study_type,phases,primary_phase,overall_status,primary_condition,lead_sponsor,collected_date,has_drug_interventions,is_synthetic,data_source,dpc_smiles,smiles_source,official_title,primary_purpose,all_conditions,keywords,why_stopped,start_date,completion_date,primary_outcomes,secondary_outcomes,outcome_count,min_age,max_age,sex,healthy_volunteers,sponsor_class,collaborator_count,enrollment_count,enrollment_type,api_version,is_interventional,is_completed,is_failed,has_safety_outcomes,failure_reason,smiles,chembl_id,smiles_match_method,has_smiles,chembl_molecular_weight,chembl_logp,chembl_clinical_phase
NCT05986162,Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis,Itolizumab,"['Itolizumab', 'T1h']",2,INTERVENTIONAL,['PHASE1'],PHASE1,NOT_YET_RECRUITING,"Dermatomyositis, Adult Type","Biotech Pharmaceutical Co., Ltd.",2025-09-01T16:18:12.187015,True,,,,NOT_FOUND,"A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Dermatomyositis",,"['Dermatomyositis, Adult Type']",[],,2023-12-30,2025-06-25,"[{'measure': 'Incidence of Treatment Emergent Adverse Events', 'description': 'Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0', 'timeFrame': 'Study Week 20'}]","[{'measure': 'Maximum serum concentration of Itolizumab, Cmax', 'description': 'Maximum serum concentration of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'Minimum serum concentration of Itolizumab, Cmin', 'description': 'Minimum serum concentration of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'Time to maximum serum concentration of Itolizumab, Tmax', 'description': 'Time to maximum serum concentration of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'Total Itolizumab exposure across time, AUC0-t', 'description': 'Total Itolizumab exposure across time', 'timeFrame': 'Study Week 16'}, {'measure': 'Half life of Itolizumab, t1/2', 'description': 'Half life of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'IL-2', 'description': 'Inflammatory Markers：IL-2', 'timeFrame': 'Study Week 16'}, {'measure': 'IL-6', 'description': 'Inflammatory Markers:IL-6', 'timeFrame': 'Study Week 16'}, {'measure': 'TNF-α', 'description': 'Inflammatory Markers: TNF-α', 'timeFrame': 'Study Week 16'}, {'measure': 'IFN-γ', 'description': 'Inflammatory Markers:IFN-γ', 'timeFrame': 'Study Week 16'}, {'measure': 'CRP', 'description': 'Inflammatory Markers:CRP', 'timeFrame': 'Study Week 16'}, {'measure': 'Serum ferritin', 'description': 'Inflammatory Markers:Serum ferritin', 'timeFrame': 'Study Week 16'}, {'measure': 'ESR', 'description': 'Inflammatory Markers:ESR', 'timeFrame': 'Study Week 16'}, {'measure': 'IgG', 'description': 'Inflammatory Markers：IgG', 'timeFrame': 'Study Week 16'}, {'measure': 'IgM', 'description': 'Inflammatory Markers：IgM', 'timeFrame': 'Study Week 16'}, {'measure': 'IgA', 'description': 'Inflammatory Markers： IgA', 'timeFrame': 'Study Week 16'}, {'measure': 'CD6 receptor expression levels', 'description': 'Mean change of CD6 receptor expression levels in relative to baseline', 'timeFrame': 'Study Week 16'}, {'measure': 'T cell subsets', 'description': 'Mean change of different proportion of T cell subsets in relative to baseline', 'timeFrame': 'Study Week 16'}, {'measure': 'Proportion of patients achieving a TIS of ≥20', 'description': 'Defined as patients with an increase of ≥20 points on the Total Improvement Score in relative to baseline.', 'timeFrame': 'Study Week 16'}, {'measure': 'Proportion of patients achieving DOI', 'description': 'DOI defined as ≥ 20% improvement in 3 of any 6 core set measures, with no more than 2 core set measures worsening by ≥ 25% (MMT-8 cannot worsen by ≥ 25%).', 'timeFrame': 'Study Week 16'}, {'measure': 'Mean Change of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score', 'description': 'Defined as the mean change of activity score of CDASI（Score Range：0\\~132，The hingher score indcates the worse outcome） relative to baseline.', 'timeFrame': 'Study Week 16'}, {'measure': 'Incidence of ADA', 'description': 'Defined as the precentage of subjects presenting anti-drug antibody', 'timeFrame': 'Study Week 16'}]",22.0,18 Years,75 Years,ALL,False,OTHER,0.0,44.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02629536,Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.,"N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet","['N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet', 'NEC']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,"Migraine, Headaches",University of Notre Dame Australia,2025-09-01T16:18:17.172387,True,,,,CHEMBL863,"Effect on Migraine Frequency of Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC): The MIGRANT Study",,"['Migraine, Headaches']",[],,2016-03,2017-03,"[{'measure': 'Difference in mean number of migraine episodes per month between baseline and final four weeks of the study, for both study groups.', 'description': 'Difference in mean number of migraine episodes per month between baseline and final four weeks of the study, for both study groups.', 'timeFrame': '16 weeks'}]","[{'measure': 'Difference in mean migraine duration (hours) per month between baseline and final four weeks of the study, for both study groups', 'description': 'Difference in mean migraine duration (hours) per month between baseline and final four weeks of the study, for both study groups', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean migraine severity score per month (categorical scale; 0 = nil, 1 = mild, 2 = moderate, 3 = severe) between baseline and final four weeks of the study, for both study groups.', 'description': 'Difference in mean migraine severity score per month (categorical scale; 0 = nil, 1 = mild, 2 = moderate, 3 = severe) between baseline and final four weeks of the study, for both study groups.', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean MIDAS per month between baseline and final four weeks of the study, for both study groups.', 'description': 'Migraine Disability Assessment Score (MIDAS).', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean MSQ score per month between baseline and final four weeks of the study, for both study groups. Migraine Specific Quality of Life Questionnaire (MSQ, Version 2.1) score.', 'description': 'Difference in mean MSQ score per month between baseline and final four weeks of the study, for both study groups. Migraine Specific Quality of Life Questionnaire (MSQ, Version 2.1) score.', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean HRQOL score per month between baseline and final four weeks of the study, for both study groups.Health Related Quality of Life (HRQOL) score', 'description': 'Difference in mean HRQOL score per month between baseline and final four weeks of the study, for both study groups.Health Related Quality of Life (HRQOL) score', 'timeFrame': '16 weeks'}, {'measure': 'Number of treatment adverse events per month Number and type of treatment-related adverse effects per month. Number and type of treatment-related adverse effect', 'description': 'Number of treatment adverse events per month', 'timeFrame': '16 weeks'}, {'measure': 'Difference in mean number of migraine days per month between baseline and final four weeks of the study, for both study groups.', 'description': 'Difference in mean number of migraine days per month between baseline and final four weeks of the study, for both study groups.', 'timeFrame': '16 Weeks'}, {'measure': 'Responder rate: Percentage of subjects reporting ≥ 30% reduction in migraine episodes per month between baseline and final four weeks of the study, for both study groups', 'description': 'Responder rate: Percentage of subjects reporting ≥ 30% reduction in migraine episodes per month between baseline and final four weeks of the study, for both study groups', 'timeFrame': '16 weeks'}]",9.0,18 Years,65 Years,ALL,True,OTHER,0.0,90.0,ESTIMATED,v2_robust,True,False,False,True,,N[C@@H](CS)C(=O)O,CHEMBL863,partial_match,True,121.16,-0.67,4.0
NCT00416793,Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer,bortezomib,"['bortezomib', 'carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Acinar Cell Adenocarcinoma of the Pancreas,National Cancer Institute (NCI),2025-09-01T16:18:10.929782,True,,,,NOT_FOUND,A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer,,"['Acinar Cell Adenocarcinoma of the Pancreas', 'Duct Cell Adenocarcinoma of the Pancreas', 'Stage IV Pancreatic Cancer']",[],Study was terminated due to poor accrual,2006-12,2009-12,"[{'measure': 'Overall Survival Rate at 6 Months', 'description': 'Overall survival (OS) at 6 months with the combination of bortezomib and carboplatin in participants who previously received 1 prior regimen for metastatic pancreatic cancer from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months. Rate equals number of participants living at 6 months following treatment divided by the total number of participants.', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Overall Response Rate', 'description': 'Overall Response Rate measured by number of patients per the total treatment population who partially or completely responded to treatment. Participants reevaluated for response every 6 weeks. In addition to a baseline scan, confirmatory scans at 4 weeks following initial documentation of objective response.', 'timeFrame': 'from assignment of treatment until the date of first documented progression, assessed up to 17 months'}]",2.0,18 Years,,ALL,False,NIH,0.0,9.0,ACTUAL,v2_robust,True,False,True,False,Study was terminated due to poor accrual,,,no_match,False,,,
NCT00600262,Intravitreal Bevacizumab for Diabetic Retinopathy,intravitreal bevacizumab,['intravitreal bevacizumab'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Severe Nonproliferative,Asociación para Evitar la Ceguera en México,2025-09-01T16:18:20.961566,True,,,,NOT_FOUND,Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.,,"['Severe Nonproliferative', 'Proliferative Diabetic Retinopathy', 'Active Photocoagulated Diabetic Retinopathy']","['severe nonproliferative', 'proliferative diabetic retinopathy', 'active photocoagulated diabetic retinopathy', 'intravitreal bevacizumab']",Undefined,2005-12,2006-06,[],[],0.0,,,ALL,False,OTHER,0.0,,,v2_robust,True,False,True,False,Undefined,,,no_match,False,,,
NCT00974584,"A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",GDC-0941,"['bevacizumab', 'GDC-0941', 'paclitaxel', 'cisplatin', 'carboplatin', 'pemetrexed']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Non-Squamous Non-Small Cell Lung Cancer,"Genentech, Inc.",2025-09-01T16:18:25.981365,True,,,,NOT_FOUND,"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",,['Non-Squamous Non-Small Cell Lung Cancer'],"['NSCLC', 'PI3K', 'Avastin']",,2009-10,2015-03,"[{'measure': 'Number of Participants with Dose Limiting Toxicities (DLTs)', 'timeFrame': 'Days 1 to 22 of Cycle 1'}, {'measure': 'Percentage of Participants with Adverse Events (AEs)', 'timeFrame': 'Up to approximately 5.5 years'}]","[{'measure': 'Maximum Plasma Concentration of Paclitaxel', 'timeFrame': 'Cycle 1 Day 2: Pre-paclitaxel infusion, end of paclitaxel infusion, 0.5, 1 and 2 hours post-paclitaxel infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-paclitaxel Day 2 infusion'}, {'measure': 'Maximum Plasma Concentration of Carboplatin', 'timeFrame': 'Cycle 1 Day 2: Pre-carboplatin infusion, end of Carboplatin infusion, 0.5, 1.5 hours post-carboplatin infusion\\n\\n'}, {'measure': 'Maximum Plasma Concentration of Pemetrexed', 'timeFrame': 'Cycle 1 Day 2: Pre-pemetrexed infusion, end of pemetrexed infusion, 1, 3 hours post-pemetrexed infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-pemetrexed Day 2 infusion\\n\\nd be ""Yes"".'}, {'measure': 'Maximum Plasma Concentration of Cisplatin', 'timeFrame': 'Cycle 1 Day 2: Pre-cisplatin infusion, end of cisplatin infusion, 3 hours post-cisplatin infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-pemetrexed Day 2 infusion\\n\\n'}, {'measure': 'Percentage of Participants with Objective Response (Complete or Partial Response), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)', 'timeFrame': 'Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)\\n\\n'}, {'measure': 'Duration of Response, as Assessed Using RECIST\\n\\n\\n', 'timeFrame': 'Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)'}, {'measure': 'Progression-free Survival (PFS), as Assessed Using RECIST\\n', 'timeFrame': 'Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)\\n\\n'}, {'measure': 'Maximum Plasma Concentration of GDC-0941', 'timeFrame': 'Cycle 1 Days 1 and 2: Pre-GDC-0941 dose, 1, 2, 3 and 4 hours post-GDC-0941 dose; Cycle 1 Days 3 and 9: Pre-GDC-0941 dose; 30 days after last dose of study treatment (up to approximately 5.5 years)'}]",10.0,18 Years,,ALL,False,INDUSTRY,0.0,65.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05485909,Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM,Regorafenib and Toripalimab Combination,['Regorafenib and Toripalimab Combination'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Colorectal Cancer Liver Metastases,Sun Yat-sen University,2025-09-01T16:18:19.667777,True,,,,NOT_FOUND,"A Single-arm, Single-center Phase II Clinical Study of Regorafenib and Toripalimab Combined With Radiofrequency Ablation (RFA) in Patients With Colorectal Cancer Liver Metastases",,['Colorectal Cancer Liver Metastases'],[],,2022-07-25,2024-06-30,"[{'measure': 'Objective response rate (ORR)', 'description': 'The ratio of patients who are evaluated as CR or PR', 'timeFrame': '2 years'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'Time from first dose to first documented disease progression or death from any cause (whichever occurs first)', 'timeFrame': '2 years'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) was defined as the time (days) from randomization to death due to any cause.', 'timeFrame': '2 years'}, {'measure': 'Disease control rate (DCR)', 'description': 'Defined as the proportion of patients whose tumors shrink or remain stable for a certain period of time, including CR, PR and SD', 'timeFrame': '2 years'}, {'measure': 'Duration of response (DOR)', 'description': 'defined as the time between the first assessment of a tumor as PR or CR and the first assessment as PD or any cause of death', 'timeFrame': '2 years.'}, {'measure': 'Time to disease progression (TTP)', 'description': 'Time from first dose to first documented disease progression', 'timeFrame': '2 years'}]",6.0,18 Years,,ALL,False,OTHER,0.0,32.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03954938,Behavioral Effects of Drugs (Inpatient): 38,Cocaine,"['Cocaine', 'Placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,TERMINATED,"Cocaine Use, Unspecified",William Stoops,2025-09-01T16:18:12.172014,True,,,,NOT_FOUND,Influence of Craving Manipulation on Cocaine Self-Administration,,"['Cocaine Use, Unspecified']",[],COVID-19,2019-05-15,2021-12-03,"[{'measure': 'Number of Times Cocaine Was Selected', 'description': 'The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects can make 5 choices for each available cocaine dose. Reinforcing effects were measured for each cocaine dose during across the craving manipulation conditions.', 'timeFrame': 'One test for each of the craving manipulations for placebo and each cocaine dose level over approximately two weeks of participation.'}]","[{'measure': 'Cocaine Craving', 'description': 'Cocaine craving was assessed using a 10 point craving questionnaire that asks subjects to rate how much they are craving cocaine at that moment. The minimum craving score is 0 (i.e., no craving), the maximum craving score is 10 (i.e., highest craving).', 'timeFrame': 'Measured for each of the craving manipulations for placebo and each cocaine dose level over approximately two weeks of participation.'}]",2.0,18 Years,55 Years,ALL,True,OTHER,0.0,5.0,ACTUAL,v2_robust,True,False,True,False,COVID-19,,,no_match,False,,,
NCT06539481,"Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.",fluocinolone acetonide 190 micrograms,['fluocinolone acetonide 190 micrograms'],1,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Non-infectious Uveitis Affecting the Posterior Segment of the Eye,Alimera Sciences,2025-09-01T16:18:15.909366,True,,,,NOT_FOUND,"A Non-randomised, Open-label, Uncontrolled, Multi-centre, Phase IIIb Study Evaluating the Safety and Efficacy of Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Paediatric Subjects From 6 Years to Less Than 18 Years With Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye",,['Non-infectious Uveitis Affecting the Posterior Segment of the Eye'],[],,2024-08-31,2028-10-31,"[{'measure': 'Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.', 'description': 'The primary endpoint for evaluating the effect of the implant on non-infectious uveitis affecting the posterior segment of the eye will be based on treatment success, determined at 6 months after administration. Treatment success will be determined based on a composite variable defined as Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.', 'timeFrame': '6 months after administration'}, {'measure': 'Rate of cataract formation and Rate of IOP elevation', 'description': 'The primary endpoint for evaluating the safety of the implant on non-infectious uveitis affecting the posterior segment of the eye will be determined.\n\n* Rate of cataract formation\n* Rate of IOP elevation (Change from baseline in IOP and incidence of significant changes in IOP, including: IOP\\>21 mmHg, IOP\\>25 mmHg, IOP\\>30 mmHg, increases from baseline of 10 mmHg or more).', 'timeFrame': '6 months after administration'}]","[{'measure': 'Changes in vision and incidence of increase in IOP, AE, and uveitis recurrence', 'description': '* Absence of CMO and decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze at end of the study\n* Uveitis recurrence rate following treatment, compared to the uveitis recurrence rate over the 12 months prior to enrolment\n* Incidence of recurrence of non-infectious uveitis affecting the posterior segment in the SE and in the FE after receiving study treatment\n* Time to recurrence of non-infectious uveitis affecting the posterior segment\n* Change in macular oedema,\n* Change in BCVA\n* Change in vitreous haze\n* Change in AC cell grade\n* Incidence of secondary increase in IOP and secondary increase in IOP requiring surgical intervention\n* Incidence and onset of secondary lens opacity and extraction\n* Number of adjunctive treatments required to treat recurrences of uveitis\n* Presence of active chorioretinal\n* Presence of retinal vascular lesions\n* Incidence of ocular infection\n* Incidence of AEs\n* Change from baseline in cup-to-disc ratio', 'timeFrame': 'Every 6 months over 3 years'}, {'measure': 'Incidence of secondary increase in IOP, secondary increase in IOP requiring surgical intervention, and ocular and non-ocular AEs.', 'description': 'Mandatory safety measures including IOP checks will be performed every 3 months.\n\nThe following secondary safety endpoints will be assessed at 6 months, 12 months or 36 months\n\n* Incidence of secondary increase in IOP\n* Incidence of secondary increase in IOP requiring surgical intervention\n* Incidence of ocular and non-ocular AEs.', 'timeFrame': '3, 6, 12, and 36 months.'}]",4.0,6 Years,17 Years,ALL,False,INDUSTRY,0.0,25.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02013648,Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™),Dasatinib,"['Cytarabine', 'ARA-cell', 'Daunorubicin', 'Daunoblastin', 'Idarubicin', 'Sprycel', 'Dasatinib']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Myeloid Leukemia (AML),University of Ulm,2025-09-01T16:18:17.184476,True,,,,NOT_FOUND,Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML),,['Acute Myeloid Leukemia (AML)'],"['AML', 'Dasatinib', 'Core Binding Factor (CBF)']",,2014-07,2024-02,"[{'measure': 'Event-free Survival', 'description': 'To assess event-free survival (EFS) after intensive induction (daunorubicin and cytarabine) and consolidation (high-dose cytarabine) chemotherapy with or without dasatinib in patients with CBF-AML', 'timeFrame': '4 years'}]","[{'measure': 'Cumulative incidence of relapse (CIR)', 'timeFrame': '4 years'}, {'measure': 'Cumulative incidence of death (CID)', 'timeFrame': '4 years'}, {'measure': 'overall survival', 'timeFrame': '4 years'}, {'measure': 'relapse-free survival', 'timeFrame': '4 years'}, {'measure': 'PIA analysis', 'description': 'Pharmacodynamic inhibition of KIT as assessed by the KIT plasma inhibitory assay (PIA)', 'timeFrame': '4 years'}, {'measure': 'toxicity', 'description': 'Type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] version 4.03), timing and relatedness of non-hematologic toxicity observed during different treatment cycles.', 'timeFrame': '7 months (standard arm) / 19 months (investigational arm)'}]",7.0,18 Years,,ALL,False,OTHER,0.0,204.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06014957,Comparison of Hemodynamic Effect Between the Spinal Anesthesia and Saddle Block Using Levobupivacaine During Transurethral Resection of the Prostate in Cardiac Elderly Patients,spinal anesthesia,"['spinal anesthesia', 'saddle block']",2,INTERVENTIONAL,['NA'],,RECRUITING,TURP Syndrome,New Valley University,2025-09-01T16:18:10.919449,True,,,,NOT_FOUND,Comparison of Hemodynamic Effect Between the Spinal Anesthesia and Saddle Block Using Levobupivacaine During Transurethral Resection of the Prostate in Cardiac Elderly Patients: A Randomized Clinical Trial,,"['TURP Syndrome', 'Spinal Anesthesia']",[],,2023-08-30,2023-12,"[{'measure': 'mean arterial blood pressure', 'timeFrame': '24 hours'}]",[],1.0,65 Years,80 Years,MALE,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02963168,"A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies",Oradoxel,"['oral docetaxel + oral HM30181A', 'Oradoxel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Solid Tumor,"Athenex, Inc.",2025-09-01T16:18:14.673735,True,,,,NOT_FOUND,"A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects With Advanced Malignancies",,['Solid Tumor'],[],,2017-04-20,2020-04-30,"[{'measure': 'The maximum tolerated dose (MTD) of Oradoxel based on dose-limiting toxicity (DLT) in subjects with advanced malignancies', 'description': 'The MTD will be the highest dose at which no more than 1 of 6 subjects experience a DLT during treatment and Oradoxel pharmacokinetics are acceptable.', 'timeFrame': '3 weeks'}]","[{'measure': 'Safety assessment using AEs of Oradoxel', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Safety assessment using SAEs of Oradoxel', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Laboratory evaluation for hematology', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Blood chemistry', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Urine analysis', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Periodic measurements of ECGs', 'timeFrame': 'Screening, Day 1, every 6 weeks thereafter up to 24 months'}, {'measure': 'Periodic measurements of vital signs', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'The incidence of unacceptable toxicity with Oradoxel', 'description': 'Unacceptable toxicity graded according to CTCAE v4.03', 'timeFrame': '24 months'}, {'measure': 'The recommended Phase 2 dose (RP2D) of Oradoxel', 'description': 'Upon determination of the overall MTD for Oradoxel, the safety and PK profile of the study treatment from all Treatment Periods will be reviewed to determine the recommended Phase 2 dose.', 'timeFrame': '24 months'}, {'measure': 'The amount of docetaxel and HM30181A in blood stream by Area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The peak plasma concentration (Cmax) and Minimum plasma concentration (Cmin)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'A biological half-life or elimination half-life (t1/2)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The accumulation ratio (R)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The apparent total clearance of the drug from plasma (CL/F)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The apparent volume of distribution (Vd/F)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'To evaluate tumor response', 'description': 'Tumor response will be evaluated according to RECIST v1.1', 'timeFrame': 'Every 12 weeks, up to 24 months'}]",17.0,18 Years,,ALL,False,INDUSTRY,0.0,24.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05794919,Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets in Chinese Healthy Volunteers,Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g,"['Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g', 'Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Bioequivalence Study,Beijing Tongren Hospital,2025-09-01T16:18:19.660638,True,,,,NOT_FOUND,Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets and Calcium Hydroxybenzene Sulfonate Tablets (Doxium®) Under Fed Conditions in Chinese Healthy Volunteers,,['Bioequivalence Study'],[],,2023-03-20,2023-12,"[{'measure': 'Bioequivalence based on Cmax', 'description': 'Cmax - Maximum Observed Concentration in Plasma', 'timeFrame': 'Pharmacokinetic plasma samples collected over 36 hour period'}, {'measure': 'Bioequivalence based on AUC 0-t', 'description': 'Area Under the Concentration-time Curve From Time Zero to Time of Last', 'timeFrame': 'Pharmacokinetic plasma samples collected over 36 hour period'}, {'measure': 'Bioequivalence based on AUC 0-∞', 'description': 'Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)', 'timeFrame': 'Pharmacokinetic plasma samples collected over 36 hour period'}]",[],3.0,18 Years,55 Years,ALL,True,OTHER,1.0,56.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04544644,A Study of Combination Therapy in NSCLC,AK104+anlotinib,['AK104+anlotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Non-small Cell Lung Cancer,Chinese PLA General Hospital,2025-09-01T16:18:08.348763,True,,,,NOT_FOUND,A Phase II Study of AK104 (Binding Kenetics to PD-1 and CTLA-4) in Combination With Anlotinib in Patients With Advanced NSCLC,,['Non-small Cell Lung Cancer'],[],,2020-09,2023-09,"[{'measure': 'ORR', 'description': 'objective response rate per RECIST1.1', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'PFS and OS', 'description': 'progression-free survival and overall survival', 'timeFrame': 'through study completion, an average of 2 years'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00435279,A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia,Eszopiclone,"['Eszopiclone', 'Effexor', 'Venlafaxine', 'Placebo', 'Lunesta']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Major Depressive Disorder,"Sumitomo Pharma America, Inc.",2025-09-01T16:18:20.960498,True,,,,NOT_FOUND,"A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia",,"['Major Depressive Disorder', 'Insomnia']","['Insomnia', 'Depression', 'Major Depressive Disorder']",,2007-06,2009-07,"[{'measure': 'The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.', 'timeFrame': 'Week 8'}]","[{'measure': 'The key secondary endpoint is the change from baseline in the mean subjective Total Sleep Time (TST) during Week 1.', 'timeFrame': 'Week 1'}]",2.0,18 Years,64 Years,ALL,False,INDUSTRY,0.0,678.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00335010,Intravenous NTG to Preserve Gastric Microcirculation During Gastric Tube Reconstruction,Nitroglycerin,['Nitroglycerin'],1,INTERVENTIONAL,['NA'],,COMPLETED,Esophageal Neoplasms,Erasmus Medical Center,2025-09-01T16:18:12.182393,True,,,,NOT_FOUND,A Prospective Double Blinded Study on the Effect of Intravenously Administrated Nitroglycerine on Gastric Tissue Microvascular Bloodflow and Microvascular Hemoglobin Saturation During Gastric Tube Reconstruction,,"['Esophageal Neoplasms', 'Microcirculation']","['Nitroglycerine', 'gastroesophageal anastomosis', 'microvascular bloodflow', 'microvascular hemoglobinsaturation']",,2005-05,2005-12,"[{'measure': 'differences in Microvascular bloodflow'}, {'measure': 'differences in microvascular hemoglobinsaturation'}]","[{'measure': 'differences in anastomotic leakage'}, {'measure': 'differences in anastomotic stenosis'}]",4.0,18 Years,,ALL,False,OTHER,0.0,32.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00618319,"An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)",BIIB021,"['BIIB021', 'CNF2024']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,GIST,Biogen,2025-09-01T16:18:24.751595,True,,,,NOT_FOUND,"An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment",,['GIST'],[],,2008-02,2010-04,"[{'measure': 'Changes in FDG-PET imaging', 'timeFrame': '28 days'}]","[{'measure': 'Characterize the safety profile of BIIB021', 'timeFrame': 'Duration of study'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04705909,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,Pitavastatin,"['HMG CoA reductase inhibitor "" Lipovastatin""', 'Pitavastatin', 'placebo']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Breast Cancer,Mansoura University,2025-09-01T16:18:14.657807,True,,,,NOT_FOUND,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,,['Breast Cancer'],[],,2021-01-15,2021-12-15,"[{'measure': 'clinical response rate', 'description': 'Response to preoperative therapy as per ultrasonographic tumor size assessment. A responder will have \\> 50% decrease in the size of the primary tumor without appearance of new lesions.', 'timeFrame': '6 months'}, {'measure': 'Relative reduction of Ki67 in tumor samples', 'description': 'It will be described as average pre-post differences in percent positive cells with 95% Wilson confidence intervals.', 'timeFrame': '6 months'}]","[{'measure': 'The change in Cyclin D1 (candidate marker associated with breast tumor proliferation)', 'timeFrame': 'Baseline up to 6 months'}, {'measure': 'The change in Cleaved caspase-3 (CC3) (candidate marker associated with tumor apoptosis)', 'timeFrame': 'Baseline up to 6 months'}]",4.0,18 Years,,FEMALE,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00660010,Study of Lupron Depot In The Treatment of Central Precocious Puberty,Lupron (leuprolide acetate),"['Lupron (leuprolide acetate)', 'Lupron']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Puberty, Precocious",Abbott,2025-09-01T16:18:09.636586,True,,,,NOT_FOUND,Study of Lupron Depot In The Treatment of Central Precocious Puberty,,"['Puberty, Precocious']","['CPP', 'central precocious puberty', 'pediatrics', 'suppression of LH', 'Lupron', 'leuprolide acetate', 'depot formulation', 'GnRHa', 'GnRH agonist', 'GNRH analog', 'LH', 'Tanner staging']",,1991-01,2009-04,"[{'measure': 'Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)', 'description': 'Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).', 'timeFrame': 'Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)', 'description': 'Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).', 'timeFrame': 'Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}]","[{'measure': 'Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations', 'description': 'Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.', 'timeFrame': 'Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Mean Stimulated Estradiol Concentrations in Females', 'description': 'Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.', 'timeFrame': 'Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Mean Stimulated Testosterone Concentrations in Males', 'description': 'Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.', 'timeFrame': 'Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}, {'measure': 'Mean Ratio of Bone Age to Chronological Age', 'description': 'Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.', 'timeFrame': 'Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit'}]",6.0,,10 Years,ALL,False,INDUSTRY,0.0,55.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,Cyclophosphamide,"['CYTOXAN, PROCYTOX', 'FLUDARA', 'Fludarabine', 'Cyclophosphamide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Metastatic, Stage III or Stage IV, Melanoma","University Health Network, Toronto",2025-09-01T16:18:15.892142,True,,,,NOT_FOUND,Phase II Study Evaluating The Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma,,"['Metastatic, Stage III or Stage IV, Melanoma']","['Measurable', 'Unresectable', 'Stage III', 'Stage IV', 'Metastatic', 'Melanoma', 'Tumor-Infiltrating Lymphocytes', 'Low-Dose Interleukin-2', 'Cyclophosphamide', 'Fludarabine']",,2013-06,2018-04,"[{'measure': 'Clinical response to treatment', 'timeFrame': '6 weeks after treatment'}]","[{'measure': 'Number occurrences and severity of side effects', 'timeFrame': 'Starting at first dose of study treatment up to 10 years'}, {'measure': 'Number of patients with an immunity and no immunity to the study treatment', 'timeFrame': 'From start of study up to 10 years'}]",3.0,18 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04804059,A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males,[14C]-APX001 Oral Solution,"['[14C]-APX001 Solution for Infusion', '[14C]-APX001 Oral Solution']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Fungal Infection,Basilea Pharmaceutica,2025-09-01T16:18:20.959195,True,,,,NOT_FOUND,"An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-APX001 in Healthy Male Subjects After Oral and Intravenous Dosing",,['Fungal Infection'],[],,2018-08-17,2018-09-26,"[{'measure': 'Mass balance recovery as measured by mass unit equiv/g after a single oral or single intravenous (IV) dose of carbon-14 (14C)-labelled APX001 ([14C]-APX001).', 'timeFrame': '3 weeks'}, {'measure': 'Profiling of metabolites of [14C]-APX001 in plasma and excreta.', 'description': 'Plasma, urine and feces samples from subjects dosed with \\[14C\\]-APX001 were analyzed using high resolution, accurate mass liquid chromatography tandem mass spectrometry (LC-MS/MS) with in-line fraction collection and off-line counting to obtain \\[14C\\]-radiochromatographic profiles and provide information on the nature of the radioactive components present, including chemical structure identification.', 'timeFrame': '3 weeks'}]","[{'measure': 'Elimination pathway of [14C]-APX001 following a single oral or single IV dose of [14C]-APX001.', 'description': 'Amount of radioactivity recovered from urine and feces over time was measured by liquid scintillation counting (LSC) and expressed as a percentage of administered radioactivity.', 'timeFrame': '3 weeks'}, {'measure': 'Extent of distribution of total radioactivity into blood cells following a single oral or single IV dose of [14C]-APX001.', 'description': 'Amount of radioactivity in whole blood over time was quantified by LSC and expressed in ng equivalents free drug/g.', 'timeFrame': '3 weeks'}]",4.0,30 Years,65 Years,MALE,True,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00601965,Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults,Escitalopram,"['Escitalopram', 'Lexapro', 'Sugar pill', 'Placebo']",4,INTERVENTIONAL,['NA'],,COMPLETED,Generalized Anxiety Disorder,Veterans Medical Research Foundation,2025-09-01T16:18:22.200282,True,,,,NOT_FOUND,CBT Augmentation of SSRI Treatment for Geriatric GAD,,['Generalized Anxiety Disorder'],[],,2007-10,2011-09,"[{'measure': 'Hamilton Anxiety Rating Scale', 'description': ""The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score \\>= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of \\>=5, for a total Hamilton \\>=14, relative to the end of the continuation phase (week 28), for a duration of at least 2 weeks, plus both clinician's and participant's judgment that the participant is experiencing a recurrence of anxiety symptoms. HAMA scores range from 0 (no anxiety) to 56 (high anxiety)."", 'timeFrame': '56 weeks'}, {'measure': 'Penn State Worry Questionnaire', 'description': 'The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Scores range from 16-80, with higher scores indicating higher levels of worry.', 'timeFrame': '56 weeks'}]",[],2.0,60 Years,,ALL,False,OTHER,1.0,73.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04049266,"A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.",KSI-301,"['KSI-301', 'Aflibercept', 'Eylea']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Wet Macular Degeneration,Kodiak Sciences Inc,2025-09-01T16:18:24.742115,True,,,,NOT_FOUND,"A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.",,['Wet Macular Degeneration'],"['AMD', 'Wet AMD', 'choroidal neovascularization secondary to age-related macular degeneration', 'KSI-301', 'Aflibercept', 'Vascular endothelial growth factor', 'VEGF', 'Anti-VEGF', 'Antibody biopolymer conjugate', 'Macular Degeneration', 'Wet Macular Degeneration', 'Retinal Degeneration', 'Retinal Diseases', 'Eye Diseases', 'Vision Disorders', 'Vision, low', 'Kodiak']",Primary Endpoint Not Met,2019-10-08,2022-04-26,"[{'measure': 'Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48 and 52, Full Analysis Set Year 1', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.', 'timeFrame': 'Year 1'}]","[{'measure': 'Percentage of Subjects on KSI-301 Arm With a Once Every 12-Weeks, 16-Weeks or 20-Weeks Treatment Interval', 'description': 'Percentage of subjects on KSI-301 arm achieving a Once Every 12-Weeks, 16-Weeks or 20-Weeks Treatment Interval based on individualized treatment response', 'timeFrame': 'Year 1'}, {'measure': 'Percentage of Subjects Gaining ≥ 5, ≥10 and ≥15 Letters in BCVA From Baseline in the Study Eye, Full Analysis Set Year 1', 'description': 'Categorical improvements in Best Corrected Visual Acuity (BCVA) of clinically relevant BCVA measurements corresponding to 1, 2 and 3 lines of the ETDRS vision testing chart', 'timeFrame': 'Year 1'}, {'measure': 'Percentage of Subjects Who Achieving BCVA Snellen Equivalent of 20/40 or Better in the Study Eye at Year 1', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. BCVA Snellen equivalent of 20/40 was defined as ≥69 ETDRS letters', 'timeFrame': 'Year 1'}, {'measure': 'Percentage of Subjects With BCVA Snellen Equivalent of 20/200 or Worse in the Study Eye at Year 1', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. BCVA Snellen equivalent of 20/200 or Worse was defined as BCVA ≤ 38 ETDRS Letters.', 'timeFrame': 'Year 1'}, {'measure': 'Mean Change in OCT Central Subfield Retinal Thickness (CST) From Day 1', 'description': 'Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) as assessed by a central reading center.', 'timeFrame': 'Year 1'}]",6.0,50 Years,,ALL,False,INDUSTRY,0.0,559.0,ACTUAL,v2_robust,True,False,True,False,Primary Endpoint Not Met,,,no_match,False,,,
NCT00796380,Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases,Xingnaojing,['Xingnaojing'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Convulsive Diseases,Shenzhen Children's Hospital,2025-09-01T16:18:20.959914,True,,,,NOT_FOUND,Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases,,['Convulsive Diseases'],[],,2008-12,2010-07,"[{'measure': 'Antipyretic rate , Frequency of convulsive episodes ,', 'timeFrame': 'one year'}, {'measure': 'Frequency of convulsive episodes', 'timeFrame': '1 year'}]",[],2.0,1 Month,18 Years,ALL,False,OTHER_GOV,0.0,1.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05998395,JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease,Ruxolitinib,['Ruxolitinib'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Kohlmeier Degos Disease With Neurologic Involvement,"National Heart, Lung, and Blood Institute (NHLBI)",2025-09-01T16:18:15.906395,True,,,,NOT_FOUND,Single Patient Study of JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease,,['Kohlmeier Degos Disease With Neurologic Involvement'],"['Rare Small Vessel Vasculopathy Of Unknown Etiology', 'Kohlmeier Degos Disease With Neurologic Involvement']",,2023-09-28,2025-02-28,"[{'measure': 'To test the hypothesis that JAK/STAT inhibition by ruxolitinib will delay progression of neuroradiological manifestations of our one patient with neurological involvement of K-D disease.', 'description': 'The primary endpoint is stability or regression of existing enhancing lesions or no development of new enhancing lesions in the brain and spine observed in MRI evaluation after 13 weeks and up to 73 weeks of ruloxitinib (10 mg BID) compared to pre-treatment MRI images.', 'timeFrame': '6 months'}]",[],1.0,18 Years,100 Years,ALL,False,NIH,0.0,1.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00517322,Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan,ramipril,"['ramipril', 'irbesartan']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Left Atrial Volume,Università degli Studi dell'Insubria,2025-09-01T16:18:08.337140,True,,,,CHEMBL1201365,Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan,,"['Left Atrial Volume', 'Hypertensive Heart Disease', 'Antihypertensive Drugs', 'Diastolic Function', 'Renin Angiotensin System']","['left atrial volume', 'hypertension', 'ramipril', 'irbesartan', 'diastolic function']",,2007-08,2010-08,"[{'measure': 'left atrial volume', 'timeFrame': 'one year'}, {'measure': 'diastolic function', 'timeFrame': 'one year'}]","[{'measure': 'systolic and diastolic blood pressure', 'timeFrame': 'one year'}]",3.0,40 Years,65 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,CHEMBL1201365,partial_match,True,388.46,1.9,2.0
NCT02481219,Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure,Senna tablets,"['Erythromycin', 'SUPREP oral sulfate solution with Gastrografin', 'Metoclopramide', 'PEG', 'SUPREP oral sulfate solution', 'Bisacodyl', 'Senna tablets']",7,INTERVENTIONAL,['NA'],,COMPLETED,Colorectal Cancer Screening,Medtronic - MITG,2025-09-01T16:18:13.424894,True,,,,NOT_FOUND,"COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure",,['Colorectal Cancer Screening'],"['Polyps', 'Capsule endoscopy', 'Bowel preparation regimen', 'Average risk patients for colorectal cancer screening']",,2015-05,2016-02,"[{'measure': 'Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)', 'description': 'The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum).', 'timeFrame': 'Within two weeks of study procedure'}]","[{'measure': 'Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assessed from RAPID video in total and by segment', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assessed from RAPID video in total and by segment', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assesses by applicable case report form (CRF)', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assesses by applicable CRF', 'timeFrame': 'Adverse Events (AE) were collected starting from the screening visit and until 5-9 days following the PillCam procedure day.'}]",6.0,50 Years,75 Years,ALL,True,INDUSTRY,0.0,122.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00734344,Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection,Raltegravir,"['Emtricitibine', 'Raltegravir', 'Tenofovir disoproxil once daily', 'Tenofovir disoproxil twice daily', 'Efavirenz']",5,INTERVENTIONAL,['NA'],,COMPLETED,Acute HIV Infection,University of Alabama at Birmingham,2025-09-01T16:18:24.756749,True,,,,NOT_FOUND,Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis,,['Acute HIV Infection'],[],,2008-09,2012-09,"[{'measure': 'Mean White Blood Cell Count Between Treatment Groups at 2 Months', 'description': 'Mean WBC count for all subjects as determined by standard lab procedures at 2 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': 'baseline to 2 months'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 4 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 4 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '4 months post baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 6 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 6 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 8 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 8 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 10 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 10 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 12 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 12 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '12 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 14 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 14 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '14 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 2 Months', 'description': 'Mean hematocrit of all subjects at 2 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '2 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 4 Months', 'description': 'Mean hematocrit of all subjects at 4 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 6 Months', 'description': 'Mean hematocrit of all subjects at 6 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 8 Months', 'description': 'Mean hematocrit of all subjects at 8 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 10 Months', 'description': 'Mean hematocrit of all subjects at 10 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 12 Months', 'description': 'Mean hematocrit of all subjects at 12 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '12 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 14 Months', 'description': 'Mean hematocrit of all subjects at 14 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '14 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 2 Months', 'description': 'The mean platelet count between treament groups at 2 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 100 per liter).', 'timeFrame': '2 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 4 Months', 'description': 'The mean platelet count between treatment groups at 4 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 6 Months', 'description': 'The mean platelet count between treatment groups at 6 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 8 Months', 'description': 'The mean platelet count between treatment groups at 8 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 10 Months', 'description': 'The mean platelet count between treatment groups at 10 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 12 Months', 'description': 'The mean platelet count between treatment groups at 12 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '12 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 14 Months', 'description': 'The mean platelet count between treatment groups at 14 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 1 Months', 'description': 'Mean CD4 count between groups 1 month after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '1 month after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 2 Months', 'description': 'Mean CD4 count between groups 2 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '2 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 3 Months', 'description': 'Mean CD4 count between groups 3 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '3 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 4 Months', 'description': 'Mean CD4 count between groups 4 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 5 Months', 'description': 'Mean CD4 count between groups 5 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '5 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 6 Months', 'description': 'Mean CD4 count between groups 6 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 7 Months', 'description': 'Mean CD4 count between groups 7 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '7 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 8 Months', 'description': 'Mean CD4 count between groups 8 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 9 Months', 'description': 'Mean CD4 count between groups 9 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '9 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 10 Months', 'description': 'Mean CD4 count between groups 10 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 11 Months', 'description': 'Mean CD4 count between groups 11 months after of starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '11 months after baseline'}]",[],32.0,19 Years,,ALL,False,OTHER,1.0,18.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05017402,Higher Dose of Alglucosidase Alpha for Pompe Disease,Alglucosidase Alfa,['Alglucosidase Alfa'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Glycogen Storage Disease Type II,"Taipei Veterans General Hospital, Taiwan",2025-09-01T16:18:13.419957,True,,,,NOT_FOUND,Higher Dose of Alglucosidase Alpha for Pompe Disease: Long-term Follow-up Study,,['Glycogen Storage Disease Type II'],[],,2021-09-01,2026-12-31,"[{'measure': 'Forced vital capacity', 'description': 'Pulmonary function test (Units: percentage of predictive value)', 'timeFrame': 'For patient older than 3-year-old, first test before study, then every six months, up to 2-years.'}, {'measure': 'Peak expiratory flow', 'description': 'Pulmonary function test (Units: percentage of predictive value)', 'timeFrame': 'For patient older than 3-year-old, first test before study, then every six months, up to 2-years.'}, {'measure': 'Polysomnography', 'description': 'Comprehensive test used to diagnose sleep disorders.', 'timeFrame': 'For patient older than 6-month-old, first test before study, then every six months, up to 2-years.'}]","[{'measure': 'uGLC4', 'description': 'Urine glucose tetrasaccharide (Units: mmol/mol Creatinine).', 'timeFrame': 'uGLC4 will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'CK', 'description': 'Blood creatine kinase (Units: units per liter, U/L).', 'timeFrame': 'CK will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'AST', 'description': 'Blood aspartate aminotransferase (Units: units per liter, U/L).', 'timeFrame': 'AST will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'ALT', 'description': 'Blood alanine aminotransferase (Units: units per liter, U/L).', 'timeFrame': 'ALT will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'Body weight', 'description': 'Change of body weight (Unit: kilogram, kg)', 'timeFrame': 'The body weight will be monitored before the treatment, then every two weeks, up to 2-years.'}, {'measure': 'Body height', 'description': 'Change of body height (Units: centimeter, cm)', 'timeFrame': 'The body height will be monitored before the treatment, then every two weeks, up to 2-years.'}, {'measure': 'Antibody titers', 'description': 'Alglucosidase alfa IgG antibody titer', 'timeFrame': 'First test will be one month later after first ERT, then every six months, up to 2-years.'}]",10.0,0 Years,60 Years,ALL,False,OTHER_GOV,0.0,36.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT03965013,A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes,NNC0268-0965,"['insulin glargine', 'NNC0268-0965', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 1",Novo Nordisk A/S,2025-09-01T16:18:07.020719,True,,,,NOT_FOUND,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0268-0965 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus",,"['Diabetes Mellitus, Type 1', 'Healthy Volunteers']",[],,2019-06-05,2019-12-14,"[{'measure': 'Number of treatment-emergent adverse events', 'description': 'Number of events', 'timeFrame': 'From trial product administration at day 1 until completion of post-treatment end-of-trial visit at day 10'}]","[{'measure': 'Number of treatment-emergent hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'From trial product administration at day 1 until completion of post-treatment end-of-trial visit at day 10'}, {'measure': 'Area under the serum NNC0268-0965 concentration-time curve after a single dose', 'description': 'pmol\\*h/L', 'timeFrame': 'From 0 hours until infinity after trial product administration (day 1)'}, {'measure': 'Maximum observed serum NNC0268-0965 concentration after a single dose', 'description': 'pmol/L', 'timeFrame': 'From 0 hours until last measurement time after trial product administration (day 1)'}]",4.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,78.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00349882,Effects of Contact Lens Care Regimens on the Corneal Epithelium,Marketed multipurpose disinfection regimen,['Marketed multipurpose disinfection regimen'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Myopia,University of Waterloo,2025-09-01T16:18:12.184459,True,,,,NOT_FOUND,Effects of Contact Lens Care Regimens on the Corneal Epithelium,,['Myopia'],[],,2005-06,,"[{'measure': 'The primary outcome measure of this study is to investigate the effects of two'}, {'measure': 'different contact lens care solutions on the cornea.'}]","[{'measure': 'The secondary outcome measure of this study is to compare the subjective and'}, {'measure': 'objective responses between two different contact lens care solutions.'}]",4.0,18 Years,,ALL,,OTHER,1.0,30.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04477512,Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial),Cabozantinib,"['Abiraterone acetate', 'Nivolumab', 'Cabozantinib', 'Prednisone']",4,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Metastatic Hormone Refractory Prostate Cancer,Washington University School of Medicine,2025-09-01T16:18:15.909269,True,,,,NOT_FOUND,A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial),,['Metastatic Hormone Refractory Prostate Cancer'],[],,2021-02-19,2025-09-11,"[{'measure': 'Frequency of dose-limiting toxicities (DLTs)', 'description': '* Protocol defined hematologic DLTs that occur during the first cycle that are attributed as possibly, probably, or definitely related to study treatment\n* Protocol defined non-hematologic DLTs possibly, probably, or definitely related grade 3 or 4 non-hematologic toxicity that occurs during the first cycle of treatment.', 'timeFrame': 'Completion of 1st cycle of treatment for patients in dose level 1 & dose level 2 (estimated to be 11 months)'}]","[{'measure': 'PSA response rate', 'description': '-Defined by at least 50% decline in PSA level from baseline measured twice at least 3 weeks apart', 'timeFrame': 'Through end of treatment (estimated to be 24 months)'}, {'measure': 'Overall response rate (ORR)', 'description': '-Defined by proportion of patients achieving complete or partial response by RECIST 1.1 or by PCWG3 criteria', 'timeFrame': 'Through end of treatment (estimated to be 24 months)'}, {'measure': 'Overall survival (OS)', 'description': '-Defined as from start of treatment to date of death (all cause) or last follow-up.', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Progression-free survival (PFS)', 'description': '-Defined from start of treatment to date of progression or death or last follow-up, whichever is earlier.', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Disease specific survival (DSS)', 'description': '-Defined as from start of treatment to to date of death due to disease or last follow-up.', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Incidence of adverse events as measured per CTCAE v 5.0', 'timeFrame': 'From time of consent through 100 days after last dose of nivolumab (estimated to be 28 months)'}, {'measure': 'Disease free survival (DFS)', 'description': '-Defined as from date of first PSA response or radiographic complete response to date of recurrence of disease', 'timeFrame': 'From start of treatment through 1 year of follow-up (estimated to be 36 months)'}, {'measure': 'Duration of response (DoR)', 'description': '-Defined from date of first PSA response to date of PSA progression or date of RECIST response to date of radiographic progression.', 'timeFrame': 'From start of first response through 1 year of follow-up (estimated to be 36 months)'}]",9.0,18 Years,,MALE,False,OTHER,2.0,18.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00667004,Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease,ecabet ophthalmic solution,"['ecabet ophthalmic solution', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Dry Eye Disease,Bausch & Lomb Incorporated,2025-09-01T16:18:19.671937,True,,,,NOT_FOUND,,,['Dry Eye Disease'],[],,2008-03-22,2008-09-12,"[{'measure': ""Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test"", 'description': ""The Schirmer's test is used determine if tear glands produce enough tears to keep eyes adequately moist. Calibrated strips of a non-toxic filter paper are used. One free end is placed within the lower eyelid. At the conclusion of the test, the paper strip is removed from the lower eyelid and the amount of wetting of the paper strip is measured."", 'timeFrame': '43 days'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,183.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01652586,Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations,dexmedetomidine-remifentanil,"['midazolam-remifentanil', 'dexmedetomidine-remifentanil']",2,INTERVENTIONAL,['NA'],,COMPLETED,Cardiac Arrhythmia,Yonsei University,2025-09-01T16:18:20.964011,True,,,,CHEMBL77921,,,['Cardiac Arrhythmia'],['cardiac ablation'],,2011-04,2011-12,"[{'measure': 'change of sedation depth', 'description': '1. Ramsay sedation score (1 = anxious and agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responsive to verbal commands, drowsy; 4 = asleep, responsive to light stimulation; 5 = asleep, slow response to stimulation; 6 = no response to stimulation)\n2. the bispectral index', 'timeFrame': '5 min after study drug adminstration, and every 10 min thereafter'}]",[],1.0,20 Years,70 Years,ALL,False,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cccc(C(C)c2c[nH]cn2)c1C,CHEMBL77921,partial_match,True,200.28,3.18,3.0
NCT00183391,Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children,Atomoxetine,"['Atomoxetine', 'Methylphenidate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Attention Deficit Disorder With Hyperactivity,Icahn School of Medicine at Mount Sinai,2025-09-01T16:18:09.634041,True,,,,CHEMBL1702,Measuring and Predicting Response to Atomoxetine and Methylphenidate,,['Attention Deficit Disorder With Hyperactivity'],"['ADHD', 'Child', 'Adolescent', 'School']",,2005-07,2011-06,"[{'measure': 'ADHD-RS Total Score', 'description': 'ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis.', 'timeFrame': 'up to 14 weeks'}]","[{'measure': 'Treatment Preference Survey', 'timeFrame': 'Measured at ends of treatments one and two'}, {'measure': 'ADHD - H/I', 'description': 'Attention deficit/hyperactivity disorder - hyperactivity/impulsivity (ADHD- H/I). Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'ADHD-RS Inattention', 'description': 'Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Clinical Global Impressions (CGI)- Severity', 'description': ""The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill."", 'timeFrame': 'up to 14 weeks'}, {'measure': 'Social Skills Rating Scale (SSRS)- Parent Version', 'description': 'Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Child Conflict Index (CCI)', 'description': 'Measure of conflict within the home over the past 24 hours. The CCI is a validated measure of family conflicts in the home and is completed by parents. It consists of 42 items (for boys) or 36 items (for girls) reflecting attention-seeking and conflictual behavior, as well as negativity and withdrawal. Items are scored as yes (1 point) or no (0 points). Mean score between 0 and 1 reported, with higher score indicating greater conflict.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Continuous Performance Test (CPT)', 'description': 'CPT Commissions, impulsive responses, higher score is worse. This scale is based on t-scores and does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': ""Children's Sleep Questionnaire"", 'description': ""Children's Sleep Problems Severity, sum of scores, higher is worse.The scale assessed contains 16 items, each scored 0 to 3, with 0 representing no problems and 3 representing daily problems. total range from 0 to 48. This score does not have psychometrics available."", 'timeFrame': 'up to 14 weeks'}, {'measure': 'Assessment of Affective Range (AAR)', 'description': 'Affective problems. This scale consists of 8 items, scored 0-3, with 0 representing no problems and 3 representing extreme problems. This analysis presents sum of scores, higher is worse. Full range from 0 to 24. This score does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Tics: Total Motor', 'description': 'Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Tics: Total Phonic', 'description': 'Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Tics: Total Impairment', 'description': 'Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Vital Signs - Systolic Blood Pressure', 'description': 'Systolic blood pressure - the amount of pressure in arteries during contraction of the heart muscle Normal range varies by age, sex, height and weight and can range from 80mm Hg to 130mmHg', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Vital Signs - Diastolic Blood Pressure', 'description': 'Diastole blood pressure - blood pressure when the heart muscle is between beats. normal range varies by age, sex, height and weight and can range from 34mm Hg to 90mmHg', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Vital Signs - Pulse', 'description': 'Heartbeats per minute. Range varies from 50-205 depending on age and level of activity.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'SES (Hollingshead)', 'description': 'Measure of socioeconomic status, score calculated from averaging likert responses, lower = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Conners-Wells Adolescent Self Report', 'description': 'Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Conners Teacher Rating Scale- Short', 'description': 'Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Child Behavior Checklist (CBCL)', 'description': 'CBCL Total Score, measure of psychosocial problems, higher is worse.', 'timeFrame': 'Measured at screening'}, {'measure': 'Social Skills Rating Scale (SSRS)- Teacher Version', 'description': 'Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Permanent Mathematics Product Test (PERMP)', 'description': 'Measure of fluency in performance of simple mathematics, sum, lower = worse', 'timeFrame': 'up to 14 weeks'}, {'measure': 'Actigraphy', 'description': 'Measure of physical activity', 'timeFrame': 'Measured daily throughout the study'}, {'measure': 'Sleep Logs', 'description': 'Questionnaire, qualitative', 'timeFrame': 'Measured daily throughout the study'}, {'measure': 'Hyperactivity, Attention, and Learning Problems (HALP) Medical and Developmental History Questionnaire', 'description': 'Questionnaire, qualitative designed to collect family history, prenatal environmental influences, and developmental history.', 'timeFrame': 'Measured at screening'}, {'measure': 'HALP Rebound Effects Questionnaire', 'description': 'Questionnaire, qualitative assesses symptoms of rebound (moodiness, irritability, aggression, and ADHD symptoms) when the medication wears off at night.', 'timeFrame': 'up to 14 weeks'}]",26.0,6 Years,17 Years,ALL,False,OTHER,1.0,232.0,ACTUAL,v2_robust,True,True,False,False,,CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl,CHEMBL1702,partial_match,True,291.82,3.72,4.0
NCT01616654,Dose Range Study of CD5789 in Acne Vulgaris,CD5789 25 µg/g cream,"['CD5789 50 µg/g cream', 'Tazarotene 0.1% gel', 'CD5789 100 µg/g cream', 'CD5789 25 µg/g cream', 'Vehicle cream']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acne Vulgaris,Galderma R&D,2025-09-01T16:18:07.030109,True,,,,NOT_FOUND,"A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris",,['Acne Vulgaris'],[],,2012-06-20,2014-06-12,"[{'measure': 'Percentage of Participants With Success Rate 1 (SR1)', 'description': 'Success Rate 1 was defined as percentage of participants who achieved at least a two-point reduction in the Investigator Global Assessment (IGA) scale from baseline at week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by last observation carried forward (LOCF).', 'timeFrame': 'From Baseline at Week 12'}, {'measure': 'Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Percentage of Participants With Success Rate 2 (SR2)', 'description': 'Success Rate 2 (SR2) was defined as the percentage of participants rated ""Clear"" (Grade 0) or ""Almost clear"" (Grade 1) with at least a two-point reduction on the IGA scale from Baseline to Week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by LOCF.', 'timeFrame': 'From Baseline to Week 12'}, {'measure': 'Absolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)', 'description': 'The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF. Percent changes in lesion counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100.', 'timeFrame': 'Baseline, Week 12'}]",6.0,12 Years,35 Years,ALL,False,INDUSTRY,0.0,304.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01939145,Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation,Normal saline,"['0.9% Saline', 'Normal saline']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Wound Infection,Georgetown University,2025-09-01T16:18:10.917042,True,,,,NOT_FOUND,A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation,,['Wound Infection'],['hospital admission'],,2013-09,2016-07,"[{'measure': 'Number of Operating Room Visits', 'description': 'Compare the number of operative room visits between Prontosan NPWTi and normal saline NPWTi.', 'timeFrame': 'Patients will be followed during their hospital stay which is an average of approximately 2 weeks.'}]","[{'measure': 'Hospital Admission Length of Stay', 'description': 'Compare the hospital admission length of stay between Prontosan NPWTi and normal saline NPWTi.', 'timeFrame': 'Patients will be followed during their hospital stay which is an average of approximately 2 weeks.'}]",2.0,18 Years,,ALL,False,OTHER,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00003881,Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,carboplatin,"['paclitaxel', 'carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Lung Cancer,Eastern Cooperative Oncology Group,2025-09-01T16:18:24.751097,True,,,,NOT_FOUND,"Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC",,['Lung Cancer'],"['recurrent non-small cell lung cancer', 'stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer']",,1999-05,2004-07,[],[],0.0,18 Years,,ALL,False,NETWORK,1.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06594692,"Node-Sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study",Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab,"['Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab', 'CAPOX Chemotherapy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Microsatellite Stable (MSS) Colon Cancer,Sir Run Run Shaw Hospital,2025-09-01T16:18:13.428420,True,,,,NOT_FOUND,"Node-sparing Modified Short-Course Radiation Combined with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer : a Randomized, Prospective, Multicenter, Open-label Clinical Trial",,"['Microsatellite Stable (MSS) Colon Cancer', 'Locally Advanced Colon Cancer']","['Locally Advanced Colon Cancer', 'Microsatellite Stable (MSS) Colon Cancer', 'Node-Sparing Radiotherapy', 'Short-Course Radiotherapy', 'Sintilimab']",,2024-10,2026-09-30,"[{'measure': 'pathological complete response rate', 'description': 'The tumor specimen from node-sparing neoadjuvant chemoradiotherapy combined with immunotherapy, followed by sequential CME (complete mesocolic excision) surgery, showed no presence of cancer cells or lymph node metastasis under microscopic examination (ypT0N0M0).', 'timeFrame': '2 weeks after surgery'}]","[{'measure': 'R0 resection rate', 'description': 'which is the percentage of patients who undergo a surgical procedure in which the tumor is completely removed with no cancer cells detected at the margins (edges) of the resected tissue. Achieving an R0 resection is a critical goal in cancer surgery, as it indicates that all visible and microscopic tumor cells have been removed, reducing the likelihood of recurrence.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'Tumor downstaging rate', 'description': 'The tumor downstaging rate refers to the percentage of patients whose tumors decrease in size or extent (stage) following neoadjuvant treatment, compared to their initial stage at diagnosis. Downstaging means that the tumor has responded to treatment to the point where it moves from a more advanced stage (e.g., from stage III to stage II or I), which may improve the likelihood of successful surgical removal and lead to better prognosis.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'The 3-year Event-Free Survival', 'description': ""The 3-year Event-Free Survival (EFS) refers to the percentage of patients who remain free from certain negative events-such as cancer progression, recurrence, or death-within three years after treatment. In clinical trials, EFS is a critical measure of a treatment's long-term efficacy, indicating how long patients can live without the disease worsening or other significant events occurring during the follow-up period."", 'timeFrame': '3 years post-treatment'}, {'measure': 'Objective Response Rate', 'description': 'Objective Response Rate (ORR) refers to the percentage of patients in a clinical study whose cancer shows a measurable reduction in tumor size in response to treatment.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'The 3-year Local Recurrence Rate', 'description': 'The 3-year Local Recurrence Rate (LRR) refers to the percentage of patients whose cancer returns at the original tumor site or nearby lymph nodes within three years after completing treatment. This measure is important for evaluating the long-term effectiveness of a treatment in preventing the return of cancer in the localized area where it was initially detected. A lower LRR suggests better local control of the disease.', 'timeFrame': '3 years post-treatment'}, {'measure': '3-year Disease-Free Survival', 'description': '3-year Disease-Free Survival (DFS) refers to the percentage of patients who remain free from any signs or symptoms of cancer for three years after completing treatment. It measures the length of time during which patients experience no recurrence of the disease and are considered to be in remission. DFS is commonly used to assess the effectiveness of a treatment in preventing cancer from returning within a specified time frame.', 'timeFrame': '3 years post-treatment'}, {'measure': '3-year Overall Survival', 'description': '3-year Overall Survival (OS) refers to the percentage of patients who are still alive three years after the completion of treatment, regardless of whether the cancer has recurred or progressed. It is a key indicator of the effectiveness of a treatment in prolonging life. Unlike Disease-Free Survival (DFS), OS does not take into account whether the disease has returned, focusing solely on survival.', 'timeFrame': '3 years post-treatment'}, {'measure': 'The incidence of grade III/IV adverse events', 'description': 'The incidence of grade III/IV adverse events refers to the percentage of patients who experience severe or life-threatening side effects (classified as grade III or IV) during a clinical trial. Grade III adverse events are considered serious but not immediately life-threatening, often requiring medical intervention, while grade IV events are life-threatening and typically require urgent medical attention. This measure is crucial for assessing the safety and tolerability of a treatment.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'EORTCQLQ-C30', 'description': ""The EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) is a standardized tool used to assess the quality of life of cancer patients. It contains 30 questions that cover a wide range of physical, emotional, and social aspects of well-being, including symptoms of cancer and treatment side effects, functioning (physical, role, emotional, cognitive, and social), and overall health. The questionnaire is widely used in clinical trials to evaluate how treatments impact the patient's quality of life during and after treatment."", 'timeFrame': '3 years post-treatment'}, {'measure': 'EORTCQLQ-CR29', 'description': ""The EORTC QLQ-CR29 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer Module) is a supplementary module to the QLQ-C30 designed specifically to assess quality of life in patients with colorectal cancer. It includes 29 questions that focus on colorectal cancer-specific symptoms and concerns, such as bowel function, body image, and sexual functioning, in addition to the general quality of life issues covered by the QLQ-C30. This questionnaire is used in clinical studies to evaluate the impact of colorectal cancer and its treatment on patients' quality of life."", 'timeFrame': '3 years post-treatment'}]",11.0,18 Years,,ALL,False,OTHER,0.0,140.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03977753,"Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts",2LVERU® or 2LVERU® JUNIOR,"['2LVERU® or 2LVERU® JUNIOR', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Common Wart,Labo'Life,2025-09-01T16:18:08.339375,True,,,,NOT_FOUND,Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.,,"['Common Wart', 'Flat Wart', 'Plantar Wart']",[],,2020-02-17,2027-03-16,"[{'measure': 'Disappearance of warts at the end of treatment (6-month visit)', 'description': 'A wart will be considered as disappeared if the colour and texture of the skin has returned to normal and can no longer be felt to the touch.', 'timeFrame': '6 months'}]","[{'measure': 'Disappearance of warts at 4 months.', 'timeFrame': '4 months'}, {'measure': 'Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months', 'timeFrame': '4 months'}, {'measure': 'Warts recurrence at 9 months', 'timeFrame': '9 months'}, {'measure': 'Pain evaluation during the study by visual analogic scale and consumption of antalgic medication.', 'description': 'Minimum value: 0 (better outcome) Maximum Value: 10 (worse outcome)', 'timeFrame': '6 months'}, {'measure': 'Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.', 'timeFrame': '6 months'}, {'measure': 'Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 6 months', 'timeFrame': '6 months'}]",7.0,3 Years,,ALL,False,INDUSTRY,0.0,162.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02749526,Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial,"""Endostar""","['Liposo', 'cisplatin', 'Gimeracil and Oteracil Potassium （Tegafur）', '""Endostar""']",4,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Esophageal,The First Affiliated Hospital with Nanjing Medical University,2025-09-01T16:18:25.986423,True,,,,NOT_FOUND,,,['Esophageal'],['Recombinant human endostatin，Endo'],low accrual rate,2016-04,2018-12,"[{'measure': 'R0 Resection rate', 'timeFrame': 'up to 8 months'}]","[{'measure': 'pCR rate', 'timeFrame': 'up to 10 months'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,70.0,ESTIMATED,v2_robust,True,False,True,False,low accrual rate,,,no_match,False,,,
NCT05832047,Aggressive Hydration With Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP Pancreatitis,Plasma solution (4-hour aggressive hydration),"['Plasma solution (4-hour aggressive hydration)', 'Hartmann Solution inno.N', '8-h AH', 'Plasma solution-A Inj.', '8-hour aggressive hydration', 'Lactated Ringer solution (4-hour aggressive hydration)']",6,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Pancreatic Disease,Do Hyun Park,2025-09-01T16:18:09.626239,True,,,,NOT_FOUND,"Aggressive Hydration With Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP (Endoscopic Retrograde Cholangiopancreatography) Pancreatitis : Multicenter, Double Blind, Randomized Controlled Trial",,['Pancreatic Disease'],"['ERCP', 'Endoscopic retrograde cholangiopancreatography', 'Pancreatitis']",,2023-06-19,2025-01-20,"[{'measure': 'Occurrence of pancreatitis after ERCP', 'description': 'The new onset or worsening of pain in the upper abdomen, accompanied by an elevation of pancreatic enzymes to at least three times the upper normal level within 24 hours after the procedure, requiring hospitalization for a minimum of two nights.', 'timeFrame': 'the next morning or within 24 hours after ERCP'}]","[{'measure': 'Occurrence of pancreatitis after ERCP at 4 hours after ERCP', 'description': 'The new onset or worsening of pain in the upper abdomen and the level of pancreatic enzymes is elevated\\>3 times the upper limit of normal level after 4 hours after ERCP', 'timeFrame': '4 hours after ERCP'}, {'measure': 'Number of Participants with Clinical signs of fluid overload', 'description': 'Clinical signs of fluid overload, for example, peripheral edema, pulmonary rales, increased jugular venous pressure, hepatojugular reflux, or both wll be monitored by investigator. If these signs are observed, hemodynamic testing or imaging studies will be done to investigate the evidence of pulmonary oedema, peripheral oedema, cardiac insufficiency and hypernatraemia.', 'timeFrame': '4 hours and, and the next morning or within 24 hours after ERCP'}, {'measure': 'Number of Participants with Asymptomatic Hyperamylasemia', 'description': 'Elevated level of serum amylase without upper abdominal pain', 'timeFrame': '4 hours and, the next morning or within 24 hours after ERCP'}, {'measure': 'Occurrence or aggravation of upper abdominal pain', 'description': 'Occurrence or aggravation of upper abdominal pain', 'timeFrame': '4 hours and, the next morning or within 24 hours after ERCP'}, {'measure': 'Days of ERCP-related hospital stay', 'description': 'Time for upper abdominal pain to disappear after the date of ERCP', 'timeFrame': 'Time for upper abdominal pain to disappear after the date of ERCP - up to 20 days'}]",6.0,18 Years,,ALL,False,OTHER,1.0,844.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00904020,"A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain",Lidoderm,"['Lidocaine patach 5%', 'Lidoderm']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postherpetic Neuralgia,Endo Pharmaceuticals,2025-09-01T16:18:12.184041,True,,,,NOT_FOUND,"A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain",,"['Postherpetic Neuralgia', 'Diabetic Neuropathy', 'Low Back Pain']",[],,2002-06,,"[{'measure': 'Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}]","[{'measure': 'Pain quality using the Neuropathic Pain Scale (NPS)', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Investigator and Patient Global Impression of Change', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Extent of numbness at the site of pain using the Numbness Questionnaire', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Patient Global Assessment of Pain Relief', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Safety assessments included Adverse Events (AE), discontinuation due to AEs, physical and neurological examination results, vital signs, clinical laboratory data, sensory testing, numbness testing, and dermal assessments', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'QoL: Pain interference (BPI Question 9)', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'QoL: Patient Global Assessment of Patch Satisfaction', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,107.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01012492,Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT,Abatacept,"['orencia', 'Abatacept']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,AML,Boston Children's Hospital,2025-09-01T16:18:17.171949,True,,,,NOT_FOUND,Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant,,"['AML', 'ALL', 'Undifferentiated Leukemia', 'Biphenotypic Leukemia', 'Refractory Anemia', 'Refractory Anemia With Ringed Sideroblasts', 'Refractory Cytopenia With Multilineage Dysplasia', 'Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts', 'Refractory Anemia With Excess Blasts-1 (5-10% Blasts)', 'Refractory Anemia With Excess Blasts-2 (10-20% Blasts)', 'Myelodysplastic Syndrome, Unclassified', 'MDS Associated With Isolated Del (5q)']","['cancer', 'leukemia', 'transplant', 'bone marrow']",,2009-11,2013-01,"[{'measure': 'Percentage of Participants With Grade III-IV Acute GVHD by Day 100.', 'description': 'Grade III-IV Acute GVHD by Day 100. The incidence of Gr III-IV acute GVHD was measured by the modified Glucksburg scale.', 'timeFrame': 'Day 100 post-transplant'}]","[{'measure': 'Percentage of Participants With Grades III-IV Acute GVHD at 2 Years', 'description': 'The rates of Grades III-IV acute GVHD were measured at 2 years according to standard Glucksberg criteria, which was 10%.', 'timeFrame': '2 years after transplant'}, {'measure': 'Hematologic and Immunologic Reconstitution', 'description': 'Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.', 'timeFrame': 'Day +100 post-transplant'}, {'measure': 'Protective Immunity', 'description': 'Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant', 'timeFrame': 'Day +365 post-transplant'}]",4.0,12 Years,,ALL,False,OTHER,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00453167,Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer,Paclitaxel,"['Gemcitabine', 'Paclitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Lung Cancer,"National Cancer Center, Korea",2025-09-01T16:18:19.662087,True,,,,NOT_FOUND,A Phase II Study of Weekly Paclitaxel and Gemcitabine as Second-line Therapy in Patients With Metastatic or Recurrence Small Cell Lung Cancer,,['Lung Cancer'],"['Small cell lung cancer', 'second-line therapy']",,2005-12,2010-03,"[{'measure': 'To evaluate the response rate of paclitaxel plus gemcitabine', 'timeFrame': 'the ratio between the number of responders and number of patients assessable for tumor response'}]","[{'measure': 'To access the toxicity', 'timeFrame': 'the first day of the treatment to 30 days after the last dose of study drug'}, {'measure': 'To estimate the time to progression', 'timeFrame': 'the first day of treatment to the date that disease progression is reported'}, {'measure': 'To examine the association between genotypes of paclitaxel biotransformation and the pharmacokinetics /', 'timeFrame': 'before the first treatment date, each response evaluation until disease progression'}, {'measure': 'To estimate the overall survival', 'timeFrame': 'the first day of treatment to death date'}]",5.0,18 Years,,ALL,False,OTHER_GOV,0.0,35.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03146325,Helicobacter Pylori and Body Iron in Adults,BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE,"['PYLERA', 'OTC OMEPRAZOLE', 'BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE', 'MATCHING PLACEBO']",4,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Helicobacter Pylori Infection,"The University of Texas Health Science Center, Houston",2025-09-01T16:18:25.989010,True,,,,NOT_FOUND,Helicobacter Pylori and Body Iron in Adults,,['Helicobacter Pylori Infection'],['H. pylori infection'],Study was not funded and PI has left the institution,2012-11,2016-08,"[{'measure': 'Serum Ferritin', 'description': 'Changes from baseline at 6 months after completing therapy, controlled by C-reactive protein', 'timeFrame': '6 months after completing therapy'}]","[{'measure': 'Body Iron', 'description': 'Changes from baseline estimated by the ratio of log base 10 of serum transferrin receptor over serum ferritin', 'timeFrame': '6 months after completing therapy'}, {'measure': 'Other markers of iron stores, and erythropoiesis', 'description': 'Changes from baseline transferrin saturation, zinc protoporphyrin to estimate free-erythrocyte protoporphyrin, and hemoglobin', 'timeFrame': '6 months after completing therapy'}]",3.0,18 Years,64 Years,ALL,True,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Study was not funded and PI has left the institution,,,no_match,False,,,
NCT05716919,Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule,Ivaltinostat,['Ivaltinostat'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Hematologic Malignancy,"Machaon Biotherapeutics, Inc.",2025-09-01T16:18:15.909681,True,,,,NOT_FOUND,"A Phase I, Double Blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'Ivaltinostat' Capsule in Healthy Male Volunteers",,"['Hematologic Malignancy', 'Solid Tumor', 'Fibrosis']",[],,2023-03-09,2023-12,"[{'measure': 'Plasma Pharmacokinetic measures (Cmax, Cmax-ss)', 'timeFrame': 'up to 4 weeks'}, {'measure': 'Plasma Pharmacokinetic measures (AUC max, AUCmax-ss)', 'timeFrame': 'up to 4 weeks'}]","[{'measure': 'The Number of Participants Who Experienced Serious or Non-Serious Adverse Events', 'timeFrame': 'Up to 4 weeks for each dosing cohort'}]",3.0,19 Years,50 Years,MALE,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00574470,Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD,"daclizumab, infliximab","['daclizumab, infliximab']",1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Graft vs Host Disease,University of Iowa,2025-09-01T16:18:07.028186,True,,,,NOT_FOUND,Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD,,['Graft vs Host Disease'],[],,2006-01,2008-08,"[{'measure': 'Complete or partial response of GVHD to treatment according to standard staging/grading scale', 'timeFrame': '28 days'}]","[{'measure': 'incidence of chronic GVHD and overall survival', 'timeFrame': '9 months'}]",2.0,18 Years,,ALL,False,OTHER,0.0,3.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02239562,sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS,sPIF,"['synthetic PreImplantation Factor', ""Ringer's lactated solution"", 'sPIF', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Autoimmune Hepatitis,"Christopher O'Brien, MD",2025-09-01T16:18:18.422791,True,,,,NOT_FOUND,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis",,['Autoimmune Hepatitis'],"['sPIF', 'synthetic PreImplantation Factor', 'Autoimmune', 'Liver', 'Hepatitis']",,2014-11-14,2016-12-29,"[{'measure': 'Safety/Tolerability Measured by Clinical Laboratory Tests, Metabolics, Cytokines, Anti-PIF Antibody, Periodic Physical Examination, Including Vital Signs Measurements and 12-lead ECG', 'description': 'Single Ascending Dose (SAD):\n\nAdverse events, concomitant medications: Days 1, 2, 3, 5, 8 Vital signs, Physical exams: Days 1, 2, 8 Complete blood counts (CBC), Serum chemistry, Liver function tests, Pharmacokinetics: Days 1, 2, 8 Lipids, Coagulation, Urinalysis, Pregnancy test: Days 1, 8 EKG, chest x-ray (CXR): Days 1 and 8\n\nMultiple Ascending Dose (MAD):\n\nAdverse events, concomitant medications: Days 1, 2, 3, 4, 5, 8, 15, 29 Vital signs, Physical exams: Days 1, 2, 3, 4, 5, 8, 15, 29 CBC, Serum chemistry, Liver function tests, Pharmacokinetics: Days 1, 3, 5, 8, 15, 29 Lipids, Coagulation, Urinalysis, Pregnancy test, EKG: Days 1, 5, 29 CXR: Days 1, 29', 'timeFrame': '29 Day'}]","[{'measure': 'Number of Participants With Anti-sPIF Antibodies and Drug Interactions', 'description': 'Following sPIF administration, using a validated assay, serum samples were tested for anti-sPIF antibodies', 'timeFrame': '29 Day'}]",2.0,18 Years,70 Years,FEMALE,False,OTHER,1.0,36.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00427128,Prozac Treatment of Major Depression: Discontinuation Study,fluoxetine,"['fluoxetine', 'Prozac', 'placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Major Depression,New York State Psychiatric Institute,2025-09-01T16:18:08.344952,True,,,,CHEMBL41,Prozac Treatment of Major Depression: Discontinuation Study,,['Major Depression'],"['Major Depression', '""true drug"" response', '""placebo response"" pattern', 'continuation treatment outcomes']",,1995-11,2003-03,"[{'measure': 'MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)', 'timeFrame': 'up to 9 mos.'}, {'measure': 'Ham-D', 'timeFrame': 'up to 9 mos.'}, {'measure': 'CGI', 'timeFrame': 'up to 9 mos.'}]",[],3.0,18 Years,65 Years,ALL,False,OTHER,1.0,627.0,ACTUAL,v2_robust,True,True,False,False,,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,CHEMBL41,exact_match,True,309.33,4.44,4.0
NCT00122863,Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,Duloxetine Hydrochloride,"['Duloxetine Hydrochloride', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Anxiety Disorders,Eli Lilly and Company,2025-09-01T16:18:08.352371,True,,,,NOT_FOUND,Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,,['Anxiety Disorders'],[],,2005-01,2007-03,[{'measure': 'Assess the long-term maintenance of efficacy of duloxetine 60 to 120 mg QD compared with placebo by a comparison of the time to relapse among patients with GAD who responded to duloxetine during the open-label acute therapy phase after 22 to 26 weeks.'}],"[{'measure': 'Self-reported anxiety symptomatology'}, {'measure': 'Pain'}, {'measure': 'Quality of Life'}, {'measure': 'Clinical Global Improvement and HAMA Factor scores'}, {'measure': 'Maintenance of Effect'}]",6.0,18 Years,,ALL,False,INDUSTRY,1.0,380.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00694044,"Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects",varenicline,"['Placebo', 'Champix, Chantix', 'varenicline']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Pfizer,2025-09-01T16:18:19.666262,True,,,,NOT_FOUND,"A Randomized, Investigator and Subject Blind, Sponsor Open Parallel Group Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pro-Cognitive Effects of Varenicline, Under Various Titration Schemes, in Healthy Elderly Non-Smoking Subjects",,"['Healthy', 'Non-Smoking']","['Safety, Tolerability, Pharmacokinetics, Cognition']",,2008-04,2008-06,"[{'measure': 'Tolerability and safety (adverse events, electrocardiogram, vital signs, clinical safety labs, self reported nausea visual analogue scales)', 'timeFrame': '21 days'}, {'measure': 'Steady state pharmacokinetics', 'timeFrame': '21 days'}, {'measure': 'Effects on cognition (computerized battery of cognitive tests)', 'timeFrame': '21 days'}]","[{'measure': 'No secondary outcomes.', 'timeFrame': 'Time frame n/a'}]",4.0,65 Years,85 Years,ALL,True,INDUSTRY,0.0,50.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05635734,Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma,Azeliragon 5 mg,"['Azeliragon 5 mg', 'Azeliragon 10 mg', 'Azeliragon 20 mg']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,ACTIVE_NOT_RECRUITING,Glioblastoma,Cantex Pharmaceuticals,2025-09-01T16:18:24.757275,True,,,,NOT_FOUND,A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined with Conventional Concurrent Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma,,['Glioblastoma'],"['Azeliragon', 'Newly diagnosed glioblastoma', 'Dose finding', 'Temozolomide', 'Radiotherapy']",,2023-09-05,2025-12,"[{'measure': 'Recommended phase 2/3 dose', 'description': 'To assess the recommended phase 2/3 dose (RP2/3D) in mg/day of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.\n\nDose limiting toxicities were defined as listed AEs, dose-reductions, treatment interruptions, or discontinuation occurring during the DLT period (28 days), which are attributable (definite, probable, possible) to azeliragon will be classified as a DLT. 6 patients must be treated at that dose level with ≤ 1 DLT observed', 'timeFrame': 'Throughout the DLT observation period, approximately 28 days per patient'}]","[{'measure': 'Incidence of adverse events (AEs)', 'description': 'Percentage of patients experiencing an adverse event', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Incidence of serious adverse events (SAEs)', 'description': 'Percentage of patients experiencing a serious adverse event', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Disease control rate (DCR)', 'description': 'Percentage of patients who experience a complete response, partial response or stable disease according to Response Assessment in Neuro-Oncology (RANO) criteria as their best response throughout the study', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as the duration of time from start of treatment to time of death', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Patients with changes in the Eastern Cooperative Oncology Group (ECOG) performance status', 'description': 'Percentage of patients who experience a change in ECOG status through the study', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'S100A9 expression levels', 'description': 'Expression levels of the S100A9 molecular biomarker in blood samples from patients. Samples will be taken at baseline, Week 10 and after progression', 'timeFrame': 'Throughout the study period, approximately 2 years per patient in 3 occasions for each patient'}]",8.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,18.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01261637,Abdominal Wall Local Anesthesia to Maximize Postoperative Pain Control After Cesarean Delivery,Saline placebo,"['Ropivicaine', 'Naropin', 'Saline placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postoperative Pain,IWK Health Centre,2025-09-01T16:18:13.420920,True,,,,NOT_FOUND,Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.,,['Postoperative Pain'],"['cesarean, pain, transversus abdominus plane block']",,2009-07,2011-01,"[{'measure': 'The primary outcome will be postoperative pain, measured by an NRS, the quality of recovery score (QoR) and a Self Assessment Diary in the first 24h postoperative period.', 'timeFrame': '24 hours'}]","[{'measure': 'NRS / QoR - 48 hour Opioid Consumption Side effects - nausea, sedation', 'timeFrame': '48 hours'}, {'measure': 'TAP block success rates and duration of block effect will be assessed using a patient diary completed every 2 hours while the patient is awake.', 'timeFrame': '24 hours'}, {'measure': 'Persistant pain outcomes will be assessed at 30 days and 6 months using 5-minute SF-36 health survey.', 'timeFrame': '6 months'}]",4.0,18 Years,,FEMALE,True,OTHER,0.0,86.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT07089901,Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment,transdermal nicotine replacement therapy,"['NRT, nicotine patch', 'transdermal nicotine replacement therapy']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Smoking,Duke University,2025-09-01T16:18:19.659154,True,,,,CHEMBL3,Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment,,['Smoking'],[],,2025-11-01,2030-07-14,"[{'measure': 'Average number of days to smoking relapse', 'description': 'Participants will self-report smoking from quit date to the 6-month follow-up visit. Days to relapse will be defined as the first of seven consecutive days of smoking.', 'timeFrame': 'From quit date to 6-month follow-up (about 6.5 months)'}]","[{'measure': 'Number of participants who self-report 7-day point prevalence abstinence', 'description': '7-day point prevalence abstinence is defined as no smoking in the prior 7 days.', 'timeFrame': '1-month follow-up (around 1.5 months after beginning treatment)'}, {'measure': 'Number of participants who self-report 7-day point prevalence abstinence', 'description': '7-day point prevalence abstinence is defined as no smoking in the prior 7 days.', 'timeFrame': '3-month follow-up (around 3.5 months after beginning treatment)'}, {'measure': 'Number of participants who self-report 7-day point prevalence abstinence', 'description': '7-day point prevalence abstinence is defined as no smoking in the prior 7 days.', 'timeFrame': '6-month follow-up (around 6.5 months after beginning treatment)'}]",4.0,21 Years,,ALL,False,OTHER,1.0,600.0,ESTIMATED,v2_robust,True,False,False,False,,CN1CCC[C@H]1c1cccnc1,CHEMBL3,partial_match,True,162.24,1.85,4.0
NCT03646604,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis",Upadacitinib (ABT-494),"['ABT-494', 'Upadacitinib (ABT-494)', 'RINVOQ']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Atopic Dermatitis,AbbVie,2025-09-01T16:18:19.671728,True,,,,NOT_FOUND,"An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis",,['Atopic Dermatitis'],"['Upadacitinib', 'ABT-494', 'Atopic Dermatitis', 'RINVOQ']",,2019-01-31,2024-08-29,"[{'measure': 'Maximum Plasma Concentration (Cmax)', 'description': 'It is defined as the maximum observed plasma concentration (Cmax) for upadacitinib.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Time to Maximum Observed Plasma Concentration (Tmax)', 'description': 'It is defined as the time to maximum plasma concentration (Tmax) of upadacitinib.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Area under the plasma concentration-time curve within a dosing interval (AUCtau)', 'description': 'The area under the plasma concentration-time curve (AUCtau) is a method of measurement of the total exposure of a drug in plasma.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Oral Clearance', 'description': 'Clearance is defined the volume of plasma cleared of the drug per unit time.', 'timeFrame': 'Up to 7 days'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAE)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.', 'timeFrame': 'Up to 2 years'}]",[],5.0,2 Years,12 Years,ALL,False,INDUSTRY,0.0,35.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04252586,"A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",GWP42003-P,"['GWP42003-P', 'Epidiolex', 'Cannabidiol', 'CBD', 'CBD-OS']",5,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Rett Syndrome,Jazz Pharmaceuticals,2025-09-01T16:18:07.027993,True,,,,NOT_FOUND,"An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",,"['Rett Syndrome', 'RTT']","['Cannabidiol', 'CBD', 'Epidiolex', 'GWP42003-P']",Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).,2020-02-28,2021-06-09,"[{'measure': 'Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs', 'description': 'Adverse events (AEs) were defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a pre-existing condition that occurs during the study. TEAEs were defined as the AEs that started or worsened in severity or seriousness following the first dose of GWP42003-P. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE'}, {'measure': 'Number of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose', 'description': 'Treatment-emergent clinical parameters were defined as the following: Treatment-emergent alanine transferase (ALT) \\> 3×upper limit of normal (ULN), \\> 5×ULN and \\> 8×ULN; Treatment-emergent aspartate aminotransferase (AST) \\> 3×ULN, \\> 5×ULN and \\> 8×ULN; Treatment-emergent ALT or AST \\> 3×ULN, \\> 5×ULN and \\> 8×ULN; Treatment-emergent ALT or AST \\> 3×ULN and either bilirubin \\> 2×ULN or international normalized ratio (INR) \\> 1.5.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose', 'description': 'Potentially clinically significant vital sign values of blood pressure (BP) were defined as sitting systolic BP (mmHg) change: \\< -20 or \\> 20 mmHg and sitting diastolic BP change: \\< -10 or \\> 10 mmHg. Vital sign measurements were taken in a sitting position at rest for 5 minutes. Blood pressure readings were recorded using the same arm throughout the trial, when possible.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE'}, {'measure': 'Number of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose', 'description': 'Potentially clinically significant vital sign values of pulse rate were defined as pulse rate change: \\< -10 or \\> 10 beats per minute. Vital sign measurements were taken in a sitting position at rest for 5 minutes.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE'}, {'measure': 'Number of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose', 'description': 'Clinically significant body weight changes were defined as the percent change in body weight (≤7% change or ≥7% change).', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result', 'description': 'Electrocardiogram assessments were performed for QTcB and QTcF \\>450 msec, \\>480 msec, and \\>500 msec. QTcB = corrected QT interval with Bazette correction. QTcF = QTc corrected by Fridericia.', 'timeFrame': 'Visit 4 (Day 29) up to Visit 15 (Day 739) in the OLE'}, {'measure': 'Number of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose', 'description': 'Participants were evaluated for any changes to typical menstrual cycles, duration of menstrual cycles, and typical strength of the menstrual cycles during the study.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose', 'description': 'Suicidal ideation and behavior was assessed by the investigator via a clinical interview with the caregiver. The questionnaire included following questions: Has the child expressed any wish to be dead?, Has the child made any suicide attempts?, Has the child shown any non-suicidal self-injurious behavior? The responses were recorded as Yes/No.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment', 'description': 'Blood samples were collected to assess changes in serum IGF-1 levels. A negative mean change from baseline indicates a reduction in IGF-1 levels.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Number of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment', 'description': 'Pubic hair growth and breast development of all adolescents were assessed by the investigator or caregiver using Tanner Staging categorization from 1 to 5.\n\nStage 1- No glandular tissue; areola follows skin contours of chest; No pubic hair Stage 2- Breast bud forms; areola begins to widen; a small amount of long, downy hair with slight pigmentation on labia majora Stage 3- Breast begins to become more elevated and extends beyond borders of the areola, which continues to widen but remains in contour with surrounding breast; Hair becomes more coarse and curly and begins to extend laterally Stage 4- Increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast; Adult-like hair quality, extending across pubis but sparing medial thighs Stage 5- Breast reaches final adult size; areola returns to the contour of the surrounding breast, with a projecting central papilla; Hair extends to medial surface of the thigh.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}]","[{'measure': 'Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment', 'description': 'RSBQ is a caregiver-completed questionnaire that assesses the overall condition (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is ""not true as far as you know,"" 1 indicating an item is ""somewhat or sometimes true,"" and 2 indicating an item that is ""very true or often true"". "" Item 31 (""Uses eye gaze to convey feelings, needs and wishes"") is reverse-scored (0 indicating ""very true or often true"", 1 indicating ""somewhat or sometimes true,"" and 2 indicating ""not true as far as you know""). The total summed score ranges from 0 to 90, with higher scores representing greater severity. A negative mean change from baseline indicates an improvement in overall condition.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment', 'description': ""CGI-I is a 7-point scale that requires the clinician to assess whether a patient's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. The mean continuous CGI-I score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher mean scores indicate worse condition."", 'timeFrame': 'Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment', 'description': ""CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This was rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =severely ill; or 7 = extremely ill. The mean continuous CGI-S score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher scores indicate more severe disease."", 'timeFrame': 'Visit 14 (Day 729) in the OLE'}, {'measure': ""Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment"", 'description': 'CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales:bedtime resistance (score range 6-18), sleep onset delay (range 1-3), sleep duration (range 3-9), sleep anxiety (range 4-12), night wakings (range 3-9), parasomnias (range 7-21), sleep-disordered breathing (range 3-9), daytime sleepiness (range 8-24). The 33 items range from 1 to 3, where 3=""usually"" (≥5 times/week), 2=""sometimes"" (2-4 times/week), and 1=""rarely"" (≤1 time/week); for items 31 and 32, 3=fall asleep, 2=very sleepy, 1=not sleepy. A score of 3 indicates greater severity; however, 6 items (1-Goes to bed at same time; 3-Falls asleep in own bed; 26-Wakes by himself; 2-Falls asleep in 20 minutes; 10-Sleeps the right amount; 11-Sleeps same amount each day) are reverse scored. The total summed score ranges from 33 to 99, with higher scores indicating disturbed sleep behavior. A negative mean change from baseline indicates improvement in sleep.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}, {'measure': 'Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment', 'description': 'MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. The MBA-9 includes 9 items (Regression of motor skills; Poor eye/social contact; Lack of sustained interest; Does not reach for objects or people; Chewing difficulties; Speech disturbance; Hand clumsiness; Dystonia; and Hypertonia/rigidity). For each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. A negative mean change from baseline indicates improvement in behavior.', 'timeFrame': 'Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE'}]",15.0,2 Years,18 Years,ALL,False,INDUSTRY,1.0,21.0,ACTUAL,v2_robust,True,False,True,True,Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).,,,no_match,False,,,
NCT05319249,Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia,Talazoparib 1 MG [Talzenna],"['Talazoparib 1 MG [Talzenna]', 'Talzenna']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,NOT_YET_RECRUITING,Acute Myeloid Leukemia,German Cancer Research Center,2025-09-01T16:18:14.666294,True,,,,NOT_FOUND,Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid Leukemia,,['Acute Myeloid Leukemia'],[],,2024-06,2028-06,"[{'measure': 'complete remission (CR/CRi)', 'description': 'response defined as complete remission (CR/CRi) for patients with overt leukemia at time of inclusion and MRD decrease \\>1log10 for patients with rising MRD at time of inclusion.', 'timeFrame': 'Collected at a minimum at baseline, day 28 and latest on day 42'}]","[{'measure': 'EFS - Event-free survival', 'description': 'Event-free survival', 'timeFrame': 'EFS is defined as the time of entry into the study to the date of primary refractory disease, or relapse from CR, or CRi, or death from any cause, whichever comes first, assessed up to 42 days.'}, {'measure': 'RFS -Relapse-free survival', 'description': 'RFS is defined only for patients achieving CR or CRi', 'timeFrame': 'Defined as the time from achieving a remission until the date of relapse or death from any cause, whichever comes first, assessed up to 42 days.'}, {'measure': 'OS - Overall survival', 'description': 'Overall survival', 'timeFrame': 'OS is defined as the time from entry into the trial to the date of death from any cause, assessed up to 42 days.'}, {'measure': 'MRD', 'description': 'Measurable Residual Disease', 'timeFrame': 'Collected at a minimum at baseline, day 28 and latest on day 42'}, {'measure': 'QoL - Quality of life - QLQ-C30', 'description': 'Validated 30-item self-assessment questionnaire to assess quality of life aspects. The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) with higher scores meaning a higher level of fatigue.', 'timeFrame': 'QoL is assessed at baseline and latest on day 42.'}]",6.0,18 Years,,ALL,False,OTHER,0.0,54.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05176314,A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants,Rosuvastatin,"['Pirtobrutinib', 'LY3527727', 'Rosuvastatin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Loxo Oncology, Inc.",2025-09-01T16:18:08.354179,True,,,,NOT_FOUND,"A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Single and Multiple Doses of Pirtobrutinib on the Pharmacokinetics of Rosuvastatin in Healthy Participants",,['Healthy'],[],,2022-01-11,2022-04-20,"[{'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin', 'description': 'PK: Cmax of Rosuvastatin', 'timeFrame': 'Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin', 'description': 'PK: AUC(0-inf) of Rosuvastatin', 'timeFrame': 'Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.'}]",[],2.0,18 Years,64 Years,ALL,True,INDUSTRY,1.0,32.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02457858,Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study,Islet isolation using BMX-010,"['Islet isolation using BMX-010', 'MnTE-2-PyP']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Type 1 Diabetes,University of Alberta,2025-09-01T16:18:14.667195,True,,,,NOT_FOUND,Manganese Porphyrin MnTE-2-PyP (BMX - 010) Preservation of Islet Cell Mass and Function for Clinical Islet Transplantation,,['Type 1 Diabetes'],"['Type 1 Diabetes', 'Islet Transplant']",,2014-08,2016-08,"[{'measure': 'Islet yield using BMX-010, compared to current standard islet isolation data', 'description': 'To assess the safety of treating pancreata using BMX-010 prior to islet transplantation, treated islet isolation data will be measured and recorded, compared to current standard islet isolation data.', 'timeFrame': 'Day -1 pre-transplant (Islet yield will be recorded as standard-of-care routine practice)'}]","[{'measure': 'Islet isolation quantity and quality using BMX-010, compared to current standard islet isolation data', 'description': 'To demonstrate efficacy of BMX-010 to improve islet isolation quantity and quality prior to islet transplantation, treated islet isolation data will be measured and recorded, compared to current standard islet isolation data.', 'timeFrame': 'Day -1 pre-transplant (Islet isolation quantity and quality will be recorded as standard-of-care routine practice)'}, {'measure': 'AE/SAE morbidity within 1 month post-transplant', 'description': 'To demonstrate safety of BMX-010 in islet transplantation, Adverse Event/Serious Adverse Event morbidity within 1 month post-transplant will be recorded.', 'timeFrame': 'up to 1 month post-transplant'}]",3.0,18 Years,68 Years,ALL,False,OTHER,1.0,5.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00896428,Effects of Gallopamil in Severe Asthma,Methoxyverapamil (gallopamil),"['Methoxyverapamil (gallopamil)', 'Placebo.']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Asthma,"University Hospital, Bordeaux",2025-09-01T16:18:19.661365,True,,,,CHEMBL6966,Effects of Gallopamil on Bronchial Smooth Muscle Remodelling in Severe Asthma: a Double Blind Study.,,['Asthma'],"['Asthma', 'gallopamil', 'airway remodelling', 'smooth muscle']",,2009-12,2012-11,"[{'measure': 'Bronchial smooth muscle remodelling assessed by optic microscopy.', 'timeFrame': 'Before and after 12 months treatment.'}]","[{'measure': 'Bronchial smooth muscle remodelling assessed by electron microscopy', 'timeFrame': 'Before and after 12 months treatment.'}, {'measure': 'Bronchial smooth muscle mitochondrial number and activity assessed in vitro', 'timeFrame': 'Before and after 12 months treatment.'}, {'measure': 'Bronchial thickness assessed by 3D analysis of computed tomography', 'timeFrame': 'Before and after 12 months treatment.'}, {'measure': 'Asthma control using asthma control questionnaire, inflammation monitoring, number of hospitalizations, number of emergency visits, number of unplanned medical visits.', 'timeFrame': 'Once per month for 12 months.'}]",5.0,18 Years,,ALL,False,OTHER,0.0,31.0,ACTUAL,v2_robust,True,True,False,False,,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,CHEMBL6966,partial_match,True,454.61,5.09,4.0
NCT06660134,Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF,Glucagon-like peptide-1 receptor agonists (GLP 1 RA),['Glucagon-like peptide-1 receptor agonists (GLP 1 RA)'],1,INTERVENTIONAL,['NA'],,COMPLETED,Type 2 Diabetes Mellitus (T2DM),Shanghai Chest Hospital,2025-09-01T16:18:19.666927,True,,,,NOT_FOUND,Strict Weight Management and Glycemic Control Based on Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment VS. Conventional Antidiabetic Drugs for Ablation Outcomes in Overweight or Obese Patients with Type 2 Diabetes and Atrial Fibrillation,,"['Type 2 Diabetes Mellitus (T2DM)', 'Atrial Fibrillation (AF)']","['Catheter ablation', 'Glucagon-like Peptide-1 receptor agonist', 'Atrial fibrillation', 'overweight', 'obesity']",,2021-08-01,2024-01-10,"[{'measure': 'Atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia events lasting ≥30 seconds occurring from the end of a 3-month blanking period post-procedure up to 12 months of follow-up.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}]","[{'measure': 'Changes in Body Mass Index (BMI) from baseline to 12 months.', 'description': 'Combine weight and height, and report the Body Mass Index (BMI) in units of kilograms per square meter (kg/m²).', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3 month blanking period'}, {'measure': 'Quality of life assessments.', 'description': 'The quality of life and cardiac function of the subjects were assessed using the World Health Organization Quality of Life (WHOQOL-100) questionnaire.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Complications associated with AF ablation and serious adverse events (such as rehospitalizations, cardiovascular rehospitalizations) occurring during the study period.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Quality of life assessments', 'description': 'Quality of life assessments were conducted within at least 12 months of follow-up using measures such as the AF6.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Quality of life assessments', 'description': 'Quality of life assessments were conducted using the AFEQT (Atrial Fibrillation Effect on Quality of Life) questionnaire.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Psychological distress', 'description': 'Psychological distress was assessed using the HADS (Hospital Anxiety and Depression Scale).', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}, {'measure': 'Functional status', 'description': 'Functional status was assessed using the CCS-SAF (Canadian Cardiovascular Society - Self-Assessed Functioning scale).', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3 month blanking period'}, {'measure': 'quality of life', 'description': 'The quality of life and cardiac function of the subjects were assessed using the New York Heart Association (NYHA) functional classification.', 'timeFrame': 'at least 12 months of follow-up, beyond the initial 3-month blanking period'}]",9.0,18 Years,,ALL,False,OTHER,3.0,174.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,Acyclovir,"['Loratadine', 'Paracetamol', 'Dexchlorpheniramine', 'Ceterizine', 'alemtuzumab GZ402673', 'Acyclovir', 'Methylprednisolone']",7,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Progressive Multiple Sclerosis,"Genzyme, a Sanofi Company",2025-09-01T16:18:13.417051,True,,,,CHEMBL1349,"A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis",,['Progressive Multiple Sclerosis'],[],,2015-12-06,2021-03-01,"[{'measure': 'Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}]","[{'measure': 'Change from baseline in lymphocyte subsets after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}, {'measure': 'Change from baseline in total lymphocyte count after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}, {'measure': 'Change from baseline in helper/suppressor ratio after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: maximum plasma concentration observed (Cmax)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: time to reach Cmax (Tmax)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration versus time curve from time zero until the last measurable concentration (AUClast)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration (AUC)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: terminal half-life (t1/2z)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Number of patients with adverse events', 'timeFrame': '4 years'}, {'measure': 'Number of patients with adverse events of special interest', 'timeFrame': '4 years'}, {'measure': 'Number of patients with injection site reactions', 'timeFrame': '2 years'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,CHEMBL1349,partial_match,True,324.34,-0.8,4.0
NCT00836693,Effect of Tadalafil Once a Day in Men With Erectile Dysfunction,tadalafil,"['tadalafil', 'placebo', 'Cialis', 'LY450190']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Erectile Dysfunction,Eli Lilly and Company,2025-09-01T16:18:08.353510,True,,,,CHEMBL779,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors",,['Erectile Dysfunction'],['Erectile Dysfunction'],,2009-01,2010-01,"[{'measure': 'Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12', 'description': 'Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 2. ""Were you able to insert your penis into your partner\'s vagina?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Sexual Encounter Profile (SEP) Diary, Question 3 Change From Baseline to Week 12 in Percentage of Yes Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 3. ""Did your erection last long enough for you to have successful intercourse?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}]","[{'measure': 'Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Number of Erectile Events Per Night', 'description': ""NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The man wears the device for three nights prior to visit 2 (baseline), visit 5 (end of randomised treatment) and visit 6 (end of follow-up). Data are entered for the 2 nights prior to the visit. During the night the man may have multiple erections. The number of erections is recorded."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Duration of Erectile Events Per Night', 'description': ""NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The duration of erections are measured and recorded. Data presented are the duration of erectile events at baseline and the change from baseline to Week 12."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Nocturnal Penile Tumescence (NPT) Pattern: Percentage Volumetric Change', 'description': ""NPT was measured using electrobioimpedance volumetric assessment (NEVA). The NEVA device measures a man's erections during the night. The percent of volume change of the penis during erections is measured and recorded for each erection. Data presented are mean percentage of volumetric change from baseline to Week 12."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in the Frequency of Spontaneous Morning Erections Captured by Patient Diary', 'description': 'The morning erection diary allows the participant to record whether he experienced an erection on waking. The participant is to complete the morning erection diary every morning during the run-in, treatment and follow-up periods. The percentage of mornings the participant reported an erection is analysed.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'The Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 12 Week Endpoint', 'description': 'The subject questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score will be obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), and multiplying by 25, thus obtaining a score that ranges from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction).', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Total and Subdomain Scores of the Self-Esteem and Relationship (SEAR) Questionnaire', 'description': 'SEAR measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). All questions except negatively worded questions 8 and 11 are scored from 1=almost never/never to 5=almost always/always. Questions 8 and 11 were reverse scored, thus a higher score signifies a more favorable response for all 14 items. Overall score is transformed into a 0 (least favorable) to 100 (most favorable) scale.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Orgasmic Functions (OF)', 'description': 'Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 2 questions of the IIEF-OF domain range from 0 to 10.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Sexual Desire (SD)', 'description': 'Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-SD domain range from 0 to 10.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Intercourse Satisfaction (IS)', 'description': 'Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF), Overall Satisfaction (OS)', 'description': 'Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 1 Percentage of ""Yes"" Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 1. ""Were you able to achieve at least some erection (some enlargement of the penis)? "" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 4 Percentage of ""Yes"" Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 4. ""Were you satisfied with the hardness of your erection?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change From Baseline to 12 Week Endpoint in Sexual Encounter Profile (SEP) Question 5 Percentage of ""Yes"" Responses', 'description': 'Assessed was the mean change from baseline in the percentage of Yes responses to the SEP diary Question 5. ""Were you satisfied overall with this sexual experience?"" Data are presented as the mean percentage of yes responses per participant.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Global Assessment Question (GAQ) Question 1 at 12 Week Endpoint', 'description': 'GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.', 'timeFrame': 'Week 12'}, {'measure': 'Global Assessment Question (GAQ) Question 2 at 12 Week Endpoint', 'description': 'GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from 1=very much better to 7=very much worse.', 'timeFrame': 'Week 12'}]",18.0,18 Years,,MALE,False,INDUSTRY,0.0,217.0,ACTUAL,v2_robust,True,True,False,False,,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O,CHEMBL779,exact_match,True,389.41,2.21,4.0
NCT00987246,Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis,Placebo Gel,"['Placebo Gel', 'LAS106521', 'LAS41005']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Actinic Keratosis,"Almirall, S.A.",2025-09-01T16:18:18.423079,True,,,,NOT_FOUND,Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II,,['Actinic Keratosis'],"['Actinic Keratosis', 'AK', 'NMSC', 'Combination']",,2008-06,2009-06,"[{'measure': 'Histological status of AK target lesion', 'timeFrame': 'Day 140'}]",[],1.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,470.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03590652,"Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma",Ixazomib,"['Ninlaro', 'Pomalidomide', 'Ixazomib', 'Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)', 'Darzalex Faspro', 'Dexamethasone', 'Decadron', 'Pomalyst']",8,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Relapsed/Refractory Multiple Myeloma,"University of California, San Diego",2025-09-01T16:18:09.625811,True,,,,CHEMBL2141296,"Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)",,['Relapsed/Refractory Multiple Myeloma'],"['multiple myeloma', 'relapsed/refractory multiple myeloma', 'Daratumumab', 'Pomalidomide', 'Ixazomib', 'Dexamethasone', 'cancer', 'Phase 2', 'Darzalex', 'Pomalyst', 'Ninlaro', 'Decadron']",,2018-10-17,2026-10-01,"[{'measure': 'Overall Response Rate', 'description': 'Anti-cancer response as defined by the International Uniform Response Criteria Consensus Recommendations', 'timeFrame': '2 years'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Treatment-emergent Grade 2-5 adverse events (AEs) will be assessed using NCI CTCAE v4.03 toxicity criteria', 'timeFrame': '2 years'}]","[{'measure': 'Clinical benefit rate', 'description': 'CBR: minimal response +ORR', 'timeFrame': '2 years'}, {'measure': 'Progression free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the duration of time from start of treatment until objective tumor progression or death', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Time to progression', 'description': 'Time to progression is defined as the duration of time from start of treatment until objective tumor progression.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival is defined as the duration of time from start of treatment to death', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}, {'measure': 'Minimal Residual Disease (MRD)', 'description': 'Assessment on the presence of minimal residual disease for those in stringent complete response', 'timeFrame': '1 year'}, {'measure': 'Quality of life (QOL) scores', 'description': 'Cancer Therapy Satisfaction Questionnaire and EORTC QLQ-MY20', 'timeFrame': '2 years'}]",8.0,18 Years,,ALL,False,OTHER,3.0,46.0,ESTIMATED,v2_robust,True,False,False,True,,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,CHEMBL2141296,exact_match,True,361.03,,4.0
NCT03168139,Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer,Olaptesed pegol - Monotherapy,"['NOX-A12', 'NOX-A12, Keytruda, MK-3475', 'Olaptesed pegol - Monotherapy', 'Olaptesed pegol + Pembrolizumab - Combination Therapy']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Metastatic Colorectal Cancer,TME Pharma AG,2025-09-01T16:18:19.657685,True,,,,NOT_FOUND,"A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer",,"['Metastatic Colorectal Cancer', 'Metastatic Pancreatic Cancer']","['Metastatic colorectal cancer', 'Metastatic pancreatic cancer', 'NOX-A12', 'Olaptesed pegol', 'Spiegelmer', 'Pembrolizumab', 'PD-1 inhibitor', 'Stromal cell-derived factor-1 (SDF-1)', 'CXCL12', 'Tumor microenvironment', 'Immunotherapy', 'Checkpoint inhibition']",,2017-04-18,2020-03-25,"[{'measure': 'Monotherapy: Pharmacodynamics', 'description': 'Evaluation of changes within the tumor microenvironment induced by CXCL12 inhibition with olaptesed pegol by comparing pre- and post-treatment biopsy specimens', 'timeFrame': 'up to 14 days'}, {'measure': 'Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratory', 'description': 'Safety and tolerability of olaptesed pegol in combination with pembrolizumab will be evaluated by assessing adverse events, vital signs (pulse rate, blood pressure), 12-lead ECG, hematology (full blood count including platelets and differential count), safety laboratory including thyroid function tests', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Monotherapy: Safety', 'description': 'Assessment of safety and tolerability of olaptesed pegol in patients with metastatic (stage IV) colorectal and pancreatic cancer (adverse events, vital signs (pulse rate, blood pressure), 12-lead ECG, hematology (full blood count including platelets and differential count), safety laboratory)', 'timeFrame': 'up to 14 days'}, {'measure': 'Monotherapy: Pharmacodynamics', 'description': 'Investigation of changes in the cytokine/chemokine signature within the tumor microenvironment and in the peripheral blood induced by CXCL12 inhibition with olaptesed pegol by comparing the pre- and post-treatment samples', 'timeFrame': 'up to 14 days'}, {'measure': 'Combination Therapy: Disease control rate (DCR)', 'description': 'DCR will be calculated as the proportion of patients with best overall response to treatment with olaptesed pegol in combination with pembrolizumab of complete response (CR), partial response (PR) or stable disease (SD).\n\nTreatment responses will be assessed according to the current guidelines of the RECIST 1.1 and irRECIST.', 'timeFrame': 'up to 24 months'}, {'measure': 'Combination Therapy: Efficacy - time to event analyses', 'description': 'Efficacy of treatment with olaptesed pegol in combination with pembrolizumab (PFS and OS)', 'timeFrame': 'up to 24 months'}]",6.0,18 Years,,ALL,False,INDUSTRY,1.0,20.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04763343,Ketamine Treatment of Youth Suicide Attempters,Ketamine Hydrochloride,"['Saline', 'Ketamine Hydrochloride']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,"Suicide, Attempted","Tatiana Falcone, MD",2025-09-01T16:18:17.186170,True,,,,CHEMBL1714,Ketamine Treatment of Youth Suicide Attempters for Fast Reduction of Severe Suicide Risk and Facilitation of Long-term Collaborative Clinical Engagement: A Double Blind Randomized Placebo Controlled Trial,,"['Suicide, Attempted']",[],,2022-06-27,2026-09,"[{'measure': 'Rate of remission of suicidal symptoms at the end of treatment.', 'description': 'Remission of suicide symptoms will be defined by a 50% or greater reduction in the clinician-rated baseline Beck Scale for Suicidal Ideation (SSI) score, and SSI score less than the score of 4. SSI scores can range from 0 to 38, and a higher score indicates increased severity of suicidal ideation. The primary outcome of the remission rate will be compared between the two groups.', 'timeFrame': 'Up to 3 months post-discharge'}]","[{'measure': 'Number of CAMS sessions needed to achieve enduring mental state', 'description': 'Number of CAMS sessions needed to achieve enduring mental state', 'timeFrame': 'Up to 3 months post-discharge'}, {'measure': 'Change of Beck Scale for Suicide Ideation score will be analyzed', 'description': 'Change of Beck Scale for Suicide Ideation (SSI) score will be analyzed. SSI scores can range from 0 to 38, and a higher score indicates increased severity of suicidal ideation.', 'timeFrame': 'Up to 3 months post-discharge'}]",3.0,14 Years,30 Years,ALL,False,OTHER,3.0,62.0,ESTIMATED,v2_robust,True,False,False,False,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,CHEMBL1714,exact_match,True,274.19,2.9,4.0
NCT05238337,"A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200",[14C]-PBI-200,['[14C]-PBI-200'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Absorption, Metabolism and Excretion in Healthy Volunteers",Pyramid Biosciences,2025-09-01T16:18:22.193049,True,,,,NOT_FOUND,"A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200 Following a Single Oral Dose in Healthy Male Subjects",,"['Absorption, Metabolism and Excretion in Healthy Volunteers']",[],,2022-02-24,2022-03-24,"[{'measure': 'Total Radioactivity in Urine and Feces', 'timeFrame': '28 days'}, {'measure': 'Area Under the Concentration-Time Curve (AUC) of PBI-200 from time zero to infinity [AUC(0-inf)]', 'timeFrame': '28 days'}, {'measure': 'Area Under the Concentration-Time Curve (AUC) of PBI-200 from time zero to the time of the last quantifiable concentration [AUC(0-tlast)', 'timeFrame': '28 days'}, {'measure': 'Maximum Observed Concentration [C(max)]', 'timeFrame': '28 days'}, {'measure': 'Time to Maximum Concentration [T(max)]', 'timeFrame': '28 days'}, {'measure': 'Apparent Terminal Elimination Half-life [t(1/2)]', 'timeFrame': '28 days'}, {'measure': 'Total Radioactivity in Plasma and Whole Blood', 'timeFrame': '28 days'}, {'measure': 'Ratio for AUC(0-inf) Blood / Plasma', 'timeFrame': '28 days'}, {'measure': 'Ratio for AUC(0-inf) Plasma PBI-200 / Total Radioactivity', 'timeFrame': '28 days'}]",[],9.0,18 Years,65 Years,MALE,True,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00882375,Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy,Nicotine,"['NRT', 'Nicotine', 'Placebo']",3,INTERVENTIONAL,['NA'],,COMPLETED,Smoking Cessation,McNeil AB,2025-09-01T16:18:10.918986,True,,,,CHEMBL3,"Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy. A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 52 Week Study in Smokers Motivated to Quit.",,['Smoking Cessation'],['Smoking Cessation'],,2009-03,2010-06,"[{'measure': 'Self-reported continuous abstinence from smoking verified by exhaled CO levels of less than 10 ppm.', 'timeFrame': 'at weeks 2, 6, 24 and 52'}]","[{'measure': 'Self-reported continuous abstinence from smoking, verified by exhaled CO levels of less than 10 ppm.', 'timeFrame': 'weeks 2, 4, 8, 12, 16, and 20'}, {'measure': 'Self-reported 7-day point prevalence abstinence from smoking verified by exhaled CO levels of less than 10 ppm.', 'timeFrame': 'weeks 4, 6, 8, 12, 16, 20, 24, and 52'}, {'measure': 'Ratings of craving/urge to smoke and withdrawal symptoms.', 'timeFrame': 'baseline to 24 weeks'}, {'measure': 'Cotinine levels in saliva.', 'timeFrame': 'baseline, and weeks 2, 6, 12 and 24'}, {'measure': 'Product acceptability', 'timeFrame': 'weeks 1, 6 and 12'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,479.0,ACTUAL,v2_robust,True,True,False,False,,CN1CCC[C@H]1c1cccnc1,CHEMBL3,exact_match,True,162.24,1.85,4.0
NCT06286397,Topical Anti-Androgens in Pilonidal Sinus Disease,1% Clascoterone,"['1% Clascoterone', 'Vehicle Cream']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Pilonidal Disease,University of Pennsylvania,2025-09-01T16:18:20.955948,True,,,,NOT_FOUND,Topical Anti-Androgens in Pilonidal Sinus Disease,,"['Pilonidal Disease', 'Pilonidal Disease of Natal Cleft', 'Pilonidal Sinus', 'Pilonidal Cyst']","['Pilonidal Cyst', 'Pilonidal Sinus', 'Clascoterone', 'Androgen']",,2025-01-10,2028-01-01,"[{'measure': 'Physician-Assessed Disease Severity Assessment', 'description': 'To objectively evaluate PSD, the investigators will obtain physical measurements of disease extent (left to right, cranial to caudal) and obtain disease photographs at baseline and weeks 4, 8, and 12. Photographs will be collected, deidentified, and provided to two colorectal surgeons for scoring. Surgeons will be asked to compare each timepoint to baseline and rate the PSD severity as significantly worsened, mildly worsened, unchanged, mildly improved, or significantly improved. Discrepant evaluations between surgeons will be referred to a third blinded surgeon. Data will be collated and analyzed in two fashions: as a 6-point ordinal outcome and collapsed into a dichotomous outcome with severely worsened to no change as a negative outcome and improvement as a positive outcome.', 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'Dermatology Life Quality Index', 'description': 'Randomized subjects will be administered the Dermatology Life Quality Index (DLQI) at baseline and at 4, 8, and 12 weeks. The DLQI is a 10-question survey scored from 0-30 that has been applied widely across multiple dermatologic conditions and covers a range of potential quality of life impacts over a weekly basis. Specifically, the DLQI inquires about the impact of skin disease on symptoms (Example: ""Over the past week, how itchy, painful, or stinging has your skin been?""), daily activities, leisure, work and school, and personal relationships, as well as a question of impact of treatment (""Over the last week, how much of a problem has the treatment of your skin been?""). Subjects respond Very much, A lot, A little, or Not at all for descending scores of 3 to zero. A score at or above 10 is considered a significant impact on quality of life.', 'timeFrame': 'From enrollment to the conclusion of treatment at 12 weeks'}]","[{'measure': 'Subcutaneous Inflammation', 'description': 'The investigators anticipate that a large portion of subjects will ultimately undergo surgery. Those that undergo surgery within 4 weeks will be selected. At surgery, blinded investigators will measure the excisional defect. The investigators will then follow patients with chart review in the electronic medical record for 8 weeks postoperatively to assess for immediate wound complications. A full thickness representative sample of the excised pilonidal cyst will analyzed including: antibodies against CD3, CD4, CD8, CD68, and D79. Investigators will assess the specimens for hyperkeratosis, and follicular hyperplasia.', 'timeFrame': 'From 12 weeks to 16 weeks after enrollment, only in patients who undergo surgery'}]",3.0,18 Years,,ALL,False,OTHER,0.0,75.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02259686,Cardiovascular Effects of Apelin In Healthy Volunteers,Apelin 1mg subcutaneous,"['5mg Sc', 'Apelin 5mg subcutaneous', '1mg iv', 'Apelin 1mg subcutaneous', '5mg iv', 'Apelin 5mg intravenous', 'Apelin 10 mg subcutaneous', '1mg Sc', '10mg sc', 'Apelin 1mg intravenous']",10,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Healthy,University of Edinburgh,2025-09-01T16:18:20.963889,True,,,,NOT_FOUND,Cardiovascular Effects of Apelin In Healthy Volunteers,,['Healthy'],"['Apelin', 'volunteers']",,2014-11,2015-05,"[{'measure': 'Change in cardiac output between different methods of apelin administration.', 'description': 'Difference in cardiac output between different treatment arms. This will be assessed by recording cardiac index in L/min/m2 and Stroke volume index mL/min/m2', 'timeFrame': '10 hours'}, {'measure': 'Change in blood pressure between different methods of apelin administration.', 'description': 'Difference in blood pressure between different treatment arms assessed by measuring mean blood pressure in mmHg. Mean arterial pressure (MAP) will be calculated as diastolic blood pressure plus a third of the pulse pressure', 'timeFrame': '10 hours'}]","[{'measure': 'Change in apelin concentrations between the different methods of administration', 'description': 'Difference in temporal profile of apelin concentrations produced by different methods of apelin administration', 'timeFrame': '24 hours'}]",3.0,18 Years,85 Years,ALL,True,OTHER,1.0,14.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02171988,Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS),Propranolol,"['Propranolol', 'Propranolol+pyridostigmine', 'Bisoprolol+pyridostgmine', 'Bisoprolol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postural Orthostatic Tachycardia Syndrome,Seoul National University Hospital,2025-09-01T16:18:23.460415,True,,,,CHEMBL27,"Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment",,['Postural Orthostatic Tachycardia Syndrome'],"['Postural Orthostatic Tachycardia Syndrome', 'propranolol', 'bisoprolol', 'pyridostigmine']",,2014-03,2016-12,"[{'measure': 'The change of the subjective symptom survey result after 3-month medical treatment.', 'timeFrame': '3 month after medical treatment'}]","[{'measure': 'Normalization of orthostatic BP-HR test after 6-month medical treatment.', 'timeFrame': '6 month'}, {'measure': 'The change of the subjective symptom after 6-month medical treatment.', 'timeFrame': '6 month'}, {'measure': 'Change of quality of life score after treatment', 'timeFrame': '6 month'}, {'measure': 'Change of depression score after treatment', 'timeFrame': '6 month'}]",5.0,15 Years,85 Years,ALL,False,OTHER,0.0,150.0,ACTUAL,v2_robust,True,True,False,False,,CC(C)NCC(O)COc1cccc2ccccc12,CHEMBL27,exact_match,True,259.35,2.58,4.0
NCT04622202,Pre-emptive Pregabalin on Attenuating Maternal Anxiety And Stress Response To Intubation During Caesarean Section,Pregabalin 150mg,"['multivitamin', 'Pregabalin 150mg', 'Lyrica', 'Placebo']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Anxiety State,Zagazig University,2025-09-01T16:18:18.432812,True,,,,NOT_FOUND,The Effects Of Pre-emptive Single Oral Dose Pregabalin on Attenuating Maternal Anxiety And Stress Response To Intubation During Caesarean Section,,"['Anxiety State', 'Sedation']",[],,2020-11-15,2021-03-01,"[{'measure': 'preoperative maternal anxiety changes', 'description': 'Anxiety by State-Trait Anxiety Inventory (STAI) questionnaire before drug administration and 60 minutes after giving drug (pre-induction).', 'timeFrame': 'change from baseline at 60 minutes after giving drug preoperative.'}]","[{'measure': 'Number of participant with changes in level of consciousness', 'description': ""changes in level of consciousness of participant by Alert, verbal response, pain response and unresponsive (AVPU) scale 60 minutes after giving drug (pre-induction).\n\nAlert: The patient is aware of the examiner and can respond to the environment around them on their own. The patient can also follow commands, open their eyes spontaneously, and track objects.\n\nVerbally Responsive: The patient's eyes do not open spontaneously. The patient's eyes open only in response to a verbal stimulus directed toward them. The patient is able to react to that verbal stimulus directly and in a meaningful way.\n\nPainfully Responsive: The patient's eyes do not open spontaneously. The patient will only respond to the application of painful stimuli by an examiner. The patient may move, moan, or cry out directly in response to the painful stimuli.\n\nUnresponsive: The patient does not respond spontaneously. The patient does not respond to verbal or painful stimuli."", 'timeFrame': 'at 60 minutes preoperative'}, {'measure': 'Heart rate', 'description': 'Heart rate will be recorded preoperative baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.', 'timeFrame': 'at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.'}, {'measure': 'mean arterial blood pressure', 'description': 'mean arterial blood pressure', 'timeFrame': 'at baseline, 0 (at intubation) 1, 3, 5, 10 and 15 minutes after intubation.'}, {'measure': 'Serum glucose', 'description': 'Serum glucose level will be recorded preoperative and at 10 minutes after intubation.', 'timeFrame': 'preoperative and at 10 minutes after intubation.'}, {'measure': 'cortisol level', 'description': 'cortisol level will be recorded preoperative and at 10 minutes after intubation.', 'timeFrame': 'preoperative and at 10 minutes after intubation.'}, {'measure': 'Baby Apgar score', 'description': 'Apgar score at 1 and 5 min after delivery Apgar Scoring\n\nApgar Sign 2 1 0 Appearance (skin color) Normal color all over (hands and feet are pink) Normal color (but hands and feet are bluish) Bluish-gray or pale all over Pulse (heart rate) Normal (above 100 beats per minute) Below 100 beats per minute Absent (no pulse) Grimace (""reflex irritability"") Pulls away, sneezes, coughs, or cries with stimulation Facial movement only (grimace) with stimulation Absent (no response to stimulation) Activity (muscle tone) Active, spontaneous movement Arms and legs flexed with little movement No movement, ""floppy"" tone Respiration (breathing rate and effort) Normal rate and effort, good cry Slow or irregular breathing, weak cry Absent (no breathing)\n\nA baby who scores a 7 or above on the test is considered in good health.', 'timeFrame': 'at 1 and 5 minutes after delivery'}]",7.0,21 Years,38 Years,FEMALE,True,OTHER_GOV,0.0,74.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02342392,"Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study",ranibizumab,"['Lucentis', 'ranibizumab']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Pterygium,Universiti Sains Malaysia,2025-09-01T16:18:13.428090,True,,,,NOT_FOUND,"Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study",,['Pterygium'],"['pterygium', 'ranibizumab', 'anti-VEGF', 'recurrence', 'vascularity', 'size']",,2012-09,2014-09,"[{'measure': 'pterygium recurrence', 'description': 'pterygium recurrence is defined as true recurrence with a fibrovascular tissue invading the cornea (grade 4 lesion)', 'timeFrame': '1 year'}]","[{'measure': 'pterygium vessel area', 'description': 'Pterygium vesel area is defined as the as the ration of pixels occupied by the vessels within the pterygium area in percentage.', 'timeFrame': '1 week'}, {'measure': 'corneal pterygium area', 'description': 'Corneal pterygium area is defined as the as the ration of pixels occupied by the pterygium within the cornea area in percentage.', 'timeFrame': '1 week'}]",3.0,,,ALL,False,OTHER,0.0,36.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01618006,Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery,Aspirin,['Aspirin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Postoperative; Dysfunction Following Cardiac Surgery,Hamilton Health Sciences Corporation,2025-09-01T16:18:17.178948,True,,,,CHEMBL25,Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery,,['Postoperative; Dysfunction Following Cardiac Surgery'],[],,2012-01,2013-08,"[{'measure': 'Serum Thromboxane: Define an inadequate aspirin response as a value >0.69 ng/ml, which is 2 SD above the mean of aspirin-treated patients', 'timeFrame': 'Postoperative Day 4'}]","[{'measure': 'Arachidonic Acid Induced Light Transmission Aggregometry (LTA): Aggregation will be expressed as the maximum percent change in light transmittance from baseline, with platelet-poor plasma used as a reference.', 'timeFrame': 'Postoperative Day 4'}, {'measure': 'Arachidonic Acid Induced Multiple Electrode Platelet Aggregometry (MEA):Aggregation was recorded for 6 minutes and will be reported as the area under the curve (aggregation units x min).', 'timeFrame': 'Postoperative Day 4'}, {'measure': 'DNA genetic analyses for single nucleotide polymorphisms', 'timeFrame': 'A single preoperative blood sample was drawn (on average of 1 week prior to surgery)'}]",4.0,18 Years,,ALL,False,OTHER,0.0,120.0,ACTUAL,v2_robust,True,True,False,False,,CC(=O)Oc1ccccc1C(=O)O,CHEMBL25,exact_match,True,180.16,1.31,4.0
NCT00574093,Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD,Ranibizumab; Verteporfin,['Ranibizumab; Verteporfin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Neovascular Age Related Macular Degeneration,"Fondazione G.B. Bietti, IRCCS",2025-09-01T16:18:17.177731,True,,,,NOT_FOUND,12 Months Case Series Open Study to Assess the Safety and Efficacy of Intravitreal Injection of Lucentis (Ranibizumab 0.5 mg)Used in Combination With Visudyne (Verteporfin PDT) in Naive Subjects With Subfoveal CNV Secondary to AMD,,['Neovascular Age Related Macular Degeneration'],"['combination therapy', 'Lucentis', 'Visudyne']",,2008-01,2009-10,"[{'measure': 'the mean change from baseline in BCVA letters with ETDRS at Month 3,6,12. -the number of retreatments, the treatment-free interval and the % of retreated patients at month 3, 6, 12. -the mean retinal thickness change from baseline at month 3, 6 and 12.', 'timeFrame': '12 months'}]","[{'measure': '% of patients that gain ≥5, ≥10, ≥15 letters BCVA; % of patients that lose <15 letters; Mean BCVA change and mean change of the total area of the lesion from baseline; Change of FA leakage; Mean retinal sensitivity change at month 3, 6 and 12', 'timeFrame': '12 months'}]",2.0,50 Years,95 Years,ALL,False,OTHER,0.0,15.0,ESTIMATED,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00554099,Asacol Acute Diverticulitis(DIVA)Study,Mesalamine,"['Align', 'Mesalamine', 'Placebo', 'Antibiotic for Diverticulitis', 'Probiotic']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Diverticulitis,Warner Chilcott,2025-09-01T16:18:17.175656,True,,,,CHEMBL704,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period",,['Diverticulitis'],[],,2007-11,2010-03,"[{'measure': 'Global Symptom Score (GSS) at Week 12, Primary Efficacy Population', 'description': 'GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': '12 Weeks'}]","[{'measure': 'Percentage of Responders at Week 12 - ITT Population', 'description': 'Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': '12 Weeks'}, {'measure': 'Percentage of Responders at Week 52 - ITT Population', 'description': 'Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': '52 Weeks'}, {'measure': 'Change in GSS From Baseline to Week 12 - ITT Population', 'description': 'GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change in GSS From Baseline to Week 52 - ITT Population', 'description': 'GSS - Abdominal Pain \\& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12', 'timeFrame': '12 Weeks'}, {'measure': 'Recurrent Diverticulitis, Percentage, ITT Population, Week 12', 'description': 'At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit).', 'timeFrame': '12 Weeks'}, {'measure': 'Recurrent Diverticulitis, Percentage, ITT Population, Week 52', 'description': 'At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit).', 'timeFrame': '52 Weeks'}]",8.0,35 Years,85 Years,ALL,False,INDUSTRY,0.0,117.0,ACTUAL,v2_robust,True,True,False,False,,Nc1ccc(O)c(C(=O)O)c1,CHEMBL704,exact_match,True,153.14,0.67,4.0
NCT00252720,DIabetic Retinopathy Candesartan Trials.,candesartan,"['ATACAND', 'candesartan']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 1 Diabetes,AstraZeneca,2025-09-01T16:18:09.637633,True,,,,CHEMBL1016,DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.,,['Type 1 Diabetes'],['Diabetes mellitus type 1'],,2001-08,2008-04,"[{'measure': 'Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale', 'description': 'Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.', 'timeFrame': 'From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.'}]","[{'measure': 'Number of Participants With a Regression of Diabetic Retinopathy.', 'description': 'Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).', 'timeFrame': 'From baseline to the end of the study, i.e., 5 years'}, {'measure': 'Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).', 'description': 'Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs.', 'timeFrame': 'From baseline to end of study, i.e. 5 years.'}, {'measure': 'Rate of Change in Urinary Albumin Excretion Rate (UAER).', 'description': 'An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient', 'timeFrame': 'From baseline to end of study, i.e. 5 years.'}]",4.0,18 Years,55 Years,ALL,False,INDUSTRY,1.0,1850.0,ACTUAL,v2_robust,True,True,False,False,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,CHEMBL1016,exact_match,True,440.46,4.03,3.0
NCT04169308,Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty,Restylane-L® Filler injection,['Restylane-L® Filler injection'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Deformity of Nasal Cartilage,DeNova Research,2025-09-01T16:18:07.014117,True,,,,NOT_FOUND,Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty on First Impressions and Quality of Life (FACE-Q Scale),,['Deformity of Nasal Cartilage'],[],,2019-01-01,2020-07-21,"[{'measure': 'To determine the effects of Restylane-L® Filler injection into the nose on first impressions and quality of life based on the validated questionnaires using FACE-Q scales.', 'description': 'We will measure changes in first impressions using a questionnaire with categories which include social skills, academic performance, dating success, occupational success, attractiveness, financial success, relationship success, and athletic skills. The 300 independent reviewers will grade each photo on a scale of 1(least favorable) to 10 (best). Evaluation of effects on quality of life will be reported through comparison of pre/post injection quality of life survey scores filled out by patients using the validated FACE-Q PRO survey measure (categories include appraisal of nasal appearance, psychological well-being, social function, and psychological distress). Maximal reported score is 4 (very satisfied) and lowest reported score is 1 (very dissatisfied).', 'timeFrame': '4 weeks'}]","[{'measure': 'To determine the efficacy of Restylane-L® Filler injection to the nose in reduction of convexity of the nasal dorsum as measured on pre/post injection 2D photographs.', 'description': 'Secondary assessment of this study is to determine the efficacy of Restylane-L® filler injection into the nose as defined by the reduction of the nasal dorsal convexity to 0mm (+/- 10% of pre injection value) as measured by differences in length of a line (from pre to post injection photos) from the highest tip of the nasal dorsum to a line drawn from the Radix to the supratip region on a lateral view 2D photograph. This will be performed through calculation of changes in nasal dorsal hump convexity for all patients. All measures will be performed in triplicate and the mean of the 3 measures will be used.', 'timeFrame': '4 weeks'}, {'measure': 'To measure changes in nasal projection and rotation after injection with Restylane-L® Filler in subset of patients who underwent nasal tip augmentation.', 'description': 'Subgroup analysis will be performed for the patients who also underwent augmentation of the nasal tip to measure changes in projection (in mm) and rotation (in degrees) achieved from injection of filler. We will be using the Goode method for measuring nasal projection. We will be reporting the following measurements:\n\nNasal projection is the perpendicular distance between the tip-defining point and a line passing through the nasion and alar crease.\n\nNasal length is the distance between the nasion and the tip-defining point. The ideal Goode ratio of 0.55 to 0.60 is the perpendicular distance between the tip-defining point and a line passing through the nasion and alar crease divided by nasal length.\n\nNasal tip rotation or the nasolabial angle (normal 90-120 degrees), is the angle defined by the columellar point-to-subnasale line intersecting with subnasale-to-labrale superius line.\n\nThe mean of the 3 measurements in (mm for distance) or (degrees for rotation) will be reported.', 'timeFrame': '4 weeks'}, {'measure': 'To determine the safety of Restylane-L® Filler injection to the nose for non-surgical rhinoplasty by recording the number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'The safety profile of injecting Restylane-L® into the nose will be measured by continually monitoring for AEs during the duration of the study and reporting the total number and description of events.', 'timeFrame': '4 weeks'}]",4.0,21 Years,,ALL,True,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02920489,Individualized Timing of Analgesia and Effectiveness of Labor Analgesia,Individualized epidural analgesia,"['Individualized epidural analgesia', 'Individualized analgesia with sufentanil and ropivacaine', 'Routine epidural analgesia', 'Routine analgesia with sufentanil and ropivacaine']",4,INTERVENTIONAL,['NA'],,COMPLETED,Labor Pain,Peking University First Hospital,2025-09-01T16:18:09.632897,True,,,,NOT_FOUND,Impact of Individualized Timing of Analgesia on the Effectiveness of Labor Analgesia: a Randomized Controlled Trial,,"['Labor Pain', 'Analgesia, Obstetrical', 'Early Medical Intervention']","['severity of labor pain', 'individualized administration', 'neuraxial labor analgesia']",,2016-08,2017-07,"[{'measure': 'The most severe labor pain score during labor', 'description': 'Assessed with numeric rating scale, where 0 indicates no pain and 10 the worst pain.', 'timeFrame': 'Assessed at 24 hours after delivery'}]","[{'measure': 'Incidence of instrumental delivery', 'description': 'Incidence of instrumental delivery', 'timeFrame': 'At the time of delivery'}, {'measure': 'Incidence of Cesarean delivery', 'description': 'Incidence of Cesarean delivery', 'timeFrame': 'At the time of delivery'}, {'measure': 'Neonatal Apgar score', 'description': 'Neonatal Apgar score', 'timeFrame': 'At 1 and 5 minutes after delivery'}, {'measure': 'Maternal satisfaction with labor analgesia', 'description': 'Assessed with the Likert scale, where 1=extremely dissatisfaction, 2=dissatisfaction, 3=neither dissatisfaction nor satisfaction, 4=satisfaction, 5=extremely satisfaction.', 'timeFrame': 'Assessed at 24 hours after delivery'}, {'measure': 'Persistent pain score at 24 hours and 42 days after delivery', 'description': 'Assessed with numeric rating scale, where 0 indicates no pain and 10 the worst pain.', 'timeFrame': 'At 24 hours and 42 days after delivery'}, {'measure': 'Rate of breast-feeding', 'description': 'Rate of breast-feeding', 'timeFrame': 'At 24 hours and 42 days after delivery'}, {'measure': 'Incidence of postpartum depression', 'description': 'Postpartum depression will be diagnosed as Edinburgh postnatal depression scale of 10 or higher.', 'timeFrame': 'At 42 days after delivery'}]",8.0,18 Years,36 Years,FEMALE,False,OTHER,0.0,200.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06992336,Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy,"Anlotinib ,","['Benmelstobart', 'Capecitabine', 'Anlotinib ,']",3,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Breast Cancer,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2025-09-01T16:18:19.664945,True,,,,NOT_FOUND,"A Phase II, Open-label, Randomized Trial to Compare Anlotinib and Immunotherapy and Capecitabine Versus Investigator's Choice Therapy in High Risk ctDNA Positive, Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy",,['Breast Cancer'],[],,2025-04-10,2036-01-01,"[{'measure': 'iDFS', 'description': 'invasive disease free survival', 'timeFrame': 'from randomization to any of the following events: local or distant relapse; contralateral breast caner, death of any cause，assessed up to 36 months.'}]","[{'measure': 'dDFS', 'description': 'distant disease free survival', 'timeFrame': 'from randomization to any of the following events: distant relapse; contralateral breast caner, death of any cause，assessed up to 36 months'}, {'measure': 'OS', 'description': 'overall survival', 'timeFrame': 'from randomization to any of the following events: death of any cause，assessed up to 120 months'}, {'measure': 'ctDNA clearance', 'description': 'the rate of patients whose ctDNA are positive after surgery and turns negative after boost therapy', 'timeFrame': 'From the time when post-operative ctDNA is tested to be positive to the time surveillence ctDNA turns negative, assessed up to 60 months'}]",4.0,18 Years,70 Years,FEMALE,False,OTHER,0.0,411.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05838885,A Trial of YPEG-rhGH in Children With Short Stature,YPEG-rhGH,"['rhGH', 'YPEG-rhGH']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Idiopathic Short Stature,"Xiamen Amoytop Biotech Co., Ltd.",2025-09-01T16:18:09.629162,True,,,,NOT_FOUND,"A Multicenter, Randomized, Open-label, Positive-controlled Phase 2 Study to Explore the Optimal Dose of Y- Shaped Pegylated Recombinant Growth Hormone (YPEG-rhGH) in Children With Short Stature (ISS, SGA, TS)",,"['Idiopathic Short Stature', 'Small for Gestational Age', 'Turner Syndrome']","['Growth hormone', 'Somatotropin', 'Short stature', 'Idiopathic short stature', 'Small for gestational age', 'Turner syndrome']",,2022-02-15,2023-12-19,"[{'measure': 'Pharmacokinetic-area under plasma concentration versus time curve', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-maximum serum concentration', 'timeFrame': 'up to 52weeks'}, {'measure': 'Pharmacokinetic-time to reach the maximum plasma concentration', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-terminal disposition phase half-life', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-terminal elimination rate constant', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-apparent clearance after extravascular administration', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Pharmacokinetic-apparent volume of distribution', 'timeFrame': 'up to 52 weeks'}]","[{'measure': 'Pharmacodynamics-the properties of Insulin-like growth facto1 and Insulin-like growth factor binding receptor 3.', 'timeFrame': 'up to 57 weeks'}, {'measure': 'Height velocity (HV, cm/year)', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Change of height velocity compared to baseline (ΔHV, cm/year)', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Height standard deviation according to chronological age (Ht SDS CA)', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Change in bone age', 'timeFrame': 'At 52 weeks of treatment'}, {'measure': 'Adverse events (including injection site reactions), changes from baseline in vital signs and laboratory tests', 'timeFrame': 'up to 57 weeks'}]",13.0,4 Years,11 Years,ALL,False,INDUSTRY,1.0,78.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04543955,Telotristat With Lutathera in Neuroendocrine Tumors,Telotristat (Low-Dose),"['Telotristat (Low-Dose)', 'Xermelo', 'Telotristat (High-Dose)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Neuroendocrine Tumors,"Lowell Anthony, MD",2025-09-01T16:18:17.184877,True,,,,NOT_FOUND,Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors,,['Neuroendocrine Tumors'],['NET'],Sponsor cancelled research,2021-09-13,2022-06-03,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Progression-free survival at 20 months.', 'timeFrame': '20 months'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'Overall response rate using RECIST v1.1 at 6 and 12 months after therapy', 'timeFrame': '6 and 12 months'}, {'measure': 'Median Progression-Free Survival (PFS)', 'description': 'Median progression-free survival.', 'timeFrame': '36 month'}, {'measure': 'Urinary 5-HIAA', 'description': 'Levels of urinary 5-Hydroxyindoleacetic acid (5-HIAA) will be measured at baseline and 12 months.', 'timeFrame': 'Baseline and 12 months'}, {'measure': 'Quality of Life (QLQ-C30)', 'description': 'The Quality of Life Questionnaire C30 (QLQ-C30) was developed by the European Organization for Research and Treatment of Cancer (EORTC) to assess quality of life in cancer patients.It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond on a four-point scale from ""not at all"" to ""very much"" for most items.Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden.', 'timeFrame': '20 month'}, {'measure': 'Quality of Life (QLQ-GI.NET21)', 'description': 'The Quality of Life GI Neuroendocrine Tumor survey (QLQ-GINET21) contains a total of 21 items: four single-item assessments relating to muscle and/or bone pain (MBP), body image (BI), information (INF) and sexual functioning (SX), together with 17 items organised into five proposed scales: endocrine symptoms (ED; three items), GI symptoms (GI; five items), treatment-related symptoms (TR; three items), social functioning (SF) and disease-related worries (DRW; three items). The response format of the questionnaire is a four-point Likert scale. Responses are linearly transformed to a 0-100 scale using EORTC guidelines, with higher scores reflecting more severe symptoms.', 'timeFrame': '20 month'}]",6.0,18 Years,100 Years,ALL,False,OTHER,1.0,1.0,ACTUAL,v2_robust,True,False,True,False,Sponsor cancelled research,,,no_match,False,,,
NCT01761201,"""Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients"".",Levofloxacin,"['Isoniazid', 'Generic name: Levofloxacin', 'Levofloxacin', 'Generic name: Isoniazid.', 'Pharmaceutical form: tablets.', 'ATC Code: J01MA.', 'Pharmaceutical form: Levofloxacin 500 mg film-coated tablets', 'ATC Code: J04AC']",8,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Latent Tuberculosis Infection,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,2025-09-01T16:18:08.343054,True,,,,CHEMBL4,"""A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients"".",,"['Latent Tuberculosis Infection', 'Infection in Solid Organ Transplant Recipients']","['Prophylaxis', 'Tuberculosis', 'Transplant recipients', 'Transplant waiting list']",Recruitment rythm not sufficent to reach the simple size needed.,2012-01,2014-02,"[{'measure': 'Difference in incidence of tuberculosis disease', 'description': 'A patient will be considered as having tuberculosis when Mycobacterium tuberculosis is isolated by culture or M. Tuberculosis DNA is isolated from a representative clinical sample, organ fluid or tissue by polymerase chain reaction. Also cases of histopathologically confirmed tuberculosis (caseating granulomas with/without demonstration of acid-alcohol resistant bacillus \\[BAAR\\]) and clinically compatible presentation will be accepted. Tuberculosis will be classified as pulmonary (pulmonary parenchymal involvement), extrapulmonary (involvement of different organs to the lung) or disseminated (involvement of at least two non-contiguous organs). Cases where tuberculosis is diagnosed on the basis of clinical and/or radiology suspicion and for whom the corresponding physician has prescribed a specific treatment will not be accepted.', 'timeFrame': '18 months of follow-up'}]","[{'measure': 'Mortality', 'description': 'Number of deaths of any cause', 'timeFrame': '18 months'}, {'measure': 'Toxicity', 'description': 'Occurrence of grade 3 or 4 toxicities according to the grading (severity) scale of the National Cancer Institute Common Toxicity Criteria Version 4.0, NCI-CTC-AE v 4.0.', 'timeFrame': 'During all the 18 months of follow-up'}, {'measure': 'Retransplantation', 'description': 'A new liver transplantation during the follow-up', 'timeFrame': '18 months'}, {'measure': 'Graft dysfunction', 'description': 'Development of advanced graft fibrosis stages 3 and 4', 'timeFrame': '18 months'}, {'measure': 'Transplant rejection', 'description': 'The occurrence of acute rejection or chronic rejection as per conventional definitions during the follow-up.', 'timeFrame': '18 months'}]",6.0,18 Years,,ALL,False,OTHER,1.0,68.0,ACTUAL,v2_robust,True,False,True,False,Recruitment rythm not sufficent to reach the simple size needed.,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,CHEMBL4,partial_match,True,361.37,1.54,4.0
NCT02604173,Altitude Sickness Prevention and Efficacy of Comparative Treatments,Budesonide,"['Diamox', 'entocort, pulmicort', 'Acetazolamide', 'Placebo', 'sugar pill', 'Budesonide']",6,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Mountain Sickness,Stanford University,2025-09-01T16:18:23.463647,True,,,,CHEMBL1370,A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments,,['Acute Mountain Sickness'],[],,2016-08,2016-09,"[{'measure': 'Number of Participants With Acute Mountain Sickness', 'description': 'Number of participants with acute mountain sickness (AMS) by Lake Lousie Questionnaire (LLQ)', 'timeFrame': '24 hours'}]","[{'measure': 'Number of Participants With Severe Acute Mountain Sickness', 'description': 'Number of participants with severe acute mountain sickness (AMS) by Lake Lousie Questionnaire (LLQ) (score \\> 5).', 'timeFrame': '24 hours'}, {'measure': 'Oxygen Saturation', 'description': 'measurement of oxygen saturation (%) by finger tip pulse oximeter.', 'timeFrame': '24 hours'}]",3.0,18 Years,65 Years,ALL,True,OTHER,0.0,103.0,ACTUAL,v2_robust,True,True,False,False,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CHEMBL1370,exact_match,True,430.54,2.72,4.0
NCT06358651,Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3),Fasedienol Nasal Spray,"['Fasedienol Nasal Spray', 'Placebo Nasal Spray']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Social Anxiety Disorder,"VistaGen Therapeutics, Inc.",2025-09-01T16:18:08.337505,True,,,,NOT_FOUND,"US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3)",,['Social Anxiety Disorder'],"['Fasedienol', 'PH94B', 'Social Anxiety Disorder', 'SAD', 'pherine', 'pherine nasal spray', 'acute treatment', 'anxiety treatment', 'acute anxiety treatment', 'anxiotlytic', 'mental health', 'anxiety', 'anxiety nasal spray', 'PSC', 'public speaking challenge', 'social phobia']",,2024-03-28,2026-06,"[{'measure': 'Subjective Units of Distress Scale (SUDS)', 'description': 'The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt).', 'timeFrame': '7 days (Visit 2 to Visit 3)'}]","[{'measure': 'Global Impression Scale of Improvement (CGI-I)', 'description': 'The CGI-I scale is a clinician-rated scale to assess illness improvement. The CGI-I scale includes one item being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.', 'timeFrame': '7 days (Visit 2 to Visit 3)'}, {'measure': 'Patient Global Impression of Change (PGI-C)', 'description': 'The PGI-C is a patient self-rated scale to assess improvement. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change.', 'timeFrame': '7 days (Visit 2 to Visit 3)'}]",3.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,236.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02222896,Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects,Chlorhexidine Gluconate,"['CHG', 'CHG 2%', 'Chlorhexidine Gluconate', 'DynaHex-2']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Surgery,Medline Industries,2025-09-01T16:18:20.960989,True,,,,CHEMBL4297088,Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation,,['Surgery'],['Preoperative surgical skin preparation'],,2014-08,2015-05,"[{'measure': 'Percent Responder Rates (%) of Bacterial Reduction on the Abdomen and Groin', 'description': 'Percent of abdomen and groin sites that showed response (achieve a 2-Log and 3-Log reduction) respectively of bacterial flora from baseline.\n\nNote: the number of participants in each treatment group (abdomen and/or groin) can vary depending on whether participants achieved qualifying microbial levels.', 'timeFrame': '10 minutes, 6 hours, 8 hours'}]",[],1.0,16 Years,,ALL,True,INDUSTRY,0.0,347.0,ACTUAL,v2_robust,True,True,False,False,,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,CHEMBL4297088,exact_match,True,897.77,4.18,4.0
NCT06457425,A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis,Flonoltinib 50mg,"['Flonoltinib 50mg', 'Ruxolitinib', 'Flonoltinib 100mg']",3,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,"MF,PMF,PPV-MF,PET-MF","Chengdu Zenitar Biomedical Technology Co., Ltd",2025-09-01T16:18:25.989407,True,,,,NOT_FOUND,"An Open-Label, Positive Drug-Controlled, Parallel, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flonoltinib Maleate Tablets in Patients With Intermediate to High-Risk Myelofibrosis",,"['MF,PMF,PPV-MF,PET-MF']",[],,2024-05-06,2026-07-06,"[{'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC)', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by researcher)', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by IRC)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline( Evaluation by IRC)', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score', 'description': 'Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score', 'timeFrame': 'Week 24 and Week 12'}, {'measure': 'Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria.', 'description': 'Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria.', 'timeFrame': 'Week 24'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,75.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00378755,Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM,velcade,['velcade'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Multiple Myeloma,Korean Multiple Myeloma Working Party,2025-09-01T16:18:25.985977,True,,,,NOT_FOUND,"Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM",,['Multiple Myeloma'],"['velcade', 'myeloma', 'VAD regimen', 'Transplantation, Autologous']",,2006-03,2008-07,"[{'measure': 'response rate of sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) induction therapy as a first line treatment for the patients with multiple myeloma'}]","[{'measure': 'the progression free survival'}, {'measure': 'duration of response'}, {'measure': 'overall survival'}, {'measure': 'toxicities'}]",5.0,15 Years,65 Years,ALL,False,OTHER,1.0,62.0,,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03481790,Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy,Lactoferrin,"['MamyVital', 'Lactoferrin', 'Pravotin', 'ferrous sulphate + folic acid (vitamin B9)', 'Ferrofol']",5,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Iron Deficiency Anemia of Pregnancy,Ain Shams Maternity Hospital,2025-09-01T16:18:23.454535,True,,,,NOT_FOUND,The Effect of Orally Administered Iron-saturated Lactoferrin on Systemic Iron Homeostasis in Pregnant Women Suffering From Iron Deficiency and Iron Deficiency Anaemia,,['Iron Deficiency Anemia of Pregnancy'],['iron deficiency anemia of pregnancy - lactoferrin'],,2017-09-01,2018-03-05,"[{'measure': 'Hemoglobin (Hb) level.', 'description': 'to be measured before and after treatment.', 'timeFrame': '4 weeks'}]","[{'measure': 'serum ferritin level.', 'description': 'to be measured before and after treatment.', 'timeFrame': '4 weeks'}]",2.0,20 Years,35 Years,FEMALE,False,OTHER,0.0,200.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00767559,Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery,warfarin,"['Fondaparinux:', 'warfarin', 'Arixtra', 'Coumadin', 'coumadin']",5,INTERVENTIONAL,['NA'],,UNKNOWN,Pulmonary Embolism,The New England Baptist Hospital,2025-09-01T16:18:07.023335,True,,,,CHEMBL1200879,Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities,,['Pulmonary Embolism'],"['Deep Vein Thrombosis, anticoagulants, surgery, pulmonary embolus, warfarin, fondaparinox']",,2008-11,2012-10,"[{'measure': 'Primary Outcome based upon intent to treat: Composite outcome of', 'timeFrame': '28 days'}, {'measure': 'Ultrasound or venogram confirmed deep vein thrombosis.', 'timeFrame': '28 days'}, {'measure': 'Lung scan, pulmonary angiogram or CTA confirmed pulmonary embolus.', 'timeFrame': '28 days'}, {'measure': 'Death due to TED', 'timeFrame': '28 days'}]","[{'measure': 'Patient compliance with preoperative and post-operative medication schedule. Not enough space to note all measures', 'timeFrame': '28 days'}, {'measure': 'Distribution of proximal vs distal deep vein thrombosis of the leg', 'timeFrame': '28 days'}, {'measure': 'Amount of intraoperative bleeding', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Amount of postoperative bleeding A. transfusion requirement B. Hematomas requiring intervention, or other bleed clinically thought to be related to study drug. C. Other hemorrhagic events.', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': ""Number of ultrasounds and V/Q or CTA's required"", 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Costs associated with each study arm, including that of drug, laboratory monitors, radiology procedures required, lengths of stay, and management of complications', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Determine if negative D-D dimer can eliminate need for ultrasound analysis at follow-up visit.', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Death due to any other cause than TED', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Use of low molecular weight dextran', 'timeFrame': 'follow until Dec. 31, 2010'}, {'measure': 'Use of nonsteroidal anti-inflammatory drugs', 'timeFrame': 'follow until Dec. 31, 2010'}]",14.0,20 Years,,ALL,True,OTHER,0.0,330.0,ESTIMATED,v2_robust,True,False,False,False,,CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[Na+],CHEMBL1200879,partial_match,True,330.31,3.61,4.0
NCT07144176,PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers,DWJ1511,"['DWJ1511', 'DWC202501']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Healthy Subjects,Daewoong Pharmaceutical Co. LTD.,2025-09-01T16:18:20.951530,True,,,,NOT_FOUND,"An Open-label, Randomized, Fasting, Single-dose, Two-treatment, Two-period, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Pharmacokinetics and Safety of ""DWJ1511"" and ""DWC202501"" in Healthy Adult Volunteers",,['Healthy Subjects'],[],,2025-09,2025-09,"[{'measure': 'Area under the plasma drug concentration-time curve [AUCt]', 'description': 'Area under the plasma drug concentration-time curve \\[AUCt\\] of DWJ1511 and DWC202501', 'timeFrame': '0-12 Hours'}, {'measure': 'Maximum plasma concentration [Cmax]', 'description': 'Maximum plasma concentration \\[Cmax\\] of DWJ1511 and DWC202501', 'timeFrame': '0-12 Hours'}]","[{'measure': 'Area under the plasma drug concentration-time curve from time 0 to infinity [AUCinf]', 'description': 'Area under the plasma drug concentration-time curve from time 0 to infinity \\[AUCinf\\] of DWJ1511 and DWC202501', 'timeFrame': '0-12 Hours'}]",3.0,19 Years,64 Years,ALL,True,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02599337,Bioequivalence Study of Sorafenib Tablet and Nexavar,Nexavar,"['Sorafenib', 'sarafenib', 'Nexavar']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Fasting,Yabao Pharmaceutical Group,2025-09-01T16:18:08.340072,True,,,,NOT_FOUND,"Randomized, Open-label, 3-way Reference Replicated Crossover Bioequivalence Study of Sorafenib 200 mg Tablet and Nexavar (Reference) Following a 200 mg Dose in Healthy Subjects Under Fasting Conditions",,['Fasting'],['bioequivalence'],,2015-07,2015-10,"[{'measure': 'Assessment of the bioequivalence of sorafenib tablet (Test)and Nexavar(Reference), on day 4.', 'description': 'Compare the rate and extent of absorption of sorafenib 200 mg tablet (Test) versus Nexavar (Reference), administered as 1 x 200 mg tablet under fasting conditions. Evaluate whether has the bioequivalence between the Test and the Reference.Criteria as follows: for a primary parameter (AUC0-t, AUC0-inf, or Cmax), if\n\n1. the point estimate of the Test-to-Reference ratio must be within 80.00% 125.00%, and\n2. the 95% upper confidence bound for the scaled average bioequivalence criterion must be equal to or less than zero (≤0) to conclude in favor of BE for that parameter.', 'timeFrame': '96 hours'}]","[{'measure': 'safety: number TEAEs, deaths, SAEs and other significant adverse events', 'description': 'Number of Treatment-Emergent Adverse Events(TEAEs). Number of deaths. Number of SAEs. Number of other significant adverse events.', 'timeFrame': '96 hours'}]",2.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01382901,Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS),Ferric Carboxymaltose (FCM),"['Placebo', 'VIT-45', 'Ferric Carboxymaltose (FCM)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Restless Legs Syndrome (RLS),"American Regent, Inc.",2025-09-01T16:18:13.423916,True,,,,NOT_FOUND,A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS),,['Restless Legs Syndrome (RLS)'],[],,2006-03,2007-07,"[{'measure': 'International Restless Legs Syndrome (IRLS) Total Score', 'description': 'The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.', 'timeFrame': 'Change from Baseline to Day 28'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,45.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01707225,Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD),Octreotide LAR Depot,['Octreotide LAR Depot'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Gastrointestinal Bleeding,Virginia Commonwealth University,2025-09-01T16:18:14.671707,True,,,,NOT_FOUND,Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI),,['Gastrointestinal Bleeding'],"['GI Bleeding', 'Gastrointestinal bleeding', 'LVAD']",,2013-02,2014-10,"[{'measure': 'Number of Participants With Side-Effects', 'description': 'Cardiovascular:\n\nSinus bradycardia (19% to 25%) Hypertension (≤13%) conduction abnormalities (9% to 10%)\n\nCentral nervous system:\n\nFatigue (1% to 32%) headache (6% to 30%) malaise (16% to 20%) fever (16% to 20%) dizziness (5% to 20%) Pain (4% to 15%)\n\nDermatologic:\n\nPruritus (≤18%) Rash (15%; depot formulation) alopecia (≤13%)\n\nEndocrine \\& metabolic:\n\nHyperglycemia (2% to 27%)\n\nGastrointestinal:\n\nAbdominal pain (5% to 61%) loose stools (5% to 61%) nausea (5% to 61%) diarrhea (34% to 58%) flatulence (≤38%) cholelithiasis (13% to 38%; length of therapy dependent) constipation (9% to 21%) vomiting (4% to 21%)\n\nHematologic Anemia (5-15%)\n\nLocal:\n\nInjection site pain (2% to 50%; dose and formulation related)\n\nNeuromuscular \\& skeletal:\n\nBack pain (1% to 27%) arthropathy (8% to 19%) myalgia (≤18%)\n\nRenal Kidney Stones (5-15%)\n\nRespiratory:\n\nUpper respiratory infection (10% to 23%)\n\nMiscellaneous:\n\nflu symptoms (1% to 20%)', 'timeFrame': '24 weeks'}]","[{'measure': 'Need for Blood Transfusion and Hospital Admission for GI Bleed', 'timeFrame': '24 weeks'}]",2.0,18 Years,,ALL,False,OTHER,2.0,10.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01104246,Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men,Testerone Transdermal System,"['Testerone Transdermal System', 'Testosterone']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypogonadism,Watson Pharmaceuticals,2025-09-01T16:18:07.025504,True,,,,NOT_FOUND,"An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men",,['Hypogonadism'],"['Hypogonadism', 'Testosterone', 'Hormone replacement therapy']",,2010-04,2010-09,"[{'measure': 'Time-average (Cavg) Steady State Testosterone Concentration Over 24 Hours', 'description': 'A 24-hour pharmacokinetic sampling was performed on Day 28/29 after the start of dosing.', 'timeFrame': 'Day 28/29'}]",[],1.0,18 Years,,MALE,False,INDUSTRY,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00548574,"Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis",SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine,"['Mesalazine', 'SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine', 'LIALDA', 'ASACOL']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Ulcerative Colitis,Shire,2025-09-01T16:18:07.018438,True,,,,NOT_FOUND,"A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis",,['Ulcerative Colitis'],[],,2003-12-04,2004-10-20,"[{'measure': 'Percentage of subjects in remission (UC-DAI score <=1, with scores of 0 for rectal bleeding and stool frequency and a sigmoidoscopy score reduction of 1 point or more from baseline)', 'timeFrame': '8 weeks'}]","[{'measure': 'Clinical improvement as defined by a drop of => 3 points from baseline in the overall UC-DAI score', 'timeFrame': '8 weeks'}, {'measure': 'Change from baseine in UC-DAI score, symptoms, sigmoidscopy score, and PGA', 'timeFrame': '8 weeks'}, {'measure': 'Clinical remission defined as subjects who scored 0 for both the total stool frequency and the total rectal bleeding score', 'timeFrame': '8 weeks'}, {'measure': 'Treatment failure defined as unchanged, worsened missing or imcomplete UC-DAI score', 'timeFrame': '8 weeks'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,343.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05695495,Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study),"N,N-Dimethyltryptamine (5mg)","['N,N-Dimethyltryptamine (5mg)', 'N,N-Dimethyltryptamine (15mg)', 'N,N-Dimethyltryptamine (20mg)', 'Placebo (saline)', 'N,N-Dimethyltryptamine (25mg)', 'N,N-Dimethyltryptamine (10mg)']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"University Hospital, Basel, Switzerland",2025-09-01T16:18:22.194635,True,,,,CHEMBL6640,Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).,,['Healthy'],[],,2024-06-12,2025-03-04,"[{'measure': 'Altered states of consciousness profile (OAV)', 'description': 'Altered states of consciousness profile (OAV) consisting of 42 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects with higher scores representing more intense effects', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}, {'measure': 'Subjective effect ratings over time', 'description': 'Participants will be asked by the investigator to repeatedly rate their subjective effects verbally on a Likert scale from 0 to 10 for: ""any drug effect"", ""good drug effect"", ""bad drug effect"", and ""fear"". Ratings will be performed before and repeatedly after substance administration and will take approximately 30 sec complete.', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}]","[{'measure': 'Psychedelic experience questionnnaire (PEQ)', 'description': 'Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 (""not at all"") to 5 (""extremely"").', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}, {'measure': 'Near death experience content scale (NDE-C)', 'description': 'The Near-Death Experience Content (NDE-C) scale is a tool to assess dimensions of near-death experience on a Likert scale ranging from 0 (""not at all"") to 4 (""extremely"").', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}, {'measure': 'Spiritual Realms Questionnaire (SRQ)', 'description': 'Assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered 100mm visual analog scales once on each study day', 'timeFrame': 'Once at the end of study day'}, {'measure': 'Blood pressure', 'description': 'Assessed multiple times on each study day via systolic and diastolic blood pressure', 'timeFrame': 'Repeatedly in short intervals (2-10 minutes) after each bolus application'}, {'measure': 'Heart rate', 'description': 'Assessed multiple times on each study day.', 'timeFrame': 'Repeatedly in short intervals (2-10 minutes) after each bolus application'}, {'measure': 'Plasma level DMT', 'description': 'Assessed multiple times on each study day.', 'timeFrame': 'Repeatedly in short intervals (2-10 minutes) after each bolus application'}, {'measure': 'Urine recovery of DMT', 'description': 'Assessed once on each study day', 'timeFrame': 'Once at the end of study day'}, {'measure': 'NEO-Five-Factor-Inventory (NEO-FFI)', 'description': 'The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the ""big five"": neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from ""completely disagree"" to ""fully agree.', 'timeFrame': 'Baseline'}, {'measure': 'Saarbrücker Personality Questionnaire (SPF)', 'description': 'The SPF defines empathy as the ""reactions of one individual to the observed experiences of another."" It assesses 28- items on a 5-point Likert scale ranging from ""Does not describe me well"" to ""Describes me very well"". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.', 'timeFrame': 'Baseline'}, {'measure': 'Elliot Humility Scale (EHS)', 'description': 'The Elliot Humility Scale (EHS) is a validated 13-item self-rating measure assessing four subscales, i.e. openness, self-forgetfulness, accurate self-assessment, and focus on others on a 5-point Likert scale ranging from ""strongly disagree"" to ""strongly agree""', 'timeFrame': 'Baseline'}]",12.0,25 Years,65 Years,ALL,True,OTHER,0.0,36.0,ACTUAL,v2_robust,True,True,False,False,,NCCc1c[nH]c2ccccc12,CHEMBL6640,partial_match,True,160.22,1.67,
NCT01522469,Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations,"Crenolanib Besylate (CP-868,596-26)","['Crenolanib Besylate (CP-868,596-26)']",1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations,"Arog Pharmaceuticals, Inc.",2025-09-01T16:18:10.909894,True,,,,CHEMBL2105728,A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations,,['Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations'],"['FLT3', 'Crenolanib', 'Acute', 'myeloid', 'leukemia', 'relapsed', 'refractory']",,2012-07,2014-11,"[{'measure': 'Overall Response Rate', 'description': 'To determine the response rate to crenolanib.Complete remission (CR) response criteria include a post-baseline bone marrow (BM) biopsy or aspiration % blasts \\<5%, absolute neutrophil count (ANC) \\>1×10\\^9/L and platelet count \\>100×10\\^9/L. CRi response included all CR criteria met, except participant did not experience either platelet recovery or ANC recovery. Partial Response (PR) response included a decrease of ≥50% in % blasts in the BM aspirate or biopsy from baseline but \\>5%. Hematologic improvement (HI) response included erythroid response where Hgb increased ≥ 1.5 g/dL, platelet response where platelets increased ≥ 30 x 10\\^9/L for patient starting with \\>20 x 10\\^9/L platelets or increase from \\<20 x 10\\^9/L to \\>20 x 10\\^9/L and by at least 100% and neutrophil response where at least 100% increase and an increase \\>0.5 x 10\\^9/L. Resistant Disease (RD) was defined as the absence of CR, CRi, CRp, PR or HI.', 'timeFrame': 'From the date of first dose to the end of protocol treatment, 1 year.'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,CHEMBL2105728,partial_match,True,443.55,3.92,3.0
NCT05154734,Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders,Belimumab,['Belimumab'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,NMO Spectrum Disorder,Tianjin Medical University General Hospital,2025-09-01T16:18:22.203942,True,,,,NOT_FOUND,Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders (BEAT NMO),,['NMO Spectrum Disorder'],[],,2021-12-12,2024-04-09,"[{'measure': 'The number of attacks', 'description': 'An acute attack was defined as a new neurological worsening lasting for at least 24 hours and occurring more than 30 days after the previous attack.', 'timeFrame': 'From baseline to one year after'}]","[{'measure': 'Worsening in EDSS', 'description': 'The Expanded Disability Status Scale (EDSS) is a rating system that is frequently used for classifying and standardizing the severity and progression. EDSS ranges from 0 to 10.', 'timeFrame': 'Worsening from baseline in EDSS to 52 weeks'}, {'measure': 'Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Optic nerve,brain and spinal cord Magnetic Resonance Imaging (MRI)', 'description': 'The total number of new and/or enlarging T2 lesions for all participants was calculated as the sum of the individual number of lesions at Weeks 12, 24, and 52', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Counts of peripheral blood B cell subsets', 'description': 'Compare peripheral blood plasma cells before and one year after initial intervention', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Determination of serum AQP4 antibodies', 'description': 'Compare serum AQP4-ab titers before and one year after initial intervention', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Incidence of treatment-emergent adverse events [safety and tolerability]', 'description': 'Adverse events related to belimumab are recorded', 'timeFrame': 'From baseline to 52 weeks'}]",6.0,18 Years,,ALL,True,OTHER,1.0,14.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04166773,A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH),Tirzepatide,"['LY3298176', 'Tirzepatide', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Nonalcoholic Steatohepatitis,Eli Lilly and Company,2025-09-01T16:18:13.414944,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)",,['Nonalcoholic Steatohepatitis'],[],,2019-11-19,2024-01-10,"[{'measure': 'Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology', 'description': 'NASH resolution is defined as the absence of fatty liver disease or simple steatosis without steatohepatitis; the absence of hepatocellular ballooning (nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) 0 for ballooning); with or without mild lobular inflammation (NAS 0 or 1 for inflammation); and any value for steatosis. No worsening of fibrosis is defined as no increase in fibrosis stage from baseline to Week 52.', 'timeFrame': 'Week 52'}]","[{'measure': 'Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology', 'description': 'NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Participants were evaluated with the NASH CRN scoring system with ≥1-point reduction without worsening of NASH (defined as no increase in the NAS score).', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology', 'description': 'Participants were evaluated with the NASH CRN scoring system with ≥1 stage increase in fibrosis.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components', 'description': 'Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in at least 2 NAS components (lobular inflammation, hepatocellular ballooning or steatosis). The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8, with the higher score indicating more aggressive disease.', 'timeFrame': 'Week 52'}, {'measure': 'Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)', 'description': 'MRI-PDFF is an established method that enables quantification of fat content in the liver. The value of whole liver fat as assessed by MRI-PDFF is expressed in percentage (%) and ranges from 0 to 100% with higher values representing higher liver fat level. Least square (LS) mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Diabetes Flag (DIABFL) + REGION1 + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Mean Change From Baseline in Body Weight', 'description': 'Change in body weight at the end of 52 weeks measured in kilogram (kg) using a calibrated scale. LS mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + DIABFL + REGION1 + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.', 'timeFrame': 'Baseline to Week 52'}]",6.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,190.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00621010,Safety Study of CTS21166 to Treat Alzheimer Disease,CTS21166 (ZPQ-21166),['CTS21166 (ZPQ-21166)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Alzheimer's Disease,CoMentis,2025-09-01T16:18:12.182402,True,,,,NOT_FOUND,A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males,,"[""Alzheimer's Disease""]",[],,2007-06,2008-02,[{'measure': 'To evaluate the safety and tolerability of single ascending doses of CTS21166 following intravenous administration'}],[{'measure': 'To evaluate the pharmacokinetics(PK) of CTS21166 and its major metabolites as assessed in plasma'}],2.0,22 Years,,MALE,True,INDUSTRY,0.0,56.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06322147,Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer,Doublet or triplet chemotherapy combined with cetuximab,['Doublet or triplet chemotherapy combined with cetuximab'],1,OBSERVATIONAL,[],,RECRUITING,Colon Cancer,Qilu Hospital of Shandong University,2025-09-01T16:18:19.673471,True,,,,NOT_FOUND,"Doublet or Triplet Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF Wild Type Unresectable Liver Metastasis Right-sided Colon Cancer With Curative Intent：Multi-center, Ambispective Observational Trial",,['Colon Cancer'],[],,2023-06-01,2025-12-30,"[{'measure': 'R0 resection rate', 'description': 'R0 resection rate upon conversion treatment with chemotherapy plus cetuximab', 'timeFrame': '1 year'}]","[{'measure': 'Objective response rate', 'description': 'CR + PR rate according to RECIST', 'timeFrame': '1 year'}, {'measure': 'Reported adverse events', 'description': 'Number of patients with adverse events and severity according to NCI CTC 4.0', 'timeFrame': '1 year'}, {'measure': 'Progression free survival', 'description': 'Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first.', 'timeFrame': '2 year'}, {'measure': 'no evidence of disease', 'description': 'the percentage of patients who had a curative liver treatment following protocol treatment', 'timeFrame': '1 year'}, {'measure': 'depth of response', 'description': 'DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier.', 'timeFrame': '1 year'}, {'measure': 'Early Tumor Shrinkage', 'description': 'Early tumor shrinkage assessed by Response rate at week 8', 'timeFrame': '1 year'}]",7.0,18 Years,75 Years,ALL,,OTHER,0.0,50.0,ESTIMATED,v2_robust,False,False,False,True,,,,no_match,False,,,
NCT01243112,Effectiveness Study of Different Local Anesthetic Mixtures,"1% Lidocaine with Epinephrine (1:100,000)","['0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)', '1% Lidocaine with Epinephrine (1:100,000)', '1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)', '0.25% Bupivacaine with Epinephrine (1:200,000)']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Pain,Scott and White Hospital & Clinic,2025-09-01T16:18:10.920037,True,,,,CHEMBL79,"Onset and Duration of Effect of Lidocaine, Bupivacaine, and Lidocaine/Bupivacaine Mixture With Epinephrine.",,['Pain'],[],,2010-05,2010-09,"[{'measure': 'Length of Action', 'description': 'The time from onset of local anesthesia until cessation of effect by sensation of sharp measured in 15 minute increments.', 'timeFrame': 'Up to 12 hours'}, {'measure': 'Onset of Action', 'description': 'Time from infusion of local anesthetic to loss of sensation to sharp.', 'timeFrame': 'Up to 5 minutes'}]",[],2.0,18 Years,60 Years,ALL,True,OTHER,0.0,25.0,ACTUAL,v2_robust,True,True,False,False,,CCN(CC)CC(=O)Nc1c(C)cccc1C,CHEMBL79,partial_match,True,234.34,2.58,4.0
NCT01998906,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer,Trastuzumab,"['Paclitaxel', 'Doxorubicin', 'CMF', 'Herceptin', 'Trastuzumab']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Breast Cancer,Hoffmann-La Roche,2025-09-01T16:18:08.354862,True,,,,NOT_FOUND,"A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer",,['Breast Cancer'],[],,2002-05,2012-07,"[{'measure': 'Event-Free Survival (EFS) - Percentage of Participants With an Event', 'description': 'EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.', 'timeFrame': 'Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Event-Free Survival', 'description': 'The median time, in months, between randomization and date of documented occurrence of an EFS event.', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Event Free at 1 Year', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Event Free at 2 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Event Free at 3 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}]","[{'measure': 'Percentage of Participants With Breast Pathological Complete Response (bpCR)', 'description': 'bpCR was defined as an absence of any invasive cancer cell of the primary tumor at the time of major surgery after neoadjuvant chemotherapy with and without trastuzumab.', 'timeFrame': 'BL, Day 1 of Cycles 1-10 (pre-surgery)'}, {'measure': 'Percentage of Participants With Total Pathological Complete Response (tpCR)', 'description': 'tpCR was defined as a determination of bpCR and an absence of positive axillary nodes on pathology.', 'timeFrame': 'BL, Day 1 of Cycles 1-10 (pre-surgery)'}, {'measure': 'Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria', 'description': 'Assessments were made based on objective tumor measurements of the lesions as recorded in the case report form. In inflammatory cancer, progressive disease (PD) was defined as progression of any of the 2 signs of breast edema and erythema. In non-inflammatory cancer, PD was concluded if either the investigator judged the participant as having progressed at any time prior to surgery, or there was at least a 20% increase in the sum of target lesions (TLs), any new lesion, or clear progression of any nontarget lesion (NTLs). Clear progression of any NTL was defined as at least a 20% increase in the sum of NTLs compared to BL. PR was defined as at least a 30% decrease from BL in the sum of the longest diameter of TLs. CR was defined as no PD as assessed by the investigator and complete disappearance of all lesions.', 'timeFrame': 'BL, Presurgery: Day 1 of Cycles 1-10'}, {'measure': 'Overall Survival (OS) - Percentage of Participants With an Event', 'description': 'OS was defined as the time from the date of randomization to the date of the death due to any cause.', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Overall Survival', 'description': 'OS was defined as the time from the date of randomization to the date of the death due to any cause.', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Surviving at 1 Year', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Surviving at 2 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}, {'measure': 'Percentage of Participants Surviving at 3 Years', 'timeFrame': 'BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter'}]",13.0,18 Years,,FEMALE,False,INDUSTRY,0.0,330.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT07098988,Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC,Matching placebo for visugromab,"['Matching placebo for visugromab', 'Carboplatin AUC 5', 'Pemetrexed 500 mg/m^2']",3,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Metastatic Non-Squamous Non-Small Cell Lung Cancer,CatalYm GmbH,2025-09-01T16:18:18.423642,True,,,,NOT_FOUND,"A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)",,"['Metastatic Non-Squamous Non-Small Cell Lung Cancer', 'Adult Solid Tumor']","['CTL-002', 'Visugromab', 'GDF-15']",,2025-07-30,2031-03-31,"[{'measure': 'Objective Response Rate', 'description': 'Percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator at any time during the core trial period', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Adverse Events', 'description': 'Incidence, type and severity of adverse events, treatment emergent adverse events, treatment-related adverse events and serious adverse events', 'timeFrame': 'up to 27 months'}, {'measure': 'CR rate', 'description': 'Complete response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'PR rate', 'description': 'Partial response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'DOR', 'description': 'Duration of response', 'timeFrame': 'up to 24 months'}, {'measure': 'ORR', 'description': 'Objective response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'TTR', 'description': 'Time-to-response rate', 'timeFrame': 'up to 24 months'}, {'measure': 'PFS', 'description': 'Progression-free survival', 'timeFrame': 'up to 48 months'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'up to 48 months'}, {'measure': 'Participant weight course over time', 'timeFrame': 'up to 48 months'}, {'measure': 'Maximum Concentration (Cmax) of visugromab', 'description': 'Cmax is the maximum observed serum concentration of visugromab', 'timeFrame': 'At designated time points (up to 24 months)'}, {'measure': 'Minimum Concentration (Cmin) of visugromab', 'description': 'Cmin is the minimum observed serum concentration of visugromab', 'timeFrame': 'At designated time points (up to 24 months)'}, {'measure': ""Participants' subjective well-being as assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)"", 'description': 'NSCLC-SAQ is a participant reported outcome with seven (7) items assessing five (5) symptom domains of NSCLC: cough, fatigue, pain, dyspnea, and appetite. Each item is scored individually from 0 (""None/Never"") to 4 (""Severe/Always""). The total score is calculated by summing domain scores, which are derived as follows: single-item domains (cough, dyspnea, appetite) use the item score; fatigue uses the mean of two items (or one if only one is answered); pain uses the highest score of two items (or one if only one is answered). The total score ranges from 0-20, with higher scores indicating more severe symptoms. If any domain score is missing, a total score is not computed.', 'timeFrame': 'up to 27 months'}, {'measure': ""Participants' quality of life as assessed by 5-day Functional Living Index-Emesis (5-day FLIE)"", 'description': 'FLIE consists of 18 items, with 9 items on nausea and 9 items on vomiting. The impact of nausea and vomiting is assessed through their effects on physical and social activities, and emotional well-being. Each item is rated using a visual analog scale (VAS) from 1 to 7 (In some questions, ""1"" means that nausea or vomiting does not affect the daily life at all, while in other questions, ""1"" means it affects the daily life a lot). Scoring is calculated per the FLIE Scoring and Administration Manual. Higher scores indicate less impact of nausea and vomiting on daily life. At least 12 of 18 items must be completed to compute the total score.', 'timeFrame': 'At designated time points (up to 3 months)'}]",14.0,18 Years,,ALL,False,INDUSTRY,0.0,107.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02334865,SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy,Lenalidomide,"['CDC 501', 'CC-5013', 'Lenalidomide', 'Revlimid', 'CC5013']",5,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Partial Response of Multiple Myeloma or Plasma Cell Leukemia,Roswell Park Cancer Institute,2025-09-01T16:18:08.345107,True,,,,CHEMBL848,"A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy",,"['Partial Response of Multiple Myeloma or Plasma Cell Leukemia', 'Plasma Cell Myeloma']",[],,2017-04-13,2026-05-19,"[{'measure': ""Toxicity profile of the SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant plus sargramostim, given before or after the start of lenalidomide maintenance"", 'description': 'The National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 will be used to evaluate toxicity. The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category and grade. The frequency of toxicities will also be tabulated for the regimen estimated to be the regimen-limiting toxicity.', 'timeFrame': 'Up to 24 weeks'}]","[{'measure': 'Immune response using interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and multimer assays', 'description': ""A responder is defined as a patient who has responded in either IFN-gamma ELISPOT or multimer assays. For both the ELISPOT and multimer assays, time course and magnitude of responses will be plotted and data will be treated using mixed-effect modeling. In addition, Kendall's tau-b will be used to determine whether ELISPOT and multimer responses are associated."", 'timeFrame': 'Up to 24 weeks'}]",2.0,18 Years,,ALL,False,OTHER,1.0,18.0,ACTUAL,v2_robust,True,False,False,True,,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,CHEMBL848,exact_match,True,259.26,0.03,4.0
NCT06393387,Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States,DTG/3TC versus BIC/F/TAF,['DTG/3TC versus BIC/F/TAF'],1,OBSERVATIONAL,[],,COMPLETED,Hiv,Midway Specialty Care Center,2025-09-01T16:18:10.929461,True,,,,NOT_FOUND,Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States (REVIVE Study),,"['Hiv', 'HIV-1-infection', 'HIV Infections']","['HIV', 'Social Determinants of Health', 'Adherence', 'Viral Suppression', 'Percent of Days Covered']",,2024-06-01,2025-04-01,"[{'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of switching treatment to DTG/3TC vs. BIC/F/TAF through 48 weeks in virally suppressed ART experienced individuals with no interruptions in prior therapy.', 'timeFrame': '48 Weeks'}]","[{'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of switching treatment to DTG/3TC vs. BIC/F/TAF through 24 weeks in virally suppressed ART experienced individuals with no interruptions in prior therapy.', 'timeFrame': '24 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 48 weeks in ART naïve individuals (i.e., no prior ART regimen received).', 'timeFrame': '48 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 24 weeks in ART naïve individuals.', 'timeFrame': '24 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 48 weeks in ART experienced individuals who are returning to care (i.e., previous ART therapy received but not in the last month).', 'timeFrame': '48 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 24 weeks in ART experienced individuals who are returning to care.', 'timeFrame': '24 Weeks'}, {'measure': 'Clinical Characteristics of Persons with HIV', 'description': 'To describe the baseline demographics and clinical characteristics of individuals on DTG/3TC and BIC/F/TAF by the following sub-groups: (1) Virally suppressed, (2) ART experienced individuals, \\& (3) ART naïve individuals ART experienced individuals who are returning to care', 'timeFrame': 'Baseline'}, {'measure': 'Tolerability', 'description': 'To assess the tolerability (i.e., all drug-related adverse reactions (ARs) as per label) of DTG/3TC vs. BIC/F/TAF through 24 weeks and 48 weeks by the following sub-groups: (1) Virally suppressed ART experienced individuals, (2) ART naïve individuals \\& (3) ART experienced individuals who are returning to care.', 'timeFrame': '24, 48 Weeks'}, {'measure': 'Treatment Discontinuation', 'description': 'To assess treatment discontinuations (i.e., withdrawals due to drug-related ARs) of DTG/3TC vs. BIC/F/TAF through 24 weeks and 48 weeks by the following sub-groups: (1) Virally suppressed ART experienced individuals, (2) ART naïve individuals, (3) ART experienced individuals who are returning to care.', 'timeFrame': '24, 48 Weeks'}]",9.0,18 Years,,ALL,False,OTHER,0.0,800.0,ACTUAL,v2_robust,False,True,False,True,,,,no_match,False,,,
NCT02882321,Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Oxidative Phosphorylation Inhibitor IACS-010759,"['Oxidative Phosphorylation Inhibitor IACS-010759', 'IACS-010759', 'OXPHOS Inhibitor IACS-010759']",3,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Recurrent Acute Myeloid Leukemia,M.D. Anderson Cancer Center,2025-09-01T16:18:14.661897,True,,,,NOT_FOUND,Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory AML,,"['Recurrent Acute Myeloid Leukemia', 'Refractory Acute Myeloid Leukemia']",[],The study was terminated by the Sponsor for apparent lack of effectiveness.,2016-09-29,2022-04-15,"[{'measure': 'Maximum Tolerated Dose (MTD) Defined as the Highest Dose Studied for Which the Observed Incidence of Dose Limiting Toxicities (DLT) is Less Than 33%', 'description': 'Will be assessed according to National Cancer Institute Common Toxicity Criteria version 4.03.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Participants With a Response', 'description': 'Response is Complete Response (CR) + Complete Response with Incomplete Blood Count Recovery (CRi) + Partial Response (PR) + Morphologic Leukemia -Free State (MLFS): CR is Bone marrow blasts \\< 5%; absence of circulating blasts and blasts with Auer rods; absence of extra-medullary disease; ANC \\> 1.0 x 10\\^9/L; platelet count \\>/= 100 x 10\\^9/L. CRi is CR except for ANC \\</= 1.0 x 10\\^9 or platelet count , 100 x 10\\^9/L. PR is decreased bone marrow blast % by at least 50% to a value of 5% to 25% and ANC \\>/= 1.0 x 10\\^9/L; platelet count \\>/= 100 x 10\\^9/L. MLFS is Bone marrow blasts \\< 5%; abcence of blasts with Auer rods; absence of extra-medullary disease; no hematologic recovery required.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Duration of Response', 'description': 'Duration of Response: length of time from the first objective evidence of response to the first objective evidence of disease progression.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Progression-free Survival', 'description': 'Progression-Free Survival: length of time (up to 5 years) from the date of first treatment to the first objective evidence of disease progression or death, whichever is earlier.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall Survival', 'description': 'Overall Survival: length of time from the date of first administration of study drug to the date of death from any cause.', 'timeFrame': 'Up to 5 years'}]",5.0,18 Years,,ALL,False,OTHER,1.0,17.0,ACTUAL,v2_robust,True,False,True,False,The study was terminated by the Sponsor for apparent lack of effectiveness.,,,no_match,False,,,
NCT02993705,Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS),Trabectedin,"['Yondelis', 'Trabectedin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Carcinosarcoma, Ovarian",Fondazione Policlinico Universitario Agostino Gemelli IRCCS,2025-09-01T16:18:20.967152,True,,,,NOT_FOUND,Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS),,"['Carcinosarcoma, Ovarian', 'Carcinosarcomas Uterine']",[],,2017-02-22,2019-11-13,"[{'measure': 'Objective response rate (ORR)', 'description': 'The primary endpoint of this study is to evaluate the activity of trabectedin in terms of the objective response rate (ORR) in patients with advanced uterine and ovarian carcinosarcoma.', 'timeFrame': 'three years'}]","[{'measure': 'Duration of response', 'timeFrame': 'three years'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'the diagnosis of progression will be assessed by radiological criteria; CA 125 increases alone (GCIG criteria of progression) will not be considered as progression of disease without a radiological confirmation of progression', 'timeFrame': 'three years'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'three years'}, {'measure': 'Adverse events', 'description': 'Incidence of adverse events, according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) v 4.03.', 'timeFrame': 'three years'}]",5.0,18 Years,100 Years,FEMALE,False,OTHER,0.0,45.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00520247,Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism,enalapril plus folic acid,['enalapril plus folic acid'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Plasma Total Homocysteine Level,Anhui Medical University,2025-09-01T16:18:17.181935,True,,,,NOT_FOUND,Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial,,"['Plasma Total Homocysteine Level', 'Blood Pressure']","['enalapril', 'folic acid', 'hyperglycemia', 'hypertension', 'fasting plasma glucose']",,2005-09,2006-02,"[{'measure': ""Blood pressure of study participants was measured at baseline, 2th week, 4th week, 6th week and at the end of trial Subjects' plasma total homocysteine concentration were measured at baseline, 4th week and at 8th week."", 'timeFrame': '8 weeks'}]","[{'measure': ""Participants' living habit and life style were collected at baseline with the original questionnaires. A follow up questionnaire was sent out at 2th week, 4th week, 6th week and at the end of the trial."", 'timeFrame': '8 weeks'}]",2.0,28 Years,75 Years,ALL,False,OTHER,6.0,443.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01994837,A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML),ABT-199,"['ABT-199', 'ABT-199 also known as venetoclax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Myelogenous Leukemia,AbbVie,2025-09-01T16:18:15.904313,True,,,,NOT_FOUND,A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML),,"['Acute Myelogenous Leukemia', 'AML', 'Acute Myeloid Leukemia']","['GDC-0199', 'Acute Myelogenous Leukemia', 'AML', 'ABT-199', 'Acute Myeloid Leukemia', 'Myeloid Leukemia']",,2013-11,2014-12,"[{'measure': 'Objective Remission Rate', 'description': 'The objective remission rate (ORR) was defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), or partial remission (PR) per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL. Partial remission (PR) was defined as normalization in peripheral blood neutrophil and platelet counts with at least a 50% decrease in blasts persisting in bone marrow versus baseline.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}]","[{'measure': 'Complete Remission Rate', 'description': 'The complete remission (CR) rate was defined as the percentage of participants who achieved CR per the International Working Group criteria for AML. Complete remission was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Duration of Remission', 'description': 'Duration of remission was defined as the number of days from the date of first remission (CR, CRi, or PR) per the International Working Group criteria for AML to the earliest recurrence or progressive disease (PD). In this study, the duration of remission analysis was not performed because of the low remission rate, per the Statistical Analysis Plan.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Time to Progression', 'description': 'Time to progression was defined as the number of months from the date of enrollment to the date of earliest disease progression. If a participant did not experience disease progression, then the data for that participant was censored at the date of the last disease assessment.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Progression-free Survival', 'description': 'Progression-free survival was defined as the number of months from the date of enrollment to the date of earliest progression or death. If a participant did not experience disease progression or death, then the data was censored at the date of the last disease assessment.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Overall Survival', 'description': 'Overall survival was defined as the number of months from the date of enrollment to the date of death for all dosed participants. For participants who did not die, their data were censored at the date of last study visit or the last known date to be alive, whichever was later.', 'timeFrame': 'Measured up to 2 years after the last subject had enrolled in the study.'}, {'measure': 'Percentage of Participants Who Received Subsequent Stem Cell Transplant', 'description': 'The percentage of participants who received a subsequent allogenic (from a healthy donor) stem cell transplant was summarized.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Rate of Minimal Residual Disease (MRD) Negativity', 'description': 'The rate of minimal residual disease (MRD) response was defined as the percentage of participants who had MRD negative status. Only participants with a reported MRD assessment (negative or positive) from the local laboratory at the investigator site were used in the calculation of MRD response rate.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Complete Remission With Incomplete Marrow Recovery (CRi) Rate', 'description': 'The complete remission with incomplete bone marrow recovery (CRi) rate was defined as the percentage of participants who achieved CRi per the International Working Group criteria for AML. Complete remission with incomplete bone marrow recovery was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}, {'measure': 'Complete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate', 'description': 'The complete remission rate and the complete remission with incomplete marrow recovery rate (Cri) was defined as the percentage of participants who achieved complete remission (CR) or complete remission with incomplete bone marrow recovery (CRi), per the International Working Group criteria for AML. Complete remission (CR) was defined as peripheral neutrophils at least 10˄3/μL, platelets ≥ 10˄5/μL and normocellular bone marrow with ≤ 5% blasts. Complete remission with incomplete bone marrow recovery (CRi) was defined as bone marrow with less than 5% blasts, with peripheral neutrophils of at least 10˄3/μL or platelets ≥ 10˄5/μL.', 'timeFrame': 'When 19 participants had completed at least 12 weeks of treatment or after all enrolled participants had discontinued venetoclax, whichever was earlier'}]",10.0,18 Years,99 Years,ALL,False,INDUSTRY,1.0,32.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03836209,Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia,Gilteritinib,"['Ara-C', 'Cytosine Arabinoside', 'ASP2215', 'Arabinosyl', 'Cytarabine', 'Daunorubicin', 'Daunorubicin hydrochloride', 'Cytosar-U', 'Gilteritinib', 'Cerubidine', 'RYDAPT', 'Rubidomycin', 'Daunomycin', 'Midostaurin']",14,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia,"PrECOG, LLC.",2025-09-01T16:18:24.758143,True,,,,NOT_FOUND,Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML),,['Acute Myeloid Leukemia'],"['Gilteritinib', 'Midostaurin', 'Daunorubicin', 'Cytarabine', 'FLT3', 'FLT3 Mutation', 'FLT3 Internal Tandem Duplication (ITD)', 'FLT3 ITD', 'FLT3 Tyrosine Kinase Domain (TKD)', 'FLT3 TKD']",,2019-12-06,2026-12,"[{'measure': 'FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction', 'description': 'FLT3 mutation negative (evaluated by polymerase chain reaction \\[PCR\\]) Composite Complete Response (CRc) \\[includes CR and CRi\\] rate after induction treatment and complete MRD assessment. The cut points used for FLT3 mutation negative are 1% (equivalent to 10-2) for FLT3-TKD and 10-4 for FLT3-ITD.', 'timeFrame': '3 months'}]","[{'measure': 'FLT3 Mutation Negative Complete Response (CR) Rate at End of Induction', 'description': 'CR evaluated by FLT3 testing after Induction', 'timeFrame': '3 months'}, {'measure': 'Minimal Residual Disease (MRD)- CRc Rate at End of Induction', 'description': 'MRD- CRc evaluated by flow cytometry after Induction', 'timeFrame': '3 months'}, {'measure': 'CRc (CR or CRi) Rate at End of Induction', 'description': 'CRc assessed in accordance with 2017 European LeukemiaNet (ELN)', 'timeFrame': '3 months'}, {'measure': 'Event Free Survival (EFS)', 'description': 'EFS assessed in accordance with 2017 ELN', 'timeFrame': '68 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS assessed in accordance with 2017 ELN', 'timeFrame': '68 months'}, {'measure': 'Number of Participants Treatment-related Adverse Events as Assessed by CTCAE v5.0', 'description': 'Number of participants with abnormal laboratory values and/or adverse events', 'timeFrame': '10 months'}]",7.0,18 Years,70 Years,ALL,False,OTHER,1.0,181.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02192294,Absolute Bioavailability Of Bosutinib,Oral Bosutinib,"['Oral Bosutinib', 'Intravenous infusion of bosutinib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Pfizer,2025-09-01T16:18:13.416992,True,,,,CHEMBL288441,"An Open-label, Randomized, 2-period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects",,['Healthy'],"['Bosutinib', 'absolute bioavailability']",,2014-08,2014-10,"[{'measure': 'Area under the Concentration-Time Curve (AUC)', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.', 'timeFrame': '96 hours'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Maximum Observed Plasma Concentration', 'timeFrame': '96 hours'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '96 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Time to Reach Maximum Observed Plasma Concentration', 'timeFrame': '96 hours'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '96 hours'}, {'measure': 'Systemic Clearance (CL)', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '96 hours'}, {'measure': 'Volume of Distribution at Steady State (Vss)', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '96 hours'}]",7.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHEMBL288441,partial_match,True,530.46,5.19,4.0
NCT02463032,Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer,GTx-024,['GTx-024'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,ER+ and AR+ Breast Cancer,GTx,2025-09-01T16:18:08.350811,True,,,,NOT_FOUND,"A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women",,['ER+ and AR+ Breast Cancer'],[],,2015-08,2019-03,"[{'measure': 'Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects', 'description': 'To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.', 'timeFrame': '24 weeks'}]","[{'measure': 'Clinical Benefit Rate, in Full Analysis Set', 'description': 'To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.', 'timeFrame': '24 weeks'}, {'measure': 'Objective Response (CR + PR) in AR+ Patients', 'description': 'To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.', 'timeFrame': '24 weeks'}, {'measure': 'Best Overall Response in AR+ Patients', 'description': 'To estimate the best overall response of GTx-024 9 mg and 18 mg', 'timeFrame': 'From treatment initiation to end of treatment'}, {'measure': 'Progression Free Survival in All Subjects', 'description': 'To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.', 'timeFrame': 'From randomization to tumor progression or death'}, {'measure': 'Time to Progression in All Subjects', 'description': 'To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.', 'timeFrame': 'From randomization to tumor progression or death'}]",6.0,18 Years,,FEMALE,False,INDUSTRY,0.0,136.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02421263,The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals,Psilocybin,['Psilocybin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Religious or Spiritual Problem,NYU Langone Health,2025-09-01T16:18:24.759594,True,,,,NOT_FOUND,A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion,,['Religious or Spiritual Problem'],"['Psilocybin', 'Pharmacologic Actions', 'Psychotropic Drugs']",,2015-04,2020-06-05,"[{'measure': 'Interim Questionnaire', 'description': ""This questionnaire asks about experiences and changes in attitudes, mood and behavior that occurred during the past 5 months. The questionnaire includes questions about salient spiritual experiences, changes in spiritual practices, changes in attitudes, moods, social interactions, and other behaviors related to participants' religious/spiritual vocation."", 'timeFrame': '6-Months after enrollment'}]",[],1.0,25 Years,76 Years,ALL,True,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03459170,Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant,rimiducid,"['AP1903', 'rimiducid']",2,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Hematologic Malignancy,Bellicum Pharmaceuticals,2025-09-01T16:18:07.028347,True,,,,CHEMBL269259,"A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant",,['Hematologic Malignancy'],"['leukemia', 'myelodysplastic syndrome', 'lymphoma', 'minimal residual disease', 'BPX-501', 'AP1903', 'rimiducid']",,2018-02-01,2035-09,"[{'measure': 'BPX-501 Safety', 'description': 'Incidence of treatment emergent adverse events of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in pediatric subjects with hematologic malignancies', 'timeFrame': 'Month 24'}, {'measure': 'Mean plasma concentration', 'description': 'Measure plasma concentrations of rimiducid (AP1903) at two doses (Arm 1: 0.04mg/kg; Arm 2: 0.4mg/kg) in pediatric subjects, during and after a 2-hour infusion', 'timeFrame': 'pre-dose, 30 min, 2 hours and 8 hours after start of infusion'}]","[{'measure': 'Overall survival', 'description': 'Measure overall survival rates after BPX-501 infusion', 'timeFrame': 'Month 24'}, {'measure': 'Response Rate', 'description': 'Assess response rates after BPX-501 infusion', 'timeFrame': 'Month 24'}]",4.0,1 Year,18 Years,ALL,False,INDUSTRY,0.0,15.0,ESTIMATED,v2_robust,True,False,False,True,,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,CHEMBL269259,exact_match,True,1411.65,,2.0
NCT04401748,Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome,Venetoclax,"['Azacitidine', 'Venclexta', 'AZA', 'GDC-0199', 'Placebo', 'ABT-199', 'Venetoclax']",7,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Myelodysplastic Syndrome (MDS),AbbVie,2025-09-01T16:18:23.445331,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)",,['Myelodysplastic Syndrome (MDS)'],"['MDS', 'Myelodysplastic Syndrome', 'Venetoclax', 'Azacitidine', 'AZA', 'Venclexta']",,2020-09-10,2026-03,"[{'measure': 'Overall survival (OS)', 'description': 'OS is defined as the number of days from the date of randomization to the date of death of any cause, or last known date to be alive.', 'timeFrame': 'Up To 5 Years'}]","[{'measure': 'Modified Overall Response (mOR)', 'description': 'mOR \\[complete remission (CR) + marrow complete remission (mCR) + partial response (PR)\\] is defined as achieving a CR, mCR, or PR at any time point during the study per the modified International Working Group (IWG) 2006 criteria for myelodysplastic syndrome (MDS).', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Percentage of Participants Achieving Overall Hematological Improvement (HI)', 'description': 'Overall HI is defined as achieving the response of HI-platelet or HI-neutrophil, or HI-erythroid at any time point during the study prior to post-treatment therapy per the modified IWG 2006 criteria for MDS.', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Complete Remission (CR)', 'description': 'CR is defined as achieving a complete remission at any time point during the study per the modified International Working Group (IWG) 2006 criteria for myelodysplastic syndrome (MDS).', 'timeFrame': 'Up To 36 Months'}, {'measure': 'Percentage of Participants Achieving Transfusion Independence (TI) Who are Transfusion Dependent at Baseline', 'description': 'TI is when the participants who were transfusion dependent on red blood cell (RBC) and/or Platelet at baseline achieve transfusion independence post baseline. TI is a period of at least 56 days with no transfusion after the date of the first dose of study drug to the last dose of study drug + 30 days, or 1 day before the date of progressive disease/ relapse from CR or PR per the modified IWG 2006 criteria for MDS, or 1 day before the initiation of post-treatment therapy or 1 day before death, whichever is earliest.', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Time to Deterioration in Physical Functioning as Measured by Physical Functioning Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scale', 'description': 'Time to deterioration in physical functioning, as measured by the EORTC QLQ-C30 physical functioning score is defined as the time from the date of randomization to the date of death of any cause, or the first time worsening of score from baseline \\>= a pre-specified threshold. Participants rate items on a 4-point scale, with 1 as ""not at all"" and 4 as ""very much.""', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Change in Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue Short Form (SF) 7a Scale Score', 'description': 'Fatigue will be assessed using the PROMIS Fatigue SF 7a Global Fatigue Score. PROMIS Fatigue SF 7a is a 7-item questionnaire that assesses the impact and experience of fatigue over the past 7 days. Participants rate items on a 5-point scale, with 1 as ""never"" an 5 as ""always"".', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Overall Response (OR)', 'description': 'OR \\[complete remission (CR) + partial response (PR)\\] is defined as achieving a CR or PR at any time point during the study per the modified IWG 2006 criteria for MDS.', 'timeFrame': 'Up To 5 Years'}]",8.0,18 Years,,ALL,False,INDUSTRY,1.0,531.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04737928,"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)",Latanoprost,"['tafluprost', 'Latanoprost']",2,INTERVENTIONAL,['NA'],,COMPLETED,"Glaucoma, Primary Open Angle","Santen Pharmaceutical (Taiwan) Co., LTD",2025-09-01T16:18:24.752547,True,,,,NOT_FOUND,"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders",,"['Glaucoma, Primary Open Angle']",[],,2018-04-02,2019-01-22,"[{'measure': 'Efficacy: Changes in the Intraocular Pressure (IOP) at each visit', 'description': 'Tonometer', 'timeFrame': '3 months'}, {'measure': 'Safety:Changes in the fluorescein staining score (NEI) at Visit 2', 'description': 'fluorescein staining', 'timeFrame': '3 months'}]","[{'measure': 'Changes in the fluorescein staining score (NEI) at Visit 1', 'description': 'fluorescein staining', 'timeFrame': '1 months'}, {'measure': 'Changes in ocular symptoms (irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation) at each visit', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Changes in the Tear Break-Up Time (TBUT) at each visit', 'description': 'slit-lamp', 'timeFrame': '3 months'}, {'measure': 'Changes in the hyperaemia at each visit', 'description': 'slit-lamp', 'timeFrame': '3 months'}, {'measure': 'Treatment compliance', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Concomitant medication', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Patient satisfaction about test medication', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Usability of eyedrop bottle', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Adverse drug reactions', 'description': 'Questionnaire', 'timeFrame': '3 months'}]",11.0,20 Years,,ALL,False,INDUSTRY,0.0,1.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00000367,Prevention of Suicide in the Elderly,Treatment of depression,"['Suicide prevention treatment', 'Treatment of depression']",2,INTERVENTIONAL,['NA'],,COMPLETED,Depression,Weill Medical College of Cornell University,2025-09-01T16:18:10.922779,True,,,,NOT_FOUND,,,['Depression'],"['Depression', 'Family', 'Female', 'Human', 'Male', 'Practice Guidelines', 'Education, Medical, Continuing', 'Patient Education', 'Suicide']",,1998-09,2003-08,[],[],0.0,60 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01370031,Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices,Clenil® Modulite® via AeroChamber Plus™,"['Clenil® Modulite® via AeroChamber Plus™ plus charcoal block', 'Clenil® Modulite® via AeroChamber Plus™', 'Clenil® Modulite® via Volumatic™ spacer', 'Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Asthma,Chiesi Farmaceutici S.p.A.,2025-09-01T16:18:08.338014,True,,,,NOT_FOUND,"Pilot, Open-Label, Randomized, Repeated Dose, 4-Way Cross-Over, Clinical Pharmacology Study of Beclomethasone Dipropionate (Clenil® Modulite®) 250 µg HFA pMDI Using the Aerochamber Plus™ Spacer Device Versus the Volumatic™ Spacer Device Without or With Charcoal Block in Asthmatic Adults Patients",,['Asthma'],"['Asthma', 'PK', 'Adults']",,2011-04,2011-06,"[{'measure': 'Systemic exposure to B17MP (active metabolite of BDP) at steady state after repeated dose of Clenil® Modulite®', 'description': 'Plasma AUC0-12h,ss for B17MP', 'timeFrame': '0-12 hours'}, {'measure': 'Systemic exposure to B17MP (active metabolite of BDP) at steady state after repeated dose of Clenil® Modulite®', 'description': 'Plasma Cmax,ss for B17MP', 'timeFrame': '0-12 hours'}]","[{'measure': 'evaluation of the pharmacokinetic profile of BDP', 'description': 'AUC and Cmax for BDP', 'timeFrame': '0-12 hours'}, {'measure': 'Vital signs assessment', 'description': 'Heart rate and Blood pressure assessment', 'timeFrame': 'from screening (week -1) to week 8'}, {'measure': 'haematology and blood chemistry assessment', 'description': 'haematology and blood chemistry assessment', 'timeFrame': 'at screening (week - 1) and week 8'}, {'measure': 'Number of patients with Adverse events', 'description': 'Adverse events', 'timeFrame': 'during the 11 weeks of study'}, {'measure': 'FEV1 predose assessment', 'description': 'FEV1 predose assessment as lung function parameter', 'timeFrame': 'from screening (week-1) to week 8'}]",7.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02828059,Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section,Ropivacaine,"['ReadyFusor', 'Ropivacaine']",2,OBSERVATIONAL,[],,WITHDRAWN,Pain,Jena University Hospital,2025-09-01T16:18:20.959733,True,,,,NOT_FOUND,Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section (Dip-Caesar),,['Pain'],['Caesarean section'],changed drug approval,2016-08,2016-08,"[{'measure': 'Maximal perceived pain intensity 24 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '24 hours'}]","[{'measure': 'Perceived pain at rest over 12 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '12 hours'}, {'measure': 'Perceived pain at mobilization over 12 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '12 hours'}, {'measure': 'Perceived pain at rest over 24 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '24 hours'}, {'measure': 'Perceived pain at mobilization over 24 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '24 hours'}, {'measure': 'Perceived pain at rest over 48 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '48 hours'}, {'measure': 'Perceived pain at mobilization over 48 h after surgery', 'description': 'Subjectively rated pain perception by a 10-point-numeric rating scale', 'timeFrame': '48 hours'}, {'measure': 'Opioid demand over 12 h after surgery', 'description': 'Cumulative dosis of Piritramide administered on demand over 12 hours', 'timeFrame': '12 hours'}, {'measure': 'Opioid demand over 24 h after surgery', 'description': 'Cumulative dosis of Piritramide administered on demand over 24 hours', 'timeFrame': '24 hours'}, {'measure': 'Opioid demand over 48 h after surgery', 'description': 'Cumulative dosis of Piritramide administered on demand over 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Satisfaction with pain management 24 h after surgery', 'description': 'Subjectively rated degree of satisfaction with analgesia by 10-point numeric Rating scale', 'timeFrame': '24 hours'}]",11.0,18 Years,,FEMALE,False,OTHER,0.0,0.0,ACTUAL,v2_robust,False,False,True,False,changed drug approval,,,no_match,False,,,
NCT06632574,A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors,paclitaxel cationic liposomes,['paclitaxel cationic liposomes'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Advanced Solid Tumor,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",2025-09-01T16:18:07.018251,True,,,,NOT_FOUND,"A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Characteristics of Paclitaxel Cationic Liposome for Injection in the Treatment of Patients With Advanced Solid Tumors Via Transcatheter Arterial Infusion Therapy.",,['Advanced Solid Tumor'],[],,2014-03-19,2027-03-31,"[{'measure': 'The incidence of dose-limiting toxicity (DLT)', 'timeFrame': 'At the end of Cycle 1 ( each cycle is 21 days)'}, {'measure': 'Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)(according to NCI-CTCAE 5.0)', 'timeFrame': 'Up to approximately 3 years'}]","[{'measure': 'AUC0-t', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'AUC0-∞', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Cmax', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Kel', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Tmax', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Vd', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 't1/2', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'CL', 'timeFrame': 'At the end of Cycle 4 ( each cycle is 21 days)'}, {'measure': 'Overall response rate (ORR)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Progression-Free-Survival (PFS)', 'timeFrame': 'Up to approximately 3 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Up to approximately 3 years'}]",15.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01963663,Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients,Metformin,"['Pioglitazone', 'Metformin']",2,INTERVENTIONAL,['NA'],,COMPLETED,Type 2 Diabetes Mellitus,Tehran University of Medical Sciences,2025-09-01T16:18:17.176627,True,,,,CHEMBL1703,Comparison of Metformin and Pioglitazone Effects on Serum YKL-40 Concentrations in Patients With Newly Diagnosed Type 2 Diabetes,,['Type 2 Diabetes Mellitus'],"['YKL-40', 'Chronic low grade inflammation', 'type 2 diabetes mellitus', 'metformin', 'pioglitazone']",,2012-11,2013-04,"[{'measure': 'Serum concentration of YKL-40', 'timeFrame': '12 weeks'}]",[],1.0,35 Years,,ALL,False,OTHER,0.0,84.0,ACTUAL,v2_robust,True,True,False,False,,CN(C)C(=N)NC(=N)N.Cl,CHEMBL1703,partial_match,True,165.63,-1.03,4.0
NCT00091897,Rituximab to Treat Stiff Person Syndrome,Rituximab,"['Rituxan', 'Rituximab', 'rituximab or placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Stiff Person Syndrome,National Institute of Neurological Disorders and Stroke (NINDS),2025-09-01T16:18:07.019935,True,,,,NOT_FOUND,Efficacy of Rituximab in Patients With Stiff Person Syndrome With Anti-GAD Antibodies: A Randomized Placebo-Controlled Trial,,['Stiff Person Syndrome'],"['RITUXAN', 'GABA', 'B Cells', 'Humanized Monoclonal Antibodies', 'GAD', 'Stiff Person Syndrome', 'SPS']",,2004-09,2009-05,"[{'measure': 'To evaluate the efficacy, safety of the chimeric monoclonal antibody Rituximab to deplete B lymphocytes in patients with Stiff Person Syndrome with high anti-GAD antibodies.', 'timeFrame': '2 Years'}]","[{'measure': 'The Heightened Sensitivity Scale will be used as a secondary outcome measure.', 'timeFrame': '2 Years'}]",2.0,25 Years,80 Years,ALL,False,NIH,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01737944,Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration,Methotrexate (MTX),"['Methotrexate (MTX)', 'Device with MTX']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Rheumatoid Arthritis,Antares Pharma Inc.,2025-09-01T16:18:13.429824,True,,,,CHEMBL34259,"Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis",,['Rheumatoid Arthritis'],"['methotrexate injection, subcutaneous, autoinjector']",,2011-01,2011-06,"[{'measure': 'Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX', 'description': 'Dose-normalized area under the curve from time zero to infinity (AUC\\[0-inf\\]/Dose) for each treatment', 'timeFrame': '24 Hour period'}, {'measure': 'Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX', 'description': 'Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC\\[0-24\\]/Dose) for each treatment', 'timeFrame': '24 Hour period'}, {'measure': 'Bioequivalence Based Upon Dose-Normalized Cmax for MTX', 'description': 'Dose-normalized maximum observed concentration for each treatment', 'timeFrame': '24 Hour period'}]",[],3.0,18 Years,,ALL,False,INDUSTRY,0.0,38.0,ACTUAL,v2_robust,True,True,False,False,,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,CHEMBL34259,partial_match,True,454.45,0.27,4.0
NCT00552110,Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500),OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY),"['OXY BID', 'MFNS + OXY combination assessing a different dose (ie, number of sprays) from that used in Group 1', 'oxymetazoline nasal spray (OXY) twice daily', 'MFNS QD', 'MFNS + OXY combination', 'Placebo', 'OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)', 'mometasone furoate nasal spray (MFNS) once daily']",8,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Seasonal Allergic Rhinitis,Organon and Co,2025-09-01T16:18:12.182242,True,,,,CHEMBL762,"Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis",,['Seasonal Allergic Rhinitis'],[],,2007-07,2008-02,"[{'measure': 'Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15', 'description': 'Subjects scored severity of rhinorrhea, nasal congestion/stuffiness, nasal itching, and sneezing at the time of evaluation (NOW) using an ordinal scale from 0 = none to 3 = severe. Evaluations were performed daily in the morning (AM) and evening (PM). For each evaluation, individual symptom scores were summed to a TNSS, which was then averaged for a single score across the 15 day treatment period.', 'timeFrame': '15 days of treatment'}, {'measure': 'Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score', 'description': 'Subjects scored nasal congestion/stuffiness using an ordinal scale from 0 = none to 3 = severe. Baseline was the average of the scores assessed every 15 minutes for 1 hour prior to dosing on Day 1. After dosing on Day 1, congestion was scored every 15 minutes for the 1st hour and every 30 minutes for the next 3 hours. Area under the curve (AUC) was calculated using the trapezoid rule, then standardization achieved by dividing the calculation by 4 hours. Treatment comparisons were examined using the standardized AUC(0-4 hr) of the change from baseline to hour 4 on Day 1.', 'timeFrame': 'from baseline to hour 4 on Day 1'}]",[],2.0,12 Years,,ALL,False,INDUSTRY,1.0,707.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,CHEMBL762,partial_match,True,260.38,2.85,4.0
NCT06332950,Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy,"Adebrelimab, Irinotecan Liposome (II)","['Adebrelimab, Irinotecan Liposome (II), Famitinib', 'Adebrelimab, Irinotecan Liposome (II)']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,NOT_YET_RECRUITING,Extensive-stage Small-cell Lung Cancer,Baohui Han,2025-09-01T16:18:07.017354,True,,,,NOT_FOUND,"A Randomized, Multi-cohort, Multi-center Phase Ib/II Study of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in Patients With ES-SCLC Pre-treated With Immune Checkpoint Inhibitor(s)",,['Extensive-stage Small-cell Lung Cancer'],[],,2024-04-01,2027-04-01,"[{'measure': '6-month progression-free survival', 'description': 'Proportion of disease progression or death from randomization to 6 months of treatment.', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Safety', 'description': 'Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.', 'timeFrame': 'Up to 3 months after the last dose'}, {'measure': 'Objective response rate', 'description': 'Objective response rate, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Progression-free survival', 'description': 'Progression Free Survival, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Overall survival', 'description': 'Overall survival is the time from randomization to death due to any reason or loss of follow-up.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Disease control rate', 'description': 'Disease Control Rate, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}, {'measure': 'Duration of response', 'description': 'Duration of Response, determined according to RECIST v1.1 criteria.', 'timeFrame': 'Up to 36 months'}]",7.0,18 Years,75 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02963181,Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension,Yohimbine,"['DIN:01901885', 'melatonin timed release; 2 or 5 mg', 'Melatonin', 'Yohimbine']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,TERMINATED,"Hypotension, Orthostatic",London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,2025-09-01T16:18:15.909619,True,,,,CHEMBL537669,Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves,,"['Hypotension, Orthostatic', 'Hypertension', 'Autonomic Nervous System Diseases']","['Melatonin', 'Yohimbine', 'Anti-hypertensive agents']",PI leaving,2018-03-01,2019-05-28,"[{'measure': 'Investigation into the integrity of post-ganglionic sympathetic nerves in idiopathic NOH', 'description': 'Markers of post-ganglionic sympathetic function will be examined (i.e. sympathetic blood markers, heart rate, blood pressure, sympathetic nerve activity, etc.)', 'timeFrame': 'Sympathetic markers will be assessed during and immediately following the test. A comparison between healthy participants and NOH patients will be ongoing throughout recruitment and upon completion of study recruitment'}, {'measure': 'Effects of melatonin on supine hypertension in persons with neurogenic orthostatic hypotension', 'description': 'Supine systolic blood pressure', 'timeFrame': '4 weeks'}, {'measure': 'Effects of melatonin on supine hypertension in patients with neurogenic orthostatic hypotension', 'description': 'Change in postural (supine-standing) systolic blood pressure', 'timeFrame': '4 weeks'}]","[{'measure': 'Serum markers of sympathetic activation', 'timeFrame': 'Before and during stimulation of sympathetic nervous system'}, {'measure': 'Carotid artery diameter', 'timeFrame': 'During stimulation of sympathetic nervous system'}, {'measure': 'Sympathetic nerve activation using microneurography', 'timeFrame': 'During stimulation of sympathetic nervous system'}, {'measure': 'Orthostatic symptoms based on standard autonomic symptom questionnaires', 'timeFrame': '30 minutes before testing'}, {'measure': 'Sleep quality assessment using Epworth Sleepiness Scale', 'timeFrame': 'Assessed at pre- and post- melatonin treatment; week 1 and week 5 of melatonin intervention timeframe'}, {'measure': 'Urine and Saliva melatonin levels', 'timeFrame': 'Assessed at pre- and post- melatonin treatment; week 1 and week 5 of melatonin intervention timeframe'}]",9.0,18 Years,80 Years,ALL,True,OTHER,0.0,10.0,ACTUAL,v2_robust,True,False,True,False,PI leaving,COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O.Cl,CHEMBL537669,partial_match,True,390.91,2.65,4.0
NCT01383135,Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2,F18-FPPRGD2,['F18-FPPRGD2'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Breast Cancer,Stanford University,2025-09-01T16:18:17.187227,True,,,,NOT_FOUND,Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2,,"['Breast Cancer', 'Non-Small-Cell Lung Cancer', 'Glioblastoma', 'Other Cancers']",['Healthy volunteers'],,2010-10,2013-12,"[{'measure': 'Tracer Dosimetry by Organ', 'description': 'Normal radiopharmaceutical biodistribution was analyzed visually to obtain dosimetry data in healthy volunteers. Organs with the highest radiation absorbed dose (dosimetry) are provided below. Dosimetry was calculated by drawing regions-of-interest around organs with visually appreciable radiopharmaceutical uptake greater than background and using organ-level internal dose assessment software from Vanderbuilt University (2003).\n\nResults are reported in mSv/MBq (milli-Sieverts per mega-Bequerel) which is a measurement of the mean absorbed radiation dose within an organ.', 'timeFrame': '5 hours'}, {'measure': 'F18-FPPRGD2 Time-activity at Specified Timepoints', 'description': 'Radiopharmaceutical pharmacokinetics describe the change in radiopharmaceutical distribution in the body (from the blood to organs, tissues, cells) over time. Radiopharmaceutical pharmacokinetics are used to determine optimal imaging time, ie, when target activity (organ or cell of interest) is greater than background activity (blood). Optimal imaging time must also be balanced with tracer bio-metabolism and radioactive decay. F18-FPPRGD2 pharmacokinetics was measured in healthy volunteers to estimate optimal imaging time. Scans were used to visually identify regions of interest (organs of F18-FPPRGD2 accumulation), and detected radiation was plotted as a measurement over time.', 'timeFrame': '30, 60, and 90 minutes post-injection'}, {'measure': 'Sensitivity of F18-FPPRGD2 PET/CT in Breast Cancer', 'description': 'Sensitivity is the ability of a test to correctly identify patients with the disease being investigated. In this instance, how well F18-FPPRGD2 PET/CT detects true-positive patients. Sensitivity is defined as \\[TP/ (TP+FN)\\], where TP= true positive, and FN = false negative. The outcome is reported as a percentage without dispersion. A higher percentage indicates a greater probability that a lesion identified based on scan results is cancerous, and a lower percentage indicates reduced confidence in that result.', 'timeFrame': '3 hours'}, {'measure': 'Specificity of F18 FPPRGD2 PET/CT in Breast Cancer', 'description': 'Specificity is the ability of a test to correctly identify patients who do not have the disease being investigated. In this instance, how well F18 FPPRGD2 PET/CT detects true-negative patients. Specificity is:\n\n\\[TN/ (TN+FP)\\], where TN= true negative, and FP = false positive.', 'timeFrame': 'an estimated average of 3 hours'}, {'measure': 'Glioblastoma Primary Tumor Response Assessed by PET Scan', 'description': 'Primary tumor response was assessed after 6 weeks of treatment as the change in tumor metabolism based on the maximum standardized uptake value (SUVmax) as determined by positron emission tomography (PET) scans. Decreased SUVmax correlates to a reduction of tumor metabolism, and is considered an indicator of primary tumor response. Reduction of SUVmax was determined as the change from baseline in uptake of F-18FPPRGD2. The outcome is reported as the baseline and week 6 values, with standard deviation.', 'timeFrame': 'Baseline and Week 6'}]","[{'measure': 'Glioblastoma Primary Tumor Response Assessed by CT Scan', 'description': 'Primary tumor response was assessed after 6 weeks of treatment as the change in tumor metabolism based on the maximum standardized uptake value (SUVmax) as determined by computed tomography (CT) scans. Decreased SUVmax correlates to a reduction of tumor metabolism, and is considered an indicator of primary tumor response. Reduction of SUVmax was determined as the change from baseline in uptake of F-18FPPRGD2. The outcome is reported as the mean difference from baseline to week 6, with standard deviation.', 'timeFrame': 'Baseline and Week 6'}]",6.0,18 Years,,ALL,True,OTHER,0.0,27.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05898087,Subpectoral Bupivacaine for Pain Management in Adolescent Reduction Mammaplasty,Marcaine 0.25 % Injectable Solution,"['Saline', 'bupivacaine 0.25% injectable solution', 'injectable saline', 'Marcaine 0.25 % Injectable Solution']",4,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Macromastia,Connecticut Children's Medical Center,2025-09-01T16:18:14.660407,True,,,,NOT_FOUND,Subpectoral Bupivacaine for Pain Management in Adolescent Reduction Mammaplasty,,"['Macromastia', 'Post-operative Pain']","['macromastia', 'post-operative pain', 'bupivacaine']",,2022-04-01,2026-04-01,"[{'measure': 'Patient Reported Pain Score', 'description': 'Post-operative pain score will be patient reported on a rating scale of 1-10. This will be recorded by the PACU nurse upon admission and upon discharge from the PACU. Patients will subsequently record a daily pain score in a home log daily until their 1 week follow-up visit. Scores will be recorded using the home log provided by the patient. We will also utilize chart review to record PACU pain score from the immediate post-operative time period.', 'timeFrame': 'Measured on day of surgery'}]","[{'measure': 'Demographics', 'description': 'Demographics including age, race, ethnicity will be collected and recorded for all patients approached to enter the study.', 'timeFrame': 'Recorded when patient is enrolled'}, {'measure': 'Total Amount of Narcotic Use', 'description': 'Narcotic use will be determined by chart review of the PACU record. The amount of narcotic pain medication will be recorded for each patient. Prescription narcotic use upon discharge will be patient-reported in their patient log.', 'timeFrame': 'Measured up until 4 weeks post-op'}, {'measure': 'Days to Return to full activity', 'description': 'Return to full activity- will be categorized as returning to school, returning to light activity, or returning to full activity/heavy exercise.', 'timeFrame': 'Measured for 4 weeks post-op'}, {'measure': 'Length of stay in post-anesthesia care unit (hours)', 'description': 'Length of stay in post-anesthesia care unit will be determined by chart review from time entering the PACU to time of discharge from the hospital.', 'timeFrame': 'Measured on day of surgery'}]",5.0,13 Years,25 Years,ALL,True,OTHER,0.0,128.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01564758,Post Marketing Surveillance Study on Linezolid,Linezolid,['Linezolid'],1,OBSERVATIONAL,[],,COMPLETED,Gram-Positive Bacterial Infections,Pfizer,2025-09-01T16:18:17.183708,True,,,,NOT_FOUND,"Post Marketing Surveillance on the Efficacy, Safety and Tolerability of Linezolid (Zyvox) in the Treatment of Gram Positive Infections",,['Gram-Positive Bacterial Infections'],"['non-interventional', 'non-comparative', 'open-label study', 'safety', 'Linezolid', 'gram positive infections', 'Filipino']",,2004-02,2005-03,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship.', 'timeFrame': 'Baseline up to End of Treatment (EOT) (Day 10 up to 28)'}]","[{'measure': 'Number of Participants With Clinical Response', 'description': 'Clinical response assessed by Investigator at EOT visit as Cure: complete resolution of signs or symptoms of infection and no need to start another antibiotic. Improvement: incomplete resolution of signs or symptoms of infection but no need to start another antibiotic. Failure: death, or need to start another antibiotic. For participants previously assessed as failures, the outcome was failure at subsequent time points.', 'timeFrame': 'EOT (Day 10 up to 28)'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,99.0,ACTUAL,v2_robust,False,True,False,True,,,,no_match,False,,,
NCT00006262,Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer,becatecarin,['becatecarin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Ovarian Cancer,Northwestern University,2025-09-01T16:18:20.961271,True,,,,CHEMBL2107313,A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer,,['Ovarian Cancer'],"['stage III ovarian epithelial cancer', 'stage IV ovarian epithelial cancer', 'recurrent ovarian epithelial cancer']",Unable to accrue patients to the study.,2000-07,2001-09,[],[],0.0,21 Years,,FEMALE,False,OTHER,1.0,,,v2_robust,True,False,True,False,Unable to accrue patients to the study.,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,CHEMBL2107313,exact_match,True,669.56,4.3,3.0
NCT06293807,Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine,"Xylocaine 2 % with 1:100,000 epinephrine","['Xylocaine 2 % with 1:100,000 epinephrine', 'Marcaine', 'Lidocaine', 'Bupivicaine 0.5% with 1:200,000 epinephrine']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Periodontal Diseases,The University of Texas Health Science Center at San Antonio,2025-09-01T16:18:19.663489,True,,,,CHEMBL679,Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine: A Short-term Clinical Response,,['Periodontal Diseases'],"['Flap debridement', 'Flap osseous', 'Tooth extractions', 'Guided Tissue Regeneration', 'IV sedation', 'Local anesthesia']",,2022-06-06,2023-04-16,"[{'measure': 'Change in pain using Visual Analog Scale (VAS)', 'description': 'Pain response recorded using a 20 point visual Analog Scale. The VAS scale is a straight line scale scored from 0-20 with 0 indicating the least amount of pain and 20 the worst pain ever experienced.', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Number of Ibuprofen administered', 'description': 'Additive number of ibuprofen taken over monitoring period', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Number of Tylenol administered', 'description': 'Additive number of acetaminophen taken over monitoring period', 'timeFrame': 'Baseline to 48 hours'}]","[{'measure': 'Arch Response', 'description': 'Difference in pain response based upon arch', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Number of teeth', 'description': 'Difference in pain response based upon number of teeth per surgical site', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Type of procedure', 'description': 'Difference in pain response based upon type of procedure', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Gender of patient', 'description': 'Difference in pain response based upon gender of participant', 'timeFrame': 'Baseline to 48 hours'}, {'measure': 'Age of patient', 'description': 'Difference in pain response based upon age of participant', 'timeFrame': 'Baseline to 48 hours'}]",8.0,18 Years,,ALL,True,OTHER,0.0,72.0,ACTUAL,v2_robust,True,True,False,False,,CNC[C@H](O)c1ccc(O)c(O)c1,CHEMBL679,partial_match,True,183.21,0.35,4.0
NCT00641771,4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230),alendronate sodium (+) cholecalciferol,"['alendronate sodium (+) cholecalciferol', 'MK0217A', 'Comparator: Placebo (unspecified)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Osteoporosis,Organon and Co,2025-09-01T16:18:13.429450,True,,,,NOT_FOUND,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter 4-Week Study to Assess the Effect of Alendronate 70 mg and Vitamin D3 2800 IU Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women",,['Osteoporosis'],[],,2004-05,2005-08,"[{'measure': 'To compare change in fractional calcium absorption following administration of MK0217A relative to matching placebo, in postmenopausal women with osteoporosis', 'timeFrame': '4 Weeks'}]",[],1.0,50 Years,80 Years,FEMALE,False,INDUSTRY,0.0,56.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00348062,A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension,Bimatoprost,['Bimatoprost'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Glaucoma,Innovative Medical,2025-09-01T16:18:15.894849,True,,,,NOT_FOUND,A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension,,['Glaucoma'],[],,,,[],[],0.0,18 Years,,ALL,,INDUSTRY,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01846273,Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT),Ranibizumab,"['Sham PDT', 'Verteporfin PDT', 'Lucentis', 'Ranibizumab']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Age-related Macular Degeneration,Novartis Pharmaceuticals,2025-09-01T16:18:23.463661,True,,,,NOT_FOUND,"A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy",,"['Age-related Macular Degeneration', 'Polypoidal Choroidal Vasculopathy']","['Polypoidal choroidal vasculopathy', 'Visual acuity', 'Ranibizumab', 'Verteporfin PDT']",,2013-08-07,2017-03-02,"[{'measure': 'Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Number of Patients With Complete Polyp Regression From Baseline at Month 12 - Study Eye', 'description': 'Polyp regression was based on the Indocyanine green angiography (ICGA) assessment by the Central Reading Center (CRC). A patient was considered to have complete polyp regression if the presence of polyps, as assessed by CRC, had value ""No."" Polyp regression which may lead to disease stabilization and consequently better vision.', 'timeFrame': 'Baseline, Month 12'}]","[{'measure': 'Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Month 24 - Study Eye', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Percentage of Patients With BCVA (Letters) Change From Baseline at Month 24 - Study Eye', 'description': 'BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Maintenance of BCVA (Within 5 Letter Change) at Month 12 and 24 Compared to BCVA at the Time Point of First Ranibizumab Treatment Interruption', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters.', 'timeFrame': 'Month 3, Month 12, Month 24'}, {'measure': 'Change in BCVA at Month 12 and 24 Compared to the Time Point of First Ranibizumab Treatment Interruption', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters.', 'timeFrame': 'Month 3, Month 12, Month 24'}, {'measure': 'Percentage of Patients With Complete Polyp Regression at Months 6 and 24 - Study Eye', 'description': 'Polyp regression was based on the Indocyanine green angiography (ICGA) assessment by the Central Reading Center (CRC). A patient was considered to have complete polyp regression if the presence of polyps, as assessed by CRC, had value ""No."" Polyp regression which may lead to disease stabilization and consequently better vision.', 'timeFrame': 'Month 6, Month 24'}, {'measure': 'Percentage of Patients With Presence of Leakage at Month 6, Month 12 and Month 24 - Study Eye', 'description': 'Presence of lesion leakage was based on Fluorescein Angiography (FA) as assessed by the Central Reading Center (CRC). The presence of leakage may lead to disease progression and worsening vision.', 'timeFrame': 'Month 6, Month 12 and Month 24'}, {'measure': 'Mean Change From Baseline in Investigator-Assessed Central Subfield Retinal Thickness (CSFT) at Month 24 - Study Eye', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. A negative number indicates a reduction in thickness, whereas a positive number indicates an increase. An increase in thickness may indicate a progression of the underlying disease.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 12', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 12', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 24', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 24', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 12', 'timeFrame': 'Month 3, Month 12'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 24', 'timeFrame': 'Month 3, Month 24'}, {'measure': 'Mean Change From Baseline in Composite Scores, National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) at Months 3, 12 and 24', 'description': ""The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Months 3, 12 and 24. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function."", 'timeFrame': 'Baseline, Month 3, Month 12, Month 24'}, {'measure': 'Number of Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary System Organ Class', 'description': 'Reported categorically: Mild, Moderate, Severe', 'timeFrame': 'Up to Month 24'}, {'measure': 'Number of Non-Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary System Organ Class', 'description': 'Reported categorically: Mild, Moderate, Severe', 'timeFrame': 'Up to Month 24'}]",18.0,18 Years,,ALL,False,INDUSTRY,0.0,321.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04495322,"To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.",TG-1000,"['TG-1000', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Chinese Volunteers,"TaiGen Biotechnology Co., Ltd.",2025-09-01T16:18:13.418230,True,,,,NOT_FOUND,"A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.",,['Healthy Chinese Volunteers'],[],,2020-07-17,2020-12-30,"[{'measure': 'Number of subjects of treatment-emergent adverse events', 'description': 'Any significant findings after dosing will be considered as adverse events.', 'timeFrame': '8 days'}, {'measure': 'Number of subjects of Significant Abnormal Vital Signs Findings', 'description': 'The systolic and diastolic blood pressure (mmHg), pulse/heart rate (beats/min), respiratory rate (breaths/min), and body temperature (oC) will be measured.', 'timeFrame': '8 days'}, {'measure': 'Number of subjects With Significant Abnormal Physical Examination Findings', 'description': 'A full general physical examination of the major body systems (General Appearance; Dermatological including skin and nails; Head and Neck; Chest region including Heart and Lung; Abdominal region including Gastrointestinal and Gastroenterology; Back region; Extremities; Psychiatric or Neurological; Lymph nodes; Other) will be performed by investigator.', 'timeFrame': '8 days.'}, {'measure': 'Number of subjects With Significant Abnormal 12-lead Electrocardiography (ECG) Findings', 'description': '12-lead ECG will be performed after a rest in a supine position. The following ECG parameters will be listed: heart rate, the time between QRS complexes (RR Interval) (ms), the beginning of the P wave to the first deflection of the QRS complex (PR Interval) (ms), first deflection of QRS complex to end of QRS complex at isoelectric line (QRS duration) (ms), first deflection of QRS complex to end of T wave at isoelectric line (QT interval) (ms), Corrected QT interval by Bazett (QTcB) (ms), and Corrected QT interval by - Fridericia (QTcF) (ms).', 'timeFrame': '8 days'}, {'measure': 'Number of subjects With Significant Abnormal Holter Electrocardiography (ECG) Findings', 'description': 'Holter ECG will be monitor continue from 12 hr pre-dose until 24 hr post-dose. The Investigator will determine whether the results of the Holter monitoring are normal or abnormal.', 'timeFrame': '12 hr pre-dose until 24 hr post-dose'}, {'measure': 'Number of Participants With Significant Abnormal Laboratory Values', 'description': 'Chemistry, Hematology, Coagulation, Urinalysis, Human Immunodeficiency Virus (HIV) test, Hepatitis A virus(HAV) test, Hepatitis B virus (HBV) test, Hepatitis C virus (HCV) test, syphilis, serum pregnancy tests and Breath Alcohol Test', 'timeFrame': '8 days'}, {'measure': 'Peak Plasma Concentration (Cmax)', 'description': 'Blood sample will be collected to evaluate PK profile and food effect of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'time to Cmax (Tmax)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'area under the curve from time zero to the time (AUC0-t)', 'description': 'Blood sample will be collected to evaluate PK profile and food effect of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'area under the concentration-time curve from time zero to infinity (AUC0-inf)', 'description': 'Blood sample will be collected to evaluate PK profile and food Effect of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'terminal elimination half-life (T1/2, z)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'apparent total body clearance (CL/F)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'apparent total volume distribution (V/F)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'plasma concentration 24 h after dosing (C24)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'urinary excretion ratio relative to dose from time zero to the time (Feu0-t)', 'description': 'Urine sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}]",[],16.0,18 Years,45 Years,ALL,True,INDUSTRY,1.0,66.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01258491,"Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects",Nicotinic Acids,['Nicotinic Acids'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Subjects,Heidelberg University,2025-09-01T16:18:20.953852,True,,,,NOT_FOUND,"Double-blind, Randomized, Placebo-controlled, Single-center, 2 Treatment, 3-way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects",,['Healthy Subjects'],[],,2005-05,2005-12,[],[],0.0,18 Years,45 Years,ALL,True,OTHER,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02566759,"A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants",TAK-831 Oral Suspension,"['TAK-831 Oral Suspension', 'TAK-831 Placebo', 'TAK-831 Tablet']",3,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,"Schizophrenia, Cerebellar Ataxia",Neurocrine Biosciences,2025-09-01T16:18:12.185604,True,,,,NOT_FOUND,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects",,"['Schizophrenia, Cerebellar Ataxia']",['Drug therapy'],The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.,2015-09-23,2016-07-12,"[{'measure': 'Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)', 'timeFrame': 'Baseline up to 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43)'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose', 'description': 'Clinical laboratory tests included hematology, serum chemistry and urinalysis.', 'timeFrame': 'Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose', 'description': 'Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (\\<) 85 millimeter of mercury (mm Hg) to greater than (\\>) 180 mm Hg; diastolic blood pressure \\< 50 mm Hg to \\>110 mm Hg; pulse rate \\<50 bpm to \\>120 bpm; Temperature \\<35.6 degree Celsius to \\>37.7 degree Celsius.', 'timeFrame': 'Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose', 'description': ""Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate \\<50 beats per minute (bpm) to \\>120 bpm; PR interval less than or equal to (\\<=) 80 millisecond (msec) to greater than or equal to (\\>=) 200 msec; QRS interval \\<=80 msec to \\>=180 msec; QT interval \\<=300 msec to \\>=460 msec; QTcB interval \\<=300 msec to \\>=500 msec or \\>=30 msec change from baseline and \\>=450 msec; QT interval with Fridericia's correction method (QTcF) interval \\<=50 msec to \\>=500 msec or \\>=30 msec change from baseline and \\>=450 msec."", 'timeFrame': 'Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4'}]","[{'measure': 'Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose'}, {'measure': 'Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831', 'timeFrame': 'Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose; Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose'}, {'measure': 'Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose'}, {'measure': 'Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831', 'timeFrame': 'Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose'}]",10.0,18 Years,55 Years,ALL,True,INDUSTRY,1.0,110.0,ACTUAL,v2_robust,True,False,True,True,The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.,,,no_match,False,,,
NCT04826497,Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction,nicorandil,"['Control Group', 'Placebo（normal saline）', 'nicorandil', 'Experiment Group']",4,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Coronary Heart Disease,Xuzhou Central Hospital,2025-09-01T16:18:20.955751,True,,,,NOT_FOUND,Effects of Nicorandil on Cardiac Sympathetic Nerve Activity and Distribution in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention,,['Coronary Heart Disease'],"['nicorandil', 'primary percutaneous coronary intervention', 'acute ST segment elevation myocardial infarction', 'cardiac sympathetic nerve']",,2021-04,2022-02,"[{'measure': 'Comparison of the delayed heart/mediastinum count (H/M) ratio', 'description': 'The delayed heart/mediastinum count (H/M) ratio was determined from 123I-meta-iodobenzylguanidine (MIBG) images', 'timeFrame': '10 days after primary PCI'}]","[{'measure': 'The total defect score (TDS)', 'description': 'The total defect score was determined from 123I-meta-iodobenzylguanidine (MIBG) images', 'timeFrame': '10 days after primary PCI'}, {'measure': 'Rate of slow re-flow/no-reflow phenomenon', 'description': 'TIMI myocardial perfusion grade (TMPG) of the final coronary flow in the culprit artery', 'timeFrame': '5 minutes after primary PCI'}, {'measure': 'Rate fo complete ST-segment resolution', 'description': 'ST-segment resolution \\>50 percent in ECG', 'timeFrame': '2 hours after primary PCI'}, {'measure': 'Rate of unplanned hospitalization for heart failure', 'description': 'Rate of unplanned hospitalization for heart failure', 'timeFrame': '6 months after primary PCI'}, {'measure': 'The washout rate (WR)', 'description': 'The washout rate (WR) were determined from 123I-meta-iodobenzylguanidine (MIBG) images', 'timeFrame': '10 days after primary PCI'}, {'measure': 'The total defect score (TDS)', 'description': 'The total defect score was determined from 99mTc-pyrophosphate scintigraphy', 'timeFrame': '7 days after primary PCI'}]",7.0,20 Years,80 Years,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03310021,"A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects",Apixaban,"['Apixaban', 'Xarelto', 'Rivaroxaban', 'Placebo', 'Savaysa, Lixiana', 'Edoxaban', 'Eliquis']",7,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Bleeding,Portola Pharmaceuticals,2025-09-01T16:18:14.662165,True,,,,NOT_FOUND,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects",,['Bleeding'],[],,2017-08-28,2019-08-13,"[{'measure': 'Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.', 'description': 'The primary efficacy endpoint is the percent change in the anti-FXa activity from baseline to the end of infusion (EOI) nadir.', 'timeFrame': 'Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours'}]","[{'measure': 'Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.', 'description': 'The percent change from baseline in anti-FXa activity at its end of bolus (EOB) nadir.', 'timeFrame': 'Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours'}, {'measure': 'Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.', 'description': 'The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOB nadir.', 'timeFrame': 'Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours'}, {'measure': 'Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.', 'description': 'The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOI nadir.', 'timeFrame': 'Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours'}, {'measure': 'Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.', 'description': 'The change in thrombin generation from baseline to its EOB peak.', 'timeFrame': 'Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours'}, {'measure': 'Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.', 'description': 'The change in thrombin generation from baseline to its EOI peak.', 'timeFrame': 'Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours'}]",6.0,18 Years,75 Years,ALL,True,INDUSTRY,0.0,108.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03691935,Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.,Ropivacaine,"['Sham anesthetic', 'Naropin', 'Ropivacaine', 'Normal saline']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Nephrectomy,Milton S. Hershey Medical Center,2025-09-01T16:18:07.013290,True,,,,NOT_FOUND,Erector Spinae Plane Block (ESPB): A New Technique for Perioperative Pain Control in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.,,"['Nephrectomy', 'Partial Nephrectomy', 'Incision Site Discomfort']","['kidney', 'surgery', 'analgesia', 'surgical incision', 'opioid sparing', 'flank pain', 'local anesthesia']",Slow enrollment related to global pandemic and changes to surgical practice.,2018-09-28,2024-02-02,"[{'measure': 'Pain Scores Using the Visual Analogue Pain Scale From Zero Pain to Level Ten Pain', 'description': 'Data will be collected via the electronic medical record and begin following patient randomization. The Visual Analogue Scale pain scales will be administered and collected on Post Operative Days 1, 2 and 3. Minimum value = 0 No Pain, Maximum value = 10 Worst possible, unbearable, excruciating pain', 'timeFrame': 'Aggregate pain scores for average length of hospital stay which is 3 days'}]",[],1.0,18 Years,85 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,False,True,False,Slow enrollment related to global pandemic and changes to surgical practice.,,,no_match,False,,,
NCT06525948,Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA,rhTPO,"['Cyclosporin A', 'rhTPO']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Aplastic Anemia,Peking Union Medical College Hospital,2025-09-01T16:18:19.675215,True,,,,NOT_FOUND,Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of Transfusion-dependent Non-severe Aplastic Anaemia (TD-NSAA),,"['Aplastic Anemia', 'Transfusion-dependent Anemia']",[],,2024-07-30,2025-12-30,"[{'measure': 'ORR', 'description': 'Overall Response Rate (ORR): meets the criteria for CR and PR.', 'timeFrame': '3 months'}, {'measure': 'CRR', 'description': 'Complete Response Rate (CRR)：ANC\\>1.5×10\\^9/L，Hb\\>100g/L，PLT\\>100×10\\^9/L；', 'timeFrame': '3 months'}]","[{'measure': 'ORR', 'description': 'Overall Response Rate (ORR): meets the criteria for CR and PR.', 'timeFrame': '6 months'}, {'measure': 'CRR', 'description': 'Complete Response Rate (CRR)：ANC\\>1.5×10\\^9/L，Hb\\>100g/L，PLT\\>100×10\\^9/L；', 'timeFrame': '6 months'}, {'measure': 'Time for platelet count to recover to ≥20 x 10^9/L with a 1-fold increase in absolute value', 'description': 'Time for platelet count to recover to ≥20 x 10\\^9/L with a 1-fold increase in absolute', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Proportion of patients with adverse events', 'description': 'safety event', 'timeFrame': 'through study completion, an average of 1 year'}]",6.0,18 Years,,ALL,False,OTHER,0.0,54.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01348490,"Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)",Ruxolitinib,"['Ruxolitinib', 'INCB018424']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,MPN (Myeloproliferative Neoplasms),Incyte Corporation,2025-09-01T16:18:20.955717,True,,,,NOT_FOUND,"An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L",,['MPN (Myeloproliferative Neoplasms)'],"['PMF', 'PPV-MF', 'PET-MF']",,2011-06-15,2018-12-19,"[{'measure': 'Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose', 'description': 'Magnetic resonance imaging (MRI) of the upper and lower abdomen and pelvis was performed to assess spleen volumes. Computed tomography (CT) scan was performed if participant was not a candidate for MRI or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percent Change From Baseline in Total Symptom Score (TSS) as Measured by the Modified Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 Diary at Week 24 by Final Titrated Dose', 'description': 'Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAE)', 'description': 'TEAE was defined as adverse events that began or worsened from baseline after the first administration of the study drug.\n\nParticipants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Percentage of Participants With New Onset Grade 4 Thrombocytopenia Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE V4.03)', 'description': 'Participants with platelet count between 50 and 100 × 10\\^9/L at the screening and/or baseline visit were enrolled in the study. Thrombocytopenia is defined as a condition with low blood platelet count. Grade 4 thrombocytopenia was platelet count \\< 25 × 10\\^9/L.\n\nParticipants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Percentage of Participants With New Onset Grade 2 or Higher Hemorrhage as Assessed by CTCAE V4.03', 'description': 'Hemorrhages were defined as any lower level terms by MedDRA included in the Standardized MedDRA Query (SMQ) for hemorrhage terms.\n\nParticipants were analyzed based on the number of subjects who received a dose within the dose group. The percentages for each column are calculated using this N. Participants who had more than 1 event in an AE category (eg, treatment-related TEAE) are counted once at each dose level the event occurred.', 'timeFrame': 'Up to Week 156'}]","[{'measure': 'Percent Change in Spleen Volume at Week 24 Compared to Baseline', 'description': 'MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant was not a candidate for MRI, or if MRI was not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percent Change in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline', 'description': 'Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms..', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With ≥ 35% Reduction in Spleen Volume at Week 24 Compared to Baseline', 'description': 'MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With ≥10% Reduction in Spleen Volume at Week 24 Compared to Baseline', 'description': 'MRI of the upper and lower abdomen and pelvis was performed, to assess spleen volumes. CT scan was performed if participant is not a candidate for MRI, or if MRI is not readily available. MRI was performed with a body coil. Spleen volume was obtained by outlining the circumference of the organ and determining the volume using the validated technique of least squares. The MRI (or CT scan in applicable participants) was performed on the first or second day of the baseline period (ie, Day -7 or Day -6), and the site radiologist sent the scan to the central imaging laboratory that same day. The CT scans were processed by the same central laboratory used for MRIs.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants With ≥ 50% Improvement in Total Symptom Score as Measured by the Modified MFSAF V2.0 Diary at Week 24 Compared to Baseline', 'description': 'Symptoms of myelofibrosis were assessed using a modified Myelofibrosis Symptom Assessment Form (MFSAF) Version 2.0 diary. Using the diary, patients rated the following symptoms on a scale from 0 (absent) to 10 (worst imaginable): night sweats, itching, abdominal discomfort, pain under ribs on left, feeling of fullness (early satiety), and muscle/bone pain. The total symptom score ranged from 0-60 and was calculated as the sum of the 6 symptom scores. A higher score indicates worse symptoms.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Change in Spleen Length Measured by Palpation', 'description': 'Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Percent Change From Baseline in Spleen Length Measured by Palpation', 'description': 'Measurement of spleen length below the left costal margin was measured by palpation at each study visit. Investigators were provided with a soft centimeter ruler so that palpable spleen length was measured in centimeters and not in finger breadths. The edge of the spleen was determined by palpation, and measured in centimeters, using a soft ruler, from the costal margin to the point of greatest splenic protrusion.', 'timeFrame': 'Up to Week 156'}, {'measure': 'Patient Global Impression of Change (PGIC) Score at Each Visit', 'description': ""Symptoms of myelofibrosis were assessed using the PGIC questionnaire. Using the questionnaire, patients rated the overall sense of treatment effect on their symptoms on a scale of 1 (very much improved)- 7(very much worse). The specific wording was: Since the start of the treatment you've received in this study, your myelofibrosis symptoms are: 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse. A higher score indicates worse symptoms."", 'timeFrame': 'Up to Week 156'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,66.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03948685,Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction,Carvedilol SR,"['Carvedilol SR', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Heart Failure With Preserved Ejection Fraction,Yonsei University,2025-09-01T16:18:25.987501,True,,,,CHEMBL723,"Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction : a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Pilot Trial (CAYMUS-HFpEF)",,['Heart Failure With Preserved Ejection Fraction'],[],,2019-05,2021-01,"[{'measure': 'The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.', 'description': 'The maximum NT-proBNP value change at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.', 'description': 'The maximum NT-proBNP value change from baseline to 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.', 'description': 'The maximum NT-proBNP value change from baseline to End of trial(24weeks).', 'timeFrame': '24 weeks'}]","[{'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) after 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) after 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) from baseline to end of trial(24 weeks)', 'timeFrame': '24 weeks'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea after 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea after 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea from baseline to end of trial(24 weeks)', 'timeFrame': '24 weeks'}, {'measure': 'the change of body weight', 'description': 'the change of body weight at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'the change of body weight', 'description': 'the change of body weight after 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'the change of body weight', 'description': 'the change of body weight after 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'the change of body weight', 'description': 'the change of body weight from baseline to end of trial(24 weeks)', 'timeFrame': '24 weeks'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': 'Baseline'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': '8 weeks'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': '16 weeks'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': '24 weeks'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': 'Baseline'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': '8 weeks'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': '16 weeks'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': '24 weeks'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': 'Baseline'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': '8 weeks'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': '16 weeks'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': '24 weeks'}]",27.0,19 Years,,ALL,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,True,False,False,False,,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,CHEMBL723,partial_match,True,406.48,3.74,4.0
NCT04534322,Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma,Melphalan Flufenamide,"['Melphalan Flufenamide', 'melflufen', 'Dexamethasone']",3,EXPANDED_ACCESS,[],,APPROVED_FOR_MARKETING,Relapsed and/or Refractory Multiple Myeloma,Oncopeptides AB,2025-09-01T16:18:13.418271,True,,,,CHEMBL4303060,An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma,,['Relapsed and/or Refractory Multiple Myeloma'],[],,,,[],[],0.0,18 Years,,ALL,,INDUSTRY,0.0,,,v2_robust,False,False,False,False,,CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1,CHEMBL4303060,exact_match,True,498.43,3.27,4.0
NCT05180890,A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea,Danavorexton,"['TAK-925', 'Placebo', 'Danavorexton']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Sleep Apnea,Takeda,2025-09-01T16:18:09.635755,True,,,,CHEMBL4650341,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Effects of Overnight Intravenous TAK-925 in Patients With Obstructive Sleep Apnea",,['Sleep Apnea'],['Drug Therapy'],,2022-03-10,2022-11-23,"[{'measure': 'Number of Participants With at Least one Treatment-emergent Adverse Event (TEAE)', 'timeFrame': 'From the first dose of danavorexton in Treatment Period 1 up to approximately 7 days after the last dose of danavorexton in Treatment Period 3 (up to 41 days)'}]","[{'measure': 'Change From Baseline in Upper Airway Collapsibility Index (UACI)', 'description': 'The UACI is a 10-minute evaluation that tests the key biological mechanism that causes obstructive sleep apnea (OSA).', 'timeFrame': 'Baseline (-15 minutes from the start of infusion [first UACI]), and at 20 minutes (second UACI), and 55 minutes (third UACI) on Day 1 of each Treatment Period'}, {'measure': 'Apnea-Hypopnea Index (AHI) Observed During Overnight Polysomnographys (PSGs)', 'description': 'PSG analysis will be performed to determine an apnea hypopnea index. AHI score is used to indicate the severity of sleep apnea. The AHI is calculated by dividing the number of apnea events by the number of hours of sleep. An apnea hypopnea index less than five events per hour is considered within normal limits.', 'timeFrame': 'Day 1 up to Day 2 of each Treatment Period'}]",3.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,13.0,ACTUAL,v2_robust,True,True,False,True,,COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@@H](c2ccccc2)CC1,CHEMBL4650341,exact_match,True,424.56,2.88,2.0
NCT02733640,Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?,Pantoprazole,"['Ranitidine', 'Pantoprazole']",2,INTERVENTIONAL,['NA'],,COMPLETED,Antiplatelet Effect,Seoul National University Bundang Hospital,2025-09-01T16:18:23.451216,True,,,,NOT_FOUND,,,['Antiplatelet Effect'],[],,2012-10,2015-05,"[{'measure': 'Number of participants with more than 5 Ω of impedance after intervention by an aggregometer which measures platelet aggregation in whole blood samples', 'description': '8 days after administration of pantoprazole (or ranitidine)', 'timeFrame': '8 days'}]","[{'measure': 'Change of the impedance value (Ω) by an aggregometer which measures platelet aggregation in whole blood samples', 'description': '8 days after administration of pantoprazole (or ranitidine)', 'timeFrame': 'baseline and 8days'}, {'measure': 'Number of participants with gastrointestinal bleeding', 'timeFrame': 'up to 2weeks'}, {'measure': 'Number of participants with reccured coronary artery disease', 'timeFrame': 'up to 2weeks'}]",4.0,18 Years,79 Years,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02782754,Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma,Carboplatin,"['Etoposide', 'Carboplatin', 'Bleomycin', 'Cyclophosphamide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Intracranial Germinoma,Samsung Medical Center,2025-09-01T16:18:15.899311,True,,,,NOT_FOUND,Treatment of Intracranial Germinoma With Chemotherapy Prior to Reduced Dose and Volume of Radiotherapy,,['Intracranial Germinoma'],[],,2013-01,,"[{'measure': 'Rate of late sequelae', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Rate of event free survival', 'timeFrame': 'Up to 5 years'}]",2.0,3 Years,30 Years,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00088400,Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors,TransMID,['TransMID'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Glioblastoma,National Institute of Neurological Disorders and Stroke (NINDS),2025-09-01T16:18:19.663054,True,,,,NOT_FOUND,"A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme",,['Glioblastoma'],"['Transferrin', 'Brain Tumor', 'Convection', 'Immunotherapy', 'Targeted Protein Toxin', 'Glioblastoma Multiforme', 'GBM']",,2004-07,2005-11,[],[],0.0,,,ALL,False,NIH,0.0,30.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01602627,Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies,Hsp90 inhibitor AUY922,"['AUY922', 'Hsp90 inhibitor AUY922']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,"Unspecified Adult Solid Tumor, Protocol Specific","Dale Shepard, MD, PhD",2025-09-01T16:18:20.963111,True,,,,NOT_FOUND,"A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies",,"['Unspecified Adult Solid Tumor, Protocol Specific']",[],Slow accrual,2011-09,2012-02,"[{'measure': 'MTD of Hsp90 inhibitor AUY922', 'description': 'A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as clinically relevant, and occurs \\< 28 days following the first dose of AUY922. Toxicity will be measured by CTCAE criteria (Version 4.02). The MTD will be determined using a standard design.', 'timeFrame': 'at 28 days'}]","[{'measure': 'Toxicity by CTCAE (v 4.02)', 'timeFrame': 'at 28 days'}, {'measure': 'Pharmacokinetic parameters, including area under the curve (AUC), clearance, volume of distribution (VD), time to the maximum concentration (Tmax), maximum plasma concentration (Cmax), and elimination half-life', 'description': 'Prior to 1st infusion; 30 minutes after start infusion; end infusion; 5, 30 minutes post-infusion; 1, 2, 4, 5, 24, 48 hours post-infusion course 1 days 8 (pretreatment) and 15 (pretreatment/end infusion); and course 2 day 1 (pretreatment/end infusion)', 'timeFrame': 'at baseline and at 28 days (first cycle)'}, {'measure': 'Tumor response will be measured by RECIST criteria (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], overall response [OR], response rate [RR])', 'description': 'Imaging with CT or MRI will be obtained at baseline (within 21 days of study Day 1) and every other cycle commencing at the end of cycle 2 (beginning of cycle 3). These scans should be schedule within 7 days of the start of the cycle. Imaging will be obtained at the end of the study.', 'timeFrame': 'at baseline and at end of cycle 2 (8 weeks)'}, {'measure': 'Geriatric assessment will be made including Mini Mental Exam, Get up and Go, assessment of comorbidity, and Geriatric Depression Scale', 'description': 'This trial will incorporate geriatric assessment to determine the relationship between functional ability or comorbidity and treatment response or toxicity. Patients will be have a geriatric assessment which will included a range of assessments, such as mini mental status, up and go test, and the geriatric depression scale, at baseline and after every 2 cycles of therapy.', 'timeFrame': 'at baseline and at end of cycle 2 (8 weeks)'}, {'measure': 'Evaluation of responses to a bioethics questionnaire will be used to assess patient factors influencing enrollment in this elderly-specific phase I trial', 'timeFrame': 'Baseline'}, {'measure': 'Number of Circulating Tumor Cells (CTC) at baseline and after treatment with Hsp90 inhibitor AUY922', 'description': 'Blood will be collected for measurement of CTCs on Cycle 1 Day 1 pre-infusion, Cycle 2 Day 1 pre-infusion, Cycle 3 Day 1, pre-infusion, then Day 1 of every other cycle until the end of the study.', 'timeFrame': 'at baseline and end of treatment'}, {'measure': 'Level of HSP70 at baseline and after treatment with Hsp90 inhibitor AUY922', 'timeFrame': 'at baseline and at 28 days (first cycle)'}, {'measure': 'Level of M30 and M65 at baseline and following therapy with Hsp90 inhibitor AUY922', 'timeFrame': 'at baseline and at 28 days (first cycle)'}]",9.0,75 Years,,ALL,False,OTHER,1.0,2.0,ACTUAL,v2_robust,True,False,True,True,Slow accrual,,,no_match,False,,,
NCT05727969,Dexmedetomidine Infusion and Surgical Pleth Index In Pediatrics,Dexmedetomidine,"['Lactated Ringer', 'Precedex', 'Dexmedetomidine', 'Solution']",4,INTERVENTIONAL,['NA'],,COMPLETED,Pain,Fayoum University Hospital,2025-09-01T16:18:10.909940,True,,,,CHEMBL778,Effect Of Dexmedetomidine Infusion On Surgical Pleth Index In Pediatrics Undergoing Hypospadias Repair; A Prospective Observational Study,,"['Pain', 'Hypospadias']","['Dexmedetomidine', 'Hypospadias', 'Postoperative analgesia', 'Surgical pleth index']",,2023-01-15,2023-12-15,"[{'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute at end of the operation after skin closure.'}]","[{'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute before induction of anesthesia.'}, {'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute after insertion of endotracheal tube.'}, {'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '1 minute after beginning of surgery with skin incision.'}, {'measure': 'Surgical pleth index number', 'description': 'from 0 to 100, higher values indicate strong surgical stimulus', 'timeFrame': '5 minutes after recovery at post anesthesia care unit.'}, {'measure': 'Mean arterial blood pressure', 'description': 'in mmHg', 'timeFrame': '5 minutes after recovery at post anesthesia care unit.'}, {'measure': 'Mean arterial blood pressure', 'description': 'in mmHg', 'timeFrame': '1 minute before induction of anesthesia.'}, {'measure': 'Mean arterial blood pressure', 'description': 'in mmHg', 'timeFrame': '1 minute after beginning of surgery with skin incision.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '1 minute after beginning of surgery with skin incision.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '1 minute before induction of anesthesia.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '5 minutes after recovery at post anesthesia care unit.'}, {'measure': 'Heart rate', 'description': 'beat/minute', 'timeFrame': '1 minute at end of the operation after skin closure.'}, {'measure': 'Mean arterial blood pressure', 'description': 'mmHg', 'timeFrame': '1 minute at end of the operation after skin closure.'}, {'measure': 'Need of vasoactive drugs', 'description': 'Yes or no', 'timeFrame': '1minute after infusion until end of surgery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '5 minutes after recovery in postanesthesia care unit'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '2 hours after recovery in postanesthesia care unit'}, {'measure': 'Ramsay sedation score', 'description': '0:5 with 0:deeply sedation to 5:no sedation', 'timeFrame': '5 minutes after recovery in postanesthesia care unit'}, {'measure': 'Ramsay sedation score', 'description': '0:5 with 0:deeply sedation to 5:no sedation', 'timeFrame': '2 hours after recovery in postanesthesia care unit'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '4 hours after discharge from recovery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '6 hours after discharge from recovery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '12 hours after discharge from recovery'}, {'measure': 'FLACC pain score', 'description': 'F:face - L:legs - A:activity - C:cry - C:consolability for description of pain degree in children', 'timeFrame': '24 hours after discharge from recovery'}, {'measure': 'Surgical time', 'description': 'from when the surgeon of record starts the procedure until complete skin closure in minutes', 'timeFrame': '1 minute after skin'}, {'measure': 'Anesthesia time', 'description': 'from the start of anesthesia to the end of an anesthesia service in minutes', 'timeFrame': '5 minutes after insertion of endotracheal tube'}, {'measure': 'Total opioid consumption', 'description': 'in milligram', 'timeFrame': '24 hours after operation'}, {'measure': 'Time of 1st analgesia dose', 'description': 'time when first analgesic drug is injected for pain (in hours)', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Total non-steroidal consumption', 'description': 'time when first usage of non-steroidal anti-inflammatory drug is injected for pain (in hours)', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Extubation time', 'description': 'time from the end of surgery to airway extubation (in minutes)', 'timeFrame': '2 minutes after removal of endotracheal tube'}]",28.0,1 Year,7 Years,ALL,True,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CHEMBL778,exact_match,True,200.28,3.18,4.0
NCT04445857,Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients,Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally,"['Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally', 'Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Analgesia,Ain Shams University,2025-09-01T16:18:22.197124,True,,,,NOT_FOUND,Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Lower Abdominal and Limb Surgeries in Tramadol-abuse Patients: a Randomized Controlled Trial,,['Analgesia'],[],,2020-09-01,2021-01-31,"[{'measure': 'The total dose of rescue analgesia (mg)', 'description': 'The total dose of rescue analgesia (mg)', 'timeFrame': 'The first 24 hours after surgery'}]",[],1.0,18 Years,60 Years,ALL,False,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06777511,Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients,5-aminolevulinic acid (5-ALA),['5-aminolevulinic acid (5-ALA)'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Amputation,Dartmouth-Hitchcock Medical Center,2025-09-01T16:18:08.347887,True,,,,NOT_FOUND,Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients,,"['Amputation', 'Osseointegration']",[],,2025-08-01,2026-08-30,"[{'measure': 'Feasibility', 'description': 'Feasibility will be defined as 80% of patients successfully completing the administration protocol as well as 1 week/2-week follow-up.', 'timeFrame': '2 weeks'}]","[{'measure': 'Treatment Evaluation Inventory-Short Form (TEI-SF)', 'description': 'The TEI-sf is a 9-item questionnaire used to measure intervention acceptability from the participants point of view. Scores range from 9 to 45, and scores above 27 are considered acceptable.', 'timeFrame': '2 weeks'}, {'measure': 'System Usability Scale (SUS)', 'description': 'The SUS is a reliable 10-item usability measure with scores that range from 0 to 100 (an above average score is 68 or higher.', 'timeFrame': '2 weeks'}, {'measure': 'Bioburden quantification (16S rRNA sequencing)', 'description': 'Bioburden will be quantified using quantitative PCR-based assays as well as addition of a ""spikein"" of a defined quantity of bacterial cells derived from halophilic organism Salnibacter ruber.', 'timeFrame': '2 weeks'}, {'measure': 'Bioburden quantification (Optical Coherence Tomography (OCT)', 'description': 'Biofilm will be imaged and quantified on the metal abutment', 'timeFrame': '2 weeks'}, {'measure': 'OCT ""virtual biopsy""', 'description': 'Presence of inflammation, hypergranulation, and any resulting changes (e.g., the degree of epidermal regression, dermal attachment to the implant, and epithelial layer thickness) can be quantified through morphologic analysis of the OCT B-scans. Scars are characterized by excessive collagen deposition, increased blood vessel density, and parallel blood vessel organization compared with normal skin.', 'timeFrame': '2 weeks'}, {'measure': 'Scar thickness', 'description': 'Scar thickness measured using OCT', 'timeFrame': '2 weeks'}, {'measure': 'Blood vessel density', 'description': 'Blood vessel density measuring using OCT', 'timeFrame': '2 weeks'}, {'measure': 'Presence of hypergranulation', 'description': 'Hypergranulation measured using OCT', 'timeFrame': '2 weeks'}, {'measure': 'Pain during light exposure', 'description': 'Patient reported pain during light exposure', 'timeFrame': '2 weeks'}, {'measure': 'Discomfort, burning, itchiness, or redness', 'description': 'Patient reported discomfort, burning, itchiness or redness', 'timeFrame': '2 weeks'}]",11.0,18 Years,,ALL,False,OTHER,1.0,10.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT05479994,Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,BGB-11417,"['BGB-11417', 'sonrotoclax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Leukemia,BeiGene,2025-09-01T16:18:18.429261,True,,,,NOT_FOUND,"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"['Leukemia', 'Lymphoma', 'Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'Small Lymphocytic Lymphoma', 'Relapsed Chronic Lymphocytic Leukemia']","['Refractory Chronic Lymphocytic Leukemia', 'Leukemia', 'Lymphoma', 'Small Lymphocytic Lymphoma']",,2022-10-24,2027-08-25,"[{'measure': 'Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)', 'description': 'Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for partiticpants with small lymphocytic lymphoma (SLL)', 'timeFrame': 'Up to 2 Years'}]","[{'measure': 'Overall Response Rate (ORR) as assessed by the investigator', 'description': 'Defined as the proportion of participants who achieved a complete response (CR), complete remission with incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR) per the 2018 iwCLL guidelines for participants with chronic lymphocytic leukemia (CLL) or Defined as the proportion of participants who achieved PR or better per the Lugano Classification for participants with small lymphocytic lymphoma (SLL)', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Duration of response (DoR) as determined by the IRC and the investigator', 'description': 'DoR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Progression Free Survival (PFS) as determined by the IRC and the investigator', 'description': 'PFS is defined as the time from the date of the first study dose until the date of first documented disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Time to Response (TTR) as assessed by investigator and IRC', 'description': 'TTR is defined as the time from treatment initiation to the first documented response.', 'timeFrame': 'Up to 2 Years'}, {'measure': 'Overall Survival (OS)', 'description': 'defined as time from the start of treatment to the date of death due to any cause', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Participants Reported Outcome as measured by EQ-5D-5L questionnaires', 'description': 'The EQ-5D-5L descriptive system assesses health in five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY / DEPRESSION), each of which has five levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems/unable to).', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Participant Reported Outcomes as measured by NFLymSI-18', 'description': ""The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index-18 (NFLymSI-18) questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score."", 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'with adverse events leading to discontinuation, and AEs graded according NCI-CTCAE Version 5 and the Grading Scale for Hematologic Toxicity in CLL Studies', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of participants with clinically significant changes from baseline in vital signs', 'description': 'Vital signs include systolic and diastolic blood pressure, heart rate, and body temperature', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of participants with clinically significant changes from baseline in clinical laboratory values', 'description': 'Laboratory values include hematology, clinical chemistry, coagulation, and urinalysis', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Number of Participants With Clinically Significant Physical Examination Findings', 'description': 'A full physical examination includes head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal and musculoskeletal systems', 'timeFrame': 'Up to 5 Years'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,100.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05286190,Caudal Block and Transversus Abdominis Plane Block in Pediatric Inguinal Hernia Repair,Bupivacaine 0.25% Injectable Solution,"['Marcaine', 'Bupivacaine 0.25% Injectable Solution']",2,INTERVENTIONAL,['NA'],,COMPLETED,Regional Anesthesia,Istanbul University,2025-09-01T16:18:12.181001,True,,,,NOT_FOUND,Effects Of Ultrasound Guided Caudal Epidural And Transversus Abdominis Plane Block On Postoperative Analgesia In Pediatric Inguinal Hernia Repair Surgeries,,"['Regional Anesthesia', 'Postoperative Pain, Acute']","['US guided Caudal Epidural Block', 'US guided Transversus Abdominis Plane Block']",,2017-10-01,2018-10-31,"[{'measure': 'FLACC SCORES (FACE, LEG, ACTIVITY, CONSOLABILITY, CRY)', 'description': 'It includes five categories of behavior, each scored on 0-2 point scale so that total score ranges from 0 to 10. Total scores of 0-3 is defined as mild, 4-7 as moderate, and 8-10 as severe pain.', 'timeFrame': 'Up to 24 hours'}]","[{'measure': 'PONV (Postoperative nausea and vomiting)', 'description': 'Number of patients with nausea vomiting', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Additional analgesic requirement', 'description': 'Number of patients who require paracetamol (15 mg/kg) and tramadol (1 mg/kg)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Family satisfaction', 'description': 'A 3-point scale (satisfied:3; neutral:2, dissatisfied:1)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Surgeon satisfaction', 'description': 'A 3-point scale (satisfied:3; neutral:2, dissatisfied:1)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Complications', 'description': 'Possible complications related to caudal and transversus abdominis plane block (hematoma, infection and perforation)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Revised Bieri faces pain scale', 'description': ""Revised Bieri faces pain scale used for assessment of chronic pain. Score the chosen face 0,2,4,6,8,10 counting left to right so '0'=no pain and '10'=very much pain"", 'timeFrame': 'At postoperative 2nd month'}, {'measure': 'Length of hospital stay', 'description': 'Hospitalisation', 'timeFrame': 'Through study completion, an average of 1 week'}]",8.0,1 Year,7 Years,ALL,True,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01352988,Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus,Fumaric acid esters,"['Fumaderm® initial', 'Fumaderm®', 'Fumaric acid esters']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Lupus Erythematosus, Cutaneous",University Hospital Muenster,2025-09-01T16:18:20.962218,True,,,,CHEMBL503160,"Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study",,"['Lupus Erythematosus, Cutaneous']","['C17.300.475', 'C17.800.480']",,2011-07,2014-02,"[{'measure': 'Primary efficacy outcome is the response rate at week 24 or at the latest assessment for patients who withdrew prematurely.', 'description': 'Response is defined as a reduction of 50% in the total RCLASI activity for skin lesions, compared to the baseline value (""RCLASI 50"").', 'timeFrame': 'Week 24 or at the latest assessment for patients who withdrew prematurely (Last Observation Carried Forward, LOCF).'}]","[{'measure': 'Proportion of patients with RCLASI 50 at week 12 of treatment', 'timeFrame': 'Week 12 of treatment'}, {'measure': 'Proportion of patients with at least partial response at end of therapy (with regard to RCLASI activity score for skin lesions)', 'timeFrame': 'End of therapy (up to 24 weeks)'}, {'measure': 'Time from start of treatment to first RCLASI 50 assessment (time to response).', 'timeFrame': 'Time to response (up to 24 weeks)'}, {'measure': ""Patient's global assessment and VAS for itch and pain 12 weeks after the beginning of treatment and at the end of therapy."", 'timeFrame': '12 weeks after the beginning of treatment and at the end of therapy (up to 24 weeks).'}, {'measure': 'Number of Participants with Adverse Events (AEs) and their severity.', 'timeFrame': '24 weeks of treatment + 4 weeks of follow up'}]",6.0,18 Years,70 Years,ALL,False,OTHER,0.0,11.0,ACTUAL,v2_robust,True,True,False,True,,O=C(O)/C=C/C(=O)O,CHEMBL503160,partial_match,True,116.07,-0.29,4.0
NCT03729128,Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder,dextromethorphan and memantine (DM+MM),"['dextromethorphan and memantine (DM+MM)', 'Placebos']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Stimulants Use Disorder,Tzu-Yun Wang,2025-09-01T16:18:15.910502,True,,,,CHEMBL807,The Potential Therapeutic Effects of add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder,,['Stimulants Use Disorder'],"['amphetamine-type stimulants use disorder', 'dextromethorphan', 'memantine', 'inflammation', 'neurodegeneration']",,2018-07-24,2020-08-31,"[{'measure': 'Urinary amphetamine tests', 'description': 'The urinary amphetamine tests will be examined during the 12 weeks of treatment period in patients with ATSUD and the results will be compared between the experimental and placebo groups.', 'timeFrame': '12 weeks'}, {'measure': 'Craving severity', 'description': 'The Visual analog scale (VAS) will be measured during the 12 weeks of treatment period in patients with ATSUD. The results will be compared between the experimental and placebo groups. The level of conscious craving was rated from 0 (none) to 100 (very much). Higher scores indicate more severe craving.', 'timeFrame': '12 weeks'}, {'measure': 'Side effects checklists', 'description': 'The investigators will use the self-reported questionnaire, side effects checklists, to evaluate the side effects during the 12 weeks of treatment period in patients with ATSUD. The side effects assessment includes, A) Mental Status/6-item, B) Genito-Urinary/4-item, C) Cardiovascular/4-item, D) Head-Neck/10-item, E) Extremities/9-item, F) Skin/4-item, and G) Gastrointestinal Tract/2-item. The severity of side effects were divided into 4 degrees as follows: 0 = Not present; 1 = Mild or occasional; 2 = Moderate or occurs several times a day; and 3 = Severe or persistent. Scores in each subscale will be summated to get the final total scores. Higher scores indicate more severe side effects. The results of side effects checklists will be compared between the experimental and placebo group.', 'timeFrame': '12 weeks'}]","[{'measure': 'Wisconsin Card Sorting Test (WCST)', 'description': 'The Wisconsin Card Sorting Test (WCST) will be measured in patients with ATSUD at the initial screen period and at the endpoint (after 12 weeks of treatment). We will compare the changes from screen period to the endpoint between experimental and placebo group. Performance on the WCST was scored in terms of the total number of errors (TNE, range form 0-128), perseverative errors (PE, range from 0-118), conceptual level responses (CLRs, range from 0-100%), number of categories completed (NCC, range form 0-12), and trials to complete the first category (TCC, range from 0-128). Higher scores indicate worse performance in TNE, PE, and TCC. Higher scores indicate better performance in CLRs and NCC.', 'timeFrame': '12 weeks'}, {'measure': 'Continuous performance tests (CPT)', 'description': 'The Continuous performance tests (CPT) will be measured in patients with ATSUD at the initial screen period and at the endpoint (after 12 weeks of treatment). We will compare the changes from screen period to the endpoint between experimental and placebo group. The CPT produces a standard set of performance measures that include the number of errors of omission and errors of commission. (1) Errors of omission occur when the participant fails to respond to the target stimulus. The omission errors t-scores are ranged from 20-80 (0-100%). Higher scores indicated worse performance. (2) Errors of commission occur when the participant responds to a non-target (X) stimulus. The commission errors t-scores are ranged from 20-80 (0-100%). Higher scores indicated worse performance.', 'timeFrame': '12 weeks'}, {'measure': 'Wechsler Memory Scale - third edition (WMS-III)', 'description': 'The Wechsler Memory Scale - third edition (WMS-III) will be measured in patients with ATSUD at the initial screen period and at the endpoint (after 12 weeks of treatment). We will compare the changes from screen period to the endpoint between experimental and placebo group. WMS-III composite scores were calculated for the eight standardized primary indices: Auditory Immediate (AIM, range from 50-156), Visual Immediate (VIM, range from 47-162 ), Immediate Memory (IM, range from 40-164 ), Auditory Delayed (ADM, range from 46-162), Visual Delayed (VDM, range from 43-156), Auditory Recognition Delayed (ARDM, range from 55-145), General Memory (GM, range from 40-168), and Working Memory (WM, range from 45-156 ). Higher scores indicate better performance.', 'timeFrame': '12 weeks'}, {'measure': 'Cytokines and neurotrophic factors', 'description': 'The plasma levels of cytokines and neurotrophic factors, tumor necrosis factor α (TNF-α\\[pg/mL\\]), transforming growth factor β1 (TGF-β1 \\[pg/mL\\]), interleukin 6( IL-6\\[pg/mL\\]), interleukin 8(IL-8\\[pg/mL\\]), interleukin 1β (IL-1β\\[pg/mL\\]), and brain-derived neurotrophic factor(BDNF\\[pg/mL\\]), will be measured in patients with ATSUD at the initial screen period, day 1(baseline), week 4, 8, and 12(endpoint). We will compare the changes from screen period to the endpoint between the experimental and placebo group.', 'timeFrame': '12 weeks'}, {'measure': 'C-reactive protein', 'description': 'The plasma levels of C-reactive protein (CRP\\[μg/mL\\]) will be measured in patients with ATSUD at the initial screen period, day 1(baseline), week 4, 8, and 12(endpoint). We will compare the changes from screen period to the endpoint between the experimental and placebo group.', 'timeFrame': '12 weeks'}]",8.0,20 Years,65 Years,ALL,False,OTHER,1.0,85.0,ACTUAL,v2_robust,True,True,False,False,,CC12CC3CC(C)(C1)CC(N)(C3)C2,CHEMBL807,partial_match,True,179.31,2.69,4.0
NCT06895538,Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy,Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG),['Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)'],1,OBSERVATIONAL,[],,RECRUITING,Leukemia,Peking University First Hospital,2025-09-01T16:18:22.212827,True,,,,NOT_FOUND,"An Exploratory, Non-Randomized, Controlled Study of the Effect of Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) Versus Anti-Thymocyte Immunoglobulin (ATG) on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematologic Diseases",,"['Leukemia', 'MDS', 'Lymphoma']","['ATLG', 'ATG', 'immune reconstitution', 'allo-HSCT']",,2025-05-03,2027-01-01,"[{'measure': 'Incidence of viral infections after hematopoietic stem cell transplantation', 'description': 'Incidence of CMV reactivation (CMV DNA ≥10\\^3) and CMV disease, incidence of EBV reactivation (incidence of EBV DNA ≥10\\^5) and lymphoproliferative disorders (PTLD), incidence of hemorrhagic cystitis, incidence of herpes simplex, adenovirus, or other viruses in both groups.', 'timeFrame': 'From enrollment to 1 year after allo-HSCT'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,24.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT05620940,"A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.",Vivitrol Injectable Product,"['IVL3004', 'Vivitrol Injectable Product', 'IVL4002']",3,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Opioid Dependence,"Inventage Lab., Inc.",2025-09-01T16:18:14.672744,True,,,,NOT_FOUND,"A Phase 1, Open-Label, Exploratory, Fixed-Sequence, Pharmacokinetic Single Dose Study of IVL3004 Versus Vivitrol® (Naltrexone) Long-Acting Injectable (LAI) and IVL4002 in Healthy Subjects",,"['Opioid Dependence', 'Alcohol Dependence']",[],,2024-09-11,2025-05-06,"[{'measure': 'AUC0-240', 'description': 'Area under the concentration-time curve from time zero to 240hrs', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'Cmax', 'description': 'The maximal observed concentration', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'AUC240-672', 'description': 'Area under the concentration-time curve from time 240 to 672hrs', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'AUC0-672', 'description': 'Area under the concentration-time curve from time zero to 672hrs', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'AUC0-inf', 'description': 'Area under the concentration-time curve from time zero to infinity', 'timeFrame': 'Pre-dose, up to Day 57'}]",[],5.0,18 Years,55 Years,MALE,True,INDUSTRY,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01001585,Anesthetic Effects in Mitochondrial Disease,sevoflurane,['sevoflurane'],1,INTERVENTIONAL,['NA'],,TERMINATED,Mitochondrial Disease,d sessler,2025-09-01T16:18:12.174741,True,,,,NOT_FOUND,Anesthetic Effects in Mitochondrial Disease,,['Mitochondrial Disease'],"['mitochondrial disease', 'sevoflurane', 'mitochondrial disease and sevoflurane sensitivity']","However, no intervention reduced the risk of major morbidity or 1 yr mortality",2006-09,2011-10,"[{'measure': 'Measure cardiovascular stability and electrical brain activity during slow induction with sevoflurane.', 'description': 'The investigators plan to monitor patients with mitochondrial disease using expanded measures of cardiovascular stability and measurements of brain electrical activity while slowly inducing general anesthesia. The investigators will use those measurements to limit the amount of anesthetic these patients receive in an attempt to minimize their risk.', 'timeFrame': 'during induction'}]","[{'measure': 'Use cardiovascular and electrical brain measurements to limit amount of sevoflurane and predict individual sensitivity.', 'description': 'In addition, the investigators will correlate their sensitivity to the type of mitochondrial defect so that it may be possible to predict which patients are likely to have an increased sensitivity.', 'timeFrame': 'during induction'}]",2.0,12 Months,16 Years,ALL,False,OTHER,0.0,55.0,ACTUAL,v2_robust,True,False,True,False,"However, no intervention reduced the risk of major morbidity or 1 yr mortality",,,no_match,False,,,
NCT03663569,A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler,Spiolto® Respimat®,['Spiolto® Respimat®'],1,OBSERVATIONAL,[],,COMPLETED,"Pulmonary Disease, Chronic Obstructive",Boehringer Ingelheim,2025-09-01T16:18:10.910130,True,,,,NOT_FOUND,Changes in Clinical Control of COPD Patients Measured by the Clinical COPD Questionnaire During Therapy With Spiolto®Respimat® in Routine Clinical Practice,,"['Pulmonary Disease, Chronic Obstructive']",[],,2018-08-15,2019-10-04,"[{'measure': 'Percentage of Patients With Therapeutic Success of Spiolto® Respimat® Treatment at Visit 2', 'description': 'Therapeutic success of Spiolto® Respimat® treatment was defined as 0.4 point decrease in the Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire - Clinical COPD Questionnaire (CCQ) score from visit 1 to visit 2. Each of the 10 CCQ questions is scored by the patient on a 7-point scale between 0 (Never/Not limited at all) and 6 (Almost all the time/Totally limited or unable to do) at baseline (Visit 1) and at the end of the observation after approximately 6 weeks (Visit 2). The sum of the scores divided by 10 gives the CCQ score, which measures the health and functional status. A higher CCQ score is indicative of worse status.', 'timeFrame': 'At Visit 2 (6 weeks after baseline visit 1)'}]","[{'measure': 'Changes in the Clinical COPD Questionnaire (CCQ) and the CCQ Symptom, Mental State and Functional State Domain Scores From Visit 1 (Baseline) to Visit 2', 'description': 'The CCQ questionnaire contained 10 questions about symptoms, functional status and mental status. Each of the 10 CCQ questions was scored by the patient on a 7-point scale between 0 and 6 at baseline and at the end of observation after approximately 6 weeks. Symptom domain covered 4 questions (number 1, 2, 5, 6), Functional state domain covered 4 questions (number 7, 8, 9, 10), and Mental state domain covered 2 questions (number 3, 4). Scores for the questions in each domain were summed up and divided by the number of questions in each domain giving the resulting score for respective domain. The sum of the scores divided by 10 gives the CCQ score which measures the health and functional status. A higher CCQ score is indicative of worse status. Change of the score was calculated as visit 2 minus visit 1.', 'timeFrame': 'At baseline visit 1 and 6 weeks thereafter at visit 2'}, {'measure': ""Physician's Global Evaluation (PGE) Score at Visit 1(Baseline)"", 'description': 'PGE score assessed the general condition of the patient on an 8-point ordinal scale from 1 (very poor) to 8 (excellent).', 'timeFrame': 'At visit 1'}, {'measure': ""Physician's Global Evaluation (PGE) Score at Visit 2"", 'description': 'PGE score assessed the general condition of the patient on an 8-point ordinal scale from 1 (very poor) to 8 (excellent).', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Patient Overall Satisfaction With Spiolto® Respimat® Treatment at Visit 2', 'description': 'Patient overall satisfaction with Spiolto® Respimat® treatment at visit 2 was reported.', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Patient Satisfaction With Inhaling From the Respimat® Device at Visit 2', 'description': 'Patient satisfaction with inhaling from the Respimat® device at visit 2 was reported', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Patient Satisfaction With Handling of the Respimat® Inhalation Device at Visit 2', 'description': 'Patient satisfaction with handling of the Respimat® inhalation device at visit 2 was reported.', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}, {'measure': 'Number of Participants Willing to Continue Treatment With Spiolto® Respimat® at Visit 2', 'description': 'Number of participants willing to continue treatment with Spiolto® Respimat® at visit 2 was reported.', 'timeFrame': 'At visit 2 (6 weeks after baseline visit 1)'}]",8.0,40 Years,,ALL,False,INDUSTRY,0.0,4819.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT00673933,Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris,Methyl aminolevulinate (MAL) PDT,['Methyl aminolevulinate (MAL) PDT'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acne Vulgaris,Photocure,2025-09-01T16:18:22.211129,True,,,,NOT_FOUND,"A Blinded, Randomized, Intra-individual, Vehicle-controlled and Multi-centre Study of Photodynamic Therapy With MAL Cream in Patients With Skin Type V or VI With Acne Vulgaris",,['Acne Vulgaris'],[],,2008-05,2008-12,"[{'measure': 'Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment', 'timeFrame': '4 weeks after last treatment, 6 weeks after baseline'}]","[{'measure': 'Erythema Score (Mild and Moderate)Immediately After First PDT', 'description': 'Patients with mild or moderate erythema after first treatment at baseline.', 'timeFrame': 'Immediately after treatment at baseline'}, {'measure': 'Change in Inflammatory Lesion Counts From Baseline', 'timeFrame': '4 weeks after last treatment, 6 weeks after baseline'}, {'measure': 'Change in Noninflammatory Lesion Counts From Baseline', 'timeFrame': '4 weeks after last treatment, 6 weeks after baseline'}, {'measure': 'Erythema Score (Mild and Moderate)Immediately After Second Treatment', 'description': 'Patients with mild or moderate erythema after second treatment.', 'timeFrame': 'Immediately after second treatment, 2 weeks after baseline'}, {'measure': 'Erythema Score (Mild and Moderate)1 Day After First Treatment', 'description': 'Patients with mild or moderate erythema 1 day after first treatment.', 'timeFrame': '1 day after 1st treatment and baseline'}]",6.0,15 Years,40 Years,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04662580,ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer,ARX517,"['Abiraterone acetate', 'Apalutamide', 'Prednisone', 'ARX517']",4,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Metastatic Prostate Cancer,"Janssen Research & Development, LLC",2025-09-01T16:18:07.023927,True,,,,NOT_FOUND,"A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer",,['Metastatic Prostate Cancer'],"['ADC', 'Antibody drug conjugate', 'Prostate neoplasia', 'Metastatic castration-resistant prostate cancer', 'PSMA', 'Prostate specific membrane antigen', 'PSMA ADC', 'Prostate Cancer']",,2024-12-09,2028-12-29,"[{'measure': 'Assess incidence of adverse events', 'description': 'Incidence and severity of adverse events or serious adverse events of ARX517 alone or in combination with ARPIs will be assessed to determine the safety and tolerability of the treatment using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5 (CTCAE).', 'timeFrame': '1.5 Years'}]","[{'measure': 'Area under the serum concentration-time curve (AUC) for ARX517 alone or in combination with ARPIs', 'description': 'Pharmacokinetic parameter area under the serum concentration-time curve (AUC) will be analyzed through different analytes such as ADC, total antibody, and pAF-AS269', 'timeFrame': '3 Year'}, {'measure': 'Maximum serum concentration (Cmax) for ARX517 alone or in combination with ARPIs', 'description': 'Pharmacokinetic parameter maximum serum concentration (Cmax) will be analyzed through different analytes such as, ADC, total antibody, and pAF-AS269', 'timeFrame': '3 Year'}, {'measure': 'Trough concentration (Ctrough) for ARX517 alone or in combination with ARPIs', 'description': 'Pharmacokinetic parameter trough concentration (Ctrough) will be analyzed through different analytes such as, ADC, total antibody, and pAF-AS269', 'timeFrame': '3 Year'}, {'measure': 'Incidence of ADA against ARX517 alone or in combination with ARPIs', 'description': 'To assess the incidence of anti-drug antibodies (ADA) against ARX517 at selected timepoints', 'timeFrame': '3 year'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as the time from first dose of study therapy to the date of death (any cause). Subjects who are alive will be censored at the last known time that the subject was alive.', 'timeFrame': '3 year'}, {'measure': 'Assess changes in serum prostate specific antigen (PSA) levels', 'description': 'Proportion of subjects who show a confirmed reduction of 30%, 50%,and 90% from baseline in serum prostate specific antigen (PSA) levels (PSA30, PSA50, PSA 90)', 'timeFrame': '3 year'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable subjects. Subjects will be censored at time of subsequent therapy', 'timeFrame': '3 year'}]",8.0,18 Years,,MALE,False,INDUSTRY,0.0,253.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06303648,"A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects",Methylone,['Methylone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Post Traumatic Stress Disorder,Transcend Therapeutics,2025-09-01T16:18:09.627555,True,,,,NOT_FOUND,"A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects",,['Post Traumatic Stress Disorder'],[],,2024-03-20,2024-05-11,"[{'measure': 'Cmax: Maximum Observed Plasma Concentration for methylone', 'timeFrame': '48 hours following the dose'}, {'measure': 'AUC: Area under the plasma concentration-time curve for methylone', 'timeFrame': '48 hours following the dose'}]","[{'measure': 'Incidence and frequency of adverse events', 'timeFrame': '10 days after the dose'}, {'measure': 'Change overtime in Visual Analog Scales', 'timeFrame': '12 hours after the dose'}]",4.0,25 Years,55 Years,ALL,True,INDUSTRY,0.0,24.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00928798,Topical Rapamycin for Fibrofolliculomas,Rapamycin,"['Rapamycin', 'Sirolimus', 'Rapamune', 'placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Birt-Hogg-Dubé Syndrome,Maastricht University Medical Center,2025-09-01T16:18:10.928489,True,,,,NOT_FOUND,Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome,,['Birt-Hogg-Dubé Syndrome'],[],,2010-01,2011-08,"[{'measure': 'Significant regression of lesions (reduction of fibrofolliculoma size and count) in the treated area.', 'timeFrame': '3 and 6 months'}]","[{'measure': 'Side effects', 'timeFrame': '3 and 6 months'}]",2.0,18 Years,,ALL,False,OTHER,1.0,19.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02301169,A Study to Investigate the Effects of a New Treatment in Patients With Chronic Pain,Administration of T4P1001 capsules,"['Administration of T4P1001 capsules', 'Administration of placebo capsules']",2,INTERVENTIONAL,['NA'],,COMPLETED,Peripheral Neuropathies,Tools4Patient,2025-09-01T16:18:18.427617,True,,,,NOT_FOUND,A Study to Investigate the Effects of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain,,['Peripheral Neuropathies'],['Pain'],,2014-03,2014-11,"[{'measure': ""Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment"", 'description': '11-point Numeric Rating Scale (NRS). Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 42'}]","[{'measure': ""Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Worst Pain Scores (WPS)"", 'description': '11-point Numeric Rating Scale (NRS) Scale from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine. Lower values represent a better outcome. Unit: arithmetic average of 7 days of a 11-point NRS', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 42'}, {'measure': ""Patient's Change From Baseline of Investigator Global Assessment of Change (IGAC)"", 'description': 'IGAC is an investigator subjective evaluation of patient condition using a NRS from 0 to 10 with 0 meaning best and 10 worst Lower values represent a better outcome.', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 28'}, {'measure': ""Patient's Change of Pain Intensity After Heat Pain Stimuli From Baseline to End of Treatment Period"", 'description': '11-point Numeric Rating Scale (NRS) from 0 to 10; 0 meaning no pain, 10 pain as bad as you can imagine Lower values represent a better outcome Unit: arithmetic average on 6 reported scores per Visit.', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 28'}, {'measure': ""Patient 's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Brief Pain Inventory (BPI)."", 'description': 'Arithmetic average of 3 questions on an 11-point Numeric Rating Scale (NRS) from 0 to 10, 0 meaning no pain, 10 pain as bad as you can imagine.\n\nLower values represent a better outcome', 'timeFrame': 'Time zero equals baseline (Day 1) up to Day 28'}]",5.0,18 Years,,ALL,False,OTHER,0.0,42.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03226691,Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients,Plerixafor,"['Mozobil®', 'Plerixafor']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Sickle Cell Disease,"National Heart, Lung, and Blood Institute (NHLBI)",2025-09-01T16:18:07.017888,True,,,,NOT_FOUND,Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor,,['Sickle Cell Disease'],"['Plerixafor', 'Leukapheresis', 'Mobilization', 'Stem Cells', 'Sickle Cell Disease']",,2017-07-25,2019-02-27,"[{'measure': 'Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events', 'description': 'Sufficient collection of HSCs (target 2.0x106 CD34+ cells/kg) from the PB after plerixafor mobilization without serious adverse events (SAEs)', 'timeFrame': '1 day'}]",[],1.0,18 Years,,ALL,False,NIH,1.0,15.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05041257,"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)",Mirvetuximab soravtansine,"['IMGN853', 'MIRV', 'Mirvetuximab soravtansine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Ovarian Cancer,AbbVie,2025-09-01T16:18:13.423338,True,,,,NOT_FOUND,"A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)",,"['Ovarian Cancer', 'Peritoneal Cancer', 'Fallopian Tube Cancer']","['Platinum-sensitive', 'Ovarian cancer', 'Folate-receptor alpha expression', 'Antibody-drug conjugate', 'Cancer', 'Ovarian Neoplasma', 'Recurrent Platinum-Sensitive,', 'High-Grade Ovarian', 'PICCOLO']",,2021-08-31,2024-12-12,"[{'measure': 'Assess Objective Response Rate', 'description': 'Objective response rate (ORR), which includes confirmed best response of complete response (CR) or partial response (PR) as assessed by the Investigator', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Assess Duration of response (DOR)', 'description': 'Duration of response (DOR), defined as the time from initial Investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the Investigator', 'timeFrame': 'up to 2 years'}, {'measure': 'Assess treatment emergent adverse events (TEAEs)', 'description': ""Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AEs will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term"", 'timeFrame': 'up to 2 years'}, {'measure': 'Assess Cancer Antigen-125', 'description': 'Cancer Antigen-125 response determined using the Gynecologic Cancer Intergroup (GCIG) criteria', 'timeFrame': 'up to 2 years'}, {'measure': 'Assess Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS), defined as the time from first dose of MIRV until Investigator-assessed radiological PD or death, whichever occurs first', 'timeFrame': 'up to 2 years'}, {'measure': 'Assess Overall survival (OS)', 'description': 'Overall survival (OS), defined as the time from first dose of MIRV until death', 'timeFrame': 'up to 2 years'}, {'measure': 'Sensitivity analysis', 'description': 'ORR, DOR, and PFS by blinded independent central review (BICR) will be summarized as sensitivity analysis', 'timeFrame': 'up to 2 years'}]",7.0,18 Years,,FEMALE,False,INDUSTRY,0.0,79.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00785395,Up-Down Oxytocin Infusion,Oxytocin infusion,['Oxytocin infusion'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Uterine Atony,IWK Health Centre,2025-09-01T16:18:15.906123,True,,,,NOT_FOUND,Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery,,['Uterine Atony'],[],,2008-06,2008-08,"[{'measure': 'The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose.', 'timeFrame': '3 minutes'}]","[{'measure': 'Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.', 'timeFrame': '2 days'}]",2.0,18 Years,,FEMALE,False,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06998056,Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis,ARQ-151 cream 0.05%,['ARQ-151 cream 0.05%'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Atopic Dermatitis (Eczema),"Arcutis Biotherapeutics, Inc.",2025-09-01T16:18:24.742760,True,,,,NOT_FOUND,"A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis",,['Atopic Dermatitis (Eczema)'],"['atopic dermatitis', 'eczema']",,2025-06-09,2026-06,"[{'measure': 'Subject incidence of adverse events', 'description': 'Number of participants with adverse events during treatment will be assessed', 'timeFrame': '4 weeks'}, {'measure': 'Subject incidence of serious adverse events', 'description': 'Number of participants with serious adverse events during treatment will be assessed', 'timeFrame': '4 weeks'}, {'measure': 'Incidence of application site reactions', 'description': 'Number of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed', 'timeFrame': '4 weeks'}]",[],3.0,3 Months,2 Years,ALL,False,INDUSTRY,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05621161,ESPB vs FICB for Pain Management Following Total Hip Prosthesis Surgery,Postoperative analgesia management,['Postoperative analgesia management'],1,INTERVENTIONAL,['NA'],,COMPLETED,Knee Osteoarthritis,Mursel Ekinci,2025-09-01T16:18:20.963378,True,,,,NOT_FOUND,Comparison of Ultrasound-Guided Lumbar Erector Spinae Plane Block And Fascia Iliaca Compartment Block for Pain Management Following Total Hip Prosthesis Surgery,,"['Knee Osteoarthritis', 'Knee Disease', 'Knee Arthritis']","['Total hip prosthesis surgery', 'Postoperative analgesia', 'Erector spina plan block', 'Fascia iliaca compartment block']",,2022-11-28,2023-09-15,"[{'measure': 'Opioid consumption', 'description': 'The tramadol consumption on PCA device will be evaluated', 'timeFrame': 'Changes from baseline opioid consumption at postoperative 1, 2, 4, 8, 16 and 24 hours.'}]","[{'measure': 'Postoperative pain score', 'description': 'Postoperative pain assessment will be performed using the Numerical Rating Scale (0 = no pain, 10 = the most severe pain felt)', 'timeFrame': 'Postoperative 1, 2, 4, 8, 16 and 24 hours'}]",2.0,18 Years,80 Years,ALL,False,OTHER_GOV,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04618601,Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure,Spironolactone,"['Aldactone', 'Spironolactone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Heart Failure Acute,"Laikο General Hospital, Athens",2025-09-01T16:18:22.197440,True,,,,CHEMBL1393,Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure,,"['Heart Failure Acute', 'Heart Failure; With Decompensation']","['diuretic resistance', 'spironolactone', 'cardio-renal syndrome', 'diuretics', 'natriuresis', 'heart failure']",,2020-10-20,2022-03-01,"[{'measure': 'Daily urine output', 'description': 'Urine output in liters per 24 hours will be tracked from enrollment to day 5.', 'timeFrame': '5 days'}]","[{'measure': 'Total urine output', 'description': 'Urine output in total liters from enrollment to day 5 will be measured.', 'timeFrame': '5 days'}, {'measure': 'Total weight change', 'description': 'Patient weight in kilos will be tracked from enrollment to day 5.', 'timeFrame': '5 days'}, {'measure': 'Daily weight change', 'description': 'Patient weight in kilos will be tracked from enrollment to day 5.', 'timeFrame': '5 days'}, {'measure': 'Natriuresis on days 1, 3 and 5', 'description': 'Urine sodium will be measured on days 1, 3 and 5', 'timeFrame': '5 days'}, {'measure': 'Changes in natriuresis between days 1, 3 and 5', 'description': 'Urine sodium will be measured on days 1, 3 and 5', 'timeFrame': '5 days'}, {'measure': 'Changes in NT-proBNP between days 1 and 5', 'description': 'NT-proBNP will be measured on days 1, 3 and 5', 'timeFrame': '5 days'}]",7.0,18 Years,,ALL,False,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12,CHEMBL1393,exact_match,True,416.58,4.85,4.0
NCT00533026,Duloxetine - Warfarin Pharmacodynamic Study,Duloxetine,"['Warfarin', 'LY248686', 'Cymbalta', 'Duloxetine']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Anticoagulant Effect of Warfarin When Taken With Duloxetine.,Eli Lilly and Company,2025-09-01T16:18:12.174056,True,,,,NOT_FOUND,Evaluation of the Effect of Duloxetine on the Pharmacodynamics of Warfarin at Steady-State in Healthy Subjects,,['Anticoagulant Effect of Warfarin When Taken With Duloxetine.'],[],,2007-07,2007-10,"[{'measure': 'International Normalized Ratio (INR)', 'timeFrame': '58 days'}]","[{'measure': 'Effect of duloxetine on pharmacokinetics of warfarin.', 'timeFrame': '58 days'}, {'measure': 'Safety/ tolerability of duloxetine and warfarin given in combination.', 'timeFrame': '58 days'}, {'measure': 'Bleeding times when duloxetine and warfarin are given in combination.', 'timeFrame': '58 days'}]",4.0,18 Years,64 Years,ALL,True,INDUSTRY,0.0,60.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01495260,"A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants",N-acetylcysteine,"['vitamin E', 'lipoic acid', 'N-acetylcysteine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Adrenomyeloneuropathy,"Pujol, Aurora, M.D.",2025-09-01T16:18:07.021016,True,,,,CHEMBL863,"A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E",,['Adrenomyeloneuropathy'],"['XALD', 'AMN']",,2011-09,2013-11,"[{'measure': 'oxidative lesion biomarkers', 'description': 'oxidative lesion biomarkers: protein, DNA and peroxidation biomarkers', 'timeFrame': '12 months'}]","[{'measure': 'clinical parameters', 'description': 'spasticity, disability,electroneurograms and evocated potentials. Cranial and spinal NMR will be done at the beginning and the end of the trial.', 'timeFrame': '2, 6 and 12 months'}]",2.0,18 Years,64 Years,ALL,False,INDIV,2.0,13.0,ACTUAL,v2_robust,True,True,False,False,,N[C@@H](CS)C(=O)O,CHEMBL863,partial_match,True,121.16,-0.67,4.0
NCT06580665,Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer,Serplulimab,['Serplulimab'],1,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Non-small Cell Lung Cancer,Shanghai Chest Hospital,2025-09-01T16:18:24.753322,True,,,,NOT_FOUND,"Randomized Clinical Trials Comparing Immunotherapy Plus Cryoablation (I-CA) Versus Cryoablation Alone for Stage I, Selected Stage IIa, Non-Small Cell Lung Cancer",,['Non-small Cell Lung Cancer'],"['Cryoablation', 'Serplulimab', 'Early non-small cell lung cancer']",,2024-09-01,2030-08-11,"[{'measure': '3-year progression-free survival (PFS)', 'description': ""This refers to the length of time between the participant's first onset of disease progression or death from any cause after treatment."", 'timeFrame': '3 years'}]","[{'measure': '1-year, 2-year, and 3-year Objective Response Rate (ORR)', 'description': 'The percentage of patients that achieve complete response (CR) and partial response (PR) after treatment.', 'timeFrame': '3 years'}, {'measure': 'Overall Survival (OS)', 'description': ""The time from the start of treatment to the patient's death or the last follow-up, with a maximum observation period of 5 years from randomization."", 'timeFrame': '5 years'}, {'measure': 'Incidence of Adverse Events', 'description': 'Adverse events include those related to the cryoablation procedure occurring during or after the procedure, as well as drug-related adverse events caused by immunotherapy.', 'timeFrame': '1 year'}, {'measure': 'Potential Predictive and Immunological Biomarkers (lymphocyte phenotypes, PD-L1 expression, cytokines)', 'description': 'This refers to the changes from baseline in the immunological responses following the cryoablation (with or without Serplulimab) and comparison between the two groups, including the percentage and function of lymphocyte phenotypes, the expression of PD-L1, the concentration of IFN-γ levels, etc.', 'timeFrame': '1 year'}]",5.0,18 Years,,ALL,False,OTHER,2.0,134.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01162551,Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,Sirolimus and Methotrexate,"['Trexall®', 'Rapamune®', 'MTX', 'SIROLIMUS', 'METHOTREXATE', 'amethopterin', 'Sirolimus and Methotrexate', 'AY-22989', 'rapamycin']",9,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cancer,Children's Hospital of Philadelphia,2025-09-01T16:18:18.431421,True,,,,CHEMBL413,Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,,"['Cancer', 'Leukemia', 'Lymphoma']","['Leukemia', ""Non-Hodgkin's Lymphoma""]",,2010-05,2017-02,"[{'measure': 'Response Rate', 'description': 'Number of participants who achieve a Complete Response (CR), Complete Response with in the absence of total platelet recovery (CRp), or Partial Response (PR). Per response criteria in this protocol: Complete Response (CR) - M1 bone marrow (\\<5% blasts) with no evidence of circulating blasts or extramedullary disease and recovery of peripheral blood counts (absolute neutrophil count (ANC)\\> 500/μL and platelets \\> 50,000/ μL); Complete Response in the absence of total platelet recovery (CRp) - M1 bone marrow (\\<5% blasts) with no evidence of circulating blasts or extramedullary disease with recovery of peripheral blood counts except for platelets (ANC\\> 500/μL, platelets \\< 50,000uL); and Partial Response (PR) - M2 bone marrow (5% but \\<25% blasts), with no evidence of circulating blasts or extramedullary disease and normalization of peripheral blood counts (ANC \\> 500/μL and platelets \\>50,000/μL).', 'timeFrame': 'Day 28'}]","[{'measure': 'Number of Dose Adjustments To Maintain Trough Levels', 'description': 'One goal of this study is to maintain trough levels of sirolimus within a certain range. The outcome measure counts the number of dose adjustments up or down that were needed to meet goal level based on weekly tough level measurements.', 'timeFrame': 'Day 28'}]",2.0,,25 Years,ALL,False,OTHER,1.0,5.0,ACTUAL,v2_robust,True,True,False,False,,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL413,partial_match,True,914.19,6.18,4.0
NCT00274287,GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere,GM CSF,"['GM CSF', 'Leukine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Prostate Cancer,"Oncology Specialists, S.C.",2025-09-01T16:18:24.760069,True,,,,NOT_FOUND,A Phase II Pilot Study Investigating the Efficacy and Activity of Single Agent GM-CSF (Leukine) Maintenance Approach in Androgen-independent Prostate Cancer (AIPC) Patients Responding to Taxotere Chemotherapy,,['Prostate Cancer'],[],,2006-01,2010-12,"[{'measure': 'Time to Disease Progression (TTP)', 'description': 'The primary end point of this study is to evaluate time to disease progression (TTP). TTP is defined as the time from starting taxotere until there is evidence of progressive disease (PD) as defined below (radiographically and/or biochemically). PD was defined as more than 20% in the sum of longest diameter of measurable lesions compared to baseline, and/or evidence of new lesions on imaging studies. Median TTP from GM-CSF administration and Median TTP from start of chemotherapy is being reported', 'timeFrame': 'up to 21 months'}]","[{'measure': 'Response Rate (PSA)', 'description': 'Biochemical PR (Partial Response) was defined as a PSA that decreases by 50% and maintains by at least 3 weeks by confirmatory measurement. Biochemical SD (stable disease) was defined as a PSA that was increased by less than 25% or decreased by less than 50% Biochemical PD (progressive disease) was defined as an increase of at least 25% confirmed 3 weeks after.', 'timeFrame': 'up to 21 months'}, {'measure': 'Response Rate (Radiographic)', 'description': 'PR was defined as more than 30% decrease in the sum of the longest diameter of measurable lesions compared to baseline. SD was defined when lesions did not meet criteria for PR or PD. PD was defined as more than 20% increase in the sum of the longest diameter of measurable lesions compared to baseline, and/or evidence of new lesions at imaging studies. The appearance of 2 or more new boney lesions on bone scan development of cord compression, and pathologic fractures constituted PD.', 'timeFrame': 'up to 21 months'}, {'measure': 'Median Overall Survival (OS)', 'timeFrame': 'up to 44 months'}, {'measure': 'Median Number of GM-CSF Cycles', 'timeFrame': 'up to 12 months'}]",5.0,18 Years,,MALE,True,OTHER,1.0,15.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05182658,Empagliflozin in Hypertrophic Cardiomyopathy,Empagliflozin 10 MG,"['Jardiance', 'Empagliflozin 10 MG', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Hypertrophic Cardiomyopathy,"National Institute of Cardiology, Warsaw, Poland",2025-09-01T16:18:25.985108,True,,,,CHEMBL2107830,The Use of Empagliflozin in Patients With Hypertrophic Cardiomyopathy,,"['Hypertrophic Cardiomyopathy', 'Heart Failure']","['Hypertrophic cardiomyopathy', 'Heart Failue', 'Empagliflozin', 'Sodium-glucose transport protein 2 inhibitor', 'SGLT2 inhibitor']",,2022-06-01,2024-08-01,"[{'measure': 'Primary Outcome: Change in peak VO2 measured in the cardiopulmonary exercise testing', 'description': 'Change in peak VO2 measured in the cardiopulmonary exercise testing', 'timeFrame': '12 months'}]","[{'measure': 'Secondary outcome: Change in peak VO2 measured in the cardiopulmonary exercise testing in patients with reduced left ventricular ejection fraction (EF <50%)', 'description': 'Change in peak VO2 measured in the cardiopulmonary exercise testing in patients with reduced left ventricular ejection fraction (EF \\<50%)', 'timeFrame': '12 months'}]",2.0,18 Years,70 Years,ALL,False,OTHER,3.0,250.0,ESTIMATED,v2_robust,True,False,False,False,,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,CHEMBL2107830,partial_match,True,450.92,1.61,4.0
NCT04464200,19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers,19(T2)28z1xx CAR T cells,['19(T2)28z1xx CAR T cells'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:10.923288,True,,,,NOT_FOUND,A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies,,"['Diffuse Large B Cell Lymphoma', 'Primary Mediastinal Large B Cell Lymphoma', 'Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma', 'Chronic Lymphocytic Leukemia', 'Indolent Non-Hodgkin Lymphoma', 'Marginal Zone Lymphoma', 'Waldenstrom Macroglobulinemia', ""Burkitt's Lymphoma"", 'Primary CNS Lymphoma']","['19(T2)28z1XX CAR T cells', '20-167']",,2020-07-06,2026-07,"[{'measure': 'Recommended Phase II Dose (RP2D)', 'description': 'Dose escalation will use a 3+3 design. DLT-evaluable participants are defined as those participants who were infused with 19(T2)28z1XX CAR T cells and who were monitored for toxicities during the first 28 days of post infusion.', 'timeFrame': '28 days post infusion'}]","[{'measure': 'overall response rate (ORR)', 'description': 'Response and progression of the disease will be evaluated in this study using the Lugano Classification', 'timeFrame': '2 years'}]",2.0,18 Years,,ALL,False,OTHER,1.0,30.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01787539,The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer,Postoperative Chemotherapy,['Postoperative Chemotherapy'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Gastric Cancer,Medical University of Lublin,2025-09-01T16:18:13.422204,True,,,,NOT_FOUND,The Role of Postoperative Chemotherapy Cycles in the Combined Modality Therapy of Gastric Cancer With Perioperative Chemotherapy and Surgery in Pathological Responders,,['Gastric Cancer'],"['gastric cancer', 'perioperative chemotherapy', 'combined modality therapy', 'gastrectomy']",,2013-02,2022-02,"[{'measure': 'cancer free and overall survival', 'timeFrame': '5 years'}]","[{'measure': 'overall and severe toxicity rate', 'timeFrame': '8 weeks'}, {'measure': 'chemotherapy related mortality', 'timeFrame': '8 weeks'}, {'measure': 'the rate of dose reduction for chemotherapeutics', 'timeFrame': '3 months'}, {'measure': 'the rate of chemotherapy cessation', 'timeFrame': '3 months'}]",5.0,18 Years,,ALL,False,OTHER,1.0,180.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01632761,Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia,omega-3 fatty acids (fish oil),['omega-3 fatty acids (fish oil)'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Anemia,Brigham and Women's Hospital,2025-09-01T16:18:07.026661,True,,,,NOT_FOUND,Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia in the Elderly,,['Anemia'],"['anemia', 'vitamin D3', 'omega-3 fatty acids', 'fish oil', 'primary prevention']",,2012-11,2019-06,"[{'measure': 'Incidence of Anemia', 'description': 'We will compare the number of participants who took vitamin D supplements who developed anemia and the number of participants who did not take vitamin D who developed anemia to current rates of development of anemia in the U.S. We will further examine whether the effect of vitamin D supplementation on anemia risk varies by race/ethnicity, gender, or baseline levels of 25(OH)D.', 'timeFrame': '2 years'}, {'measure': 'Long-term Changes in Blood Protein Levels', 'description': 'We will examine the samples from the 900 boston participants and determine whether vitamin D supplementation affects long-term changes in hemoglobin, red blood cell (RBC) indices, hepcidin, and erythropoietin (EPO) levels. These protein levels will be assessed in both anemic and non-anemic individuals in fresh samples at baseline \\[pre-randomization\\] and at 2 years of follow-up post-randomization.', 'timeFrame': '2 years'}]","[{'measure': 'Incidence of Anemia', 'description': 'We will compare the number of participants taking fish oil supplements who developed anemia and the number of participants not taking fish oil supplements who developed anemia to the current rates of development of anemia in the U.S. We will also study the number participants diagnosed with anemia over 4 years of follow-up and whether the effect of taking fish oil supplements on anemia risk varies by race/ethnicity, gender, or baseline levels of omega-3 fatty acid.', 'timeFrame': '2 years'}, {'measure': 'Long-term Changes in Protein Levels', 'description': 'We will examine the samples collected from the 900 Boston participants and determine whether fish oil supplementation affects long-term changes in hemoglobin, red blood cell(RBC) indices, hepcidin, and erythropoietin (EPO) levels. These protein levels will be assessed in both anemic and non-anemic individuals in fresh samples at baseline \\[pre-randomization\\] and at 2 years of follow-up post-randomization.', 'timeFrame': '2 years'}]",4.0,50 Years,,ALL,True,OTHER,3.0,2000.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00095121,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,Placebo (PLB),"['Placebo (PLB)', 'Adefovir Dipivoxil (ADV)', 'Lamivudine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Hepatitis B,Gilead Sciences,2025-09-01T16:18:19.670530,True,,,,NOT_FOUND,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B",,['Chronic Hepatitis B'],"['Hepatitis B', 'Children', 'Pediatric', 'Adefovir Dipivoxil']",,2004-06,2010-04,"[{'measure': 'Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal Alanine Aminotransferase (ALT) at Week 48 (Missing = Failure)', 'description': 'In the absence of biopsy data from these pediatric participants, this endpoint enables assessments of drug effect on viral replication and the underlying degree of inflammation in the liver.', 'timeFrame': 'Week 48'}]","[{'measure': 'Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment - Missing = Failure) (ADV Week 192)', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV Week 192'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)', 'timeFrame': 'ADV Week 240'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 192)', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV Week 192'}, {'measure': 'Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)', 'timeFrame': 'ADV Week 240'}, {'measure': 'Adefovir (ADV) Baseline Serum HBV DNA', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Change From ADV Baseline to ADV Week 192 for Serum HBV DNA', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV baseline to ADV 192 weeks'}, {'measure': 'Change From ADV Baseline to ADV Week 240 for Serum HBV DNA', 'timeFrame': 'ADV baseline to ADV 240 weeks'}, {'measure': 'ADV Baseline ALT', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]).', 'timeFrame': 'ADV baseline'}, {'measure': 'Change From ADV Baseline to ADV Week 192 for ALT', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192).', 'timeFrame': 'ADV baseline to ADV 192 weeks'}, {'measure': 'Change From ADV Baseline to ADV Week 240 for ALT', 'timeFrame': 'ADV baseline to ADV 240 weeks'}, {'measure': 'Percentage of Participants With Normal ALT at Adefovir Baseline (Missing = Failure)', 'description': 'The ADV baseline was defined as the day of first dose of ADV (ie, Week 0 for participants originally randomized to double-blind ADV \\[ADV-ADV group\\] and Week 48 for those originally randomized to placebo \\[PLB-ADV group\\]). Normal ALT: 0-1 year old = \\<=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L.', 'timeFrame': 'ADV baseline'}, {'measure': 'Percentage of Participants With Normal ALT at ADV Week 192 (Missing = Failure)', 'description': 'Adefovir week was defined as the windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). Normal ALT: 0-1 year old = \\<=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L.', 'timeFrame': 'ADV Week 192'}, {'measure': 'Percentage of Participants With Normal ALT at ADV Week 240 (Missing = Failure)', 'description': 'Normal ALT: 0-1 year old = \\<=54 U/L; females 1-88 years old and males 1-10 years old = 8-34 U/L; males 10-88 years old = 8-43 U/L.', 'timeFrame': 'ADV Week 240'}, {'measure': 'Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss or Seroconversion by End of Blinded Treatment (Study Week 48; Randomized and Treated Analysis Set)', 'description': 'HBeAg loss is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and hepatitis B e antibody + (anti-HBe+) post baseline.', 'timeFrame': 'Study Week 0 to Study Week 48 (double-blind period)'}, {'measure': 'Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 192 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)', 'description': 'ADV baseline = 1st ADV-dose day = Week 0 for ADV-ADV group and Week 48 for PLB-ADV group. ADV week = windowed visit week relative to ADV baseline. Thus, participants in the ADV-ADV group could have received up to 240 weeks of ADV treatment (ADV Week 240), whereas participants in the PLB-ADV group could receive only up to 192 weeks of ADV treatment (ADV Week 192). HBeAg loss is defined per individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and anti-HBe+ post baseline.', 'timeFrame': 'ADV baseline to ADV Week 192'}, {'measure': 'Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 240 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)', 'description': 'Per protocol, participants could discontinue study medication due to HBeAg seroconversion and remain in the study in order to evaluate the durability of seroconversion. HBeAg loss is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- post baseline. HBeAg seroconversion is defined for an individual participant as HBeAg+ at ADV baseline and HBeAg- and anti-HBe+ post baseline.', 'timeFrame': 'ADV baseline to ADV Week 240'}, {'measure': 'Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance)', 'description': 'Resistance surveillance was conducted annually for all participants who remained on treatment and had HBV DNA concentrations greater than or equal to the level of detection (\\>= 169 copies/mL) by PCR. The last on-ADV sample for all participants in the study was analyzed in the cumulative Week 240 resistance surveillance analysis.', 'timeFrame': '240 weeks'}, {'measure': 'Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance) for Subjects Who Received Combination ADV + Lamivudine Therapy', 'description': 'Resistance surveillance was conducted at Week 240/last on-treatment study visit for all participants who had HBV DNA concentrations greater than or equal to the level of detection (\\>= 169 copies/mL) by PCR while on combination ADV + lamivudine treatment.', 'timeFrame': '240 weeks'}, {'measure': 'Percentage of Participants With Durable HBeAg Seroconversion', 'description': 'A participant was defined to have durable HBeAg seroconversion only if she/he remained in a seroconverted state (HBeAg-, hepatitis B e antibody + \\[anti-HBe+\\]) from the date that she/he first seroconverted through and including her/his last study visit. This endpoint could only be assessed for participants who (HBeAg-) seroconverted on-treatment and subsequently discontinued open-label dosing.', 'timeFrame': '240 weeks'}]",22.0,2 Years,17 Years,ALL,False,INDUSTRY,0.0,173.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03776968,A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics,HC1119,['HC1119'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Metastatic Castration Resistant Prostate Cancer,Hinova Pharmaceuticals Inc.,2025-09-01T16:18:07.016514,True,,,,NOT_FOUND,A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics in Healthy Chinese Adults,,['Metastatic Castration Resistant Prostate Cancer'],[],,2017-10-24,2018-07-03,"[{'measure': 'Area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration(AUC0-t)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Peak concentration (Cmax)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Peak time (Tmax)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Elimination half life (t1/2)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Apparent clearance (CL/F) (prototype)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Apparent volume of distribution (Vd/F) (prototype)', 'timeFrame': 'From the first dose of the study drug to day 50'}, {'measure': 'Mean residence time (MRT)', 'timeFrame': 'From the first dose of the study drug to day 50'}]","[{'measure': 'Number of patients with adverse events', 'description': 'Safety measures', 'timeFrame': 'From the first dose of the study drug to day 50'}]",9.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,47.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00981357,"A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee",PF-04457845,"['Naproxen', 'PF-04457845']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Osteoarthritis, Knee",Pfizer,2025-09-01T16:18:24.749870,True,,,,NOT_FOUND,"A Phase 2a Randomized, Double-blinded, Double Dummy, Placebo And Active Controlled, Two-way Cross-over, Flare-enriched Multi-centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A Fatty Acid Amide Hydrolase (Faah) Inhibitor Pf-04457845 In Patients With Osteoarthritis Of The Knee.",,"['Osteoarthritis, Knee']",['Cross-over evaluate the efficacy of PF-04457845 in relieving pain due to osteoarthritis OA knee osteoarthritis of knee pain due to osteoarthritis'],,2009-11,2010-05,"[{'measure': 'To evaluate the efficacy of PF-04457845 (administered QD) versus placebo in relieving pain as measured by the WOMAC Pain sub-score in patients with osteoarthritis of the knee', 'timeFrame': '8 weeks'}, {'measure': 'To evaluate the safety and tolerability of PF-04457845 in patients with osteoarthritis.', 'timeFrame': '10 weeks'}]","[{'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the WOMAC Stiffness domain score (Likert scale for 2 items, overall score ranges from 0-8) in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the WOMAC Physical Function domain score (Likert scale for 17 items, overall score ranges from 0-68) in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the WOMAC Total Score in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the Importance weighted Total WOMAC score in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the Daily pain diary over weeks 1 and 2 of each treatment period using an 11-point Numeric Rating Scale (NRS) in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': ""Efficacy of PF-04457845 (administered QD) versus placebo as measured by the Subjects' use of rescue medication on either treatment."", 'timeFrame': '8 weeks'}, {'measure': 'Summary of plasma concentrations of PF-04457845.', 'timeFrame': '8 weeks'}, {'measure': 'Residual FAAH activity in leukocytes for subjects recruited prior to the interim analysis.', 'timeFrame': '8 weeks'}, {'measure': 'Plasma fatty acid amide levels (OEA, PEA, LEA and AEA) for subjects recruited prior to the interim analysis.', 'timeFrame': '8 weeks'}]",11.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,76.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02821871,"the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers",SP2086,['SP2086'],1,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Type 2 Diabetes,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:19.665835,True,,,,NOT_FOUND,,,['Type 2 Diabetes'],[],,2016-03,2016-09,"[{'measure': 'The maximum plasma concentration (Cmax) of SP2086', 'description': ""Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086"", 'timeFrame': 'up to Day 12'}, {'measure': 'The maximum plasma concentration (Cmax) of SP2086 acid', 'description': ""Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086."", 'timeFrame': 'up to Day 12'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of SP2086', 'description': ""AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086."", 'timeFrame': 'up to Day 12'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of SP2086 acid', 'description': ""AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086."", 'timeFrame': 'up to Day 12'}, {'measure': 'Cumulative percentage drainage of SP2086 in urine', 'timeFrame': 'up to Day 12'}, {'measure': 'Cumulative percentage drainage of SP2086 in fecal', 'timeFrame': 'up to Day 12'}]","[{'measure': 'The number of volunteers with adverse events as a measure of safety and tolerability', 'timeFrame': 'up to Day 12'}]",7.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,24.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00537056,Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI,F-18 Fluoro-deoxi-glucose,"['Fludeoxyglucose (18F)', 'Sutent', 'F-18 Fluoro-deoxi-glucose', 'FDG', '18F-FDG', 'Gadolinium-DTPA', 'fluorodeoxyglucose (18F)', 'Gd-DTPA', 'SU11248', 'gadopentetate dimeglumine', 'Gadopentetic acid', 'Berlex', 'Sunitinib']",13,INTERVENTIONAL,['NA'],,COMPLETED,Kidney Neoplasms,Stanford University,2025-09-01T16:18:08.336374,True,,,,NOT_FOUND,Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI,,"['Kidney Neoplasms', 'Carcinoma, Renal Cell', 'Kidney (Renal Cell) Cancer']",[],,2007-10,2012-04,"[{'measure': 'F-18 FDG Tumor Uptake (SUV Max)', 'description': 'The maximum standardized uptake value (SUVmax) is a measurement of tumor metabolism as determined by the PET scan before and after 12-weeks of sunitinib therapy. Decreased SUVmax correlates to a reduction of tumor metabolism. Increased SUVmax correlates to an increase in tumor metabolism.\n\nReduction or increased SUVmax will be determined as the change from baseline in uptake of F18 FDG.\n\nResults were based on the European Organization for Research and Treatment of Cancer (EORTC) for predicting progression free survival. EORTC criteria is a ± 25% change of SUVmax for assessment of progressive disease, stable disease and partial response.', 'timeFrame': '12 weeks minus baseline'}]","[{'measure': 'Histopathology', 'description': 'Histopathologic findings were correlated to the pre-treatment 18F-fluorodeoxyglucose positron emission tomography (F-18 FDG PET/CT) scan. Outcome is reported as the number of participants for whom both histopathology and F-18 FDG PET/CT indicated that active cancers was present.', 'timeFrame': '1 day'}, {'measure': 'Initial Comprehensive Metabolic Panel', 'description': 'A comprehensive metabolic panel is a blood test that measures sugar (glucose) level, electrolyte and fluid balance, kidney function, and liver function. It was performed prior to the administration of gadolinium contrast. For patients with normal renal function, approximately 90% of gadolinium contrast is excreted through the urinary system. These patients have known renal cell carcinoma, so it was important to perform a metabolic function panel prior to gadolinium injection, specifically to determine kidney function. Reported as the number of patients for whom the initial comprehensive metabolic panel was within institutional standards.', 'timeFrame': 'Prior to baseline DCE MRI'}, {'measure': 'Adverse Events', 'description': 'Adverse events were monitored for on F-18 FDG PET/CT and DCE MRI imaging days: baseline (n=17); interim (n=12); and post-sunitinib therapy (n=17). Reported as the overall number of adverse events experienced.', 'timeFrame': 'up to 12 months'}, {'measure': 'Tumor Necrosis', 'description': 'The degree of tumor necrosis was measured using values obtained from dynamic contrast enhanced magnetic resonance imaging (DCE MRI) pre- and post-sunitinib therapy. Gadolinium contrast material given intravenously during the DCE MRI scan is used to improve visualization of blood vessels, tumors, and/or organs.', 'timeFrame': '12 weeks'}, {'measure': 'Tumor Size by Computed Tomography (CT) Scan', 'description': 'Tumor size was measured based on computed tomography (CT) pre- and post-sunitinib therapy. CT was performed immediately prior to the PET scan and is used to determine both the PET scan imaging area and PET image attenuation correction (AC). F-18 FDG PET provides the metabolic and physiologic data while CT provides the anatomical data.', 'timeFrame': '12 weeks'}, {'measure': 'Tumor Size by DCE Magnetic Resonance Imaging (MRI) Scan', 'description': 'Tumor size was measured using values obtained from DCE MRI pre- and post-sunitinib therapy. Gadolinium contrast material given intravenously during the DCE MRI scan is used to improve visualization of blood vessels, tumors, and/or organs.', 'timeFrame': '12 weeks'}, {'measure': 'DCE MRI AUC Peak Flow', 'description': 'Area under the curve (AUC) was measured using receiver operating characteristic (ROC) curve analysis. ROC curve analysis measures sensitivity (true-positives, correctly diagnosed positive pathologies) against specificity (true-negatives, correctly diagnosed negative pathologies or free of disease) of the DCE MRI scan. An area of 1.0 under the curve would equal a perfect test (with 100% sensitivity; 100% specificity) while an area of 0.5 would equal a useless test (50% sensitivity; 50% specificity).', 'timeFrame': '12 weeks'}, {'measure': 'Initial Tumor Size', 'description': 'Initial tumor size was measured using values obtained from computed tomography (CT) pre-sunitinib therapy. CT is performed immediately prior to the PET scan and is used to determine both the PET scan imaging area and PET image attenuation correction (AC). F-18 FDG PET provides the metabolic and physiologic data while CT provides the anatomical data.', 'timeFrame': 'pre-sunitinib therapy'}]",9.0,18 Years,,ALL,False,OTHER,1.0,17.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00649636,Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg,Fluoxetine Capsules 40 mg,"['Prozac Pulvules 40 mg', 'Fluoxetine Capsules 40 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Mylan Pharmaceuticals Inc,2025-09-01T16:18:08.347591,True,,,,CHEMBL41,Single-Dose Fasting Bioequivalence Study of Fluoxetine Capsules (40 mg; Mylan) and Prozac Pulvules (40 mg; Dista) in Healthy Adult Volunteers,,['Healthy'],[],,2006-02,2006-04,"[{'measure': 'Bioequivalence', 'timeFrame': 'within 30 days'}]",[],1.0,18 Years,,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,CHEMBL41,partial_match,True,309.33,4.44,4.0
NCT00143676,Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia,Lapaquistat acetate and atorvastatin,"['TAK-475', 'Atorvastatin', 'Lapaquistat acetate and atorvastatin', 'TAK475', 'Lapaquistat', 'Lipitor']",6,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hypercholesterolemia,Takeda,2025-09-01T16:18:25.989639,True,,,,CHEMBL435224,"A Double-blind, Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of TAK-475 50 mg, 100 mg, or Placebo When Co-administered With Atorvastatin (10 mg to 40 mg) in Subjects With Primary Hypercholesterolemia",,['Hypercholesterolemia'],"['Hyperlipidemia', 'Dyslipidemia', 'Drug Therapy']",,2005-08,2006-08,"[{'measure': 'Change from Baseline in Low Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}]","[{'measure': 'Adverse Events', 'timeFrame': 'Weeks: 2, 4, 8, 12, 16, 20, and 24 or Final Visit'}, {'measure': 'Physical Examination', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Safety Laboratory Tests', 'timeFrame': 'Weeks: 2, 4, 8, 12, 16, 20, and 24 or Final Visit'}, {'measure': 'Electrocardiogram assessments', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Best Corrected Visual Acuity results', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Vital Signs', 'timeFrame': 'Weeks: 2, 4, 8, 12, 16, 20, and 24 or Final Visit'}, {'measure': 'Change from Baseline in Triglycerides', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in Total Cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in Very Low Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in apolipoprotein A1', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in apolipoprotein B', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in non- High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in high-sensitivity C-reactive protein', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.813 mmol/L (70 mg/dL)', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.590 mmol/L (100 mg/dL)', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.367 mmol/L (130 mg/dL)', 'timeFrame': 'Week 24 or Final Visit'}]",21.0,18 Years,,ALL,False,INDUSTRY,0.0,448.0,ACTUAL,v2_robust,True,True,False,True,,COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC,CHEMBL435224,partial_match,True,645.15,4.87,3.0
NCT00585975,Efficacy and Safety of Bromfenac Ophthalmic Solution,bromfenac ophthalmic solution,['bromfenac ophthalmic solution'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cataract Surgery,Bausch & Lomb Incorporated,2025-09-01T16:18:24.749270,True,,,,NOT_FOUND,,,['Cataract Surgery'],[],,2007-10,,"[{'measure': 'Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero', 'description': 'Participants with SOIS of 1. Scale: 0=0 cells (complete absence); 0.5=1-5 cells (trace); 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=\\>50 cells (intense)', 'timeFrame': 'Day 15'}]","[{'measure': 'Number of Participants That Are Pain Free', 'description': 'Participant description of being pain free taken from patient questionnaire with multiple possible responses', 'timeFrame': 'Day 1'}]",2.0,18 Years,,ALL,True,INDUSTRY,0.0,568.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06334432,Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors,NUV-1511,['NUV-1511'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Advanced Solid Tumor,Nuvation Bio Inc.,2025-09-01T16:18:24.758592,True,,,,NOT_FOUND,"A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors",,"['Advanced Solid Tumor', 'HER2-negative Breast Cancer', 'Metastatic Castration-resistant Prostate Cancer (mCRPC)', 'Pancreatic Cancer', 'Platinum-resistant Ovarian Cancer (PROC)']",[],,2024-03-14,2027-10,"[{'measure': 'Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors', 'description': 'Number of patients with dose limiting toxicities, treatment emergent adverse events (TEAE) and serious adverse events (SAE) and laboratory abnormalities', 'timeFrame': 'First 28 days of dosing (DLT evaluation period)'}, {'measure': 'Phase 1: Identify recommended dosing schedule(s) and corresponding Phase 2 dose(s) (RP2D(s))', 'description': 'Number of patients with DLTs, TEAEs and SAEs and laboratory abnormalities', 'timeFrame': 'First 28 days of dosing (DLT evaluation period)'}, {'measure': 'Phase 2: Evaluate the efficacy of NUV-1511 in advanced solid tumors and selected tumor type(s)', 'description': 'Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Confirm the optimal NUV-1511 dose level/schedule for further development', 'description': 'Overall response rate per RECIST 1.1 (Composite response rate for mCRPC patients only, if enrolled in Phase 2)', 'timeFrame': 'Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Confirm the optimal NUV-1511 target tumor types for further development', 'description': 'Overall response rate per RECIST 1.1 (Composite response rate for mCRPC patients only, if enrolled in Phase 2)', 'timeFrame': 'Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}]","[{'measure': 'Phase 1: Explore preliminary efficacy of NUV-1511', 'description': 'Overall response rate and duration of response per RECIST 1.1. Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI.', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 1: Explore preliminary efficacy of NUV-1511', 'description': 'Overall response rate and duration of response per composite response rate (for mCRPC). Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI.', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 1: Explore preliminary efficacy of NUV-1511', 'description': 'Overall response rate and duration of response per response rates in specific disease markers. Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI.', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Characterize the PK profile of NUV-1511', 'description': 'Parameters include, but not limited to, maximum observed plasma concentration (Cmax)', 'timeFrame': 'Periodic PK sample collection from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first.'}, {'measure': 'Characterize the PK profile of NUV-1511', 'description': 'Parameters include, but not limited to, area under the plasma concentration-time curve (AUC)', 'timeFrame': 'Periodic PK sample collection from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first.'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Incidence of TEAEs and SAEs', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Laboratory abnormalities', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Duration of response', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Clinical best response', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Progression free survival', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Overall survival', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'PK exposure-response modeling, which includes measuring plasma concentration versus overall response rate', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'PK exposure-response modeling, which includes measuring plasma concentration versus progression free survival', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'PK exposure-response modeling, which includes measuring plasma concentration versus treatment emergent adverse events and serious adverse events.', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Response rates in disease-specific markers', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}]",20.0,18 Years,,ALL,False,INDUSTRY,0.0,466.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00282412,Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism,Fludarabine,"['Fludara', 'Mycophenolate Mofetil', 'Campath 1H', 'Alemtuzumab', 'Cyclosporins', 'Cyclophosphamide', 'Neupogen', 'Cellcept', 'GCSF', 'CSA', 'Fludarabine', 'Cytoxan, Neosar']",12,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Rheumatoid Arthritis,Northwestern University,2025-09-01T16:18:08.343268,True,,,,NOT_FOUND,Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism,,['Rheumatoid Arthritis'],[],No participant enrolled for three years. No plan to continue study.,2002-09,2016-06,"[{'measure': 'Survival', 'description': 'The number of participants who survived treatment', 'timeFrame': 'up to 5 years'}]",[],1.0,18 Years,60 Years,ALL,False,OTHER,0.0,4.0,ACTUAL,v2_robust,True,False,True,False,No participant enrolled for three years. No plan to continue study.,,,no_match,False,,,
NCT01130259,"An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer",iniparib,"['iniparib', 'BSI-201']",2,EXPANDED_ACCESS,[],,NO_LONGER_AVAILABLE,Breast Cancer,Sanofi,2025-09-01T16:18:12.185483,True,,,,NOT_FOUND,"An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer",,['Breast Cancer'],"['mTNBC', 'triple negative breast cancer', 'metastatic triple negative breast cancer', 'metastatic breast cancer that is ER-, PR-, and HER2-negative']",,,,[],[],0.0,18 Years,,FEMALE,,INDUSTRY,0.0,,,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT02402270,Safety and Tolerability Study of an Edible Colon Preparation,NuLYTELY® (PEG 3350),"['NuLYTELY® (PEG 3350)', 'ECP-019', 'MoviPrep® (PEG 3350)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Bowel Preparation,ColonaryConcepts LLC,2025-09-01T16:18:13.414425,True,,,,NOT_FOUND,"An Adaptive, Single-Blind, Parallel, Randomized, Phase 2, Formulation Screening/Proof of Concept, Safety, Tolerability and Efficacy Study of Three Formulations/Dosing Regimens of ECP (PEG 3350) Colon Prep Kit Compared to Comparators.",,['Bowel Preparation'],"['Colonoscopy', 'Preparation']",,2015-05,2016-06,"[{'measure': 'The proportion of patients with successful colon cleansing as assessed by the blinded gastroenterologists using the Aronchick Scale.', 'timeFrame': 'One year'}]","[{'measure': 'Percentage of patients who completed each of the ECP-019 formulation/dosing regimens', 'timeFrame': 'One year'}]",2.0,18 Years,74 Years,ALL,True,INDUSTRY,0.0,69.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05703685,[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET,Apremilast,"['18F-PF-06445974', 'Apremilast']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Depression,National Institute of Mental Health (NIMH),2025-09-01T16:18:19.676730,True,,,,NOT_FOUND,[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET,,['Depression'],"['PET Imaging', 'Depression', 'Phosphodiesterase-4']",,2023-06-22,2029-04-11,"[{'measure': 'To measure distribution volume', 'description': 'Target quantification', 'timeFrame': '36 months'}]","[{'measure': 'To determine the optimal length', 'description': 'Target quantification', 'timeFrame': '36 months'}, {'measure': 'To measure whole-brain distribution volume in retest', 'description': 'Target quantification', 'timeFrame': '36 months'}, {'measure': 'measure clinical rating scales and PDE4B binding', 'description': 'Assess the severity of depression', 'timeFrame': '36 months'}]",4.0,18 Years,70 Years,ALL,True,NIH,0.0,108.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01709760,A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA,Methotrexate,"['Methotrexate', 'TuNEX', 'ENIA11', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Rheumatoid Arthritis,Mycenax Biotech Inc.,2025-09-01T16:18:18.418334,True,,,,CHEMBL34259,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis",,['Rheumatoid Arthritis'],"['ENIA11', 'MTX', 'RA', 'TNF']",,2012-11,2019-12,"[{'measure': 'ACR20 responder at last treatment visit', 'description': 'The primary efficacy endpoint is defined as ACR20 responder at last treatment visit (Week 24).', 'timeFrame': 'Week 24'}]",[],1.0,20 Years,,ALL,False,INDUSTRY,0.0,91.0,ACTUAL,v2_robust,True,False,False,False,,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,CHEMBL34259,exact_match,True,454.45,0.27,4.0
NCT02681887,Effect of Melatonin on Cardiometabolic Risk- FULL,Melatonin,"['Circadian', 'Melatonin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Obesity,Brigham and Women's Hospital,2025-09-01T16:18:14.661029,True,,,,CHEMBL45,Effect of Melatonin on Cardiometabolic Risk- FULL,,"['Obesity', 'Prediabetic State']",[],,2016-09,2021-12,"[{'measure': 'change in insulin sensitivity', 'description': 'measure insulin sensitivity using hyperinsulinemic clamp', 'timeFrame': '12 weeks'}, {'measure': 'change in beta-islet cell function', 'description': 'measure beta-iset cell function measured using a hyperglycemic clamp', 'timeFrame': '12 weeks'}]","[{'measure': 'change in 24 hour ambulatory blood pressure', 'description': 'evaluate the effect of supplementation on 24-hour ambulatory blood pressure', 'timeFrame': '12 weeks'}, {'measure': 'change in nocturnal blood pressure', 'description': 'evaluate the effect of supplementation nocturnal blood pressure', 'timeFrame': '12 weeks'}, {'measure': 'change in endothelial dependent vasodilation', 'description': 'Measurements of the brachial diameter will be made under basal conditions and during reactive hyperemia following five minutes of ischemic stimulus', 'timeFrame': '12 weeks'}, {'measure': 'change in endothelial independent vasodilation', 'description': 'measuring brachial artery diameter under basal conditions and 3 minutes following the administration of sublingual nitroglycerine (0.4mg)', 'timeFrame': '12 weeks'}, {'measure': 'change in catecholamine production', 'description': 'using 24 hour urine collection, measure catecholamines from (epinephrine, norepinephrine and dopamine) using a RIA', 'timeFrame': '12 weeks'}, {'measure': 'change in plasma renin level', 'description': 'effect of melatonin on RAS', 'timeFrame': '12 weeks'}, {'measure': 'change in angiotensin II level', 'description': 'effect of melatonin on RAS', 'timeFrame': '12 weeks'}, {'measure': 'change in cellular cytokine level', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in CC family chemokine expression', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in high sensitivity CRP', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in IL-6 level', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in TNF-alpha', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}]",14.0,18 Years,,ALL,True,OTHER,0.0,120.0,ESTIMATED,v2_robust,True,False,False,False,,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,CHEMBL45,exact_match,True,232.28,1.86,4.0
NCT03456843,Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer,Antiandrogen Therapy,"['Anti-androgen Treatment', 'Androgen Deprivation Therapy', 'Anti-androgen Therapy', 'Taxotere', 'Docecad', 'ADT', 'RP56976', 'Antiandrogen Therapy', 'Hormone-Deprivation Therapy', 'Taxotere Injection Concentrate', 'Docetaxel', 'Hormone Deprivation Therapy', 'Antiandrogen Treatment']",13,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Stage IV Prostate Adenocarcinoma AJCC v7,Yale University,2025-09-01T16:18:17.186428,True,,,,NOT_FOUND,SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer,,['Stage IV Prostate Adenocarcinoma AJCC v7'],[],,2018-03-20,2027-03,"[{'measure': 'Failure-free survival (FFS)', 'description': 'Failure is defined as any one of the following events: PSA progression, clinical progression, radiographic progression, or death from prostate cancer. The % of men who fail within 2 years of randomization will be compare between the two groups using a one-sided log-rank test.', 'timeFrame': 'At 2 years'}]","[{'measure': 'Cancer-specific survival', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall complication rate', 'timeFrame': 'Up to 2 years'}, {'measure': 'Time to biochemical progression', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'timeFrame': 'Through study completion, a minimum of 4 years'}]",5.0,18 Years,,MALE,False,OTHER,1.0,190.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,natalizumab,"['BG00002', 'Tysabri', 'natalizumab', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Secondary Progressive Multiple Sclerosis,Biogen,2025-09-01T16:18:08.343685,True,,,,NOT_FOUND,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension",,['Secondary Progressive Multiple Sclerosis'],"['Natalizumab', 'secondary', 'multiple sclerosis', 'MS', 'SPMS', 'Tysabri']",The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.,2011-09-13,2016-04-13,"[{'measure': 'Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)', 'description': 'Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):\n\n* Confirmed progression in EDSS (EDSS score increased from baseline \\[BL\\] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);\n* Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);\n* Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).\n\nThe EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.', 'timeFrame': 'Up to 96 weeks (2 years)'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.', 'timeFrame': '218 weeks'}]","[{'measure': 'Part 1: Percentage of Participants With a T25FW Response', 'description': 'T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.', 'timeFrame': 'Up to 96 weeks'}, {'measure': 'Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)', 'description': 'MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.', 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire', 'description': ""The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND."", 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score', 'description': ""The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29."", 'timeFrame': 'Baseline and Week 96'}, {'measure': 'Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96', 'description': 'Whole brain volume as measured by MRI.', 'timeFrame': 'Week 24 and Week 96'}, {'measure': 'Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores', 'description': 'The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:\n\n* an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or\n* an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.\n\nA confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.', 'timeFrame': 'Up to 96 weeks'}, {'measure': 'Part 2: Percentage of Participants With Disability Worsening at 156 Weeks', 'description': 'Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS \\> 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.', 'timeFrame': 'Week 156'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in T25FW', 'description': 'The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in T25FW', 'description': 'The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)', 'description': 'The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in EDSS', 'description': 'The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in EDSS', 'description': 'The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)', 'description': 'The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.', 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in the 6MWT', 'description': 'The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.', 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score', 'description': ""The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29."", 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score', 'description': ""The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29."", 'timeFrame': 'Baseline (Part 1) and Weeks 156, 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)', 'description': 'SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).', 'timeFrame': 'Baseline (Part 1) and every 4 weeks from Week 108 to Week 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in the SDMT', 'description': 'SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).', 'timeFrame': 'Baseline (Part 1) and every 4 weeks from Week 108 to Week 204'}, {'measure': 'Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire', 'description': 'The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment \\[absenteeism plus presenteeism\\]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'Part 2 Baseline (Week 108) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire', 'description': 'The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment \\[absenteeism plus presenteeism\\]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'Part 2 Baseline (Week 108) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume', 'description': 'Whole brain volume as measured by MRI.', 'timeFrame': 'Week 24 (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume', 'description': 'Whole grey matter brain volume as measured by MRI.', 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}, {'measure': 'Part 2: Summary of New/Enlarging T2 Lesion Counts', 'description': 'New or enlarging T2 lesions as measured by MRI.', 'timeFrame': 'Baseline (Part 1) up to Week 204'}, {'measure': 'Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions', 'description': 'New or enlarging T2 lesions as measured by MRI.', 'timeFrame': 'Baseline (Part 1) and Weeks 156 and 204'}]",29.0,18 Years,58 Years,ALL,False,INDUSTRY,0.0,889.0,ACTUAL,v2_robust,True,False,True,True,The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.,,,no_match,False,,,
NCT00672867,A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B,Clevudine,"['Adefovir dipivoxil', 'Levovir', 'Clevudine', 'Hepsera']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Patients With LC-B,Bukwang Pharmaceutical,2025-09-01T16:18:17.170063,True,,,,NOT_FOUND,A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B,,['Patients With LC-B'],[],,2007-12,2014-09,[{'measure': 'Proportion of patients with HBV DNA below 12 IU/mL by Real-Time PCR'}],"[{'measure': 'The change of HBV DNA from the baseline.'}, {'measure': 'Child-Pugh score improvement'}, {'measure': 'MELD score improvement'}, {'measure': 'Biochemical improvement'}, {'measure': 'Proportion of patients with HBeAg loss and/or seroconversion'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,102.0,ESTIMATED,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06073184,Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium,Mounjaro,"['Mirena', 'Tirzepatide', 'Progestin-releasing intra-uterine device (pIUD)', 'Mounjaro']",4,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Endometrial Cancer,"University Health Network, Toronto",2025-09-01T16:18:19.672657,True,,,,NOT_FOUND,Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE),,"['Endometrial Cancer', 'Atypical Hyperplasia']","['Tirzepatide', 'pIUD']",,2025-08,2032-02,"[{'measure': 'Assessment of Complete Pathologic Response', 'description': 'Proportion of patients (%) who achieve pathological complete response at 48 weeks after initiation of pIUD and tirzepatide.', 'timeFrame': '48 weeks'}]","[{'measure': 'Assessment of Safety and Tolerability', 'description': 'Adverse events during treatment period', 'timeFrame': '48 weeks'}, {'measure': 'Assessment of Feasibility', 'description': 'Rate of accrual; Patient compliance; Retention', 'timeFrame': '2.5 years'}, {'measure': 'Assessment of Secondary Oncologic Outcomes', 'description': 'Time to achieve complete response; Duration of response; Recurrence rate; Time to recurrence; Progression/persistence rate', 'timeFrame': '6 years'}, {'measure': 'Assessment of Reproductive Outcomes', 'description': 'Rate of pregnancy; Live birth; Miscarriage; Pregnancy complications', 'timeFrame': '6 years'}, {'measure': 'Assessment of Patient Reported Outcomes', 'description': 'Quality of Life; Psychological functioning and fertility concerns after cancer diagnosis', 'timeFrame': '48 weeks'}, {'measure': 'Assessment of Metabolic Outcomes', 'description': 'Weight; BMI; Waist/hip circumference; Serum biomarkers of obesity and insulin resistance', 'timeFrame': '48 weeks'}]",7.0,18 Years,41 Years,FEMALE,False,OTHER,0.0,71.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00002214,Phase I Trial of S-1153 in Patients With HIV Infection,Capravirine,['Capravirine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,HIV Infections,Lexigen Pharmaceuticals,2025-09-01T16:18:08.354036,True,,,,NOT_FOUND,Phase I Trial of S-1153 in Patients With HIV Infection,,['HIV Infections'],"['Dose-Response Relationship, Drug', 'Reverse Transcriptase Inhibitors']",,,,[],[],0.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,40.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00369200,AFP464 in Treating Patients With Advanced Solid Tumors,AFP464,['AFP464'],1,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,"Unspecified Adult Solid Tumor, Protocol Specific",National Cancer Institute (NCI),2025-09-01T16:18:24.754430,True,,,,NOT_FOUND,A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors,,"['Unspecified Adult Solid Tumor, Protocol Specific']",[],,2006-06,,"[{'measure': 'Maximum tolerated dose determined by dose-limiting toxicity', 'timeFrame': '28 days'}, {'measure': 'Types and grades of toxicity', 'description': 'Full frequency distributions of grade of toxicity, by toxicity type, will be generated, by dose level. Among all treated patients, both point and exact confidence interval estimates of the rate of every specific type of Grade 3-4 toxicity will be calculated, by dose level. Grade 2 DLCO rates (point and confidence level) will also be computed, by dose level.', 'timeFrame': 'Up to 4 weeks'}]","[{'measure': 'Pharmacokinetic, pharmacodynamic, and pharmacogenomic parameters', 'timeFrame': 'Up to 4 weeks'}, {'measure': 'Response rate', 'description': 'Point and exact confidence interval estimates of response rate will be provided for all eligible patients combined, and if warranted, by specific dose levels.', 'timeFrame': 'Up to 4 weeks'}]",4.0,18 Years,,ALL,False,NIH,0.0,60.0,ACTUAL,v2_robust,True,False,True,False,,,,no_match,False,,,
NCT03487939,Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer,FOLFOXIRI,"['Irinotecan', '5-Fluorouracil', 'FOLFOXIRI', 'Oxaliplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Colorectal Neoplasms,"China Medical University, China",2025-09-01T16:18:19.657211,True,,,,NOT_FOUND,"Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer：an Open-label, Single-arm, Multicenter Phase II Study",,"['Colorectal Neoplasms', 'Drug Therapy']",[],,2018-05-01,2021-10-01,"[{'measure': 'The ratio of tumor downstaging to stage 0 and stage I', 'description': 'Tumor downstaging from stage II or III to pathologic complete response (stage 0) and stage I', 'timeFrame': '2 years'}]","[{'measure': 'Tumor regression grade (TRG)', 'description': 'The level of tumor regression under pathological examination', 'timeFrame': '2 years'}, {'measure': 'Disease free survival', 'description': 'Estimated from the date of surgery to the date of recurrence.', 'timeFrame': '3 years'}, {'measure': 'Overall survival time', 'description': 'Estimated from the date of enrollment to death from any cause.', 'timeFrame': '3 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'The grade of toxicity will be assessed using the NCI-CTCAE version 4.0.', 'timeFrame': '3 years'}, {'measure': 'ctDNA assessment and relation to clinical outcome', 'description': 'The relationship between ctDNA and survival will be evaluated.', 'timeFrame': '3 years'}, {'measure': 'SUVmax assessment and relation to clinical outcome', 'description': 'Tumor metabolic response through FDG-PET examination before and after 4 cycles of neoadjuvant FOLFOXIRI chemotherapy', 'timeFrame': 'At the beginning of Cycle 1 and the end of Cycle 4 (each cycle is 14 days)'}, {'measure': 'Quality of life (QLQ C30)', 'description': 'Scores according to EORTC QLQ-C30 scoring manual', 'timeFrame': 'Every 2 weeks after the first treatment until 3 years'}]",8.0,18 Years,75 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02753088,Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis,BCD-063,"['mannitol', 'glatiramer acetate', 'Copaxone-Teva', 'Placebo', 'BCD-063']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Relapsing-remitting Multiple Sclerosis,Biocad,2025-09-01T16:18:09.641618,True,,,,NOT_FOUND,"International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC ""BIOCAD"", Russia) and Copaxone®-Teva (""Teva Pharmaceutical Industries Limited"", Israel) in Patients With Relapsing-remitting Multiple Sclerosis",,['Relapsing-remitting Multiple Sclerosis'],"['Equivalence', 'BCD-063', 'Copaxone-Teva']",,2013-10,2015-11,"[{'measure': 'Cumulative Unique Activity lesions', 'description': 'Cumulative Unique Activity (CUA) detected by MRI', 'timeFrame': '48 weeks'}]","[{'measure': 'Annual relapse rate', 'description': 'Relapse per patient per year', 'timeFrame': '48 weeks'}, {'measure': 'Proportion of patients without relapses', 'description': 'Proportion of patients without confirming relapses with magnetic resonance imaging (MRI)', 'timeFrame': '48 weeks'}, {'measure': 'Changing in volume of hypointense T1 lesions', 'timeFrame': '48 weeks'}, {'measure': 'Changing in volume of T2 lesions', 'timeFrame': '48 weeks'}, {'measure': 'Amount of new or extended lesions in T2 regimen', 'timeFrame': '48 weeks'}, {'measure': 'Patients proportion without lesions', 'timeFrame': '48 weeks'}, {'measure': 'T1 lesions amount', 'timeFrame': '48 weeks'}, {'measure': 'Expanded Disability Status Scale dynamics', 'description': 'Expanded Disability Status Scale (EDSS) scale count at 24th and 48th week, comparing count at week 24 to week 48 for each group', 'timeFrame': 'Week 24, Week 48'}, {'measure': 'Progression on Multiple Sclerosis Functional Composite scale comparing to the baseline', 'timeFrame': '48 weeks'}, {'measure': 'Risk of relapse', 'description': 'Relative Risk Ratio for relapse in each group', 'timeFrame': '48 weeks'}, {'measure': 'Time till the first relapse', 'timeFrame': '48 weeks'}, {'measure': 'Multiple Sclerosis Functional Composite scale dynamics', 'description': 'Multiple Sclerosis Functional Composite (MSFC) scale count at 24th and 48th week, comparing count at week 24 to week 48 for each group', 'timeFrame': '24, 48 weeks'}]",13.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,158.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00696111,Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea,Depot Lupron followed by estrogen plus placebo,"['Arm 1', 'Depot Lupron followed by estrogen plus placebo']",2,INTERVENTIONAL,['NA'],,COMPLETED,Polycystic Ovary Syndrome,University of Chicago,2025-09-01T16:18:08.347835,True,,,,NOT_FOUND,"PCOS, Sleep Apnea and Metabolic Risk in Women",,"['Polycystic Ovary Syndrome', 'Obstructive Sleep Apnea']","['PCOS', 'OSA', 'Metabolism', 'Diabetes']",,2007-12,2022-06-30,"[{'measure': 'Estrogen Levels', 'description': 'Estrogen levels measured every 20 minutes for 24 hours and the the average of those values are presented. The units of measurement are picograms per milliter (pg/ml).', 'timeFrame': 'Baseline'}, {'measure': 'Sleep Efficiency Measured at Baseline', 'description': 'Sleep efficiency recorded with polysomnography minimum value = 0%, maximum value = 100%, higher values are a better outcome.', 'timeFrame': 'Baseline'}, {'measure': 'Total Testosterone', 'description': 'Total Testosterone levels measured every 20 minutes for 24 hours and the average of those values are presented. The units of measurement are picograms per milliter (pg/ml).', 'timeFrame': 'Baseline'}]","[{'measure': 'Intravenous Glucose Tolerance Test', 'description': 'Acute Insulin Response measured by the intravenous glucose tolerance test measured during baseline. The unit of measurement is mg/dl.', 'timeFrame': 'Baseline'}]",4.0,18 Years,40 Years,FEMALE,False,OTHER,2.0,18.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00756912,A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors,E5564,"['E5564', 'Eritoran']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Leukemia,Eisai Inc.,2025-09-01T16:18:08.343220,True,,,,NOT_FOUND,"A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors",,['Leukemia'],"['ANC', 'BMT', 'graft versus leukemia', 'graft vs. host disease', 'MD2 (endotoxin binding-protein)', 'undergo allogeneic BMT', 'myeloablative', 'conditioning', 'therapy']","This study was terminated in November 2008 due to ""a business decision (resources)"".",2008-09,,"[{'measure': 'Safety and assessments will be done daily.', 'timeFrame': 'Performed daily through Day 28, with follow-up every other week to Day 100 and at 1 year post-transplant.'}]",[],1.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,False,True,True,"This study was terminated in November 2008 due to ""a business decision (resources)"".",,,no_match,False,,,
NCT01696123,Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine,MLC601,"['NeuroAid', 'MLC601']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,2025-09-01T16:18:18.420378,True,,,,NOT_FOUND,,,['Alzheimer Disease'],"['Alzheimer disease', 'Cholinesterase inhibitors', 'MLC601', 'NeuroAiD', 'neuroprotection', 'neuroregeneration']",,2011-01,2012-08,"[{'measure': 'changes in the Mini-Mental State Examination (MMSE) relative to baseline measurements', 'description': 'change in the Mini-Mental State Examination (MMSE) relative to baseline measurements will be evaluated every 4 weeks up to 18 months.', 'timeFrame': 'every 4 weeks up to 18 months'}, {'measure': 'changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements', 'description': 'change in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurements will be evaluated every 4 weeks up to 18 months.', 'timeFrame': 'every 4 weeks up to 18 months'}]","[{'measure': 'to measure included adverse events (AEs)', 'description': 'Safety and tolerability evaluations included physical examinations, electrocardiography, vital sign monitoring and laboratory testing weekly for the first 8 weeks and every 4 weeks thereafter. AEs were defined as any sign, symptom, syndrome or disease that occurred for the first time or worsened after baseline, whether they were considered treatment related.', 'timeFrame': 'every 4 weeks'}, {'measure': 'measuring withdrawal rate', 'description': 'measuring any withdrawal rate among intervention group', 'timeFrame': 'every 4 weeks'}]",4.0,50 Years,,ALL,False,OTHER,0.0,125.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04101812,"Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer",pegylated liposomal doxorubicin (PLD),"['pegylated liposomal doxorubicin (PLD)', 'Doxorubicin Hydrochloride Liposome Injection', 'PD-1']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Muscle Invasive Bladder Cancer,Tianjin Medical University Second Hospital,2025-09-01T16:18:19.660023,True,,,,NOT_FOUND,"A Non-randomized, Prospective Clinical Study of Pegylated Liposomal Doxorubicin and PD-1 in the Second-line Treatment of Relapse or Metastatic Muscle Invasive Bladder Cancer",,['Muscle Invasive Bladder Cancer'],[],,2019-09-17,2021-05-31,"[{'measure': 'Disease control rate', 'description': 'Disease control rate defined as confirmed complete response or partial response or stable disease under RECIST 1.0 criteria.', 'timeFrame': 'at least 10 months'}, {'measure': 'Objective response rate', 'description': 'Objective response rate defined as confirmed complete response or partial response under RECIST 1.0 criteria.', 'timeFrame': 'at least 10 months'}]","[{'measure': 'Progression free survival', 'description': 'Progression-free survival estimated using Kaplan-Meier methods is defined as the time from registration to the earlier of death or disease progression.', 'timeFrame': 'at least 10 months'}, {'measure': 'Overall survival', 'description': 'Overall survival estimated using Kaplan-Meier methods is defined as the time from treatment initiation to death by any cause', 'timeFrame': 'at least 10 months'}]",4.0,18 Years,75 Years,ALL,False,OTHER,1.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03898193,"Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions",Montelukast,"['Singulair', 'The reference product', 'The test product', 'Montelukast']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Adults,Pharmtechnology LLC,2025-09-01T16:18:22.207414,True,,,,NOT_FOUND,"Single-Dose Open-label Randomized Crossover, in Two Periods and in Two Sequences, Single-Center Comparative Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Republic of Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions",,['Healthy Adults'],"['Bioequivalence', 'Montelukast', 'Singulair']",,2019-03-23,2019-04-08,"[{'measure': 'Cmax of montelukast for the test and the reference products', 'description': 'Maximum concentration in plasma among observed concentrations at pre-specified time points', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'AUC0-t of montelukast for the test and the reference products', 'description': 'Area under the plasma concentration versus time curve from time 0 to the last measured concentration', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}]","[{'measure': 'AUC0-∞ of montelukast for the test and the reference products', 'description': 'Area under the plasma concentration versus time curve from time 0 to infinite time', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'Tmax of montelukast for the test and the reference products', 'description': 'Time to maximum measured plasma concentration', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'T1/2 of montelukast for the test and the reference products', 'description': 'Elimination or terminal half-life', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'Kel of montelukast for the test and the reference products', 'description': 'Elimination rate constant', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'AUCresid of montelukast for the test and the reference products', 'description': 'Residual area under the pharmacokinetic curve from the time of the last measured concentration to infinite time', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol', 'description': 'An AE is defined as any untoward medical occurrence in a subject will be administered an investigational product and which does not necessarily have a causal relationship with the treatment. The data from subjects who will take at least one investigational product will be analyzed.', 'timeFrame': '8 days'}]",8.0,18 Years,45 Years,ALL,True,INDUSTRY,1.0,34.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02943135,Lidocaine In-situ Gel Before Intrauterine Device Insertion,lidocaine in-situ gel,"['placebo in-situ gel', 'lidocaine in-situ gel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Pain Relief,Assiut University,2025-09-01T16:18:12.176422,True,,,,CHEMBL79,Effect of Self-administered Lidocaine In-situ Gel on Intrauterine Device Insertion Pain: A Randomized Controlled Trial,,['Pain Relief'],[],,2017-10-01,2020-03-30,"[{'measure': 'Mean pain score during intrauterine device insertion', 'timeFrame': '30 min'}]",[],1.0,20 Years,50 Years,FEMALE,False,OTHER,0.0,120.0,ACTUAL,v2_robust,True,True,False,False,,CCN(CC)CC(=O)Nc1c(C)cccc1C,CHEMBL79,partial_match,True,234.34,2.58,4.0
NCT00160537,POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis),Levocetirizine,['Levocetirizine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Seasonal Allergic Rhinitis,UCB Pharma,2025-09-01T16:18:18.433553,True,,,,NOT_FOUND,"A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen",,['Seasonal Allergic Rhinitis'],"['Seasonal Allergic Rhinitis (SAR), Grass pollen, SAR Symptoms (sneezing, rhinorrhea, nasal / ocular pruritus, nasal congestion)', 'POPULAR, Xyzal, Levocetirizine']",,2005-05,2005-07,"[{'measure': ""Subjects' satisfaction / dissatisfaction after the first week of treatment.""}]","[{'measure': ""allergic rhinitis symptoms scores over the first week of treatment , subject's satisfaction / dissatisfaction of their choice of treatment after the first week of treatment, time to first feeling of (sufficient) symptom improvement during the first we""}]",2.0,18 Years,,ALL,,INDUSTRY,0.0,200.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00722709,Intraperitoneal Local Anaesthetic in Colonic Surgery,Ropivacaine,"['0.9% Saline', 'Ropivacaine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Colon Surgery,"University of Auckland, New Zealand",2025-09-01T16:18:24.758044,True,,,,NOT_FOUND,Randomised Double Blind Trial to Investigate the Effects of Intraperitoneal Local Anaesthetic Following Colonic Surgery.,,['Colon Surgery'],"['Pain', 'Fatigue', 'Colon', 'Surgery', 'ERAS', 'Fastrack', 'Local anaesthetic', 'Peritoneum', 'Metabolic', 'Endocrine', 'Post surgical metabolic response', 'Complications', 'Time to passage of flatus', 'Time to passage of stool', 'Time to discharge from facility', 'Re-admission rate']",,2008-09,2010-01,"[{'measure': 'Post operative recovery using the Identity consequence fatigue scale (ICFS)', 'timeFrame': 'Base-line, Day 1, Day 3, Day 7, Day 14, Day 30, Day 60'}]","[{'measure': 'Post-operative rest, movement and cough pain using Visual analogue score', 'timeFrame': '2,4,6,8,12,24,48,72 hours and on day 7'}, {'measure': 'Post operative analgesia use using morphine equivalence data', 'timeFrame': 'Total use on day 1, day 2, day 3 post operatively and total use until discharge'}, {'measure': 'Serum Ropivacaine level, serum Cytokine, serum Cortisol, serum glucose and serum CRP. Albumin, haematological parameters and biochemical parameters.', 'timeFrame': 'Pre-operatively, 8, 20, 48,72 hours post operatively'}, {'measure': 'Questions aimed at symptoms of local anaesthetic toxicity', 'timeFrame': '2, 4, 6, 8, 12, 24, 48, 72 hours post operatively'}, {'measure': 'Recovery of bowel function measured by time to pass flatus and time to pass stool post-operatively.', 'timeFrame': 'Assessed at 2, 4, 6, 8, 12, 24, 36, 48, 60, 72 hours.'}, {'measure': 'Quality of care assessment based on a 100mm visual analogue scale (1-10).', 'timeFrame': 'pre-op, day1, day 2, day3, day 7, day 30 and day 60 post operatively'}]",7.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03814746,Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients,Crizanlizumab (SEG101),"['SEG101', 'Crizanlizumab (SEG101)', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Sickle Cell Disease (SCD),Novartis Pharmaceuticals,2025-09-01T16:18:13.410755,True,,,,NOT_FOUND,"A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)",,['Sickle Cell Disease (SCD)'],"['Sickle Cell Disease', 'SCD', 'SEG101', 'Crizanlizumab', 'Hydroxyurea/ Hydroxycarbamide Therapy', 'Vaso-Occlusive Crises', 'SCA', 'blood disorders', 'hemoglobin', 'red blood cells', 'sickle-like shape', 'mutation in hemoglobin gene', 'sickle-cell trait', 'sickle-cell crisis']",,2019-07-26,2026-12-14,"[{'measure': 'Annualized Rate of Vaso-occlusive Crisis (VOC) Events Leading to a Healthcare Visit', 'description': 'VOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration.\n\nHealthcare visit is defined as any visit to a medical facility such as emergency room (ER), hospital and/or office visit, which includes pain management of VOC in situ.\n\nAnnualized rate of corresponding VOC events = (Number of corresponding VOC events \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).', 'timeFrame': '1 year'}]","[{'measure': 'Annualized Rate of All VOCs Leading to a Healthcare Visit and Treated at Home Over the First-year Post Randomization (Key Secondary)', 'description': 'VOCs are based on documentation by provider following contact with participant. VOC:pain crisis requiring therapy with oral/parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome, priapism and hepatic or splenic sequestration. Healthcare visit:a visit to a medical facility (ER, hospital \\&/or office visit resulting in pain management of VOC. Managed at home: no visit to any medical facility \\&/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice is allowed. Annualized rate of corresponding VOC events = (# of corresponding VOC events \\* 365)/(# of days in observation period). Observation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor \\& erythropoietin therapies to treat SCD \\&/or to prevent/reduce VOCs), date of randomization + 365 days)', 'timeFrame': '1 year'}, {'measure': 'Annualized Rate of All VOCs Leading to a Healthcare Visit and Treated at Home Over 5 Years Post Randomization (Key Secondary)', 'description': 'To compare the efficacy of 5.0 mg/kg vs placebo \\& 7.5 mg/kg vs placebo on the annualized rate of all VOCs based on documentation by provider following contact with participant. VOC is defined as pain crisis (an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) requiring therapy with oral/parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome, priapism and hepatic or splenic sequestration. Healthcare visit is defined as a visit to a medical facility (emergency room, hospital and/or office visit resulting in pain management of VOC. Managed at home is defined as no visit to any medical facility and/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice is allowed. The annualized rate of VOC leading to healthcare visit is the number of VOC leading to healthcare visit multiplied by 365 \\& divided by the number of days in observation period.', 'timeFrame': '5 years'}, {'measure': 'Mean Duration of VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the duration of VOCs leading to healthcare visit in each group. Mean duration of VOC per participant is defined as the average duration of all individual episodes of VOCs leading to healthcare visits of a given participant (a VOC duration is defined as end date of the VOC - start date of the VOC + 1). Participants with no VOC leading to healthcare visits have been excluded.', 'timeFrame': '1 year'}, {'measure': 'Number of Participants Free From VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the number of participants free from VOCs leading to healthcare visit.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. A participant is free from VOC if they do not have a VOC crisis.', 'timeFrame': '1 year'}, {'measure': 'Percentage of Participants Free From VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the percentage of participants free from VOCs leading to healthcare visit. VOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. A participant is free from VOC if they do not have a VOC crisis.', 'timeFrame': '1 year'}, {'measure': 'Time to First and Second VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the time to first and second VOC leading to healthcare visit in each group.\n\nTime to first occurrence of VOC leading to a healthcare visit is defined as the time from the date of randomization to the date of the first occurrence of the VOC.\n\nTime to second occurrence of VOC leading to a healthcare visit is defined as the time from date of randomization to the date of the second occurrence of VOC.', 'timeFrame': '1 year'}, {'measure': 'Annualized Rate of Visits to Clinic, Emergency Room (ER) and Hospitalizations, Both Overall and VOC-related Over the First-year Post-randomization', 'description': 'To assess Healthcare resource utilization (visits to clinic, Emergency room (ER) and hospitalizations) both overall and VOC-related in each group.\n\nAnnualized rate of corresponding healthcare visits =(Number of corresponding healthcare visits \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days)', 'timeFrame': '1 year'}, {'measure': 'Annualized Days of Visits to Clinic, Emergency Room (ER) and Hospitalizations, Both Overall and VOC-related Over the First-year Post-randomization', 'description': 'To assess Healthcare resource utilization (visits to clinic, Emergency room (ER) and hospitalizations) both overall and VOC-related in each group.\n\nAnnualized days of corresponding healthcare visits =(Number of days =(Number of days of corresponding healthcare visits \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).', 'timeFrame': '1 year'}, {'measure': 'Evolution of Albumin Creatinine Ratio (ACR) Over the First-year Post-randomization (Change From Baseline)', 'description': 'Laboratory values for parameters related to renal function (creatinine, estimated glomerular filtration rate, urine microalbumin, and urine albumin/creatinine ratio) were measured at 6-month intervals over time from baseline.', 'timeFrame': 'Over first year post-randomization (Baseline, Week 27 Day 1, Week 51 Day 1)'}, {'measure': 'Evolution of Albuminuria (Urine Microalbumin) Over the First-year Post-randomization (Change From Baseline)', 'description': 'Laboratory values for parameters related to renal function (creatinine, estimated glomerular filtration rate, urine microalbumin, and urine albumin/creatinine ratio) were measured at 6-month intervals over time from baseline.', 'timeFrame': 'Over first year post-randomization (Baseline, Week 27 Day 1, Week 51 Day 1)'}, {'measure': 'Pharmacokinetic (PK) Profile of Crizanlizumab: AUCd15, AUCtau', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: Area under the (concentration-time profile) curve.', 'timeFrame': 'AUCd15 (first-dose) was assessed at W1D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose) to W3D1; AUCtau (steady-state) was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PK Profile of Crizanlizumab: Cmax', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: Maximum concentration.', 'timeFrame': 'first-dose was assessed at W1D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose) through to W3D1; steady-state was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PK Profile of Crizanlizumab: Tmax', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: Time to maximum concentration.', 'timeFrame': 'first-dose was assessed at W1D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose) through to W3D1; steady-state was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PK Profile of Crizanlizumab: Half-life', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: half life.', 'timeFrame': 'steady-state was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PD Parameter (P-selectin Inhibition)', 'description': 'To characterize the pharmacodynamic (PD) of crizanlizumab at 5.0 and 7.5 mg/kg: P-selectin inhibition (% inhibition multipled by hr)', 'timeFrame': 'AUCd15 (first dose): W1D1, W1D2, W1D4, W2D1 and W3D1; steady state: W15D1, W15D2, W15D4, W16D1, W17D1 W18D1 and W19D1'}, {'measure': 'Annualized Rate of Various Subtypes of VOCs Leading to a Healthcare Visit at 1 Year', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOCs leading to healthcare visit. VOC is defined as pain crisis which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. Healthcare visit: any visit to a medical facility such as ER, hospital and/or office visit, which includes pain management of VOC in situ.\n\nAnnualized rate of corresponding VOC events = (Number of corresponding VOC events \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).', 'timeFrame': '1 year'}, {'measure': 'Annualized Rate of Various Subtypes of VOCs Leading to a Healthcare Visit at 5 Years', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOCs leading to healthcare visit.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration.\n\nHealthcare visit is defined as any visit to a medical facility such as emergency room, hospital and/or office visit, which includes pain management of VOC in situ.\n\nThe annualized rate of VOC leading to healthcare visit is the number of VOC leading to healthcare visit multiplied by 365 and divided by the number of days in the observation period.', 'timeFrame': '5 years'}, {'measure': 'Annualized Rate of All VOCs Leading to a Healthcare Visit and Treated at Home at 5 Years', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the rates of all VOCs (managed at home + leading to healthcare visit).', 'timeFrame': '5 years'}, {'measure': 'Number of VOCs Managed at Home at Year 1', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the number of VOC events that were managed at home.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. Managed at home is defined as no visit to any medical facility and/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice was allowed.', 'timeFrame': '1 year'}, {'measure': 'Number of VOCs Managed at Home at 5 Years', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the number of VOC events that were managed at home.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. Managed at home is defined as no visit to any medical facility and/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice was allowed.', 'timeFrame': '5 years'}, {'measure': 'Absolute Change From Baseline in Hemoglobin', 'description': 'To assess safety of crizanlizumab over the study period.', 'timeFrame': '5 years'}, {'measure': 'Growth and Sexual Maturity Assessment in Adolescents (Tanner Stage)', 'description': 'To assess safety of crizanlizumab over the study period.', 'timeFrame': '5 years'}, {'measure': 'Immunogenicity: Measurement of Anti-drug Antibodies (ADA) to Crizanlizumab', 'description': 'To assess immunogenicity of crizanlizumab over the study period.', 'timeFrame': '5 years'}]",24.0,12 Years,100 Years,ALL,False,INDUSTRY,0.0,257.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00145626,HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies,Chemotherapy and antibodies,"['Chemotherapy and antibodies', 'OKT3', 'Cyclophosphamide', 'Fludarabine', 'Thiotepa', 'Melphalan']",6,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Myeloid Leukemia,St. Jude Children's Research Hospital,2025-09-01T16:18:09.628162,True,,,,NOT_FOUND,HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies,,"['Acute Myeloid Leukemia', 'Acute Lymphocytic Leukemia', 'Myelodysplasia', 'Chronic Myeloid Leukemia', 'Histiocytosis']","['Stem cell transplantation', 'Stem cell transplant', 'Haploidentical transplant']",,2004-05,2016-07,"[{'measure': 'One-year Survival', 'description': 'The one-year survival of infants with high-risk hematologic malignancies who receive a haploidentical transplant procedure using a total body irradiation (TBI)-excluding conditioning regimen followed by an HLA-nonidentical family donor hematopoietic stem cell (HSC) graft depleted of T cells ex vivo using the CliniMACS CD34+ selection system, with a subsequent infusion of donor NK cells purified ex vivo using the CliniMACS CD3+ depletion and CD56+ enrichment system.\n\nThe Kaplan-Meier estimate for one-year survival is reported.', 'timeFrame': 'One year after transplant'}]","[{'measure': 'Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality', 'description': 'The cumulative incidences of regimen-related mortality will be estimated using method of Kalbfleisch and Prentice.', 'timeFrame': '100 days post-transplantation'}, {'measure': 'Number of Transplant-Related Adverse Outcomes: Engraftment Failure', 'description': 'Engraftment failure is defined as \\<10% donor cell chimerism at any time point between 28 and 100 days after transplant with no evidence of disease relapse or requiring stem cell boost.', 'timeFrame': '100 days post-transplantation'}, {'measure': 'Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)', 'description': 'The cumulative incidence estimate for occurrence of fatal acute GVHD by the end of the first 100 days post-transplant was calculated using method of Kalbfleisch and Prentice.', 'timeFrame': '100 days post-transplantation'}, {'measure': 'Number of Incidences of Chronic GVHD.', 'description': ""Chronic GVHD was graded according to Seattle Criteria: limited or extensive. Limited is defined as localized skin and/or hepatic dysfunction. Extensive is defined as one or more of the following:\n\n* generalized skin involvement\n* liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis\n* eye dryness with Schirmer's test \\<5 mm wetting\n* oral: involvement of salivary glands or oral mucosa\n* other: another target organ involvement"", 'timeFrame': 'Up to 5 years after transplant'}, {'measure': 'Factors Affecting One-year Survival: Median Age of Donor at HSCT', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Median Dose of CD34', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Median Dose of NK Cells', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Disease Status at HSCT', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Donor Type', 'description': 'Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Match N/6 HLA Loci', 'description': 'HLA typing determined the degree of match by looking at 6 different HLA loci. The results indicate the number of the 6 loci that matched for each participant. Due to small sample size (n=14) and total number of events (n=7), the analysis to check the various factors that affect the one-year survival was not performed (using logistic and cox model).', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Factors Affecting One-year Survival: Minimal Residual Disease (MRD)', 'description': 'Detection of leukemia blasts in bone marrow by flow cytometry', 'timeFrame': 'Up to one year after transplant'}, {'measure': 'Incidence of and Risk Factors for Organ Dysfunction.', 'description': 'The organ dysfunction will be summarized using summary statistics and assessed in a longitudinal manner and analyzed accordingly.', 'timeFrame': 'Up to 5 Years after transplant'}, {'measure': 'Incidence of and Risk Factors for Long-term Neurocognitive Deficit.', 'description': 'The long-term neurocognitive deficit will be summarized using summary statistics and assessed in a longitudinal manner and analyzed accordingly.', 'timeFrame': 'Up to 5 Years after transplant'}, {'measure': 'Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation', 'description': 'The presence or absence of MRD before and after the bone marrow transplant (BMT) and its frequency distribution will be obtained for each time point separately.', 'timeFrame': 'Baseline before HSCT, 1 year post HSCT, and up to 5 years post HSCT'}, {'measure': 'Kinetics of Lymphohematopoietic Reconstitution', 'description': 'The lymphohematopoietic reconstitution will be summarized using summary statistics and assessed in a longitudinal manner and analyzed accordingly.', 'timeFrame': 'From 0-3 months after HSCT through 4-5 years after HSCT'}]",16.0,,24 Months,ALL,False,OTHER,1.0,40.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04539626,Estrogen Therapy in Non-severe COVID-19 Patients,Estrogen Therapy,"['Norelgesetromin', 'Ethinyl estradiol', 'Estrogen Therapy']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Covid-19,"CMN ""20 de Noviembre""",2025-09-01T16:18:09.628186,True,,,,NOT_FOUND,Estrogen Therapy in Non-severe COVID-19 Patients: Proposed Treatment Scheme in a Tertiary Hospital,,['Covid-19'],"['COVID-19', 'Estrogens', 'Severe Acute Respiratory Syndrome Coronavirus-2']",,2020-10-01,2023-12-31,"[{'measure': 'Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients', 'description': '* Success rate in reducing hospitalization days\n* Success rate in no oxygen therapy use (low or high-flow oxygen)\n* Success rate in no intubation and/or mechanical ventilation\n* Success rate in non mortality occurrence', 'timeFrame': 'Day 7'}, {'measure': 'Clinical improve to estrogen therapy in non-severe COVID-19 patients', 'description': '* Success rate in reducing hospitalization days\n* Success rate in no oxygen therapy use (low or high-flow oxygen)\n* Success rate in no intubation and/or mechanical ventilation\n* Success rate in non mortality occurrence', 'timeFrame': 'Day 14'}, {'measure': 'Clinical improve to estrogen therapy in non-severe COVID-19 patients', 'description': '* Success rate in reducing hospitalization days\n* Success rate in no oxygen therapy use (low or high-flow oxygen)\n* Success rate in no intubation and/or mechanical ventilation\n* Success rate in non mortality occurrence', 'timeFrame': 'Day 21'}]","[{'measure': 'Symptomatic improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.', 'timeFrame': 'Day 7'}, {'measure': 'Symptomatic improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.', 'timeFrame': 'Day 14'}, {'measure': 'Symptomatic improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.', 'timeFrame': 'Day 21'}, {'measure': 'Biochemical improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'Percentage change from hemoglobin, hematocrit, leukocytes, erythrocytes, platelets, prothrombin, partial thromboplastin activation time, anti-thrombin activity, fibrinogen, fibrin degradation products, D-Dimer, ALT, AST, ALP, GGT, LD, albumin, cholesterol, triglycerides, HDL, LDL, C-reactive protein, estrogens and progesterone levels, pro inflammatory cytokine and nitric oxide profile.', 'timeFrame': 'Day 7'}, {'measure': 'Biochemical improve to estrogen therapy in non-severe COVID-19 patients', 'description': 'Percentage change from hemoglobin, hematocrit, leukocytes, erythrocytes, platelets, prothrombin, partial thromboplastin activation time, anti-thrombin activity, fibrinogen, fibrin degradation products, D-Dimer, ALT, AST, ALP, GGT, LD, albumin, cholesterol, triglycerides, HDL, LDL, C-reactive protein, estrogens and progesterone levels, pro inflammatory cytokine and nitric oxide profile.', 'timeFrame': 'Day 14'}, {'measure': 'Angiotensin 1-7 change after estrogen therapy in non-severe COVID-19 patientsCOVID-19 patients', 'description': 'Percentage change from Angiotensin 1-7, measured with the Human Angiotensin 1-7 ELISA kit (colorimetric) \\[pg/mL\\]', 'timeFrame': 'Day 21'}]",9.0,18 Years,70 Years,ALL,False,OTHER,0.0,44.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04529187,Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.,Midazolam,"['Midazolam', 'Dormicum® (Roche, F. Hoffmann-La Roche Ltd Basel, Switzerland)', 'Dexmedetomidine', 'Dexdor® (Orion Corporation, Nasdaq OMX Helsinki: ORNAV and ORNBV, Finland)']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Cardiac Function,Masaryk Hospital Krajská zdravotní a.s.,2025-09-01T16:18:22.207107,True,,,,NOT_FOUND,Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.,,"['Cardiac Function', 'Sedation', 'Magnetic Resonance Imaging']",[],,2018-01-01,2019-12-31,"[{'measure': 'Changes in cardiac output following sedation administration', 'description': 'Using cardiac MRI stroke volume (measured in mL) of both heart ventricles will be registered prior and after sedation administration.', 'timeFrame': '5 minutes following sedation administration.'}, {'measure': 'Changes in diastolic heart function following sedation administration', 'description': 'Using cardiac MRI maximum flow velocity through the mitral valve (measured in mL/s) during early and late diastole will be measured prior and after sedation administration.', 'timeFrame': '5 minutes following sedation administration.'}]",[],2.0,18 Years,65 Years,ALL,True,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02381561,Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy,Ropidoxuridine,"[""5-Iodo-2-pyrimidinone 2' deoxyribonucleoside"", 'IPdR', 'Ropidoxuridine', ""5-Iodo-2-pyrimidinone-2'-deoxyribose""]",4,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Advanced Bile Duct Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:13.412971,True,,,,CHEMBL100259,Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers,,"['Advanced Bile Duct Carcinoma', 'Stage II Esophageal Cancer AJCC v7', 'Stage II Pancreatic Cancer AJCC v6 and v7', 'Stage IIA Esophageal Cancer AJCC v7', 'Stage IIA Pancreatic Cancer AJCC v6 and v7', 'Stage IIB Esophageal Cancer AJCC v7', 'Stage IIB Pancreatic Cancer AJCC v6 and v7', 'Stage III Colon Cancer AJCC v7', 'Stage III Esophageal Cancer AJCC v7', 'Stage III Gastric Cancer AJCC v7', 'Stage III Liver Cancer', 'Stage III Pancreatic Cancer AJCC v6 and v7', 'Stage III Rectal Cancer AJCC v7', 'Stage III Small Intestinal Cancer AJCC v7', 'Stage IIIA Colon Cancer AJCC v7', 'Stage IIIA Esophageal Cancer AJCC v7', 'Stage IIIA Gastric Cancer AJCC v7', 'Stage IIIA Rectal Cancer AJCC v7', 'Stage IIIA Small Intestinal Cancer AJCC v7', 'Stage IIIB Colon Cancer AJCC v7', 'Stage IIIB Esophageal Cancer AJCC v7', 'Stage IIIB Gastric Cancer AJCC v7', 'Stage IIIB Rectal Cancer AJCC v7', 'Stage IIIB Small Intestinal Cancer AJCC v7', 'Stage IIIC Colon Cancer AJCC v7', 'Stage IIIC Esophageal Cancer AJCC v7', 'Stage IIIC Gastric Cancer AJCC v7', 'Stage IIIC Rectal Cancer AJCC v7', 'Stage IV Colon Cancer AJCC v7', 'Stage IV Esophageal Cancer AJCC v7', 'Stage IV Gastric Cancer AJCC v7', 'Stage IV Liver Cancer', 'Stage IV Pancreatic Cancer AJCC v6 and v7', 'Stage IV Rectal Cancer AJCC v7', 'Stage IV Small Intestinal Cancer AJCC v7', 'Stage IVA Colon Cancer AJCC v7', 'Stage IVA Liver Cancer', 'Stage IVA Rectal Cancer AJCC v7', 'Stage IVB Colon Cancer AJCC v7', 'Stage IVB Liver Cancer', 'Stage IVB Rectal Cancer AJCC v7']",[],,2016-02-01,2026-03-14,"[{'measure': 'Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity', 'timeFrame': 'Up to 28 days'}]","[{'measure': '%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in tumor biopsies', 'description': 'Correlate %IUdR-DNA incorporation in human gastrointestinal (GI) tumor biopsies in the proposed phase I and pharmacokinetic (PK) clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic radiation therapy (RT) by linear regression.', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Pharmacokinetic (PK) incorporation in tumor biopsies', 'description': 'Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression.', 'timeFrame': 'Days 1, 15 and 22 before drug administration, at 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration'}, {'measure': '%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in peripheral (circulating) granulocytes', 'description': 'Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression.', 'timeFrame': 'Up to 4 weeks after completion of study treatment'}, {'measure': 'Pharmacokinetic (PK) incorporation in peripheral (circulating) granulocytes', 'description': 'Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression.', 'timeFrame': 'Days 1, 15 and 22 before drug administration, 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration'}, {'measure': 'Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements', 'description': 'Tumor response is the dependent variable and can be binomial (i.e. response versus \\[vs.\\] no response) or multinomial (i.e. complete response, partial response, stable disease or progressive disease) and the %IUdR-DNA incorporation is the independent variable.', 'timeFrame': 'Day 8'}]",6.0,18 Years,,ALL,False,NIH,0.0,19.0,ACTUAL,v2_robust,True,False,False,False,,O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL100259,partial_match,True,244.2,-2.85,3.0
NCT00003453,Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer,Antineoplaston therapy (Atengenal + Astugenal),"['Antineoplaston therapy (Atengenal + Astugenal)', 'A10 (Atengenal); AS2-1 (Astugenal)ANP']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Stage IV Adrenocortical Carcinoma,Burzynski Research Institute,2025-09-01T16:18:13.420348,True,,,,NOT_FOUND,Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland,,['Stage IV Adrenocortical Carcinoma'],['recurrent adrenocortical carcinoma'],Slow enrollment,1996-08-21,2011-07-05,"[{'measure': 'Number of Participants With Objective Response', 'description': 'Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \\>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks.', 'timeFrame': '12 months'}]","[{'measure': 'Percentage of Participants Who Survived', 'description': '6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival', 'timeFrame': '6 months, 12 months, 24 months, 36 months, 48 months, 60 months'}]",2.0,6 Months,99 Years,ALL,False,OTHER,0.0,6.0,ACTUAL,v2_robust,True,False,True,False,Slow enrollment,,,no_match,False,,,
NCT06654635,Ultrasound Guided Rhomboid Intercostal Plane Block Versus Thoracic Erector Spinae Plane Block in Upper Abdominal Surgery,Rhomboid intercostal plane block,['Rhomboid intercostal plane block'],1,INTERVENTIONAL,['NA'],,RECRUITING,Ultrasound,Tanta University,2025-09-01T16:18:17.187032,True,,,,NOT_FOUND,Comparison Between Ultrasound Guided Rhomboid Intercostal Plane Block and Thoracic Erector Spinae Plane Block in Patients Undergoing Upper Abdominal Surgery: A Randomized Controlled Trial,,"['Ultrasound', 'Rhomboid Intercostal Plane Block', 'Thoracic Erector Spinae Plane Block', 'Upper Abdominal Surgery']",[],,2024-01-01,2025-05-01,"[{'measure': 'Total morphine consumption', 'description': 'Rescue analgesia will be provided in the form of IV morphine 3 mg boluses if the patient indicates The visual analogue scale (VAS). ≥ 4 with maximum dose 20 mg for 24 hours. The total amount of morphine (mg) given will be recorded for the 3 groups.', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Degree of pain', 'description': 'Postoperative pain will be assessed by visual analogue scale (VAS) 30 min from admission to PACU, 2, 4, 6, 12, 18 and 24 h postoperative (0= no pain, 10= sever pain).', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Time to 1st request of rescue analgesia', 'description': 'Time to 1st request for the rescue of analgesia (time from the end of surgery till first dose of morphine administrated ) will be recorded.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Heart rate', 'description': 'Heart rate will be measured preoperative, after induction, after receiving block and every 15 min till the end of surgery', 'timeFrame': 'Every 15 min till the end of surgery'}, {'measure': 'Mean arterial blood pressure', 'description': 'Mean arterial blood pressure will be measured preoperative, after induction, after receiving block and every 15 min till the end of surgery', 'timeFrame': 'Every 15 min till the end of surgery'}, {'measure': 'Incidence of side effects', 'description': 'Any undesirable adverse events will be treated and recorded (e.g., bradycardia, hypotension, pneumothorax, hematoma, nerve injury and nausea, vomiting, local anesthetic systemic toxicity (LAST), respiratory depression or any other complication).', 'timeFrame': '24 hours Postoperatively'}]",6.0,21 Years,65 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03067753,Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis,Monosialoganglioside Ganglioside,"['Methylprednisolone (Steroid Hormone)', 'Prednisolone', 'Monosialoganglioside Ganglioside']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Cerebral Radiation Necrosis,Zhejiang Cancer Hospital,2025-09-01T16:18:18.432992,True,,,,NOT_FOUND,,,['Cerebral Radiation Necrosis'],[],,2016-12,2019-09,"[{'measure': 'Objective response rate', 'description': 'Response Evaluation Criteria in Solid Tumors (RECIST) were used.', 'timeFrame': 'From the first day of treatment, to 3 months after treatment'}]",[],1.0,18 Years,70 Years,ALL,False,OTHER,0.0,28.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02231190,GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage,GSK1278863,"['GSK1278863', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Tendon Injuries,GlaxoSmithKline,2025-09-01T16:18:09.635715,True,,,,NOT_FOUND,"A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers",,['Tendon Injuries'],"['muscle soreness', 'Muscle damage and recovery', 'muscle function', 'eccentric exercise']",,2015-01-15,2015-06-12,"[{'measure': 'Maximal voluntary contraction (MVC) following eccentric exercise in subjects treated with GSK1278863 or placebo', 'description': 'Muscle strength is a measure of the amount of force produced during a maximal voluntary contraction of the elbow flexors. It will be assessed in the non-dominant arm by a maximal isometric (fixed length) contraction using Cybex ergometer in a seated position after completion of eccentric exercise', 'timeFrame': 'Up to 72 hours (hrs)'}]","[{'measure': 'Change in MVC following eccentric exercise from pre-eccentric exercise in subjects treated with GSK1278863 or placebo', 'description': 'Change in muscle strength from pre-eccentric exercise to completion of eccentric exercise will be assessed', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Percent change in MVC following eccentric exercise from pre-eccentric exercise in subjects treated with GSK1278863 or placebo', 'description': 'Percent change in muscle strength from pre-eccentric exercise to completion of eccentric exercise will be assessed', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Number of subjects with adverse events(AE)', 'description': 'An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product', 'timeFrame': 'Up to Day 15'}, {'measure': 'Vital signs assessment as a safety measure', 'description': 'Vital signs includes systolic and diastolic blood pressure, pulse rate and respiratory rate', 'timeFrame': 'Up to Day 15'}, {'measure': 'Electrocardiogram (ECG) assessment as a safety measure', 'description': ""Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, Total cardiac output (QT), and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals"", 'timeFrame': 'Up to Day 15'}, {'measure': 'Laboratory parameters assessment as a safety measure', 'description': 'Laboratory parameters include hematology, clinical chemistry, and urinalysis', 'timeFrame': 'Up to Day 15'}, {'measure': 'Change in subject pain assessment using a visual analog scale', 'description': 'Arm pain will be assessed for the exercised arm with a visual analog scale on a scale of 0-100 millimeter (mm) during two stimuli; during passive stretching and during MVC contraction, post-exercise and after completion of eccentric exercise', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Change in degree of motion and resting arm angle from post-exercise', 'description': 'Subjects will be asked to maximally flex their elbow and then maximally extend their elbow, joint angle will be measured using a manual goniometer at maximum flexion and maximum extension. Range of motion will be calculated by subtracting the flexion angle from the extension angle', 'timeFrame': 'Up to 72 hrs'}, {'measure': 'Composite of PK parameters', 'description': 'PK parameters include maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), and Area under the concentration-time curve from zero (pre-dose) to 24h \\[AUC(0-24)\\]', 'timeFrame': 'Up to Day 2'}]",10.0,18 Years,35 Years,MALE,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00826085,Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,ThermoDox in combination with Microwave Hyperthermia (heat),['ThermoDox in combination with Microwave Hyperthermia (heat)'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Breast Cancer,Imunon,2025-09-01T16:18:19.676607,True,,,,NOT_FOUND,"A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.",,['Breast Cancer'],"['Breast Cancer', 'Recurrent Chest Wall Cancer', 'Loco-regional Recurrent Breast Cancer', 'Breast Cancer Recurrence at the Chest Wall']",,2013-02,2016-06,"[{'measure': 'To determine the bioequivalence of ThermoDox when used with hyperthermia among patients with RCW breast cancer.', 'timeFrame': 'PK collection at Cycle 1 and Cycle 2'}, {'measure': 'To determine efficacy of ThermoDox in combination with Hyperthermia', 'timeFrame': 'Efficacy assessed at Cycle 3, Cycle 5 and End of Treatment'}]","[{'measure': 'To evaluate the safety of ThermoDox in combination with Hyperthermia', 'timeFrame': 'Through 6 treatment Cycles'}]",3.0,18 Years,,FEMALE,False,INDUSTRY,0.0,17.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00075257,Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder,DVS-233 SR,['DVS-233 SR'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Major Depressive Disorder,Wyeth is now a wholly owned subsidiary of Pfizer,2025-09-01T16:18:24.749708,True,,,,NOT_FOUND,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of DVS-233 SR For Prevention Of Depressive Relapse In Adult Outpatients With Major Depressive Disorder",,['Major Depressive Disorder'],[],,,2005-08,[],[],0.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,603.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00185068,An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension,Olmesartan medoxomil,"['Olmesartan medoxomil/hydrochlorothiazide', 'Olmesartan medoxomil', 'Hydrochlorothiazide']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypertension,Daiichi Sankyo,2025-09-01T16:18:20.952922,True,,,,NOT_FOUND,"A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension",,['Hypertension'],"['Systolic hypertension, Angiotensin receptor blocker']",,2004-03,2004-10,[{'measure': 'Change in mean trough seated systolic blood pressure compared to the start of the study'}],"[{'measure': '1. Blood pressure changes from baseline at the end of each titration period.'}, {'measure': '2. Percentage of patients responding to therapy'}, {'measure': '3. Percentage of patients achieving various blood pressure target goals'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,110.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05299424,A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma,CM336_group 1,"['CM336_group 9', 'CM336_group 3b', 'CM336_group 1', 'CM336_group 4a', 'CM336_group 3a', 'CM336_group 8b', 'CM336_group 6b', 'CM336_group 6a', 'CM336_group 8a', 'CM336_RP2D', 'CM336_group 2b', 'CM336_group 7', 'CM336_group 4b', 'CM336_group 2a', 'CM336_group 5']",15,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Multiple Myeloma,Keymed Biosciences Co.Ltd,2025-09-01T16:18:20.958129,True,,,,NOT_FOUND,"A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma",,['Multiple Myeloma'],[],,2022-08-09,2026-12,"[{'measure': 'Dose-limiting toxicities (DLTs)', 'description': 'Dose-limiting toxicities (DLTs)', 'timeFrame': '21 days after the first dose'}, {'measure': 'Adverse events (AEs)', 'description': 'Adverse events (AEs), including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.', 'timeFrame': 'Up to 4.5 years'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'Assessed according to International Myeloma Working Group (IMWG) response criteria.', 'timeFrame': 'up to 4.5 years'}]",[],3.0,18 Years,,ALL,False,INDUSTRY,0.0,48.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00882323,Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA),"Cyclophosphamide, Fludarabine, Thymoglobulin","['Cyclophosphamide, Fludarabine, Thymoglobulin']",1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Aplastic Anemia,The Korean Society of Pediatric Hematology Oncology,2025-09-01T16:18:09.638511,True,,,,NOT_FOUND,"Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia",,['Aplastic Anemia'],[],,2008-11,2012-10,"[{'measure': 'To evaluate engraftment potential of reduced toxicity fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}]","[{'measure': 'To evaluate toxicities of reduced toxicity fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for UBMT/PBSCT in SAA.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}, {'measure': 'To evaluate overall and EFS rate after UBMT/PBSCT.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}, {'measure': 'To evaluate GVHD and immunologic recovery after UBMT/PBSCT.', 'timeFrame': 'From Nov. 2008 to Oct. 2012'}]",4.0,1 Year,21 Years,ALL,False,NETWORK,0.0,33.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01032694,Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia,Azithromycin SR,"['Azithromycin SR', 'Amoxiclav']",2,OBSERVATIONAL,[],,TERMINATED,Community-Acquired Pneumonia,Pfizer,2025-09-01T16:18:20.967237,True,,,,NOT_FOUND,Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia,,['Community-Acquired Pneumonia'],"['Community-Acquired Pneumonia', 'Azithromycin SR', 'Amoxiclav']","This study was terminated January 11, 2011 due to low enrollment. This study is not being terminated because of safety or efficacy concerns.",2010-04,2010-12,"[{'measure': 'Percentage of Participants With Response of Very Convenient or Somewhat Convenient', 'description': ""Participant reported outcome questionnaire was the assessment of participant's convenience with drug treatment based on following categories: very convenient or somewhat convenient and not convenient or not at all convenient. Value of 1 was reported if participant answered 'very convenient' or 'somewhat convenient' and 0 if participant answered 'not convenient' or 'not at all convenient'."", 'timeFrame': 'Days 11-12'}]","[{'measure': 'Percent Compliance With the Prescribed Treatment Regimen', 'description': 'Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed).', 'timeFrame': 'Days 11-12'}, {'measure': 'Percentage of Participants Who Were 100 Percent Compliant With Prescribed Treatment Regimen', 'description': 'Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed). Value of 1 was reported if percent compliance equals to 100, and 0 if percent compliance was non-missing and less than 100.', 'timeFrame': 'Days 11-12'}]",3.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,False,False,True,False,"This study was terminated January 11, 2011 due to low enrollment. This study is not being terminated because of safety or efficacy concerns.",,,no_match,False,,,
NCT06904027,A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders,Glycerol phenylbutyrate Oral Liquid,"['Glyceryl tri-(4-phenylbutyrate)', 'HPN-100', 'Glycerol phenylbutyrate Oral Liquid', 'RAVICTI', 'GT4P']",5,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Urea Cycle Disorders,Tongji Hospital,2025-09-01T16:18:18.424570,True,,,,NOT_FOUND,"A Single-arm, Prospective, Multi-center Post-market Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders",,['Urea Cycle Disorders'],"['Chinese', 'Pediatric patients', 'Urea cycle disorders', 'Glycerol phenylbutyrate']",,2025-07,2031-07,"[{'measure': 'Mean blood ammonia levels at month 3 after enrollment.', 'description': 'The average of blood ammonia levels at months 3 after enrollment.', 'timeFrame': 'months 3'}]","[{'measure': 'Mean blood ammonia levels', 'description': 'The average of blood ammonia levels at period of baseline, month 1, month 6, and every 6 months thereafter (1-5 years)', 'timeFrame': 'Baseline, Month 1, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Maximum blood ammonia levels', 'description': 'The maximum blood ammonia levels at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)', 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Frequency of hyperammonaemic crisis', 'description': 'The frequency of hyperammonaemic crisis at period of baseline, month 1, month 3, month 6, and every 6 months thereafter (1-5 years)', 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Height', 'description': ""The change of height to the baseline in children aged 0-18 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old (WS/T 423-2022) and standard for height level classification among children and adolescents aged 7\\~18 years (WS/T 612-2018）issued by the National Health Commission of the People's Republic of China."", 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years).'}, {'measure': 'Weight', 'description': ""The change of weight to the baseline in children aged 0-7 years old, and the proportion of weight in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022)."", 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Head circumference', 'description': ""The change of head circumference to the baseline in children aged 0-3 years old, and the proportion of head circumference in the upper, upper-middle, middle, lower-middle, and lower categories for each age group, according to the growth standards for children under 7 years old issued by the National Health Commission of the People's Republic of China (WS/T 423-2022)."", 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Dose adjustment changes', 'description': 'The changes of dose adjustment in glycerol phenylbutyrate throughout the study', 'timeFrame': 'Baseline, Month 1, Month 3, Month 6, and every 6 months thereafter (1-5 years)'}, {'measure': 'Mean Neonatal Behavioral Neurological Assessment Scores: Behavioral ability, passive muscle tone, active muscle tone, primitive reflexes, and general assessment', 'description': 'The neonatal behavioral neurological assessment (NBNA) scale was used for newborn participants who were at least 2 months of age, consisting of 20 items, with a maximum score of 40 points. The total scores of the NBNA are derived from the cumulative sum of the scores obtained in behavioral ability (6 items), passive muscle tone (4 items), active muscle tone (4 items), primitive reflexes (3 items), and general assessment (3 items), which are collected according to the scales have been actually completed by the subjects in the clinical practice. The total scores greater than 37 is considered normal, while a score less than or equal to 37 is considered abnormal.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Bayley Scale of Infant Development Scores: mental scale, motor scale', 'description': 'The Bayley Scale of Infant Development was used for infant participants whose ages range from 2 months to 30 months, consisting of 244 behavioral items, including 163 items on the mental scale and 81 items on the motor scale. The scores of each infant on the mental and motor scales are converted into standard scores with a mean of 100 and a standard deviation of 16 according to age groups, thereby calculating the Mental Development Index (MDI) and the Psychomotor Development Index (PDI). A total score of MDI and PDI, which are collected according to the scales have been actually completed by the subjects in the clinical practice, are less than 70 indicates developmental delay, 70-79 indicates a borderline state, 80-89 indicates low average, 90-109 indicates average, 110-119 indicates high average, 120-129 indicates superior, and a score of 130 or above indicates very superior.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Gesell Developmental Diagnosis Scale Scores', 'description': 'The assessment for Gesell Developmental Diagnosis Scale Scores was used for participants whose ages range from 30 months to 6 years, including five areas: gross motor skills, fine motor skills, adaptive behavior, language, and personal-social behavior. The observed behavioral patterns are identified based on the standard of normal behavioral patterns and are expressed in terms of age. This age is then compared with the actual age to calculate the Developmental Quotient (DQ), which is DQ = Developmental Age / Actual Age × 100, and the values of DQ are collected according to the scales have been actually completed by the subjects in the clinical practice. A DQ of 85 or above is considered normal for the nervous system, a DQ between 75 and 85 (inclusive of 75 but exclusive of 85) indicates a borderline level of nervous system impairment, and a DQ below 75 indicates nervous system damage.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Wechsler Preschool and Primary Scale of Intelligence Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient', 'description': 'The Chinese - Wechsler Preschool and Primary Scale of Intelligence (C - WYCSI) was used for children participants whose ages range from 4 to 6 years. The Verbal Intelligence Quotient (VIQ) test includes five subtests: Information, Picture Vocabulary, Arithmetic, Picture Comprehension, and Comprehension. The Performance Intelligence Quotient (PIQ) test includes five subtests: Animal Hatching, Picture Completion, Mazes, Geometric Shapes, and Block Design. The intelligence quotient (IQ) score obtained from the 10 subtests of VIQ and PIQ is the Full Intelligence Quotient (FIQ). The values for VIQ, PIQ and FIQ are collected according to the scales have been actually completed by the subjects in the clinical practice. FIQ is divided into five levels: ≥130 is superior, 116 - 129 is above average, 85 - 115 is average, 70 - 84 is below average, and \\< 70 is intellectual disability.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}, {'measure': 'Mean Wechsler Intelligence Scale for Children Scores: The Verbal Intelligence Quotient, the Performance Intelligence Quotient', 'description': 'The Chinese-Wechsler intelligence scale of children (C-WISC）was used for participants whose ages range from 7 to 18 years. This scale consists of 11 subtests. The Verbal Intelligence Quotient (VIQ) test includes Information, Comprehension, Similarities, Arithmetic, Digit Span, and Vocabulary. The Performance Intelligence Quotient (PIQ) test includes Picture Completion, Picture Arrangement, Block Design, Object Assembly, and Coding. First, the raw score is calculated based on the test results of the examinee. Then, the corresponding age-specific scale score coefficient is checked and converted into a scale score. The sum of the VIQ and PIQ scale scores is the full intelligence quotient (FIQ) score, which are collected according to the scales have been actually completed by the subjects in the clinical practice. A FIQ of ≥120 is classified as high intelligence, 90-119 is classified as normal intelligence, and a score \\< 90 is classified as low intelligence.', 'timeFrame': 'Month 6, every year thereafter (1-5 years)'}]",13.0,0 Years,18 Years,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT04902131,A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women,"A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL","['A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL', 'A MENOPUR powder including solvent for solution for injection, 75 IU', 'Highly purified menotropin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Infertility, Female",Ferring Pharmaceuticals,2025-09-01T16:18:24.744707,True,,,,NOT_FOUND,"An Open-label, Randomised, 2-way Crossover, Single-dose, Bioequivalence Trial Comparing MENOPUR Solution for Injection in Pre-filled Pen and MENOPUR Powder and Solvent for Solution for Injection, After Subcutaneous Administration in Healthy Women",,"['Infertility, Female']",[],,2021-11-02,2022-08-15,"[{'measure': 'Pharmacokinetic parameter of FSH: AUCt', 'description': 'AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before investigational medicinal product [IMP] administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: Cmax', 'description': 'Cmax is defined as baseline adjusted maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}]","[{'measure': 'Pharmacokinetic parameter of FSH: AUCinf', 'description': 'AUCinf is defined as area under concentration-time curve from dosing to infinity using baseline adjusted concentrations.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: Tmax', 'description': 'Tmax is defined as time of maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: CL/F', 'description': 'CL/F is defined as apparent systemic clearance.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: Vz/F', 'description': 'Vz/F is defined as apparent volume of distribution during terminal phase.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: λz', 'description': 'λz is defined as first-order rate constant associated with the terminal (log-linear) portion of the concentration-time curve.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: t½', 'description': 't½ is defined as terminal half-life.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of human chorionic gonadotrophin (hCG): AUCt', 'description': 'AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of hCG: AUCinf', 'description': 'AUCinf is defined as area under concentration-time curve from dosing to infinity using baseline adjusted concentrations.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of hCG: Cmax', 'description': 'Cmax is defined as baseline adjusted maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of LH: AUCt', 'description': 'AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and 4, 8, 12, 24 and 48 hours after administration'}, {'measure': 'Pharmacokinetic parameter of LH: Cmax', 'description': 'Cmax is defined as baseline adjusted maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and 4, 8, 12, 24 and 48 hours after administration'}, {'measure': 'Frequency of adverse events (AEs) stratified by intensity', 'description': 'The frequency of subjects with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented.\n\nAn AE was any untoward medical occurrence in a subject participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activities); moderate = disruption of usual activities (disturbing); or severe = inability to work or perform usual activities (unacceptable).', 'timeFrame': 'From signing of the informed consent up to the end-of-trial (11 to 18 days after the last IMP administration)'}, {'measure': 'Frequency of injection site reactions stratified by intensity', 'description': 'The presence of injection site reactions (redness, pain, itching, swelling and bruising) immediately, 0.5 hours and 24 hours after the injection are presented.\n\nThe injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.', 'timeFrame': 'Immediately after administration, and at 0.5 and 24 hours after administration on Day 1 and Day 2 of Treatment period 1 (TP1) and Time period 2 (TP2)'}, {'measure': 'Change from baseline of vital signs (systolic and diastolic blood pressure)', 'description': 'Vital signs comprising systolic and diastolic blood pressure will be presented.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of vital sign (pulse)', 'description': 'Vital sign comprising pulse will be presented.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of vital sign (body temperature)', 'description': 'Vital sign comprising body temperature will be presented.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead electrocardiogram (ECG): Heart rate', 'description': 'Change from baseline for 12-lead ECG (heart rate) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: PR interval', 'description': 'Change from baseline for 12-lead ECG (PR interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: RR interval', 'description': 'Change from baseline for 12-lead ECG (RR interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QRS interval', 'description': 'Change from baseline for 12-lead ECG (QRS interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QT interval', 'description': 'Change from baseline for 12-lead ECG (QT interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QTc interval', 'description': 'Change from baseline for 12-lead ECG (QTc interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QRS axis', 'description': 'Change from baseline for 12-lead ECG (QRS axis) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, Alkaline phosphatase, Aspartate aminotransferase, and Gamma glutamyl transferase.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Albumin', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Albumin.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Glucose', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Glucose.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Calcium', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Calcium.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Chloride', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Chloride.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Cholesterol', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Cholesterol.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Phosphate', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Phosphate.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Potassium', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Potassium.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Sodium', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Sodium.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Urea (blood urea nitrogen)', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Urea (blood urea nitrogen).', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: C-reactive protein', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: C-reactive protein.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Creatinine, Total bilirubin', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameters including: Creatinine, Total bilirubin.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Thyroid stimulating hormone', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Thyroid stimulating hormone.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Free triiodothyronine', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Free triiodothyronine.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Free thyroxine', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Free thyroxine.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: FSH', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: FSH.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Estradiol', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Estradiol.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Haematocrit', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Haematocrit.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Haemoglobin', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Haemoglobin.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Mean cellular volume', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Mean cellular volume.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Mean corpuscular haemoglobin content', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Mean corpuscular haemoglobin content.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Mean corpuscular haemoglobin concentration', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Mean corpuscular haemoglobin concentration.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Red blood cell (RBC) count', 'description': 'Blood samples were collected for the analysis of haematology parameter including: RBC count.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Platelet count', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Platelet count.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Reticulocytes', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Reticulocytes.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: White blood cell count', 'description': 'Blood samples were collected for the analysis of haematology parameter including: White blood cell count.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Protein', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Glucose', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Bilirubin', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: pH and Specific Gravity', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Nitrite', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Ketone', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Urobilinogen', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Blood', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Leukocytes', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}]",60.0,21 Years,40 Years,FEMALE,True,INDUSTRY,0.0,95.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02223611,Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection,S1 capsule,"['S1 capsule', 'S1: Gimeracil and oteracil porassium capsules', 'Vinorelbine: Navelbine,vinorelbine bitartrate injection', 'Vinorelbine', 'Cisplatin: Cisplatin for injection']",5,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Non-small Cell Lung Cancer Stage Ⅱ,Hebei Medical University Fourth Hospital,2025-09-01T16:18:19.665223,True,,,,NOT_FOUND,Phase ⅡTrial of S1 Capsule Plus Cisplatin Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage Ⅱ-ⅢA Non-small Cell Lung Cancer (NSCLC) After Complete Resection,,"['Non-small Cell Lung Cancer Stage Ⅱ', 'Non-small Cell Lung Cancer Stage ⅢA']",['Stage Ⅱ-ⅢA NSCLC S1 capsule Completely resection'],,2014-12,2018-12,"[{'measure': 'Disease free survival rate', 'timeFrame': '2 years'}]","[{'measure': 'Disease free survival', 'description': 'The period from the date of enrollment to the date on which the recurrence was first confirmed. For patients who died before disease progression from any cause, death was attributed to recurrence.', 'timeFrame': '4 years'}, {'measure': 'Overall survival', 'description': 'The period from the date of enrollment to the date of death from any cause.', 'timeFrame': '4 years'}, {'measure': 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'description': 'The incidences of adverse events were calculated according to the National Cancer Institute Cancer Common Toxicity Criteria, version 4.0.', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 3 weeks.'}, {'measure': 'Quality of life (QOL)', 'description': 'QOL was assessed with the lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and Lung Cancer Symptom Scale(LCSS).', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 3 weeks.'}]",5.0,18 Years,75 Years,ALL,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03861338,An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder,Sublocade,"['buprenorphine extended-release injection', 'Sublocade']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Opioid-use Disorder,New York State Psychiatric Institute,2025-09-01T16:18:23.443995,True,,,,NOT_FOUND,An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder,,['Opioid-use Disorder'],"['opioid use disorder, sublocade, buprenorphine']",,2019-03-01,2020-02-28,"[{'measure': 'Sublocade Induction', 'description': 'Number of participants successfully inducted onto Sublocade (BXR)', 'timeFrame': 'Study week 1'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04505904,Oxytocin and Approach-avoid in Grief,Syntocinon,"['Syntocinon', 'Placebo']",2,INTERVENTIONAL,['NA'],,COMPLETED,Prolonged Grief Disorder,University of Arizona,2025-09-01T16:18:17.179487,True,,,,NOT_FOUND,A Pull to be Close: the Differentiating Effects of Oxytocin and Grief Stimulus Type on Approach Behavior in Complicated Grief,,"['Prolonged Grief Disorder', 'Bereavement']","['Oxytocin', 'Approach/Avoid', 'Older adults', 'Complicated Grief']",,2015-03-20,2017-05-12,"[{'measure': 'Reaction Time (ms) of a Push or Pull of a Joystick in a Standard Interactive Approach/Avoid Task.', 'description': 'Participants completed the approach avoid task twice per session, with reversed instructions on the second run (i.e., ""pull for yellow"" became ""push for yellow""). Each seven-minute run of the task consisted of 144 2500ms trials (288 trials per visit, 576 trials total across runs/sessions; 500ms inter-trial-interval). Order of instructions (i.e., ""push yellow"" vs. ""pull yellow"") was randomized and counterbalanced across participants and sessions, to address potential for order effects/habituation. Stimuli were presented via Inquisit 4 (2014), in a pseudorandomized order determined by genetic algorithm (Wager \\& Nichols, 2003).\n\nRelative approach/avoidance bias was computed by subtracting median response time (RT; latency to joystick full extension) on PULL/approach trials in each stimulus category from PUSH/avoid trials in the same category (Rinck \\& Becker, 2007). Positive response bias values indicate relative approach bias; negative values indicate relative avoidance bias.', 'timeFrame': '120 minutes'}]",[],1.0,55 Years,80 Years,ALL,False,OTHER,0.0,44.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05834738,"Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy",Atrasentan,"['Atrasentan Hydrochloride', 'Placebo', 'CHK-01', 'ABT-627', 'Atrasentan']",5,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,IgA Nephropathy,Novartis Pharmaceuticals,2025-09-01T16:18:17.182859,True,,,,CHEMBL2106068,"A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)",,"['IgA Nephropathy', 'Immunoglobulin A Nephropathy']","['Kidney Diseases', 'Kidney Disease, Chronic', 'Urologic Diseases', 'Glomerulonephritis', 'Glomerular Disease', 'Glomerulonephritis, IGA', 'Glomerulopathy', 'Immunoglobulin Disease']",,2023-07-20,2026-08-19,"[{'measure': 'Change From Baseline in Proteinuria at Week 12 in Both Treatment Periods 1 and 2', 'description': 'The change in urine protein: creatinine ratio (UPCR) from baseline to Week 12', 'timeFrame': 'Baseline and 12 weeks or approximately 3 months'}]","[{'measure': 'Change From Baseline in Proteinuria at Week 24 in Treatment Periods 2', 'description': 'The change in UPCR from baseline to Week 24', 'timeFrame': 'Baseline and 24 weeks or approximately 6 months'}, {'measure': 'Number of Subjects With Adverse Events (AEs)', 'description': 'Type, incidence, severity, seriousness, and relatedness of AEs will be collected.', 'timeFrame': 'From informed consent until end of study, approximately 60 weeks'}, {'measure': 'Plasma Concentration of Atrasentan', 'description': 'Blood samples will be collected for the measurement of plasma concentrations of atrasentan.', 'timeFrame': 'Treatment Period 1: Pre-dose on Weeks 2, 6 and 12; Treatment Period 2: Pre-dose on Weeks 2, 6, 12 and 24'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,54.0,ACTUAL,v2_robust,True,False,False,True,,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1.Cl,CHEMBL2106068,partial_match,True,547.09,4.69,3.0
NCT04399226,Dexmedetomidine-Propofol and Ketamine-Propofol During Upper Gastrointestinal System Sedation,Dexmedetomidine,"['ketamine', 'propofol', 'Dexmedetomidine']",3,OBSERVATIONAL,[],,COMPLETED,Anesthesia; Reaction,Yuzuncu Yıl University,2025-09-01T16:18:17.185081,True,,,,CHEMBL778,Efficacy and Safety of Deksmedetomidine-propofol or Ketamine-propofol,,['Anesthesia; Reaction'],"['Dexmedetomidine, Ketamine, Propofol, Sedation']",,2019-10-18,2020-03-13,"[{'measure': 'Demographic data', 'description': 'no difference', 'timeFrame': '2 minutes'}]","[{'measure': 'adverse events', 'description': 'Nausea, vomiting and allergic reaction, cough', 'timeFrame': '2 minutes'}]",2.0,18 Years,60 Years,ALL,True,OTHER,0.0,60.0,ACTUAL,v2_robust,False,True,False,True,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CHEMBL778,exact_match,True,200.28,3.18,4.0
NCT05445011,Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia,Fludarabine + Cyclophosphamide + TAA05 Cell Injection,"['Fludarabine + Cyclophosphamide + TAA05 Cell Injection', 'Fludarabine + Cyclophosphamide + Anti-FLT3 CAR-T Cell']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Acute Myeloid Leukemia,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2025-09-01T16:18:22.202450,True,,,,NOT_FOUND,Safety and Efficacy of Anti-FLT3 CAR- T Cell (TAA05 Cell Injection) in the Treatment of Relapsed/ Refractory Acute Myeloid Leukemia,,['Acute Myeloid Leukemia'],['FLT3 positive Acute Myeloid Leukemia'],,2022-06-14,2027-06-14,"[{'measure': 'Maximal tolerable dose (MTD)', 'description': 'Fludarabine + Cyclophosphamide + TAA05 Cell Injection Patients will receive lymphodepletion with fludarabine (25 mg/kg) and cyclophosphamide (250 mg/kg) for 3 days on day -7\\~-2, followed by the infusion of TAA05 Cell with the dose of 1×10\\^8, 2×10\\^8 or 4×10\\^8 cells on day 0. If no dose-limited toxicity(DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. MTD is defined as the highest dose at which DLT occurs in no more than 2 of the 6 patients. After the end of dose climbing, if the maximum dose group(MTD) is still not observed, the highest dose group is defined as MTD.', 'timeFrame': 'within 2 yeas after infusion'}]","[{'measure': 'Incidence of Treatment-related Adverse Events', 'description': 'Adverse events will be assessed according to NCI-CTCAE v5.0, cytokine release syndrome and CAR-T cell-related encephalopathy syndrome will be assessed according to ASTCT criteria.', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Overall response rate(ORR) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'OR will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Complete response rate(CRR) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'CRR will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Overall survival(OS) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'OS will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Progress-free survival(PFS) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'PFS will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Duration of Response(DOR) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'DOR will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'In vivo expansion and survival of Anti-FLT3 CAR-T Cell', 'description': 'Quantity of CAR copies in bone marrow and peripheral blood will be determined by using qPCR.', 'timeFrame': 'within 2 yeas after infusion'}]",8.0,18 Years,70 Years,ALL,False,OTHER,1.0,12.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04556773,A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer,Trastuzumab deruxtecan,"['Paclitaxel', 'Anastrozol', 'Taxol A', 'MEDI4736', 'DS-8201a, T-DXd', 'Fulvestrant', 'Capecitabine', 'AZD5363', 'Capivasertib', 'Anastrozole', 'Trastuzumab deruxtecan', 'Durvalumab']",12,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,AstraZeneca,2025-09-01T16:18:10.909375,True,,,,NOT_FOUND,"A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)",,['Metastatic Breast Cancer'],"['Breast Cancer', 'HER2-negative', 'HER2-low', 'Trastuzumab Deruxtecan', 'T-DXd', 'DS-8201a', 'DESTINY-Breast08', 'Anti-HER2 Antibody Drug Conjugate (ADC)', 'Triple-negative breast cancer (TNBC)']",,2020-12-17,2025-12-04,"[{'measure': 'Occurrence of adverse events (AEs)- Part 1', 'description': 'Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Occurrence of serious adverse events (SAEs)- Part 1', 'description': 'Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Occurrence of adverse events (AEs)- Part 2', 'description': 'Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Occurrence of serious adverse events (SAEs)- Part 2', 'description': 'Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0', 'timeFrame': 'Up to follow-up period, approximately 24 months'}]","[{'measure': 'Objective Response Rate (ORR)- Part 2', 'description': 'ORR defined as the proportion of patients who have a confirmed CR or PR, as determined by the investigator at local site per RECIST 1.1', 'timeFrame': 'Until progression, assessed up to approximately 24 months'}, {'measure': 'Progression Free Survival (PFS)- Part 2', 'description': 'PFS defined as time from the date of first dose until the date of progression as determined by the investigator at local site per RECIST 1.1, or death due to any cause', 'timeFrame': 'Until progression or death, assessed up to approximately 24 months'}, {'measure': 'Duration of Response (DoR)- Part 2', 'description': 'DoR defined as time from the date of first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression', 'timeFrame': 'Until progression or death, assessed up to approximately 24 months'}, {'measure': 'Overall Survival (OS)- Part 2', 'description': 'OS defined as time from the date of first dose until the date of death by any cause', 'timeFrame': 'Until death, assessed up to approximately 24 months'}, {'measure': 'Serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a', 'description': 'Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration', 'timeFrame': 'While on study drug up to study completion, approximately 24 months'}, {'measure': 'Immunogenicity of trastuzumab deruxtecan', 'description': 'Percentage of patients who develop ADA for trastuzumab deruxtecan', 'timeFrame': 'Up to follow-up period, approximately 24 months'}, {'measure': 'Serum Concentration of durvalumab', 'description': 'Determination of durvalumab concentration in serum at different time points after administration', 'timeFrame': 'While on study drug up to study completion, approximately 24 months'}, {'measure': 'Immunogenicity of durvalumab', 'description': 'Percentage of patients who develop ADAs for durvalumab', 'timeFrame': 'Up to follow-up period, approximately 24 months'}]",12.0,18 Years,,ALL,False,INDUSTRY,2.0,138.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02901106,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate,Dimethyl fumarate,['Dimethyl fumarate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,"Multiple Sclerosis, Relapsing-Remitting",Fondation Ophtalmologique Adolphe de Rothschild,2025-09-01T16:18:22.209818,True,,,,NOT_FOUND,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP,,"['Multiple Sclerosis, Relapsing-Remitting']","['Multiple Sclerosis, Relapsing-Remitting', 'Dimethyl fumarate']","Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment.",2017-05-23,2017-10-17,"[{'measure': 'Number of patients with a relapse and/or progressive worsening of disease (EDSS score)', 'timeFrame': 'After one year of treatment'}]",[],1.0,18 Years,,ALL,False,NETWORK,0.0,11.0,ACTUAL,v2_robust,True,False,True,False,"Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment.",,,no_match,False,,,
NCT02159872,Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,Omacetaxine,"['Omacetaxine', 'Homoharringtonine', 'Synribo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Leukemia,M.D. Anderson Cancer Center,2025-09-01T16:18:15.905789,True,,,,CHEMBL46286,A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure,,['Leukemia'],"['Leukemia', 'Myelodysplastic Syndrome', 'MDS', 'Omacetaxine', 'Synribo', 'Homoharringtonine']",,2015-05-18,2020-04-14,"[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method.', 'timeFrame': 'Up to 2.5 Years'}, {'measure': 'Number of Participants With a Response', 'description': 'Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with \\</= 5% bone marrow blasts, a peripheral blood granulocyte count \\>/= (1.0x10\\^9/L, and a platelet count \\>/= 100x10\\^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if \\<15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to \\>/=100x10\\^9L.', 'timeFrame': 'Up to 2 years'}]",[],2.0,18 Years,,ALL,False,OTHER,1.0,48.0,ACTUAL,v2_robust,True,True,False,False,,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4,CHEMBL46286,partial_match,True,545.63,2.58,4.0
NCT04521868,A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients,Sulforaphane,"['Sulforaphane', 'Nutramax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Schizophrenia,Central South University,2025-09-01T16:18:09.633459,True,,,,NOT_FOUND,A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Negative Symptoms and Cognition Impairment of Schizophrenia Patients,,['Schizophrenia'],"['schizophrenia', 'sulforaphane']",,2020-08-31,2022-08-12,"[{'measure': 'Change of clinical symptoms by PANSS', 'description': 'The change of Positive And Negative Syndrome Scale (PANSS) total, positive and negative symptoms before and after treatment at different follow up point. The PANSS total score ranges from 30-210 points,the higher the score, the worse the symptoms.', 'timeFrame': '24 weeks'}, {'measure': 'Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score', 'description': 'The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure.The MCCB total score is about 50 in healthy participants, patients with schizophrenia are reported to have scores as low as two standard deviations below the mean points; the higher the score, the better the cognition performance.', 'timeFrame': '24 weeks'}]","[{'measure': 'side effects by TESS', 'description': 'The investigators will evaluate side effect by Treatment Emergent Symptom Scale. It is consisted of behavioural toxicity, laboratory abnormalities, nervous system, automatic nervous system, cardiovascular system and six other aspects, was used to evaluate adverse drug reactions based on the scores, ranging from 0 to 4 (the higher the score, the more serious the adverse reactions).', 'timeFrame': '24 weeks'}, {'measure': 'Change of clinical symptoms by SANS', 'description': 'The change of Scale for Assessment of Negative Symptoms (SANS) to evaluate negative symptoms before and after treatment at different time point. It measures 25 items of negative symptoms across 5 categories: affective blunting, alogia, avolition-apathy, anhedonia-asociality, and inattention, ranging from 0-120.', 'timeFrame': '24 weeks'}, {'measure': 'Change of clinical symptoms of CGI', 'description': 'The change of Clinical Global Impression (CGI) before and after treatment at different follow up point. Its assess Severity of Illness (CGI-S), Global Improvement (CGI-I), and Efficacy Index (CGI-E). CGI-S is a 7-point scale, the higher score means the more severe the illness; CGI-I is a 7 point scale, the higher score means the less improved symptoms after treatment; CGI-E is is a 4×4 rating scale that assesses the therapeutic effect of treatment with psychiatric medication and associated side effects.', 'timeFrame': '24 weeks'}, {'measure': 'Change of psychological, social, and occupational functioning by GAF', 'description': 'The change of Global Assessment of Functioning (GAF) Scale before and after treatment at different follow up point.ranging from 0 to 100.The higher scores means the better functioning performance.', 'timeFrame': '24 weeks'}]",6.0,18 Years,50 Years,ALL,False,OTHER,0.0,125.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00087048,Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer,topotecan hydrochloride,['topotecan hydrochloride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Lung Cancer,Case Comprehensive Cancer Center,2025-09-01T16:18:25.985517,True,,,,NOT_FOUND,The Use Of Weekly Topotecan As Second Line Therapy In Small Cell Lung Cancer,,['Lung Cancer'],"['extensive stage small cell lung cancer', 'recurrent small cell lung cancer']",Slow accrual,2004-04,2006-02,[{'measure': 'Overall survival'}],"[{'measure': 'Safety and toxic effects'}, {'measure': 'Recurrence-free survival'}, {'measure': 'Time to response and tumor response'}, {'measure': 'Quality of life'}]",5.0,18 Years,,ALL,False,OTHER,1.0,1.0,ACTUAL,v2_robust,True,False,True,True,Slow accrual,,,no_match,False,,,
NCT03246529,"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)",BL-8040 1.25 mg/kg + G-CSF,"['BL-8040 1.25 mg/kg + G-CSF', 'Placebo +G-CSF']",2,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Multiple Myeloma,"BioLineRx, Ltd.",2025-09-01T16:18:20.969320,True,,,,NOT_FOUND,"A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study",,['Multiple Myeloma'],[],,2018-03-23,2029-09-30,"[{'measure': 'Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions', 'description': 'Percentage of subjects mobilizing ≥6 × 10\\^6 CD34+ cells/kg with up to 2 apheresis sessions in preparation for autologous hematopoetic cell transplantation (auto-HCT) after treatment with G-CSF + single administration of BL-8040/placebo.\n\nBased on central laboratory data.', 'timeFrame': 'From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6'}]","[{'measure': 'Percentage of Subjects Mobilizing ≥2 × 10^6 CD34+ Cells/kg in 1 Apheresis Session', 'description': 'Percentage of subjects mobilizing ≥2 × 10\\^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo.', 'timeFrame': 'From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5'}, {'measure': 'Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg in 1 Apheresis Session', 'description': 'Percentage of subjects mobilizing ≥6 × 10\\^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo.', 'timeFrame': 'From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5'}, {'measure': 'Time to Neutrophil Engraftment, After Auto-HCT', 'description': 'Time to neutrophil engraftment after auto-HCT, where engraftment was defined as absolute neutrophil count (ANC) ≥0.5 × 10\\^9/L for 3 days or ≥1.0 × 10\\^9/L for 1 day following the conditioning regimen associated nadir.', 'timeFrame': 'End of engraftment period, which was defined as 29 days post transplantation'}, {'measure': 'Time to Platelet Engraftment, After Auto-HCT', 'description': 'Time to platelet engraftment, after auto-HCT, where engraftment was defined as the first of 3 consecutive measurements of platelet count ≥20 × 10\\^9/L without platelet transfusion support for 7 days following the conditioning regimen associated nadir.', 'timeFrame': 'End of engraftment period, which was defined as 29 days post transplantation'}, {'measure': 'Subjects With Graft Durability at 100 Days Post Transplant/ Early Termination', 'description': 'Subjects achieving graft durability were defined as meeting the following 2 criteria:\n\n* Platelet count ≥50 × 10\\^9/L without transfusion for at least 2 weeks.\n* Hemoglobin level ≥10 g/dL with no erythropoietin support or transfusions for at least 1 month.\n\nThis analysis was performed in part 2 of the study only.', 'timeFrame': 'Day 100 Post-Transplantation (± 7 days)'}, {'measure': 'Graft Durability at 6 Months Post Transplantation', 'description': 'Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 6 months post transplantation', 'timeFrame': '6 Months Post Transplantation'}, {'measure': 'Graft Durability at 9 Months Post Transplantation', 'description': 'Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 9 months post transplantation', 'timeFrame': '9 Months Post Transplantation'}, {'measure': 'Graft Durability at 12 Months Post Transplantation', 'description': 'Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 12 months post transplantation', 'timeFrame': '12 Month Post Transplantation'}]",9.0,18 Years,78 Years,ALL,False,INDUSTRY,0.0,180.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04985201,Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy,Irinotecan,"['Irinotecan', 'Simvastatin', 'Simvastatin 40mg', 'Irinotecan injection']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Small Cell Lung Cancer,"Shanghai Pulmonary Hospital, Shanghai, China",2025-09-01T16:18:08.343126,True,,,,NOT_FOUND,Clinical Study of Irinotecan With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy,,['Small Cell Lung Cancer'],"['ES-SCLC', 'Chemo-resistance', 'Simvastatin']",,2021-11-01,2023-08-01,"[{'measure': 'Progression-free survival (PFS)', 'description': 'To evaluate the progression-free survival (PFS) of patients.', 'timeFrame': '12 weeks'}]","[{'measure': 'Disease control rate (DCR)', 'description': 'To assess disease control rate (DCR) after treatment.', 'timeFrame': '6 weeks'}, {'measure': 'Overall response rate (ORR)', 'description': 'To assess best overall response rate (ORR) after treatment.', 'timeFrame': '6 weeks'}, {'measure': 'Overall survival (OS)', 'description': 'To estimate overall survival (OS) of patients with ES-SCLC.', 'timeFrame': '24 weeks'}, {'measure': 'Number of participants with treatment-related adverse events (AE) as assessed by CTCAE v4.0', 'description': 'To evaluate the toxicity profile.', 'timeFrame': '24 weeks'}]",5.0,18 Years,75 Years,ALL,False,OTHER,1.0,40.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00001495,A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors,irinotecan (CPT-11),['irinotecan (CPT-11)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Neoplasms,National Cancer Institute (NCI),2025-09-01T16:18:24.747948,True,,,,NOT_FOUND,A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors,,['Neoplasms'],"['Camptothecin', 'Cancer', 'Chemotherapy', 'Natural Products', 'Neoplasms']",,1995-11,2000-10,[],[],0.0,,,ALL,False,NIH,0.0,40.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00075621,Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis,filgrastim,"['filgrastim', 'melphalan', 'alkeran']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Multiple Myeloma,Boston Medical Center,2025-09-01T16:18:12.167608,True,,,,NOT_FOUND,A Phase II Trial of Tandem Transplantation in AL Amyloidosis,,['Multiple Myeloma'],['primary systemic amyloidosis'],,2000-08,2020-09-04,"[{'measure': 'safety', 'timeFrame': '100 days, 6 months, and annual'}]","[{'measure': 'Efficacy', 'timeFrame': 'one year'}]",2.0,18 Years,65 Years,ALL,False,OTHER,0.0,62.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT07034456,Sensory and Vascular Effects of Kinesio and Magnetic Tape in Healthy Subjects,Topical Anesthetic Cream,['Topical Anesthetic Cream'],1,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Healthy Volunteers,Patricia Beltra Lopez,2025-09-01T16:18:18.430598,True,,,,NOT_FOUND,Possible Mechanisms of Action of Magnetic Tape Through Its Application on the Epidermis,,['Healthy Volunteers'],"['Magnetic Tape', 'Cutaneous Stimulation', 'Somatosensory System', 'Blood Flow']",,2025-07,2026-01,"[{'measure': 'Mechanical pain sensitivity (300g Von Frey monofilament)', 'description': 'Pain intensity will be assessed using a 300g Von Frey filament applied to the skin. Participants will report pain on an 11-point verbal Numeric Rating Scale (vNRS) from 0 (no pain) to 10 (worst imaginable pain). This measurement is performed in three regions (lumbar area, posterior thigh, and forearm) before and after each intervention. Higher NRS scores indicate greater mechanical pain sensitivity.\n\nAdditionally, it will be applied on intervention location site to assess the cream effect and confirm the anesthetic effects', 'timeFrame': 'Baseline (pre-intervention), Post-cream (immediately after cream removal), Mid-intervention (with tape on), and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}]","[{'measure': 'Mechanical Detection Threshold (Von Frey Filaments)', 'description': 'A set of von Frey filaments of increasing thickness (0.008-300 g) will be applied until the participant detects the stimulus in 3 out of 5 attempts. The smallest filament force (in grams) perceived is recorded as the threshold. Measurements are taken in the lumbar region, posterior thigh, and forearm. Higher thresholds indicate reduced tactile sensitivity.\n\nAdditionally, it will be applied on intervention location site to assess the cream effect and confirm the anesthetic effects', 'timeFrame': 'Baseline (pre-intervention), Post-cream (immediately after cream removal), Mid-intervention (with tape on), and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Pressure Pain Threshold (Algometer)', 'description': 'A digital algometer with a 1-cm² probe will be pressed gradually (1 kg/s) against the skin until participants report the first painful sensation. The force (kg/cm²) at which pain is first perceived is the PPT. Measurements are taken twice at each site (lumbar, thigh, forearm), and the average is used for analysis. Higher PPT values indicate lower pain sensitivity', 'timeFrame': 'Baseline (pre-intervention), Mid-intervention (with tape on) and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Painful pressure sensitivity (algometer)', 'description': 'A standard pressure of 5 kg is applied with an algometer on the lumbar region, thigh and forearm. Participants rate their pain on a 0-10 verbal Numeric Rating Scale (vNRS). This is done twice and averaged. Higher scores indicate greater evoked pain under a fixed force', 'timeFrame': 'Baseline (pre-intervention), Mid-intervention (with tape on) and Immediate Post-intervention (immediately after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Blood Flow Assessed by Color Doppler Ultrasound', 'description': 'Blood flow in the paravertebral lumbar region, thigh and forearm will be assessed using power Doppler ultrasound. Perfusion parameters (e.g., number of color signals, fractional moving blood volume) are recorded over 20-30 seconds at rest, before and after the intervention. Higher perfusion values may indicate increased blood flow', 'timeFrame': 'Baseline (pre-intervention), Mid-intervention (5 min with tape on) and Immediate Post-intervention (5 min after tape removal) at each weekly visit (Visits 1-4)'}, {'measure': 'Assessment of participant blinding post-intervention', 'description': 'After each session, participants complete a brief questionnaire indicating whether they believe they received magnetic or placebo tape, and anesthetic or moisturizing cream. The proportion of correct guesses is used to evaluate blinding effectiveness', 'timeFrame': 'Immediately Post-intervention after each of the four intervention visits (Visits 1-4)'}]",6.0,18 Years,35 Years,ALL,True,OTHER,3.0,30.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00859937,Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors,Dasatinib,"['Sprycel', 'BMS-354825', 'Dasatinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Malignant Salivary Gland Neoplasm,National Cancer Institute (NCI),2025-09-01T16:18:18.433529,True,,,,NOT_FOUND,Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors,,"['Malignant Salivary Gland Neoplasm', 'Recurrent Salivary Gland Carcinoma', 'Salivary Gland Adenoid Cystic Carcinoma', 'Stage IV Major Salivary Gland Cancer AJCC v7']",[],,2009-03-16,,"[{'measure': 'Response Rate', 'description': 'Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.', 'timeFrame': 'Up to 2 months'}, {'measure': 'Progression-free Survival', 'description': 'Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.', 'timeFrame': 'up to 5 years'}]","[{'measure': 'Overall Survival', 'description': 'Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Changes in Laboratory Correlates', 'description': ""Changes in laboratory correlates pre-post therapy will be analyzed using paired t-tests. The association between RET gene rearrangements/mutations and tumor response, as well as the association between germ-line polymorp response, will be analyzed using Fisher's exact test. The correlative and genetic data will also be entered as cova only due to the small sample size) in a Cox regression model of progression-free survival."", 'timeFrame': 'Baseline and 4 weeks'}]",4.0,18 Years,,ALL,False,NIH,0.0,55.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04885218,Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia,SHR-1209 ;placebo,['SHR-1209 ;placebo'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Non-familial Hypercholesterolemia,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:14.676030,True,,,,NOT_FOUND,"A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in the Stable Treatment of Patients With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia .",,"['Non-familial Hypercholesterolemia', 'Mixed Hyperlipidemia']",[],,2021-07-30,2023-05-23,"[{'measure': 'Percentage change in LDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment'}]","[{'measure': 'The value of change in LDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment'}, {'measure': 'Percentage change in LDL-C relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'The value of change in LDL-C relative to baseline ,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in non-HDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in non-HDL-C relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in ApoB relative to baseline', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in ApoB relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in TC/HDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in TC/HDL-C relative to baseline,', 'timeFrame': 'at 48 weeks of treatment'}, {'measure': 'Percentage change in ApoB/ApoA1 relative to baseline,', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in ApoB/ApoA1 relative to baseline,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in LP (a) relative to baseline,', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in LP (a) relative to baseline,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in TG relative to baseline', 'timeFrame': 'at 24 weeks of treatment'}, {'measure': 'Percentage change in TG relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage of patients who achieved LDL-C goal according to presence of ASCVD at baseline,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage of patients who achieved LDL-C goal according to presence of ASCVD at baseline,', 'timeFrame': 'at 48 weeks of treatment.'}]",18.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,692.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06979544,A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD,LPCN 1154A,"['Brexanolone', 'LPCN 1154A', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,"Depression, Postpartum",Lipocine Inc.,2025-09-01T16:18:17.173515,True,,,,NOT_FOUND,"A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression",,"['Depression, Postpartum', 'Depression, Post-Partum', 'Postpartum Depression (PPD)', 'Post-Natal Depression', 'Peripartum Depression', 'Postnatal Depression']",[],,2025-06-16,2026-05,"[{'measure': 'Change from baseline in HAM-D17 total score compared to placebo', 'description': 'The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline to Hour 60'}]","[{'measure': 'Incidence, severity, and causality of AEs and SAEs', 'description': 'Adverse events (AEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'upto Day 30'}, {'measure': 'Change from baseline in HAM-D17 total score', 'description': 'The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) evaluates mood, suicide, work and interests, retardation, agitation, gastrointestinal symptoms, somatic symptoms, hypochondriasis, body weight and insight The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline at Hours 12, and 36, Day 7 and Day 30'}, {'measure': 'HAM-D17 response', 'description': 'Defined as having a 50% or greater reduction from baseline in HAM-D17 total score. The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline to Hours 12, and 36, 60, Day 7 and Day 30'}, {'measure': 'HAM-D17 remission', 'description': 'Defined as having a HAM-D17 total score ≤7. The total score ranges from 0 to 52, with higher scores indicating more severe depression.', 'timeFrame': 'Hours 12, and 36, 60, Day 7 and Day 30'}, {'measure': 'Patient Global Impression - Change (PGI-C) scale positive response', 'description': 'The PGI-C scale is a 7-point scale that ranges from ""1-very much better"" to ""7-very much worse"" that allows participants to self- report their perception of improvement or decline of overall symptoms since starting treatment.', 'timeFrame': 'Hours 12, and 36, 60, Day 7 and Day 30'}, {'measure': 'Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score', 'description': 'The MADRS is a 10-item assessment that evaluates mood/thoughts, sleep, appetite, tension, concentration The total score ranges from 0 to 60, with higher scores indicating more severe depression.', 'timeFrame': 'Baseline to Hour 60 and Day 30'}, {'measure': 'Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score', 'description': 'The HAM-A is a 14-item assessment that evaluates mood, tension, fear, memory/concentration, sleep, and physical symptoms affecting somatic, sensory, respiratory, cardiovascular, gastrointestinal, genitourinary, and autoimmune systems as it relates to anxiety. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety.', 'timeFrame': 'Baseline to Hours 12, 36, 60 Day 7 and Day 30'}]",8.0,15 Years,45 Years,FEMALE,False,INDUSTRY,0.0,80.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04274608,"Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial",Botulinum toxin type A,['Botulinum toxin type A'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Obesity,Tan Tock Seng Hospital,2025-09-01T16:18:20.950551,True,,,,NOT_FOUND,"Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial",,"['Obesity', 'Weight Loss']",[],,2020-01-01,2022-07,"[{'measure': 'Weight loss', 'description': 'Examine the average weight loss', 'timeFrame': '1 year'}, {'measure': 'Time to weight regain following a single injection of intra-gastric Botox', 'timeFrame': '1 year'}]","[{'measure': 'Gut hormone level', 'description': 'Ghrelin', 'timeFrame': '1 year'}, {'measure': 'Gut hormone level ( Leptin)', 'description': 'Leptin', 'timeFrame': '1 year'}, {'measure': 'Satiety index', 'timeFrame': '1 year'}, {'measure': 'Co-morbidities', 'description': 'Diabetes, hypertension, hyperlipidemia', 'timeFrame': '1 year'}]",6.0,21 Years,65 Years,ALL,True,OTHER,0.0,18.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",Dabrafenib,"['Dabrafenib', 'Trametinib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Melanoma,Novartis Pharmaceuticals,2025-09-01T16:18:24.755633,True,,,,NOT_FOUND,"A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",,['Melanoma'],"['Spartalizumab (PDR001)', 'dabrafenib', 'trametinib', 'melanoma', 'immunotherapy', 'PD 1 inhibitor', 'anti PD1', 'PD-1', 'anti-PD-1', 'combination treatment', 'malignant skin cancer', 'skin cancer', 'BRAF V600', 'unresectable BRAF V600 mutated melanoma', 'metastatic BRAF V600 mutated melanoma']",Sponsor decision,2017-02-17,2024-08-21,"[{'measure': 'Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)', 'description': 'DLT was defined as an adverse event or abnormal laboratory value that was unrelated to disease, disease progression, inter-current illness, or concomitant medications and occured within 8 weeks of treatment with spartalizumab in combination with dabrafenib and trametinib. The DLT criteria included Grade 4 hematological adverse events, Grade 4 bilirubin elevation, specific gastrointestinal adverse events, symptomatic serum amylase or lipase elevation, Grade 3 or higher hypertension, Grade 3 or higher cardiac events, Grade 2 or higher pneumonitis, Grade 3 or higher immune-related toxicities, infusion-related reactions, other clinically significant adverse events, and toxicities leading to a dosing delay of over 12 weeks. NCI CTCAE v4.03 was used for grading DLTs', 'timeFrame': 'Up to 8 weeks (Part 1)'}, {'measure': 'Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib', 'description': 'Change from baseline in PD-L1 expression (as determined by immunohistochemistry in tissue samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2', 'timeFrame': 'Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days'}, {'measure': 'Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib', 'description': 'Change from baseline in CD8+ cells (as determined by flow cytometry in blood samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2', 'timeFrame': 'Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days'}, {'measure': ""Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1"", 'description': ""Progression-free survival was defined as the time from the date of first dose to the date of the first documented radiological progression per investigator's assessment according to RECIST 1.1 or death due to any cause. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment."", 'timeFrame': 'Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival was defined as the time from date of randomization to date of death due to any cause', 'timeFrame': 'Up to death due to any cause, assessed up to approximately 7 years'}, {'measure': ""Overall Response Rate (ORR) as Per Investigator's Assessment by RECIST 1.1"", 'description': ""ORR was defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\<10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters"", 'timeFrame': 'Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 years'}, {'measure': ""Duration of Response (DOR) as Per Investigator's Assessment by RECIST 1.1"", 'description': 'DOR was defined as the time from first documented response of CR or PR to date of first documented progression or death, according to RECIST 1.1 criteria. The distribution of DOR was estimated using the KM method. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\<10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters', 'timeFrame': 'From first documented response to date of first documented progression or death, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3)'}, {'measure': ""Disease Control Rate (DCR) as Per Investigator's Assessment by RECIST 1.1"", 'description': 'DCR was defined as the percentage of participants with CR or PR or subjects with stable disease (SD) lasting for a duration of at least 24 weeks as per local review according to RECIST 1.1 criteria. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\<10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.', 'timeFrame': 'Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 year'}, {'measure': 'Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status Scores', 'description': ""The EORTC QLQ-C30 was a 30-item questionnaire that patients complete, consisting of both multi-item scales and single-item measures. It included five functional scales, three symptom scales, six single items, and a Global Health Status/Quality of Life (GHS/QoL) scale. The GHS/QoL scale had seven possible response scores ranging from 1 (very poor) to 7 (excellent), which were averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life. The change from baseline in GHS/QoL scores was calculated. A positive change from baseline indicated improvement in the patient's quality of life."", 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Physical Functioning Scale Scores', 'description': 'The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The EORTC QLQ-C30 physical functioning scale measured a patient\'s ability to carry out daily activities and tasks requiring physical exertion. It consisted of five questions asking patients to rate their level of physical functioning, with response options ranging from 1=""not at all"" to 4=""very much"". The scores for each item were summed and transformed to a 0 to 100 scale, with higher scores indicating better physical functioning. The change from baseline in physical functioning scale scores was calculated. A positive change from baseline indicated improvement in physical functioning.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Pain Symptom Scale Scores', 'description': 'The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The EORTC QLQ-C30 pain symptom scale was one of the symptom scales in the questionnaire, which measured the severity of pain experienced by the patient. The pain symptom scale consisted of two items, one measuring the severity of pain and the other measuring the use of painkillers. The items were rated on a 4-point scale ranging from 1=""not at all"" to 4=""very much"". The scores for each item were summed and transformed to a 0 to 100 scale, with higher scores indicating more severe pain. The change from baseline in pain symptom scale scores was calculated. A negative change from baseline indicated improvement.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Time to 10 Point Definitive Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status', 'description': 'The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The GHS/QoL scale had seven possible response scores ranging from 1 (very poor) to 7 (excellent), which were averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life. The time to definitive 10 point deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the GHS/QoL score or death due to any cause. If a subject had not had an event, the time to deterioration was censored at the date of the last adequate assessment. The distribution was estimated using KM method.', 'timeFrame': 'From baseline to date of at least 10 points relative to baseline worsening of the global health status score or death due to any cause, up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in Function Assessment Cancer Therapy-melanoma (FACT-M) Melanoma Subscale Score', 'description': 'The Functional Assessment of Cancer Therapy-Melanoma (FACT-M) quality of life questionnaire was composed of the FACT-General (FACT-G) plus the Melanoma Subscale and the Melanoma Surgery Subscale, which complemented the general scale with items specific to quality of life (QoL) in melanoma. The Melanoma Subscale of FACT-M included 16 questions, with response options of 0= ""Not at all"", 1= ""a little bit"", 2= ""somewhat"", 3= ""quite a bit"" and 4= ""very much"". The FACT-M melanoma subscale score ranged from 0 to 64, with higher scores indicating a higher quality of life in relation to melanoma. The change from baseline in melanoma subscale scores was calculated. A positive change from baseline indicated improvement.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in EuroQoL 5-level Instrument (EQ-5D-5L)- Visual Analog Scale (VAS) Score', 'description': 'The EQ-5D-5L is a standardized questionnaire used to assess health-related quality of life, and it includes a Visual Analog Scale (VAS). The VAS score is obtained by asking the individual to rate their current health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The change from baseline in EQ-5D-5L VAS score was calculated. A positive change from baseline indicates improvement in the health status.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': ""Randomized (Part 3): PFS as Per Investigator's Assessment by RECIST 1.1 by PD-L1 Expression"", 'description': ""PFS was defined as the time from the date of first dose to the date of the first documented radiological progression as per investigator's assessment using RECIST 1.1 response criteria or death due to any cause. The distribution of PFS was estimated using the KM method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment. PFS analysis was performed by PD-L1 status (positive, negative) where a positive status was defined as having ≥ 1% expression and a negative status was defined as having \\< 1% expression."", 'timeFrame': 'Up to disease progression or death due to any cause, up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): OS by PD-L1 Expression', 'description': 'Overall survival was defined as the time from date of randomization to date of death due to any cause. OS analysis was performed by PD-L1 subgroup (positive, negative) where a positive status was defined as having ≥ 1% expression and a negative status was defined as having \\< 1% expression.', 'timeFrame': 'Up to death due to any cause, assessed up to approximately 7 years'}, {'measure': 'Spartalizumab Anti-drug Antibody (ADA) Prevalence at Baseline', 'description': 'Spartalizumab ADA prevalence at baseline was calculated as the percentage of participants who had an spartalizumab ADA positive result at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'Spartalizumab ADA Incidence', 'description': 'Spartalizumab ADA incidence was calculated as the percentage of participants who were treatment-induced spartalizumab ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted spartalizumab ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)', 'timeFrame': 'Throughout study until 150 days after the last dose of spartalizumab, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3).'}, {'measure': 'Trough Concentration (Ctrough) for Spartalizumab', 'description': 'Ctrough for spartalizumab refers to the serum concentration of spartalizumab immediately prior to the administration of a dose of spartalizumab on Day 1 of Cycle 2 and later cycles.', 'timeFrame': 'Pre-infusion on Day 1 of each Cycle starting from Cycle 2, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days'}, {'measure': 'Pre-dose Plasma Concentration for Dabrafenib', 'description': 'Plasma concentration of dabrafenib immediately prior to the administration of a dose of dabrafenib.', 'timeFrame': 'Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days'}, {'measure': 'Pre-dose Plasma Concentration for Trametinib', 'description': 'Plasma concentration of trametinib immediately prior to the administration of a dose of trametinib.', 'timeFrame': 'Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days'}, {'measure': 'Number of Participants With Dose Interruptions', 'description': 'Number of participants with dose interruptions for spartalizumab, dabrafenib and trametinib', 'timeFrame': 'From baseline to end of treatment, assessed up to approximately 7 years'}, {'measure': 'Number of Participants With Dose Reductions', 'description': 'Number of patients with dose reductions for spartalizumab, dabrafenib and trametinib', 'timeFrame': 'From baseline to end of treatment, assessed up to approximately 7 years'}, {'measure': 'Relative Dose Intensity', 'description': 'Relative dose intensity for spartalizumab, dabrafenib and trametinib computed as the ratio (expressed as percentage) of dose intensity and planned dose intensity:\n\n* Spartalizumab (PDR001) = \\[Dose intensity (mg/4W) / planned dose intensity (mg/4W)\\]\\*100.\n* Trametinib and Dabrafenib = \\[Dose intensity (mg/day) / planned dose intensity (mg/day)\\]\\*100.', 'timeFrame': 'From baseline to end of treatment, assessed up to approximately 7 years'}]",24.0,18 Years,100 Years,ALL,False,INDUSTRY,0.0,568.0,ACTUAL,v2_robust,True,False,True,True,Sponsor decision,,,no_match,False,,,
NCT03760991,Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin,INSULIN GLARGINE (U300),"['INSULIN GLARGINE (U300)', 'HOE901, Toujeo, Gla-300']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 2 Diabetes Mellitus,Sanofi,2025-09-01T16:18:09.634310,True,,,,NOT_FOUND,"A Multicenter, Multinational, Prospective, Interventional, Single-arm, Phase IV Study Evaluating the Clinical Efficacy and Safety of 26 Weeks of Treatment With Insulin Glargine 300 U/mL (Gla-300) in Patients With Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin",,['Type 2 Diabetes Mellitus'],[],,2018-12-18,2020-09-23,"[{'measure': 'Change in glycated hemoglobin (HbA1c)', 'description': 'Absolute change in HbA1c', 'timeFrame': 'Baseline to Week 26'}]","[{'measure': 'Change in glycated hemoglobin (HbA1c)', 'description': 'Absolute change in HbA1c', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Participants with HbA1c below 7%', 'description': 'Percentage of participants with HbA1c below 7%', 'timeFrame': 'Week 12 and 26'}, {'measure': 'Participants with fasting self-monitored plasma glucose (SMPG) of 80 to 110 mg/dL (4.4 to 7.2 mmol/L)', 'description': 'Percentage of participants reaching targeted fasting SMPG of 80 to 110 mg/dL (4.4 to 7.2 mmol/L)', 'timeFrame': 'Week 12 and 26'}, {'measure': 'Change in fasting SMPG', 'description': 'Absolute change in fasting SMPG', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Change in SMPG profile', 'description': 'Absolute change in SMPG profile', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Change in fasting plasma glucose (FPG)', 'description': 'Absolute change in FPG', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Percentage of participants requiring rescue therapy', 'description': 'Percentage of participants requiring rescue therapy by additional antidiabetic medication', 'timeFrame': 'Baseline to Week 12 and 26'}, {'measure': 'Number of participants with hypoglycemia events', 'description': 'Number of participants with at least 1 hypoglycemia event', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Number of participants with adverse events (AEs)', 'description': 'Number of participants with AEs, serious adverse events (SAEs) (including hypoglycemic episodes associated with seizures, coma, or unconsciousness).', 'timeFrame': 'Baseline to Week 27'}, {'measure': 'Change in Treatment satisfaction', 'description': 'Change in treatment satisfaction as measured by insulin treatment satisfaction questionnaire', 'timeFrame': 'Baseline to Week 26'}, {'measure': 'Number of participants with health care utilization', 'description': 'Number of participants with health care utilization, including hospitalization, emergency room visits, and office \\[or specialty\\] visits', 'timeFrame': 'Baseline to Week 26'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,372.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05552625,The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19,TADIOS,"['Lactose hydrate', 'TADIOS', 'Herbs', 'Placebo']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,WITHDRAWN,COVID-19,"Helixmith Co., Ltd.",2025-09-01T16:18:07.014768,True,,,,NOT_FOUND,"Multicenter, Double-blind, Placebo-controlled, Maximum 10 Days Administration Study to Evaluate the Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19",,['COVID-19'],"['COVID-19', 'Antioxidative biomarker', 'Inflammatory biomarker', 'TADIOS']",This Phase I study was conducted in India and no subject data was provided to sponsor.,2021-05-06,2022-02-24,"[{'measure': 'Evaluation of antioxidative and inflammatory Biomarkers', 'description': 'Change from baseline in Antioxidative and inflamatory biomarkers: TNF-α, CRP, IL-6, IL-1ra, Hb, and ferritin.', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Clinical measurements - Ordinal Scale for COVID-19 Assessment', 'description': 'Change from baseline in Covid-19 8-point Ordinal Scale: 0 = Uninfected, 1 = Ambulatory without limitation of activity, 2 = Ambulatory with limitation of activity, 3 = Hospitalized mild disease, no oxygen, 4 = Hospitalized mild disease, supplemental oxygen, 5 = Hospitalized severe disease, non-invasive ventilation or high-flow oxygen, 6 = Hospitalized severe disease, intubation and mechanical ventilation, 7 = Hospitalized severe disease, ventilation plus additional organ support, 8 = Death.', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Clinical measurements - Clinical Recovery Scale for COVID-19 Assessment', 'description': 'Time to clinical recovery in COVID-19 Clinical Symptom Scale: The clinical symptom scale has been designed for this study to access the clinical state and time taken to relieve the clinical symptoms of COVID-19 (fever, dry cough, tiredness, aches and pains, sore throat, diarrhea, headache, loss of taste, loss of smell, difficulty in breathing or shortness of breath and chest pain or pressure).', 'timeFrame': 'Every day from screening till discharge and Day 14 after last IP administration'}, {'measure': 'Clinical measurements Clinical Improvement Scale for COVID-19 Assessment', 'description': 'Proportion of Clinical Improvement in Clinical Symptom Scale (Count of subjects with and without a symptom by treatment group on each day with the previous day counts during the study period).', 'timeFrame': 'Daily from screening to discharge or Day 14 after last IP administration'}, {'measure': 'Assessment of Quality of life - WHO-5 Well-Being Index', 'description': 'Change from baseline in WHO-5 Well-Being Index: The total raw score, ranging from 0 to 25, will be multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Assessment of Quality of life - Fatigue Severity Score', 'description': ""Change from baseline in Fatigue Severity Score: Minimum total score possible is nine and the maximum is 63. The higher the score, the more severe the fatigue is and the more it affects the person's activities."", 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Hospitalization - Time to discharge', 'description': '1. Duration of hospitalization\n2. Time to discharge', 'timeFrame': 'Day 1, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10)'}]","[{'measure': 'Safety and tolerability assessment after administration of TADIOS 1', 'description': 'Subject incidence of Treatment-Emergent Adverse Events (TEAEs) and total number of unique TEAEs.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Hematology', 'description': 'Change from baseline in Hematology, Complete Blood Count results WBC, RBC, Hb, HCT, MCV, MCH, MCHC, PLT, MPV, differential count of WBC (Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil), and ESR.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Serum Chemistry', 'description': 'Change from baseline in Serum Chemistry results: total protein, albumin, globulin, A/G ratio, total bilirubin, AST, ALT, GGT, Random glucose, BUN, creatinine, estimated GFR, Ca2+, phosphate, Na+, K+, Cl-, CRP, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Urinalysis', 'description': 'Change from baseline in Urinalysis results: Color, pH, Specific gravity, albumin, bilirubin, glucose, urobilinogen, ketone, nitrite, hematuria, leukocyte and microscopy.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, from Day 1 to Day 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Blood Pressure', 'description': 'Change from baseline in Blood Pressure in mm Hg.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Body Temperature', 'description': 'Change from baseline in Body Temperature ℃.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Pulse Rate', 'description': 'Change from baseline in Pulse Rate in beats per minute.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}, {'measure': 'Safety and tolerability assessment after administration of TADIOS - Respiration Rate', 'description': 'Change from baseline in Respiration Rate in breaths per minute.', 'timeFrame': 'Screening, Maximum Day 10 (The date of discharge or early termination, at Day 1, 2, 4, 7, 10) and Day 14 after last IP administration'}]",15.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,This Phase I study was conducted in India and no subject data was provided to sponsor.,,,no_match,False,,,
NCT01223690,Clarithromycin as Immunomodulator for the Management of Sepsis,Clarithromycin,"['Klaricid IV', 'Dextrose solution', 'Clarithromycin', 'Dextrose 5%']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Sepsis,University of Athens,2025-09-01T16:18:14.676144,True,,,,CHEMBL1741,A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis,,"['Sepsis', 'Severe Sepsis', 'Septic Shock']","['sepsis', 'infection', 'bacteremia', 'clarithromycin']",,2007-07,2011-04,"[{'measure': 'Effect of clarithromycin in mortality and risk for death by severe sepsis/shock and multiple organ dysfunction compared with placebo', 'description': 'Survival analysis for 28 days will be done between placebo-treated patients and clarithromycin-treated patients separately for patients with sepsis; for patients with severe sepsis; and for patients with septic shock. Odds ratios for death by septic shock and/or multiple organ dysfunction will be assessed separately for each arm. Comparison of odds ratios will be done.', 'timeFrame': '28 days'}]","[{'measure': 'Effect of clarithromycin compared with placebo in time to resolution of infection', 'description': 'Time analysis between placebo-treated patients and clarithromycin-treated patients will be done', 'timeFrame': '28 days'}, {'measure': 'Effect of clarithromycin compared with placebo in time to resolution of sepsis', 'description': 'Time analysis between placebo-treated patients and clarithromycin-treated patients will be done', 'timeFrame': '28 days'}, {'measure': 'Effect of clarithromycin compared with placebo in time to progression to severe sepsis or septic shock and multiple organ failure', 'description': 'Time analysis between placebo-treated patients and clarithromycin-treated patients will be done', 'timeFrame': '28 days'}, {'measure': 'Influence of administration of clarithromycin compared with placebo on systemic inflammatory response', 'description': 'Comparative analysis of serum markers estimated at consecutive time intervals over the first 10 days of follow-up', 'timeFrame': '10 days'}]",5.0,18 Years,,ALL,False,OTHER,0.0,600.0,ACTUAL,v2_robust,True,True,False,False,,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,CHEMBL1741,exact_match,True,747.96,2.44,4.0
NCT03824808,Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery,Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution,"['Normal Saline', 'Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution', '0.9% Sodium Chloride Injection', 'Lidocaine']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Kidney Cancer,University of Missouri-Columbia,2025-09-01T16:18:14.671582,True,,,,CHEMBL79,"A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy",,"['Kidney Cancer', 'Prostate Cancer']","['prostatectomy', 'partial nephrectomy', 'robotic surgery', 'intravenous lidocaine', 'lidocaine hydrochloride']",Challenges with recruitment of surgical research subjects in the target population.,2019-02-26,2020-03-26,"[{'measure': 'Difference in Post-operative Pain Scores Measured by Visual Analog Scale', 'description': '10-cm Visual Analog Scale (VAS), score of 0 ""no pain"" to a score of 10 ""worst pain ever""', 'timeFrame': 'Through study completion, assessed at 1h, 2h, 4h, 6h, 12h and 24h post operatively, then every 24 hours until discharge, and at the post operative visit which occurred within 21-days post-operatively.'}]","[{'measure': 'Opioid Consumption', 'description': 'Difference in opioid consumption in first 24 hours, discharge and 21 days post-operatively (morphine equivalents)', 'timeFrame': 'Through study completion, assessed for first 24-hours post operatively, then every 24 hours until discharge, and at the post operative visit which occurred within 21-days post-operatively.'}, {'measure': 'Length of Hospital Stay', 'description': 'Difference in length of hospital stay determined by surgeon excluding social factors that may delay discharge', 'timeFrame': 'At participant discharge, assessed up to 14 days (+/-) 7 days'}, {'measure': 'Duration of Post-operative Ileus', 'description': 'Difference in post-operative Ileus duration', 'timeFrame': 'Through study completion, assessed at 1h, 2h, 4h, 6h, 12h and 24h post operatively, then every 24 hours until discharge, and at the post operative visit which occurred within 21-days post-operatively.'}, {'measure': 'Post-operative PACU Time', 'description': 'Difference in time in the Post Anesthesia Care Unit (PACU) after surgery', 'timeFrame': 'During hospitalization, approximately 2 hours post-surgery'}, {'measure': 'Return of Flatus', 'description': 'Difference in return of flatus after surgery', 'timeFrame': 'During hospitalization at 1h, 2h, 4h, 6h, 12h, and 24h post operatively, then every 24 hours thereafter until discharge.'}, {'measure': 'Time to Out of Bed', 'description': 'Difference in time to out of bed to chair after surgery', 'timeFrame': 'During hospitalization regular intervals for the first 24 hours, then every 24 hours until discharge.'}, {'measure': 'First Ambulation in the Hallway', 'description': 'Difference in time to first ambulation in the hallway after surgery', 'timeFrame': 'During hospitalization at 1h, 2h, 4h, 6h, 12h, and 24h post operatively, then every 24 hours until discharge.'}]",8.0,18 Years,,ALL,False,OTHER,0.0,21.0,ACTUAL,v2_robust,True,False,True,False,Challenges with recruitment of surgical research subjects in the target population.,CCN(CC)CC(=O)Nc1c(C)cccc1C,CHEMBL79,partial_match,True,234.34,2.58,4.0
NCT04651049,Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas,propranolol,['propranolol'],1,OBSERVATIONAL,[],,COMPLETED,Infantile Haemangiomas,Qilu Hospital of Shandong University,2025-09-01T16:18:09.626730,True,,,,CHEMBL27,Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas,,['Infantile Haemangiomas'],[],,2010-07-15,2020-02-10,"[{'measure': 'Change on the height of the patients', 'description': 'we recorded the height of the patients in meters.', 'timeFrame': 'at the beginning of the treatment, at the end of treatment and 2 years after the treatment'}, {'measure': 'Change on the weight of the patients', 'description': 'we recorded the weight of the patients in kilograms.', 'timeFrame': 'at the beginning of the treatment, at the end of treatment and 2 years after the treatment'}]",[],2.0,2 Weeks,54 Weeks,ALL,False,OTHER,0.0,128.0,ACTUAL,v2_robust,False,True,False,False,,CC(C)NCC(O)COc1cccc2ccccc12,CHEMBL27,exact_match,True,259.35,2.58,4.0
NCT02325492,Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study,Aramchol,"['Placebo', 'Aramchol']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Gallstones,Galmed Pharmaceuticals Ltd,2025-09-01T16:18:19.663844,True,,,,NOT_FOUND,Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study,,['Gallstones'],"['bariatric surgery', 'NASH', 'ARAMCHOL']",Protocol redesign,2014-10,2015-10,"[{'measure': 'Complete dissolution of existing gallstones proven by repeated US examined gallbladder', 'description': 'Change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}]","[{'measure': 'Decrease of more than a 50% in number of stones. (change from baseline)', 'description': 'change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}, {'measure': 'Prevention of formation of new gallstones during the study period', 'description': 'change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}, {'measure': 'Dissolution of sludge.', 'description': 'change from baseline measured by US scan', 'timeFrame': 'At baseline and week 12'}]",4.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,False,True,False,Protocol redesign,,,no_match,False,,,
NCT04491942,"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer",Cisplatin,"[""Peyrone's Chloride"", 'DDP', 'ATR Kinase Inhibitor BAY1895344', 'BAY-1895344', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Placis', 'Platinol', 'Platinum Diamminodichloride', 'Citoplatino', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'BAY1895344', 'Gemcitabine HCI', 'ATR Inhibitor BAY1895344', 'Gemzar', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Platinum', 'Platinex', ""Peyrone's Salt"", 'Blastolem', 'Cis-platinum II', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'LY188011', 'Lederplatin', 'Platiran', 'dFdCyd', 'Abiplatin', 'Cis-diamminedichloro Platinum (II)', 'Cisplatin', 'Gemcitabine Hydrochloride', 'Cis-diammine-dichloroplatinum', 'Platamine', 'Briplatin', 'BAY 1895344', 'Cis-diamminedichloroplatinum', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'Difluorodeoxycytidine Hydrochloride', 'Platiblastin', 'Cis-platinum', 'Citosin', 'Cisplatina', 'Platosin', 'Elimusertib', 'Cis-dichloroammine Platinum (II)', 'LY-188011', 'LY 188011', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",57,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Advanced Bile Duct Carcinoma,National Cancer Institute (NCI),2025-09-01T16:18:07.027159,True,,,,NOT_FOUND,A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma,,"['Advanced Bile Duct Carcinoma', 'Advanced Breast Carcinoma', 'Advanced Cervical Carcinoma', 'Advanced Endometrial Carcinoma', 'Advanced Esophageal Carcinoma', 'Advanced Gastric Carcinoma', 'Advanced Head and Neck Carcinoma', 'Advanced Lung Non-Small Cell Carcinoma', 'Advanced Lung Small Cell Carcinoma', 'Advanced Malignant Solid Neoplasm', 'Advanced Ovarian Carcinoma', 'Advanced Penile Carcinoma', 'Advanced Pleural Malignant Mesothelioma', 'Advanced Urothelial Carcinoma', 'Anatomic Stage III Breast Cancer AJCC v8', 'Anatomic Stage IV Breast Cancer AJCC v8', 'Clinical Stage III Gastric Cancer AJCC v8', 'Clinical Stage IV Gastric Cancer AJCC v8', 'Stage III Cervical Cancer AJCC v8', 'Stage III Distal Bile Duct Cancer AJCC v8', 'Stage III Intrahepatic Bile Duct Cancer AJCC v8', 'Stage III Lung Cancer AJCC v8', 'Stage III Ovarian Cancer AJCC v8', 'Stage III Penile Cancer AJCC v8', 'Stage III Pleural Malignant Mesothelioma AJCC v8', 'Stage IV Cervical Cancer AJCC v8', 'Stage IV Distal Bile Duct Cancer AJCC v8', 'Stage IV Intrahepatic Bile Duct Cancer AJCC v8', 'Stage IV Lung Cancer AJCC v8', 'Stage IV Ovarian Cancer AJCC v8', 'Stage IV Penile Cancer AJCC v8', 'Stage IV Pleural Malignant Mesothelioma AJCC v8', 'Triple-Negative Breast Carcinoma', 'Unresectable Urothelial Carcinoma']",[],,2021-08-25,2026-06-30,"[{'measure': 'Incidence of adverse events', 'description': 'Toxicities will be tabulated and reported according to dose level, grade, type, cycle, and attribution. Tables will be created to summarize these toxicities and side effects, overall and by cohort. Proportions and associated 95% confidence intervals will be calculated for each cohort separately. Cumulative incidence curves will be used to estimate the proportion of patients who will discontinue therapy for reasons of toxicity or general inability to tolerate the regimen.', 'timeFrame': 'Up to 28 days after completion of study treatment'}, {'measure': 'Recommended phase 2 dose (RP2D) of BAY 1895344', 'timeFrame': 'Up to 21 days from treatment start date'}]","[{'measure': 'Pharmacokinetic (PK) parameter - maximum concentration (Cmax)', 'description': 'Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine).', 'timeFrame': 'Day 2 and day 9 after treatment start date'}, {'measure': 'PK parameter - area under the concentration-time curve (AUC)', 'description': 'Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). The impact of cisplatin on BAY 1895344 exposure will be evaluated by calculation of the AUC ratio of (day 9 / day 2) and testing non-parametrically with a null hypothesis of a ratio = 1.', 'timeFrame': 'Day 2 and day 9 after treatment start date'}, {'measure': 'Deoxyribonucleic acid (DNA) damage repair (DDR) mutations', 'description': 'The association between DDR mutations and responses will be described, with a table outlining patients who achieved by progressive disease, stable disease, partial or complete responses and DDR mutation status.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Response rate', 'description': 'The percent of responders will be calculated and associated exact 95% confidence intervals will be constructed.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Kaplan-Meier plots will be used to summarize PFS.', 'timeFrame': 'Up to 2 years'}]",7.0,18 Years,,ALL,False,NIH,0.0,74.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00283621,Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide,Aranesp (darbepoetin alfa),"['Ifosfamide', 'Adriamycin', 'Adriamycin RDF', 'Doxorubicin Hydrocholoride', 'Aranesp (darbepoetin alfa)', 'Ifex', 'Neulasta (pegfilgrastim)', 'Adriamycin PFS']",8,INTERVENTIONAL,['NA'],,COMPLETED,Sarcoma,M.D. Anderson Cancer Center,2025-09-01T16:18:08.353596,True,,,,NOT_FOUND,A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide,,['Sarcoma'],"['Aranesp', 'Darbepoetin Alfa', 'Pegfilgrastim', 'Neulasta', 'Sarcoma', 'Adriamycin', 'Doxorubicin Hydrocholoride', 'Adriamycin PFS', 'Adriamycin RDF', 'Ifosfamide']",,2003-06-02,2006-04-12,"[{'measure': 'CBC diff/platelet counts', 'timeFrame': 'Monitored at least twice a week and daily during severe myelosuppression.'}, {'measure': 'Iron Stores', 'timeFrame': 'Blood drawn at baseline during cycle 3 and at the end of study.'}, {'measure': 'Peripheral blood and bone marrows', 'timeFrame': 'Performed at baseline and post treatment.'}]","[{'measure': 'Neurocognitive functions and Symptom burden assessment', 'timeFrame': 'Assessed at baseline, after 3 cycles of treatment and at the end of the study.'}]",4.0,18 Years,65 Years,ALL,True,OTHER,1.0,51.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00636558,Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04),CVA21,"['CVA21', 'CAVATAK']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Melanoma,Viralytics,2025-09-01T16:18:14.667036,True,,,,NOT_FOUND,"A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)",,"['Melanoma', 'Breast Cancer', 'Prostate Cancer']","['coxsackie virus', 'melanoma', 'breast cancer', 'prostate cancer']",,2008-02-29,2012-01-12,"[{'measure': 'The primary objective of the study is to determine the safety and tolerability of CVA21 given by intravenous infusion in multiple escalating doses.', 'timeFrame': 'Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84'}]","[{'measure': 'To obtain preliminary efficacy data, determine the time course of viraemia and its elimination post-administration of CVA21', 'timeFrame': 'Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84'}, {'measure': 'To characterise the time course of the anti-CVA21 antibody response', 'timeFrame': 'Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,8.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05346107,PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer,"pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage","['pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage']",1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Breast Cancer,Xijing Hospital,2025-09-01T16:18:22.201711,True,,,,NOT_FOUND,PLD Plus Cyclophosphamide Followed by Nab-paclitaxel (Nab-P) as Primary Chemotherapy Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer: A Single-arm Phase 2 Trial(Brecan Trial),,"['Breast Cancer', 'HER2-positive Breast Cancer']",[],,2020-01-01,2023-12-31,"[{'measure': 'Rate of pathological complete response', 'description': 'absence of invasive carcinoma in the breast and axillary lymph nodes, while residual ductal carcinoma in situ was accepted (ypT0orTisypN0)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 14 days)'}]","[{'measure': 'adverse effects', 'description': 'Serious adverse effect occur within neoadjuvant chemotherapy', 'timeFrame': 'during the period of neadjuvant chemotherapy, an average of 14 days'}]",2.0,18 Years,80 Years,FEMALE,False,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03117725,Melatonin Study Between Diminished and Normal Responder in IVF,Melatonin adminstration,"['placebo administration', 'Melatonin adminstration']",2,INTERVENTIONAL,['NA'],,UNKNOWN,"Infertility, Female",Bundang CHA Hospital,2025-09-01T16:18:07.014389,True,,,,CHEMBL45,Comparison of IVF Outcome and Endometrium Effect in Infertility Patients Between Diminished and Normal Ovarian Reserve After Melatonin Administration.,,"['Infertility, Female']","['oxidative stress', 'antioxidants', 'diminished ovarian reserve']",,2017-05-12,2019-10-31,"[{'measure': 'IVF outcome - oocyte quality', 'description': 'Evaluate oocyte quality on morphological standard as following category- Mature oocyte, Intermediate oocyte, atretic oocyte, post mature oocyte', 'timeFrame': '3 days after oocyte retrieval'}, {'measure': 'IVF outcome - embryo quality', 'description': 'grade the embryos\\& blastocysts according to the Lucinda Veeck \\& Gardner', 'timeFrame': '3 to 5 days after oocyte retrieval'}, {'measure': 'IVF outcome -biochemical pregnancy rate', 'description': 'serum human chorionic gonadotropin level\\>10 IU', 'timeFrame': 'on day 12~14 after embryo transfer'}, {'measure': 'IVF outcome - clinical pregnancy rate', 'description': 'presence of G-sac in the uterine cavity', 'timeFrame': 'at 6-8 weeks of gestation'}]","[{'measure': 'acquired oocyte No', 'description': 'number', 'timeFrame': '20weeks'}, {'measure': 'fertilization rate', 'description': 'ratio of no. of fertilized egg/ no of total retrieved eggs', 'timeFrame': '20weeks'}, {'measure': 'Comparing Pittsburgh sleep quality index', 'description': 'questionaires to evaluate the participants quality of the sleep. cut off : 13 points This questionaire is to be asked to the participants twice, before and after the administration of the drug', 'timeFrame': '20weeks'}, {'measure': 'marker(melatonin level, receptor, 8-OHdg) in serum, follicular fluid and endometrium during IVF', 'description': ':pg/ml units are used', 'timeFrame': '20weeks'}]",8.0,20 Years,40 Years,FEMALE,True,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,CHEMBL45,partial_match,True,232.28,1.86,4.0
NCT01861522,The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis,Bepotastine besilate,"['TALION 5mg tablets', 'Bepotastine besilate', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Perennial Allergic Rhinitis,Mitsubishi Tanabe Pharma Corporation,2025-09-01T16:18:15.901357,True,,,,NOT_FOUND,"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)",,['Perennial Allergic Rhinitis'],"['TAU-284', 'Bepotastine besilate', 'Histamine H1 receptor antagonists', 'children']",,2013-04,2013-12,"[{'measure': 'Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]', 'description': 'Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 5-point scale ranging from 0 (no symptoms) to 4 (very severe).', 'timeFrame': 'Baseline and Week 2'}]","[{'measure': 'Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]', 'timeFrame': 'baseline, Week1 and Week 2'}, {'measure': 'Change From Baseline in Individual Nasal Symptom Scores (Sneezing, Rhinorrhea, Nasal Congestion, and Impairment in Daily Activities)', 'timeFrame': 'baseline, Week1 and Week 2'}, {'measure': 'Change From Baseline in Individual Scores for Local Nasal Findings (Rhinoscopic Findings)', 'timeFrame': 'baseline, Week1 and Week 2'}, {'measure': 'Change From Baseline in Severity Score for Symptoms of Allergic Rhinitis', 'timeFrame': 'Randomization, Week1 and Week 2'}, {'measure': 'Adverse Events and Adverse Drug Reactions', 'timeFrame': 'Week 2'}]",6.0,7 Years,15 Years,ALL,False,INDUSTRY,0.0,473.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00989768,Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A,Botulinum Toxin Type A (Dysport®),"['Botulinum Toxin Type A (Dysport®)', 'Botulinum Toxin Type A/Dysport®', 'Botulinum Toxin Type A/Botox®']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Wrinkles in Frontal Area,Brazilan Center for Studies in Dermatology,2025-09-01T16:18:09.633414,True,,,,NOT_FOUND,Field Effects of Two Commercial Preparations of Botulinum Toxin Type a Administered to the Frontalis Muscles,,['Wrinkles in Frontal Area'],"['Botulinum toxin type A', 'field effects', 'dose-equivalence', 'anhydrotic action halos']",,2005-05,2007-12,"[{'measure': 'Horizontal Action Halo Diameter at 28 Days', 'description': ""The colorful complex formed by Minor's test allows the visualization of the area covered by the effects of botulinum toxin on sweat glands, also known as action halos. The horizontal diameter at day 28 were expressed in centimeters and quantified by the software Mirror® (Canfield Scientific Inc., USA)."", 'timeFrame': '28 Days'}, {'measure': 'Horizontal Action Halo Diameter at 112 Days', 'description': ""The colorful complex formed by Minor's test allows the visualization of the area covered by the effects of botulinum toxin on sweat glands, also known as action halos. The horizontal diameter at day 112 were expressed in centimeters and quantified by the software Mirror® (Canfield Scientific Inc., USA)."", 'timeFrame': '112 days'}]","[{'measure': 'ECMAP in m. Frontialis', 'description': 'The measurement of the ECMAP(Evoked Compound Muscle Action Potentials) used surface electrodes on the forehead and electrical stimulation of the facial nerve, according to standard neurophysiological procedures. The amplitude of the ECMAP in the m. frontalis on stimulation of the facial nerve was performed by an experienced neurologist. ECMAP was assessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).', 'timeFrame': '28 days'}, {'measure': 'ECMAP in m. Frontialis', 'description': 'The measurement of the ECMAP(Evoked Compound Muscle Action Potentials) used surface electrodes on the forehead and electrical stimulation of the facial nerve, according to standard neurophysiological procedures. The amplitude of the ECMAP in the m. frontalis on stimulation of the facial nerve was performed by an experienced neurologist. ECMAP was assessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).', 'timeFrame': '112 days'}]",4.0,18 Years,60 Years,FEMALE,True,OTHER,0.0,29.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02974374,Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects,PF-06835919,['PF-06835919'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Non-alcoholic Fatty Liver Disease,Pfizer,2025-09-01T16:18:09.635038,True,,,,NOT_FOUND,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects",,['Non-alcoholic Fatty Liver Disease'],[],,2016-10,2017-01,"[{'measure': 'Number of Subjects experiencing an Adverse Event', 'description': 'Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements. Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.', 'timeFrame': 'Screening up to 28 days after last dose of study medication'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax) for PF-06835919', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Time to Reach Maximum Observed Concentration for PF-06835919', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06835919', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06835919', 'description': 'AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity).', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Plasma Decay Half-Life (t1/2) for PF-06835919 (as permitted)', 'description': 'Plasma Decay Half-Life (t1/2)', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Apparent Total Body Clearance (CL/F) for PF-06835919 (as permitted)', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after apparent total body clearance is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}, {'measure': 'Apparent Volume of Distribution (Vz/F) for PF-06835919 (as permitted)', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'timeFrame': '0, 0.33, 1, 2, 3, 4, 5, 6, 8,10, 12, 16, 24, and 48 hours post dose'}]",8.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03306446,Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab,Start adalimumab in monotherapy,"['Start adalimumab in monotherapy', 'begin humira in monotherapie in Early crohn disease patient']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,CD,Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives,2025-09-01T16:18:09.641061,True,,,,NOT_FOUND,Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab,,['CD'],[],,2015-03-17,2025-03,"[{'measure': 'Sustained deep remission rate', 'description': 'Number of patients with sustained deep remission at one year', 'timeFrame': '12 months'}]","[{'measure': '2-year deep remission rate', 'description': 'Number of patients with 2-year deep remission rate among patients who did not achieve 1-year remission', 'timeFrame': '2 years'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,203.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02390375,Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia,DW-0929,"['DW-0929', 'Rosuvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hypercholesterolemia,"Daewon Pharmaceutical Co., Ltd.",2025-09-01T16:18:10.918970,True,,,,NOT_FOUND,,,['Hypercholesterolemia'],[],,2014-11,2016-05,"[{'measure': 'LDL-C level', 'timeFrame': '8 weeks'}]",[],1.0,19 Years,,ALL,False,INDUSTRY,0.0,348.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02448290,"Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy",docetaxel plus selumetinib,['docetaxel plus selumetinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gastric Adenocarcinoma,Samsung Medical Center,2025-09-01T16:18:23.454306,True,,,,NOT_FOUND,"Phase II, Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy",,['Gastric Adenocarcinoma'],"['gastric adenocarcinoma patients with low/high MEK signature,']",,2014-11-12,2018-05-17,"[{'measure': 'response rate', 'timeFrame': '24 weeks'}]","[{'measure': 'duration of response', 'timeFrame': '24 weeks'}, {'measure': 'disease control rate', 'timeFrame': '8weeks'}, {'measure': 'overall survival', 'timeFrame': 'up to 100weeks'}, {'measure': 'progression-free survival', 'timeFrame': 'up to 100weeks'}, {'measure': 'safety assessed by safety( AEs/SAEs)', 'description': 'The following parameters will be recorded for each ECG: date and time of ECG, heart rate (beats/min), QT (ms), QTcB (ms), sinus rhythm (yes/no), and overall evaluation (normal/abnormal)', 'timeFrame': 'up to 100weeks'}]",6.0,20 Years,,ALL,False,OTHER,0.0,25.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02213861,"Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma",SHAPE,"['SHP-141', 'SHAPE']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Cutaneous T-Cell Lymphoma (CTCL),TetraLogic Pharmaceuticals,2025-09-01T16:18:07.026853,True,,,,NOT_FOUND,"A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma",,['Cutaneous T-Cell Lymphoma (CTCL)'],"['CTCL', 'Cutaneous T-Cell Lymphoma', 'Early-stage', 'SHAPE', 'SHP-141', 'topical', 'Histone deacetylase inhibitor', 'CAILS', 'mSWAT', 'mycosis fungoides']",,2014-11,2016-10,"[{'measure': 'Lesion severity using CAILS (Composite Assessment of Index Lesion Severity)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks thereafter for patients who continue on study (up to 52 weeks).'}]","[{'measure': 'modified Severity Weighted Assessment Tool (mSWAT)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks therafter for patients who continue on study (up to 52 weeks).'}, {'measure': 'Patient assessment of pruritis using a Visual Analog Scale (VAS)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks thereafter for patients who continue on study (up to 52 weeks).'}, {'measure': 'Skindex-29 Quality of Life Tool', 'timeFrame': 'Every 4 weeks for 26 weeks'}, {'measure': 'modified Composite Assessment of Index Lesion Severity (CAILS)', 'timeFrame': 'Every 4 weeks for 26 weeks and every 4 weeks therafter for patients who continue on study (up to 52 weeks).'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01120730,Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury,fluid resuscitation,"['fluid resuscitation', 'Fluid resuscitation']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Survival,University of Zurich,2025-09-01T16:18:13.425577,True,,,,NOT_FOUND,Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury,,"['Survival', 'Renal Failure']",[],,1997-04,2009-03,"[{'measure': 'Intensive care unit mortality', 'description': '28 days', 'timeFrame': '28 days'}]","[{'measure': 'fluid amount during the first 72 hours', 'description': 'Fluid resuscitation after burn', 'timeFrame': '28 days'}]",2.0,18 Years,80 Years,ALL,False,OTHER,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05470595,A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung,Atezolizumab,['Atezolizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Large Cell Neuroendocrine Carcinoma of the Lung,Technische Universität Dresden,2025-09-01T16:18:10.917838,True,,,,NOT_FOUND,"A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung",,['Large Cell Neuroendocrine Carcinoma of the Lung'],"['Lung Cancer', 'LCNEC', 'Neuroendocrine Carcinoma']",,2022-01-18,2029-01-31,"[{'measure': 'Overall survival', 'description': 'To assess the efficacy of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC as measured by overall survival.', 'timeFrame': 'appr. 72 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'According to RECIST v1.1 as assessed by local investigator.', 'timeFrame': 'appr. 72 months'}, {'measure': 'Immune Objective Response Rate (iORR)', 'description': 'According to iRECIST as assessed by local investigator.', 'timeFrame': 'appr. 72 months'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'According to RECIST v1.1 as assessed by local investigator.', 'timeFrame': 'appr. 72 months'}, {'measure': 'Progression Free Survival (PFS)', 'timeFrame': 'appr. 72 months'}, {'measure': 'Immune Progression Free Survival (iPFS)', 'timeFrame': 'appr. 72 months'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': 'appr. 72 months'}, {'measure': 'Progression Free Survival (PFS) rate at one year', 'timeFrame': '1 year'}, {'measure': 'Immune Progression Free Survival (iPFS) rate at one year', 'timeFrame': '1 year'}, {'measure': 'Overall survival at one year', 'timeFrame': '1 year'}, {'measure': 'Incidence, intensity, seriousness, relationship to Atezolizumab, and outcome of adverse events graded according to NCI CTCAE (v5.0).', 'timeFrame': 'appr. 72 months'}]",11.0,18 Years,,ALL,False,OTHER,1.0,67.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01345578,Hepatocyte Transplantation for Liver Based Metabolic Disorders,human hepatocyte transplantation,"['hepatocyte transplant', 'human hepatocyte transplantation']",2,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Metabolic Diseases,Ira Fox,2025-09-01T16:18:14.668805,True,,,,NOT_FOUND,Hepatocyte Transplantation for Liver Based Metabolic Disorders,,['Metabolic Diseases'],"['Urea Cycle Disorders', 'Carbamoyl-Phosphate Synthase I Deficiency Disease', 'Citrullinemia', 'Ornithine Carbamoyltransferase Deficiency Disease', 'Crigler-Najjar Syndrome']",seeking additional funding,2011-03,2022-03-31,"[{'measure': 'Improvement in enzyme physiologic function at 6 months', 'description': 'After infusing donor allogeneic hepatocytes through the portal vein following preparative hepatic irradiation, improvement in enzyme physiologic function will be assessed at 6 months.', 'timeFrame': '6 months post hepatocyte transplant'}]",[],1.0,,21 Years,ALL,False,OTHER,0.0,5.0,ACTUAL,v2_robust,True,False,True,False,seeking additional funding,,,no_match,False,,,
NCT01866007,A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants,Guselkumab (lyophilized formulation),"['Guselkumab (liquid formulation with PFS-U)', 'Guselkumab (liquid formulation with PFS FID)', 'CNTO1959', 'Guselkumab (liquid formulation)', 'Guselkumab (lyophilized formulation)']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,"Janssen Research & Development, LLC",2025-09-01T16:18:08.346365,True,,,,NOT_FOUND,"Phase 1, Open-label, Randomized, Parallel Study to Assess the Pharmacokinetic Comparability of 2 Formulations and to Evaluate Pharmacokinetic Comparability of Guselkumab (CNTO1959) Delivered by 2 Different Devices in Healthy Subjects",,['Healthy'],"['Healthy', 'Guselkumab', 'CNTO1959', 'Pharmacokinetics', 'UltraSafe Passive Delivery System (PFS-U)', 'Prefilled syringe facilitated injection device (PFS FID)']",,2013-05-09,2013-10-09,"[{'measure': 'Maximum observed serum concentration (Cmax) of guselkumab', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Area under the curve (AUC) from time 0 to 70 days of guselkumab', 'timeFrame': 'Day 1 through Week 12'}]","[{'measure': 'Absolute bioavailability of guselkumab', 'description': 'Bioavailability will be evaluated by using formula: AUC from time zero to infinity with extrapolation of the terminal phase of SC injection divided by AUC from time zero to infinity with extrapolation of the terminal phase of IV infusion of guselkumab and multiplied by 100.', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Immunogenicity of guselkumab', 'description': 'Plasma levels of antibodies to guselkumab for evaluation of potential immunogenicity.', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Up to 12 weeks'}]",5.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,141.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02489487,"Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500",VM-1500,"['Darunavir', 'Ritonavir', 'VM-1500', 'Raltegravir']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,HIV-infection,Viriom,2025-09-01T16:18:10.929352,True,,,,NOT_FOUND,"Phase I, Drug-drug Interaction Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 When Administered Orally, in Combination With Raltegravir or Darunavir",,['HIV-infection'],[],,2014-09,2014-10,"[{'measure': 'Number of participants with treatment-related adverse events as assessed by Division of AIDS table for grading the severity of ADULT Adverse Events', 'description': 'Safety and tolerability of VM-1500 alone or in combination with raltegravir or darunavir in adult healthy subjects', 'timeFrame': '36 days'}]","[{'measure': 'Plasma concentrations of VM-1500 from Day 1 to Day 36', 'description': 'Plasma concentrations of VM-1500 given alone or in combination with raltegravir or darunavir', 'timeFrame': '36 days'}, {'measure': 'Plasma concentrations of VM1500A (active metabolite of VM1500) from Day 1 to Day 36', 'description': 'Plasma concentrations of VM-1500A alone or in combination with raltegravir or darunavir', 'timeFrame': '36 days'}]",3.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01361633,The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly,d-cycloserine,"['Sugar Pill', 'd-cycloserine', 'Placebo', 'Seromycin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Treatment,Hartford Hospital,2025-09-01T16:18:19.672888,True,,,,CHEMBL11298,The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly,,"['Treatment', 'Placebo']","['d-cycloserine', 'geriatric', 'neuropsychology', 'cognition', 'cognitive-enhancer', 'aging', 'neuropsychological functioning']",,2008-01,2009-02,"[{'measure': 'California Verbal Learning Test-II (CLVT-II)', 'description': 'The CLVT-II is an assessment of verbal learning and memory which measures recall and recognition scores, encoding strategies, learning rates and error types. A list learning task with 16 words from 4 semantic categories are read over a series of 5 list presentations. Recall is assessed after learning and at a 20-minute delay. Software produces a report that computes raw and standardized scores. Our dependent variable was the age adjusted t-score for total number of words recalled after 5 trials. A higher score indicated better recall. The maximum possible score was 80 and a minimum was 0.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without patient follow up. Scores for the experimental and control group were compared.'}]","[{'measure': 'Continuous Performance Test', 'description': 'Sustained attention was assessed using the Penn version of the Continuous Performance Test. During the CPT the participant responds to a target stimulus (e.g., the letter ""A""), while inhibiting responding to distractor stimuli. Reaction time to correct targets (true positives) was used as the dependent variable. Faster reaction times indicate better performance.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Controlled Oral Word Association Test', 'description': 'The Controlled Oral Word Association Test is a measure of the ability to orally generate words to a phonemic cue within a 60-second time interval. Age and education-adjusted t-scores were used as the dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. A higher T-score is a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Wisconsin Card Sort Test', 'description': 'The Wisconsin Card Sorting Test is a test of rule-learning and conceptual flexibility. The participant is required to learn to sort a series of cards according to one of three principles (color, form or number) based on response feedback. The age-adjusted t-score for total number of errors was used as a dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. A higher T-score is a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Trails B', 'description': 'Trails B is a measure of cognitive flexibility. The participant alternates sequencing between numbers and letters. An age and education-adjusted t-score for time to complete the exercise was used as the dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. A higher T-score is a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Stroop', 'description': 'The Stroop Color Word Test is a measure of selective attention and cognitive flexibility. This measure consists of three conditions: word reading, color naming and color-word naming. The interference score (t-score) was used as the dependent variable. A T-score of 50 is equal to the mean, with a standard deviation of 10 points. Higher t-scores represent a more favorable outcome.', 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}, {'measure': 'Implicit Memory Task', 'description': ""Participants were presented with 32 stimulus words: 16 neutral and 16 threatening words. After a filler task (crossing out 8's on a sheet of randomized numbers) participants completed a response sheet including the stems for the 32 words presented to participants (primed words) along with stems for the 32 unprimed words. Participants were instructed to write down the first word that came to mind that completes each word stem. The priming effect was determined using the difference score between the correct number of stem completions for primed versus unprimed words. This is a value determined for each participant using the following equation: correct number of stem completions for primed word minus the correct number of stem completions for unprimed words. A larger difference score indicates a stronger implicit memory."", 'timeFrame': 'Outcome measures will be collected during a single neuropsychological testing administration lasting approximately 3 hours without further patient follow-up'}]",7.0,60 Years,,ALL,True,OTHER,0.0,51.0,ACTUAL,v2_robust,True,True,False,False,,N[C@@H](CO)C(=O)O,CHEMBL11298,partial_match,True,105.09,-1.61,3.0
NCT00005795,Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia,arsenic trioxide,['arsenic trioxide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Leukemia,Northwestern University,2025-09-01T16:18:10.917880,True,,,,NOT_FOUND,"Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old",,['Leukemia'],"['recurrent adult acute myeloid leukemia', 'untreated adult acute myeloid leukemia', 'adult acute erythroid leukemia (M6)', 'adult acute myeloblastic leukemia without maturation (M1)', 'adult acute myeloblastic leukemia with maturation (M2)', 'adult acute myelomonocytic leukemia (M4)', 'adult acute monoblastic leukemia (M5a)', 'adult acute megakaryoblastic leukemia (M7)', 'secondary acute myeloid leukemia', 'adult acute monocytic leukemia (M5b)', 'adult acute minimally differentiated myeloid leukemia (M0)']",,2000-02,2002-07,[],[],0.0,16 Years,,ALL,False,OTHER,1.0,11.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02796105,Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors,Progevera,"['Progevera', 'Orgalutran']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Infertility,Fundació Privada Eugin,2025-09-01T16:18:18.428865,True,,,,NOT_FOUND,Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors,,['Infertility'],[],,2016-06,2017-07-10,"[{'measure': 'donor ovarian response', 'timeFrame': '1 month'}]",[],1.0,18 Years,35 Years,FEMALE,False,OTHER,0.0,232.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01023490,Vitamin D Treatment to Patients Suffering From Chronic Pain and Vitamin D Hypovitaminosis,Vitamin D,"['Vitamin D', 'Placebo']",2,INTERVENTIONAL,['NA'],,COMPLETED,Back Pain,Tel-Aviv Sourasky Medical Center,2025-09-01T16:18:14.676399,True,,,,NOT_FOUND,"A Randomised, Double-blind, Placebo-controlled Study to Check Whether Vitamin D Will Lead to a Decrease in Pain Intensity in Patients Suffering From Chronic Pain and Hypovitaminosis D",,"['Back Pain', 'Hypovitaminosis D']","['back pain', 'hypovitaminosis D']",,2010-01,2012-10,"[{'measure': 'The objective of this study is to check whether vitamin D will lead to a decrease in pain intensity compare to placebo, in patients suffering from chronic pain.', 'timeFrame': 'one year'}]",[],1.0,18 Years,90 Years,ALL,False,OTHER_GOV,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05692180,"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)",Benralizumab,"['Benralizumab', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Asthma,AstraZeneca,2025-09-01T16:18:09.639299,True,,,,NOT_FOUND,Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA),,['Asthma'],"['Eosinophilic asthma', 'Pediatric Patients', 'Severe asthma']",,2023-04-05,2032-05-16,"[{'measure': 'Time to first asthma exacerbation', 'description': 'The effect of benralizumab on asthma exacerbations in paediatric and adolescent patients with uncontrolled asthma will be evaluated.', 'timeFrame': 'From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period'}]","[{'measure': 'Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA)', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in Asthma symptom score', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in rescue medication use', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in night-time awakenings due to asthma', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in peak expiratory flow (PEF)', 'description': 'The effect of benralizumab on asthma control and symptoms will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Serum benralizumab trough concentration', 'description': 'The pharmacokinetics of benralizumab will be characterised.', 'timeFrame': 'During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period'}, {'measure': 'Anti-benralizumab antibodies', 'description': 'The immunogenicity of benralizumab will be characterised.', 'timeFrame': 'During Day -7, Day 56, Day 112, every 16 weeks and at EOT DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score', 'description': 'The effect of benralizumab on asthma health-related quality of life will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)', 'description': 'The effect of benralizumab on pulmonary function (FEV1) will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1', 'description': 'The effect of benralizumab on pulmonary function (FEV1) will be assessed.', 'timeFrame': 'From Baseline (Week 0) to EOT in DB treatment period'}, {'measure': 'The Annualised asthma exacerbation rate (AAER) in the DB treatment period', 'description': 'The asthma exacerbations reported during the DB treatment period of the study will be described.', 'timeFrame': 'From Screening until the EOT double blind treatment period'}]",12.0,6 Years,18 Years,ALL,False,INDUSTRY,1.0,200.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03059381,Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures,Fycompa,['Fycompa'],1,OBSERVATIONAL,[],,COMPLETED,Partial Seizures (With or Without Secondary Generalized Seizures),"Eisai Co., Ltd.",2025-09-01T16:18:13.424489,True,,,,NOT_FOUND,Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures,,"['Partial Seizures (With or Without Secondary Generalized Seizures)', 'Primary Generalized Tonic-clonic Seizures']","['adolescent epilepsy participants', 'partial seizures', 'primary generalized Tonic-clonic seizures']",,2016-08-01,2021-03-21,"[{'measure': 'Number of participants with any serious adverse event', 'timeFrame': 'from 0 to 104 weeks'}, {'measure': 'Number of participants with any non-serious adverse event', 'timeFrame': 'from 0 to 104 weeks'}]","[{'measure': 'Number of participants experiencing seizures', 'timeFrame': 'from 0 to 104 weeks'}, {'measure': 'Overall improvement rating in seizure frequency', 'timeFrame': 'from 0 to 104 weeks'}]",4.0,12 Years,17 Years,ALL,False,INDUSTRY,0.0,519.0,ACTUAL,v2_robust,False,True,False,True,,,,no_match,False,,,
NCT02226185,Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence,Berberine hydrochloride,"['Berberine hydrochloride', 'placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Colorectal Adenoma,Shanghai Jiao Tong University School of Medicine,2025-09-01T16:18:23.446878,True,,,,NOT_FOUND,"A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas",,['Colorectal Adenoma'],[],,2014-11,2018-12-29,"[{'measure': 'Recurrence rates of CRA', 'description': 'The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after Berberine hydrochloride or placebo intervention.', 'timeFrame': 'until the last patient reached the 2 years follow-up'}]","[{'measure': 'The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer', 'description': 'The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer after Berberine hydrochloride or placebo intervention', 'timeFrame': 'until the last patient reached the 2 years follow-up'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,1108.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01176318,Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD),Erdosteine,"['Erdosteine', 'erdotin', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Chronic Obstructive Pulmonary Disease,Hull University Teaching Hospitals NHS Trust,2025-09-01T16:18:12.180676,True,,,,NOT_FOUND,"A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)",,['Chronic Obstructive Pulmonary Disease'],"['cough', 'exacerbation', 'quality of life']",grant was withdrawn no financial support to conduct the study.,2010-08-10,2012-01-13,"[{'measure': '24 hr cough recording', 'description': 'The primary objective is to evaluate the effectiveness of standard care plus erdosteine in reducing hourly cough (24 hour cough recording using automated cough recorder) measureing differerrence in hourly cough rate from baseline (Day 0) and Day 5 of treatment, compared with standard care plus placebo', 'timeFrame': '5 days'}]","[{'measure': 'Quality of life questionnaire', 'description': 'QOL questionnaire score,Compare differece in scores recorded at baseline (day 0) and day 10, compare the difference between erdosteine plus standard care with that of standard care plus placebo.', 'timeFrame': '10 days'}]",2.0,40 Years,80 Years,ALL,False,OTHER_GOV,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,grant was withdrawn no financial support to conduct the study.,,,no_match,False,,,
NCT00240474,A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study),Telmisartan 80 mg + hydrochlorothiazide 12.5 mg,"['Amlodipine 10 mg + hydrochlorothiazide 12.5 mg', 'Telmisartan 80 mg + hydrochlorothiazide 12.5 mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypertension,Boehringer Ingelheim,2025-09-01T16:18:23.453594,True,,,,CHEMBL435,"A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)",,['Hypertension'],[],,2002-12,2004-03,"[{'measure': 'Change from baseline in the last 6-hour mean (relative to dose time) in SBP as measured by 24-hour ABPM at the end-of-study visit', 'timeFrame': '14 weeks'}]","[{'measure': 'Change from baseline in DBP in the last six hours of the 24-hour dose period', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline in pulse pressure (PP) in the last six hours of the 24-hour dose period', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline SBP and DBP for other time intervals ( i.e. 24-hour mean, morning mean (06:00-11:59), daytime mean (06:00-21:59), and night-time mean (22:00-05:59))', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline in patient HRQL as measured by the Psychological General Well-Being (PGWB) index.', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline in SBP in the last six hours of the 24-hour dose period (as measured by 24-hour ABPM).', 'timeFrame': '8 weeks'}, {'measure': 'Proportion of patients achieving a target response in SBP', 'timeFrame': '14 weeks'}, {'measure': 'Proportion of patients achieving SBP control', 'timeFrame': '14 weeks'}, {'measure': 'Proportion of patients achieving normal blood pressure', 'timeFrame': '14 weeks'}, {'measure': 'Proportion of patients achieving high-normal blood pressure', 'timeFrame': '14 weeks'}, {'measure': 'Change from baseline in trough seated SBP', 'timeFrame': '14 weeks'}, {'measure': 'Change from baseline in trough seated DBP', 'timeFrame': '14 weeks'}, {'measure': 'Safety and tolerability of the combination of telmisartan 80 mg and HCTZ 12.5 mg compared with amlodipine 10 mg and HCTZ 12.5 mg', 'timeFrame': '14 weeks'}]",13.0,60 Years,,ALL,False,INDUSTRY,0.0,1000.0,,v2_robust,True,True,False,True,,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,CHEMBL435,partial_match,True,297.75,-0.35,4.0
NCT04044937,Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms,F-18 Fluoroethyltyrosine (FET),"['Fluoroethyltyrosine F18', 'O-(2[F18]fluoroethyl)-L-tyrosine', ""Fluorine-18 2''-Fluoroethyl-L-tyrosine"", '[18F]-Fluoro-ethyl-L-tyrosine', ""2''-[F18] Fluoro-ethyl-L-tyrosine"", 'F-18 Fluoroethyltyrosine (FET)', '18FET', '18F-FET']",8,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Intracranial Neoplasm,Thomas Hope,2025-09-01T16:18:13.420694,True,,,,CHEMBL925,Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm,,"['Intracranial Neoplasm', 'Low Grade Glioma', 'Recurrent Glioblastoma', 'Recurrent World Health Organization (WHO) Grade II Glioma', 'Recurrent WHO Grade III Glioma']",[],,2018-10-29,2024-03-31,"[{'measure': 'Misclassification rate for either having recurrent disease or not having recurrent disease for patients previously treated for glial and metastatic disease (Population 1)', 'description': 'Radiologists will classify lesions as having recurrent disease or not having recurrent disease. True Positives (TP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates tumor recurrence in at least one biopsy sample, False positives (FP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates negative tumor recurrence in all of the biopsy samples, True negatives (TN) are defined as an FET PET read as negative for tumor and pathology/follow-up also negative tumor recurrence in all of the biopsy samples and a false negative (FN) is defined as an FET PET read as negative for tumor and pathology/follow-up demonstrates tumor recurrence in at least one biopsy sample. Misclassification rate = \\[FP+FN)\\]/\\[FP+FN+TP+TN\\]', 'timeFrame': 'Up to 6 months'}, {'measure': 'Misclassification rate for either high grade or low grade in patients with suspected neoplasms (Population 2)', 'description': 'Readers will have access only to FET PET images for participants with suspected glial neoplasms (Grade 2-4) planning to undergo biopsy or surgery prior to primary treatment during evaluation and will grade the lesions in a binary fashion as having Grade II glial neoplasms or having Grade III/IV glial neoplasms. True positive (TP2): FET PET read as positive for Grade III/IV neoplasm, pathology demonstrates Grade III/IV neoplasm. False positive (FP2): FET PET read as positive for Grade III/IV neoplasm, pathology demonstrates Grade II neoplasm. True negative (TN2): FET PET read as positive for Grade II neoplasm, pathology demonstrates Grade II neoplasm. False negative (FN2): FET PET read as positive for Grade II neoplasm, pathology demonstrates Grade III/IV neoplasm. Misclassification rate = \\[FP2+FN2\\]/\\[FP2+FN2+TP2+TN2\\]', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Binary characterization of follow-up imaging as positive/negative for tumor recurrence', 'description': 'Participants with available histology (performed within 4 weeks of FET scans) or follow-up imaging (performed within 6 months of FET scan) will be included and a composite truth standard for recurrence or treatment-related changes will be evaluated for each case. In the absence of pathology, the composite truth standard will use available clinical information to make a determination. Positive for tumor recurrence on follow-up imaging will be based on Response assessment in neuro-oncology criteria (RANO) criteria reads. Follow-up imaging has to be performed within six months of the FET PET imaging study to be considered for evaluation. Additionally, the composite truth standard may consider tumor board notes and subsequent management of the patient to make a determination.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Misclassification rate for FET PET in the evaluation of recurrent low-grade gliomas (Population 1)', 'description': 'Low-grade glioma is defined by low uptake of FET. Radiologists will classify lesions based on imaging as either having recurrent disease or not having recurrent disease. True Positives (TP1L) are defined as an FET PET read positive for low-grade tumor and pathology/follow-up demonstrates low-grade tumor recurrence in at least one biopsy sample, False positives (FP1L) are defined as an FET PET read positive for low grade tumor recurrence and pathology/follow-up demonstrates negative low-grade tumor recurrence in all of the biopsy samples, True negatives (TN1L) are defined as an FET PET read as negative for low-grade tumor recurrence and pathology/follow-up also negative for low grade tumor recurrence in all of the biopsy samples and a false negative (FN1L) is defined as an FET PET read as negative for low grade tumor recurrence and pathology/follow-up demonstrates low grade tumor recurrence in at least one biopsy sample. Misclassification rate = \\[FP1L+FN1L)\\]/\\[FP1L+FN1L+TP1L+TN1L\\]', 'timeFrame': 'Up to 6 months'}, {'measure': 'Degree of inter-rater reliability for tracer uptake', 'description': ""Fleiss' kappa statistic will be used to determine the agreement between the assessment of FET-PET tumor targeting (tracer uptake in target lesion: yes/ no), as assessed by three independent blinded readers. Scores range from 0 to 1 with higher scores indicating a great degree of agreement"", 'timeFrame': 'Up to 6 months'}, {'measure': 'Degree of inter-rater reliability for radiological interpretations', 'description': ""Cohen's kappa statistics will be used to determine the reproducibility of the assessment by individual readers when analyzing the same data repeatedly and measures the agreement between two raters who each classify items into mutually exclusive categories."", 'timeFrame': 'Up to 6 months'}]",6.0,3 Years,,ALL,False,OTHER,0.0,143.0,ACTUAL,v2_robust,True,True,False,False,,N[C@@H](Cc1ccc(O)cc1)C(=O)O,CHEMBL925,partial_match,True,181.19,0.35,4.0
NCT00607542,Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity,baclofen,"['baclofen', 'Lioresal']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Spasticity,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2025-09-01T16:18:07.027492,True,,,,CHEMBL2107312,Pediatric Pharmacokinetic and Pharmacodynamic Study of Oral Baclofen for the Treatment of Spasticity Associated With Cerebral Palsy,,"['Spasticity', 'Cerebral Palsy']","['spasticity', 'cerebral palsy', 'baclofen', 'pharmacokinetics', 'pharmacodynamics', 'dosing', 'safety', 'efficacy']",,2008-11,2011-01,"[{'measure': 'Determine pharmacokinetic parameters of oral baclofen in children with spasticity associated with cerebral palsy (CP).', 'timeFrame': '1 year'}, {'measure': 'Describe the relationship between plasma concentrations of oral baclofen and clinical measures of spasticity.', 'timeFrame': '1 year'}, {'measure': 'Determine optimal dosing range and interval for administration of oral baclofen for use in a randomized clinical trial of safety and efficacy.', 'timeFrame': '1 year'}]","[{'measure': 'Describe the relationship between plasma concentrations of oral baclofen and measures of strength, function, ease of care, pain/comfort and health related quality of life.', 'timeFrame': '1 year'}, {'measure': 'Describe the safety and tolerability of oral baclofen in children with spasticity associated with CP.', 'timeFrame': '1 year'}, {'measure': 'Investigate preliminarily whether oral baclofen improves dystonia', 'timeFrame': '1 year'}]",6.0,2 Years,16 Years,ALL,False,NIH,0.0,61.0,ACTUAL,v2_robust,True,True,False,True,,CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C,CHEMBL2107312,partial_match,True,399.87,3.81,3.0
NCT04893148,Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes,IGlarLixi,"['Dulaglutide', 'IGlarLixi', 'Insulin Glargine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Type 2 Diabetes Mellitus,Chungbuk National University Hospital,2025-09-01T16:18:12.172916,True,,,,NOT_FOUND,Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy,,"['Type 2 Diabetes Mellitus', 'Glucose, High Blood']","['IGlarLixi', 'Dulaglutide', 'Continuous glucose monitoring system', 'Type 2 diabetes mellitus']",,2020-05-26,2022-12-30,"[{'measure': 'Changes in glycated hemoglobin (HbA1c)', 'description': 'HbA1c will be measured at baseline and week 12', 'timeFrame': 'Baseline, week 12'}]","[{'measure': 'Changes in fasting plasma glucose (FPG)', 'description': 'Comparison of FPG changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in glucose time in range (TIR)', 'description': 'Comparison of %TIR changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in glucose time above range (TAR)', 'description': 'Comparison of %TAR changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in glucose time below range (TBR)', 'description': 'Comparison of %TBR changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Incidence of hypoglycemia', 'description': 'Comparison of the incidence of hypoglycemia between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in weight', 'description': 'Comparison of weight changes in week 12 from baseline between the two', 'timeFrame': 'Baseline, week 12'}]",7.0,18 Years,,ALL,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05261139,EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease,nirmatrelvir,"['nirmatrelvir', 'ritonavir']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,COVID-19,Pfizer,2025-09-01T16:18:13.422179,True,,,,NOT_FOUND,"A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE",,['COVID-19'],"['Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)', 'Pediatrics']",,2022-03-07,2026-07-30,"[{'measure': 'Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir', 'timeFrame': 'Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose'}, {'measure': 'Cohort 1-2: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir', 'timeFrame': 'Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose'}, {'measure': 'Incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuations.', 'timeFrame': 'From Baseline up through Day 34'}, {'measure': 'Incidence of Serious Adverse Events (SAEs) leading to discontinuations.', 'timeFrame': 'From Baseline up through Day 34'}, {'measure': 'Incidence of Adverse Events (AEs) leading to discontinuations.', 'timeFrame': 'From Baseline up through Day 34'}, {'measure': 'Number of participants with change from Baseline in Vital Signs', 'timeFrame': 'From Baseline up through Day 34'}]","[{'measure': 'Viral load assessment titers measured via reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal or nasal swabs over time', 'timeFrame': 'Baseline, Day 5, 6, 10, 14 and 28'}, {'measure': 'Proportion of participants with COVID-19 related hospitalization or death from any cause', 'timeFrame': 'From Baseline through Day 28'}, {'measure': 'Patient assessment on acceptability and palatability of nirmatrelvir/ritonavir (film-coated tablets and oral powder)', 'description': 'Frequency of responses to visual questionnaire on taste.', 'timeFrame': 'At baseline only for tablets and after each dose for powder formulation'}]",9.0,0 Years,17 Years,ALL,False,INDUSTRY,0.0,160.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05442411,Regional Scalp Block Versus IV Parecoxib for Post-operative Cranioplasty Surgery Pain: A Comparison of Pain Score.,Ropivacaine 0.75% Injectable Solution,"['Ropivacaine 0.75% Injectable Solution', 'parecoxib 40mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Postoperative Pain,Universiti Sains Malaysia,2025-09-01T16:18:08.347717,True,,,,NOT_FOUND,Regional Scalp Block Versus IV Parecoxib for Post-operative Cranioplasty Surgery Pain: A Comparison of Pain Score.,,['Postoperative Pain'],[],,2021-03-09,2022-03-30,"[{'measure': 'pain score', 'description': 'visual analog score', 'timeFrame': '12 hours'}]","[{'measure': 'total morpine requirement', 'description': 'PCA post operatively', 'timeFrame': '12 hours'}]",2.0,18 Years,60 Years,ALL,True,OTHER,0.0,58.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01949610,"A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants",14C-JNJ26489112,['14C-JNJ26489112'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Participants,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:18.417057,True,,,,NOT_FOUND,"Absorption, Metabolism, and Excretion of 14C-JNJ26489112 After a Single Oral Dose in Healthy Male Subjects",,['Healthy Participants'],"['Healthy Participants', 'JNJ26489112', '14C-JNJ26489112', 'Absorption', 'Metabolism', 'Excretion']",,2010-01,2010-03,"[{'measure': 'Pharmacokinetics of 14C-JNJ-26489112 in plasma', 'timeFrame': '240 hours'}, {'measure': 'Mass balance after an oral dose of 14C-JNJ-26489112 as generated from recovery of total radioactivity excreted in urine and feces', 'timeFrame': '240 hours'}, {'measure': 'Routes of 14C-JNJ-26489112 elimination measured through total radioactivity concentrations in urine and feces', 'timeFrame': '240 hours'}, {'measure': 'Whole blood and plasma partitioning of total radioactivity through measurement of total radioactivity levels in blood', 'timeFrame': '240 hours'}, {'measure': 'Identification of major metabolites in plasma, urine, and feces', 'timeFrame': '240 hours'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Up to Day 15'}, {'measure': 'Number of participants with a suicide-related outcome', 'description': 'Suicide related outcome measures will be assessed by using Columbia-Suicide Severity Rating Scale (C-SSRS). By using the C-SSRS, potential suicide-related events will be categorized using the codes defined by the Columbia Classification Algorithm of Suicide Assessment from Code 0: no event that can be assessed based on the C-SSRS to Code 9: not enough information, nonfatal. The 4 suicide-related outcomes of interest are the following: suicidal ideation (Code 4), suicidal behavior (Codes 1 to 3), suicidal behavior or ideation (Codes 1 to 4), and possible suicidal behavior or ideation (Codes 1 to 6 and 9).', 'timeFrame': 'Screening (Days -21 to -1), Day 2 and end-of-study (Day 15)'}]",7.0,18 Years,55 Years,MALE,True,INDUSTRY,0.0,10.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00373243,A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment,GW406381,['GW406381'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pain,GlaxoSmithKline,2025-09-01T16:18:14.669668,True,,,,NOT_FOUND,"An Open-label, Non-randomised Study of 20 mg GW406381 Single Dose Pharmacokinetics in Healthy Subjects and in Volunteers With Moderate Hepatic Impairment",,['Pain'],['hepatic impairment pharmacokinetics'],,2005-10-19,2006-09-26,"[{'measure': 'GW406381 pharmacokinetic parameters AUC and Cmax', 'timeFrame': 'throughout the study'}]","[{'measure': 'GW406381 pharmacokinetic parameters Tmax, Total plasma clearance, and if data permits the t1/2 of GW406381 GW404347 pharmacokinetic parameters AUC and Cmax Ex vivo protein binding Clinical laboratory values, adverse events, vital signs and 12 lead ECG', 'timeFrame': 'throughout the study'}]",2.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01478607,A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients,QUTENZA,"['QUTENZA', 'Capsaisin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Painful Diabetic Peripheral Neuropathy (PDPN),Astellas Pharma Inc,2025-09-01T16:18:13.427901,True,,,,NOT_FOUND,"A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy",,['Painful Diabetic Peripheral Neuropathy (PDPN)'],"['Painful Diabetic Peripheral Neuropathy', 'Qutenza']",,2011-11,2014-02,"[{'measure': 'Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale', 'timeFrame': 'Baseline till endpoint (discontinuation or End of Study visit) (up to 64 weeks)'}]","[{'measure': 'Neurological function as assessed by the Utah Early Neuropathy Scale (UENS) and sensory testing', 'description': 'Physicians measuring neurological function will be blinded to treatment', 'timeFrame': 'Baseline till End of Study (up to 64 weeks)'}, {'measure': 'Tolerability of patch application by dermal assessment', 'timeFrame': 'Screening till Last visit when QUTENZA patch is applied (up to 53 weeks)'}, {'measure': 'Tolerability of patch application by ""pain now"" Numeric Pain Rating Scale (NPRS) scores after patch application', 'description': 'Assessed within 15 minutes and 60 minutes after patch removal.', 'timeFrame': 'Baseline till Last visit when QUTENZA patch is applied (up to 52 weeks)'}, {'measure': 'Tolerability of patch application by rescue medication use', 'timeFrame': 'Days 1 through 5 after each patch application'}, {'measure': 'Adverse Events and serious adverse Events', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Vital Signs (heart rate and blood pressure)', 'description': 'In case of patch application to be performed within 15 minutes before topical anesthetic application and within 15 minutes after patch removal.', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Laboratory Analyses', 'description': 'The tests performed at the screening visit will include Hematology: Red Blood Cell Count, White Blood Cell Count, Lymphocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Hemoglobin, Hematocrit and Platelets. Biochemistry: Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT), Alkaline Phosphatase, Sodium, Potassium, Blood Urea Nitrogen (BUN), Creatinine and Lipid profile. Subsequent HbA1c and lipid profile follow-up will be done at bi-monthly visits. The other tests will be performed if clinically indicated.', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Intensity of neuropathic pain using ""average pain"" NPRS scores', 'description': 'Question 5 of Brief Pain Inventory-Diabetic Neuropathy (BPI-DN)', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Brief Pain Inventory (BPI) pain severity index and pain interference index', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Patient Global Impression of Change', 'timeFrame': 'After each patch re-application, from first patch re-application through End of Study visit (up to 56 weeks)'}, {'measure': 'Generic HRQOL measured by European Quality of Life - 5 Dimensions (EQ-5D) questionnaire', 'timeFrame': 'After each patch application, from first patch application through End of Study (up to 64 weeks)'}, {'measure': 'Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit', 'timeFrame': 'End of Study (up to 65 weeks)'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,468.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00810108,Lopinavir/Ritonavir (Kaletra) PK in Children,lopinavir/ritonavir (Kaletra®) tablets,"['lopinavir/ritonavir (Kaletra®) tablets', 'Kaletra®']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,HIV/AIDS Treatment,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2025-09-01T16:18:20.950516,True,,,,CHEMBL729,Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients,,"['HIV/AIDS Treatment', 'HIV Infections']","['HIV/AIDS', 'pediatrics', 'resource-limited settings', 'lopinavir', 'ritonavir', 'Kaletra®', 'antiretroviral treatment', 'crushed tablets', 'treatment experienced']",,2006-06,2009-05,"[{'measure': 'Lopinavir Area Under the Curve (AUC)', 'description': 'Lopinavir Area Under the Plasma Concentration versus Time Curve (AUC)', 'timeFrame': 'pre-dose, 1,2,4,6,8, and 12 hours post-dose'}]",[],1.0,6 Years,17 Years,FEMALE,False,NIH,1.0,12.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,CHEMBL729,partial_match,True,628.81,4.33,4.0
NCT02647424,A Comparison of Letrozole and Clomifene Citrate,Letrozole,"['Letrozole group', 'Clomiphene group', 'Clomiphene', 'Letrozole']",4,INTERVENTIONAL,['NA'],,UNKNOWN,Polycystic Ovarian Syndrome,The University of Hong Kong,2025-09-01T16:18:23.457524,True,,,,NOT_FOUND,A Comparison of Hormonal Profile and the Follicular Development Between Letrozole and Clomifene Citrate in Anovulatory Women With Polycystic Ovary Syndrome and Ovulatory Women,,"['Polycystic Ovarian Syndrome', 'Subfertility']",[],,2015-12,2017-12,"[{'measure': 'FSH concentrations', 'timeFrame': 'Alternative day during ovulation induction cycle (for about 3 month)'}]","[{'measure': 'LHconcentration', 'timeFrame': 'Alternative day during ovulation induction cycles (for about 3 month)'}, {'measure': 'Endometrial Thickness', 'timeFrame': 'Monitoring during ovulation induction cycle (for about 3 month)'}, {'measure': 'Oestradiol concentration', 'timeFrame': 'Alternative day during ovulation induction cycles (for about 3 month)'}, {'measure': 'Progesterone concentration', 'timeFrame': 'Alternative day during ovulation induction cycles (for about 3 month)'}, {'measure': 'Number of growing follicles', 'timeFrame': 'Monitoring during OI cycles (for about 3 month)'}]",6.0,18 Years,39 Years,FEMALE,False,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02798107,Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients,idarucizumab,['idarucizumab'],1,OBSERVATIONAL,[],,WITHDRAWN,Hemorrhage,Boehringer Ingelheim,2025-09-01T16:18:19.663766,True,,,,NOT_FOUND,Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study,,['Hemorrhage'],[],No recruitment,2019-05-20,2019-05-24,"[{'measure': 'Safety outcomes until hospital discharge * Incidence of thromboembolic events (ie. obstruction of a blood vessel by the formation of a thrombus - e.g. ischemic stroke, MI, DVT, PE) after administration', 'timeFrame': 'Up to 33 months'}, {'measure': 'Safety outcomes until hospital discharge * Incidence of hypersensitivity/anaphylactic reactions', 'timeFrame': 'Up to 33 months'}, {'measure': 'Safety outcomes until hospital discharge * Incidence of AE, SAE, ADR, SADR reporting', 'timeFrame': 'Up to 33 months'}, {'measure': 'Safety outcomes until hospital discharge * Cause of death and in-hospital mortality rate', 'timeFrame': 'Up to 33 months'}]","[{'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Incidence of thromboembolic events (ie. obstruction of a blood vessel by the formation of a thrombus - e.g. ischemic stroke, MI, DVT, PE) after administration', 'timeFrame': 'Up to 33 months'}, {'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Incidence of hypersensitivity/anaphylactic reactions', 'timeFrame': 'Up to 33 months'}, {'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Incidence of AE, SAE, ADR, SADR reporting', 'timeFrame': 'Up to 33 months'}, {'measure': 'Comparison of patient characteristics of paediatric patients with & without outcome events * Cause of death and in-hospital mortality rate', 'timeFrame': 'Up to 33 months'}]",8.0,,17 Years,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,False,False,True,True,No recruitment,,,no_match,False,,,
NCT01415583,Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy,Dexamethasone,"['Dexamethasone', 'Decadron']",2,INTERVENTIONAL,['NA'],,COMPLETED,Post-operative Hemorrhage,Massachusetts Eye and Ear Infirmary,2025-09-01T16:18:18.428213,True,,,,CHEMBL1530428,Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy,,['Post-operative Hemorrhage'],[],,2010-07,2011-11,"[{'measure': 'Number of Participants With Post-tonsillectomy Bleeding', 'timeFrame': '2 weeks after surgery'}]",[],1.0,3 Years,18 Years,ALL,False,OTHER,0.0,314.0,ACTUAL,v2_robust,True,True,False,False,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CHEMBL1530428,partial_match,True,434.5,2.47,4.0
NCT04260854,Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery,Bupivacaine Hydrochloride,"['Saline', 'Bupivacaine Hydrochloride']",2,INTERVENTIONAL,['PHASE1'],PHASE1,ENROLLING_BY_INVITATION,"Pain, Postoperative",Northwestern University,2025-09-01T16:18:15.899284,True,,,,NOT_FOUND,Locally Administered Bupivacaine Hydrochloride for Post-operative Pain Control in Cutaneous Surgery: a Randomized Controlled Trial,,"['Pain, Postoperative']",[],,2024-01-24,2025-06,"[{'measure': 'Reported opioid and non-opioid pain medications taken', 'description': 'Patients will report the amount of pain medications taken 3 days immediately following surgery', 'timeFrame': '3 Days Post-Surgery'}]",[],1.0,19 Years,,ALL,True,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01405651,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects",ONO-6950,['ONO-6950'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Adult Subjects,Ono Pharma USA Inc,2025-09-01T16:18:24.743829,True,,,,NOT_FOUND,"A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects",,['Healthy Adult Subjects'],"['ONO-6950', 'Healthy adult subjects']",,2011-07,,"[{'measure': 'Safety and tolerability of ONO-6950 using vital signs, pulmonary function tests ECGs, laboratory tests and physical examinations', 'timeFrame': 'At protocol-specified timepoints before and after study drug administration up to 21 days'}]","[{'measure': 'Characterization of PK ( Cmax, Tmax, AUC, ty2, etc.) and PD profiles of ONO-6950 using plasma concentration of ONO-6950 in blood and pulmonary function tests', 'timeFrame': 'At protocol-specified timepoints before and after study drug administration up to 21 days'}]",2.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00381251,Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.,Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg,['Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Postmenopausal Osteoporosis,Wyeth is now a wholly owned subsidiary of Pfizer,2025-09-01T16:18:24.744265,True,,,,NOT_FOUND,"An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Two New Formulations of 0.45 mg/1.5 mg Premarin / Medroxyprogesterone Acetate (MPA) Compared With a Reference Formulation of 0.45mg/1.5mg Premarin / MPA (Prempro™) in Healthy Postmenopausal Women.",,"['Postmenopausal Osteoporosis', 'Postmenopause']","['vaginal atrophy', 'postmenopausal osteoporosis', 'menopause', 'hot flashes']",,2006-09,2007-01,"[{'measure': 'Pharmacokinetic blood samples for unconjugated and total (unconjugated plus conjugated) estrogens and MPA will be obtained. The following pharmacokinetic parameters will be determined: Cmax, Tmax, t½, AUC0-T, AUC0-¥.'}]",[],1.0,35 Years,70 Years,FEMALE,True,INDUSTRY,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06896565,Effect of Nano Hydroxy Apatite Varnish and Potassium Nitrate Gel on the MIH-affected Permanent Teeth,nano hydroxy apatite varnish,"['Potassium Nitrate Gel', 'Ultradent UltraEZ Desensitizing Gel, Ultradent Inc., USA', ""Fygg's professional strength, Fygg, USA"", 'DentKist Charm Varnish 5% Sodium Fluoride Varnish', 'nano hydroxy apatite varnish', 'Varnishes, Fluoride']",6,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Molar Incisor Hypomineralisation,Cairo University,2025-09-01T16:18:08.345370,True,,,,NOT_FOUND,Comparative Evaluation of Three Different Topically Applied Materials as Non-invasive Treatment of Permanent Teeth With Molar Incisor Hypo-mineralization: Randomized Clinical Trial,,['Molar Incisor Hypomineralisation'],[],,2025-06-01,2026-08-01,"[{'measure': 'Dentin Hypersensitivity', 'description': 'Measured by:\n\nFace scale: scores from 0-4. the higher the score the worse the sensitivity.', 'timeFrame': 'Baseline, 15 miutes pot-op, 2 weeks post-op, and 4 weeks post op.'}, {'measure': 'Dentin Hypersensitivity', 'description': 'Measured by:\n\nSchiff Cold Air Blasting Sensitivity Scale: scores from 0-3. The higher the score the worse the sensitivity.', 'timeFrame': 'Baseline, 15 miutes pot-op, 2 weeks post-op, and 4 weeks post op.'}]","[{'measure': 'Post-eruptive enamel breakdown', 'description': 'Measured by Wurzburg Molar Incisor Hypomineralization - Treatment Need Index (MIH-TNI): ordinal scores: 1,2,3, 4a, 4b, 4c.', 'timeFrame': ': baseline, 3-, 6-, 9-, and 12- month post-op.'}, {'measure': 'Caries incidence', 'description': 'Measured by International Caries Detection and Assessment System (ICDAS II) criteria: scores from 0-6.\n\nThe higher the score the worse the caries.', 'timeFrame': 'baseline, 3-, 6-, 9-, and 12- month post-op.'}, {'measure': 'Oral hygiene', 'description': 'Measured by Plaque Control Record: Percentage.', 'timeFrame': 'baseline, 2-, and 4- week post-op.'}, {'measure': 'Oral health-related quality of life', 'description': 'Measured by: Short form Parental-Caregiver Perceptions Questionnaire (P-CPQ): from 0 -32.\n\nThe higher the score the worse the Oral Health Related Quality of Life.', 'timeFrame': 'baseline, 6-, and 12- month post-op.'}, {'measure': 'Cost Effectiveness Ratio (CER) and Incremental Cost Effectiveness Ratio (ICER', 'description': 'Measured by: Equation : CER = C / E, where C is the average direct medical cost calculated for the group, and E is the health effectiveness measure for the same group (change in hypersensitivity score).\n\nICER = (CI - CC) / (EI - EC), where CI is the average direct medical cost of the intervention group CC is the average direct medical cost in the control group, EI is the health effectiveness measure (change in hypersensitivity score) in the intervention group, and EC is the health effectiveness measure in the control group', 'timeFrame': '12-month- post-op.'}]",7.0,6 Years,10 Years,ALL,False,OTHER,0.0,48.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,Fluorouracil,"['Folinate Calcium', 'Tonofolin', 'Ro-2-9757', 'Paclitaxel', '5 Fluorouracil', '5FU', 'Dalisol', 'Taxol', 'Citrec', 'Flurablastin', 'Ribofluor', 'Folinoral', 'Leucovorin Calcium', 'AccuSite', 'Calcium Folinate', '5-Fluorouracil', 'Rescuvolin', 'Citofolin', 'Irinotecan Hydrochloride Trihydrate', 'Taxol Konzentrat', '5-FU', 'Citrovorum Factor', 'Folaxin', 'Folinic Acid Calcium Salt Pentahydrate', 'Camptosar', 'Irinotecan Monohydrochloride Trihydrate', 'Calfolex', 'CPT-11', 'Calinat', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', 'Fluoro Uracil', 'Irinotecan', 'Divical', 'Calcium (6S)-Folinate', 'Disintox', 'Emovis', 'Fluroblastin', 'Wellcovorin', 'Leucovorin', 'Rescufolin', 'Asotax', 'Cehafolin', 'Folinic acid', 'leucovorin', 'Imo', 'Irinomedac', 'Folix', 'Camptothecin-11', 'Folidar', 'Factor, Citrovorum', 'Folaren', 'Praxel', 'Lederfolat', 'Ecofol', 'Folinac', '5 Fluorouracilum', 'Flynoken A', 'Ro 2-9757', 'U-101440E', 'Fluouracil', 'CPT 11', 'Campto', 'Bristaxol', 'Fluracil', 'Fluracedyl', '5 FU', 'Camptothecin 11', 'FOLI-cell', 'Irinotecan Hydrochloride', 'Anzatax', 'folinic acid', 'Lederfolin', 'Cromatonbic Folinico', 'Calcifolin', 'Foliben', 'Fluril', 'Carac', 'Leucosar', '5-Fluracil', 'Adinepar', 'Foliplus', 'Calcium Leucovorin', 'Fluorouracil', 'Folidan', 'Folinvit']",85,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Metastatic Small Intestinal Adenocarcinoma,SWOG Cancer Research Network,2025-09-01T16:18:14.673928,True,,,,CHEMBL566,Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma,,"['Metastatic Small Intestinal Adenocarcinoma', 'Stage III Small Intestinal Adenocarcinoma AJCC v8', 'Stage IIIA Small Intestinal Adenocarcinoma AJCC v8', 'Stage IIIB Small Intestinal Adenocarcinoma AJCC v8', 'Stage IV Small Intestinal Adenocarcinoma AJCC v8']",[],,2020-06-01,2027-08-01,"[{'measure': 'Progression free survival (PFS)', 'description': 'PFS will be assessed in all eligible and evaluable (received at least one dose of protocol therapy) patients using the Kaplan-Meier method, with statistical differences in event rates between treatment arms assessed via stratified Cox regression model.', 'timeFrame': 'From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years'}]","[{'measure': 'Overall survival (OS)', 'description': 'Probabilities of OS will be estimated using the method of Kaplan-Meier, with statistical differences in event rates between treatment arms assessed via stratified Cox regression model.', 'timeFrame': 'From date of registration to date of death due to any cause, assessed up to 3 years'}, {'measure': 'Overall response rate', 'description': 'Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be compared across treatment arms via chi-square tests.', 'timeFrame': 'Up to 3 years after registration'}, {'measure': 'Incidence of adverse events', 'description': 'Will be compared across treatment arms via chi-square tests.', 'timeFrame': 'Up to 3 years after registration'}]",4.0,18 Years,,ALL,False,NETWORK,1.0,94.0,ESTIMATED,v2_robust,True,False,False,True,,O=c1cc[nH]c(=O)[nH]1,CHEMBL566,partial_match,True,112.09,-0.94,3.0
NCT06371807,Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab,Pembrolizumab injection,"['Paclitaxel', 'Pembrolizumab injection', 'Carboplatin', 'Cyclophosphamide', 'Doxorubicin or Epirubicin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Early Breast Cancer,Fundacao Champalimaud,2025-09-01T16:18:19.663558,True,,,,NOT_FOUND,"Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline Versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR",,"['Early Breast Cancer', 'Triple Negative Breast Cancer']",[],,2024-07,2026-12,"[{'measure': 'Detect immunologic activation signal and the immunologically defined most suitable patient population for the synergistic interaction between pembrolizumab and chemotherapy backbone', 'description': 'Compare signals of immunological activation or a more favorable immunological context beetween T cell subpopulations and transcriptional changes of T cell populations infiltrating tumors at baseline and C2D1', 'timeFrame': 'At the end of cycle 1 (each cycle is 28 days)'}, {'measure': 'Rate of pCR', 'description': 'Compare the rate of pCR in subjects with locally advanced TNBC with TILs ≥ 10% in arm A and arm B at cycle 4', 'timeFrame': '6 months to one year after subject inclusion'}, {'measure': 'Primary translational endpoint', 'description': 'Quantification of number of T cells per mm2 with different phenotypes using fate bifurcation as defined as the proportion of TILs with the phenotype T-bet(hi) PD1(mid) CD8+.', 'timeFrame': '6 months to one year after subject inclusion'}]","[{'measure': 'Changes in the immunogenic phenotype', 'description': 'Determine changes in the immunogenic phenotype by longitudinally evaluating RNA-based gene expression signatures (e.g., tumor inflammation signature expression of granzyme A \\[GZMA\\] and perforin 1 at baseline and at C2D1.', 'timeFrame': '6 months to one year after subject inclusion'}, {'measure': 'Incidence of treatment relatred Adverse events', 'description': 'Describe the safety and tolerability of the combinations of pembrolizumab plus chemotherapy (either EC/AC or paclitaxel + carboplatin) in the Neoadjuvant and Adjuvant setting throught the CTCAE version 5.0 adverse event evaluation', 'timeFrame': '6 months to one year after subject inclusion'}]",5.0,18 Years,100 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02217813,A Bioequivalence Study Comparing Two Different Tafamidis Formulations,Tafamidis,"['Tafamidis', 'Vyndaqel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Pfizer,2025-09-01T16:18:12.182538,True,,,,NOT_FOUND,"A Phase 1, Open-label, Randomized, Crossover, Single Dose Study To Determine The Bioequivalence Of Pf-06291826 (Tafamidis) 20 Mg Capsule Manufactured By Catalent Versus Capsule Manufactured By Pii In Healthy Subjects Under Fasted Conditions",,['Healthy Volunteers'],[],,2014-10,2014-11,"[{'measure': 'Area under the Concentration-Time Curve (AUC)', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.', 'timeFrame': '168 hours'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '168 hours'}]","[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]', 'description': 'AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)', 'timeFrame': '168 hours'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '168 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '168 hours'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '168 hours'}]",6.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01170780,Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair,Dexamethasone,"['Saline', 'Natriumchlorid, B. Braun 9 mg/ml', 'Dexamethasone', 'Fortecontin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Inguinal Hernia,Mette Astrup Madsen,2025-09-01T16:18:15.893540,True,,,,CHEMBL1530428,Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair,,"['Inguinal Hernia', 'Femoral Hernia']","['Inguinal hernia', 'Transabdominal preperitoneal hernia repair', 'TAPP', 'Dexamethasone', 'Pain']",,2010-08,2011-08,"[{'measure': 'pain during coughing', 'description': 'Assessed with visual analog scale (VAS 0-100 mm)', 'timeFrame': 'day 1'}]","[{'measure': 'pain during coughing', 'description': 'Assessed with VAS', 'timeFrame': '4 days'}, {'measure': 'pain at rest', 'description': 'Assessed with VAS', 'timeFrame': '4 days'}, {'measure': 'convalescence', 'description': 'Registration of number of days after operation before returning to work and recreational activities.', 'timeFrame': '1 month'}, {'measure': 'pain at rest', 'description': 'Assessed with verbal rating scale (VRS:no pain, mild pain, severe pain, worst thinkable pain)', 'timeFrame': '4 days'}, {'measure': 'nausea', 'description': 'Assessed with verbal rating scale (VRS: no nausea, mild nausea, severe nausea, worst thinkable nausea)', 'timeFrame': '2 days'}, {'measure': 'vomiting', 'description': 'yes/no question. If yes, how many times have you been vomiting?', 'timeFrame': '2 days'}, {'measure': 'discomfort', 'description': 'Assessed with visual analog scale (VAS, 0-100 mm)', 'timeFrame': '4 days'}, {'measure': 'fatigue', 'description': 'Assessed with numeric rating scale (NRS, 1-10)', 'timeFrame': '4 days'}]",9.0,18 Years,85 Years,MALE,False,OTHER,0.0,80.0,ACTUAL,v2_robust,True,True,False,False,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CHEMBL1530428,partial_match,True,434.5,2.47,4.0
NCT04492293,An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer,ICP-192,['ICP-192'],1,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Bladder Urothelial Cancer,"Beijing InnoCare Pharma Tech Co., Ltd.",2025-09-01T16:18:22.207872,True,,,,NOT_FOUND,"A Phase 2, Multicenter, Single Arm, Open-lable Study of ICP-192 in Subjects With Surgically Unresectable or Metastatic Bladder Urothelial Cancer With FGFR Genetic Aberrations.",,['Bladder Urothelial Cancer'],[],,2020-05-27,2025-06-30,"[{'measure': 'ORR', 'description': 'Objective Response Rate', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}]","[{'measure': 'DOR', 'description': 'Duration of response', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}, {'measure': 'DCR', 'description': 'Disease Control Rate', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}, {'measure': 'PFS', 'description': 'Progression Free Survival', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 1 months'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,115.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05735197,Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients,Dapagliflozin 10mg Tab,"['control', 'Placebo', 'Dapagliflozin 10mg Tab', 'Dapagliflozin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Kidney Diseases,Mansoura University,2025-09-01T16:18:12.181852,True,,,,NOT_FOUND,Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Kidney Disease Progression and Bone Mineral Metabolism in Non-diabetic Patients With Chronic Kidney Disease,,"['Chronic Kidney Diseases', 'Bone Diseases, Metabolic']","['CKD', 'Bone mineral disease', 'SGLT2i']",,2022-09-01,2023-11-01,"[{'measure': 'Effect of dapagliflozin on CKD progression', 'description': 'effect of Dapagliflozin on eGFR (ml/min)', 'timeFrame': '1 year'}, {'measure': 'Effect of dapagliflozin on Bone', 'description': 'effect on serum levels of bone turnover markers measured by ELISA', 'timeFrame': '1 year'}, {'measure': 'Effect of dapagliflozin on minerals', 'description': 'effect of Dapagliflozin on calcium, phosphorus and magnesium', 'timeFrame': '1 year'}, {'measure': 'Effect of dapagliflozin on BMD', 'description': 'assess Bone mineral disease (BMD) by using quantitative CT (QCT)', 'timeFrame': '1 year'}]","[{'measure': 'Effect of dapagliflozin on blood pressure', 'description': 'follow up systolic and diastolic blood pressure throughout the study', 'timeFrame': '1 year'}]",5.0,18 Years,,ALL,False,OTHER,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01090492,PF-00489791 For The Treatment Of Raynaud's,PF-00489791,['PF-00489791'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Raynaud's Disease,Pfizer,2025-09-01T16:18:13.428330,True,,,,NOT_FOUND,"A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon",,"[""Raynaud's Disease"", 'Peripheral Vascular Disease']","[""Raynaud's phenomenon"", 'vasospasm', 'scleroderma', 'systemic sclerosis', 'CREST', 'phosphodiesterase inhibitor']",,2010-08-04,2011-05-31,"[{'measure': ""Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4"", 'description': ""The Raynaud's Condition score (RCS) is participant's rating of difficulty considering number of attacks, duration, amount of pain, numbness, or other symptoms caused in the fingers (including painful sores) due to the Raynaud's phenomenon every day and impact of Raynaud's alone on use of hands every day. An 11 point Likert scale is used to rate the difficulty caused by the condition each day with 0 = no difficulty and 10 = extreme difficulty. Participants were asked to select the number that best describes their difficulty, with higher score indicating worse condition. Average daily score was considered for participants completing more than 1 Raynaud's pain score scale on a day. Baseline value was calculated as mean of the scores over 7 days prior to treatment start. Week 4 value was calculated as mean of the scores over the 7-day period prior to Week 4."", 'timeFrame': 'Baseline, Week 4'}]","[{'measure': ""Change From Baseline in the Number of Raynaud's Attacks at Week 1, 2, 3 and 4"", 'description': ""Change from baseline in the number of Raynaud's attacks at Week 1, Week 2, Week 3 and Week 4 was calculated from the number of attacks reported over the 7-day period prior to each week from the patient diary, respectively."", 'timeFrame': 'Baseline, Week 1, Week 2, Week 3, Week 4'}, {'measure': ""Change From Baseline in Mean Duration of Raynaud's Attacks at Week 4"", 'description': ""Mean duration of Raynaud's attacks for a time period was calculated as sum of recorded durations of attacks in the time period divided by total number of attacks in the time period where duration was recorded."", 'timeFrame': 'Baseline, Week 4'}, {'measure': ""Change From Baseline in the Mean Raynaud's Pain Score at Week 1, 2, 3 and 4"", 'description': ""Participants were asked to rate their worst Raynaud's pain in the past 24 hours using an 11 point Likert scale, with 0 = no Raynaud's pain and 10 = the worst possible pain. Highest (most severe) response was considered for participants responding at more than 1 point on the scale. Average daily score was considered for participants completing more than 1 Raynaud's pain score scale on a day. Baseline value was calculated as mean of the scores over 7 days prior to treatment start. Post-baseline value was calculated as mean of the scores over the 7-day period prior to the visit."", 'timeFrame': 'Baseline, Week 1, 2, 3, 4'}, {'measure': ""Number of Participants With Decrease From Baseline in Digital Ulcers at Day 14 and 28: Secondary Raynaud's Phenomenon Cohort"", 'description': 'Presence of ulcer was assessed at baseline. At post-baseline visits, each ulcer was measured and scored: 1= smaller or improved compared to previous visit, 2= same as previous visit, 3= bigger or worse than previous visit, and 4= new. If a new digital ulcer develops during the course of the study, the measurement and scoring were initiated on this additional ulcer. Healed ulcers were not counted into the number of ulcers. Participants with SRP in the per-protocol population with at least 1 digital ulcer present at any assessment were evaluable for this measure. Results are reported for participants with presence of ulcer at baseline and decrease from baseline in ulcers at post-baseline visits.', 'timeFrame': 'Baseline, Day 14, 28'}, {'measure': 'Plasma Concentration of PF-00489791 and Its Metabolites', 'description': 'Only participants receiving PF-00489791 were to be analyzed for this outcome. Data have been calculated by setting plasma concentration values below the lower limit of quantification to 0. The lower limit of quantification is 0.0100 microgram per milliliter (mcg/mL). Data for plasma concentration of PF-00489791 metabolites was not analyzed, as it was not intended to be a secondary endpoint and was deemed optional.', 'timeFrame': 'Day 1, 15, 29 (Day 1, 15, 29 for first intervention period), 43, 57, 71 (Day 1, 15, 29 for second intervention period)'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities', 'description': 'Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (less than \\[\\<\\] 0.8\\*lower limit of normal\\[LLN\\]); leukocytes (\\<0.6 LLN /greater than \\[\\>\\] 1.5\\*upper LN \\[ULN\\]; platelets (\\<0.5\\*LLN/\\>1.75\\*ULN); neutrophils, lymphocytes (\\<0.8\\* LLN/\\>1.2\\*ULN); eosinophils, basophils, monocytes (\\>1.2\\*ULN); bilirubin (\\>1.5\\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), Gamma GT, alkaline phosphatase (\\>3\\*ULN); BUN, creatinine (\\>1.3\\*ULN); glucose (\\<0.6 LLN/\\>1.5\\*ULN); uric acid (\\>1.2\\*ULN); sodium (\\<0.95\\*LLN/\\>1.05\\*ULN); potassium, calcium, chloride, bicarbonate (\\<0.9\\*LLN/\\>1.1\\*ULN); albumin, total protein (\\<0.8\\*LLN/\\>1.2\\*ULN); creatine kinase (\\>2.0\\*ULN); Urine Specific Gravity, Urine pH, urine blood, urine glucose, urine protein, urine ketones, urine leukocytes esterase (\\>=1 high-powered field). Total number of participants with any laboratory abnormalities was reported.', 'timeFrame': 'Screening up to 28 days after last study dose (up to 98 days)'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs and Orthostatic Blood Pressure Measurements', 'description': ""Vital signs assessment included measurement of supine and standing pulse rate, systolic and diastolic blood pressures. Criteria for clinically significant vital signs and orthostatic blood pressure measurements were based on investigator's judgement."", 'timeFrame': 'Screening up to 28 days after last study dose (up to 98 days)'}, {'measure': 'Number of Participants With Abnormal Electrocardiogram (ECG) Values', 'description': ""ECG assessment included measurement of PR, QRS, QT,corrected QT interval (QTc)values. Criteria for clinically significant ECG values were based on investigator's judgement."", 'timeFrame': 'Screening up to 28 days after last study dose (up to 98 days)'}]",9.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,243.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04146935,Examining the Effect of Burosumab on Muscle Function,Burosumab Injection [Crysvita],"['Crysvita', 'Burosumab Injection [Crysvita]']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,X-linked Hypophosphatemia,Yale University,2025-09-01T16:18:17.187404,True,,,,NOT_FOUND,Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy,,['X-linked Hypophosphatemia'],"['Crysvita', 'Burosumab']",,2019-11-13,2022-08-25,"[{'measure': 'Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate', 'description': 'Rates of mitochondrial phosphorylation activity were assessed in the soleus/gastrocnemius muscle complex of the right calf by 31P magnetic resonance spectroscopy saturation transfer technique (micro-mol/g/min)', 'timeFrame': '2.5 months'}]","[{'measure': 'Serum Phosphate', 'description': 'measured in mg/dl', 'timeFrame': '2.5 months'}, {'measure': 'Intracellular Phosphate Concentration in Umol/g Muscle', 'description': 'Intracellular phosphorus concentration in skeletal muscle (umol/g muscle)', 'timeFrame': '2.5 months'}]",3.0,18 Years,65 Years,ALL,False,OTHER,0.0,10.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01518985,The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking,Bendavia,"['Bendavia', 'Sterile saline (0.9%)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Stealth BioTherapeutics Inc.,2025-09-01T16:18:14.668828,True,,,,NOT_FOUND,"A Phase 1, Placebo-Controlled Trial to Evaluate the Impact of Intravenous (IV) Bendavia™ (MTP-131) on Endothelial Reactivity Dysfunction Induced by Cigarette Smoking",,['Healthy Volunteers'],[],,2012-01,2012-03,"[{'measure': 'Analysis of variance (ANOVA) between group mean endothelial function (EndoPAT Index) following smoking a single cigarette with and without Bendavia', 'description': 'Endothelial function will be determined using EndoPAT 2000 (Itamar Medical Ltd) prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of endothelial function (EndoPAT Index) between placebo and active study drug within a subject will be performed.\n\nEndoPAT quantifies the endothelium-mediated changes in vascular tone. A post-occlusion to pre-occlusion ratio is calculated providing the EndoPAT index.', 'timeFrame': 'Baseline, +30, +60, +90 minutes post-study-drug administration start'}]","[{'measure': 'Anova between group mean inflammatory laboratory marker (hs-CRP; mg/L) after smoking one cigarette with and without Bendavia', 'description': 'hs-CRP will be evaluated prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of hs-CRP levels between placebo and active study drug within a subject will be performed.', 'timeFrame': 'Baseline to 24 hours post-study-drug administration'}, {'measure': 'ANOVA between group means of urinary 8-isoprostane (ng/mg of creatinine) after smoking one cigarette with and without Bendavia', 'description': '8-isoprostane will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed.', 'timeFrame': 'Baseline to 48 hours post-study-drug administration'}, {'measure': 'Number adverse events with and without Bendavia', 'description': 'Adverse events will be tabulated by treatment group. No statistical analysis will be preformed.', 'timeFrame': 'Baseline to Study Day 10'}, {'measure': 'Assessment of Bendavia exposure measured by area Under the Curve (AUC; ng*hr/mL)', 'description': 'Bendavia levels will be measured and pharmacokinetic parameters reported.', 'timeFrame': 'Baseline to 48 hours post-study-drug administration'}, {'measure': ""ANOVA between group means of urinary 8-hydroxy-2'-deoxyguanosine (pg/mL) after smoking one cigarette with and without Bendavia"", 'description': ""8-hydroxy-2'-deoxyguanosine will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed."", 'timeFrame': 'Baseline to 48 hours post-study-drug administration'}]",6.0,18 Years,65 Years,MALE,True,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03063112,Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain,Lidocaine,"['Ethyl alcohol', 'Chemical neuolysis', 'Lidocaine']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Abdominal Cancer,South Egypt Cancer Institute,2025-09-01T16:18:10.920006,True,,,,CHEMBL79,Comparative Study Between Radiofrequency Thermocoagulation and Chemical Neurolysis of Thoracic Splanchnic Nerve Bilaterally for the Management of Abdominal Cancer Pain,,['Abdominal Cancer'],[],,2016-10-01,2017-05-01,"[{'measure': 'Pain relief', 'description': 'Visual analogue pain scale', 'timeFrame': '3 months'}]","[{'measure': 'Decrease the need for analgesic drugs', 'description': 'Reduction of total oral morphine consumption dose in mg per day', 'timeFrame': '3 months'}]",2.0,18 Years,70 Years,ALL,False,OTHER,0.0,79.0,ESTIMATED,v2_robust,True,False,False,False,,CCN(CC)CC(=O)Nc1c(C)cccc1C,CHEMBL79,exact_match,True,234.34,2.58,4.0
NCT00757835,24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG,treatment with latanoprost/timolol fixed combination,"['treatment with latanoprost/timolol fixed combination', 'latanoprost/timolol fixed combination drops']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Glaucoma,Aristotle University Of Thessaloniki,2025-09-01T16:18:23.448906,True,,,,NOT_FOUND,"24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma",,['Glaucoma'],"['24-hour IOP', 'exfoliative glaucoma', 'travoprost/timolol', 'latanoprost/timolol', 'fixed combinations']",,2008-05,2009-03,"[{'measure': 'Travoprost/timolol fixed combination will demonstrate better quality of 24-hour IOP control than latanoprost/timolol', 'timeFrame': '3 months'}]","[{'measure': 'Incidence of side effects with the two medications', 'timeFrame': '3 months'}]",2.0,21 Years,85 Years,ALL,False,OTHER,1.0,40.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05108870,TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers,HB-201,"['Paclitaxel', 'Carboplatin', 'TheraT® Vectors', 'HB-201', 'HB-202']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Human Papilloma Virus,University of Chicago,2025-09-01T16:18:23.463424,True,,,,NOT_FOUND,A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer,,"['Human Papilloma Virus', 'HPV', 'HPV Positive Oropharyngeal Squamous Cell Carcinoma', 'Head and Neck Cancer']","['throat cancer', 'human papilloma virus', 'HPV16', 'head and neck cancer']",,2024-07-17,2026-01-01,"[{'measure': 'Phase 1 Primary Outcome: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy', 'description': 'The phase 1 dose of HB-201 monotherapy and alternating HB-201 and 202 therapy in combination with chemotherapy in patients with HPV 16 head and neck cancer as assessed by data on reported dose-limiting toxicities (side effects) among participants. These side effects will be measures according to the Common Terminology Criteria for Adverse Events version 5', 'timeFrame': '2 years'}, {'measure': 'Phase 2 Primary Outcome: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with Chemotherapy', 'description': 'The deep response rate (DRR) of participants who receive neoadjuvant HB-201 monotherapy combined with chemotherapy or alternating doses of HB-201 and HB-202 combined with chemotherapy. This response rate will be assessed by tumor shrinkage according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).', 'timeFrame': '2 years'}]","[{'measure': 'Correlation Between Plasma HPV-DNA and Tumor HPV-DNA', 'description': 'Correlation between plasma HPV-DNA and tumor HPV-DNA as assessed by an analysis of plasma and sputum samples of participants using next generation sequencing analysis.', 'timeFrame': '2 years'}, {'measure': 'Changes in Plasma HPV-DNA During Study Treatment with HB-201 and Alternating HB201/202 Combined with Chemotherapy', 'description': ""Changes in the amount of HPV-DNA found in plasma during neoadjuvant HB-201 monotherapy and HB-201 and HB-202 alternating two-vector therapy combined with chemotherapy as assessed by next generation sequencing analysis of participants' plasma samples."", 'timeFrame': '2 years'}, {'measure': 'Pathologic Response in Participants Undergoing Transoral Robotic Surgery (TORS)', 'description': 'Pathologic response in patients undergoing TORS following neoadjuvant HB-201 monotherapy and HB-202 alternating two-vector therapy combined with chemotherapy. Response will be assessed by tumor shrinkage according to Response Evaluation Criteria in Solid Tumors 1.1.', 'timeFrame': '2 years'}, {'measure': 'Progression Free Survival', 'description': 'Progression-free survival of participants as assessed by data recorded in study/clinical records and statistical analysis.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival', 'description': 'Overall survival of participants as assessed by data recorded in study/clinical records and statistical analysis.', 'timeFrame': '2 years'}, {'measure': 'Locoregional Control', 'description': 'Locoregional control of participants as assessed by data recorded in study/clinical records and statistical analysis.', 'timeFrame': '2 years'}]",8.0,18 Years,,ALL,False,OTHER,0.0,98.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01393158,Apremilast for Atopic Dermatitis - A Pilot Study in Adults,Apremilast,"['Otezla', 'Apremilast']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Atopic Dermatitis,Oregon Health and Science University,2025-09-01T16:18:19.674730,True,,,,NOT_FOUND,A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults,,['Atopic Dermatitis'],[],,2009-05,2011-07,"[{'measure': 'Change in EASI Scores', 'description': ""The eczema area and severity index (EASI) is a composite score measuring physical signs of atopic dermatitis. The scale ranges from 0-72. The components measuring severity are four signs/symptoms of atopic dermatitis: erythema, population, excoriation and lichenification on a scale of 0-3 for each body of the four body regions (head/neck, trunk, arms, legs). The component measuring area is a body surface area measurement of each region. The area and severity of each body region is weighted based on size of region which are added together for the complete score. The score for each patient's with scores between 0 and 7 are considered mild ,between 7 and 21 are considered moderate, and greater than 21 are considered severe. In this study the change in EASI score between baseline and month three (end of study) in the 20 mg arm and month six in the 30 mg arm, baseline EASI score was subtracted from month 3 or month 6 score in the 30mg arm,and calculated as a final outcome data point."", 'timeFrame': 'Mean change in EASI score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}]","[{'measure': 'Number of Participants in Each IGA Category', 'description': 'The investigator global assessment scale is a gestalt global assessment made by an investigator describing the overall disease severity of the patient. It is a categorical scale that includes 0-clear, 1-almost clear, 2-mild,3- moderate, 4-severe, and 5-very severe. The reduction in IGA score from baseline to month three (end of study) in the 20mg arm and month six (end of study) in the 30mg arm was evaluated for efficacy.', 'timeFrame': 'Mean change in IGA score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}, {'measure': 'Change in Pruritus (Visual Analog Scale) Score', 'description': ""The pruritus visual analog scale (VAS) is a 10 cm (100 mm) visual analog scale that measures up patient's itch severity with 10 (100 mm) representing the worst imaginable and 0 representing no itch. This is a validated scale with a change of three from baseline to month three in the 20mg arm (end of study) and month six in the 30mg arm (end of study) being clinically relevant."", 'timeFrame': 'Mean change in Pruritus (Visual Analog Scale) score measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}, {'measure': 'Change In DLQI Scores', 'description': 'The dermatology life quality index (DLQI) is a validated quality-of-life scale that measures the impact of skin disease. It is a 10 question instrument. Scores of 0 over 0-1 means there is no effect on the patient\'s life. Scores between 2 and 5 represent a small effect on patient\'s life. Scores between 6 and 10 correspond to a moderate effect on patient\'s life. Scores between 11 and 20 correspond to a very large effect on the patient\'s life. And scores between 21 and 30 correspond to an extremely large effect on patient\'s life. The range of the scale between 0 and 30 for the added total of the patient\'s responses. Each question can be answered on a scale of 0-""not at all"", 1-""a little"", 2-"" a lot"", 3- ""very much"" with some questions having the option of ""not relevant"". The difference in DLQI score from baseline to month three (end of study) in the 20mg arm and month six (end of study) in the 30mg arm was evaluated for efficacy.', 'timeFrame': 'Mean change in DLQI scores measured at Baseline and Month 3, (if on 20mg arm) or Baseline and Month 6 (if on 30mg arm)'}]",4.0,18 Years,,ALL,False,OTHER,1.0,16.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00036361,Broad Effectiveness: Study With Aripiprazole,Aripiprazole,['Aripiprazole'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Schizophrenia,"Otsuka Pharmaceutical Development & Commercialization, Inc.",2025-09-01T16:18:20.963401,True,,,,NOT_FOUND,Broad Effectiveness: Study With Aripiprazole,,"['Schizophrenia', 'Schizoaffective Disorder']",[],,2002-07,2003-01,[{'measure': 'Safety Assessments'}],[{'measure': 'Safety Assessments'}],2.0,18 Years,75 Years,ALL,False,INDUSTRY,1.0,444.0,,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03198143,Effect of Ghrelin on Decision-Making,Ghrelin,"['Ghrelin', 'Saline', 'Octanoyl Ghrelin', 'Acylated Ghrelin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,WITHDRAWN,Healthy Volunteers,"Jenny Tong, MD, MPH",2025-09-01T16:18:12.175405,True,,,,NOT_FOUND,Effect of Ghrelin on Nutritional and Financial Decision-Making,,"['Healthy Volunteers', 'Obesity']","['Decision-making', 'Ghrelin', 'Healthy Volunteers', 'Obese']",PI leaving institution,2019-10,2022-02,"[{'measure': 'Effect of Ghrelin on food choices in Task 1.', 'description': 'The difference in the proportion of healthy and unhealthy choices in the Saline and Ghrelin conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Effect of Ghrelin on temporal choices in Task 2', 'description': 'The difference in the proportion of smaller sooner and larger later choices in the Saline and Ghrelin conditions', 'timeFrame': 'Approximately 25 minutes'}]","[{'measure': 'Dwell time on each choice during Task 1', 'description': 'For eye-tracking, total dwell time (in ms) on each item in a food choice will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Number of fixations on foods during Task 1', 'description': 'The total number of fixations on each food option will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Dwell time on each choice during Task 2', 'description': 'For eye-tracking, total dwell time (in ms) on each item in the monetary choice will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Number of fixations on foods during Task 2', 'description': 'The total number of fixations on each monetary option will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}]",6.0,18 Years,40 Years,ALL,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,PI leaving institution,,,no_match,False,,,
NCT04645303,Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger,hyaluronic acid (20 mg/2 mL),"['hyaluronic acid (20 mg/2 mL)', 'Triamcinolone acetonide 10mg/ml', 'Kenalog 10 mg/ml', 'Hyalgan 20 mg in 2 ML Prefilled Syringe']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Trigger Finger,Dubai Health Authority,2025-09-01T16:18:23.461012,True,,,,NOT_FOUND,Ultrasound-Guided Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger: Randomized Controlled Study,,['Trigger Finger'],"['Trigger finger', 'Hyaluronic Acid', 'Corticosteroid', 'Ultrasound-guided injection']",,2020-11-06,2021-06-04,"[{'measure': 'Change in Quinnell trigger finger grading system:', 'description': 'Change in Quinnell grading overtime within 3 months after injection. Trigger fingers are rated as follows: Grade 0: normal finger movements, Grade 1: uneven finger movements, Grade 2: actively correctable triggering, Grade 3: passively correctable triggering, and Grade 4: locked digit.', 'timeFrame': '1 and 3 months post-injection'}]","[{'measure': 'Visual analogue scale (VAS) of pain', 'description': 'Change in pain Visual analogue scale will be recorded. The patient marks on the 100 mm in length line the point that he/she feels to represent his/her perception of pain at the current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks ( a higher score indicates greater pain intensity). Categorization of none, mild, moderate and severe pain will be also used (none = 0, mild = 1-4, moderate = 5-6, and severe = 7-10).', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Frequency of tender trigger nodules', 'description': 'Identifying the presence of tender nodules at A1-pulley of the affected finger by palpation', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'The Quick Disability of the Arm, Shoulder and Hand score', 'description': 'Patients will be asked to fill a questionnaire form. It is an 11-item form that assesses the upper limb function on a scale of 1-5, with scores ranging from 11 to 55, with the higher scores representing more disability and worse upper limb function.', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Changes in Grip strength', 'description': 'Measured by the dynamometer strength test (Jamar grip dynamometer)', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Patient satisfaction with therapy', 'description': 'Participating patients will be asked to classify their result into 1 of 4 categories: (1) complete resolution of symptoms, (2) improved result, but incomplete resolution of symptoms, not warranting further treatment, (3) partial response, but unsatisfactory, warranting further treatment, and (4) no response.', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Ultrasound evaluation of A1-Pulley', 'description': 'Detailed ultrasonography evaluation of A1-Pulley. Comparing the A1-Pulley ultrasonographic parameters over 3 months after injection (at the follow-up appointment)', 'timeFrame': '1 and 3 months post-injection'}]",7.0,19 Years,,ALL,False,OTHER_GOV,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00706771,Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study,Sodium bicarbonate,"['Sodium bicarbonate', 'Sodium chloride']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Systemic Inflammatory Response Syndrome,Austin Health,2025-09-01T16:18:13.429379,True,,,,CHEMBL1353,"A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels",,"['Systemic Inflammatory Response Syndrome', 'Oliguria', 'Renal Impairment']","['sodium bicarbonate', 'serum neutrophil gelatinase associated lipocalin', 'renal impairment', 'renal failure', 'systemic inflammatory response syndrome', 'defined', 'by serum NGAL ≥ 100 ng/ml.']",,2010-02,2012-09,"[{'measure': 'The ability to deliver the study protocol safely and rapidly with a trend to improved renal outcomes', 'timeFrame': '28 days'}]","[{'measure': 'Attenuation in lipocalin levels', 'timeFrame': '28 days'}, {'measure': 'Decrease in the magnitude in serum creatinine rise', 'timeFrame': '28 days'}, {'measure': 'Ability to deliver the study protocol without significant biochemical side effects', 'timeFrame': '28 days'}]",4.0,18 Years,,ALL,False,OTHER_GOV,0.0,70.0,ESTIMATED,v2_robust,True,True,False,False,,O=C([O-])O.[Na+],CHEMBL1353,exact_match,True,84.01,,4.0
NCT03917043,APG-2449 in Patients With Advanced Solid Tumors,APG-2449,"['APG-2449 Capsule', 'APG-2449']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Advanced Solid Cancer,Ascentage Pharma Group Inc.,2025-09-01T16:18:14.669425,True,,,,CHEMBL5095166,"A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors",,"['Advanced Solid Cancer', 'Non Small Cell Lung Cancer', 'Esophageal Cancer', 'Ovarian Cancer', 'Malignant Pleural Mesothelioma']",[],,2019-05-27,2028-01,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'To determine the maximum tolerated dose (MTD) of APG-2449 in subjects with advanced solid tumors', 'timeFrame': '28 days'}, {'measure': 'Recommended Phase 2 dose (RP2D)', 'description': 'To determine the tentative recommended Phase 2 dose (RP2D) of APG-2449 in subjects with advanced solid tumors', 'timeFrame': '28 days'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'description': 'Maximum plasma concentration (Cmax) will be assessed on all participants with APG-2449 treatments', 'timeFrame': '28 days'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'Area under the plasma concentration versus time curve (AUC) will be assessed on all participants with APG-2449 treatments', 'timeFrame': '28 days'}, {'measure': 'Phosphorylation of FAK protein', 'description': 'Phosphorylation of FAK protein will be assessed in peripheral blood mononuclear cells on all participants with APG-2449 treatments', 'timeFrame': '28 days'}, {'measure': 'Preliminary efficacy assessment: Response Evaluation Criteria In Solid Tumors (RECIST) 1.1', 'description': 'To assess preliminary efficacy in subjects with solid tumors using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1', 'timeFrame': '4 weeks'}]",6.0,18 Years,,ALL,False,INDUSTRY,1.0,165.0,ESTIMATED,v2_robust,True,False,False,False,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1=CCN(C2CCOCC2)CC1,CHEMBL5095166,exact_match,True,640.25,7.16,1.0
NCT03045770,mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA,Fluorouracil,"['Paclitaxel', 'Oxaliplatin', 'Irinotecan', '5-FU', 'CPT-11', 'Fluorouracil', 'PTX', 'calcium levofolinate', 'OXA']",9,INTERVENTIONAL,['NA'],,UNKNOWN,Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction,Fujian Cancer Hospital,2025-09-01T16:18:07.028470,True,,,,CHEMBL566,"A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction",,['Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction'],[],,2017-02-10,2019-12-30,"[{'measure': 'Progression-Free Survival (PFS)', 'timeFrame': '24 months'}, {'measure': 'Adverse Event（AE）', 'description': 'NCI CTC 4.03', 'timeFrame': '35 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'timeFrame': '24 months'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': '24 months'}, {'measure': 'Overall Survival (OS)', 'timeFrame': '35 months'}, {'measure': 'Quality of Life (QoL)', 'description': 'Use the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 \\[EORTC QLQ-C30\\].', 'timeFrame': '35 months'}]",6.0,18 Years,70 Years,ALL,False,OTHER_GOV,0.0,150.0,ESTIMATED,v2_robust,True,False,False,True,,O=c1cc[nH]c(=O)[nH]1,CHEMBL566,partial_match,True,112.09,-0.94,3.0
NCT02136641,Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia,Midazolam,"['Ketamine hydrochloride', 'Midazolam', 'Midazolam+Ketamine Combination', 'Midazolam+Fentanyl Combination', 'Fentanyl']",5,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Anesthesia; Reaction,Universidad de Cartagena,2025-09-01T16:18:23.465223,True,,,,NOT_FOUND,Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia,,['Anesthesia; Reaction'],"['Anesthesia', 'Spinal Anesthesia', 'Conscious Sedation', 'Operating Rooms.']",,2011-06,2012-06,"[{'measure': 'Sedation level reached according RANSAY SCALE with the use of three schemes sedation to spinal anesthesia', 'description': 'Sedation/Analgesia conscious was considered adequate when a RANSAY 2 or 3 was achieved (BASED ON THE RANSAY SCALE), without the need for other anesthetic drugs are different from the protocol, has been the gold standard in many studies that evaluated sedation; as you increase the level on the scale, increasing the degree of sedation . Being awake patient can be found in a level 1, referring to an anxious and / or agitated patients in level 2, when partner is quiet and focused and have spontaneous eye opening, or a level 3 when has closed eyelids, but quickly responds to verbal stimuli. When the patient was found asleep, level 4 will be called if you are still with closed eyes and responds quickly to tactile and verbal stimuli strong, level 5 when it has a slower response and only responds to important and / or painful stimuli and level 6 when does not respond to any stimulu', 'timeFrame': 'one year'}]","[{'measure': 'Number of participants satisfied with the use of three schemes sedation to spinal anesthesia', 'description': 'The Satisfaction was measured with a SATISFACTION SCALE TYPE LIKERT, this scale was used to subjectively evaluate how satisfied was the patient with spinal anesthesia under sedation, the scale is not validated, giving a score of 1 to refer to be very satisfied, 2 if only felt satisfied, a score of 3 to be dissatisfied, 4 if it meant feeling unsatisfied and finally a rating of 5 if it meant being very dissatisfied.', 'timeFrame': 'one year'}]",2.0,18 Years,60 Years,ALL,True,OTHER,0.0,75.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00510484,Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Pancrelipase Delayed Release,"['Pancrelipase Delayed Release', 'Placebo Comparator']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Cystic Fibrosis,Solvay Pharmaceuticals,2025-09-01T16:18:17.180361,True,,,,NOT_FOUND,"A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",,['Cystic Fibrosis'],"['Pancreatic exocrine insufficiency', 'Cystic Fibrosis']",,2007-11,2008-03,"[{'measure': 'Coefficient of Fat Absorption (%)', 'description': 'This coefficient is calculated from fat intake and fat excretion : 100\\*\\[fat intake-fat excretion\\]/fat intake. Stools were collected on 3 days during the 5 days treatment period. Higher values indicate a better response.', 'timeFrame': '5 days'}]","[{'measure': 'Coefficient of Nitrogen Absorption (%)', 'description': 'This coefficient is calculated from nitrogen intake and nitrogen excretion : 100\\*\\[nitrogen intake-nitrogen excretion\\]/nitrogen intake. Stools were collected on 3 days during the 5 days treatment period. Higher values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Total Fat Excretion (Grams)', 'description': 'Total amount of fat excreted during the stool collection period. Stools were collected on 3 days during the 5 days treatment period. Lower values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Total Stool Weight (Grams)', 'description': 'Total weight of the stools collected during the stool collection period. Stools were collected on 3 days during the 5 days treatment period. Lower values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Stool Frequency', 'description': 'Stool frequency is the average of the daily number of stools recorded during the treatment period. Lower values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Percentage of Days With no Flatulence.', 'description': 'The percentage of days with no flatulence is calculated from the diary during the treatment period: 100\\*(number of days with no flatulence/number of days recorded in diary). Higher values indicate a better response.', 'timeFrame': '5 days'}, {'measure': 'Percentage of Days With no Abdominal Pain.', 'description': 'The percentage of days with no abdominal pain is calculated from the diary during the treatment period: 100\\*(number of days with no abdominal pain / number of days recorded in diary). Higher values indicate a better response.', 'timeFrame': '5 days'}]",7.0,12 Years,,ALL,False,INDUSTRY,0.0,35.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02627950,Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction,Morphinhydrochloricum,"['Morphin-hameln (manufacturer: hameln pharmaceuticals)', 'Isotonic sodium chloride', 'Ticagrelor', 'MCP-ratiopharm (manufacturer: Ratiopharm)', 'Metoclopramide', 'Morphinhydrochloricum', 'Brilique (manufacturer: AstraZeneca)', 'NaCl (manufacturer: Berlin-Chemie Menarini)']",8,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Acute Myocardial Infarction,University of Luebeck,2025-09-01T16:18:20.953445,True,,,,NOT_FOUND,Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction,,['Acute Myocardial Infarction'],[],,2015-12,2018-10,"[{'measure': 'Platelet activity 2 hours after administration of loading dose of ticagrelor measured by VerifyNow-P2Y12-test', 'timeFrame': '2 hours'}]","[{'measure': 'Platelet reactivity 0.5, 1, 4, 6 and 24 hours after loading dose of ticagrelor measured by VerifyNow-P2Y12-test', 'timeFrame': '0.5, 1, 4, 6 h and 24 hours'}, {'measure': 'Platelet reactivity 0.5, 1, 2, 4, 6 and 24 hours after loading dose of ticagrelor measured by Vasodilator Stimulated Phosphoprotein-test', 'timeFrame': '0.5, 1, 2, 4, 6 h and 24 hours'}, {'measure': 'Percentage of patients with high on-treatment platelet reactivity 0.5, 1, 2, 4, 6 and 24 hours after loading dose of ticagrelor (measured by VerifyNow-P2Y12-test)', 'timeFrame': '0.5, 1, 2, 4, 6 h and 24 hours'}, {'measure': 'Ticagrelor plasma levels and levels of active serum metabolites after 0.5, 1, 2, 4, 6 and 24 hours', 'timeFrame': '0.5, 1, 2, 4, 6 h and 24 hours'}, {'measure': 'Infarct size measured by delayed enhancement magnetic resonance imaging', 'timeFrame': 'Day 1-4'}, {'measure': 'Microvascular obstruction measured by delayed enhancement magnetic resonance imaging', 'description': 'Cardiac magnetic resonance imaging equivalent of angiographic no-reflow, expressed as percentage of left ventricular mass', 'timeFrame': 'Day 1-4'}]",7.0,18 Years,,ALL,False,OTHER,0.0,138.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02839226,"Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds",AR/101,"['AR/101', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Wounds,Arava Bio Tech Ltd.,2025-09-01T16:18:09.628390,True,,,,NOT_FOUND,"Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients",,"['Wounds', 'Other Ulcers Wounds and Skin Problems']","['ulcers', 'wounds', 'diabetes', 'venous ulcers', 'arterial ulcers', 'granulation tissue', 'protein kinase c']",,2016-08,2017-12,"[{'measure': 'comparison of the formation of new granulation tissue according to a Granulation Score, between the AR/101 treated group and the placebo group, during the treatment phases', 'timeFrame': '28 days'}]","[{'measure': ""Percentage of patients ready for skin grafting or healing by secondary intention during treatment phase 1 and treatment phase 2 based on physician's assessment"", 'timeFrame': '28 days'}, {'measure': 'Percent of patient responders of equal or more then 75% granulation tissue during two weeks of treatment phase 1', 'timeFrame': '14 days'}, {'measure': 'Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 1', 'timeFrame': '14 days'}, {'measure': 'Mean time to response (equal or more then 75% of granulation tissue) during two weeks of treatment phase 2', 'timeFrame': '14 days'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04598009,Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma,Binimetinib,"['Binimetinib', 'Imatinib Mesylate', 'Mektovi', 'ARRY-162', 'Imatinib', 'MEK162', 'Binimetinib Oral']",7,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Melanoma Stage III,"University of California, San Francisco",2025-09-01T16:18:17.175091,True,,,,NOT_FOUND,A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant Melanoma,,"['Melanoma Stage III', 'Melanoma Stage IV']","['KIT-Mutant', 'Unresectable Melanoma', 'Melanoma']",,2021-03-03,2027-03-31,"[{'measure': 'Objective response rate (ORR)', 'description': 'Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the null hypothesis at each stage will use the method of Koyama \\& Chen and 90% confidence interval will be reported.', 'timeFrame': 'Up to week 16'}]","[{'measure': 'Proportion of participants with treatment-related adverse events (AE)', 'description': 'Proportion of participants with treatment-related AEs greater than grad2 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported by toxicity.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Median duration of response', 'description': 'Will estimate the probability-of-being-in-response function, assuming time to response is exponentially distributed.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Participants with an objective response will be followed for survival from initiation of study treatment until date of disease progression or death from any cause', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'Participants will be followed from initiation of study treatment until date of disease progression or death from any cause and estimated using the Kaplan-Meier method to estimate the survival rate (95% CI)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Clinical benefit rate (CBR)', 'description': 'Defined as CR, PR, or stable disease (SD) \\>= 16 weeks by RECIST. CBR will be defined as the proportion of participants with CR, PR, or SD for \\>= 16 weeks.', 'timeFrame': 'Up to 2 years'}]",6.0,18 Years,,ALL,False,OTHER,1.0,25.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06395610,"Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers",CHF6001 DPI,"['CHF6001 DPI', 'Erythromycin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Chronic Obstructive Pulmonary Disease,Chiesi Farmaceutici S.p.A.,2025-09-01T16:18:12.182305,True,,,,NOT_FOUND,"Open-label, Non-randomised, One-sequence Crossover Study to Investigate the Effect of Inhibition of CYP3A4/5 by Erythromycin on the Pharmacokinetics of CHF6001 in Healthy Subjects",,['Chronic Obstructive Pulmonary Disease'],"['Drug-drug Interaction study', 'CYP3A4/5 inhibitor', 'CYP3A4/5 substrate']",,2024-03-28,2024-06-18,"[{'measure': 'Pharmacokinetic parameter (AUC0-t)', 'description': 'Area under the curve from time 0 to the last quantifiable concentration (AUC0-t)', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (Cmax)', 'description': 'Maximum plasma concentration (Cmax) of CHF6001 without and with the concomitant administration of Erythromycin', 'timeFrame': 'Over 96 hours after administration in blood'}]","[{'measure': 'Pharmacokinetic parameter (AUC0-96)', 'description': 'Area under plasma concentration from 0 to 96 hours (AUC0-96) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (AUC0-∞)', 'description': 'Area under curve extrapolated to infinity (AUC0-∞) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (tmax)', 'description': 'Time to the maximum plasma concentration (tmax) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (CL/F)', 'description': 'Apparent systemic clearance for CHF6001', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (t1/2)', 'description': 'Terminal elimination half-life (t1/2) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (AUC0-t)', 'description': 'Area under the plasma concentration versus time curve (AUC0-t) for CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (Cmax)', 'description': 'Peak Plasma Concentration (Cmax) for CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}]",9.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00550459,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Tolvaptan,"['OPC-41061', 'Placebo', 'Tolvaptan']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hyponatremia,"Otsuka Pharmaceutical Development & Commercialization, Inc.",2025-09-01T16:18:18.420712,True,,,,NOT_FOUND,"A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients",,['Hyponatremia'],"['Hyponatremia', 'Cognitive', 'Neurological Function', 'Elderly']",,2007-08,2009-03,"[{'measure': 'Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)', 'description': 'Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize ""yes"" 50 times;Choice=recognize ""yes"" or ""no"" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \\& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data', 'timeFrame': 'baseline and Day 22'}]","[{'measure': 'Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests', 'description': 'Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Overall Neurocognitive Composite Score', 'description': 'Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)', 'description': 'Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Postural Stability Test', 'description': 'Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population', 'timeFrame': 'baseline and Day 22'}, {'measure': 'Change From Baseline in Serum Sodium; ITT Population', 'description': 'Change from Baseline to Day 22 in Serum Sodium; ITT population', 'timeFrame': 'Baseline and Day 22'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Blood Pressure', 'description': 'Incidence of abnormal systolic \\& diastolic blood pressure values post-baseline (abnormal systolic values: \\>=180 mmHg + increase of \\>=20 mmHg, \\<= 90 mmHg + decrease \\>=20 mmHg; abnormal diastolic values: \\>=105 mmHg+increase of \\>=15 mmHg, \\<=50 mmHg + decrease of \\>= 15 mmHg)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Pulse Rate', 'description': 'Incidence of abnormal pulse rate post-baseline \\[abnormal values: \\>=120 beats per minute (bpm) + increase of \\>=15 bpm; \\<=50 bpm + decrease of \\>=15 bpm\\]', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Body Weight', 'description': 'Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \\>=7%)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Body Temperature', 'description': 'Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \\>=1.1 to \\>=38.3 degrees Celsius)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin', 'description': 'Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)', 'description': 'Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes', 'description': 'Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Neutrophils', 'description': 'Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)', 'description': 'Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid', 'description': 'Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol', 'description': 'Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose', 'description': 'Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium', 'description': 'Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QT\\>500 msec) post-baseline', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval', 'description': 'Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \\> 100 msec)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment', 'description': 'Incidence of potentially clinically significant ECG abnormalities: ST Segment', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave', 'description': 'Incidence of potentially clinically significant ECG abnormalities: T wave', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)', 'description': 'Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)', 'timeFrame': '28 days'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia', 'description': 'Incidence of potentially clinically significant ECG abnormalities: arrhythmia', 'timeFrame': '28 days'}]",29.0,50 Years,,ALL,False,INDUSTRY,1.0,57.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02117076,"Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome",Gabapentin immediate release,"['Gabapentin enacarbil extended release', 'Neurontin', 'Horizant', 'Gabapentin immediate release']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Restless Leg Syndrome,"Theresa Zesiewicz, MD",2025-09-01T16:18:07.015329,True,,,,NOT_FOUND,"Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome",,['Restless Leg Syndrome'],"['Restless leg syndrome', 'RLS', 'gabapentin', 'gabapentin enacarbil', 'Neurontin', 'Horizant']",Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.,2014-04,2016-06,"[{'measure': 'International Restless Leg Syndrome Rating Scale (IRLS)', 'description': 'The IRLS is a measure of severity of Restless Legs Syndrome. It includes 10 items, measured on a scale of 0-4. A score of 1-10 indicates mild severity, 11-20 indicates moderate severity, 21-30 is severe and 31-40 is very severe. Primary outcome is the difference in IRLS scores for each of the treatment regimens.\n\nfrom 0 to 4.', 'timeFrame': '10 weeks'}]","[{'measure': 'Restless Leg Syndrome Quality of Life Scale (RLSQoL)', 'description': 'The Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) assesses the impact of RLS on daily life, emotional well-being, social life, and work life.', 'timeFrame': 'Baseline, day 35, day 54.'}]",2.0,18 Years,80 Years,ALL,False,OTHER,0.0,5.0,ACTUAL,v2_robust,True,False,True,False,Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.,,,no_match,False,,,
NCT01709474,Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus,Vitamin D3 6000 IU,"['high-dose 25(OH)D', 'Vitamin D3 400 IU', 'high-dose cholecalciferol (D3)', 'standard-dose vitamin D', 'Vitamin D3 6000 IU', 'standard-dose 25(OH)D', 'standard-dose cholecalciferol (D3)', 'high-dose vitamin D']",8,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Systemic Lupus Erythematosus,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:09.634848,True,,,,NOT_FOUND,Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE),,['Systemic Lupus Erythematosus'],"['SLE', 'Vitamin D3', 'Vitamin D deficiency', 'IFN alpha expression']",Due to slow enrollment,2013-06,2014-07,"[{'measure': 'Change in Average IFN Module Expression Level', 'description': 'No mechanistic analyses were performed due to recruitment feasibility issues.', 'timeFrame': 'Baseline to Week 18'}, {'measure': 'Percentage of Subjects by Treatment Arm Experiencing Any Adverse Event (AE) ≥ Grade 3', 'description': 'Adverse event grading based on National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0', 'timeFrame': 'Baseline to 18 Weeks'}]",[],2.0,5 Years,20 Years,ALL,False,NIH,1.0,7.0,ACTUAL,v2_robust,True,False,True,True,Due to slow enrollment,,,no_match,False,,,
NCT05445843,Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.,JDQ443,['JDQ443'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation,Novartis Pharmaceuticals,2025-09-01T16:18:19.676954,True,,,,NOT_FOUND,KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.,,['Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation'],"['Lung cancer', 'NSCLC', 'KRAS G12C', 'STK11', 'PD-L1', 'JDQ443']",,2022-10-31,2027-11-30,"[{'measure': 'Overall Response Rate (ORR) as determined by the Investigator in Cohort A', 'description': 'Overall Response Rate (ORR) is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort A', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'Key Secondary Outcome Measure: Overall Response Rate (ORR) as determined by the Investigator in Cohort B', 'description': 'Overall Response Rate (ORR) is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort B', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of adverse events and serious adverse events as assessed by CTCAE criteria', 'description': 'An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.\n\nTreatment emergent Adverse Event (TEAEs) in this study were events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.', 'timeFrame': 'Up to approximately 60 months'}, {'measure': 'Maximum concentration (Cmax) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to reach maximum concentration at steady-state (Tmax,ss) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Area Under the Curve From Time Zero to the last measurable concentration sampling time at steady-state (AUClastss) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Observed concentration at the end of a dosing interval at steady-state (Cmin,ss) of JDQ443 in plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Total body clearance (CL/F) of JDQ443 from the plasma', 'description': 'Blood samples will be collected for pharmacokinetics characterization.', 'timeFrame': 'Up to approximately 24 months'}]",9.0,18 Years,100 Years,ALL,False,INDUSTRY,0.0,96.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03239223,Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection,ABI-1968,['ABI-1968'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,HSIL,Antiva Biosciences,2025-09-01T16:18:20.958981,True,,,,NOT_FOUND,"A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)",,"['HSIL', 'HSIL of Cervix', 'High-Grade Squamous Intraepithelial Lesions', 'High-grade Cervical Intraepithelial Neoplasia', 'Human Papilloma Virus', 'Cervical Cancer', 'Cervical Intraepithelial Neoplasia', 'Cervical Neoplasm', 'Cervical Dysplasia', 'CIN']",[],,2018-01-01,2018-10-30,"[{'measure': 'Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of cHSIL', 'description': 'Number of participants with Adverse Events related to treatment to determine MTD', 'timeFrame': '85 Days'}]","[{'measure': 'Systemic exposure to Topical ABI-1968 Cream following topical application to the cervix.', 'description': 'Plasma concentrations of ABI-1968 over time to determine systemic exposure', 'timeFrame': '85 Days'}, {'measure': 'Histopathology of areas with biopsy-proven disease following multiple doses of Topical ABI-1968 Cream.', 'description': 'Number of subjects with complete and or partial regression of cHSIL by Colposcopy and histopathology to determine change and impact over 4 weekly doses', 'timeFrame': '85 Days'}]",3.0,25 Years,50 Years,FEMALE,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03744182,A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD,HM15211,"['Placebo of HM15211', 'HM15211']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,NAFLD,Hanmi Pharmaceutical Company Limited,2025-09-01T16:18:09.637977,True,,,,NOT_FOUND,"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD",,['NAFLD'],[],,2018-11-01,2020-03-18,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'Cardiovascular events, rash/inflammatory dermatitis and other skin disorders, GI events, and gallstone formation \\[cholelithiasis\\] were managed following a separate AE guidance document', 'timeFrame': '12 weeks'}, {'measure': 'Incidence of Clinical Renal Function Lab Abnormalities', 'description': 'Observed Values and Change from Baseline in Renal Function of Urea Nitrogen', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Vital Signs', 'description': 'Change from baseline in vital signs (Systolic Blood)', 'timeFrame': 'baseline and 12 weeks'}, {'measure': '12-lead ECG', 'description': 'Change from baseline in 12-lead ECG; the primary ECG endpoint was QTcF', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'Body Mass Index', 'description': 'Change of Body Mass Index from baseline to 12 weeks after IP injection', 'timeFrame': 'baseline and 12 weeks'}]",5.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,66.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01473524,Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis,Obeticholic Acid (OCA),"['Obeticholic Acid (OCA)', '6α-ethyl chenodeoxycholic acid (6-ECDCA)', 'Placebo', 'INT-747']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Primary Biliary Cirrhosis,Intercept Pharmaceuticals,2025-09-01T16:18:09.638349,True,,,,CHEMBL566315,"A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis",,['Primary Biliary Cirrhosis'],"['Primary Biliary Cholangitis', 'Primary Biliary Cirrhosis', 'PBC', 'Cirrhosis', 'Liver']",,2012-01,2018-12-17,"[{'measure': 'DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo', 'description': 'Percentage of participants at Month 12 with ALP \\< 1.67 x upper limit of normal (ULN) and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 12'}, {'measure': 'LTSE Phase: Composite Endpoint ALP And Total Bilirubin', 'description': 'Percentage of participants at Months 24, 36, 48, and 60 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. DB Month 12 is the baseline for the LTSE phase.', 'timeFrame': 'Baseline (DB Month 12), LTSE Months 24, 36, 48, and 60'}]","[{'measure': 'DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo', 'description': 'Percentage of participants at Month 6 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 6'}, {'measure': 'DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo', 'description': 'Percentage of participants at Month 12 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 12'}, {'measure': 'DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo', 'description': 'Percentage of participants at Month 6 with ALP \\< 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.', 'timeFrame': 'DB Month 6'}, {'measure': 'DB Phase: ALP Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for ALP levels. ALP Absolute Change From Baseline (ALP at Month 12 - ALP at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for bilirubin levels. Total bilirubin absolute change from baseline (total bilirubin at Month 12 - total bilirubin at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for bilirubin levels. Direct bilirubin absolute change from baseline (direct bilirubin at Month 12 - direct bilirubin at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for ALT levels. ALT absolute change from baseline (ALT at Month 12 - ALT at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for AST levels. AST absolute change from baseline (AST at Month 12 - AST at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12', 'description': 'Blood samples were evaluated for GGT levels. GGT absolute change from baseline (GGT at Month 12 - GGT at Baseline) is presented.', 'timeFrame': 'Baseline, DB Month 12'}, {'measure': 'LTSE Phase: ALP Levels', 'description': 'Blood samples were evaluated for ALP levels.', 'timeFrame': 'LTSE Day 0 and LTSE Months 12, 24, 36, 48, and 60'}, {'measure': 'LTSE Phase: ALP Change From DB Baseline', 'description': 'Blood samples were evaluated for ALP levels. ALP Change From Baseline (ALP at LTSE Months 12, 24, 36, 48, and 60 - ALP at Baseline) is presented. DB baseline is the mean of all available evaluations prior to DB treatment.', 'timeFrame': 'DB Baseline, LTSE Months 12, 24, 36, 48, and 60'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,217.0,ACTUAL,v2_robust,True,True,False,False,,CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12,CHEMBL566315,partial_match,True,420.63,5.11,4.0
NCT05951309,Myoinositol Treatment and Asprosin Levels in PCOS,inofolic combi,"['inofolic combi, ITF company', 'Glucophage 500Mg Tablet', 'glucophage, Merck company', 'inofolic combi']",4,INTERVENTIONAL,['NA'],,COMPLETED,PCOS,"Near East University, Turkey",2025-09-01T16:18:22.205307,True,,,,NOT_FOUND,Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients,,"['PCOS', 'Insulin Resistance']","['Polycystic ovary syndrome', 'Myoinositol', 'Metformin', 'Insulin resistance', 'Asprosin']",,2021-09-01,2023-06-03,"[{'measure': 'Serum asprosin levels 1', 'description': 'First measurement of serum asprosin level at initial examination', 'timeFrame': 'Second or third day of menstruation'}, {'measure': 'Serum asprosin levels 2', 'description': 'Serum asprosin levels after 12-16 weeks from initial examination', 'timeFrame': 'After 12-16 weeks from first examination'}]",[],2.0,18 Years,40 Years,FEMALE,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01075698,A Trial of Telmisartan Prevention of Cardiovascular Disease,Non-ARB (standard therapy),"['Non-ARB (standard therapy)', 'ARB (Telmisartan)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypertension,Kumamoto University,2025-09-01T16:18:10.928683,True,,,,NOT_FOUND,A Trial of Telmisartan Prevention of Cardiovascular Disease,,['Hypertension'],"['Type 2 Diabetes', 'Cerebrovascular disease', 'Coronary Artery Disease', 'Chronic Kidney Disease', 'Peripheral Artery Disease']",,2009-07,2016-03,"[{'measure': 'The effects of ARB therapy and that of standard therapy except ARB on the biomarker levels (UACR and BNP)', 'timeFrame': 'for three years'}]","[{'measure': 'The effect of the two treatments on the incidence of events, and the relationship between the incidence of events and the biomarker levels (UACR, BNP, urine 8-hydroxy-2-deoxyguanosine, serum adiponectin, serum high-molecule adiponectin, eGFR)', 'timeFrame': 'for three years'}]",2.0,40 Years,79 Years,ALL,False,OTHER,1.0,1228.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00921726,Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults,Zanamivir,"['Oseltamivir', 'Zanamivir', 'Tamiflu', 'Relenza']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Influenza,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:12.173812,True,,,,NOT_FOUND,"Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects",,"['Influenza', 'Virus Diseases']",['Drug Interaction'],,2009-07,2009-10,"[{'measure': 'Oseltamivir carboxylate Cmax and AUC (0-12)', 'timeFrame': 'Throughout study'}]","[{'measure': 'Zanamivir Cmax and AUC (0-12) for continuous infusion and Zanamivir Cmax, AUC (-12), and C12 for intermittent infusions', 'timeFrame': 'Throughout study'}, {'measure': 'Oseltamivir Cmax, AUC (0-12), and C12', 'timeFrame': 'Throughout study'}, {'measure': 'Oseltamivir carboxylate AUC (0-24), C12, delta-z, and t(1/2)', 'timeFrame': 'Throughout study'}]",4.0,18 Years,60 Years,ALL,True,NIH,1.0,17.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00670423,"A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation",Tacrolimus,"['Rapamune®', 'Bortezomib', 'Velcade®', 'Sirolimus', 'Prograf®', 'Tacrolimus']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Graft vs Host Disease,Jennifer E. Schwartz,2025-09-01T16:18:20.959066,True,,,,CHEMBL269732,"A Phase I Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation",,"['Graft vs Host Disease', 'Peripheral Blood Stem Cell Transplantation', 'Transplantation, Homologous']","['Tacrolimus', 'Sirolimus', 'Bortezomib', 'Acute Graft Versus Host Disease', 'Allogeneic Peripheral Blood Stem Cell Transplantation']",,2008-05-16,2013-10-16,"[{'measure': 'To evaluate the maximum tolerated dose (MTD) of bortezomib in combination with tacrolimus and sirolimus as GVHD prophylaxis in patients undergoing myeloablative allogeneic peripheral blood stem cell transplantation.', 'timeFrame': 'Baseline through end of study'}]","[{'measure': 'To assess the toxicity of bortezomib', 'timeFrame': 'Baseline through end of study'}, {'measure': 'To describe engraftment', 'timeFrame': 'Baseline through end of study'}, {'measure': 'To describe the incidence of acute and chronic GVHD', 'timeFrame': 'Baseline through end of study'}]",4.0,18 Years,,ALL,False,OTHER,1.0,27.0,ACTUAL,v2_robust,True,True,False,False,,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,CHEMBL269732,partial_match,True,804.03,4.64,4.0
NCT06084507,Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants,GST-HG171/ritonavir,"['GST-HG171/ritonavir', 'ritonavir']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,COVID-19 Respiratory Infection,"Fujian Akeylink Biotechnology Co., Ltd.",2025-09-01T16:18:10.923669,True,,,,CHEMBL163,Food Effects Study of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants,,['COVID-19 Respiratory Infection'],[],,2023-05-04,2023-12-27,"[{'measure': 'Cmax', 'description': 'Maximum Observed Plasma Concentration (Cmax) of GST-HG171', 'timeFrame': 'Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose'}, {'measure': 'AUCinf', 'description': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of GST-HG171', 'timeFrame': 'Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose'}, {'measure': 'AUClast', 'description': 'Area Under the Curve From Time Zero o Last quantifiable concentration (AUClast) of GST-HG171', 'timeFrame': 'Day 1 pre-dose, 0.25、0.5、0.75、1、1.25、1.5、2、3、4、6、8、12、24、48 and 72 hour post-dose'}]","[{'measure': 'urine', 'description': 'Total recovery of GST-HG171 -related substances in urine', 'timeFrame': '120 hours from GST-HG171 administration'}, {'measure': 'feces', 'description': 'Total recovery of GST-HG171 -related substances in feces', 'timeFrame': '120 hours from GST-HG171 administration'}]",5.0,18 Years,50 Years,ALL,True,INDUSTRY,0.0,18.0,ESTIMATED,v2_robust,True,False,False,False,,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,CHEMBL163,partial_match,True,720.96,5.91,4.0
NCT06819436,Effect of Dexamethasone on Post-spinal Hypotension,Dexamethasone,['Dexamethasone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Post Spinal Anaesthesia Hypotension,Shaheed Mohtarma Benazir Bhutto Institue of Trauma,2025-09-01T16:18:24.755681,True,,,,CHEMBL1530428,Effect of Dexamethasone on Post-spinal Hypotension in Geriatric Patients Undergoing Orthopaedic Surgery at Tertiary Care Hospital Karachi.,,"['Post Spinal Anaesthesia Hypotension', 'Geriatric Population', 'Orthopedic Surgeries']",[],,2025-02,2025-05,"[{'measure': 'Post spinal Anesthesia Hypotension', 'description': 'Hypotension will be considered if there will be 25% decrease below the baseline for (Mean Arterial Pressure) MAP and will be managed by 300 ml of (Normal Saline) NS solution with incremental intravenous 5 mg doses of ephedrine. The proportion of patients with hypotension at any time during the first 20 min after induction of the (Spinal Anesthesia) SA and before starting the surgical procedure will be considered as the outcome of the study.', 'timeFrame': 'From enrollment to 30 minutes after spinal anesthesia'}]",[],1.0,65 Years,85 Years,ALL,True,OTHER,0.0,170.0,ESTIMATED,v2_robust,True,False,False,False,,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CHEMBL1530428,partial_match,True,434.5,2.47,4.0
NCT01306123,Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration,"Nascobal nasal spray (cyanocobalamin, USP)","['Vitamin B12-ratiopharm N, injection solution', 'Nascobal nasal spray (cyanocobalamin, USP)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Focus: Bioavailability,Swedish Orphan Biovitrum,2025-09-01T16:18:09.638476,True,,,,NOT_FOUND,"An Open, Randomized, Single-dose, Two-way Crossover Study to Characterize the Pharmacokinetic Properties of Cyanocobalamin When Administered as an Intranasal Spray and an Intramuscular Injection to Healthy Volunteers",,['Focus: Bioavailability'],"['bioavailability', 'pharmacokinetics', 'cyanocobalamin', 'intranasal', 'intramuscular']",,2011-02,2011-05,"[{'measure': 'Relative bioavailability', 'description': 'Relative bioavailability (Frel) based on the area under the serum concentration-time curve during 72 hours (AUC0-72h) for the test and reference products.', 'timeFrame': '0-72 hours'}]","[{'measure': 'Additional PK characteristics', 'description': 'Maximum serum concentration (Cmax), time of Cmax (tmax) and AUC0-24h.', 'timeFrame': '0-72h'}]",2.0,18 Years,40 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05135286,Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia,BRIMOCHOL™ PF,"['Vehicle', 'carbachol monotherapy', 'carbachol/brimonidine tartrate', 'BRIMOCHOL™ PF', 'Carbachol PF']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Presbyopia,Visus Therapeutics,2025-09-01T16:18:15.897207,True,,,,NOT_FOUND,"Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia",,['Presbyopia'],[],,2022-03-15,2025-03-13,"[{'measure': 'Change from baseline in near VA', 'description': 'Percentage of subjects with 3-line improvement in near VA without the loss of at least 1 line in distance VA', 'timeFrame': 'Baseline Day 1'}]",[],1.0,45 Years,80 Years,ALL,True,OTHER,0.0,629.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00446017,The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG,adrenaline,"['milrinone', 'adrenaline']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Cardiac Output, Low",University of Luebeck,2025-09-01T16:18:12.177812,True,,,,NOT_FOUND,Phase 3 Study of Adrenaline and Milrinone in Patients With Myocardial Dysfunction,,"['Cardiac Output, Low']","['coronary artery bypass grafting', 'inotropes', 'metabolism', 'renal failure']",,2003-06,2007-04,[{'measure': 'Plasma lactate concentration in the immediate postoperative period'}],"[{'measure': 'Hemodynamics'}, {'measure': 'Plasma pyruvate'}, {'measure': 'Plasma glucose'}, {'measure': 'Plasma creatinine'}, {'measure': 'Urinary excretion of alpha-1-microglobulin'}, {'measure': 'Plasma cystatin C'}]",7.0,18 Years,85 Years,ALL,False,OTHER,1.0,60.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00369512,A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma,Erlotinib,"['Tarceva', 'Erlotinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Cancer,University of Alabama at Birmingham,2025-09-01T16:18:10.920157,True,,,,NOT_FOUND,A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas,,['Cancer'],"['Phase II', 'Erlotinib', 'Radiotherapy', 'Squamous Cell Carcinomas', 'Cutaneous', 'Stage III']",,2006-08,2012-09,"[{'measure': 'Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments.', 'description': 'Number of gradeable toxicities (via CTCAE manual) experienced by patients on this protocol--number of events', 'timeFrame': '2 years'}, {'measure': 'Median Time to Cancer Recurrence', 'description': 'Per protocol, patients were followed every 3 months for recurrent disease by physical exam and imaging (MRI/CT). Recurrence, in most cases, is detected during routine history/physical exam. If disease was detected during follow-up, every attempt was made to obtain pathological confirmation of recurrence.', 'timeFrame': '2 years'}, {'measure': 'Number of Patients With Recurrence at 2 Years', 'description': 'Rate of recurrence at 2 years.', 'timeFrame': '2 years'}]",[],3.0,19 Years,,ALL,False,OTHER,2.0,15.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05923281,A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance,K-877 0.2 mg/day (once daily),"['K-877 0.2 mg/day (once daily)', 'Pemafibrate 0.4mg/day (once daily)', 'K-877 0.4 mg/day (once daily)', 'Placebo (once daily)', 'Pemafibrate 0.2mg/day (once daily)']",5,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Hypercholesterolemia,"Kowa Company, Ltd.",2025-09-01T16:18:19.660202,True,,,,NOT_FOUND,"A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-",,['Hypercholesterolemia'],[],,2023-05-01,2024-10-31,"[{'measure': 'Percent change from baseline in LDL-C (formula F).', 'description': 'Percent change = (measured value at each time point - baseline value) / baseline value', 'timeFrame': '4, 8, and 12 weeks after administration'}]","[{'measure': 'Efficacy: % change from baseline in fasting serum LDL-C (mg/dL)(Direct)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum HDL-C (mg/dL)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum non HDL-C (mg/dL)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum TG (mg/dL)', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum LDL-C（formula F）/HDL-C', 'timeFrame': '4, 8, and 12 week after administration'}, {'measure': 'Efficacy: % change from baseline in fasting serum non HDL-C/HDL-C', 'timeFrame': '4, 8, and 12 week after administration'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04918771,Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old,Raphamin,"['Raphamin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Respiratory Viral Infection,Materia Medica Holding,2025-09-01T16:18:10.925542,True,,,,NOT_FOUND,Multicenter Double Blind Placebo-controlled Parallel-group Randomized Clinical Study of Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 12-18 Years Old,,['Acute Respiratory Viral Infection'],[],,2021-04-29,2023-07-21,"[{'measure': 'Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).', 'description': 'Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}]","[{'measure': 'Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).', 'description': 'The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score).\n\nTSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules:\n\nif temp \\<= 37.3 then score = 0 (none) if 37.3 \\< temp \\<= 38.0 then score = 1 (mild) if 38.0 \\< temp \\<= 39.0 then score = 2 (moderate) if 39.0 \\< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.', 'timeFrame': 'Day1 through Day6 of the treatment and observation'}, {'measure': 'Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).', 'description': 'ARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}, {'measure': 'Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).', 'description': 'ARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}, {'measure': 'Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).', 'description': 'Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nARVI\'s resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from ""0"" to ""42"". The TSS higher score is the worse outcome.', 'timeFrame': '14 days of observation'}, {'measure': 'Dosing Frequency of Antipyretics.', 'description': 'Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.', 'timeFrame': '3 days of therapy'}, {'measure': 'Percentage of Patients Reporting Worsening of Illness.', 'description': 'Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.', 'timeFrame': 'Day 4 through day 14 of the treatment and observation period'}, {'measure': 'Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.', 'description': '1. The intensity (severity) of adverse events.\n2. Causal relationship of AEs to the sudy drug.\n3. Outcome of AEs. Based on medical records.', 'timeFrame': '14 days of observation'}, {'measure': 'Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).', 'description': ""The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7)."", 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}, {'measure': 'Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.', 'description': ""Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7)."", 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}, {'measure': 'Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).', 'description': ""Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7)."", 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}, {'measure': 'Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.', 'description': 'Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.', 'timeFrame': 'Day 1 through day 7 of the treatment and observation period.'}]",12.0,12 Years,18 Years,ALL,False,INDUSTRY,0.0,435.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03320694,Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus,Metformin,"['Insulin', 'Glucophage', 'Humulin R U 100 and Humulin N', 'Metformin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Gestational Diabetes Mellitus in Pregnancy,"Services Institute of Medical Sciences, Pakistan",2025-09-01T16:18:13.417329,True,,,,CHEMBL1703,Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus,,['Gestational Diabetes Mellitus in Pregnancy'],"['Gestational Diabetes Mellitus, Metformin, Insulin']",,2016-02-01,2017-06-30,"[{'measure': 'maternal glycemic control', 'description': 'Maternal glycemic control was measured by blood sugar levels', 'timeFrame': 'From time of randomisation till 40 weeks'}]","[{'measure': 'Fetal macrosomia', 'description': 'Birth weight more than 4kg', 'timeFrame': 'at birth'}, {'measure': 'Apgar score', 'description': '\\<7 at 5min', 'timeFrame': 'at birth'}, {'measure': 'Neonatal intensive care unit (NICU) stay', 'description': 'Admitted to NICU', 'timeFrame': '>24 hours after birth'}, {'measure': 'Perinatal death', 'description': 'Fetal or neonatal death within 7 days', 'timeFrame': '7 days of delivery'}, {'measure': 'mode of delivery', 'description': 'Lower segment cesarean section , Spontaneous Vaginal Delivery, Instrumental delivery', 'timeFrame': 'at delivery'}, {'measure': 'Neonatal hypoglycemia', 'description': 'Neonatal blood sugar was checked at birth and if \\<2.2mmol/l, was labelled', 'timeFrame': 'at birth'}]",7.0,18 Years,45 Years,FEMALE,True,OTHER_GOV,0.0,278.0,ACTUAL,v2_robust,True,True,False,False,,CN(C)C(=N)NC(=N)N.Cl,CHEMBL1703,partial_match,True,165.63,-1.03,4.0
NCT01781455,A Study of BBI503 in Adult Patients With Advanced Solid Tumors,BBI503,['BBI503'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Cancer, Advanced Solid Tumors","Sumitomo Pharma America, Inc.",2025-09-01T16:18:23.445650,True,,,,NOT_FOUND,A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors,,"['Cancer, Advanced Solid Tumors']",[],,2012-02,2020-06,"[{'measure': 'Number of participants with Adverse Events as a Measure of Safety and Tolerability', 'description': 'Assessment of safety of BBI503 by reporting of adverse events and serious adverse events.', 'timeFrame': 'Adverse events will be assessed at baseline, while the participant is taking BBI503, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.'}, {'measure': 'Determination of the recommended Phase 2 dose', 'timeFrame': 'Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 weeks'}]","[{'measure': 'Pharmacokinetic profile (Area under the curve) of BBI503', 'description': 'Blood sampling to assess the pharmacokinetic profile (Area under the curve) of BBI503.', 'timeFrame': 'During the first 28 days of treatment'}, {'measure': 'Pharmacodynamic activity', 'description': 'Tumor Biopsy(s) to provide information on analysis of the targets and downstream genes/ effect of BBI503 on cancer stem cells through immunohistochemistry.', 'timeFrame': 'During the first 28 days of treatment'}, {'measure': 'Anti-tumor activity', 'description': 'To assess the preliminary anti-tumor activity of BBI503.', 'timeFrame': 'Participants will be assessed every eight weeks for anti-tumor activity.'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,311.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02146638,Post Operative Pain Control: Morphine vs Fentanyl,Morphine,"['Fentanest', 'Fentanyl', 'Morphine']",3,INTERVENTIONAL,['NA'],,COMPLETED,Post Operative Analgesia,Catholic University of the Sacred Heart,2025-09-01T16:18:17.183069,True,,,,CHEMBL556578,Post Operative Pain Control: Continuous Infusion of Morphine vs Fentanyl. Clinical Outcomes,,['Post Operative Analgesia'],"['post operative analgesia, morphine, fentanyl']",,2012-04,2012-09,"[{'measure': 'pain scores', 'description': 'data were recorded at 1,6,18 and 24 hours after surgery', 'timeFrame': 'data were recorded during the 24 post operative hours'}]","[{'measure': 'analgesic requirements', 'description': 'if VAS value was equal or higher than 6 patients received ketorolac 30 mg iv', 'timeFrame': 'during the 24 hours after surgery'}]",2.0,35 Years,59 Years,FEMALE,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.Cl,CHEMBL556578,partial_match,True,321.8,1.2,4.0
NCT01234675,The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia,Milnacipran,"['Savella', 'Placebo', 'Sugar pill', 'Milnacipran']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Sleep Disorders,Mansoor Ahmed M.D.,2025-09-01T16:18:13.422800,True,,,,CHEMBL4297064,The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia,,"['Sleep Disorders', 'Fibromyalgia', 'Sleep']","['Fibromyalgia', 'Sleep disorders', 'Forest Laboratories', 'Milnacipran']",,2010-11,2014-02,"[{'measure': 'Number of Awakenings After Sleep Onset (NAASO)', 'description': 'Number of awakenings after defined sleep onset until lights on.', 'timeFrame': '4-Week maintenance treatment with milnacipran and placebo'}, {'measure': 'Sleep Efficiency (SE)', 'description': 'Percentage of time spent asleep while in bed', 'timeFrame': '4-Week maintenance treatment with milnacipran and placebo'}, {'measure': 'Wake After Sleep Onset (WASO)', 'description': 'Wake time after defined sleep onset until lights on.', 'timeFrame': '4-Week maintenance treatment with milnacipran and placebo'}]","[{'measure': 'Latency to Persistent Sleep Onset (LPS)', 'description': 'It is defined as time from lights out to the first consecutive 2 minutes of uninterrupted sleep.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Total Sleep Time (TST)', 'description': 'Total sleep of all Rapid Eye Movement (REM) and Non- Rapid Eye Movement Sleep (NTREM) from lights out to lights on.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Arousal Index (AI)', 'description': 'Number of arousals per hour of sleep', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Slow Wave Sleep (SWS)', 'description': 'Time spent in stage 3 of non-rapid eye movement sleep and often referred to as deep sleep.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)', 'description': 'This is a subjective index derived from the medical outcomes study sleep scale (MOS-SS) scored on a 0-100 possible range with higher scores indicating more severe sleep disruption. The scale is a self-report instrument consisting of 12 items that assess perceived initiation and maintenance of sleep, respiratory problems during sleep, sleep duration, perceived adequacy of sleep and daytime somnolence.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Sleep Quality Scale', 'description': 'Sleep quality measure derived from daily sleep diary rating ranging from 0 (""very poor"") to 10 (""excellent"")', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Fatigue Severity Scale (FSS) Total Score', 'description': 'The scale is a 9-item self-report of fatigue in the past week and scored on a 7-point scale with 1 = strongly disagree and 7 = strongly agree. Scores range from 9 to 63 with higher scores indicating higher fatigue severity. A total score greater or equal to 36 suggests fatigue.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Fibromyalgia Impact Questionnaire (FIQ) Total Score', 'description': ""The scale is composed of 10 items relating to fibromyalgia symptoms experienced in the past week. Score ranges from 0 to 100 with higher scores indicating a greater effect of fibromyalgia on a person's life."", 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Brief Pain Inventory (BPI) Mean Severity Score', 'description': 'The score is derived from the BPI scale and measures pain intensity in the past 24 hour. The pain severity score is derived as the average score of 4 pain items assessing pain at its ""worst"", ""least"", ""average"" and ""now"" and ranges from 0-10 with higher scores reflecting greater pain', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Brief Pain Inventory (BPI) Mean Interference Score', 'description': 'The score is derived from the BPI scale and measures the effect of pain on functioning in the past 24 hour. It is the average score of 7 items interfering with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Score ranges from 0-10 with higher scores reflecting greater interference.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}]",13.0,18 Years,,ALL,False,OTHER,1.0,19.0,ACTUAL,v2_robust,True,True,False,False,,CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl,CHEMBL4297064,partial_match,True,282.81,1.77,4.0
NCT05413850,Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection,Lutetium (177Lu) rhPSMA-10.1 Injection,"['Lutetium (177Lu) rhPSMA-10.1 Injection', '177Lu-rhPSMA-10.1']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Prostate Cancer,Blue Earth Therapeutics Ltd,2025-09-01T16:18:09.633613,True,,,,NOT_FOUND,"An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer",,"['Prostate Cancer', 'Metastatic Castration-resistant Prostate Cancer', 'mCRPC', 'Urogenital Neoplasms', 'Prostatic Neoplasms', 'Prostatic Diseases']","['PSMA', 'mCRPC', 'Prostate cancer', '177Lu rhPSMA-10.1', '18F-rhPSMA-7.3', 'BET-PSMA-121', 'Blue Earth Therapeutics Limited', 'Radiohybrid', 'Radiopharmaceuticals']",,2022-07-20,2028-03-31,"[{'measure': 'Phase 1 Incidence of DLTs', 'description': 'Incidence of DLTs during the DLT observation period.', 'timeFrame': '6 weeks post final IMP'}, {'measure': 'Phase 1 Frequency and nature of TEAEs', 'description': 'Frequency and nature of treatment-emergent adverse events (TEAEs).', 'timeFrame': 'End of study'}, {'measure': 'Phase 2 Evaluate the efficacy of Lutetium (177Lu) rhPSMA-10.1 Injection', 'description': 'The number of subjects with an anti-tumour response defined as ≥50% reduction in PSA level from baseline to the end of treatment.', 'timeFrame': '6 weekly intervals'}]",[],3.0,18 Years,,MALE,False,INDUSTRY,1.0,82.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04431518,Pharmacokinetics of JULUCA in Hemodialysis,JULUCA 50Mg-25Mg Tablet,['JULUCA 50Mg-25Mg Tablet'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,HIV/AIDS,Indiana University,2025-09-01T16:18:20.955075,True,,,,NOT_FOUND,The Steady-State Pharmacokinetics (PK) of Dolutegravir/Rilpivirine Fixed Dose Combination (FDC) in Patients With End Stage Renal Disease (ESRD) Requiring Hemodialysis (HD),,"['HIV/AIDS', 'ESRD']","['HIV', 'ESRD', 'Hemodialysis', 'Pharmacokinetics']",,2021-04-23,2023-07-31,"[{'measure': 'Dolutegravir (DTG) Ctau', 'description': 'Steady-state plasma Ctau for dolutegravir at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}, {'measure': 'Rilpivirine (RPV) Ctau', 'description': 'Steady-state plasma Ctau for rilpivirine at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}]","[{'measure': 'Safety of DTG', 'description': 'The attributable grade 3 or 4 adverse events associated with use of DTG will be assessed during the study. Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Grade 3 indicates a severe event, and Grade 4 indicates a potentially life-threatening event.', 'timeFrame': '30 days'}, {'measure': 'DTG AUC', 'description': 'Steady-state plasma AUC for dolutegravir at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}, {'measure': 'DTG Cmax', 'description': 'Steady-state plasma Cmax for dolutegravir at the intensive study visit, which occurred between days 11 and 14', 'timeFrame': '0 to 24 hours post-dose on the intensive study visit'}]",5.0,18 Years,65 Years,ALL,True,OTHER,0.0,8.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01282970,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes",BI 135585,"['Placebo to BI 135585', 'BI 135585']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,2025-09-01T16:18:20.964296,True,,,,NOT_FOUND,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (5 to 100 mg q.d. for 14 Days) of BI 135585 XX in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)",,"['Diabetes Mellitus, Type 2']",[],,2011-02,,"[{'measure': 'Safety and tolerability of BI 135585 will be assessed in a descriptive way using physical examinations (occurence of findings), vital signs, electrocardiograms, laboratory tests, and incidence and severity of adverse events.', 'timeFrame': 'up to 16 days post treatment'}]","[{'measure': 'Assessment of Pharmacokinetic parameter Cmax (maximum measured concentration of the analyte in plasma) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter tmax (time from dosing to maximum measured concentration) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter λz (terminal rate constant in plasma) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter λz,ss (terminal rate constant in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter t1/2,ss (terminal half-life of the analyte in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter MRTpo,ss (mean residence time of the analyte in the body after multiple oral administrations at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter PTF (Peak-Trough Fluctuation) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cavg (average concentration of the analyte in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple dose oral administration over a uniform dosing interval τ, expresses ratio of Cmax at steady state and after single dose)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple dose oral administration over a uniform dosing interval τ, expresses ratio of AUC at steady state and after single dose)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cpre,N (the predose concentration of the analyte in plasma immediately before administration of the Nth dose after N-1 doses were administered)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Exploratory evaluation of the pharmacodynamics of BI 135585 by determination of 11beta-hydroxysteroid dehydrogenase type 1 activity in adipose tissue (ex vivo)', 'timeFrame': 'up to 24 hours post treatment'}, {'measure': 'Exploratory evaluation of the pharmacodynamics of BI 135585 by measuring of cortisol and cortisone and their metabolites in urine', 'timeFrame': 'up to 24 hours post treatment'}]",27.0,20 Years,70 Years,ALL,False,INDUSTRY,0.0,72.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05099835,Ultrasound-Guided Stellate Ganglion Block With Botulinum,Botox,"['Botox', 'triamcinolonacetonide']",2,INTERVENTIONAL,['NA'],,COMPLETED,Change From Baseline House-Brackmann,Assiut University,2025-09-01T16:18:07.013310,True,,,,NOT_FOUND,Ultrasound-Guided Stellate Ganglion Block With Botulinum Toxin Versus Steroid in Refractory Bell's Palsy,,['Change From Baseline House-Brackmann'],[],,2021-11-01,2022-07-01,"[{'measure': 'Change from Baseline House-Brackmann', 'description': 'Change from Baseline House-Brackmann', 'timeFrame': ': Baseline ,change from baseline House-Brackmann at 7th day,one month,two month, three month'}]",[],1.0,18 Years,60 Years,ALL,False,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04645667,Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT),Tacrolimus,"['Prograf', 'Tacrolimus']",2,OBSERVATIONAL,[],,COMPLETED,Acute GVHD,UNC Lineberger Comprehensive Cancer Center,2025-09-01T16:18:13.427125,True,,,,CHEMBL269732,Development of a Population Pharmacokinetic Model to Optimize Tacrolimus Dosing in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplant.,,['Acute GVHD'],"['tacrolimus', 'aGVHD', 'pharmacokinetics', 'pharmacodynamics', 'pharmacogenomics', 'CYP3A5 genetic polymorphisms']",,2021-02-01,2023-10-15,"[{'measure': 'Tacrolimus clearance', 'description': ""Patient's clearance calculated after the first day on tacrolimus and patient's clearance calculated after 5-6 doses of tacrolimus after they reach steady-state"", 'timeFrame': 'Day +1 of tacrolimus administration to Day +4 of tacrolimus administration'}]","[{'measure': 'Incidence and severity of aGVHD', 'description': 'The duration from the day of transplant to the first occurrence of aGVHD, censored at 100 days post-HCT.', 'timeFrame': 'Day +21 to Day +100 from HCT'}, {'measure': 'Incidence of tacrolimus-induced toxicities', 'description': 'The duration from the day of transplant to the first occurrence of tacrolimus-induced toxicities (AKI, hypertension, and metabolic abnormalities)', 'timeFrame': 'Day -3 to Day +100 from HCT'}, {'measure': 'Time to aGVHD', 'description': 'The duration from the day of transplant to the first occurrence of aGVHD, censored at 100 days post-HCT.', 'timeFrame': 'Day +21 to Day +100 from HCT'}, {'measure': 'Time to tacrolimus-induced toxicities (AKI, hypertension, metabolic panel abnormalities)', 'description': 'The duration from the day of transplant to the first occurrence of AKI, hypertension, and metabolic panel abnormalities, censored at 100 days post-HCT.', 'timeFrame': 'Day -3 to Day +100 from HCT'}]",5.0,18 Years,,ALL,False,OTHER,1.0,38.0,ACTUAL,v2_robust,False,True,False,False,,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,CHEMBL269732,partial_match,True,804.03,4.64,4.0
NCT00313976,"Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)","Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)","['Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)']",1,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Multiple Sclerosis,Bayer,2025-09-01T16:18:09.631416,True,,,,NOT_FOUND,"A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis",,['Multiple Sclerosis'],"['Multiple Sclerosis', 'Early secondary progressive Multiple Sclerosis']",,,,"[{'measure': 'Magnetic Resonance Imaging (MRI): T2-lesions', 'timeFrame': 'At week 104'}]","[{'measure': 'Further Magnetic Resonance Imaging (MRI) parameters', 'timeFrame': 'At week 104'}, {'measure': 'Relapses', 'timeFrame': 'At week 104'}, {'measure': 'Changes in Expanded Disability Status Score (EDSS) and Multiple Sclerosis Impact Scale (MSIS)', 'timeFrame': 'At week 104'}, {'measure': 'Hospitalizations', 'timeFrame': 'At week 104'}, {'measure': 'Neutralizing antibodies', 'timeFrame': 'At week 104'}, {'measure': 'Adverse events', 'timeFrame': 'At week 104'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,,,,no_match,False,,,
NCT02749994,A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study),Rosuvastatin,"['Ezetimibe', 'Rosuvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hypercholesterolemia,IlDong Pharmaceutical Co Ltd,2025-09-01T16:18:15.900285,True,,,,NOT_FOUND,,,['Hypercholesterolemia'],[],,2016-04,2017-02,"[{'measure': 'Percent change from baseline to 8 week in LDL-Cholesterol', 'timeFrame': 'baseline and 8 week'}]","[{'measure': 'Percent change from baseline to 4 and 8 week in Total Cholesterol', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in Triglyceride', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in HDL-Cholesterol', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in non-HDL-Cholesterol', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in Apolipoprotein B', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in Apolipoprotein A1', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 week in LDL-Cholesterol', 'timeFrame': 'baseline to 4 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in hs-CRP(high-sensitivity C-reactive protein)', 'timeFrame': 'baseline to 4 and 8'}, {'measure': 'The change of LDL-Cholesterol/HDL-Cholesterol ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The change of Total Cholesterol/HDL-Cholesterol ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The change of non-HDL-Cholesterol/HDL-Cholesterol ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The change of Apolipoprotein B/Apolipoprotein A1 ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The ratio of subjects who reach the goal of LDL-Cholesterol according to NCEP(National Cholesterol Education Program Adult Treatment Panel) III Guideline', 'timeFrame': 'baseline to 4 and 8 week'}]",14.0,19 Years,79 Years,ALL,False,INDUSTRY,0.0,396.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04846868,Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1),Iclepertin,"['Iclepertin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Schizophrenia,Boehringer Ingelheim,2025-09-01T16:18:14.673689,True,,,,NOT_FOUND,"A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)",,['Schizophrenia'],[],,2021-09-08,2024-10-01,"[{'measure': 'Change from baseline in overall composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) after 26 weeks of treatment', 'description': 'MCCB comprises 10 tests, which assess 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition', 'timeFrame': 'at baseline and at week 26'}]","[{'measure': 'Change from baseline in the Schizophrenia Cognition Rating Scale (SCoRS) interviewer total score after 26 weeks of treatment', 'description': 'SCoRS is a 20-item interview-based assessment of cognitive deficits and the degree to which they affect day-to-day functioning. Each item is rated on a 4-point scale. Higher ratings reflect a greater degree of impairment.', 'timeFrame': 'at baseline and at week 26'}, {'measure': 'Change from baseline to Week 26 in the adjusted total time T-score in the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)', 'timeFrame': 'at baseline and at week 26'}, {'measure': 'Change from baseline to Week 26 in the T-score of the number of correct responses on Tower of London (ToL) test', 'timeFrame': 'at baseline and at week 26'}, {'measure': 'Change from screening visit 1a to Week 24 in Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) total score', 'description': ""PRECIS is a patient reported outcome (PRO) for recording patients' subjective experience of Cognitive Impairment Associated with Schizophrenia (CIAS). The questionnaire contains 28 items covering 6 domains: Memory (6 items), communication (4 items), self-control (3 items), executive function (4 items), attention (6 items), and sharp thinking (3 items). Two additional items assess the overall degree of bother associated with all domains. Questions are answered via a 5-category Likert scale, with higher scores corresponding to worse patient experience. The Total Score is derived by calculating the simple average score of the first 26 items."", 'timeFrame': 'up to 24 weeks'}]",5.0,18 Years,50 Years,ALL,False,INDUSTRY,0.0,620.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04644354,The Efficacy of Nifedipine in the Management of Preterm Labor,Nifedipine 10 mg,['Nifedipine 10 mg'],1,OBSERVATIONAL,[],,UNKNOWN,Preterm Labor,"Ethem Unal, M.D., PhD, Associate Prof of Surgery & Surgic",2025-09-01T16:18:13.416468,True,,,,NOT_FOUND,The Tocolytic Efficacy of Nifedipine in the Management of Threatened and Advanced Preterm Labor: A Study on 444 Singleton Pregnant Women With Intact Membranes,,"['Preterm Labor', 'Preterm Birth', 'Preterm Labor Without Delivery', 'Preterm Labor With Preterm Delivery in Third Trimester', 'Calcium-Channel Blockers Toxicity', 'Side Effect of Drug']","['Nifedipine', 'Tocolytics']",,2020-12-15,2020-12-30,"[{'measure': 'Delay Delivery for 1 day', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is only 24 hours', 'timeFrame': '1 day'}, {'measure': 'Delay Delivery for 2 days', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is 48 hours', 'timeFrame': '2 days'}, {'measure': 'Delay Delivery for 3 days', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is 72 hours', 'timeFrame': '3 days'}, {'measure': 'Delay Delivery for 7 days', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is 168 hours', 'timeFrame': '7 days'}, {'measure': 'Birth before 34 weeks', 'description': 'After start of tocolytic nifedipine, the preterm birth occurs before 34 weeks', 'timeFrame': 'till 34 weeks of gestation'}, {'measure': 'Birth before 37 weeks', 'description': 'After start of tocolytic nifedipine, the preterm birth occurs before 37 weeks', 'timeFrame': 'till 37 weeks of gestation'}, {'measure': 'Birth after 37weeks', 'description': 'After start of tocolytic nifedipine, the preterm birth occurs after 37 weeks (Normal birth)', 'timeFrame': 'after 37 weeks of gestation-normal birth'}]",[],7.0,,,FEMALE,False,OTHER_GOV,0.0,444.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT00576615,Propofol's Hypnotic and Memory Effects,Placebo solution,"['Placebo solution', 'propofol']",2,OBSERVATIONAL,[],,COMPLETED,Healthy,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:12.175657,True,,,,NOT_FOUND,CNS Targets of Propofol's Hypnotic and Memory Effects,,['Healthy'],"['healthy volunteers', 'amnesic effects']",,2002-05,2016-05,"[{'measure': 'Demonstrate the persistence of defined stimulation-related changes in brain activity during various levels of propofol and thiopental sedation.', 'timeFrame': 'fifteen hours over several different days'}]","[{'measure': 'Identify the neuroanatomical regions mediating propofol-induced amnesia and sedation.', 'timeFrame': 'fifteen hours over several different days'}]",2.0,18 Years,45 Years,ALL,True,OTHER,2.0,102.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT04224441,Repurposing Chlorpromazine in the Treatment of Glioblastoma,Chlorpromazine Pill,"['Temozolomide', 'Chlorpromazine Pill']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Glioblastoma Multiforme,"Marco G Paggi, MD, PhD",2025-09-01T16:18:13.416340,True,,,,CHEMBL564,Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme,,"['Glioblastoma Multiforme', 'MGMT-Unmethylated Glioblastoma']","['drug repurposing', 'antipsychotic drugs', 'glioblastoma']",,2019-12-15,2022-12-15,"[{'measure': 'Evaluation of toxicity', 'description': 'Toxicity evaluation of the combined treatment. Subjects will be evaluated for symptoms and adverse effects according to the NCI-CTCAE version 5.0 grading tool', 'timeFrame': '6 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Effect of of adding CPZ to the standard GBM therapy, when compared with the standard therapy alone', 'timeFrame': '6 months'}]","[{'measure': 'Evaluation of tumor response', 'description': 'Effect of of adding CPZ to the standard glioblastoma multiforme (GBM) therapy, when compared with the standard therapy alone', 'timeFrame': '6 months'}, {'measure': 'Overall survival (OS)', 'description': 'Effect of of adding CPZ to the standard glioblastoma multiforme (GBM) therapy, when compared with the standard therapy alone', 'timeFrame': '6 months'}]",4.0,18 Years,70 Years,ALL,False,OTHER,3.0,41.0,ESTIMATED,v2_robust,True,False,False,True,,CN(C)CCCN1c2ccccc2Sc2ccccc21,CHEMBL564,partial_match,True,284.43,4.24,4.0
NCT02373865,Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes,Sitagliptin,"['Glimepiride-Placebo', 'Sitagliptin', 'Glimepiride', 'Sitagliptin-Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Diabetes Mellitus Type 2,GWT-TUD GmbH,2025-09-01T16:18:24.753277,True,,,,NOT_FOUND,Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy,,['Diabetes Mellitus Type 2'],"['Diabetes mellitus type 2', 'nocturnal hypoglycemia', 'metformin monotherapy']",Premature termination due to insufficient patient recruitement..,2015-09,2017-01,"[{'measure': 'Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride', 'description': 'measurement of hypoglycemic episodes including event duration at baseline and EOT after 12 weeks of treatment and measurement of time spent below critical values for hypoglycemic episodes are the primary objectives of this study. We will calculate overall episodes/time (5 days) and nocturnal episodes.', 'timeFrame': '12 weeks (at baseline and at EOT)'}]","[{'measure': 'Occurence and Number of Nocturnal Ventricular Arrhythmias', 'description': 'measurement of nocturnal ventricular arrhythmias at baseline and EOT (after 12 weeks of treatment) - per patient, couplets per patient, triplets per patient)', 'timeFrame': '12 weeks (at baseline and at EOT)'}, {'measure': 'Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride', 'description': 'The glycemic profile is defined as the area under the glucose-timeprofile obtained by continuous glucose monitoring (5 days baseline and 5 days after 12 weeks of each treatment)', 'timeFrame': '12 weeks (at baseline and at EOT)'}]",3.0,40 Years,80 Years,ALL,False,OTHER,0.0,4.0,ACTUAL,v2_robust,True,False,True,False,Premature termination due to insufficient patient recruitement..,,,no_match,False,,,
NCT03315494,"Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers",SKI-O-703 capsule,"['Placebo capsule', 'SKI-O-703 capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Arthritis, Rheumatoid",Oscotec Inc.,2025-09-01T16:18:15.900270,True,,,,NOT_FOUND,"A Phase 1, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of SKI-O-703 in Healthy Volunteers",,"['Arthritis, Rheumatoid']","['rheumatoid arthritis', 'healthy volunteers', 'moderate to severe']",,2016-09-22,2016-12-21,"[{'measure': 'Number of participants (Healthy Volunteers) with reported adverse events receiving multiple dose of SKI-O-703 as assessment of safety and tolerability.', 'description': 'Safety and tolerability of SKI-O-703 as measured by subject incidence of treatment-related Adverse Events.', 'timeFrame': '21 days'}]","[{'measure': 'Area under the concentration versus time curve within a dosing interval (AUC0-tau), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'AUC0-tau will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC0-t), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'AUC0-t will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Area under the concentration versus time curve within a dosing interval (AUC0-inf), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'AUC0-inf will be reported.', 'timeFrame': 'Day 7 only'}, {'measure': 'Maximum observed concentration (Cmax), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Cmax will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Apparent oral clearance (CL/F), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'CL/F will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Terminal elimination rate constant (Kel), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Kel will be reported.', 'timeFrame': 'Day 7'}, {'measure': 'Time to reach the maximum observed concentration, to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Tmax will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Apparent terminal elimination half-life (t1/2), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 't1/2 will be reported.', 'timeFrame': 'Day 7 only'}, {'measure': 'Apparent volume of distribution (Vd/F), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Vd/F will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Metabolite ratio (Rmet), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Rmet will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Accumulation ratio based on AUC0-tau (RAUC), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'RAUC will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}]",12.0,18 Years,55 Years,ALL,True,INDUSTRY,1.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05287984,Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL,"Zanubrutinib, Fludarabine, cyclophosphamide and rituximab","['Zanubrutinib, bendamustine, rituximab', 'Zanubrutinib, Fludarabine, cyclophosphamide and rituximab', 'ZFCR regimen', 'ZBR regimen']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Chronic Lymphocytic Leukemia,"Institute of Hematology & Blood Diseases Hospital, China",2025-09-01T16:18:08.355469,True,,,,CHEMBL226335,A Phase 2 Clinical Trial to Evaluate the Efficacy of Zanubrutinib Followed Zanubrutinib Plus FCR (Fludarabine Cyclophosphamide and Rituximab) / BR(Bendamustine and Rituximab) in Newly Diagnosed Symptomatic CLL/SLL (STOP Trial),,"['Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma', 'Newly Diagnosed']","['chronic lymphocytic leukemia', 'Small Lymphocytic Lymphoma', 'newly diagnosed', 'Zanubrutinib']",,2022-03-22,2024-11-29,"[{'measure': 'MRD negative rate of CR patients', 'description': 'The negative MRD rate of patients with CR at the end of 16 cycles of treatment', 'timeFrame': 'up to the end of 16 cycles of treatment (each cycle is 28 days)'}]","[{'measure': 'overall response rate(ORR)', 'description': 'Defined as the proportion of patients whose BICR was assessed for CR, CRi, or PR according to IWCLL 2018 criteria at or before initiation of subsequent antitumor therapy.', 'timeFrame': 'up to the end of 16 cycles of treatment (each cycle is 28 days)'}, {'measure': 'Complete response (CR)', 'description': 'Defined as the percentage of subjects who achieved CR after treatment in the conformance population and the intentionality treatment population.', 'timeFrame': 'up to the end of 16 cycles of treatment (each cycle is 28 days)'}, {'measure': 'Duration of tumor remission(DOR)', 'description': 'Defined as the time interval between the first documented remission of disease and the first documented evidence of PD for patients in the intentional-treatment population (ITT). Exit with no progress or no recorded time of disease progression, with the date of the last examination as the end date.', 'timeFrame': 'up to 5 years'}, {'measure': 'time to next treatment(TTNT)', 'description': 'Patients in the treatment-intentionality population (ITT) were defined from the beginning of first-line treatment to the beginning of back-line treatment or the time of death.', 'timeFrame': 'up to 5 years'}, {'measure': 'Progress-free survival(PFS)', 'description': 'the time from treatment initiation until disease progression or death, If there was no progress at the time of withdrawal or the time of disease progression was not recorded, the end date was the date of the last examination.', 'timeFrame': 'up to 5 years'}, {'measure': 'The time at which the median MRD turned positive', 'description': 'It was defined as the time for the median peripheral and/or bone marrow MRD to become positive in patients with CR/CRi and MRD negative in bone marrow and peripheral blood after the 16th cycle of treatment.', 'timeFrame': 'up to 5 years'}, {'measure': 'overall survival', 'description': 'Defined as the time interval from enrollment to death for patients in the treatment-intentionality population (ITT). If the patient remains alive or if it is not known whether the patient is alive or dead, the date of death will be adopted at the most recent point in time when the patient is known to be alive.', 'timeFrame': 'up to 5 years'}, {'measure': 'Safety of treatment regimens', 'description': 'Defined as treatment-related toxicity', 'timeFrame': 'up to 5 years'}]",9.0,18 Years,,ALL,False,OTHER,0.0,63.0,ESTIMATED,v2_robust,True,False,False,True,,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,CHEMBL226335,partial_match,True,610.52,-1.69,2.0
NCT02519140,Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections,Cook Medical EMR Gel,"['Cook Medical EMR Gel will be injected submucosally', 'Cook Medical EMR Gel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Gastric Cancer,Antonios Likourezos,2025-09-01T16:18:07.015917,True,,,,NOT_FOUND,Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections,,"['Gastric Cancer', 'Colon Cancer']","['Gastric cancer', 'colon cancer', 'EMR', 'biopsy', 'bariatric surgery']",,2014-08-01,2022-11-30,"[{'measure': 'Lift Efficacy', 'description': 'Lifting characteristics which would be measured by height of the mucosa after submucosal gel injection.', 'timeFrame': '1 hour'}]","[{'measure': 'Dissection Adequacy', 'description': 'Dissection adequacy which would be measured by time which the gel stays within the tissues. Anything less than one hour will be considered failure.', 'timeFrame': '1 hour'}]",2.0,18 Years,65 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,,,,no_match,False,,,
NCT03522662,Anti IL-18 (GSK1070806) in Behcet's Disease,GSK1070806,"['anti IL-18', 'GSK1070806']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Behcet's Disease,Cambridge University Hospitals NHS Foundation Trust,2025-09-01T16:18:12.187001,True,,,,NOT_FOUND,An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease,,"[""Behcet's Disease""]",[],,2018-08-01,2020-04-01,"[{'measure': 'The occurrence of all moderate, severe and life threatening adverse events', 'description': 'Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)', 'timeFrame': '24 weeks'}]","[{'measure': 'All adverse events, including mild events', 'description': 'Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)', 'timeFrame': '24 weeks'}, {'measure': 'Measurement of disease activity', 'description': ""Using a clinical scoring tool, the Behcet's disease current activity form (BDCAF)"", 'timeFrame': '24 weeks'}, {'measure': 'Measurement of the accumulation of damage', 'description': 'Using a clinical scoring tool, the Vasculitis Damage Index (VDI)', 'timeFrame': '24 weeks'}]",4.0,18 Years,,ALL,False,OTHER,0.0,12.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00003198,Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors,ifosfamide,"['topotecan hydrochloride', 'ifosfamide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Unspecified Adult Solid Tumor, Protocol Specific",Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:19.669452,True,,,,CHEMBL889,A Phase I Dose-Escalation Study of Topotecan and Ifosfamide in Patients With Refractory Non-Hematologic Malignancies.,,"['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",,1997-11,2000-05,[],[],0.0,18 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,True,False,False,,O=P(O)(NCCCl)NCCCl,CHEMBL889,partial_match,True,221.02,0.74,3.0
NCT05093920,Role of DEB-TACE Versus c-TACE in Treatment of HCC,Doxorubicin-Eluting Beads,"['Doxorubicin-Eluting Beads', 'Lipidol-Doxorubicin emulsion']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Hepatocellular Carcinoma,Sohag University,2025-09-01T16:18:15.890925,True,,,,NOT_FOUND,Role of Drug Eluting Bead Transarterial Chemoebolization Versus Conventional Transarterial Chemoembolization in Treatment of Hepatocellular Carcinoma,,['Hepatocellular Carcinoma'],[],,2022-01-01,2024-01-30,"[{'measure': 'Tumor size', 'description': 'Triphasic CT scan of the liver measures the maximum diameter of tumor according to modified RECIST (mRecist) criteria.', 'timeFrame': 'four-six weeks after treatment'}]","[{'measure': 'Serum Alpha-fetoprotein level ng/ml.', 'description': 'Laboratory test of Serum alpha-fetoprotein level (AFP) ng/ml.', 'timeFrame': 'four-six weeks after treatment'}]",2.0,,,ALL,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01313702,Single Pill to Avert Cardiovascular Events,polipillV1,"['polipillV2', 'polipillV1', 'lisinopril', 'simvastatin', 'acetylsalicilic acid', 'atenolol', 'hidrochlorotiazide', 'no other name', 'usual care']",9,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Cardiovascular Disease,Hospital do Coracao,2025-09-01T16:18:15.903172,True,,,,NOT_FOUND,Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial,,['Cardiovascular Disease'],"['polypill, compliance, cardiovascular disease']",,2012-10,2014-07,"[{'measure': 'compliance with treatment', 'timeFrame': '18 months'}, {'measure': 'changed in blood pressure', 'timeFrame': '18 months'}, {'measure': 'changes in LDL-cholesterol levels', 'timeFrame': '18 months'}]","[{'measure': 'the main reason for non compliance with treatment', 'timeFrame': '18 months'}, {'measure': 'safety of poli pill measures by laboratorial tests', 'description': 'hemogram and blood platelets count, liver function tests (ALT, AST), renal function tests (creatinine).', 'timeFrame': '18 months'}, {'measure': 'combined outcome', 'description': 'compound of cardiovascular and total mortality, major cardiovascular events and cholesterol levels.', 'timeFrame': '18 months'}]",6.0,18 Years,,ALL,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,,,,no_match,False,,,
NCT04263090,Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment,Rigosertib,"['Nivolumab', 'Rigosertib']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Non-small Cell Lung Cancer,Icahn School of Medicine at Mount Sinai,2025-09-01T16:18:09.635771,True,,,,NOT_FOUND,A Phase1/2a Study of Rigosertib Plus Nivolumab in Stage IV Lung Adenocarcinoma Patients With KRAS Mutation Who Progressed on First-Line Treatment,,"['Non-small Cell Lung Cancer', 'Adenocarcinoma', 'Stage IV']","['KRAS', 'Metastatic', 'Rigosertib', 'Immunotherapy', 'Nivolumab']",,2020-06-29,2023-12-20,"[{'measure': 'Maximal Tolerated Dose (MTD)', 'description': 'MTD is defined as the highest dose for which at most 1 patient out of 6 experiences a dose-limiting toxicity (DLT)', 'timeFrame': 'DLTs will be evaluated at the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'ORR is defined as achieving an objective response of either complete response or partial response', 'timeFrame': '2 years'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'Phase 2: PFS is defined as the duration of time from start of treatment to the first occurrence of disease progression or death on study from any cause, whichever occurs earlier.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS) at MTD', 'description': 'Phase 2: OS at MTD is defined as the time from the first dose of study treatment to the date of death (whatever the cause).', 'timeFrame': '2 years'}]",4.0,18 Years,,ALL,False,OTHER,2.0,25.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03036293,"Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders",Tenoten,"['Tenoten', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Anxiety,Materia Medica Holding,2025-09-01T16:18:22.207670,True,,,,NOT_FOUND,"International Multicenter, Double-blind, Randomized Placebo-controlled Phase IV Clinical Trial of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders",,['Anxiety'],[],,2017-02-08,2018-09-22,"[{'measure': 'Change From Baseline in the Mean HAM-A Score at 12 Weeks of Treatment: 1. Group 1 (Tenoten®, 4 Tablets a Day); 2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '12 weeks'}]","[{'measure': 'Change From Baseline in the Mean HAM-A Score at 4 Weeks of Treatment: 1.1. Group 1 (Tenoten®, 4 Tablets a Day); 1.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '4 weeks'}, {'measure': 'The Mean HAM-A Score at 8 Weeks of Treatment: 2.1. Group 1 (Tenoten®, 4 Tablets a Day); 2.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '8 weeks'}, {'measure': 'Percentage of Patients Had at Least a 50% Improvement in the HAM-A Score: 3.1. Group 1 (Tenoten® 4 Tablets a Day): After 4, 8 and 12 Weeks; 3.2. Group 3 (Tenoten® 8 Tablets a Day): After 4, 8 and 12 Weeks.', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '4,8,12 weeks'}, {'measure': 'Percentage of Patients With no Anxiety (HAM-A Score <14) in: 4.1. Group 1 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks; 4.3. Group 3 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks.', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '4,8,12 weeks'}, {'measure': 'Change From Baseline in the Total EQ-5D-3L Score at 12 Weeks of Treatment in Patients From: 5.1. Group 1 (Tenoten®, 4 Tablets a Day); 5.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'European Quality of Life Instrument questionnaire (EQ-5D-3L) is designed for the evaluation of the quality of life.The score ranges between 5-15. Higher values represent a worse outcome.', 'timeFrame': '12 weeks'}, {'measure': 'Total CGI Scores in Patients From: 6.1. Group 1 (Tenoten®, 4 Tablets a Day); 6.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': ""Clinical Global Impession (CGI) provides a brief assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. Total range 0-16. Higher values represent a worse outcome"", 'timeFrame': '12 weeks'}]",7.0,18 Years,45 Years,ALL,False,INDUSTRY,0.0,390.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03962543,MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas,Mirdametinib (PD-0325901) oral capsule or dispersible tablet,"['Mirdametinib', 'PD-0325901', 'Mirdametinib (PD-0325901) oral capsule or dispersible tablet']",3,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Plexiform Neurofibroma,"SpringWorks Therapeutics, Inc.",2025-09-01T16:18:09.629727,True,,,,NOT_FOUND,A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity,,"['Plexiform Neurofibroma', 'Neurofibromatosis Type 1 (NF1)']","['Neurofibromatosis', 'Neurofibromatosis 1', 'Plexiform Neurofibroma', 'PD-0325901', 'MEK Inhibitor', 'Neurofibroma', 'Mirdametinib']",,2019-09-29,2028-12-22,"[{'measure': 'Confirmed Objective Response Rate at the End of the Treatment Phase.', 'description': 'Response will be determined by a blinded centralized review of volumetric MRI. The confirmed objective response rate (complete or partial response) by the end of Treatment Phase (i.e., Cycle 24) is defined as the proportion of participants who have a confirmed ≥ 20% reduction in target tumor volume as compared to baseline as assessed by a BICR, and the response needs to be confirmed by BICR in a consecutive tumor assessment within 2 - 6 months. Partial response is defined as a ≥ 20% reduction in target tumor volume from baseline. Complete response is defined as the complete resolution of the target tumor.', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Percentage of Patients With Treatment-Emergent Adverse Events.', 'description': 'All adverse events were coded using MedDRA Version 24.0. Adverse events will be assessed according to toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.', 'timeFrame': 'All SAEs and AEs were collected from the time of signing ICF until 30 days after the last dose of study treatment, an average of 1 year and 10 months and up to 3 years and 10 months.'}, {'measure': 'Duration of Response (DOR) for Participants Who Meet Criteria for Confirmed Objective Response.', 'description': 'Duration of response is defined as the time in months between the first instance of response that is subsequently confirmed, until the date of radiographic disease progression or death, whichever occurs first. For participants who enter the LTFU Phase, all MRI assessments in both the Treatment Phase and LTFU Phase will be used to determine duration of response. Participants without radiographic disease progression or death while on study will have their results censored to their most recent adequate (i.e. evaluable) tumor assessment date.', 'timeFrame': 'Starting on the onset of confirmed objective response in the Treatment Phase and afterwards on the 15th day of every 4 cycles (each cycle is 28 days) until disease progression or death, whichever comes first, assessed up to approximately 3 years'}, {'measure': 'Change From Baseline on Quality of Life (QOL) as Measured by the Pediatric Quality of Life Inventory (PedsQL) at Cycle 13, Acute Version.', 'description': 'The PedsQL consists of a 23-item core measure of global QOL that can be completed in approximately 5 minutes. There is a total score and four subscales: physical functioning, emotional functioning, social functioning and school/work functioning. Participants ≥ 5 years of age complete an age-appropriate self-report; and parents/guardians of children ages 2-17 complete a parent proxy report of the age-specific QOL. The recall period is 7 days. PedsQL items are answered on a Likert scale with responses ranging from 0 to 4 (where 0 means it is never a problem and 4 means it is almost always a problem). These items are then reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. On this scale, higher scores indicate better outcomes. Overall scale scores are calculated as the mean of the scores for the questions in said scale (or of all questions for the total score). The change from baseline is modelled using a mixed-model for repeated measures.', 'timeFrame': 'Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months'}, {'measure': 'Change From Baseline in Pain as Measured by the Numeric Rating Scale-11 (NRS-11) at Cycle 13.', 'description': 'The NRS-11 is a self-reported 11-point numerical scale that assesses pain severity. Participants ≥ 8 years of age are asked to select a number from 0 (no pain) to 10 (worst pain you can imagine) that best describes their worst pain. The recall period is 24 hours. The change from baseline is modelled using a mixed-model for repeated measures.', 'timeFrame': 'Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months'}, {'measure': 'Change From Baseline in Pain as Measured by the Pain Interference Index (PII) at Cycle 13.', 'description': 'The PII assesses relevant aspects of one\'s life, including pain interference with activities, spending time with family/friends, mood, sleep and attention. Participants ≥ 6 years of age complete a self-report, and parents/guardians of children aged 6-17 complete a parent proxy report. The recall period is 24 hours. The PII consists of 6 questions, each asking the responder to select one number from 0 to 6 that best describes how their/their proxy\'s pain has impacted various items over the past 24 hours with 0 representing ""Not at all"" and 6 representing ""Completely"". The mean of the completed items is taken as the PII score for a single assessment. The PII score presented each visit will be taken as the average of the PII scores over the 7 consecutive days up to and including visit day, with no transformation applied. The change from baseline is modelled using a mixed-model for repeated measures.', 'timeFrame': 'Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months'}]",6.0,2 Years,,ALL,False,INDUSTRY,0.0,114.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05740280,"iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects",iCP-NI,"['iCP-NI', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,SUSPENDED,Healthy Volunteers,"Cellivery Therapeutics, Inc.",2025-09-01T16:18:18.421450,True,,,,NOT_FOUND,"iCP-NI - A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Intravenous Infusion, Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects",,['Healthy Volunteers'],"['COVID-19', 'Pneumonia', 'Virus Diseases', 'Infections']",The Sponsor has put the study on hold and will recommence in due time.,2023-01-19,2023-08-17,"[{'measure': 'Part A: Incidence and severity of adverse events (AEs)', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part B: Incidence and severity of adverse events (AEs)', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Number of participants with abnormal 12-lead ECG parameters', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Number of participants with abnormal 12-lead ECG parameters', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Number of participants with abnormal vital signs measurements', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Number of participants with abnormal vital signs measurements', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}, {'measure': 'Part A: Number of participants with abnormal physical examinations', 'timeFrame': 'Screening to Follow Up (Day 7)'}, {'measure': 'Part B: Number of participants with abnormal physical examinations', 'timeFrame': 'Screening to Follow Up (Day 28+2 days)'}]","[{'measure': 'Part A: Pharmacokinetics (PK): Area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Area under the concentration time curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Area under the concentration time curve from time 0 to the time of the last quantifiable concentration (AUC0-tlast) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Area under the concentration-time curve over a dosing interval (τ) (AUC0-τ) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Area under the concentration-time curve over a dosing interval (τ) (AUC0-τ) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Maximum observed concentration (Cmax) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Maximum observed concentration (Cmax) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Time of the maximum observed concentration (tmax) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Time of the maximum observed concentration (tmax) of iCP-NI', 'timeFrame': 'Day 1 (pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Apparent terminal elimination half life (t1/2) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Apparent terminal elimination half life (t1/2) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Pharmacokinetics (PK): Accumulation ratio based on AUC0-τ (ARAUC) of iCP-NI', 'timeFrame': 'Day 1: Pre-dose up to 12 hours post start of infusion'}, {'measure': 'Part B: Pharmacokinetics (PK): Accumulation ratio based on AUC0-τ (ARAUC) of iCP-NI', 'timeFrame': 'Day 1 (Pre-dose) up to Day 7 (12 hours post start of infusion)'}, {'measure': 'Part A: Serum concentrations of anti-iCP-NI antibodies', 'description': 'Serum concentrations of anti-iCP-NI antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Follow up (Day 7) and Immunogenicity Visit (Day 28 + 2 days)'}, {'measure': 'Part B: Serum concentrations of anti-iCP-NI antibodies', 'description': 'Serum concentrations of anti-iCP-NI antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Day 7 (pre-am dose) and Follow up (Day 28 + 2 days)'}, {'measure': 'Part A: Serum concentrations of neutralizing antibodies', 'description': 'Serum concentrations of neutralizing antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Follow up (Day 7) and Immunogenicity Visit (Day 28 + 2 days)'}, {'measure': 'Part B: Serum concentrations of neutralizing antibodies', 'description': 'Serum concentrations of neutralizing antibodies will be determined using a validated analytical procedure.', 'timeFrame': 'Day -1, Day 7 (pre-am dose) and Follow up (Day 28 + 2 days)'}]",28.0,18 Years,55 Years,ALL,True,INDUSTRY,1.0,64.0,ESTIMATED,v2_robust,True,False,True,True,The Sponsor has put the study on hold and will recommence in due time.,,,no_match,False,,,
NCT02316834,"Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",BMN 673,"['TALAZOPARIB', 'BMN 673']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Fallopian Tube Serous Adenocarcinoma,M.D. Anderson Cancer Center,2025-09-01T16:18:10.926323,True,,,,NOT_FOUND,POSITION: A Pilot Study of Induction PARP Inhibition in Ovarian Cancer,,"['Fallopian Tube Serous Adenocarcinoma', 'High Grade Ovarian Serous Adenocarcinoma', 'Ovarian Mass', 'Primary Peritoneal Serous Adenocarcinoma', 'Stage III Fallopian Tube Cancer AJCC v7', 'Stage III Ovarian Cancer AJCC v6 and v7', 'Stage III Primary Peritoneal Cancer AJCC v7', 'Stage IIIA Fallopian Tube Cancer AJCC v7', 'Stage IIIA Ovarian Cancer AJCC v6 and v7', 'Stage IIIA Primary Peritoneal Cancer AJCC v7', 'Stage IIIB Fallopian Tube Cancer AJCC v7', 'Stage IIIB Ovarian Cancer AJCC v6 and v7', 'Stage IIIB Primary Peritoneal Cancer AJCC v7', 'Stage IIIC Fallopian Tube Cancer AJCC v7', 'Stage IIIC Ovarian Cancer AJCC v6 and v7', 'Stage IIIC Primary Peritoneal Cancer AJCC v7', 'Stage IV Fallopian Tube Cancer AJCC v6 and v7', 'Stage IV Ovarian Cancer AJCC v6 and v7', 'Stage IV Primary Peritoneal Cancer AJCC v7']",[],,2015-06-02,2022-01-14,"[{'measure': 'Change in deoxyribonucleic acid (DNA) copy number', 'description': 'Will use descriptive statistics and graphical methods to summarize the change in DNA copy number. Will summarize these changes for untreated patients. Will use a paired t-test to test that mean changes are different from 0. Will test median changes with a Wilcoxon signed-rank test. Will use a 2-sample t-test to compare mean changes between treated and untreated patients. Will compare median changes between treated and untreated patients with a Wilcoxon rank sum test.', 'timeFrame': 'Baseline to the day of tumor reductive surgery'}, {'measure': 'Change in ribonucleic acid (RNA) protein expression', 'description': ""Will use descriptive statistics and graphical methods to summarize the change in RNA protein expression. Will summarize these changes for untreated patients. Will use a paired t-test to test that mean changes are different from 0. Will test median changes with a Wilcoxon signed-rank test. Will use a 2-sample t-test to compare mean changes between treated and untreated patients. Will compare median changes between treated and untreated patients with a Wilcoxon rank sum test. Will use McNemar's test to compare the changes based on homologous recombination deficiency (HRD) assay results."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}]","[{'measure': 'Overall survival', 'description': 'Will use Cox proportional hazards regression methods to model overall survival as a function of DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Tumor response', 'description': 'Will use logistic regression methods to model tumor response as a function of changes in DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Tumor volume', 'description': 'Will use linear regression methods to model tumor volume as a function of changes in DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Apoptosis', 'description': 'Will use linear regression methods to model apoptosis as a function of changes in DNA copy number, changes in RNA protein expression, and HRD assay result.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Completion Rate of BMN 673 to determine feasibility', 'description': 'Treatment with BMN 673 considered feasible if 70% of patients complete all planned doses of talazoparib and post-operative chemotherapy.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Incidence of adverse events', 'description': 'Will tabulate toxicities by grade and relationship to treatment.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Proportion of patients that exhibit an increase (or decrease) in RNA protein expression greater than 50%', 'description': ""Will use Fisher's exact test to compare treated and untreated patients with respect to the proportion of patients that exhibit an increase (or decrease) in RNA protein expression. Will compare the mean change in RNA protein expression between those patients with and without a HRD on assay at baseline using a 2-sample t-test. Will compare the median changes between these 2 groups of patients with a Wilcoxon rank sum test. Will compare these 2 groups of patients with respect to HRD assay result using Fisher's exact test."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}, {'measure': 'Change in DNA copy number', 'description': ""Will use Fisher's exact test to compare treated and untreated patients with respect to the increase (or decrease) in DNA copy number. Will compare the mean change in DNA copy number between those patients with and without a HRD on assay at baseline using a 2-sample t-test. Will compare the median changes between these 2 groups of patients with a Wilcoxon rank sum test. Will compare these 2 groups of patients with respect to HRD assay result using Fisher's exact test."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}, {'measure': 'Change in RNA protein expression', 'description': ""Will use Fisher's exact test to compare treated and untreated patients with respect to the increase (or decrease) in RNA protein expression. Will compare the mean change in RNA protein expression between those patients with and without a HRD on assay at baseline using a 2-sample t-test. Will compare the median changes between these 2 groups of patients with a Wilcoxon rank sum test. Will compare these 2 groups of patients with respect to HRD assay result using Fisher's exact test."", 'timeFrame': 'Baseline to the day of tumor reductive surgery'}]",11.0,18 Years,,FEMALE,False,OTHER,1.0,4.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00498251,Prevention of Lung Edema After Thoracic Surgery,inhalation of salbutamol (5 mg),"['inhalation of salbutamol (5 mg)', 'ipratropium']",2,INTERVENTIONAL,['NA'],,COMPLETED,"Lung Injury, Acute","University Hospital, Geneva",2025-09-01T16:18:18.431376,True,,,,NOT_FOUND,Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study,,"['Lung Injury, Acute', 'Thoracotomy', 'Anesthesia', 'Intensive Care, Surgical', 'Extravascular Lung Water']","['lung injury, acute', 'thoracic surgical procedures', 'lung cancer', 'salbutamol']",,2004-09,2007-06,"[{'measure': 'reduction in extravascular lung water', 'timeFrame': 'within the first 24 hours after lung surgery'}]","[{'measure': 'changes in oxygenation indices, hemodynamics and radiological lung injury score', 'timeFrame': 'within the first 48 hours'}]",2.0,,,ALL,False,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06484868,Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy,Metreleptin,['Metreleptin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Partial Lipodystrophy,Amryt Pharma,2025-09-01T16:18:09.633381,True,,,,NOT_FOUND,"A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy",,['Partial Lipodystrophy'],['Metreleptin'],,2024-02-08,2028-02,"[{'measure': 'Number of patients with decrease of at least 0.5% in glycated haemoglobin (HbA1c) at Month 12 compared to Baseline or HbA1c <6.5 % at Month 12, in patients with baseline HbA1c ≥6.5%.', 'description': 'To evaluate the efficacy (HbA1c) of metreleptin treatment in patients with PL', 'timeFrame': '12 months'}, {'measure': 'Number of patients with decrease of at least 30% in triglycerides (TG) at Month 12 compared to Baseline, in patients with baseline TG levels ≥500 mg/dL (5.65 mmol/L)', 'description': 'To evaluate the efficacy (TG) of metreleptin treatment in patients with PL', 'timeFrame': '12 months'}]","[{'measure': 'Number of patients with decrease of at least 0.5% in HbA1c at Month 24 compared to Baseline or HbA1c <6.5 % at Month 24, in patients with baseline HbA1c ≥6.5%.', 'description': 'To evaluate the long-term efficacy of metreleptin treatment in patients with PL', 'timeFrame': '24 months'}, {'measure': 'Number of patients with decrease of at least 30% in TG levels at Month 24 compared to Baseline, in patients with baseline TG levels ≥500 mg/dL (5.65 mmol/L).', 'description': 'To evaluate the long-term efficacy of metreleptin treatment in patients with PL', 'timeFrame': '24 months'}, {'measure': 'Change from baseline in liver volume at Month 12 and Month 24', 'description': 'To assess changes in liver volume.', 'timeFrame': '12 months and 24 months'}, {'measure': 'Incidence of, Treatment emergent adverse events (TEAEs), Deaths and other serious adverse events (SAEs), Treatment related adverse events (AEs), AEs of special interest (AESIs) and AEs leading to study drug discontinuation', 'description': 'To evaluate the safety of metreleptin treatment in patients with PL', 'timeFrame': '24 months'}]",6.0,12 Years,,ALL,False,INDUSTRY,0.0,12.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00626886,"Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy",Bupivacaine Collagen Sponge,"['CollaRx Bupivacaine Implant', 'placebo collagen sponge', 'Bupivacaine Collagen Sponge', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Postoperative Pain,Innocoll,2025-09-01T16:18:13.414152,True,,,,NOT_FOUND,"A Phase II, Randomized, Single Dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx® Bupivacaine Implant in Men After Open Mesh Herniorrhaphy",,"['Postoperative Pain', 'Inguinal Hernia']","['Herniorrhaphy', 'Inguinal Hernia Repair', 'Postoperative pain']",,2008-03-11,2009-01-29,"[{'measure': 'Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours', 'description': 'Total Use of Opioid Rescue Analgesia (mg) Over 0 to 24 Hour - number count - higher score means worse outcome', 'timeFrame': '0 to 24 hours postoperatively'}]","[{'measure': 'Total Use of Opioid Rescue Analgesia Over 0 to 48 Hours', 'description': 'Number count. Higher score means worse outcome', 'timeFrame': '0 to 48 hours postoperatively'}, {'measure': 'Total Use of Opioid Rescue Analgesia Over 0 to 72 Hours', 'description': 'Number count - higher score means worse outcome', 'timeFrame': '0 to 72 hours postoperatively'}, {'measure': 'Summed Pain Intensity VAS Scores (VAS at Rest and After Cough)', 'description': 'Summed pain intensity (SPI) (VAS at rest and after cough): - For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor. Each timepoint consist of two measurements (Resting \\& Coughing) - The lower the score the better outcome for the patient. The highest total score (worst possible score) for the 10 timepoints would be 2000.', 'timeFrame': '1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0'}, {'measure': ""Patient's Global Evaluation of the Study Treatment on a 5 Point Likert Scale"", 'description': 'For the 5-point categorical scale global evaluation of study treatment, the patient was instructed to score his global evaluation of the pain control provided by the study treatment where: 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent', 'timeFrame': 'At 72 hours after time 0'}, {'measure': 'VAS Pain Intensity Scores Over Time', 'description': 'For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.', 'timeFrame': 'At 1, 1.5, 2,3,4,5,6,24,48,72 Hours'}, {'measure': 'Categorical Pain Intensity Scores Over Time - AT REST', 'description': 'For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = ""none,"" 1 = ""mild,"" 2 = ""moderate"" and 3 = ""severe.""', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}, {'measure': 'Categorical Pain Relief Scores Over Time - AT REST', 'description': 'For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}, {'measure': 'Categorical Pain Intensity Scores Over Time (After Cough)', 'description': 'For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = ""none,"" 1 = ""mild,"" 2 = ""moderate"" and 3 = ""severe."" Higher Score means a worse outcome', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}, {'measure': 'Categorical Pain Relief Scores Over Time (After Cough)', 'description': 'For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}]",10.0,18 Years,,MALE,False,INDUSTRY,1.0,53.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00725608,Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444),buprenorphine/naloxone,"['buprenorphine/naloxone', 'Suboxone, SCH 000484']",2,OBSERVATIONAL,[],,COMPLETED,Opioid-Related Disorders,Indivior Inc.,2025-09-01T16:18:07.013773,True,,,,NOT_FOUND,"Evaluation of Transfer From Subutex or Other Treatment for Opioid Drug Dependence to Suboxone: Acceptability, Safety and Impact on Medication Dispensing",,"['Opioid-Related Disorders', 'Opiate Dependence', 'Drug Abuse']","['Suboxone', 'Subutex', 'Buprenorphine', 'Naloxone']",,2008-05,2011-04,"[{'measure': 'Retention Rate', 'description': 'The primary objective of this study was to determine the retention rate of patients after 6 and 12 months of treatment with buprenorphine/naloxone measured by the percentage of patients remaining in the study', 'timeFrame': 'month 6, month 12'}]","[{'measure': 'Dosing of Suboxone (Buprenorphine Plus Naloxone)', 'description': 'One of the secondary objectives was to evaluate the effect of the switch to buprenorphine/naloxone on medication dispensing measured by dose.', 'timeFrame': 'day 1, month 6, month 12'}, {'measure': 'Dispensing of Suboxone (Buprenorphine Plus Naloxone)', 'description': 'Another of the secondary objectives was to evaluate the effect of the switch to Suboxone (buprenorphine plus naloxone) on medication dispensing measured by frequency of visits to the treating physician or pharmacy to receive the medication (daily, biweekly, once weekly, monthly, other)', 'timeFrame': 'month 6, month 12'}]",3.0,15 Years,,ALL,False,INDUSTRY,0.0,339.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT00644696,Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma,Irinotecan and Bortezomib,"['Cefpodoxime', 'Velcade', 'Irinotecan and Bortezomib', 'Cefixime']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Neuroblastoma,University of Michigan Rogel Cancer Center,2025-09-01T16:18:18.422107,True,,,,NOT_FOUND,A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma,,['Neuroblastoma'],"['Neuroblastoma', 'Irinotecan', 'Bortezomib']",,2008-04,2012-07,"[{'measure': 'Determine highest dose of IV irinotecan administered in conjunction with bortezomib without causing severe side effects.', 'timeFrame': '3 years'}]","[{'measure': 'Measure the neuroblastoma tumors after treatment with irinotecan and bortezomib to determine whether there was a change in size.', 'timeFrame': '24 months'}]",2.0,1 Year,25 Years,ALL,False,OTHER,1.0,18.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01208714,Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study),Optimal medical therapy,['Optimal medical therapy'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Renal Artery Stenosis,University Hospital Padova,2025-09-01T16:18:12.168258,True,,,,NOT_FOUND,Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney.,,['Renal Artery Stenosis'],"['Renal artery stenosis', 'Atherosclerosis', 'Arterial hypertension', 'Percutaneous renal angioplasty', 'Stenting']",,2010-12,2016-03,"[{'measure': 'Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'The Primary Objective of the study is to determine if revascularization by means of PTRAS is superior or equivalent to optimal medical treatment for preserving glomerular filtration rate in the ischemic kidney as assessed by 99TcDTPA sequential renal scintiscan', 'timeFrame': '24 months'}]","[{'measure': 'Lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'timeFrame': '1, 3, 6, 12, 24, 36, 48 and 60 months'}, {'measure': 'Preserving overall renal function after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in preserving overall renal function, as assessed by total estimated GFR, the reciprocal of serum creatinine, and indexes of Ca2+ and PO43- metabolism.', 'timeFrame': '1, 3, 6, 12, 24, 36, 48 and 60 months'}, {'measure': 'Regression of damage in the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in tregressing damage of the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness.', 'timeFrame': '1, 3, 6, 12, 24, 36, 48 and 60 months'}]",4.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT06499285,"The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)",Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Myelodysplastic Syndromes,"Keros Therapeutics, Inc.",2025-09-01T16:18:09.629125,True,,,,NOT_FOUND,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)",,['Myelodysplastic Syndromes'],"['Anemia', 'Elritercept', 'Myelodysplastic neoplasms', 'KER-050', 'MDS']",,2025-06,2032-05,"[{'measure': 'Efficacy evaluation of KER-050: Proportion of participants achieving TI for ≥ 8 weeks', 'description': 'To evaluate the efficacy of KER-050 in reducing RBC transfusions', 'timeFrame': 'from baseline through week 24'}]","[{'measure': 'Efficacy evaluation of KER-050: Proportion of participants achieving TI for ≥ 24 weeks', 'description': 'To evaluate the efficacy of KER-050 in reducing RBC transfusions over longer intervals', 'timeFrame': 'from baseline through week 48'}, {'measure': 'Efficacy evaluation of KER-050: Proportion of participants with HTB achieving TI for ≥ 8 weeks', 'description': 'To evaluate the efficacy of KER-050 in reducing RBC transfusions in participants with HTB', 'timeFrame': 'from baseline through week 24'}, {'measure': 'Safety and tolerability assessment of KER-050: Incidence of TEAEs and SAEs, change in clinical laboratory values, vital signs, and ECGs', 'description': 'To assess the safety and tolerability of KER-050', 'timeFrame': 'change from baseline'}]",4.0,18 Years,,ALL,False,INDUSTRY,1.0,225.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06946277,Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG,Preemptive Analgesia Of Dexmedetomidine,['Preemptive Analgesia Of Dexmedetomidine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Total Hip Arthroplasty (THA),China International Neuroscience Institution,2025-09-01T16:18:22.196051,True,,,,CHEMBL77921,Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain,,"['Total Hip Arthroplasty (THA)', 'Intrathecal Anesthesia', 'Hip Osteoarthritis']",[],,2025-04-25,2025-05-26,"[{'measure': 'Resting EEG', 'description': 'Resting-state electroencephalography (rsEEG) was recorded at three phases: before dexmedetomidine infusion (non-dosing phase), during dexmedetomidine infusion (DEX phase), and after dexmedetomidine infusion cessation (Cessation phase).', 'timeFrame': 'During the whole operation'}]","[{'measure': 'ERP', 'description': 'Event-related potential (ERP) was measured at three phases: before dexmedetomidine infusion (Non-dosing phase), during dexmedetomidine infusion (DEX phase), and after infusion cessation (Cessation phase)', 'timeFrame': 'During the whole operation'}]",2.0,18 Years,70 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,,Cc1cccc(C(C)c2c[nH]cn2)c1C,CHEMBL77921,partial_match,True,200.28,3.18,3.0
NCT05145218,A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer,Anlotinib Hydrochloride Capsules,"['TQB2450 injection', 'Anlotinib Hydrochloride Capsules', 'Paclitaxel injection']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Recurrent Platinum-resistant Ovarian Cancer,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:20.955022,True,,,,NOT_FOUND,"A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer",,['Recurrent Platinum-resistant Ovarian Cancer'],[],,2021-09-28,2024-12,"[{'measure': 'Disease progression-free survival(PFS) evaluated by Independent Review Committee(IRC)', 'description': 'The period from the first use of the drug to disease progression or death (whichever occurs first);', 'timeFrame': 'Baseline up to two years'}, {'measure': 'Overall survival (OS)', 'description': 'The preriod from the first use of the drug to death from all causes. For subjects who are still alive at the last follow-up, the OS will be counted as data censored based on the last follow-up. For subjects who are lost follow-up, the OS will be counted as data cesored based on the last confirmed survival time before being lost to follow-up.', 'timeFrame': 'Baseline up to two years'}]","[{'measure': 'Disease PFS evaluated by investigators', 'description': 'The period from the first use of the drug to disease progression or death (whichever occurs first)', 'timeFrame': 'Baseline up to two years'}, {'measure': 'PFS rate of 6 months: including PFS rate of 6 months evaluated by IRC and investigators;', 'description': 'The proportion of subjects reaching 6 months from firstly- recorded objective tumor response (complete remission(CR) or partial remission(PR)) to firstly-recorded objective tumor progression or death due to any cause (whichever occurred first) .', 'timeFrame': 'Baseline up to six months'}, {'measure': 'Objective response rate (ORR) evaluated by IRC and investigators', 'description': ', the proportion of subjects whose tumors are evaluated as complete remission(CR) and partial remission(PR) by IRC and investigators. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.', 'timeFrame': 'Baseline up to two years'}, {'measure': 'Duration of response (DOR)', 'description': 'The period from firstly-recorded objective tumor response (CR or PR) to firstly-recorded objective tumor progression or death due to any cause (whichever occurs first) .', 'timeFrame': 'Baseline up to two years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Proportion of subjects whose tumors shrink or remain stable for a certain period, including complete remission（CR）, partial remission（PR） and stable disease（SD）;', 'timeFrame': 'Baseline up to two years'}, {'measure': 'OS rate of 12 months', 'description': 'The proportion of subjects who survive for 12 months after the first dose', 'timeFrame': 'Baseline up to one year'}, {'measure': 'Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)，as well as abnormal laboratory examination indicators.', 'description': 'The proportion of AEs and SAEs recorded afte signing the informed consent form(ICF).', 'timeFrame': 'Baseline up to two years'}]",9.0,18 Years,75 Years,FEMALE,False,INDUSTRY,0.0,405.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03939767,Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease,"Aflibercept (Eylea, BAY86-5321)","['Aflibercept (Eylea, BAY86-5321)']",1,OBSERVATIONAL,[],,COMPLETED,Wet Age-related Macular Degeneration,Bayer,2025-09-01T16:18:13.427054,True,,,,NOT_FOUND,Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD),,['Wet Age-related Macular Degeneration'],[],,2019-05-12,2023-10-17,"[{'measure': 'The change in BCVA (best corrected visual acuity)', 'description': 'In treatment-naïve wAMD patients treated with IVT aflibercept in a flexible proactive treatment pattern (fixed dosing or T\\&E (Treat and Extend Regimen)) by label regimen.', 'timeFrame': 'Baseline to 12 months'}]","[{'measure': 'The change in BCVA', 'timeFrame': 'Baseline to 24 and 36 months'}, {'measure': 'The change in BCVA by intended treatment regimen', 'timeFrame': 'Baseline to 12, 24 and 36 months'}, {'measure': 'The proportion of patients (eyes) gaining or losing a visual acuity compared to baseline', 'description': 'With letter score of ≥ 0 letters, ≥5 letters, ≥ 10 letters, ≥ 15 letters.', 'timeFrame': 'Baseline at 12, 24 and 36 months'}, {'measure': 'The proportion of patients (eyes) achieving a Snellen equivalent of 20/40 or better (approximately 73 ETDRS letters)', 'timeFrame': 'At 12, 24 and 36 months'}, {'measure': 'The changes in central retinal thickness (CRT)', 'timeFrame': 'Baseline to 12, 24 and 36 months'}, {'measure': 'The number of injections', 'timeFrame': 'Baseline to 12, 24 and 36 months'}, {'measure': 'The distribution of the intervals between injections', 'timeFrame': 'Up to 36 months'}]",8.0,50 Years,,ALL,False,INDUSTRY,0.0,1563.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT00918385,Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer,Nilutamide,"['Sprycel', 'Nilandron', 'Nilutamide', 'Dasatinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Prostate Cancer,Duke University,2025-09-01T16:18:23.446807,True,,,,NOT_FOUND,A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer,,['Prostate Cancer'],"['hormone resistant prostate cancer', 'castration resistant prostate cancer', 'hormone refractory prostate cancer', 'metastatic prostate cancer', 'hormonal therapy', 'antiandrogen therapy', 'androgen receptor', 'nilutamide', 'dasatinib', 'genomics', 'genomic signature', 'genomic predictor', 'genomic analysis', 'genomic expression profile']",Permanent closure of trial to further accrual based on IDE disapproval,2009-05,2013-08,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is the interval from start of monotherapy until first disease progression or death, whichever occurred first.', 'timeFrame': 'During monotherapy ( at least 12 weeks)'}]","[{'measure': 'Overall Response Rate of Men With High AR Activity', 'description': 'Tumor response was based on Response Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.', 'timeFrame': 'During monotherapy (at least 12 weeks)'}, {'measure': 'Overall Response Rate of Men With Low AR Activity', 'description': 'Tumor response is based on Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.', 'timeFrame': 'During dasatinib monotherapy ( at least 12 weeks)'}]",3.0,18 Years,,MALE,False,OTHER,1.0,57.0,ACTUAL,v2_robust,True,False,True,False,Permanent closure of trial to further accrual based on IDE disapproval,,,no_match,False,,,
NCT02513485,Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa,Levodopa+carbidopa,"['Sinemet', 'Levodopa+carbidopa', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Depression,Emory University,2025-09-01T16:18:25.987036,True,,,,NOT_FOUND,"""Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa""; ""Inflammation Effects on Corticostriatal Connectivity and Reward: Role of Dopamine""",,['Depression'],"['Inflammation', 'Anhedonia', 'Psychomotor retardation']",,2015-10-09,2020-08-01,"[{'measure': 'Change in Functional Corticostriatal Connectivity', 'description': ""Corticostriatal connectivity was assessed by functional magnetic resonance imaging (fMRI). Resting-state and task-based (monetary incentive delay \\[MID\\]) fMRI scans were conducted on a 3 Tesla Siemens Trio MRI scanner. Subject-level correlations for degree of cortical and striatal functional connectivity were Fisher's Z transformed {Z(R)=0.5ln\\[(1+R)/(1-R)\\]}, a standard method for calculating fMRI functional connectivity. Greater Fisher's Z-scores reflected stronger correlated fMRI activity (i.e., higher corticostriatal connectivity)."", 'timeFrame': 'Scans approximately 45 min post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers', 'description': 'Peripheral blood samples were analyzed for levels of immune markers like plasma C-reactive protein (CRP), interleukin-6 (IL-6), soluble interleukin-6 receptor (sIL-6R), tumor necrosis factor (TNF) -alpha, soluble cytokine receptor2 (TNFR 2), interleukin-1 beta (IL-1 beta), interleukin-1 receptor antagonist (IL-1Ra), interleukin 10 (IL-10) and monocyte chemoattractant protein-1 (MCP-1).', 'timeFrame': 'Scans approximately 45 minutes post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}]","[{'measure': 'Effort-Expenditure for Rewards Task (EEfRT) Neurocognitive Test', 'description': 'The Effort-Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess motivation. Possible results range between 0 to1 with 1 being a better outcome. Results show mean probability of hard (high effort) choice.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'The Trail Making Test (TMT) Neurocognitive Assessment', 'description': 'The Trail Making Test (TMT) is used to measure basic attention and psychomotor processing speed. Time taken to complete each task is recorded in seconds, whereby the greater the number of seconds, the slower the psychomotor speed.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Digit Symbol Task Neurocognitive Test', 'description': 'The Digit Symbol Task was used to assess graphomotor speed, visual scanning and memory processing speed involving numbers and a corresponding blank box where subjects are asked to fill in matching symbol as fast as they can. Results show the average number of correct symbols completed in up to 100 boxes in 90 seconds.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Finger Tapping Task (FTT) Neurocognitive Test', 'description': 'The Finger Tapping Task (FTT) assesses motor speed and can detect subtle motor impairment. The test measures the average number of taps per 10 second trial. A greater number of taps reflects faster motor speed.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Reaction Time Task (CANTAB) Neurocognitive Test', 'description': 'The reaction time test includes simple and choice reaction time tasks and is divided into 5 stages requiring increasingly complex chains of responses. The task provided distinction between reaction (or decision) time and movement latencies (milliseconds) based on touch responses made to a single (simple) or chosen from multiple (choice) stimuli flashed on a computer screen. Results show mean response latency in milliseconds.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Multidimensional Fatigue Inventory (MFI) Self-report Questionnaire', 'description': 'The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure severity of fatigue based on five dimensions of fatigue, general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The total MFI scores range from 20 to 100 where high scores indicate greater fatigue.', 'timeFrame': 'At baseline and Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Snaith-Hamilton Pleasure Scale (SHAPS) Self-report Questionnaire', 'description': 'The Snaith-Hamilton Pleasure Scale (SHAPS), a 14-item self-report scale with high psychometric validity for assessing the presence of anhedonia, was used to assess hedonic capacity. Participants rated how much they agreed or disagreed with the 14 items phrased as ""I would enjoy \\_\\_"" based on their ability to experience pleasure. Of the four possible response categories (Definitely Agree, Agree, Disagree, and Strongly Disagree), either of the Disagree responses received a score of 1 and either of the Agree responses received a score of 0. The SHAPS score calculated as the sum of these 14 items ranged from 0 to 14, and higher SHAPS scores indicated greater anhedonia.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}, {'measure': 'Inventory of Depressive Symptoms-Self Report (IDS-SR) Questionnaire', 'description': 'The Inventory of Depressive Symptoms-Self Report (IDS-SR) is a 30-item self-report instrument with excellent psychometric properties for measuring symptom constructs consistent with current Diagnostic and Statistical Manual of Mental Disorders (DSM) nosology and that is widely used to measure depression severity in clinical trials. Response scores are summed and range from 0 to 84, with higher scores reflecting greater depression severity.', 'timeFrame': 'At baseline and Visit 1: Pre drug/placebo, Visit 2: Pre drug/placebo (spaced by approximately 1 week)'}, {'measure': 'Beck Depression Inventory (BDI-II), Anhedonia Subscale Score', 'description': 'The Beck Depression Inventory-II (BDI-II) is a widely used self-report for measuring depression severity over the past two weeks and the anhedonia subscale is one of several validated subscales in the BDI-II. Responses are given on a 4-point scale where 0 = the symptom of depression has not been experienced and 3 = the symptom of depression is severe. The anhedonia subscale score is created by summing responses to four items of the BDI-II that assess loss of pleasure, loss of interest, loss of energy, loss of sex drive. The total score of the anhedonia subscale ranges from 0 to 12 where higher scores reflect greater severity of anhedonia symptoms.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 2: Pre drug/placebo (spaced by approximately 1 week)'}, {'measure': 'Profile of Mood States (POMS) Scale', 'description': 'The Profile of Mood States (POMS) scale is a 30-item psychological rating scale used to assess transient, distinct mood states. Participants rate the extent to which they feel unhappy, blue, lonely, gloomy, and worthless on a scale from 0 (not at all) to 4 (extremely). Scores range from 0 to 120 with higher scores reflecting a more negative mood state.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}, {'measure': 'State-Trait Anxiety Inventory (STAI) State Scale', 'description': 'The 20-item self-report State-Trait Anxiety Inventory (STAI) State scale was used to measure severity of anxiety symptoms. Total scores range from 20 to 80 with higher scores reflecting greater anxiety. Scores in the high 40s are considered clinically significant.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}, {'measure': 'Change in Motivation and Pleasure (MAP) Scale Score', 'description': 'The motivation and pleasure (MAP) questionnaire is an 18-item self-report inventory that was created to disentangle state-wise motivational and consummatory components of everyday activities over a 24-hour period. This scale was used to assess self-reported changes in symptoms of anhedonia before and after inflammation blockade. Respondents respond to statements about daily activities on a scale from 0 (no pleasure/not at all) to 4 (extreme pleasure/very often). Total scores range from 0 to 72 where higher scores indicate greater motivation and effort given to everyday situations.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}]",14.0,18 Years,65 Years,ALL,False,OTHER,1.0,57.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT07132398,Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD,Slow-tapering glucocorticoids + Inebilizumab,"['Rapid-tapering glucocorticoids + Inebilizumab', 'Slow-tapering glucocorticoids + Inebilizumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Neuromyelitis Optica (NMO),Tianjin Medical University General Hospital,2025-09-01T16:18:14.659892,True,,,,NOT_FOUND,"The Efficacy of Slow - Tapering Versus Rapid - Tapering Glucocorticoid Strategies in Preventing Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD) When Combined With Inebilizumab: A Multicenter, Open - Label, Randomized Parallel - Controlled Clinical Trial",,"['Neuromyelitis Optica (NMO)', 'Neuromyelitis Optica Spectrum Disorders (NMOSD)']","['NMO', 'NMOSD', 'Inebilizumab', 'Glucocorticoids']",,2025-09-01,2028-08-31,"[{'measure': 'First adjudicated relapse event within 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}]","[{'measure': 'Change in Expanded Disability Status Scale (EDSS) score from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Low-contrast Visual Acuity (LCVA) from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Timed 25-Foot Walk (T25-FW) test from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Expanded Disability Status Scale (EDSS) score from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Low-contrast Visual Acuity (LCVA) from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Timed 25-Foot Walk (T25-FW) test from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in serum Neurofilament Light chain (sNfL) levels at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in serum Glial Fibrillary Acidic Protein (sGFAP) levels at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in serum AQP4-IgG titer at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in serum Neurofilament Light chain (sNfL) levels at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in serum Glial Fibrillary Acidic Protein (sGFAP) levels at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in serum AQP4-IgG titer at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Visual Analogue Scale (VAS) score from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Visual Analogue Scale (VAS) score from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Quality of Life (QoL) score from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Quality of Life (QoL) score from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Proportion of Relapse-free Participants at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Proportion of Relapse-free Participants at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Percentage of patients in glucocorticoid-free remission between 54 and 106 weeks', 'timeFrame': '54 Weeks, 106 Weeks'}, {'measure': 'Annualized Relapse Rate (ARR) at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Annualized Relapse Rate (ARR) at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Daily and acumulate dose of glucocorticoids at relapse before 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Adverse events (AEs) and Serious AEs (SAEs) at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Immunoglobulin levels at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Pelvic X-ray at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Adverse events (AEs) and Serious AEs (SAEs) at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Immunoglobulin levels at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Pelvic X-ray at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}]",29.0,18 Years,,ALL,False,OTHER,0.0,170.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06011460,Observation of Clozapine Treatment Safety in Bipolar Disorder.,Clozapine,['Clozapine'],1,OBSERVATIONAL,[],,ENROLLING_BY_INVITATION,Bipolar Disorder,Medical University of Gdansk,2025-09-01T16:18:09.637171,True,,,,CHEMBL42,Observation of Clozapine Treatment Safety in Bipolar Disorder.,,['Bipolar Disorder'],"['clozapine', 'bipolar disorder', 'suicidality', 'adverse events']",,2023-02-23,2027-06-30,"[{'measure': 'Safety measures of clozapine treatment in patients with bipolar disorder.', 'description': 'Incidence of possible occurrence of adverse events during treatment with clozapine in patients with bipolar disorder.', 'timeFrame': '1 year'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,False,False,False,True,,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,CHEMBL42,exact_match,True,326.83,3.72,4.0
NCT02456662,Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial,Ondansetron,"['Ondansetron', 'zofran', 'Placebo']",3,INTERVENTIONAL,['NA'],,COMPLETED,Drug-induced Nausea and Vomiting,University of Rochester,2025-09-01T16:18:15.894651,True,,,,CHEMBL46,A Randomized Controlled Trial of Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline,,['Drug-induced Nausea and Vomiting'],[],,2015-10-07,2019-04-03,"[{'measure': 'Number of Participants Experiencing Symptoms', 'description': 'Number of participants experiencing symptoms (vomiting or nausea+vomiting) at the time of or after doxycycline', 'timeFrame': '24 hours'}]",[],1.0,18 Years,45 Years,FEMALE,True,OTHER,0.0,319.0,ACTUAL,v2_robust,True,True,False,False,,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,CHEMBL46,exact_match,True,293.37,3.13,4.0
NCT04989816,Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens,Trastuzumab Deruxtecan,"['DS8201a; AZD4552; T-DXd', 'Trastuzumab Deruxtecan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma,AstraZeneca,2025-09-01T16:18:08.354456,True,,,,NOT_FOUND,A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06),,['Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma'],"['Gastric Cancer', 'Gastroesophageal Junction Adenocarcinoma', 'HER2', 'Trastuzumab', 'Deruxtecan', 'T-DXd', 'DS-8201a', 'ERBB2']",,2021-08-20,2024-02-28,"[{'measure': 'Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)', 'description': 'Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months'}, {'measure': 'Best Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)', 'description': 'The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months'}]","[{'measure': 'Progression-free Survival (PFS) Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}, {'measure': 'Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 3 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 6 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 9 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 12 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 15 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 18 months using the Kaplan-Meier technique'}, {'measure': 'Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)', 'description': 'PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 21 months using the Kaplan-Meier technique'}, {'measure': 'Disease Control Rate (DCR) Based on Independent Central Review (ICR)', 'description': 'Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD)', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}, {'measure': 'Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12', 'description': 'Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD) for at least 11 weeks (ie 12 weeks - 1 week to allow for an early assessment within the assessment window)', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. DCR assessed at Week 12'}, {'measure': 'Duration of Response (DoR) Based on Independent Central Review (ICR)', 'description': 'DoR defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) or death in the absence of progression based on investigator assessments by using RECIST version 1.1', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}, {'measure': 'Overall Survival (OS) Based on Independent Central Review (ICR)', 'description': 'OS based on ICR is defined as the time from date of enrolment until the date of death due to any cause', 'timeFrame': 'From date of enrolment until death due to any cause. Assessed up to approximately 30 months (from date of first subject in to data cut-off 28February2024)'}, {'measure': 'Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)', 'description': 'Best percentage change based on ICR is defined as the best change in target lesion tumour size from baseline (maximum reduction or minimum increase from baseline in the absence of a reduction)', 'timeFrame': 'Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months'}]",15.0,18 Years,,ALL,False,INDUSTRY,1.0,95.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00952302,Study of the Effects of Iron Levels on the Lungs at High Altitude,Iron sucrose,"['Venofer', 'Iron sucrose', 'Normal saline']",3,INTERVENTIONAL,['NA'],,COMPLETED,Pulmonary Hypertension,University of Oxford,2025-09-01T16:18:08.338236,True,,,,NOT_FOUND,Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension,,"['Pulmonary Hypertension', 'Mountain Sickness']","['Hypoxia', 'Iron', 'Hypoxia-Inducible Factor 1', 'Chronic mountain sickness']",,2008-10,2008-11,"[{'measure': 'Change in pulmonary artery systolic pressure', 'timeFrame': 'One week (SLR arm) and one month (CMS arm)'}]",[],1.0,18 Years,60 Years,MALE,True,OTHER,1.0,33.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01406197,Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor,Experimental: Vaginal progesterone,"['No other name available', 'Experimental: Topical progesterone', 'Experimental: Vaginal progesterone', 'Watson Laboratories', 'Prochieve, Columbia Laboratories', 'Experimental: Intramuscular progesterone']",6,INTERVENTIONAL,['NA'],,WITHDRAWN,Preterm Labor,"St. Joseph's Hospital and Medical Center, Phoenix",2025-09-01T16:18:07.020051,True,,,,CHEMBL103,Uterine Abdominal Electromyography Measurements Before and After Progesterone Treatments for Preterm Labor,,['Preterm Labor'],"['Progesterone', 'Progestins', 'Preterm labor', 'Premature birth', 'Uterine electromyography', 'Uterine contractility']",Investigator left organization prior to study initiation,2011-07,2013-10,"[{'measure': 'Inhibition of uterine electromyographic (EMG) activity by various formulations of progesterone.', 'description': 'Uterine electrical activity will be recorded (for 30 minutes at each time point) from the abdominal surface of pregnant patients before (30 minutes before treatment) and following treatment (at 2, 4, 8, 12, 24 and up to 48 hours) with either vehicles or progesterone treatments to evaluate if the treatments reduce EMG activity and therefore may be potential candidates for possible interventions for treating a preterm labor.', 'timeFrame': 'EMG will be measured at various times including 0 time pretreatment and up to 48 hours after treatments'}]","[{'measure': 'Effects of progesterone on uterine EMG activity and preterm birth', 'description': 'Secondary measures: Patients will be followed (up to 16 weeks) until delivery by vaginal or Cesarian section to see if any intervention (progesterone treatment) affects timing of birth.', 'timeFrame': 'Various times after treatments up to 16 weeks to determine when the patients deliver'}]",2.0,17 Years,40 Years,FEMALE,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Investigator left organization prior to study initiation,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL103,partial_match,True,314.47,4.72,4.0
NCT03380975,Role of Montelukast in Asthma and Allergic Rhinitis Patients,Montelukast 10mg,"['Montelukast 10mg', 'Aireez']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Asthma and Allergic Rhinitis,Clinision,2025-09-01T16:18:13.422879,True,,,,NOT_FOUND,Role of Montelukast in Asthma and Allergic Rhinitis Patients,,['Asthma and Allergic Rhinitis'],"['MAAP', 'Asthma', 'Allergic rhinits']",,2018-08-28,2019-06-30,"[{'measure': 'Efficacy of montelukast on asthma day and night symptoms changes from baseline after 4 weeks of treatment', 'description': 'To determine the efficacy of montelukast on asthma day and night symptoms changes from baseline after 4 weeks of treatment \\[Designated as safety issue: No\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}]","[{'measure': 'Efficacy of montelukast on allergic rhinitis symptoms changes from baseline after 4 weeks of treatment', 'description': 'To determine the efficacy of montelukast on allergic rhinitis symptoms changes from baseline after 4 weeks of treatment \\[Designated as safety issue: No\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}, {'measure': 'Effect of montelukast in change in individual quality of life using Quality of life questionnaire after 4 weeks of treatment', 'description': 'To determine the effect of montelukast in change in individual quality of life using Quality of life questionnaire after 4 weeks of treatment \\[Designated as safety issue: No\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}, {'measure': 'Proportion of participants experiencing an adverse event (AE)', 'description': 'Proportion of participants experiencing an adverse event (AE) \\[Designated as safety issue: Yes\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,600.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03145038,Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects,"Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed","['Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast', 'Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast', 'Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed', 'Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast', 'Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed', 'Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pharmacokinetics,Bayer,2025-09-01T16:18:23.444034,True,,,,CHEMBL4066936,Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects,,['Pharmacokinetics'],[],,2017-05-16,2017-10-09,"[{'measure': 'Vericiguat area under the plasma concentration vs. time curve divided by dose (AUC/D)', 'description': 'AUC is the area under the curve (mathematically known as definite integral) in a plot of concentration of vericiguat after single dose administration in blood plasma against time (pre-dose until 72 hours after administration). AUC from time 0 to the last data point greater than lower limit of quantification divided by dose (AUC(0-tlast)/D) will be used as primary parameter if AUC cannot be calculated for all profiles, or mean AUC from the last data point to infinity \\[AUC(tlast-∞)\\] \\>20% of AUC. AUC will be analyzed by means of descriptive statistics.', 'timeFrame': '0 - 72 hours'}, {'measure': 'Vericiguat maximum plasma concentration divided by dose (Cmax/D))', 'description': 'Cmax is the maximum observed vericiguat concentration in measured plasma after single dose administration (pre-dose until 72 hours after administration). Cmax/D is the maximum observed drug concentration in measured matrix after single dose administration divided by dose.Cmax will be analyzed by means of descriptive statistics', 'timeFrame': '0 - 72 hours'}]","[{'measure': 'Number of Adverse Events', 'description': 'As a secondary objective of this study the numbers of AEs will be used to assess safety and tolerability of vericiguat.\n\nIn a clinical study, an AE is any untoward medical occurrence (i.e. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.\n\nIndividual listings of AEs will be provided. The incidence of treatment-emergent AEs an drug-related AEs, respectively, will be summarized by treatment using MedDRA terms (highly specific standardised medical terminology).', 'timeFrame': 'pre-dose until 7 to 14 days after last administration of vericiguat'}, {'measure': 'Palatability of the oro-dispersible tablets and the crushed IR tablets assessed by questionnaire', 'description': 'As a secondary objective of this study the taste and texture of pediatric formulation (palatability) (mini tablets) and of the crushed IR tablet will be assessed', 'timeFrame': 'up to 5 minutes after drug administration'}]",4.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,True,False,True,,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,CHEMBL4066936,partial_match,True,426.39,2.56,4.0
NCT02461056,Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain,Ibuprofen,"['Dilid', 'Hydromorphone', 'Ibuprofen', 'Caldolor']",4,INTERVENTIONAL,['NA'],,COMPLETED,Breast Cancer,Samsung Medical Center,2025-09-01T16:18:10.913640,True,,,,CHEMBL521,Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain,,['Breast Cancer'],"['ibuprofen', 'hydromorphone', 'drug interactions']",,2014-06,2014-07,"[{'measure': 'Pain scores on the numeric rating scale (NRS)', 'timeFrame': 'postoperative 1 hour'}]",[],1.0,19 Years,80 Years,FEMALE,False,OTHER,0.0,90.0,ACTUAL,v2_robust,True,True,False,False,,CC(C)Cc1ccc(C(C)C(=O)O)cc1,CHEMBL521,exact_match,True,206.28,3.07,4.0
NCT03271983,Pharmacokinetics of Metronidazole Dermal Products,Metronidazole gel 1,"['Metronidazole cream', 'Metronidazole gel 1', 'metronidazole', 'Metronidazole gel 2']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Bioequivalence,"University of Maryland, Baltimore",2025-09-01T16:18:18.427829,True,,,,NOT_FOUND,Evaluation of the Bioavailability of Metronidazole Dermal Products,,['Bioequivalence'],[],,2019-04-09,2019-11-03,"[{'measure': 'PK Parameters', 'description': 'Area under the concentration-time curve from 0 to 25 h', 'timeFrame': '3 study sessions/subject; each session was 25 h; blood samples obtained at the following time points: -60 min, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 23, 24, 25 h; at least one week washout period between each study session'}]",[],1.0,18 Years,45 Years,ALL,True,OTHER,1.0,7.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05578001,Efficacy of Pilocarpine 1% in Presbyopia,Pilocarpine Ophthalmic,"['Pilocarpine Ophthalmic', 'Glaupin 1%']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Presbyopia,Isfahan University of Medical Sciences,2025-09-01T16:18:13.423730,True,,,,NOT_FOUND,Efficacy of Pilocarpine 1% in Pseudophakia Individuals With Presbyopia,,"['Presbyopia', 'Pseudophakia']","['Pilocarpine', 'Presbyopia', 'Pseudophakia']",,2022-07-01,2023-03-30,"[{'measure': 'Best Corrected Near Visual Acuity', 'description': 'Comparison of the BCNVA before and after instillation of Pilocarpine 1%', 'timeFrame': '20 minutes'}]","[{'measure': 'Best Corrected Distance Visual Acuity', 'description': 'Comparison of the BCDVA before and after instillation of Pilocarpine 1%', 'timeFrame': '20 minutes'}]",2.0,40 Years,,ALL,True,OTHER,0.0,25.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02572336,"A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA",THR-18,"['THR-18', 'Tissue Plasminogen Activator (tPA)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Ischemic Stroke,D-Pharm Ltd.,2025-09-01T16:18:19.664515,True,,,,NOT_FOUND,"Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18",,['Ischemic Stroke'],[],,2015-10,2016-04,"[{'measure': 'physical examination', 'timeFrame': '30 days after administration'}, {'measure': 'ASPECTS score', 'timeFrame': '2 days after administration'}, {'measure': 'ECASS-II bleeding grades', 'timeFrame': '2 days after administration'}, {'measure': 'Severity of cerebral edema per computerized tomography according to the IST-3 grades', 'timeFrame': '2 days after administration'}, {'measure': 'Final infarct volume per computerized tomography', 'timeFrame': '30 days after administration'}, {'measure': 'Neurological deficits per the NIH stroke scale', 'timeFrame': '30 days after administration'}, {'measure': 'Functional capacity per the modified Rankin Score', 'timeFrame': '30 days after administration'}, {'measure': 'Change in blood levels of matrix metalloproteinase 9', 'timeFrame': '3 days after administration'}, {'measure': 'heart rate', 'timeFrame': '30 days after administration'}, {'measure': 'blood pressure', 'timeFrame': '30 days after administartion'}, {'measure': 'electrocardiogram', 'timeFrame': '30 days after administration'}, {'measure': 'persons with adverse events', 'timeFrame': '30 days after administration'}]",[],12.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,40.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06789796,a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.,Iparomlimab and Tuvonralimab (QL1706),"['Iparomlimab and Tuvonralimab (QL1706)', 'placebo for Iparomlimab and Tuvonralimab (QL1706)', 'placebo for QL1604', 'QL1604']",4,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Small-cell Lung Cancer,"Qilu Pharmaceutical Co., Ltd.",2025-09-01T16:18:15.894201,True,,,,NOT_FOUND,"A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.",,['Small-cell Lung Cancer'],[],,2025-02,2030-03,"[{'measure': 'Progression-free survival (PFS)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after chemoradiotherapy (CRT) for patients with LS-SCLC as measured by Blinded Independent Review Committee (BIRC)-assessed PFS', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by OS', 'timeFrame': 'up to 5 years'}]","[{'measure': 'objective response rate (ORR)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by ORR', 'timeFrame': 'up to 2 years'}, {'measure': 'disease control rate (DCR)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by DCR', 'timeFrame': 'up to 2 years'}, {'measure': 'duration of response (DoR)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by DoR', 'timeFrame': 'up to 2 years'}, {'measure': 'PFS', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by Investigator-assessed PFS', 'timeFrame': 'up to 2 years'}, {'measure': '1-year OS rate', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by 1-year OS rate', 'timeFrame': 'up to 1 year'}, {'measure': '2-year OS rate', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by 2-year OS rate', 'timeFrame': 'up to 2 years'}, {'measure': 'adverse events', 'description': 'To compare and evaluate the safety of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by the incidence of adverse events (Percentage of participants with treatment-related adverse events as assessed by CTCAEv5.0.) and abnormal laboratory parameters.', 'timeFrame': 'up to 2 years'}]",9.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,636.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00609128,Effect of Olopatadine on Allergic Tear Mediators,olopatadine,['olopatadine'],1,INTERVENTIONAL,['NA'],,COMPLETED,Allergic Conjunctivitis,"University of Wisconsin, Madison",2025-09-01T16:18:22.199792,True,,,,CHEMBL1719,Expression of Inflammatory Mediators in Allergic Conjunctivitis,,['Allergic Conjunctivitis'],"['tears', 'conjunctival epithelial cells', 'olopatadine', 'eosinophils']",,2000-09,2009-11,"[{'measure': 'Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine Treatment) Promotes Eosinophil Adhesion', 'description': 'Outcome:\n\nThe collected tears (from 10 subjects)were pooled, incubated with primary conjunctival epithelial cells before eosinophil adhesion was measured via eosinophil peroxidase assay.\n\nEosinophils in eosinophils / square cm measured.', 'timeFrame': '1 week for tear collection, tears stored at - 80 C until used'}]",[],1.0,18 Years,65 Years,ALL,True,OTHER,1.0,21.0,ACTUAL,v2_robust,True,True,False,False,,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,CHEMBL1719,partial_match,True,373.88,3.59,4.0
NCT00702351,A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788),Org 36286 (corifollitropin alfa),"['corifollitropin alfa', 'Org 36286 (corifollitropin alfa)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,In Vitro Fertilization,Organon and Co,2025-09-01T16:18:20.968919,True,,,,NOT_FOUND,"A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 μg or 150 μg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI Using a Long Protocol of GnRH Agonist (Study 38833)",,['In Vitro Fertilization'],"['Infertility', 'Pharmacological effects of drugs', 'Drug therapy', 'Hormones', 'GnRH agonist', 'RecFSH', 'Corifollitropin alfa', 'Open-label']",,2005-12-09,2007-07-11,"[{'measure': 'serum inhibin-B levels; follicle number and follicle size distribution', 'timeFrame': 'One cycle'}]","[{'measure': 'Amount of recFSH needed from Stimulation Day 8 onwards to the Day of hCG; Endocrinological parameters (FSH, LH, E2, P); Number and quality of oocytes retrieved', 'timeFrame': 'One cycle'}, {'measure': 'Number of fertilized oocytes; Fertilization rate; Number and quality of embryos; Implantation rate; Miscarriage rate; Clinical outcome', 'timeFrame': 'One cycle'}]",3.0,18 Years,39 Years,FEMALE,False,INDUSTRY,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01227408,"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer","doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate","['doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate']",1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Breast Cancer,University of Southern California,2025-09-01T16:18:14.671403,True,,,,CHEMBL34259,"Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",,['Breast Cancer'],['Patients with confirmed breast cancer for neoadjuvant chemotherapy'],Sponsor withdrew due to funding issues,2009-02,2011-02,"[{'measure': 'Response', 'timeFrame': 'At surgical resection on about week 30'}]","[{'measure': 'Toxicity', 'timeFrame': 'Every 4 weeks'}]",2.0,18 Years,,FEMALE,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Sponsor withdrew due to funding issues,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,CHEMBL34259,partial_match,True,454.45,0.27,4.0
NCT02495077,Effects of Inhibiting Early Inflammation in Kidney Transplant Patients,Methylprednisolone,"['Solu-Medrol', 'Tylenol®', 'Benadryl', 'CellCept®', 'Mycophenolate Mofetil', 'Claritin®', 'Loratadine', 'FK-506', 'Diphenhydramine', 'MMF', 'Acetaminophen', 'Prograf®', 'Tacrolimus', 'FR-900506', 'Prednisone', 'Methylprednisolone']",16,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Kidney Transplant,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:10.918722,True,,,,CHEMBL1364144,Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19),,['Kidney Transplant'],"['Kidney Transplantation', 'infliximab', 'Tissue Donors', 'Remicade', 'Induction Therapy', 'Deceased Donor Kidney Transplant Recipients']",,2015-11-02,2021-07-23,"[{'measure': 'The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups.', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the month 24 eGFR for each treatment group.', 'timeFrame': '24-Month post-transplantation'}]","[{'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR)', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of greater than or equal to IA with or without clinical symptoms within 6 months of transplant were determined to have met the endpoint. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection.Criteria include: IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '6 month post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR).', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of greater than or equal to IA with or without clinical symptoms within 24 months of transplant were determined to have met the endpoint. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection. Criteria include: IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'BANFF Grades of First Acute Cellular Rejections (ACR).', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of greater than or equal to IA with or without clinical symptoms within 6 months of transplant were determined to have met the endpoint. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection.Criteria include: IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '6 month post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection.', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of borderline or greater than or equal to IA with or without clinical symptoms within 6 months of transplant were determined to have met the endpoint. Severity is graded as Borderline, IA, IB, IIA, IIB, or III, with borderline representing possible cellular rejection, IA being the mildest form of cellular rejection, and III being the most severe form of cellular rejection.Criteria include: Borderline-no intimal arteritis is present but foci of mild tubulitis; IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Cellular Rejection (BPAR) or Borderline Rejection', 'description': 'Acute cellular rejection was defined based on central lab pathology interpretation using the Banff 2007 criteria. Participants with a Banff grade of borderline or greater than or equal to IA with or without clinical symptoms within 24 months of transplant were determined to have met the endpoint. Severity is graded as Borderline, IA, IB, IIA, IIB, or III, with borderline representing possible cellular rejection, IA being the mildest form of cellular rejection, and III being the most severe form of cellular rejection. Criteria include: Borderline-no intimal arteritis is present but foci of mild tubulitis; IA-significant interstitial infiltration and foci of moderate tubulitis; IB-significant interstitial infiltration and foci of severe tubulitis; IIA-mild to moderate intimal arteritis; IIB-severe intimal arteritis; III-transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR)', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR within 6 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, or C4d staining positive.Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection (AMR).', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR within 24 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, or C4d staining positive. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR or suspicious for AMR within 6 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, C4d staining positive, or suspicious. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes; suspicious-when 2 of 3 factors for acute/active are present.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Biopsy Proven Acute Antibody Mediated Rejection AMR or Suspicious for AMR.', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR or suspicious for AMR within 24 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, C4d staining positive, or suspicious. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes; suspicious-when 2 of 3 factors for acute/active are present', 'timeFrame': '24 months post-transplantation'}, {'measure': 'BANFF Grades of First AMR.', 'description': 'Antibody mediated rejection (AMR) was defined based on central lab pathology interpretation using the Banff 2013 criteria. Participants with a Banff finding of AMR within 6 months of transplant were determined to have met the endpoint. AMR is classified as acute/active, chronic/active, or C4d staining positive. Criteria include: acute/active-histologic evidence of acute tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of donor-specific antibodies (DSAs); chronic/active-morphologic evidence of chronic tissue injury, evidence of current/recent antibody interaction with vascular endothelium, and serologic evidence of DSAs; C4d staining positive-linear C4d staining in peritubular capillaries, glomerulitis=0, peritubular capillary=0, chronic glomerulopathy=0, no acute cell-mediated rejection or borderline changes.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With BANFF Chronicity Scores > or Equal 2 on the 24 Month Biopsy.', 'description': 'The Banff 2013 classification involves scoring numerous characteristics of renal biopsy specimens. The ci (interstitial fibrosis) and ct (tubular atrophy) scores are two such characteristics. The scores can take values of 0, 1, 2, or 3 for each characteristic (ci and ct), indicating increasing severity of disease as the scores increase. Participants are considered to have met this endpoint if their ci + ct score on the 24 month biopsy summed to be \\> or equal to 2.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Change in BANFF Chronicity Scores Between Implantation and the 24 Month Biopsy.', 'description': 'The Banff 2013 classification involves scoring numerous characteristics of renal biopsy specimens. The ci (interstitial fibrosis) and ct (tubular atrophy) scores are two such characteristics. The scores can take values of 0, 1, 2, or 3 for each characteristic (ci and ct), indicating increasing severity of disease as the scores increase. For this endpoint, the sum of ci+ct scores from the implantation biopsy was subtracted from the sum of the ci+ct scores from the month 24 biopsy and the difference between the two time points was classified as 0, 1, 2, or 3+. Higher values of this difference indicate more severe disease.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.', 'description': 'Biopsies were read by the local pathologist at the hospital where the participant was a patient. These local reads informed clinical care for the participant, which may or may not include prescribing/administering medication to the participant to help with clinical concerns or findings noted on a biopsy. Participants were considered to have met this endpoint if they have a report of receiving treatment for clinical or biopsy-proven rejection during the first 6 months post-transplant.', 'timeFrame': '6 months post-transplantation'}, {'measure': 'Percent of Participants With Locally Treated Rejection, Defined as Treatment Administered for Rejection Based on Clinical Signs or Biopsy Findings.', 'description': 'Biopsies were read by the local pathologist at the hospital where the participant was a patient. These local reads informed clinical care for the participant, which may or may not include prescribing/administering medication to the participant to help with clinical concerns or findings noted on a biopsy. Participants were considered to have met this endpoint if they have a report of receiving treatment for clinical or biopsy-proven rejection during the 24 month post-transplant follow-up.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Change in eGFR Between 3 Months and 24 Months as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 3 and 24 was calculated as the month 24 eGFR minus the month 3 eGFR for each participant. A window of +/- 14 days was used for month 3 and +/- 1 month was used for month 24.', 'timeFrame': '3 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between 3 Months and 24 Months as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 3 and 24 was calculated as the month 24 eGFR minus the month 3 eGFR for each participant. A window of +/- 14 days was used for month 3 and +/- 1 month was used for month 24.', 'timeFrame': '3 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. Post-transplant nadir was defined as the lowest value of eGFR from the first 6 months post-transplant. The change in eGFR between nadir and month 24 was calculated as the month 24 eGFR minus the nadir eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between Post-transplant Nadir and 24 Months as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. Post-transplant nadir was defined as the lowest value of eGFR from the first 6 months post-transplant. The change in eGFR between nadir and month 24 was calculated as the month 24 eGFR minus the nadir eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between 6 Months and 24 Months as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 6 and 24 was calculated as the month 24 eGFR minus the month 6 eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'Change in eGFR Between 6 Months and 24 Months as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. The change in eGFR between months 6 and 24 was calculated as the month 24 eGFR minus the month 6 eGFR for each participant. A window of +/- 21 days was used for month 6 and +/- 1 month was used for month 24.', 'timeFrame': '6 months and 24 months post-transplantation'}, {'measure': 'eGFR Values as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Day 7 post-transplantation'}, {'measure': 'eGFR Values as Measured by MDRD', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Days 30, 60, and 180 post-transplantation'}, {'measure': 'eGFR Values as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Day 7 post-transplantation'}, {'measure': 'eGFR Values as Measured by CKD-EPI', 'description': 'Glomerular filtration rate (GFR) is a measure of kidney function and helps determine the stage of kidney disease. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) equation. A value of 90+ means kidney function is normal. A value between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Values between 30 and 59 indicates moderately reduced kidney function. Values between 15 and 29 indicate severely reduced kidney function. Values below 15 indicate very severe or endstage kidney failure. eGFR values from day 7 and months 1, 3, 6, 12, 18, and 24 were used to generate an estimate of the eGFR at each time point of interest for each treatment group.', 'timeFrame': 'Days 30, 90, and 180 post-transplantation'}, {'measure': 'Percent of Participants With Death or Graft Failure.', 'description': 'Participants who died or experienced graft failure were considered to have met this endpoint. Graft failure was defined as the need for post-transplant dialysis for more than 56 days.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Only Graft Failure.', 'description': 'Participants who experienced graft failure were considered to have met this endpoint. Graft failure was defined as the need for post-transplant dialysis for more than 56 days.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants That Required at Least One Dialysis Treatment.', 'description': 'Dialysis within the first week post-transplant is used in the setting of delayed graft function (DGF). Participants are considered to have had DGF if they had at least one dialysis treatment in the first week post-transplant.', 'timeFrame': '1 week post-transplantation'}, {'measure': 'Number of Dialysis Sessions.', 'description': 'The number of dialysis sessions a person had during their first 8 weeks post-transplant was used for this endpoint.', 'timeFrame': '8 weeks post-transplantation'}, {'measure': 'Duration of Delayed Graft Function (DGF), Defined as Time From Transplantation to the Last Required Dialysis Treatment.', 'description': 'Participants are considered to have had DGF if they had at least one dialysis treatment in the first week post-transplant. For this endpoint, duration was calculated as the date of last post-transplant dialysis treatment minus the date of the first post-transplant dialysis treatment.', 'timeFrame': 'First post-transplant dialysis treatment to last post-transplant dialysis treatment'}, {'measure': 'Percent of Participants With Primary Non-Function (PNF), Defined as Dialysis-dependency for More Than 3 Months.', 'description': 'Post-transplant dialysis is sometimes required in the setting of kidney transplant. If such dialysis continues for more than 3 months, the participant is considered to have PNF and, as such, meets this endpoint definition.', 'timeFrame': 'Transplantation through at least month 3 up to month 24'}, {'measure': 'Change From Baseline (Immediately After Surgery) in Serum Creatinine.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. eGFR values from 24, 48, and 72 hours post-transplant (i.e., days 1, 2, and 3) were used to generate an estimate of the serum creatinine at each time point of interest for each treatment group.', 'timeFrame': '24, 48 and 72 hours post-transplantation'}, {'measure': 'Days From Transplantation Until Event (ACR, AMR, or Hospitalization for Infection and/or Malignancy)', 'description': 'Participants are considered to have met this endpoint if they experienced biopsy-proven T-cell mediated rejection (ACR) or antibody mediated rejection (AMR) based on central pathology reading or were hospitalized for infection and/or malignancy. For participants who met one or more of these three components, the earliest event date of the three components was used as the time of meeting the endpoint. Participants who did not meet any of the three components were censored at their last date of follow-up. Event (or censor) day was calculated as event (or censor) date minus transplant date.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'The Percent of Participants With a Serum Creatinine of More Than 3 mg/dL.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. This endpoint is ascertaining slow graft function in the immediate days post-transplant. A participant was considered to have met this endpoint if their day 5 serum creatinine was greater than 3 mg/dL.', 'timeFrame': 'Day 5 post-transplantation'}, {'measure': 'Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 2 Divided by he First Creatinine After Surgery', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 2 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function.', 'timeFrame': 'Day 2 post-transplantation'}, {'measure': 'Creatinine Reduction Ratio (CRR), Defined as the First Creatinine on Day 5 Divided by the First Creatinine After Surgery.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 5 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function.', 'timeFrame': 'Day 5 post-transplantation'}, {'measure': 'The Percent of Participants Whose Day 5 Serum CRR Was Less Than 70%.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 5 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function. A participant was considered to have met this endpoint if their day 5 serum CRR was less than 70%.', 'timeFrame': 'Day 5 post-transplantation'}, {'measure': 'The Percent of Participants Whose Day 2 Serum CRR Was Less Than 30%.', 'description': 'Serum creatinine (mg/dL) is used to measure kidney function. A normal result is 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for women. Higher results indicate poorer kidney function, as creatinine is removed from the body by the kidneys. CRR was calculated as the day 1 post-transplant creatinine value minus the day 2 creatinine value divided by the day 1 creatinine value and multiplied by 100, resulting in a percentage. Higher numbers indicate a greater reduction in serum creatinine and, thus, potentially better kidney function. A participant was considered to have met this endpoint if their day 2 serum CRR was less than 30%.', 'timeFrame': 'Day 2 post-transplantation'}, {'measure': 'The Percent of Participants Who Need Dialysis After Week 1.', 'description': 'Participants who needed dialysis after the first week post-transplant were considered to have met this endpoint.', 'timeFrame': '1 week to 24 months post-transplantation'}, {'measure': 'Percent of Participants With de Novo DSA.', 'description': ""Donor specific antibody (DSA) can be formed post-transplant as part of the recipient's alloimmune response to the transplanted organ. DSA was determined by a central laboratory. Participants with newly developed DSA (i.e., de novo) following transplant were considered to have met this endpoint."", 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Any Infection Requiring Hospitalization or Resulting in Death.', 'description': 'Participants were considered to have met this endpoint if they had an infection that required hospitalization or resulted in death.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Mycobacterial or Fungal Infections', 'description': 'Participants were considered to have met this endpoint if they had at least one mycobacterial of fungal infection.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With CMV Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site', 'description': 'Participants were considered to have met this endpoint if they had a reported case of CMV viremia that required a change in their existing immunosuppression or the use of anti-viral therapy.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With BK Viremia That Require a Change in Immunosuppression or Anti-viral Treatment as Per Standard of Care at the Site.', 'description': 'Participants were considered to have met this endpoint if they had a reported case of BK viremia that required a change in their existing immunosuppression or the use of anti-viral therapy.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Malignancy.', 'description': 'Participants were considered to have met this endpoint if they had a reported case of malignancy.', 'timeFrame': '24 months post-transplantation'}, {'measure': 'Percent of Participants With Impaired Wound Healing Manifested by Wound Dehiscence, Wound Infection, or Hernia at the Site of the Transplant Incision', 'description': 'Participants were considered to have met this endpoint if they had a reported case of impaired wound healing at the site of the transplant incision manifested by one wound dehiscence, wound infection, or hernia.', 'timeFrame': '24 months post-transplantation'}]",46.0,18 Years,,ALL,False,NIH,2.0,290.0,ACTUAL,v2_robust,True,True,False,False,,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,CHEMBL1364144,partial_match,True,416.51,2.37,4.0
NCT06379659,Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer,Growh hormone,['Growh hormone'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Thin Endometrium,Isfahan University of Medical Sciences,2025-09-01T16:18:12.185692,True,,,,NOT_FOUND,Effectiveness of Intrauterine Growth Hormone Infusion as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer: A Double-blinded Parallel Exploratory Randomized Controlled Clinical Trial,,"['Thin Endometrium', 'Infertility Female', 'Infertility']","['Infertility', 'Infertility, Female', 'endometrial thickness', 'Thin Endoetrium', 'Growth Hormone', 'Human Growth Hormone', 'Somatropin', 'Intra-uterine infusion']",,2024-05-01,2024-09-14,"[{'measure': 'Endometrial thickness', 'description': ""Measurement of endometrial thickness will be performed utilizing transvaginal sonography due to its closer proximity to the endometrium and with an empty bladder. To minimize the potential bias of measuring endometrial thickness during uterus contraction, occur during contractions, measurements will be taken only after the patient's contractions have ceased."", 'timeFrame': 'Baseline (On the 10th day of menstrual cycle), and On the day of response to treatment (in case of response) and in case of non-response to treatment on the 18th day of the mesntrual cycle'}]","[{'measure': 'Clinical Pregnancy Rate', 'description': 'The number of fetuses that have a heartbeat and are not ectopic evaluated by Transvaginal Ultrasonography', 'timeFrame': '6-8 of gestational week'}, {'measure': 'Response to treatment', 'description': 'The number of patients that reach at least 7 mm of endometrial thickness', 'timeFrame': '2 days following the last dose of placebo or growth hormone'}, {'measure': 'Implantation rate', 'description': 'The number of gestational sacs to the number of transferred embryos evaluated by Transvaginal ultrasonography', 'timeFrame': '6-8 of gestational week'}, {'measure': 'IVF cancellation rate', 'description': 'The number of patients who do not reach enough endometrial thickness for transferring despite maximum treatment', 'timeFrame': '2 days following the last dose of placebo or growth hormone'}, {'measure': 'Early pregnancy complications', 'description': 'Including early miscarriage (miscarriage in less than 12th gestational week) and Ectopic pregnancy', 'timeFrame': 'During the first 12 weeks of pregnancy'}]",6.0,18 Years,45 Years,FEMALE,False,OTHER,0.0,54.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00408941,EEG and Auditory Evoked Potentials During Local Anesthesia,Propofol,"['Prilocaine', 'Propofol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Healthy,Technical University of Munich,2025-09-01T16:18:18.428313,True,,,,NOT_FOUND,EEG and Auditory Evoked Potentials During Local Anesthesia,,['Healthy'],"['EEG', 'AEP', 'Artefacts', 'Propofol', 'Local Anaesthesia']",,2006-12,2006-12,[{'measure': 'differences of AEP during sedation with and without local anaesthesia'}],"[{'measure': 'fraction of high frequency artefacts'}, {'measure': 'time to LOC'}, {'measure': 'differences AEP awake with and without local anaesthesia'}]",4.0,18 Years,35 Years,MALE,True,OTHER,0.0,15.0,,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04042727,Controlling Rapid Atrial Fibrillation With Dexmedetomidine,Dexmedetomidine Hydrochloride,"['Dexmedetomidine Hydrochloride', 'Precedex']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Rapid Atrial Fibrillation,Stony Brook University,2025-09-01T16:18:07.026530,True,,,,CHEMBL77921,Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD) Trial,,"['Rapid Atrial Fibrillation', 'Heart Rate Control']","['Dexmedetomidine', 'Critical Care', 'Atrial Fibrillation']","Futility, as a result of COVID-19 impact",2019-08-21,2021-12-31,"[{'measure': 'Mean Systolic Blood Pressure', 'description': 'Assess mean systolic blood pressure measurements between the two arms', 'timeFrame': 'During Study Drug Infusion Period'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,13.0,ACTUAL,v2_robust,True,False,True,False,"Futility, as a result of COVID-19 impact",Cc1cccc(C(C)c2c[nH]cn2)c1C,CHEMBL77921,partial_match,True,200.28,3.18,3.0
NCT02512562,A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers,AL-335,"['Olysio', 'AL-335', 'Simeprevir', 'ACH-3102']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Chronic Hepatitis C,Alios Biopharma Inc.,2025-09-01T16:18:07.025291,True,,,,NOT_FOUND,"A Phase-1, Open-label, Two Group, Fixed-Sequence Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers",,['Chronic Hepatitis C'],[],,2015-07-31,2015-08-31,"[{'measure': 'Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites', 'description': 'To evaluate the effect of multiple oral doses of ACH-3102, on the multiple oral dose PK of AL-335 and metabolites', 'timeFrame': 'From screening to Day 28 follow-up visit'}, {'measure': 'Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites', 'description': 'To evaluate the effect of multiple oral doses of Simeprevir, on the multiple oral dose PK of AL-335 and metabolites', 'timeFrame': 'From screening to Day 24 visit'}, {'measure': 'Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 and Simeprevir on AL-335 and metabolites', 'description': 'To evaluate the effect of multiple oral doses of ACH-3102 and Simeprevir, on the multiple oral dose PK of AL-335 and metabolites', 'timeFrame': 'From screening to Day 28 follow-up visit'}]","[{'measure': 'Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results', 'description': 'Tabulation of the number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results (including chemistry, hematology, and urine).', 'timeFrame': 'From screening to Day 28 follow-up visit'}, {'measure': 'Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and ACH-3102 on Simeprevir', 'description': 'To determine the potential effect of AL-335 and/or ACH-3102 on the steady-state PK of Simeprevir.', 'timeFrame': 'From screening to Day 28 follow-up visit'}, {'measure': 'Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and Simeprevir on ACH-3102', 'description': 'To determine the potential effect of AL-335 and/or Simeprevir on the steady-state PK of ACH-3102.', 'timeFrame': 'From screening to Day 28 follow-up visit'}]",6.0,18 Years,60 Years,ALL,True,INDUSTRY,1.0,32.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06688175,IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma,IMRT combined with lobaplatin-based concurrent chemotherapy,['IMRT combined with lobaplatin-based concurrent chemotherapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ENROLLING_BY_INVITATION,Nasopharyngeal Neoplasms,The First Affiliated Hospital of Xiamen University,2025-09-01T16:18:13.422870,True,,,,NOT_FOUND,Intensity-modulated Radiotherapy Combined With Lobaplatin-based Concurrent Chemotherapy in the Treatment of Elderly Patients With Nasopharyngeal Carcinoma,,"['Nasopharyngeal Neoplasms', 'Elderly', 'Chemotherapy']",[],,2024-11-13,2027-12-31,"[{'measure': 'objective response rate (ORR)', 'description': 'ORR encompasses both CR and PR.', 'timeFrame': '6 months'}]","[{'measure': 'Safety', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '3 months'}, {'measure': 'Overall survival (OS)', 'description': 'OS was defined as the time of NPC diagnosis until death from any cause.', 'timeFrame': '3 years'}, {'measure': 'Locoregional relapse-free survival (LRFS)', 'description': 'LRFS was measured as the duration time from the diagnosis of nasopharyngeal carcinoma to the occurrence of relapse in the nasopharynx or neck lymph nodes or until the last follow-up.', 'timeFrame': '3 years'}, {'measure': 'Distant metastasis-free survival (DMFS)', 'description': 'DMFS was defined as the duration time of nasopharyngeal carcinoma diagnosis to the time of distant metastasis or the last follow-up.', 'timeFrame': '3 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS was referred to as the time from nasopharyngeal carcinoma diagnosis to the date of disease progression.', 'timeFrame': '3 years'}]",6.0,65 Years,80 Years,ALL,False,OTHER,0.0,32.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01072201,To Access the Effects of Mucositis in Adults With Dental Implants,Triclosan and Fluoride,"['Total Toothpaste', 'Triclosan and Fluoride', 'Fluoride', 'Ultrabrite toothpaste']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Mucositis,Colgate Palmolive,2025-09-01T16:18:22.197535,True,,,,CHEMBL849,To Access the Effects of Mucositis in Adults With Dental Implants,,['Mucositis'],[],,2007-06,2007-12,"[{'measure': 'Bleeding on Probing', 'description': 'Percentage of Bleeding Scale: The bleeding sites are identified by either a 0 or 1. (0=no bleeding \\& 1= bleeding) The number of spots between teeth that bleed are divided by number of spots between teeth that are scored.', 'timeFrame': '6 months'}, {'measure': 'Mean Pocket Depth', 'description': 'Measurement scale: 0 millimeter measurement= no pocket depth. 3, 4, 5, \\& 6 millimeter are indications of deeper Pocket depth.', 'timeFrame': '6 Months'}, {'measure': 'Mean Percentage of Plaque Scores', 'description': 'Mean Percentage (%) of dental plaque on all tooth surfaces, including implants and natural teeth. Plaque Scale is 0=no plaque and 1= dental plaque present. Percentage is derived from sum of all plaque scores divided by the number of tooth surfaces scored.', 'timeFrame': '6 Months'}]",[],3.0,30 Years,70 Years,ALL,True,INDUSTRY,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,CHEMBL849,partial_match,True,289.55,5.14,4.0
NCT06900543,"Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere",NRT6003 Injection,"['cTACE', 'Yttrium-90 carbon microspheres', 'NRT6003 Injection', 'transarterial chemoembolization']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Unresectable Hepatocellular Carcinoma,Chengdu New Radiomedicine Technology Co. LTD.,2025-09-01T16:18:09.629402,True,,,,NOT_FOUND,"A Randomized, Open-label, Multicenter Study Comparing the Efficacy and Safety of NRT6003 Injection With Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)",,['Unresectable Hepatocellular Carcinoma'],"['Selective internal radiation therapy', 'Yttrium-90', 'Transarterial Radioembolization', 'Conventional Transarterial Chemoembolization']",,2025-04-15,2027-12,"[{'measure': 'Time to Progression (TTP)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Localized Time to Progression (localized TTP)', 'description': 'Evaluated by the Blinded Independent Review Committee (BIRC) in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Time to Progression', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Localized Time to Progression', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Objective Response Rate', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Duration of Response', 'description': 'Evaluated by the investigator in accordance with the mRECIST criteria', 'timeFrame': 'Through study completion, at least 18 months'}, {'measure': 'Surgery Rate', 'description': 'Resection rate of liver target lesions', 'timeFrame': 'From the administration to study completion, at least 18 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Based on survival follow-up information', 'timeFrame': 'From the administration to study completion, at least 18 months'}, {'measure': 'Changes in Tumor Biomarkers', 'description': 'The variation of alpha fetoprotein (AFP) levels', 'timeFrame': 'From the administration to study completion, at least 18 months'}, {'measure': 'Incidence and severity of adverse events (AE) and severe adverse events (SAE)', 'description': 'In accordance with NCI-CTCAE 5.0', 'timeFrame': 'Throughout the study, at least 18 months'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,108.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02823964,EASY: Extended Access to Sollpura Over Years,Liprotamase,"['Sollpura', 'Liprotamase']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Exocrine Pancreatic Insufficiency,Anthera Pharmaceuticals,2025-09-01T16:18:19.667683,True,,,,NOT_FOUND,An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,,"['Exocrine Pancreatic Insufficiency', 'Cystic Fibrosis']","['exocrine pancreatic insufficiency', 'cystic fibrosis', 'pancreatic enzyme replacement therapy']",,2016-09,2018-03,"[{'measure': 'Safety, as Measured by Number of Participants With Adverse Events Including Clinical or Laboratory Abnormalities', 'description': 'Descriptive analysis', 'timeFrame': '12 months'}]",[],1.0,7 Years,,ALL,False,INDUSTRY,0.0,25.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00573534,Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse,Vyvanse,"['Lisdexamphetamine is marketed as Vyvanse', 'Vyvanse']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Attention Deficit Hyperactivity Disorder,New York State Psychiatric Institute,2025-09-01T16:18:22.204373,True,,,,NOT_FOUND,Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence,,['Attention Deficit Hyperactivity Disorder'],"['Attention Deficit Hyperactivity Disorder', 'ADHD', 'ADD', 'Prevention', 'Substance use', 'Adolescent']",,2008-03,2010-03,"[{'measure': 'Number of Participants With at Least 70% Reduction in ADHD Symptoms as Measured by Change in ADHD Rating Scale From First to Last Visit', 'description': ""The outcome is the number of subjects who achieved a clinically meaningful reduction in ADHD symptoms. This is defined as a 70% reduction from baseline as measured by change in the ADHD Rating Scale (ADHD-RS). The ADHD RS quantifies symptoms on a 0-3 scale, 0 meaning never present, 1 sometimes, 2 often present, 3 very often present. For this study, the scale was clinician administered using both parent and adolescent to achieve a consensus score, or a best estimate on the clinician's part when consensus could not be achieved"", 'timeFrame': 'up to 24 weeks'}]","[{'measure': 'Number of Participants With Low or no Substance Use During the Study vs the Number With Intermittent Use Judged by (1)Time Line Follow Back (Confidential Clinician Administered Record of Recent Substance Use) (2) Urine Toxicology.', 'description': 'This outcome measure integrates data from self report supplied in the Time Line Follow Back (a self report summary of all substance and alcohol use over the previous week or month) with evidence from periodic (weekly to monthly) urine toxicologies.', 'timeFrame': 'up to 24 weeks'}]",2.0,11 Years,15 Years,ALL,False,OTHER,0.0,8.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06780462,Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome,Corticosteroids + Rivaroxaban,"['Corticosteroids + Rivaroxaban', 'Corticosteroids alone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Behcet Syndrome,Assistance Publique - Hôpitaux de Paris,2025-09-01T16:18:12.187203,True,,,,NOT_FOUND,Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome,,['Behcet Syndrome'],[],,2025-01-15,2028-01-15,"[{'measure': 'Rate of success', 'description': 'Defined as absence of deep venous thrombosis relapse and of major bleeding event, without introduction of additional immunosuppressive medication for BS activity other than thrombotic events at 6 months.', 'timeFrame': 'At 6 months'}]","[{'measure': 'Cumulative incidence of deep venous thrombosis and superficial venous thrombosis relapse', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of major venous thrombosis', 'description': 'pulmonary embolism, vena cava , Budd Chiari syndrome , intra-cardiac relapse', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of venous repermeabilization', 'description': 'assessed by vascular imaging', 'timeFrame': 'At 6 months'}, {'measure': 'Proportion of patients with a dose ≤ 5 mg/day of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 6 months'}, {'measure': 'Proportion of patients with a dose ≤ 5 mg/day of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 12 months'}, {'measure': 'Dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 3 months'}, {'measure': 'Dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 6 months'}, {'measure': 'Dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 3 months'}, {'measure': 'Cumulative dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 6 months'}, {'measure': 'Cumulative dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of major bleeding event', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of bleeding event', 'timeFrame': 'At 12 months'}, {'measure': 'Number of adverse events', 'timeFrame': 'At 3 months'}, {'measure': 'Number of adverse events', 'timeFrame': 'At 6 months'}, {'measure': 'Number of adverse events', 'timeFrame': 'At 12 months'}, {'measure': 'Change in SF-36 quality-of-life', 'description': 'The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.', 'timeFrame': 'At 3 months'}, {'measure': 'Change in SF-36 quality-of-life', 'description': 'The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.', 'timeFrame': 'At 6 months'}, {'measure': 'Change in SF-36 quality-of-life', 'description': 'The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.', 'timeFrame': 'At 12 months'}, {'measure': ""Change in Behçet's Disease Current Activity Form"", 'description': 'It is a 7 items score ranging from 0 to 12. The higher the sore the higher the severity of the disease.', 'timeFrame': 'At 3 months'}, {'measure': ""Change in Behçet's Disease Current Activity Form"", 'description': 'It is a 7 items score ranging from 0 to 12. The higher the sore the higher the severity of the disease.', 'timeFrame': 'At 6 months'}, {'measure': ""Change in Behçet's Disease Current Activity Form"", 'description': 'It is a 7 items score ranging from 0 to 12. The higher the sore the higher the severity of the disease.', 'timeFrame': 'At 12 months'}, {'measure': ""Change in Behçet's Syndrome Assessment Score"", 'description': ""It is based on various clinical manifestations of Behçet's disease. Score ranges from 0 to 12. The higher the score the higher the severity of the disease."", 'timeFrame': 'At 3 months'}, {'measure': ""Change in Behçet's Syndrome Assessment Score"", 'description': ""It is based on various clinical manifestations of Behçet's disease. Score ranges from 0 to 12. The higher the score the higher the severity of the disease."", 'timeFrame': 'At 6 months'}, {'measure': ""Change in Behçet's Syndrome Assessment Score"", 'description': ""It is based on various clinical manifestations of Behçet's disease. Score ranges from 0 to 12. The higher the score the higher the severity of the disease."", 'timeFrame': 'At 12 months'}, {'measure': 'Change in Physician Global Assessment', 'description': 'Evaluation of the disease activity. It ranges from 0 to 10. The higher the score the higher the activity of the disease.', 'timeFrame': 'At 3 months'}, {'measure': 'Change in Physician Global Assessment', 'description': 'Evaluation of the disease activity. It ranges from 0 to 10. The higher the score the higher the activity of the disease.', 'timeFrame': 'At 6 months'}, {'measure': 'Change in Physician Global Assessment', 'description': 'Evaluation of the disease activity. It ranges from 0 to 10. The higher the score the higher the activity of the disease.', 'timeFrame': 'At 12 months'}, {'measure': 'Overall survival', 'timeFrame': 'At 12 months'}, {'measure': 'Event free survival', 'timeFrame': 'At 12 months'}, {'measure': 'Proportion of post thrombotic syndrome', 'description': ""According to Villalta's post-thrombotic syndrome scale. It assesses the prensece and severity of post thrombotic syndrome. The score ranges from 0 to 30. The higher the score the more severe are the symptoms"", 'timeFrame': 'At 12 months'}, {'measure': ""Changes in Villalta's post-thrombotic syndrome scale"", 'description': ""According to Villalta's post-thrombotic syndrome scale. It assesses the prensece and severity of post thrombotic syndrome. The score ranges from 0 to 30. The higher the score the more severe are the symptoms"", 'timeFrame': 'At 6 months'}, {'measure': ""Changes in Villalta's post-thrombotic syndrome scale"", 'description': ""According to Villalta's post-thrombotic syndrome scale. It assesses the prensece and severity of post thrombotic syndrome. The score ranges from 0 to 30. The higher the score the more severe are the symptoms"", 'timeFrame': 'At 12 months'}, {'measure': 'Proportion of remission', 'description': 'According to other organs involved', 'timeFrame': 'At 3 months'}, {'measure': 'Proportion of remission', 'description': 'According to other organs involved', 'timeFrame': 'At 6 months'}, {'measure': 'Proportion of remission', 'description': 'According to other organs involved', 'timeFrame': 'At 12 months'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 1 month'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 3 months'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 6 months'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 12 months'}]",41.0,18 Years,,ALL,False,OTHER,0.0,134.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05851768,Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain,Bupivacaine,"['Bupivacaine + Magnesium', 'Bupivacaine + Dexmedetomidine', 'Bupivacaine']",3,INTERVENTIONAL,['NA'],,RECRUITING,Analgesia,"National Cancer Institute, Egypt",2025-09-01T16:18:14.673346,True,,,,NOT_FOUND,Analgesic Efficacy of Adding Dexmedetomidine VS Magnesium Sulphate as Adjuvants With Bupivacaine in Ultrasound-guided Erector Spinae Plane Block for Post Thoracotomy Pain,,['Analgesia'],[],,2023-05-15,2024-04-27,"[{'measure': 'Total postoperative morphine consumption', 'description': 'Total dose of morphine needed postoperatively in the first 24 h', 'timeFrame': 'First 24 hours postoperatively'}]","[{'measure': 'Time to first postoperative rescue analgesia.', 'description': 'Time to first postoperative rescue analgesia.', 'timeFrame': 'First 24 hours postoperatively'}]",2.0,18 Years,65 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT06066528,A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight,Survodutide,"['Survodutide', 'BI 456906', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Obesity,Boehringer Ingelheim,2025-09-01T16:18:08.344737,True,,,,NOT_FOUND,"A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus",,"['Obesity', 'Diabetes Mellitus, Type 2']",[],,2023-11-27,2026-04-03,"[{'measure': 'Percentage change in body weight from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}]","[{'measure': 'Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in body weight (kg)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in waist circumference (cm)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in ""Capacity to Resist"" domain score of Eating Behaviour patient reported outcome (PRO)', 'description': '""Capacity to Resist"" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total score', 'description': 'Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in HbA1c (mmol/mol)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in total cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in triglycerides (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in free fatty acids (mg/dL)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)', 'timeFrame': 'Baseline and at Week 76'}, {'measure': 'Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)', 'timeFrame': 'Baseline and at Week 76'}]",24.0,18 Years,,ALL,False,INDUSTRY,0.0,756.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00632008,Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers,Soluble beta-glucan (SBG),"['Placebo comparator', 'Soluble beta-glucan (SBG)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Diabetic Foot Ulcers,Biotec Pharmacon ASA,2025-09-01T16:18:17.187433,True,,,,NOT_FOUND,"A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes",,['Chronic Diabetic Foot Ulcers'],[],,2007-03,2009-10,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,122.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04195633,"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",Cyclophosphamide,"['Fosfaseron', 'Claphene', 'Gengraf', 'Sandimmune', 'Carloxan', 'Cyclophosphan', 'Neosar', 'Cytoxan', 'WR- 138719', 'ERL 080A', '27-400', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Cyclophosphamide Monohydrate', 'Genuxal', 'Revimmune', 'Cycloblastine', 'Cicloxal', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cyclophosphamidum', 'Cycloblastin', 'Cyclophosphamide', 'Ledoxina', 'Cellcept', 'Cyclostine', 'Neoral', 'SangCya', 'Dihydroxybusulfan', 'Fludarabine', 'Treosulfan', 'Cyclophospham', 'CP monohydrate', 'CTX', 'Cyclosporine Modified', 'Cytophosphan', 'Cyclophosphane', 'Socium Mycophenolate', 'Clafen', 'CsA', 'Genoxal', '1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-', 'Tresulfon', 'Treosulphan', 'Ovastat', 'OL 27-400', 'Mycophenolate Mofetil', 'Syklofosfamid', 'ERL 080', 'Cyclophosphanum', 'Cyclosporine', 'MMF', 'Mycophenolate Sodium', 'Cytophosphane', 'Ciclosporin', 'Ciclofosfamida', 'Cyclophosphamid monohydrate', 'Cyclosporin', 'Fluradosa', 'Cyclosporin A', 'CYCLO-cell', 'Mitoxan']",62,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Acute Leukemia,Fred Hutchinson Cancer Center,2025-09-01T16:18:09.625221,True,,,,NOT_FOUND,Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen,,"['Acute Leukemia', 'Acute Lymphoblastic Leukemia', 'Acute Myeloid Leukemia', 'Adult Diffuse Large Cell Lymphoma', 'Anaplastic Large Cell Lymphoma', 'Burkitt Lymphoma', 'Chronic Myeloid Leukemia, BCR-ABL1 Positive', 'Chronic Myelomonocytic Leukemia', 'Hodgkin Lymphoma', 'Lymphoblastic Lymphoma', 'Lymphoplasmacytic Lymphoma', 'Mantle Cell Lymphoma', 'Mixed Phenotype Acute Leukemia', 'Myelodysplastic Syndrome', 'Prolymphocytic Leukemia', 'Refractory Chronic Lymphocytic Leukemia', 'Refractory Follicular Lymphoma', 'Refractory Marginal Zone Lymphoma', 'Refractory Small Lymphocytic Lymphoma']",[],,2021-01-25,2028-01-10,"[{'measure': 'Graft failure/rejection', 'description': 'The analysis for graft failure will be conducted among all patients as well as separately among patients by Arm A versus Arm B.', 'timeFrame': 'Up to 2 years post-transplant'}]","[{'measure': 'Overall survival', 'timeFrame': 'At 1- and 2-years post-transplant'}, {'measure': 'Progression free survival', 'description': 'Defined as the probability of being alive without sign of disease relapse or progression. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'At 1 year post-transplant'}, {'measure': 'Non-relapse mortality', 'description': 'Defined as death from any cause without sign of disease progression or relapse. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'At day 100 and 1 year post-transplant'}, {'measure': 'Cumulative incidence of relapse', 'timeFrame': 'At 1- and 2-years post-treatment'}, {'measure': 'Acute graft versus host disease', 'description': 'Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Chronic graft versus host disease', 'description': 'Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Clinically significant infections', 'description': ""Clinically significant infections include infections that have a significant impact on patient's clinical recovery, for instance infections that require in-patient hospitalization or prolongs existing hospitalization. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate."", 'timeFrame': 'Up to 2 years post-transplant'}, {'measure': 'Platelet engraftment', 'description': 'Defined as the first of three consecutive days with platelet count \\>= 20,000/uL on the peripheral blood, without platelet transfusion in the previous seven days. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.', 'timeFrame': 'At day 100 post-transplant'}]",9.0,6 Months,,ALL,True,OTHER,1.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05059470,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,Pembrolizumab,['Pembrolizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Thyroid,M.D. Anderson Cancer Center,2025-09-01T16:18:07.028160,True,,,,NOT_FOUND,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,,['Thyroid'],[],\<75% participant accrual,2022-02-11,2025-07-01,"[{'measure': 'To establish the median progression-free survival (PFS).', 'timeFrame': 'through study completion, an average of 1 year'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,6.0,ACTUAL,v2_robust,True,False,True,False,\<75% participant accrual,,,no_match,False,,,
NCT04697654,"The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers",TLC19,"['TLC19 Vehicle (same formulation as TLC19 but without the active ingredient)', 'TLC19 (Hydroxychloroquine Liposome Inhalation Suspension)', 'TLC19 Vehicle', 'TLC19']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,COVID-19,Taiwan Liposome Company,2025-09-01T16:18:18.428659,True,,,,NOT_FOUND,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers",,['COVID-19'],"['hydroxychloroquine', 'Inhalation']",,2020-10-08,2021-06-18,"[{'measure': 'Incidence of AEs', 'description': 'To evaluate the severity, seriousness, outcome, and action taken of AE', 'timeFrame': '0-28 Days'}]","[{'measure': 'Maximum blood concentration', 'description': 'Cmax', 'timeFrame': '0-168 hours'}, {'measure': 'Time to reach maximum blood concentration', 'description': 'Tmax', 'timeFrame': '0-168 hours'}, {'measure': 'Area under the blood concentration-time curve', 'description': 'AUC0-last', 'timeFrame': '0-168 hours'}]",4.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00141154,"Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan",Celecoxib,"['Celecoxib', 'Loxoprofen', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Low Back Pain,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,2025-09-01T16:18:10.911693,True,,,,NOT_FOUND,"A Randomized, Multicenter, Active And Placebo Controlled Parallel Group Study To Evaluate The Efficacy And Safety Of Celecoxib (Ym177) 200 Bid Compared To Loxoprofen 60 Mg Tid In Patients With Low Back Pain",,['Low Back Pain'],[],,2004-10,,"[{'measure': ""Patient's pain assessment (VAS: Visual Analogue Scale)""}]","[{'measure': ""Patient's global assessment (VAS), Physician's global assessment (VAS), Roland Morris Disability Questionnaire (RDQ)""}]",2.0,20 Years,,ALL,False,INDUSTRY,0.0,1234.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01139138,"Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer",Panitumumab,"['Vectibix', 'Irinotecan', 'Everolimus', 'Panitumumab', 'RAD001']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Colorectal Cancer,The Queen Elizabeth Hospital,2025-09-01T16:18:25.984749,True,,,,NOT_FOUND,"A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT",,"['Colorectal Cancer', 'Colorectal Carcinoma', 'Colorectal Tumors', 'Neoplasms, Colorectal']","['Colorectal Cancer', 'Colorectal Carcinoma', 'Colorectal Tumors', 'Neoplasms, Colorectal']",,2010-06,2017-06,"[{'measure': 'Dose limiting toxicities', 'description': 'To determine the maximum tolerated dose (MTD)of everolimus, irinotecan and panitumumab when given in combination for patients with Kras WT mCRC', 'timeFrame': 'at end of cycle 2 (each cycle is 14 days)'}]","[{'measure': 'Safety & toxicity', 'description': 'Safety and toxicity assessed weekly during the phase Ib component (as per NCI CTCAE version 3.0) and fortnightly during the phase II component', 'timeFrame': 'Approximately 24 weeks'}, {'measure': 'Response rate', 'description': 'Objective tumour response as per RECIST criteria V1.0', 'timeFrame': 'Assessed every 6 weeks until disease progression'}, {'measure': 'Progression free survival', 'timeFrame': 'Until disease progression, occurrence of new disease or death'}, {'measure': 'Overall Survival', 'timeFrame': 'Assessed 3 monthly until death'}]",5.0,18 Years,,ALL,False,OTHER,2.0,49.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,Endocrine therapy combined with trastuzumab,"['Endocrine therapy combined with trastuzumab', 'Tamoxifen', 'Chemotherapy combined with trastuzumab', 'trastuzumab', 'Capecitabine', 'Gemcitabine', 'Vinorelbine', 'aromatase inhibitors']",8,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Breast Cancer,Sun Yat-sen University,2025-09-01T16:18:20.957663,True,,,,NOT_FOUND,"A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype",,['Breast Cancer'],"['Luminal B2 subtype', 'First line treatment']",,2013-09-16,2020-05-31,"[{'measure': 'progression-free survival (PFS)', 'description': 'The interim analysis and the final analysis are expected ot occur 18 and 36 months after the end of recruitment.', 'timeFrame': '36 months'}]",[],1.0,18 Years,75 Years,FEMALE,False,OTHER,0.0,392.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00467051,Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors,Carboplatin,"['Tronoxal', 'Blastocarb', 'Iphosphamide', 'Taxol Konzentrat', 'Seromida', 'Naxamide', 'Paraplatin', 'Holoxane', 'Carboplatino', 'Paraplatine', 'Iphosphamid', 'Z 4942', 'Ribocarbo', 'IFO-Cell', 'Ifolem', 'Isophosphamide', 'IFX', 'Ercar', 'Bristaxol', 'Paclitaxel', 'Novoplatinum', 'Carbotec', 'Carboplat', 'Asotax', 'Carboplatin', 'Asta Z-4942', 'Cyfos', 'Carbosol', 'Ifex', 'Carbosin', 'Holoxan', 'Z-4942', 'Taxol', 'Ifomide', 'Anzatax', 'Ifosfamidum', 'Platinwas', 'Isoendoxan', 'MJF-9325', 'Nealorin', 'Displata', 'Iso-Endoxan', 'CBDCA', 'Ifoxan', 'MJF 9325', 'Praxel', 'Ifosfamide', 'JM-8', 'Ifomida', 'Asta Z 4942', 'Paraplatin AQ', 'Carboplatin Hexal', 'Mitoxana', 'IFO']",54,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Childhood Extracranial Germ Cell Tumor,Children's Oncology Group,2025-09-01T16:18:15.901862,True,,,,NOT_FOUND,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",,"['Childhood Extracranial Germ Cell Tumor', 'Childhood Extragonadal Malignant Germ Cell Tumor', 'Childhood Malignant Ovarian Germ Cell Tumor', 'Childhood Malignant Testicular Germ Cell Tumor', 'Ovarian Choriocarcinoma', 'Ovarian Embryonal Carcinoma', 'Ovarian Yolk Sac Tumor', 'Recurrent Childhood Malignant Germ Cell Tumor', 'Recurrent Malignant Testicular Germ Cell Tumor', 'Recurrent Ovarian Germ Cell Tumor', 'Testicular Choriocarcinoma', 'Testicular Embryonal Carcinoma', 'Testicular Mixed Choriocarcinoma and Embryonal Carcinoma', 'Testicular Mixed Choriocarcinoma and Yolk Sac Tumor', 'Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor', 'Testicular Yolk Sac Tumor']",[],,2007-11-05,2018-06-30,"[{'measure': 'Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria', 'description': 'Patients who demonstrate a PR or CR, as defined below, will be considered as responders. RECIST criteria: CR (complete response) = disappearance of all target lesions, PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions, PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions and SD (stable disease) = small changes that do not meet above criteria.', 'timeFrame': 'At baseline (day 1) and after completion of protocol therapy (2 cycles or 42 days)'}]","[{'measure': 'The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity.', 'timeFrame': 'Two cycles of chemotherapy; expected to be 42 days of treatment.'}]",2.0,,21 Years,ALL,False,NETWORK,1.0,20.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00161018,New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia,"Quetiapine, Risperidone, Fluphenazine","['Quetiapine, Risperidone, Fluphenazine']",1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Schizophrenia,"University of Maryland, Baltimore",2025-09-01T16:18:09.635284,True,,,,CHEMBL85,,,['Schizophrenia'],[],,2003-11,2004-11,"[{'measure': 'To evaluate the efficacy and safety of the new antipsychotics, quetiapine(300-500mg/day) and risperidone(3-5mg/day) compared to each other and to fluphenazine(10-15mg/day), a high potency typical antipsychotic'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,0.0,150.0,,v2_robust,True,True,False,True,,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,CHEMBL85,partial_match,True,410.49,3.59,4.0
NCT01921231,Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine,Hyperbaric Prilocaine 1%,"['Hyperbaric bupivacaine 0.5%', 'Hyperbaric Prilocaine 1%']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Knee Arthroscopy (for Diagnostic or Therapy),Dr. Pere Roura-Poch,2025-09-01T16:18:18.432339,True,,,,NOT_FOUND,Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine in Knee Arthroscopy and Inguinal Hernia Repair in Ambulatory Surgery,,"['Knee Arthroscopy (for Diagnostic or Therapy)', 'Inguinal Hernia Repair (Not Urgent)']",[],,2007-05,2007-12,"[{'measure': 'Length of stay in post-operative care unit (in minutes)', 'description': 'Time in minutes from closing the surgical incision until to having criteria for discharge to home.', 'timeFrame': 'Participants will be followed an average of 6 hours from surgical incision closure to accomplish discharge criteria to go home'}]","[{'measure': 'Level of motor blocking', 'description': 'Assessed by Bromage score who ranges from Complete block (unable to move feet or knees, score 1) to Able to perform partial knee bend (score 6 who means nil block).', 'timeFrame': 'At surgical incision and at 60 minutes after anesthesia'}, {'measure': 'Fast-track (by-pass recovery area)', 'description': ""Number (and percentage) of patients in each arm that can be transferred directly from the operating room to postsurgical ward. A minimal score of 12 (on modified Aldrete's scoring system with no score \\<1 in any individual category) would be required for a patient to be fast-tracked."", 'timeFrame': 'Participants will be assessed when surgical incision is closed with surgical staples'}, {'measure': 'Peak sensory block level', 'description': 'The sensory block level was determined pricking dermatomes with a pin from down to up.', 'timeFrame': 'One minute before surgical incision'}, {'measure': 'Transient neurological symptoms', 'description': 'Researchers surveyed if appears pain originated in gluteal region and radiating to both lower extremities following patients by phone.', 'timeFrame': 'At hospital discharge (an average of 8 hours after admission), and at home at 24, 48 and 72 hours after surgery'}]",5.0,18 Years,,ALL,False,OTHER,0.0,119.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01758978,A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet,a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).,['a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pain,"Teva Branded Pharmaceutical Products R&D, Inc.",2025-09-01T16:18:19.676416,True,,,,NOT_FOUND,"A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 30-mg and One 60-mg Hydrocodone Bitartrate Extended-Release Tablet",,['Pain'],"['bioequivalence, hydrocodone bitartrate extended-release tablets']",,2012-12,2013-01,"[{'measure': 'Maximum observed plasma drug concentration (Cmax)', 'description': 'To assess the bioequivalence between 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Area under the plasma drug concentration by time curve AUC 0-∞', 'description': 'To assess bioequivalence between two 30-mg tablets and one 60-mg tablet of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}]","[{'measure': 'Time to maximum observed plasma drug concentration (tmax)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'AUC from time 0 to 72 hours after study drug administration (AUC0-72)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Percentage extrapolation, 100x(AUC0-∞-AUC0-t)/AUC0-∞)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Apparent plasma terminal elimination rate constant (λz) and associated elimination half life (t½)', 'description': 'To characterize the pharmacokinetics of the hydrocodone bitartrate extended-release tablet.', 'timeFrame': 'Approximately 5 minutes prior to study drug administration up to 72 post study drug administration.'}, {'measure': 'Recording of Adverse Events', 'description': 'To characterize the safety of the hydrocodone bitartrate extended-release tablet in healthy naltrexone-blocked subjects.', 'timeFrame': 'From ICF signing to 48-72 hours after discharge from the study center following the last administration of the hydrocodone bitartrate extended-release tablet.'}]",8.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,54.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03979976,"Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus",Ramipril,"['Ramipril', 'angiotensin-converting enzyme inhibitor (ACEI)']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Systemic Lupus Erythematosus,Federal University of São Paulo,2025-09-01T16:18:07.015371,True,,,,CHEMBL1201365,Ramipril Improves Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus: a Randomized and Controlled Study.,,['Systemic Lupus Erythematosus'],"['systemic lupus erythematosus', 'endothelium', 'ramipril']",,2011-03,2013-09,"[{'measure': 'Endothelial function - Variation of Flow mediated dilation percentage', 'description': 'Patients were evaluated at baseline and after 12 weeks by high-resolution ultrasound of brachial artery in resting conditions, after reactive hyperaemia (flow-mediated dilation-FMD) and after oral glyceryl trinitrate to assess endothelial function', 'timeFrame': '12 weeks'}, {'measure': 'Number of endothelial progenitor cells (EPC)', 'description': 'Patients were evaluated at baseline and after 12 weeks. EPCs were evaluated by flow cytometry using anti-CD34 (cluster of differentiation 34) (FITC), anti-CD133 (PE) and anti-kinase domain receptor (KDR) (APC) and by cell culture with quantification of colony formation units (CFUs).', 'timeFrame': '12 weeks'}]",[],2.0,18 Years,,FEMALE,False,OTHER,1.0,37.0,ACTUAL,v2_robust,True,True,False,False,,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,CHEMBL1201365,partial_match,True,388.46,1.9,2.0
NCT03669783,"Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)",treatment Vincristin,"['treatment Vincristin', 'Etoposide', 'treatment Carboplatin', 'treatment Actinomycin-D', 'treatment Doxorubicin']",5,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Childhood Renal Tumor,Assistance Publique Hopitaux De Marseille,2025-09-01T16:18:20.965815,True,,,,NOT_FOUND,"Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)",,['Childhood Renal Tumor'],[],,2023-02-03,2033-10-03,"[{'measure': 'Metastatic response assessment by neoadjuvant chemotherapy only', 'description': 'percentage of patients with complete response (CR) or Very Good Partial Response (VGPR) of metastasis of nephroblastoma after 6 weeks of preoperative chemotherapy', 'timeFrame': '6 weeks'}]","[{'measure': 'Secondary metastatic response assessment', 'description': 'percentage of patients after 6 weeks of preoperative chemotherapy achieving a CR after surgery of metastasis at time of nephrectomy', 'timeFrame': '6 weeks'}, {'measure': 'Clinical outcome after treatment', 'description': 'stage of local tumor (for each arm)', 'timeFrame': '2 and 5 years'}, {'measure': 'Histological response to preoperative treatment', 'description': 'stage distribution of local tumor histological subtype distribution of local tumor (low, intermediate or high risk (LR, IR, HR))', 'timeFrame': '6 weeks'}]",4.0,,17 Years,ALL,False,OTHER,1.0,110.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03514511,Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis,LEO 138559,"['LEO 138559 placebo', 'LEO 138559']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Atopic Dermatitis,LEO Pharma,2025-09-01T16:18:17.172847,True,,,,NOT_FOUND,"Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis",,['Atopic Dermatitis'],[],,2018-05-07,2021-03-02,"[{'measure': 'Safety of LEO 138559 - numbers of subjects with adverse events', 'timeFrame': 'Day 1 to Day 120'}, {'measure': 'Safety of LEO 138559 - number of adverse events', 'timeFrame': 'Day 1 to Day 120'}, {'measure': 'Tolerability of LEO 138559 - number of local site reactions', 'timeFrame': 'Day 1 to Day 120'}]",[],3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,47.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05487976,Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor,Recombinant human activated coagulation factor VII for injection,['Recombinant human activated coagulation factor VII for injection'],1,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Hemophilia A,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",2025-09-01T16:18:25.989806,True,,,,NOT_FOUND,A Phase III Clinical Study of the Efficacy and Safety of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitors,,"['Hemophilia A', 'Hemophilia B']",[],,2022-04-28,2023-04,"[{'measure': 'Number of bleeding Effective rate of hemostasis', 'description': 'Hemostasis is effective after the bleeding event if the bleeding event has not received other treatment within 12 hours since the first treatment and achieved moderate or above remission (based on the four-point scoring standard)', 'timeFrame': 'Each new blood event was assessed within 12 hours of initial treatment'}, {'measure': 'Activity recovery of first dose', 'description': 'The peak coagulation factor VII activity measured within 1 hour after the end of the infusion was subtracted from the baseline coagulation factor VII activity and expressed as \\[IU/ml\\]/\\[IU/kg\\].', 'timeFrame': 'Within 1 hour of completion of infusion'}]","[{'measure': 'Number of bleeding effective rate of hemostasis within 8 hours', 'description': 'Excellent remission (based on the four-point scoring standard)', 'timeFrame': 'Each new blood event was assessed within 8 hours of initial treatment'}, {'measure': 'Number of bleeding effective rate continuous hemostatic', 'description': 'Moderate or above remission (based on grade 4 scoring criteria) without receiving other treatment within 24 hours after the occurrence of bleeding event is considered as effective hemostasis after the occurrence of bleeding event.', 'timeFrame': 'Each new blood event was assessed within 24 hours of initial treatment'}, {'measure': 'Activity recovery after repeated administration', 'description': 'The peak coagulation factor VII activity measured within 1 hour after the end of the infusion was subtracted from the baseline coagulation factor VII activity and expressed as \\[IU/ml\\]/\\[IU/kg\\].', 'timeFrame': 'Within 1 hour of completion of infusion'}, {'measure': 'Dose of injections for each new blood transfusion', 'description': 'Dose of injections for each new blood transfusion.The dose of injections (including average injection dose and total dose) of each new blood transfusion were recorded.', 'timeFrame': 'Up to 24 weeks.'}, {'measure': 'Number of injections for each new blood transfusion', 'description': 'Number of injections for each new blood transfusion.The number of injections of each new blood transfusion were recorded.', 'timeFrame': 'Up to 24 weeks.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation tests: Changes of activated partial thromboplastin time (APTT).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: Changes of prothrombin time (PT).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: Changes of thrombin time(TT).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: Changes of fibrinogen (Fbg).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: thrombin production test (TGA):Changes of thrombin production potential (ETP) in TGA at each test time.', 'timeFrame': 'First and week 24，within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}]",12.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02354027,The Drug-drug Interaction of SHR3824 and Metformin,SHR3824 metformin,"['Henagliflozin metformin', 'SHR3824 metformin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Type 2 Diabetes,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:15.896348,True,,,,NOT_FOUND,Drug Interaction Study of Henagliflozin and Metformin in Healthy Subjects,,['Type 2 Diabetes'],['SHR3824 metformin drug-drug interaction'],,2014-09,2015-01,"[{'measure': 'The maximum plasma concentration (Cmax) of SHR3824.', 'description': ""Cmax (a measure of the body's exposure to SHR3824) will be compared before and after administration of a single dose of metformin."", 'timeFrame': 'At protocol-specified times up to Day 9.'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of SHR3824.', 'description': ""AUC (a measure of the body's exposure to SHR3824) will be compared before and after administration of a single dose of metformin."", 'timeFrame': 'At protocol-specified times up to Day 9.'}, {'measure': 'The maximum plasma concentration (Cmax) of metformin.', 'description': ""Cmax (a measure of the body's exposure to metformin) will be compared. before and after administration of multiple doses of SHR3824"", 'timeFrame': 'At protocol-specified times up to Day 9.'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of metformin', 'description': ""AUC (a measure of the body's exposure to metformin) will be compared before and after administration of multiple doses of SHR3824."", 'timeFrame': 'At protocol-specified times up to Day 9.'}]","[{'measure': 'The number of volunteers with adverse events as a measure of safety and tolerability.', 'timeFrame': 'Up tp day 9.'}]",5.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03763643,PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant,Rituximab,['Rituximab'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,Focal Segmental Glomerulosclerosis,University of Minnesota,2025-09-01T16:18:17.186376,True,,,,NOT_FOUND,PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant,,['Focal Segmental Glomerulosclerosis'],[],,2019-07-01,2026-12-31,"[{'measure': 'Feasibility assessment', 'description': 'quantifying the number and proportion of patients who can undergo the steps of recruitment, informed consent, enrollment, randomization, and follow-ups within the time frame of interest.', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'Patient and graft survival at 1 year post-transplant', 'description': 'Outcome is reported as the number of participants who survive with a functional graft one year post-transplant.', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Graft function at 1 year post-transplant', 'description': 'Graft function will be assessed using the glomerular filtration rate (GFR) and Schwartz equation (for age ≤17 years) or the CKD-EPI (for age ≥18 years).', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Proportion with acute rejection at 1 year post-transplant', 'description': 'Outcome is reported as the percentage of participants who experience an acute graft rejection at one ear post-transplant.', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Proportion with CD19+ <1%', 'description': 'Outcome is reported as the percentage with participants with a reconstitution of CD19+ B cells at one year post-transplant.', 'timeFrame': '1 month, 6 months, and 12 months'}, {'measure': 'Recurrent FSGS free survival', 'description': 'To determine the difference in rate of recurrent FSGS after 1 year post-transplant in patients receiving plasmapheresis and rituximab prior to or at the time of kidney transplantation compared to those receiving plasmapheresis alone.', 'timeFrame': 'after 1 year post-transplant'}]",6.0,1 Year,65 Years,ALL,False,OTHER,1.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03686722,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin,Metformin,"['Daclatasvir', 'Metformin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 2",Mohamed Raslan,2025-09-01T16:18:10.914256,True,,,,CHEMBL1703,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetics and Pharmacodynamics of Metformin,,"['Diabetes Mellitus, Type 2', 'Hepatitis C', 'Drug Interactions']",[],,2017-09-09,2017-12-06,"[{'measure': '(AUC0→12)', 'description': 'Area under the plasma concentration-time curve measured in (nanogram(ng).hr/ml)', 'timeFrame': 'From first sampling interval(time zero) up to 12 hours'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to infinity (AUC0→∞)', 'description': 'Area under the plasma concentration-time curve from time 0 to infinity measured in(ng.hr/ml)', 'timeFrame': 'From first sampling interval up to infinity'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to tau(AUC0→tau)', 'description': 'Area under the plasma concentration-time curve from time 0 to tau measured in(ng.hr/ml)', 'timeFrame': 'From first sampling interval up to dosing interval(Tau)'}, {'measure': 'Maximum drug concentration in plasma at steady state(Cpss)', 'description': 'Maximum drug concentration in plasma at steady state measured in (ng/ml)', 'timeFrame': 'Time corresponding to maximum drug concentration in plasma at steady state'}, {'measure': 'Half life( t½) of drug in plasma', 'description': 'Half life of drug measured in Hours(hr)', 'timeFrame': 'Up to 12 hours'}, {'measure': 'Mean residence time of drug(MRT)', 'description': 'Mean residence time of drug in plasma measured in (hr)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'steady state Clearance of drug(CLss)', 'description': 'steady state Clearance of drug measured in (ml/min)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'Renal Clearance of drug(CLr)', 'description': 'Renal Clearance of drug measured in (ml/min)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'Cumulative amount of drug eliminated in urine (Ae)', 'description': 'Cumulative amount of drug eliminated in urine measured in (microgram(ug)/ml)', 'timeFrame': 'From first sampling interval up to 12 hours'}, {'measure': 'Maximum excretion rate (Urate max)', 'description': 'Maximum excretion rate for the drug measured in (milligram(mg)/hr)', 'timeFrame': 'From first sampling interval up to 12 hours'}]","[{'measure': 'Blood Glucose(BG) levels', 'description': 'Blood glucose levels measured in (mg/dl)', 'timeFrame': 'up to 3 hours'}, {'measure': 'Area under the BG-time curve(AUG)0-3hr', 'description': 'Area under the BG-time curve measured in (mg.hr/dl)', 'timeFrame': 'up to 3 hours'}, {'measure': 'Maximum Glucose concentration(Gmax)', 'description': 'Maximum Glucose concentration measured in (mg/dl)', 'timeFrame': 'up to 3 hours'}]",13.0,18 Years,55 Years,MALE,True,OTHER,2.0,20.0,ACTUAL,v2_robust,True,True,False,False,,CN(C)C(=N)NC(=N)N.Cl,CHEMBL1703,partial_match,True,165.63,-1.03,4.0
NCT00867334,New Individualized Therapy Trial for Metastatic Colorectal Cancer,Imatinib mesylate and panitumumab,"['Vectibix', 'ABX-EGF monoclonal antibody', 'Imatinib mesylate and panitumumab', 'Gleevec', 'Standard-of-care treatment with panitumumab', 'ST1571']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Colorectal Neoplasm,Inova Health Care Services,2025-09-01T16:18:08.349262,True,,,,NOT_FOUND,A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay,,"['Colorectal Neoplasm', 'Colorectal Cancer']","['colorectal neoplasm', 'colorectal cancer', 'imatinib mesylate', 'Gleevec', 'Physiological Effects of Drugs', 'panitumumab', 'Vectibix', 'c-kit receptor', 'Receptor', 'Platelet-Derived Growth Factor alpha']",,2009-06,2011-08,"[{'measure': 'Number of Patients With Adverse Events', 'description': 'Information about all adverse events, whether volunteered by the subject, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected and recorded.', 'timeFrame': 'From consent up until 4 weeks after patient has stopped study participation'}]","[{'measure': 'Number of Participants With Stabilization or Reduction in Tumor Size', 'description': 'Results reported as number of patients with stabilization or reduction in tumor size. Tumor response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) solid tumor response criteria, evaluated by CT.', 'timeFrame': '8 weeks after baseline'}]",2.0,18 Years,,ALL,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03174847,Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism,Mineralocorticoid Receptor Antagonists,"['Eplerenone', 'Amiloride', 'Mineralocorticoid Receptor Antagonists', 'Spironolactone']",4,OBSERVATIONAL,[],,COMPLETED,Primary Aldosteronism,Changi General Hospital,2025-09-01T16:18:25.983468,True,,,,NOT_FOUND,"Prospective Study Assessing Blood Pressure, Cardiovascular, Endothelial and Other Outcomes poSt-surgical and Medical Treatment in Patients With Primary Aldosteronism",,"['Primary Aldosteronism', 'Primary Aldosteronism Due to Aldosterone Producing Adenoma', 'Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)']","['Primary aldosteronism', 'Blood pressure', 'Adrenalectomy', 'Mineralocorticoid-receptor Antagonists', 'Cardiovascular', 'Endothelial', 'Renal']",,2017-02-20,2020-09-20,"[{'measure': 'Blood Pressure', 'description': 'Blood pressure assessed by 24hr ambulatory BP', 'timeFrame': 'Change from Baseline Blood Pressure at 12 months'}]","[{'measure': 'Use of antihypertension medications', 'description': 'Use of antihypertension medications as expressed in daily defined dosages and total number of medications', 'timeFrame': 'Change from Baseline Antihypertension medications at 12 months'}, {'measure': 'Blood Pressure', 'description': 'Clinic blood pressure', 'timeFrame': 'Change from Baseline Clinic Blood Pressure at 12 months'}, {'measure': 'Cardiac function', 'description': 'Cardiac function using 2DE', 'timeFrame': 'Change from Baseline Cardiac function at 12 months.'}, {'measure': 'Left ventricular hypertrophy', 'description': 'as assessed by 2DE and ECG', 'timeFrame': 'Change from Baseline Left ventricular hypertrophy at 12 months'}, {'measure': 'Renal Function', 'description': 'change in serum creatinine, calculated GFR, albuminuria (prevalence and severity)', 'timeFrame': 'Change from Baseline Renal Function at 12 months'}, {'measure': 'Quality of Life (RAND-36)', 'description': 'RAND-36', 'timeFrame': 'Change from Baseline Quality of Life RAND-36 at 12 months'}, {'measure': ""Quality of Life ( Beck's depression inventory II)"", 'description': ""Beck's depression inventory II"", 'timeFrame': 'Change from Baseline Quality of Life (BDI-II) at 12 months'}, {'measure': 'Quality of Life (EQ5D)', 'description': 'EQ5D', 'timeFrame': 'Change from Baseline EQ5D at 12 months'}, {'measure': 'Lipids', 'description': 'Lipids', 'timeFrame': 'Change from Baseline Lipids at 12 months'}, {'measure': 'Transaminitis', 'description': 'ALT, AST,', 'timeFrame': 'Change from Baseline transaminitis at 12 months'}, {'measure': 'Insulin Resistance', 'description': 'Measured with HOMA', 'timeFrame': 'Change from Baseline Insulin resistance at 12 months'}, {'measure': 'Fasting glucose', 'description': 'Fasting glucose', 'timeFrame': 'Change from Baseline Fasting glucose at 12 months'}, {'measure': 'weight', 'description': 'change in weight', 'timeFrame': 'Change from Baseline weight at 12 months'}, {'measure': 'Control of hypertension', 'description': 'Proportion of patients reaching normal BP (ambulatory /home BP \\<135/85 or clinic BP \\<140/90)', 'timeFrame': 'Change from Baseline Status of hypertension control at 12 months'}, {'measure': 'Cure of Primary aldosteronism', 'description': 'Proportion of patients with cure of PA after adrenalectomy', 'timeFrame': 'Change from Baseline Status of primary aldosteronism at 12 months'}]",16.0,21 Years,80 Years,ALL,False,OTHER,0.0,57.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT00189514,A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects,pramlintide acetate,"['pramlintide acetate', 'Symlin', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Obesity,AstraZeneca,2025-09-01T16:18:12.168449,True,,,,NOT_FOUND,Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects,,['Obesity'],"['obesity', 'weight loss', 'Amylin', 'pramlintide']",,2005-09,2007-06,"[{'measure': 'Examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight in obese subjects.', 'timeFrame': 'open ended'}, {'measure': 'Examine the long-term safety and tolerability of SC injected pramlintide in obese subjects.', 'timeFrame': 'open ended'}]","[{'measure': 'Investigate the long-term effect of SC injected pramlintide in obese subjects on various anthropometric and pharmacodynamic parameters.', 'timeFrame': 'open ended'}]",3.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,210.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04925063,The Effect of Metformin in Patients With Newly Diagnosed mHSPC,Metformin,"['Metformin Hydrochloride Sustained Release Tablets', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Metastatic Prostate Cancer,Sun Yat-sen University,2025-09-01T16:18:17.176657,True,,,,CHEMBL1703,"A Prospective, Randomized Trial Comparing Metformin Plus Androgen Deprivation Therapy (ADT) and Abiraterone With ADT Plus Abiraterone in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer",,['Metastatic Prostate Cancer'],['metastatic hormone sensitive prostate cancer; abiraterone; metformin'],,2021-06-16,2027-08-31,"[{'measure': 'Castration-resistant prostate cancer free survival', 'description': 'Duration from randomization to time till development of CRPC (Castration-resistant prostate cancer). CRPC is defined by disease progression despite castration level of testosterone and may present as either a biochemical progression and/or radiological progression.', 'timeFrame': '5 years'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival is defined from randomization until death due to any reason.', 'timeFrame': '5 years'}, {'measure': 'Radiographic progression-free survival', 'description': 'Radiographic progression-free survival is defined from randomization until radiographic progression.', 'timeFrame': '5 years'}, {'measure': 'Safety', 'description': 'Adverse events will be assessed according to NCI-CTC AE 5.0.', 'timeFrame': '5 years'}]",4.0,18 Years,,MALE,False,OTHER,0.0,266.0,ESTIMATED,v2_robust,True,False,False,True,,CN(C)C(=N)NC(=N)N.Cl,CHEMBL1703,partial_match,True,165.63,-1.03,4.0
NCT00212290,Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes,pioglitazone,"['pioglitazone', 'placebo', 'nateglinide']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Insulin Resistance,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),2025-09-01T16:18:09.635742,True,,,,CHEMBL1715,,,"['Insulin Resistance', 'Type 2 Diabetes Mellitus']",['impaired glucose tolerance'],,2002-11,2006-12,"[{'measure': 'Verbal memory (main study)'}, {'measure': 'Selective attention (main study)'}, {'measure': 'Plasma beta-amyloid levels (main study)'}, {'measure': 'Cerebral glucose metabolism (sub-study)'}, {'measure': 'Inflammatory markers in spinal fluid (sub-study)'}, {'measure': 'Beta-amyloid in spinal fluid (sub-study)'}]","[{'measure': 'Psychomotor speed'}, {'measure': 'Verbal fluency'}, {'measure': 'Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers'}]",9.0,55 Years,,ALL,True,NIH,0.0,140.0,ESTIMATED,v2_robust,True,True,False,False,,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,CHEMBL1715,partial_match,True,392.91,3.16,4.0
NCT05570708,The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training,"MDMA, LSD, psilocybin","['MDMA, LSD, psilocybin']",1,INTERVENTIONAL,['NA'],,ENROLLING_BY_INVITATION,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD",Felix Mueller,2025-09-01T16:18:14.670960,True,,,,NOT_FOUND,The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training,,"['Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD']",[],,2022-10-25,2029-06-01,"[{'measure': 'TASC-2 scale', 'description': 'The primary endpoint is changes on the TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)', 'timeFrame': 'Three weeks after last PE'}]","[{'measure': 'semi-structured interview', 'description': 'A semi-structured interview will be used to explore the range of effects and systematically collect and record subjective effects of the personal experience', 'timeFrame': 'Five months after last PE'}, {'measure': 'TASC-2 scale', 'description': 'TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'SOCS-S', 'description': 'Compassion with self', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'SPCS-O', 'description': 'Compassion with others', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'SPF/IRI', 'description': 'Empathy questionnaire', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': '5D-ASC', 'description': '5 dimensions of altered states of consciousness questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'CEQ', 'description': 'Challenging experience questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'APEQ', 'description': 'Acceptance /avoidance-promoting experiences questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'PIQ', 'description': 'Psychological insights questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'CSOWD', 'description': 'Connectedness scale', 'timeFrame': 'Directly after each PE'}, {'measure': 'EBI', 'description': 'Emotional breakthrough inventory', 'timeFrame': 'Directly after each PE'}, {'measure': 'BFW/E', 'description': 'Berner Subjective Well-Being questionnaire', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'PEQ', 'description': 'Persisting effects questionnaire', 'timeFrame': 'Three weeks after each PE and six months after last PE'}]",14.0,27 Years,,ALL,True,OTHER,1.0,48.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT06451705,Pecs Block vs Local Infiltration in Mastectomy,PECS II block,"['PECS II block', 'LIA']",2,INTERVENTIONAL,['NA'],,COMPLETED,"Pain, Postoperative",Hasanuddin University,2025-09-01T16:18:24.741402,True,,,,NOT_FOUND,"Comparison Between Pectoral Nerve Block II and Local Anesthesia Infiltration of Isobaric Bupivacaine 0.25% 50 MG on Neutrophil-Lymphocyte Ratio, Interleukin-6 Levels, Pain Intensity, and Post-surgical Opioid Requirements in Modified Radical Mastectomy Patients",,"['Pain, Postoperative']","['postoperative pain', 'modified radical mastectomy', 'peripheral nerve block', 'local infiltration anesthesia', 'pectoralis nerve block']",,2024-03-01,2024-04-30,"[{'measure': 'Concentration of Plasma Interleukin-6', 'description': 'in pg/dL', 'timeFrame': '1 hour before surgery, 2 hour after surgery, 12 hour after surgery'}, {'measure': 'Neutrophil-lymphocyte ratio', 'description': 'Neutrophil divided by lymphocyte', 'timeFrame': '1 hour before surgery, 2 hour after surgery, 12 hour after surgery'}, {'measure': 'Pain intensity (Using Numeric Rating Scale)', 'description': 'Scale from 0-10, lower score = better outcome', 'timeFrame': 'hour 0, 2, 4, 6, 12, 24'}, {'measure': 'Rescue opioid requirement', 'description': 'Using fentanyl at a dose of 0.5-1 μg/kg/IV titrated as needed, in mcg (given if the patient had NRS of \\>4/10)', 'timeFrame': 'Within 24 hours after surgery'}]","[{'measure': 'Demographic baseline data', 'description': 'Medical record number, age, body weight (in kilogram), height (in centimeter), BMI (in kg/m2), ASA PS class, duration of surgery (in minutes)', 'timeFrame': 'baseline (before the surgery)'}, {'measure': 'Time until first rescue opioid requirement', 'description': 'in minutes', 'timeFrame': 'Within 24 hours after surgery'}, {'measure': 'Nausea and vomiting', 'description': 'Nausea and vomiting were assessed using a numerical scale (0 = no nausea, 1 = mild nausea, 2 = severe nausea or vomiting once, and 3 = vomiting more than once). If the score was \\> 2, rescue antiemetics with ondansetron 0.1 mg/IV were given.', 'timeFrame': 'Within 24 hours after surgery'}]",7.0,18 Years,60 Years,ALL,True,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00754871,Pharmacodynamic Characterization of Dienogest,Dienogest (81150037),"['Dienogest (81150037)', 'Dienogest (81150746)', 'Dienogest (81150231)', 'Dienogest (SH T00660A)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pharmacodynamics,Bayer,2025-09-01T16:18:22.203541,True,,,,NOT_FOUND,"A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days",,['Pharmacodynamics'],[],,2008-09,2009-09,"[{'measure': 'No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned', 'timeFrame': 'No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned'}]","[{'measure': 'Course of gonadotropins (FSH, LH, P, E2)', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Endometrial thickness', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Grading of ovarian activity', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Effects on the cervix and the cervical mucus', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'mRNA expression profile of endometrial biopsies and in blood', 'timeFrame': 'once in pre-treatment and during treatment'}, {'measure': 'Concentrations of DNG in serum', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Safety and tolerability', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}]",8.0,18 Years,35 Years,FEMALE,True,INDUSTRY,0.0,102.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00112515,Modafinil in Treating Fatigue in Patients With Cancer,modafinil,['modafinil'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Cognitive/Functional Effects,University of Virginia,2025-09-01T16:18:09.629909,True,,,,CHEMBL1373,"Pilot Study Evaluating the Safety and Efficacy of Modafinil in Improving Fatigue, Mood, Cognitive Ability, Functional Status, and Quality of Life of Cancer Patients",,"['Cognitive/Functional Effects', 'Depression', 'Fatigue', 'Unspecified Adult Solid Tumor, Protocol Specific']","['depression', 'cognitive/functional effects', 'fatigue', 'unspecified adult solid tumor, protocol specific']",,2004-02,,"[{'measure': 'Safety, in terms of adverse events and dose-limiting toxicity, as measured by NCI CTC v2.0 at up to 4 weeks after the start of treatment'}, {'measure': 'Fatigue as measured by Brief Fatigue Inventory at 2 and 4 weeks after the start of treatment'}]","[{'measure': 'Mood as measured by Hamilton Rating Scale for Depression at 2 and 4 weeks after the start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Hopkins Verbal Learning Test at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Grooved Pegboard Test at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Controlled Oral Word Association Test from the Multilingual Aphasia Examination at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Trail Making Test A and B at 2 and 4 weeks after start of treatment'}, {'measure': 'Cognitive ability (i.e., memory, fine motor control, fluency, general mental ability, & delayed memory) by Recall and Recognition of Word List encoded from the Hopkins Verbal Learning Test at 2 and 4 weeks after start of treatment'}, {'measure': 'Functional status as measured by Barthel Index and ECOG performance status at 2 and 4 weeks after the start of treatment'}, {'measure': 'Quality of life as measured by Functional Assessment of Cancer Therapy-Br at 2 and 4 weeks after the start of treatment'}]",10.0,18 Years,,ALL,False,OTHER,1.0,,,v2_robust,True,False,False,True,,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,CHEMBL1373,exact_match,True,273.36,2.01,4.0
NCT01809847,Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation,Ofatumumab,"['Ofatumumab', 'Anti-CD20 antibody', 'Arzerra']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chronic Lymphatic Leukemia,Technische Universität Dresden,2025-09-01T16:18:12.171319,True,,,,NOT_FOUND,Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation(CLL-X4 Trial),,['Chronic Lymphatic Leukemia'],"['CLL', 'Chronic Lymphatic Leukemia', 'Leukemia', 'HLA', 'Histocompatibility', 'HCT', 'hematopoietic stem cell transplantation', 'Ofatumumab', 'CD20']",,2013-03,2015-01,"[{'measure': 'Response rate after induction therapy', 'description': 'efficacy analysis of anti-CD20 blockade with ofatumumab', 'timeFrame': 'week 9'}, {'measure': 'rate of MRD-negative patients', 'description': 'rate of MRD-negative patients who did not experience relapse, progression or death within the first 14 months after study enrollment', 'timeFrame': 'baseline, week 9, month 14'}]","[{'measure': 'Rate of allogeneic HCT', 'description': 'Rate of patients who reach allogeneic HCT if HLA-matched donor is available', 'timeFrame': 'month 9'}, {'measure': 'adverse drug reactions grade III/IV', 'timeFrame': 'week 1 till week 9; month 4 till month 9; month 12; month 14; until 30 days after last administration of the study medication'}, {'measure': 'Overall, event-, and progression free survival', 'timeFrame': 'week 1 till week 9; month 4 till month 9; month 12; month 14; up to 5 years follow-up'}, {'measure': 'relapse incidence', 'timeFrame': 'month 4 till month 9; month 12; month 14; up to 5 years follow-up'}, {'measure': 'non-relapse mortality', 'timeFrame': 'week 1 till week 9; month 4 till month 9; month 12; month 14; up to 5 years follow-up'}, {'measure': 'Incidences of acute and chronic GVHD', 'description': 'provided that allogeneic HCT was conducted', 'timeFrame': 'during maintenance therapy; month 12, month 14; up to 5 years follow-up'}]",8.0,56 Years,,ALL,False,OTHER,4.0,20.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06773130,HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma,HRS-4642,"['Nimotuzumab', 'HRS-4642']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Pancreatic Ductal Adenocarcinoma (PDAC),West China Hospital,2025-09-01T16:18:15.910292,True,,,,NOT_FOUND,An Exploratory Clinical Study of HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma,,['Pancreatic Ductal Adenocarcinoma (PDAC)'],[],,2025-02-10,2027-03,"[{'measure': 'RP2D', 'description': 'RP2D will be determined on the basis of evaluation on safety and efficacy data in dose escalation stages.', 'timeFrame': 'Approximately 12 months'}, {'measure': 'ORR', 'description': 'ORR was evaluated by RECIST v1.1.', 'timeFrame': 'Approximately 12 months'}]","[{'measure': 'DCR', 'description': 'Disease control rate (DCR) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'DoR', 'description': 'Duration of response (DoR) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'PFS', 'description': 'Progression-free survival (PFS) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'OS', 'description': 'Overall survival (OS) is assessed by investigators using RECIST 1.1 criteria.', 'timeFrame': '2 years'}, {'measure': 'AEs', 'description': 'AEs are assessed by NCI-CTCAE v5.0', 'timeFrame': '2 years'}]",7.0,18 Years,75 Years,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02680561,A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma,Fluticasone Propionate MDPI,"['Fluticasone Propionate MDPI', 'Fluticasone propionate/salmeterol', 'FS MDPI', 'DISKUS', 'Fp MDPI', 'ADVAIR', 'Fluticasone Propionate/Salmeterol MDPI']",7,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Asthma,"Teva Branded Pharmaceutical Products R&D, Inc.",2025-09-01T16:18:20.963410,True,,,,NOT_FOUND,"A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to ADVAIR® DISKUS® in Patients With Persistent Asthma 4 Through 11 Years of Age",,['Asthma'],[],,2016-04,2016-08,"[{'measure': 'Maximum observed plasma drug concentration (Cmax)', 'timeFrame': '4 months'}, {'measure': 'Area under the plasma drug concentration-time curve (AUCO-t)', 'timeFrame': '4 months'}]","[{'measure': 'Time to maximum observed plasma drug concentration (tmax)', 'timeFrame': '4 months'}]",3.0,4 Years,11 Years,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00472199,"Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",Pramipexole,"['Pramipexole', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Restless Legs Syndrome,Boehringer Ingelheim,2025-09-01T16:18:08.350400,True,,,,CHEMBL2105687,"A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period",,['Restless Legs Syndrome'],[],,2007-05,,"[{'measure': 'Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks', 'description': 'IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)', 'timeFrame': 'Baseline and 26 weeks'}]","[{'measure': 'Clinical Global Impression - Global Improvement (CGI-I) Responder Rate', 'description': ""CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)"", 'timeFrame': 'after 26 weeks of treatment'}, {'measure': 'International Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate', 'description': 'IRLS response was defined as at least 50% reduction in IRLS total score from baseline. IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)', 'timeFrame': 'after 26 weeks of treatment'}, {'measure': 'Patient Global Impression (PGI) Responder Rate', 'description': ""PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)"", 'timeFrame': 'after 26 weeks of treatment'}, {'measure': 'Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score ""Satisfaction With Sleep"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Severity Falling Asleep"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Severity During the Night"" After 26 Weeks', 'description': 'The question was rated on an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Severity During the Day When at Rest"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline RLS-6 Score ""Severity During the Day Engaged in Activities"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in RLS-6 Score ""Tired or Sleepy During the Day"" After 26 Weeks', 'description': 'The score is an 11-point Likert scale, ranging from ""none/not at all"" (0) to ""very severe"" (10), to reflect the patient\'s condition during the previous week', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks', 'description': 'Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks', 'description': 'The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks', 'description': 'RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life', 'timeFrame': 'Baseline and 26 weeks of treatment'}, {'measure': 'Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating less bodily pain', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension General Health After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better health status', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better mental health', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better physical functioning', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better social functioning', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Vitality After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better vitality', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better health', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks', 'description': 'Score ranging from 0 to 100 with higher scores indicating better health', 'timeFrame': 'Baseline and 26 weeks'}, {'measure': 'Diagnosis of Classified Augmentation According to Independent Expert Panel', 'description': 'Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.', 'timeFrame': 'after at least 4 weeks of treatment'}, {'measure': 'Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation', 'description': 'Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation).\n\nAssessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline.', 'timeFrame': 'after at least 1 week of treatment discontinuation'}, {'measure': 'Baseline, Week 26 Mean Supine Systolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Standing Systolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Supine Diastolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Standing Diastolic Blood Pressure', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Supine Pulse Rate', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Baseline, Week 26 Mean Standing Pulse Rate', 'timeFrame': 'Baseline, Week 26'}]",31.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,331.0,ACTUAL,v2_robust,True,True,False,False,,CCCN[C@@H]1CCc2nc(N)sc2C1.Cl.Cl.O,CHEMBL2105687,partial_match,True,302.27,1.58,3.0
NCT02119221,Copanlisib Mass Balance Study,Copanlisib (BAY80-6946),['Copanlisib (BAY80-6946)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Bayer,2025-09-01T16:18:19.670111,True,,,,NOT_FOUND,"Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects",,['Healthy Volunteers'],[],,2014-02,2014-10,"[{'measure': 'Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in plasma by Cmax', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in plasma by AUC', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in whole blood by Cmax', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in whole blood by AUC', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Radioactivity excreted in urine as a percentage of the dose (AE,ur)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Radioactivity excreted in feces as a percentage of the dose (AE,fec)', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Metabolite profile in plasma', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Metabolite profile in urine', 'timeFrame': 'Multiple time points up to 336 hours'}, {'measure': 'Metabolite profile in feces', 'timeFrame': 'Multiple time points up to 336 hours'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Until 30 days after study drug administration'}]",15.0,45 Years,65 Years,MALE,True,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02056366,The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy,α-lipoic acid,"['α-lipoic acid', 'Neuropaid OD Tablet']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 2 Diabetes,The Catholic University of Korea,2025-09-01T16:18:07.031854,True,,,,NOT_FOUND,"The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study",,"['Type 2 Diabetes', 'Cardiac Autonomic Neuropathy']",['Cardiac Autonomic Neuropathy'],,2010-01,2013-09,"[{'measure': 'Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy', 'description': 'check the Heart rate variability(HRV) Index', 'timeFrame': 'up to 24weeks'}]","[{'measure': 'Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy', 'description': 'Check the Autonomic Nerve System(ANS) function 5 test', 'timeFrame': 'up to 24weeks'}]",2.0,20 Years,80 Years,ALL,False,OTHER,0.0,91.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00044902,Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade),epratuzumab,['epratuzumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-Hodgkin's Lymphoma,Amgen,2025-09-01T16:18:22.192188,True,,,,NOT_FOUND,,,"[""Non-Hodgkin's Lymphoma""]",[],,,,[],[],0.0,18 Years,,ALL,False,INDUSTRY,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06693284,"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",mirdametinib and vorinostat,['mirdametinib and vorinostat'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,RECRUITING,Primary Malignant Peripheral Nerve Sheath Tumors,University of Minnesota,2025-09-01T16:18:25.981407,True,,,,NOT_FOUND,"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",,['Primary Malignant Peripheral Nerve Sheath Tumors'],[],,2024-12-01,2026-01-01,"[{'measure': 'Assess the toxicity of the combination of mirdametinib and vorinostat in patients with NF1-associated high grade MPNSTs.', 'description': 'As a result of the vaccine, both unique CNS toxicity and edema have been previously observed as soon as 10 days from the initiation of therapy. Neurotoxicity ≤ Grade 3 is an expected risk of this treatment. This will be measured as the number of participants experiencing this adverse event.', 'timeFrame': '48 months'}, {'measure': 'Determine the response of therapeutic targets', 'description': 'measuring phospho-ERK and histone H3K27 acetylation in post-therapy tumor tissue as compared to pre-treatment tumor tissue.', 'timeFrame': '48 months'}, {'measure': 'Evaluate the utility of radiographic response to this regimen', 'description': 'using MRI and PET.\n\nEach patient will undergo MRI of the primary lesion and CT/PET scan for staging and assessment of FDG uptake in the tumor at diagnosis and after completing 28 days of therapy with mirdametinib and vorinostat. Each patient will have a diagnostic tumor biopsy performed as a condition of entry into the study and to measure specific molecular tumor markers. A second biopsy will be performed at the completion of protocol therapy to assess tumor response to the therapy and to see if the specific tumor markers have changed as a result of the therapy given.', 'timeFrame': '48 months'}]",[],3.0,12 Years,,ALL,False,OTHER,0.0,8.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01506908,Provoked Craving Assessment,oral nicotine,"['oral nicotine', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Smoking Dependence,GlaxoSmithKline,2025-09-01T16:18:20.949974,True,,,,CHEMBL3,Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving,,"['Smoking Dependence', 'Smoking']",['craving'],,2011-09,2011-12,"[{'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 5 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-cue baseline,5 minutes'}]","[{'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 1 Minute', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-cue baseline, 1 minute post treatment administration'}, {'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 3 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-cue Baseline, 3 minutes post treatment administration'}, {'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 7 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-Cue Baseline, 7 minutes post treatment administration'}, {'measure': 'Change From Post-cue Baseline in Nicotine Craving Score at 10 Minutes', 'description': 'Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.', 'timeFrame': 'Post-Cue Baseline, 10 minutes post treatment administration'}, {'measure': 'Number of Participants With Adverse Events (AEs), Treatment Related AEs, and Serious AEs (SAEs)', 'description': 'AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with study treatment/s. Treatment related AE was defined as any AE considered to be possibly, probably or highly probably related to study medication. SAE was defined as any untoward medical occurrence that at any dose results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization results in disability/ incapacity; is a congenital anomaly/ birth defect.', 'timeFrame': 'Baseline to Day 5 post treatment administration'}]",6.0,18 Years,,ALL,True,INDUSTRY,0.0,323.0,ACTUAL,v2_robust,True,True,False,True,,CN1CCC[C@H]1c1cccnc1,CHEMBL3,partial_match,True,162.24,1.85,4.0
NCT03394222,Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV,preoperative budesonide inhalation,"['preoperative budesonide inhalation', 'preoperative normal saline inhalation']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Lung Cancer,Fujian Medical University Union Hospital,2025-09-01T16:18:08.336856,True,,,,CHEMBL1370,Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt in Patients Received One-lung Ventilation,,['Lung Cancer'],[],,2016-07,2017-04,"[{'measure': 'Arterial blood oxygenation', 'description': 'Arterial blood oxygenation was assessed through blood gas analysis of sample taken from radial artery', 'timeFrame': 'Arterial blood oxygenation was assessed through blood gas analysis before intervention,before OLV ,10 min after OLV,30 min after OLV,60 min after OLV and 10min after two-lung ventilation.'}]","[{'measure': 'Intrapulmonary shunt', 'description': 'Intrapulmonary shunt was assessed through blood gas analysis of sample taken', 'timeFrame': 'Intrapulmonary shunt was assessed through blood gas analysis before intervention,before OLV ,10 min after OLV,30 min after OLV,60 min after OLV and 10min after two-lung ventilation'}]",2.0,45 Years,65 Years,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CHEMBL1370,partial_match,True,430.54,2.72,4.0
NCT06956482,PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis,N-Acetylcysteine (NAC) Treatment,"['Placebo of Prednisolone', 'Prednisolone', 'N-Acetylcysteine (NAC) Treatment', 'Placebo of N-acetylcysteine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Alcoholic Hepatitis,"University Hospital, Lille",2025-09-01T16:18:18.419094,True,,,,CHEMBL863,PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis,,['Alcoholic Hepatitis'],"['Alcoholic hepatitis', 'survival, prednisolone', 'N-acetylcysteine', 'liver insufficiency']",,2025-10,2026-10,"[{'measure': 'Rate of patients alive with compensated liver disease', 'description': 'Rate of patients alive with compensated liver disease defined as a MELD score \\<17 at 90 days.\n\nMELD score will be calculated according to the formula given in Dunn et al. Hepatology 2005:\n\nMELD = 9.57 x ln (creatinine in mg/dL) + 3.78 x ln (bilirubin in mg/dL) + 11.2 x ln (INR) + 6.43', 'timeFrame': '90 days'}]",[],1.0,18 Years,75 Years,ALL,False,OTHER,0.0,477.0,ESTIMATED,v2_robust,True,False,False,False,,N[C@@H](CS)C(=O)O,CHEMBL863,partial_match,True,121.16,-0.67,4.0
NCT01736917,Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors,Fosaprepitant,"['Fosaprepitant', 'Dexamethasone', '5HT3']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Chemotherapy-Induced Nausea and Vomiting,Lawrence Einhorn,2025-09-01T16:18:07.015748,True,,,,NOT_FOUND,Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153,,['Chemotherapy-Induced Nausea and Vomiting'],"['Fosaprepitant', '5HT3 Receptor Antagonists', 'Dexamethasone', 'Germ Cell Tumors', 'Testis Cancer', 'Rescue Medications']",,2013-01,2015-06,"[{'measure': 'Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting', 'description': 'complete response (CR) of both acute (days 1 through 5) and delayed (days 6 through 8) CINV, defined by no emetic episodes or use of rescue medications', 'timeFrame': 'Days 1-8 of chemotherapy regimen'}]","[{'measure': 'Total Number of Emetic Episodes', 'description': 'total number of emetic episodes', 'timeFrame': 'Days 1-8 of chemotherapy regimen'}, {'measure': 'Use of Rescue Medications.', 'description': 'Total number of patients who received rescue medications.', 'timeFrame': 'Days 1-8 of chemotherapy regimen'}, {'measure': 'Self-Reported Assessment of Nausea', 'description': ""the patient's self-reported assessment of nausea Days 1-8 using a 0-100mm visual analog scale (VAS) median.\n\nThe Visual Analouge (VAS) 100mm Scale Score for Chemotherapy Induced Nausea and Vomiting (CINV). Participants were asked to mark a linear scale 100mm in length representing their level of nausea with 0mm indicating no nausea and 100mm indicating severe nausea. Median VAS scores (in mm) are reported, per day."", 'timeFrame': 'Days 1-8 of chemotherapy regimen'}]",4.0,15 Years,,MALE,False,OTHER,2.0,65.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01218698,"Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition",Losartan Potassium Tablets,['Losartan Potassium Tablets'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Torrent Pharmaceuticals Limited,2025-09-01T16:18:24.759293,True,,,,NOT_FOUND,"An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition",,['Healthy'],[],,,,"[{'measure': 'Bioequivalence based on AUC parameters'}, {'measure': 'Bioequivalence based on Cmax'}]",[],2.0,18 Years,45 Years,,,INDUSTRY,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04949438,"A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers",AZD4831,['AZD4831'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Renal Impairment,AstraZeneca,2025-09-01T16:18:25.984845,True,,,,NOT_FOUND,"A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers",,['Renal Impairment'],"['AZD4831', 'Pharmacokinetics', 'Estimated glomerular filtration rate']",,2022-01-21,2022-03-04,"[{'measure': 'Maximum observed plasma concentration (Cmax)', 'description': 'Assessment of Cmax of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Time to reach maximum observed plasma concentration (tmax)', 'description': 'Assessment of tmax of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)', 'description': 'Assessment of t½λz of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Apparent total body clearance of drug from plasma after extravascular administration (CL/F)', 'description': 'Assessment of CL/F of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Apparent total non-renal body clearance of drug from plasma after extravascular administration (CLNR/F)', 'description': 'Assessment of CLNR/F of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)', 'description': 'Assessment of Vz/F of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast)', 'description': 'Assessment of AUClast of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Area under plasma concentration-time curve from time zero to infinity (AUCinf)', 'description': 'Assessment of AUCinf of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Renal clearance of drug from plasma (CLR)', 'description': 'Assessment of CLR of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'Days 1 and 2'}]","[{'measure': 'Number of participants with adverse events', 'description': 'Assessment of the safety and tolerability of a single oral dose administration of AZD4831 in participants with severe renal impairment and their matched healthy volunteers.', 'timeFrame': 'From Screening (Day -21 to Day -1) until Day 15 or Early Termination Visit'}]",10.0,18 Years,80 Years,ALL,True,INDUSTRY,1.0,20.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00630877,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Niacin extended-release (NER),"['Aspirin (ASA)', 'ABT-919', 'Niaspan', 'acetylsalicylic acid', 'Aspirin (ASA) placebo', 'Niacin extended-release (NER) placebo', 'Niacin extended-release (NER)']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Dyslipidemia,Abbott,2025-09-01T16:18:19.657886,True,,,,NOT_FOUND,"A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or Niaspan® Placebo Plus ASA Placebo Daily for Six Weeks",,['Dyslipidemia'],[],,2008-02,2008-06,"[{'measure': 'Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score', 'description': 'Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Test-retest Reliability--maximum Flushing Severity Score', 'description': 'Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe.', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Cross-sectional Construct Validity--mean Flushing Severity Score', 'description': 'The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.', 'timeFrame': 'Week 1'}, {'measure': 'FAST Cross-sectional Construct Validity--maximum Flushing Severity Score', 'description': 'The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome.', 'timeFrame': 'Week 1'}, {'measure': 'FAST Longitudinal Construct Validity--mean Flushing Severity Score', 'description': 'The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Longitudinal Construct Validity--maximum Flushing Severity Score', 'description': 'The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start).', 'timeFrame': 'Week 1 to Week 2'}, {'measure': 'FAST Responsiveness--mean Flushing Severity Score', 'description': 'The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.', 'timeFrame': 'Study start to Day 43'}, {'measure': 'FAST Responsiveness--maximum Flushing Severity Score', 'description': 'The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened.', 'timeFrame': 'Study start to Day 43'}]","[{'measure': 'Maximum Severity of Flushing Events Overall During the Study', 'description': 'The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups.', 'timeFrame': 'Week 1 to Week 6'}]",9.0,18 Years,,ALL,False,INDUSTRY,0.0,276.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01671800,Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating,Botulinum Type B,"['Myobloc', 'Botulinum Type B', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hyperhidrosis,Henry M. Jackson Foundation for the Advancement of Military Medicine,2025-09-01T16:18:19.662775,True,,,,NOT_FOUND,"Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis Associated Symptomatic Sweating, or Residual Limb Hyperhidrosis in Amputees",,['Hyperhidrosis'],"['Hyperhidrosis', 'Botulinum Toxin', 'Amputation', 'Phantom limb pain']",,2008-09,2012-12,"[{'measure': 'Amount of sweating', 'description': 'The amount of sweating will be assessed via gravimetry, which is an accepted method for determining sweating in a particular area. This method involves covering the area of the residual limb in question with filter paper for five minutes. After five minutes, the filter paper is removed and weighed. The weight of the dry filter paper is subtracted to give the approximate weight of the sweat produced. This study will use the total weight of sweat produced as a method of objectively quantifying the amount of sweating in the residual limb. Gravimetry will be used as a measure of change from pre-treatment to post-treatment.', 'timeFrame': 'one month after initial injection'}]",[],1.0,18 Years,50 Years,ALL,True,OTHER,1.0,20.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05349006,Azathioprine in MOGAD,Azathioprine,['Azathioprine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Central Nervous System Inflammation,Hospices Civils de Lyon,2025-09-01T16:18:25.980667,True,,,,NOT_FOUND,"A Randomized, Placebo-controlled Phase 3 Trial of Azathioprine for the Prevention of Relapse in Myelin-oligodendrocyte-glycoprotein (MOG)-Antibody Associated Disease",,"['Central Nervous System Inflammation', 'MOG-IgG Associated Disease']","['MOGAD', 'azathioprine', 'optic neuritis', 'myelitis', 'neuromyelitis optica', 'MOG-IgG associated disease']",,2023-12-12,2029-12-12,"[{'measure': 'Time to first relapse (in days), comparing azathioprine-treated vs placebo-treated patients during a randomized control period of a maximum of three years.', 'description': 'A definite relapse will be defined as such:\n\n* When a patient is diagnosed as experiencing a relapse by the local investigator, the anonymized file will be reviewed within 4 days by a second investigator neurologist, not aware of the randomization group nor of the center treating the patient.\n* If this second neurologist also considers the patient as experiencing a relapse, the patient will be considered as relapsing for the main analysis.\n* If the second neurologist disagrees, the opinion of a third neurologist will be asked and the majority opinion will be retained.\n\nAs to ensure a maximum of homogeneity, we also propose a protocol-defined criteria for a MOGAD relapse, validated by the steering committee and available to every investigator (see Annex 2).', 'timeFrame': 'During a randomized control period of a maximum of three years'}]","[{'measure': 'Number and type of adverse events, including serious adverse events, related to azathioprine and/or steroids and placebo', 'timeFrame': ': During a randomized control period of a maximum of three years'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Global disability at 36 months assessed by EDSS: The EDSS scale is a method of quantifying disability and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of patients with inflammatory disorders of the central nervous system. The EDSS scale ranges from 0 to 10 in 0.5-unit increments (20 values) that represent higher levels of disability. Scoring is based on an examination by a neurologist.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Worsening from baseline to 36 months of the EDSS', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Ambulation status at 36 months assessed by the Ambulation Score. Scoring is based on a measurement of the distance the patient is able to walk (in meters) and then classified in 12 levels.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Worsening from baseline to 36 months of the Ambulation Score.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Best-corrected high contrast visual acuity at 36 months measured (each eye tested separately) using the standard Snellen chart or equivalent.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Worsening from baseline to 36 months of visual disability assessed by change of the best- corrected high-contrast visual acuity using the standard Snellen chart or equivalent (each eye tested separately).', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Best-corrected low-contrast visual acuity at 36 months using the Sloan Charts at 2.5%, in each eye.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Worsening from baseline to 36 months of low-contrast visual acuity using the Sloan Charts at 2.5%, in each eye.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Inner retinal layers thicknesses at 36 months assessed by the spectral domain OCT (each eye tested separately)', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Worsening from baseline to 36 months of the peripapillary retinal nerve fiber layer thickness (μm) and the ganglion cell complex thickness (μm) assessed with spectral domain OCT (each eye tested separately).', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Quality of life will be assessed using the EuroQOL EQ-5D-3L at 36 months', 'description': 'https://euroqol.org', 'timeFrame': 'at 36 months'}, {'measure': 'Compliance to treatment', 'description': 'percentage of untaken pills (left in the blisters) regarding each patient', 'timeFrame': 'During a randomized control period of a maximum of three years'}, {'measure': 'Exploratory radiological features', 'description': 'Description, and comparison between the two groups, of worsening of MRI (brain and spinal cord and visual) from baseline to 36 months assessed by number of new/enlarging T2 lesions', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Exploratory radiological features', 'description': 'Description and comparison between the two groups of worsening of MRI (brain and/or spinal cord and/or visual) from baseline to 36 months assessed by number of new T1 gadolinium enhancing lesions', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Exploratory biological features', 'description': 'In each group of treatment, association between MOG-Ab titer at first episode and the risk of relapse', 'timeFrame': 'at screening, at 6 months, at 12 months, at 36 months and in case of a relapse'}, {'measure': 'Exploratory biological features', 'description': 'In each group of treatment, association between MOG-Ab titer at onset and the level of global disability assessed by the EDSS at 36 months.', 'timeFrame': 'at screening, at 6 months, at 12 months, at 36 months and in case of a relapse'}, {'measure': 'Exploratory biological features', 'description': 'In each group of treatment, prognostic value of longitudinal MOG-Ab-titers to predict relapse.', 'timeFrame': 'at screening, at 6 months, at 12 months, at 36 months and in case of a relapse'}]",19.0,18 Years,,ALL,False,OTHER,0.0,126.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06917508,"A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants",EDP-323,"['Caffeine', 'Midazolam', 'EDP-323', 'Rosuvastatin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,RSV Infection,"Enanta Pharmaceuticals, Inc",2025-09-01T16:18:14.671003,True,,,,NOT_FOUND,"A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-323 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Participants",,"['RSV Infection', 'Drug Drug Interaction']",['Drug Drug Interaction'],,2025-03-13,2025-06-13,"[{'measure': 'Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323', 'timeFrame': 'Up to 17 Days'}, {'measure': 'AUC of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323', 'timeFrame': 'Up to 17 Days'}]","[{'measure': 'Safety measured by adverse events', 'timeFrame': 'Up to 22 days'}]",3.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03592082,Use of Bismuth Subsalicylate in Clostridium Difficile Colitis,Bismuth Subsalicylate,"['standard antibiotic therapy', 'Bismuth Subsalicylate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Clostridium Difficile Infection,Bassett Healthcare,2025-09-01T16:18:12.184479,True,,,,NOT_FOUND,Can Use of Bismuth Subsalicylate in Clostridium Difficile Patients Decrease the Length of Stay and Time to Resolution of Symptoms,,['Clostridium Difficile Infection'],[],Investigator left institution,2018-03-01,2018-07-01,"[{'measure': 'Length of stay', 'description': 'number of days hospitalized after the initiation of treatment for CDiff', 'timeFrame': '70 days (study period = 14 days of antibiotic treatment plus 8 weeks/56 days post treament completion)'}]","[{'measure': 'Time to resolution of symptoms', 'description': 'Resolution of symptoms is defined as having \\< 3 diarrheal episodes in 24 hours', 'timeFrame': '70 days'}, {'measure': 'CDiff Recurrence', 'description': 'Recurrence is defined as the reappearance of symptoms within 8 weeks of the completion of antibiotic treatment and the resolution of initial symptoms', 'timeFrame': '70 days'}]",3.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Investigator left institution,,,no_match,False,,,
NCT04761614,Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,Fluorouracil,"['Folinate Calcium', 'Tonofolin', 'Ro-2-9757', '5 Fluorouracil', '5FU', 'Dalisol', 'Citrec', 'Flurablastin', 'Ribofluor', 'Folinoral', 'Diaminocyclohexane Oxalatoplatinum', 'Leucovorin Calcium', 'AccuSite', 'Calcium Folinate', '5-Fluorouracil', 'Rescuvolin', 'Citofolin', 'Citrovorum Factor', 'Folaxin', '5-Fu', 'Folinic Acid Calcium Salt Pentahydrate', 'Oxalatoplatin', 'Calfolex', 'Calinat', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', 'Aiheng', 'Fluoro Uracil', 'Divical', 'Riluzole', 'RP 54780', 'Calcium (6S)-Folinate', 'JM-83', 'Disintox', 'Emovis', 'Fluroblastin', 'Wellcovorin', '1-OHP', 'Rescufolin', 'Dacplat', 'SR-96669', 'Cehafolin', 'leucovorin', 'Imo', 'Folix', 'Folidar', 'Oxaliplatin', 'Factor, Citrovorum', 'Eloxatin', 'Folaren', 'Oxalatoplatinum', 'Lederfolat', 'Ecofol', 'Folinac', 'RP-54780', '5 Fluorouracilum', 'Flynoken A', 'Rilutek', 'Ro 2-9757', 'Fluouracil', 'Fluracil', 'Fluracedyl', '5 FU', 'FOLI-cell', 'folinic acid', 'Lederfolin', 'Cromatonbic Folinico', 'Eloxatine', 'Ai Heng', 'Calcifolin', 'Foliben', 'Fluril', 'Carac', 'Leucosar', '5-Fluracil', 'Adinepar', 'Foliplus', 'Calcium Leucovorin', 'Fluorouracil', 'Folidan', 'Folinvit', 'Dacotin']",81,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Metastatic Colorectal Carcinoma,Ning Jin,2025-09-01T16:18:24.761323,True,,,,CHEMBL566,A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer,,"['Metastatic Colorectal Carcinoma', 'Stage IV Colorectal Cancer AJCC v8', 'Stage IVA Colorectal Cancer AJCC v8', 'Stage IVB Colorectal Cancer AJCC v8', 'Stage IVC Colorectal Cancer AJCC v8']",[],,2021-04-02,2023-05-06,"[{'measure': 'Dose limiting toxicities (DLTs)', 'description': 'Will be defined by treatment related grade \\>= 4 adverse events or \\>= grade 3 alanine aminotransferase or aspartate aminotransferase elevation during the DLT period using the Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 4 weeks (2 cycles of treatment) (1 cycle = 14 days)'}]","[{'measure': 'Pharmacokinetic (PK) profile of riluzole (Cmax)', 'description': ""K data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including Cmax. Peak Plasma Concentration (Cmax)"", 'timeFrame': 'Day 1 on cycle 1 (each cycle is 14 days)'}, {'measure': 'Pharmacokinetic (PK) profile of riluzole (AUC)', 'description': ""PK data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including AUC. Area under the plasma concentration versus time curve (AUC)"", 'timeFrame': 'Day 1 on cycle 1 (each cycle is 14 days)'}]",3.0,18 Years,,ALL,False,OTHER,0.0,13.0,ACTUAL,v2_robust,True,True,False,True,,O=c1cc[nH]c(=O)[nH]1,CHEMBL566,partial_match,True,112.09,-0.94,3.0
NCT02828098,Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors,Part 1: BO-112,"['Part 1: BO-112', 'anti-PD1 monoclonal antibody', 'Part 2: BO-112']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Cancer,Highlight Therapeutics,2025-09-01T16:18:22.206404,True,,,,NOT_FOUND,"An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment",,['Cancer'],['aggressive solid tumors'],,2016-06,2020-07,"[{'measure': 'Number of subjects with adverse events', 'description': 'To evaluate the safety and tolerability of B0-112 in terms of adverse events at every visit', 'timeFrame': 'Part 1: Day 30 after administration of the last dose. Part 2: 12 weeks and for patients who continue up to 1 year'}]","[{'measure': 'Circulating cytokines including type I IFNs, TNFalpha and IL6 (by ELISA)', 'timeFrame': 'Part 1: At three independent points during the study. Day 7-1 prior to administration, 24 hours after administration and 7-14 days after administration of the agent. Part 2: 12 weeks'}, {'measure': 'Plasma levels of BO-112', 'description': 'To characterize the pharmacokinetics (PK) of BO-112 by measuring the amount in plasma at regular timepoints during the study', 'timeFrame': 'Part 1: 0-15-30-240 minutes and 24 hours after administration of the drug. Part 2: 1 day'}, {'measure': 'Anti-tumor activity', 'description': 'Part 2 only: To evaluate the antitumor activity of the combination of BO-112 and anti-PD1 treatment', 'timeFrame': '12 weeks and for patients who continue up to 1 year'}]",4.0,18 Years,,ALL,False,INDUSTRY,1.0,44.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03531918,"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm",Cladribine,"['Leustatine', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Aracytine', 'hP67.6-Calicheamicin', 'U 19920', 'Alexan', 'Mitoxantroni Hydrochloridum', 'ARA-cell', 'Gemtuzumab Ozogamicin', 'Cladribine', '.beta.-Cytosine arabinoside', 'Mylotarg', 'CL 232315', '1-.beta.-D-Arabinofuranosylcytosine', 'WR-28453', 'CdA', 'Erpalfa', 'Cytarbel', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Cladribina', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Cytosar', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', 'CHX-3311', 'Dihydroxyanthracenedione Dihydrochloride', 'Udicil', 'Novantrone', 'Ara-C', 'Cytosine Arabinoside', 'Mitoxantrone Dihydrochloride', 'gemtuzumab', 'Aracytidine', 'Mitoxantrone Hydrochloride', 'Cytosine-beta-arabinoside', 'Mitroxone', 'WAY-CMA-676', 'Cytosine-.beta.-arabinoside', 'Cytarabinum', '2CDA', 'U-19920', 'Arabinofuranosylcytosine', 'DHAQ', 'Aracytin', 'DHAD', 'Onkotrone', '2-CdA', 'Starasid', 'Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody', '1.beta.-D-Arabinofuranosylcytosine', 'CDP-771', 'RWJ-26251', 'CMA-676', 'Cytarabine', 'Arabinosylcytosine', 'Tarabine PFS', '1-Beta-D-arabinofuranosylcytosine', 'Neotalem', 'Pralifan', 'Leustat', 'Leustatin', 'Arabine', 'Mitozantrone Hydrochloride', 'Beta-cytosine Arabinoside']",63,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Acute Myeloid Leukemia,Fred Hutchinson Cancer Center,2025-09-01T16:18:20.954668,True,,,,NOT_FOUND,"A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm",,['Acute Myeloid Leukemia'],[],,2018-09-14,2021-11-01,"[{'measure': 'Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1)', 'description': 'Defined as the highest dose studied in which the incidence of Dose Limiting Toxicity (DLT) is ≤33% (≤4 of 12 patients experiencing DLT), defined as any Grade 3 non-hematologic toxicity lasting \\>48 hours that results in \\>7-day delay of the subsequent treatment cycle, with the exception of febrile neutropenia or infection or toxicities secondary to febrile neutropenia or infection, or any Grade ≥4 non-hematologic toxicity except febrile neutropenia/infection (or toxicities secondary to febrile neutropenia or infection) unless felt to be a direct consequence of treatment-related toxicity (e.g. intestinal infection following mucosal barrier breakdown), and with the exception of constitutional symptoms if recovery to Grade ≤2 within 14 days. The National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 will be used.', 'timeFrame': 'At time of count recovery, second cycle of treatment, response assessment or removal from protocol (at approximately 1 month).'}, {'measure': 'Event-free Survival (EFS) Rate (Phase 2)', 'description': 'A two-stage design will be used to evaluate the EFS. Patients treated at the maximum tolerated dose (MTD) from the phase 1 portion of the trial will be used in the phase 2 analysis. If censoring occurs, secondary analyses analyzing 6-month or 1-year EFS accounting for censoring will be done, including estimating 6-month or 1-year EFS using the Kaplan-Meier method. The first stage of the two-stage phase 2 design will evaluate 30 patients. If 20 or more of the first 30 patients are alive without event at 6-months after study registration, an additional 30 patients will be enrolled. If 46 or more of the 60 patients treated at the MTD are alive and without event at 6-months after study registration, the study will consider the regimen of interest for further investigation. Patients last known to be alive in CR were censored at date of last contact.', 'timeFrame': 'From the start of study treatment, assessed at 6 months and 1 year'}]","[{'measure': '30-day All-cause Mortality', 'description': 'As a summary of adverse events (captured on trial using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0), 30-day all cause mortality is reported as a percent of patients treated at the MTD/RP2D.\n\nWill be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.', 'timeFrame': 'Up to 5 years. 30-day all-cause mortality is reported'}, {'measure': 'Relapse-free Survival of GO3 Cohort', 'description': 'RFS was calculated for participants who achieved a complete remission (with or without count recovery; CR or CRi) and measured from the date remission to the first of relapse from CR/CRi or death from any cause. Patients last known to be alive in CR /CRi were censored at date of last contact. Will be estimated using the Kaplan-Meier method. Time to relapse will be estimated using non-parametric estimates of the cumulative incidence curve with death analyzed as a competing event. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.', 'timeFrame': 'Up to 5 years. 2-year RFS reported.'}, {'measure': 'Overall Survival', 'description': 'OS was calculated for all participants and measured from initial trial therapy to death from any cause. Patients last known ot be alive were censored at date of last contact. Will be estimated using the Kaplan-Meier method. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.', 'timeFrame': '3 years and 1 month'}, {'measure': 'Measurable Residual Disease (MRD) Rates and Remission Rates: CR', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nComplete response (CR) rate is defined as the frequency of patients achieving CR, which is defined by the European LeukemiaNet 2017 guidelines as bone marrow blasts \\<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 x 109/L (1000/mL); platelet count ≥100 x 109/L. (100 000/mL). MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: CRi (MRDneg)', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nComplete response with incomplete hematologic recovery (CRi) rate is defined as the frequency of patients achieving CRi, which is defined by the European LeukemiaNet 2017 guidelines as all CR criteria except for residual neutropenia (ANC \\<1.0 x 109/L \\[1000/mL\\]) or thrombocytopenia (platelet count \\<100 x 109/L \\[100,000/mL\\]). MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: CR/CRi', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nComplete response (CR) + complete response with incomplete hematologic recovery (CRi) rate is defined as the frequency of patients achieving CR or CRi per the European LeukemiaNet 2017 criteria as defined above. MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: MLFS (MRDneg)', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\nMorphologic leukemia free state (MLFS) rate is defined as the frequency of patients achieving MLFS, which is defined by the European LeukemiaNet guidelines as bone marrow blasts \\<5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. At least 200 cells should be enumerated or cellularity should be at least 10%. MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance', 'timeFrame': '90 days'}, {'measure': 'Measurable Residual Disease (MRD) and Remission Rates: Alapasia (MRDneg)', 'description': 'Will be estimated and 95% confidence intervals will be calculated. Regression models (logistic regression for binary endpoints, Cox regression for time-to-event endpoints \\[Cox models for the hazard of the subdistribution for events with competing risks\\]) will be used to compare outcomes with patients who have received GCLAM without GO at our institution, controlling for measured prognostic factors.\n\no Aplasia rate is defined in this protocol as frequency of patients without blood count recovery after chemotherapy and bone marrow examination showing hypocellularity not meeting cellularity criteria for morphologic leukemia free state (MLFS). MRD negative (MRDneg) status is defined as negative for leukemic markers by multiparameter flow cytometry.\n\nAplasia was defined as absence of tumoral cells but cellularity not meeting criteria for MLFS.\n\nStatistical significance tests were not performed.', 'timeFrame': '90 days'}]",10.0,18 Years,,ALL,False,OTHER,1.0,66.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02584283,Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation,Glutathione,['Glutathione'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Liver Failure,Robert J. Porte,2025-09-01T16:18:07.029332,True,,,,NOT_FOUND,A Multicenter Randomized Controlled Trial to Compare the Efficacy of End-ischemic Dual Hypothermic Oxygenated Perfusion With Standard Static Cold Storage of Liver Grafts Donated After Circulatory Death in Preventing Biliary Complications,,"['Liver Failure', 'End Stage Liver Disease', 'Biliary Tract Diseases']","['Liver Transplantation', 'Donation after Circulatory Death', 'Machine Perfusion']",,2016-01,2020-01,"[{'measure': 'The incidence of symptomatic non-anastomotic biliary strictures (NAS)', 'description': 'NAS is defined as all of the following criteria:\n\n* any irregularities or narrowing of the lumen of the intra- or extrahepatic donor bile ducts, but not at the anastomosis\n* which are diagnosed by cholangiogram (preferably by MRCP)\n* in the presence of a patent hepatic artery demonstrated by Doppler ultrasonography and if necessary, by computed tomography angiography\n* and as assessed by the Adjudication Committee\n* when imaging is indicated by clinical signs (i.e., jaundice, cholangitis) or elevation of cholestatic laboratory parameters in blood samples taken during follow-up', 'timeFrame': '6 months'}]","[{'measure': 'Asymptomatic NAS', 'description': 'Asymptomatic NAS is defined as all of the following:\n\n* irregularities or narrowing of the lumen of the intra- or extrahepatic donor bile ducts, but not at the anastomosis\n* which are diagnosed by cholangiogram (preferably by MRCP)\n* in the presence of a patent hepatic artery demonstrated by Doppler ultrasonography and if necessary, by computed tomography angiography\n* in the absence of clinical signs (i.e., jaundice, cholangitis) or elevation of cholestatic laboratory parameters in blood samples taken during follow-up', 'timeFrame': '6 months'}, {'measure': 'The severity of NAS', 'description': 'Severity and location of NAS is based on assessment of the images of the MRCP obtained in all patients at six months after transplantation (time window of 15 days) which will be performed based on a scoring system described by Buis et. al. And required treatment for NAS (i.e. ursodeoxycholic acid, ERCP, retransplantation)', 'timeFrame': '6 months'}, {'measure': 'The location of NAS', 'description': 'Assessment of the images of the MRCP obtained in all patients at six months after transplantation (time window of 15 days) which will be performed based on a scoring system described by Buis et. al.', 'timeFrame': '6 months'}, {'measure': 'Graft (censored and uncensored for patient death) survival', 'timeFrame': '7 days, 1, 3 , 6, and 12 months after transplantation'}, {'measure': 'Patient survival', 'timeFrame': '7 days, 1, 3 , 6, and 12 months after transplantation'}, {'measure': 'Primary non-function', 'description': 'Defined as liver failure requiring retransplantation or leading to death within seven days after transplantation without any identifiable cause such as surgical problems, hepatic artery thrombosis, portal vein thrombosis and acute rejection', 'timeFrame': '7 days'}, {'measure': 'Initial poor function', 'description': 'Defined as a modification of the Olthoff criteria: Prothrombin time/ international normalized ratio (INR) \\>1.6 and or serum total bilirubin \\>10 mg/dL on postoperative day 7', 'timeFrame': '7 days'}, {'measure': 'Biochemical analysis of graft function and ischemia-reperfusion injury', 'description': 'serum levels of alanine aminotransferase (ALT), AST, alkaline phosphatase (AlkP), gamma-glutamyl transferase (γGT), and total bilirubin', 'timeFrame': 'Postoperative day 0 - 7 and 1, 3, 6 months'}, {'measure': 'Blood pressure', 'description': 'mm Hg', 'timeFrame': '5 min before reperfusion, at reperfusion and after 10 and 20 minutes of reperfusion'}, {'measure': 'Heart rate', 'description': 'beats per minute', 'timeFrame': '5 min before reperfusion, at reperfusion and after 10 and 20 minutes of reperfusion'}, {'measure': 'Vasopressor dosage', 'description': 'microgram/kg/min', 'timeFrame': '5 min before reperfusion, at reperfusion and after 10 and 20 minutes of reperfusion'}, {'measure': 'Length of stay', 'description': 'Length of initial ICU and initial hospital stay is determined in days of admission following liver transplantation. Duration of follow-up hospital stay is determined in days of hospital admission after discharge and up to six months after liver transplantation', 'timeFrame': '6 months'}, {'measure': 'Postoperative complications', 'description': 'According to the comprehensive complication index (CCI)', 'timeFrame': '6 months'}, {'measure': 'Renal function', 'description': 'Estimated glomerular filtration rate (eGFR) according to the 4-variable Modification of Diet in Renal Disease (MDRD) equation', 'timeFrame': 'day 7, and 1, 3, 6 months'}, {'measure': 'Flow', 'description': 'ml/min', 'timeFrame': 'At 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after start of perfusion'}, {'measure': 'Pressure', 'description': 'mm Hg', 'timeFrame': 'At 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after start of perfusion'}, {'measure': 'Resistance', 'description': 'ml/min/mm Hg', 'timeFrame': 'At 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's pH"", 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's sodium"", 'description': 'mmol/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's potassium"", 'description': 'mmol/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's bicarbonate"", 'description': 'mmol/l', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's lactate"", 'description': 'mmol/l', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's alanine transaminase (ALT)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's aspartate transaminase (AST)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's alkaline phosphatase (AlkP)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's gamma glutamyltransferase (γGT)"", 'description': 'U/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's urea"", 'description': 'mmol/L', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's total bilirubin"", 'description': 'umol/l', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's thrombomodulin"", 'description': 'pg/dl', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's high mobility group box-1 (HMBG) protein"", 'description': 'μg/mL', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': ""(In selected centers) value of perfusate's cytochrome C"", 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA CDmiR-30e in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA CDmiR-222 in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA CDmiR-296 in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA HDmiR-122 in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': '(In selected centers) level of miRNA HDmiR-148a in perfusate', 'description': 'relative levels compared to perfusate', 'timeFrame': 'At 5 minutes before and at 0.5 hour, 1 hour, 1.5 hours and 2 hours after start of perfusion'}, {'measure': 'Histopathological status liver and bile ducts (in selected centers)', 'timeFrame': 'Within 0 to 30 minutes before perfusion, at 2 hours of perfusion, and at 1 hour after reperfusion'}, {'measure': 'New onset diabetes after transplantation', 'description': '* Symptoms of diabetes and random plasma glucose ≥11.1 mmol/L. Symptoms include polyuria, polydipsia, and unexplained weight loss. OR\n* Fasting plasma glucose ≥7.0 mmol/L. Fasting is defined as no caloric intake for at least eight hours. OR\n* Two-hour plasma glucose ≥11.1 mmol/L during an oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.', 'timeFrame': '90 days'}, {'measure': 'Costs of treatment (in selected centers)', 'description': 'according to the Cost and Outcome analysis of Liver Transplantation (COLT) study', 'timeFrame': 'within 6 months after transplantation, including transplant operation'}, {'measure': 'Health related quality of life', 'description': 'EQ6D questionnaire', 'timeFrame': 'within 6 months before transplantation and 6 months after transplantation'}]",41.0,18 Years,100 Years,ALL,False,OTHER,5.0,157.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03778879,Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B,CCX872-B,['CCX872-B'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,WITHDRAWN,Adenocarcinoma of the Pancreas,Alan Katz,2025-09-01T16:18:07.023973,True,,,,NOT_FOUND,A Phase 1b Trial of Neoadjuvant Stereotactic Body Radiotherapy With or Without CCR2 Inhibitor (CCX872-B) Immunotherapy for Preoperative Treatment of Resectable Pancreatic Cancer,,"['Adenocarcinoma of the Pancreas', 'Pancreas Cancer']","['Adenocarcinoma', 'Pancreas', 'Radiation Therapy', 'CCX872-B']",CCX872-B will not be available in sufficient quantity to conduct the study.,2019-08-01,2019-08-31,"[{'measure': 'Percentage of patients who complete radiation therapy, drug treatment and surgery', 'description': 'Number of patients who proceed through radiation and drug treatment and undergo surgical resection in a timely manner.', 'timeFrame': '6 weeks'}, {'measure': 'Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone', 'description': 'Assessment of whether patients are made ineligible for surgical resection solely due to toxicities from SBRT + CCX872-B or SBRT alone.\n\nMeasure of Grade 3 toxicity directly attributable to SBRT+ CCX872-B or SBRT alone.\n\nAnalyze rate of grade 2 or greater acute toxicity caused by SBRT with or without CCX872-B.\n\nDetermination of intraoperative and postoperative surgical morbidity following neoadjuvant treatment including the amount of fibrosis and total operative time.', 'timeFrame': '12 weeks'}]","[{'measure': 'Number of participants with no further growth of cancer at original site', 'description': 'Count subjects with no further growth of cancer at original site', 'timeFrame': '2 years'}, {'measure': 'Number of subjects with recurrence of cancer in other body sites', 'description': 'Compare recurrence locations (metastases to other organs or non-regional adenopathy) of treated patients relative to historical controls', 'timeFrame': '2 years'}, {'measure': 'Mean time to progression of pancreatic cancer', 'description': 'Duration of progression free survival of treated patients', 'timeFrame': '4 years'}, {'measure': 'Mean time to death', 'description': 'Measure duration of survival of treated patients', 'timeFrame': '4 years'}]",6.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,CCX872-B will not be available in sufficient quantity to conduct the study.,,,no_match,False,,,
NCT00235001,Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension,trandolapril/verapamil,"['trandolapril/verapamil', 'ABT-TARKA', 'Tarka']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hypertension,Abbott,2025-09-01T16:18:19.659011,True,,,,CHEMBL6966,"A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension",,['Hypertension'],"['Hypertension', 'Tarka']",,2004-06,,"[{'measure': 'Change in blood pressure from baseline/blood pressure control', 'timeFrame': 'Baseline to 3 months of Tx'}]","[{'measure': 'Absolute BP reduction from baseline, safety', 'timeFrame': 'Baseline to 3 months of Tx'}]",2.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,120.0,ACTUAL,v2_robust,True,True,False,True,,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,CHEMBL6966,partial_match,True,454.61,5.09,4.0
NCT02688400,Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis,Diacerein,"['Artrodar, Artrodarin, Artrolyt, Fisiodar, Galaxdar, Glizolan, Verboril', 'Celebrex', 'Placebo', 'Diacerein', 'Celecoxib']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Osteoarthritis,TRB Chemedica International SA,2025-09-01T16:18:10.923215,True,,,,CHEMBL41286,"An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging",,"['Osteoarthritis', 'Osteoarthritis, Knee']","['Osteoarthritis', 'Knee', 'Osteoarthritis, Knee', 'Diacerein', 'Celecoxib', 'Phase III', 'Phase IV', 'Phase III-IV', 'Canada', 'Spain', 'Austria', 'Czech Republic', 'WOMAC']",,2016-05,2018-06-28,"[{'measure': 'Change Form Baseline in WOMAC A Pain Subscale', 'description': 'Change form baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) A pain subscale after 182 days of treatment.\n\nWOMAC A pain subscale: 0 - 50 cm; 50 = worse', 'timeFrame': 'baseline and 182 days'}]","[{'measure': 'Change From Baseline in WOMAC OA Scores', 'description': 'Absolute Changes from Baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) after 182 days of treatment.\n\nWOMAC scale: 0 - 240 cm; 240 = worse - Intention-To-Treat (N=370) Pain subscale: 0-50cm; 50 = worse; Stifness subscale: 0-20cm; 20 = worse; Function subscale: 0-170cm; 170 = worse Absolute changes in WOMAC scores: \\<0 = improvement; 0 = stable; \\>0 = worsening', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Absolute Changes From Baseline in Pain Visual Analogue Scale', 'description': 'Absolute Changes from Baseline in Pain Visual Analogue Scale (VAS): 0-10 cm; 10 = worse', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'OARSI Responders', 'description': 'Osteoarthritis Research Society International (OARSI) Responders', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Assessment of Joint Swelling, Effusion or Both', 'description': 'Assessment of Joint Swelling, joint Effusion or Both', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Consumption of Acetaminophen', 'description': 'Overall Daily number of tablets taken during the 6 month study', 'timeFrame': 'Day 182 or early termination'}, {'measure': ""Change From Baseline in Patient's Global Assessment of Disease Activity"", 'description': 'Change from baseline in global assessment of disease activity was assessed using a VAS scale (0-10cm; 10=worse)', 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Global Assessment of Response to Therapy', 'description': ""Between group comparison in Patient's and Investigator's Global Assessment of Response to Therapy using a 0-10 cm disease activity VAS scale: 0 cm = very well; 10 cm = very poorly"", 'timeFrame': 'Day 182 or early termination'}, {'measure': 'Quality of Life SF-36', 'description': 'Absolute Changes from Baseline in Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from the Quality of Life questionnaire SF-36. Scale range for each component (PCS and MCS): minimum = 0, maximum = 100, with higher scores indicating better quality of life. Absolute changes in each component (PCS and MCS): \\>0 = improvement; 0 = stable; \\<0 = worsening.', 'timeFrame': 'Day 182 or early termination'}]",9.0,50 Years,,ALL,False,INDUSTRY,1.0,380.0,ACTUAL,v2_robust,True,True,False,False,,CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,CHEMBL41286,exact_match,True,368.3,2.01,4.0
NCT01560702,Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers,Epinephrine,['Epinephrine'],1,INTERVENTIONAL,['NA'],,COMPLETED,"Blood, Injection, Injury Type Phobia",Zagazig University,2025-09-01T16:18:24.745185,True,,,,CHEMBL679,Endoscopic Injection of Autologous Blood Versus Diluted Epinephrine for Control of Actively Bleeding Gastroduodenal Ulcers,,"['Blood, Injection, Injury Type Phobia', 'Gastrointestinal Ulcer Haemorrhage', 'Adverse Reaction to Epinephrine']","['autologous blood', 'epinephrine', 'endoscopy', 'ulcer', 'hemostasis']",,2012-03,2013-09,"[{'measure': 'hemostasis from the ulcer after injection and/or stoppage of haematemesis and melena one day after the procedure.', 'timeFrame': '12 months'}]","[{'measure': 'development of re-bleeding after 24 hours after the procedure (occurrence of hematemesis or melena or drop of hemoglobin level >2gm/dl).', 'timeFrame': '12 months'}]",2.0,16 Years,60 Years,ALL,False,OTHER_GOV,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,,CNC[C@H](O)c1ccc(O)c(O)c1,CHEMBL679,exact_match,True,183.21,0.35,4.0
NCT04968184,Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD),Placebo,"['KBP-5074', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Chronic Kidney Diseases,KBP Biosciences,2025-09-01T16:18:19.672284,True,,,,NOT_FOUND,A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD,,['Chronic Kidney Diseases'],"['Stage 3b/4 chronic kidney disease', 'Hypertension', 'Uncontrolled Hypertension', 'Blood pressure', 'Mineralocorticoid Receptor Antagonist', 'Randomized withdrawal']",Interim futility analysis showed primary endpoint not achieved,2021-11-05,2024-07-10,"[{'measure': 'Change in seated trough cuff SBP from baseline to Week 12', 'description': 'Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, will be evaluated.', 'timeFrame': 'From baseline to Week 12'}, {'measure': 'Change in seated trough cuff SBP from Week 48 to Week 52', 'description': 'Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}]","[{'measure': 'Change in seated trough cuff SBP from baseline to Week 24', 'description': 'Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, will be evaluated.', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12 and Week 24', 'description': 'Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated.', 'timeFrame': 'From baseline to Week 12 and Week 24'}, {'measure': 'Changes in seated trough cuff SBP and DBP from baseline to Week 48', 'description': 'Effect of KBP-5074 on SBP and DBP by assessing change in seated trough cuff SBP and DBP, will be evaluated.', 'timeFrame': 'From baseline to Week 48'}, {'measure': 'Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline', 'description': 'Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12 and Week 24'}, {'measure': 'Percentage changes in UACR from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline', 'description': 'Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12 and Week 24'}, {'measure': 'Changes in UACR from baseline to Week 12, Week 24, and Week 48', 'description': 'Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12, Week 24, and Week 48'}, {'measure': 'Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48', 'description': 'Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'From baseline to Week 12, Week 24, and Week 48'}, {'measure': 'Change in seated trough cuff DBP from Week 48 to Week 52', 'description': 'Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}, {'measure': 'Change in UACR from Week 48 to Week 52', 'description': 'Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}, {'measure': 'Percentage change in UACR from Week 48 to Week 52', 'description': 'Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \\<300 mg/g) at baseline, will be evaluated.', 'timeFrame': 'Week 48 to Week 52'}, {'measure': 'Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'description': 'The safety and tolerability of KBP-5074,will be evaluated.', 'timeFrame': 'Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination'}]",13.0,18 Years,,ALL,False,INDUSTRY,0.0,652.0,ACTUAL,v2_robust,True,False,True,True,Interim futility analysis showed primary endpoint not achieved,,,no_match,False,,,
NCT04459377,Ketamine Analgesia in Third Molar Surgery,S-Ketamine,"['Sodium Chloride 0.9% Inj', 'S-Ketamine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Pain,"Dalarna County Council, Sweden",2025-09-01T16:18:19.657771,True,,,,NOT_FOUND,"An Analysis of Ketamine Analgesia in Third Molar Surgery -Effects, Safety and Influence on Inflammatory Biomarkers in Plasma",,"['Pain', 'Postoperative']","['Ketamine', 'Postoperative', 'Pain management', 'Third molar']",,2017-02-14,2022-09-30,"[{'measure': 'Pain (VAS)', 'description': 'Postoperative pain measured by Visual analog scale (VAS). From minimum 0mm to maximum 100mm. 0mm is no pain and 100mm is worst pain imaginable. Changes in Visual Analog Scale value from preoperatively to 4 hours postoperatively', 'timeFrame': '4 hours postoperatively'}]","[{'measure': 'Safety (Oxygen saturation)', 'description': 'Change in oxygen saturation measured by pulseoximeter %. Intra individually and between the groups. From start to completion of the ketamine infusion.', 'timeFrame': 'Up to 2 hours.'}]",2.0,18 Years,44 Years,ALL,False,OTHER,2.0,168.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00231569,Dose-escalating Safety Study in Subjects on Stable Statin Therapy,ISIS 301012 or Placebo,['ISIS 301012 or Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Hypercholesterolemia,"Kastle Therapeutics, LLC",2025-09-01T16:18:07.028969,True,,,,NOT_FOUND,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy",,['Hypercholesterolemia'],"['LDL-cholesterol', 'apoB-100', 'apoB-48']",,2005-09,2007-12,"[{'measure': 'Percent reduction in LDL-cholesterol from baseline', 'timeFrame': 'From baseline measurement'}]","[{'measure': 'Percent reduction in apoB-100', 'timeFrame': 'From baseline measurement'}, {'measure': 'Percent change in HDL-cholesterol, triglycerides, total cholesterol, non-HDL cholesterol, VLDL plus LDL-cholesterol and LDL-cholesterol particle size and concentration', 'timeFrame': 'From baseline measurement'}, {'measure': 'Percent change from baseline in LDL/HDL and apoB-100/apo-A1 ratios', 'timeFrame': 'From baseline measurement'}, {'measure': 'AEs, SAEs, physical examination data, vital signs, and laboratory analyzes', 'timeFrame': 'Duration of study'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,1.0,74.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05656534,Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder,Suvorexant,"['Belsomra', 'Suvorexant']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Alcohol Use Disorder,Ohio State University,2025-09-01T16:18:17.173967,True,,,,NOT_FOUND,Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder,,['Alcohol Use Disorder'],"['suvorexant', 'alcohol use disorder', 'electromyography', 'functional magnetic resonance imaging']",,2022-11-29,2024-08-01,"[{'measure': 'Startle reactivity to stress with an acute dose of suvorexant.', 'description': 'Changes in acoustic startle electromyographic (EMG) response during stress anticipation following an acute dose of suvorexant.', 'timeFrame': 'Change from baseline to 2 hours post-ingestion of an acute dose of suvorexant.'}, {'measure': 'Startle reactivity to stress with daily use of suvorexant.', 'description': 'Changes in acoustic startle electromyographic (EMG) response during stress anticipation following daily use of suvorexant.', 'timeFrame': 'Change from baseline to post-treatment, up to 1.5-2 months.'}, {'measure': 'Alcohol behavior and daily use of suvorexant.', 'description': 'Changes in proportion of heavy drinking days and drinks per drinking day following daily use of suvorexant.', 'timeFrame': 'Change from baseline to post-treatment, up to 1.5-2 months.'}]","[{'measure': 'Brain change and daily use of suvorexant.', 'description': 'Changes in the anterior insula (aINS) and dorsal anterior cingulate cortex (dACC) reactivity and connectivity during stress anticipation following daily use of suvorexant.', 'timeFrame': 'Change from baseline to post-treatment, up to 1.5-2 months.'}]",4.0,18 Years,65 Years,ALL,False,OTHER,0.0,71.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00145509,40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786),Asenapine,"['Asenapine', 'Org 5222', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Bipolar Disorder,Organon and Co,2025-09-01T16:18:24.758165,True,,,,NOT_FOUND,"A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode",,['Bipolar Disorder'],[],,2005-08,2007-12,"[{'measure': 'Number of Participants Who Experienced an Adverse Event', 'description': 'Participants who experienced treatment-emergent adverse events, defined as adverse events reported on or after the first dose of study medication in the 12-week lead-in study through the last dose of study drug + 7 days (or + 30 days for serious adverse events).', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Number of Participants Who Discontinued Because of an Adverse Event', 'description': 'Participants who discontinued study medication due to adverse events.', 'timeFrame': '40 weeks'}, {'measure': 'Change From Baseline to Week 52 on the Young-Mania Rating Scale (Y-MRS) Score', 'description': 'The Y-MRS is an 11-item, clinician-rated instrument used for assessing the symptoms of mania. Y-MRS total score range = 0-60; higher scores indicate greater severity of symptoms.', 'timeFrame': 'Baseline and 52 Weeks'}, {'measure': 'Change From Baseline to Week 52 on the Montgomery Asberg Depression Rating Scale (MADRS) Score', 'description': 'The MADRS is a 10-item clinician-rated scale for assessing the severity of symptoms of depression. MADRS total score range = 0-60; higher scores indicate greater severity of symptoms.', 'timeFrame': 'Baseline and 52 Weeks'}]",[],4.0,18 Years,,ALL,False,INDUSTRY,0.0,77.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06215833,Recovery of TIVA vs Inhalation in Pediatric Anesthesia,Propofol,"['Propofol', 'Cetal suppository', 'Sevoflurane']",3,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Best Technique for Pediatric Anesthesia,Assiut University,2025-09-01T16:18:17.180695,True,,,,NOT_FOUND,Comparison of Emergence and Recovery Profile After Total Intravenous Anesthesia ( TIVA ) Vs Inhalational Anesthesia in Opioid Free Pediatric Tonsillectomy,,['Best Technique for Pediatric Anesthesia'],[],,2024-01-30,2025-12-30,"[{'measure': 'level of consciousness score', 'description': '* Awake =2\n* Arousal with minimal stimulation =1\n* Responsive only to tactile stimulation =0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'physical activity score', 'description': '* Able to move on command =2\n* Some weakness in movement = 1\n* Unable to voluntarily move = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'hemodynamic stability score', 'description': '* Blood pressure \\< 15% of baseline MAP value =2\n* Blood pressure 15%-30% of baseline MAP value =1\n* Blood pressure \\< 30% below baseline MAP value =0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'respiratory stability score', 'description': '* Able to breathe deeply = 2\n* Tachypnea with good coughs =1\n* Dyspneic with weak cough = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'Oxygen saturation score', 'description': '* Maintain value \\> 90% on room air = 2\n* Requires supplemental O2 to maintain value \\> 90% = 1\n* So2 \\< 90% with supplemental O2 = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'post operative pain score', 'description': '* None or mild = 2\n* Moderate to severe pain controlled =1\n* Persistent severe pain = 0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}, {'measure': 'post operative emetic score', 'description': '* None or mild nausea with no active vomiting = 2\n* Transient vomiting =1\n* Persistent moderate to severe nausea and vomiting=0\n* No score 0 is required \\& High score mean more safe and better method of anesthesia .', 'timeFrame': 'About 20 minutes after stopping anesthesia and emergence from anesthesia begin'}]",[],7.0,4 Years,10 Years,ALL,False,OTHER,0.0,120.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT06007014,Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes,Chiglitazar sodium,"['Chiglitazar sodium', 'Chiglitazar placebo']",2,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients,Yanbing Li,2025-09-01T16:18:24.761398,True,,,,NOT_FOUND,"A Multi-Center, Randomised, Double-blind, Placebo Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes",,"['Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients', 'Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect', '128 Patients Were Randomly Assigned 1:1', 'Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day Group', 'Metformin and Insulin Glargine Combined With Placebo Group', 'InvestigatorInitiate Trial', 'Changes in HbA1C From Baseline at 18 Weeks of Treatment']","['Chiglitazar', 'T2DM', 'Randomised', 'Double-blind', 'Placebo Parallel Controlled']",,2023-10-31,2025-12-30,"[{'measure': 'HbA1C', 'description': 'Changes in HbA1C from baseline', 'timeFrame': '18 weeks of treatment'}]","[{'measure': 'Insulin', 'description': 'Changes in the daily dose of insulin from baseline', 'timeFrame': '6 weeks and 18 weeks of treatment'}, {'measure': 'Triglyceride', 'description': 'Changes in the daily dose of triglyceride from baseline', 'timeFrame': '18 weeks of treatment'}, {'measure': 'Fasting blood glucose', 'description': 'Changes in the daily dose of fasting blood glucose from baseline', 'timeFrame': '6 weeks and 18 weeks of treatment'}, {'measure': 'Fasting C-Peptide', 'description': 'Changes in the daily dose of fasting C-Peptide from baseline', 'timeFrame': '18 weeks of treatment'}]",5.0,18 Years,,ALL,False,OTHER,0.0,128.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01134952,Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV),Mycophenolate to sirolimus switch,"['Mycophenolate to sirolimus switch', 'rapamune', 'mycophenolic acid', 'mycophenolic mofetil', 'rapamycin', 'cellcept']",6,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hepatitis C,London Health Sciences Centre,2025-09-01T16:18:14.665461,True,,,,CHEMBL413,A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection,,['Hepatitis C'],"['sirolimus', 'everolimus', 'mycophenolic acid', 'hepatitis C virus', 'tacrolimus', 'viral load']",,2010-06,2014-12,"[{'measure': 'Delta Hepatitis C Viral Load', 'description': 'Percent change in HCV load determined 3 months after switch from MMF to SRL.', 'timeFrame': '3 month'}]","[{'measure': 'Final Hepatitis C Viral Load', 'description': 'Percent change in HCV load determined 3 months after switch from SRL to MMF', 'timeFrame': '3 month'}, {'measure': 'Sirolimus Trough Level', 'timeFrame': '3 month'}, {'measure': 'Delta Tacrolimus Trough Level', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Bilirubin', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Alkaline Phosphatase', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Alanine Aminotransferase', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Hemoglobin', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Platelet Count', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Cholesterol Fasting Level', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Triglyceride Fasting Level', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}]",11.0,18 Years,,ALL,False,OTHER,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CHEMBL413,partial_match,True,914.19,6.18,4.0
NCT06230588,A Clinical Trial of TQH3906 Capsules in Healthy Volunteers,TQH3906 capsule,"['TQH3906 capsule', 'TQH3906 placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Psoriasis,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",2025-09-01T16:18:20.962340,True,,,,NOT_FOUND,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy Volunteers",,['Psoriasis'],[],,2024-02-02,2025-04-27,"[{'measure': 'Adverse events (AE)', 'description': 'Incidence of adverse events (AE)', 'timeFrame': 'Up to 18 days'}, {'measure': 'Serious Adverse Events (SAE)', 'description': 'Incidence of serious adverse events (SAE)', 'timeFrame': 'Up to 18 days'}, {'measure': 'Treatment-emergent adverse events (TEAEs)', 'description': 'Incidence of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 18 days'}]","[{'measure': 'Time to peak concentration (Tmax)', 'description': 'The time it takes to reach the peak concentration', 'timeFrame': 'Up to 18 days'}, {'measure': 'Peak concentration (Cmax)', 'description': 'Maximum plasma drug concentration', 'timeFrame': 'Up to 18 days'}, {'measure': 'Area under the blood concentration-time curve', 'description': 'The amount of drug absorbed into the circulation after administration of a single dose can be estimated from the area under the blood concentration-time curve, with Auc in units of concentration \\* time.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Apparent volume of distribution (Vd/F)', 'description': 'It is the ratio of the amount of drug in the body to the blood concentration of the drug when the drug reaches dynamic equilibrium in the body is called the apparent volume of distribution.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Plasma clearance (CL/F)', 'description': 'It is the sum of drug clearance by the liver and kidneys, etc., i.e., how many volumes of plasma are cleared of drug per unit of time in L/h, or L/(kg-h) if calculated on the basis of body weight.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Plasma elimination half-life (t1/2)', 'description': 'The time required for the concentration of a drug in the blood or the amount of drug in the body to be reduced to 1/2. The time required for absorption, distribution and elimination of half the amount of drug (or blood concentration) in the body becomes the absorption half-life, distribution half-life and elimination half-life, respectively.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Steady-state peaking time (Tmax, ss)', 'description': 'The time required to reach a steady-state peak concentration after administration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Steady state peak concentration (Cmax, ss)', 'description': 'The steady-state blood drug concentration is a serrated plasma drug concentration curve, with the highest steady-state blood drug concentration being the peak steady-state blood drug concentration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Steady state valley concentration (Cmin, ss)', 'description': 'The steady-state blood drug concentration is a serrated plasma drug concentration curve, with the lowest steady-state blood drug concentration being the trough of the steady-state blood drug concentration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Average steady-state blood drug concentration (Cav, ss)', 'description': 'The average concentration reached when the drug concentration reaches a steady state after a continuous given dose of medication.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Area under steady-state blood drug concentration time curve (AUC0- τ)', 'description': 'After a single dose administration, the amount of medication absorbed into the human bloodstream can be estimated using the area under the blood drug concentration time curve, with the unit of Auc being concentration \\* time.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Accumulation ratio (Rac)', 'description': 'The ratio of the required dose for a single administration to the total dose required for a split administration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Renal clearance rate (CLr/F)', 'description': 'The ability of both kidneys to completely remove a substance equivalent to several milliliters of plasma within one minute.', 'timeFrame': 'Up to 18 days'}, {'measure': 'INF-γ release', 'description': 'Inhibition efficiency of INF-γ release by TQH3906 in IL-12/IL-18-stimulated peripheral blood mononuclear cells from subjects.', 'timeFrame': 'Up to 18 days'}, {'measure': 'QTcF interval', 'description': 'Effect of TQH3906 on the QTcF interval in healthy subjects.', 'timeFrame': 'Up to 18 days'}]",18.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,96.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06519266,PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases,IPI1/NIVO3,"['Nivolumab 1 mg/kg', 'IPI3/NIVO1', 'Nivolumab 3 mg/kg', 'Ipilimumab 1 mg/kg', 'Ipilimumab 3 mg/kg', 'IPI1/NIVO3']",6,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Uveal Melanoma,Vastra Gotaland Region,2025-09-01T16:18:18.430435,True,,,,NOT_FOUND,A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination With Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients With Uveal Melanoma Liver Metastases,,"['Uveal Melanoma', 'Liver Metastases']","['Percutaneous Hepatic Perfusion', 'Immunotherapy', 'Uveal Melanoma', 'Liver metastases', 'SCANDIUM III trial']",,2024-06-10,2030-12-31,"[{'measure': 'Progression-free survival (PFS)', 'description': 'The primary objective is to evaluate progression-free survival in patients with uveal melanoma hepatic dominant metastases randomized to either percutaneous hepatic perfusion (PHP) in combination with IPI1/NIVO3 or the combination of IPI3/NIVO1 only', 'timeFrame': '24 month'}]","[{'measure': 'Adverse events', 'description': 'Frequency and severity of AEs and SAEs graded according to the NCI CTCAE v5.0.', 'timeFrame': '24 month'}, {'measure': 'Overall response rate', 'description': 'Evaluation of objective response rate (ORR), defined as the percentage of patients achieving a confirmed complete or partial response, as defined by RECIST version 1.1 criteria', 'timeFrame': '24 month'}, {'measure': 'Clinical benefit rate', 'description': 'Evaluation of clinical benefit rate (CBR), defined as the percentage of patients achieving confirmed SD or any confirmed CR or PR. As defined by RECIST version 1.1 criteria', 'timeFrame': '24 month'}, {'measure': 'Hepatic progression-free survival', 'description': 'Evaluation of hepatic PFS (hPFS), defined as the time-to-event defined by the first documented disease progression in the liver or death due to any cause, whichever occurs first, from randomization. hPFS will be determined based on tumor assessment using RECIST version 1.1 criteria.', 'timeFrame': '24 month'}, {'measure': 'Overall survival', 'description': 'Evaluation of overall survival (OS), defined as the time from randomization to death from any cause.', 'timeFrame': '24 month'}, {'measure': 'Melanoma-specific survival', 'description': 'Evaluation of melanoma-specific survival (MSS), defined as the time from randomization to death from uveal melanoma', 'timeFrame': '24 month'}, {'measure': 'Duration of response', 'description': 'Evaluation of duration of response (DOR), defined as the time to first documented progression or death due to underlying cancer from the first document CR or PR', 'timeFrame': '24 month'}, {'measure': 'Quality of Life as assessed by FACT-G', 'description': 'Evaluation of QoL using The Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire, where overall scores for FACT-G and the sub scales physical (PWB), social (SWB), emotional (EWB), and functional well-being (FWB) will be reported.', 'timeFrame': '24 month'}, {'measure': 'Quality of Life as assessed by EQ-5D-5L', 'description': 'Evaluation of QoL using EQ-5D-5L where EQ-VAS (0-100) will be reported', 'timeFrame': '24 month'}]",10.0,18 Years,,ALL,False,OTHER_GOV,0.0,40.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03423121,A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis,Tauroursodeoxycholic Acid,"['Taurolite', 'Tauroursodeoxycholic Acid', 'Placebo oral capsule']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Progressive Multiple Sclerosis,Johns Hopkins University,2025-09-01T16:18:12.167975,True,,,,NOT_FOUND,A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients,,['Progressive Multiple Sclerosis'],[],,2018-06-19,2022-07-05,"[{'measure': 'Number of Participants With at Least One Treatment-related Adverse Event', 'description': 'Safety and tolerability will be assessed based on treatment-related adverse events in the two arms.', 'timeFrame': '16 weeks'}, {'measure': 'Number of Total Treatment-related Adverse Events', 'description': 'Safety and tolerability will be assessed based on treatment-related adverse events in the two arms.', 'timeFrame': '16 weeks'}, {'measure': 'Incidence of Treatment-related Adverse Events (AE)', 'description': 'Safety and tolerability will be assessed based on treatment-related adverse events in the two arms. AE incidence will be measured as total number of events per 1000 exposure years.', 'timeFrame': '16 weeks'}]","[{'measure': 'Change in Fasting Bile Acid Levels in Plasma', 'description': 'The change of targeted bile acid levels over the course of 16 weeks (duration of the study) is reported.\n\nBile acid levels (ng/mL) were log transformed before analysis to approximate normal distribution. Units are log(levels) per 16 weeks. Values are derived from linear mixed-effects models.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Change in Microbiome Alpha-diversity Measured by Shannon Index at the End of the Study', 'description': 'Change in Shannon index of the gut microbiota between baseline and end of study (16 weeks). Shot-gun metagenomic sequencing in first morning stool specimen was utilized to derive the microbiome composition. Higher values of the index indicate more diversity in the microbial community. The minimum value the Shannon index can take is 0 (no diversity). There is no upper limit to the index.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Change in Flow Cytometric Assessments of Peripheral Blood Mononuclear Cells (PBMCs)', 'description': 'Change in flow cytometric assessments over the course of 16 weeks (duration of the study).\n\nCells are expressed as ratios of their parent types. Units reported as change in the ratio per 16 weeks. Values are derived from linear mixed-effects models.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Change in Quality of Life Based on Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument', 'description': 'Change in physical and mental health scores as assessed using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) instrument over the course of 16 weeks (duration of the study). This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. Two summary scores - physical health and mental health - are derived from a weighted combination of scale scores. Higher scores suggest a better quality of life. Scores can range from 0 to 100.', 'timeFrame': 'Baseline to 16 weeks'}]",7.0,18 Years,,ALL,False,OTHER,0.0,59.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01737320,Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia,short-course antibiotic treatment,"['accepted prolonged antibiotic treatment', 'short-course antibiotic treatment']",2,INTERVENTIONAL,['NA'],,COMPLETED,Gram Negative Bacteremia,Rabin Medical Center,2025-09-01T16:18:07.021292,True,,,,NOT_FOUND,Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia - a Randomized Controlled Trial,,['Gram Negative Bacteremia'],"['gram negative bacteremia', 'Duration of antibiotic treatment', 'safety', 'efficacy', 'short-course']",,2013-01,2018-03-04,"[{'measure': 'composite of the following', 'description': 'The primary outcome is a composite of the following outcome measures', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'All -cause mortality', 'description': 'All- cause mortality', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Treatment Failure', 'description': 'Failure including any of the following:\n\n1. Relapse: a recurrent bacteraemia due to the same microorganism occurring from day of randomization and until day 9013\n2. Local suppurative complication that was not present at infection onset (e.g. renal abscess in pyelonephritis, empyema in pneumonia)\n3. Distant complications of initial infection, defined by growth of the same bacteria as in the initial bacteremia', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Hospital re-admissions or extended hospitalization', 'description': 'We will define re-admission as a new hospitalization for any cause occurring more than14 days from start of appropriate antibiotic treatment. Patients hospitalized after day 14 (were never discharged or 7-day regimen who were readmitted between days 7-14) will be counted as failures for this outcome.\n\nWe will define re-admission as a new hospitalization for any cause occurring more than14 days from start of appropriate antibiotic treatment. Patients hospitalized after day 14 (were never discharged or 7-day regimen who were readmitted between days 7-14) will be counted as failures for this outcome.', 'timeFrame': 'Until day 90 after randomization'}]","[{'measure': 'Clostridium difficile associated diarrhea', 'description': 'Clostridium difficile associated diarrhea', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Development of Antibiotic resistance', 'description': 'Development of resistance, defined as clinical isolates resistant to antibiotics previously used in the bacteremia episode. Surveillance sampling will not be conducted.', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Carriage of carbapenem resistant Klebsiella pneumonia.', 'description': 'Carriage of carbapenem resistant Klebsiella pneumonia (screened routinely)', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Total in hospital days', 'description': 'Total in hospital days within 30 and 90 days', 'timeFrame': 'Until day 90 after randomization.'}, {'measure': 'Total antibiotic days', 'description': 'Total antibiotic days', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Adverse events', 'description': '* Any diarrhea\n* Liver function test abnormalities, defined as elevated bilirubin x 1.5 of upper limit of normal or transaminases x 2.5 of upper limit of normal\n* Antibiotic rash\n* Acute kidney injury - defined according to RIFLE criteria as increased creatinine level x 1.5 from baseline or glomerular filtration rate (GFR) decrease \\>25% or urine output of \\<0.5 ml/kg/h for 6 hours22', 'timeFrame': 'Until day 30 after randomization'}, {'measure': 'Infection caused by other than gram-negative bacteremia', 'description': 'Development of either clinically or microbiologically documented infection other than gram-negative bacteremia. We will use the 2008 CDC/NHSN surveillance definitions of health-care associated infections for bacterial infections', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Number of hospital re-admissions', 'description': 'Number of hospital re-admissions until day 90', 'timeFrame': 'Until day 90 after randomization'}, {'measure': 'Functional capacity and time to return to baseline activity', 'description': 'Functional capacity and time to return to baseline activity', 'timeFrame': 'Until day 30 after randomization'}]",13.0,18 Years,,ALL,False,OTHER,0.0,604.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02028403,Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy,BMS-936559,"['Placebo for BMS-936559', 'BMS-936559']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,HIV Infections,National Institute of Allergy and Infectious Diseases (NIAID),2025-09-01T16:18:20.962529,True,,,,NOT_FOUND,"Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study",,['HIV Infections'],[],,2014-06,2015-11,"[{'measure': 'Occurrence of a Grade 3 or greater adverse event (AE), including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment', 'description': 'As judged by the core team, blinded to treatment arm; any time from study treatment administration until 28 days after the administration.', 'timeFrame': 'Measured through Day 28'}, {'measure': 'Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune-mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study', 'description': 'As judged by the core team, blinded to treatment arm; any time from study treatment administration until 28 days after the administration.\n\n(Pneumonitis is Category A, B, or C)', 'timeFrame': 'Measured through Day 28'}, {'measure': 'Frequency of HIV-1 Gag-specific CD8 T-cells by intracellular staining for interferon (IFN)-gamma at baseline and after treatment (through Day 28)', 'timeFrame': 'Measured through Day 28'}, {'measure': 'HIV-1 RNA by single copy assay (SCA) at baseline and after treatment (through Day 28)', 'timeFrame': 'Measured through Day 28'}]","[{'measure': 'PK parameters from non-compartmental analysis (area under curve [AUC], Cmax, V, Tmax, CL/F, t1/2)', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Exploratory pharmacodynamic parameters (Emax, EC50)', 'timeFrame': 'Measured through Week 48'}, {'measure': 'HIV-1 DNA at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Programmed cell death 1 ligand 1 (PD-L1) receptor occupancy', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Proportion of total and HIV-1 gag-specific CD8 T-cells expressing programmed cell death 1 (PD-1), PD-L1, and other exhaustion markers', 'timeFrame': 'Measured through Week 48'}, {'measure': 'CD107a mobilization and carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution of HIV-1 gag-specific CD8 T-cells', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Polyfunctionality of HIV-1 specific CD8 and CD4 T-cells', 'timeFrame': 'Measured through Week 48'}, {'measure': 'CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T-cells', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Gene expression profiles in whole blood', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Detection of antibody to study treatment in plasma', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Occurrence of a Grade 3 or greater AE, including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment', 'description': 'As judged by the core team, blinded to treatment arm; any time greater than or equal to 29 days after the study treatment administration', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study', 'description': 'As judged by the core team, blinded to treatment arm; any time greater than or equal to 29 days after the study treatment administration', 'timeFrame': 'Measured through Week 48'}, {'measure': '2-long terminal repeat (2LTR) circle DNA at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Cell-associated HIV-1 RNA at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'RNA/DNA ratios in total CD4 cells at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Expression of programmed cell death 1 ligand 2 (PD-L2) on dendritic cells and monocyte-derived macrophages', 'timeFrame': 'Measured through Week 48'}]",20.0,18 Years,70 Years,ALL,False,NIH,0.0,8.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02324049,"Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)",SBC-103,"['recombinant human alpha-N-acetylglucosaminidase', 'SBC-103']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Mucopolysaccharidosis IIIB,"Alexion Pharmaceuticals, Inc.",2025-09-01T16:18:22.212439,True,,,,NOT_FOUND,"A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously",,['Mucopolysaccharidosis IIIB'],"['MPS IIIB', 'Mucopolysaccharidosis', 'Mucopolysaccharidosis type IIIB', 'Sanfilippo Syndrome', 'Metabolism, Inborn Errors', 'Metabolic Diseases', 'Genetic Diseases, Inborn', 'Carbohydrate Metabolism, Inborn Errors', 'Connective Tissue Diseases', 'Lysosomal Storage Diseases', 'Mucinoses', 'Mucopolysaccharidoses', 'Pathologic Processes']",,2015-01-22,2017-10-16,"[{'measure': 'Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)', 'description': 'TEAEs were defined as any adverse event (AE) that occurred after administration of the first dose of study drug on Day 1 (Part A). A severe AE was defined as an AE that was incapacitating and required medical intervention. TEAEs were summarized cumulatively over the entire study and separately for Part C, data for all severe TEAEs throughout the entire study is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline to Week 142'}]",[],1.0,2 Years,12 Years,ALL,False,INDUSTRY,0.0,11.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02933229,"The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study",H. pylori eradication,['H. pylori eradication'],1,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Helicobacter Pylori,Shandong University,2025-09-01T16:18:18.431569,True,,,,NOT_FOUND,,,"['Helicobacter Pylori', 'the Operative Link on Gastric Intestinal Metaplasia', 'Operative Link on Gastric Intestinal Assessment']",[],,2016-10,2031-10,"[{'measure': 'The proportion of more severe inflammation in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status', 'timeFrame': '15 years'}, {'measure': 'The proportion of more severe atrophy in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status', 'timeFrame': '15 years'}, {'measure': 'The proportion of more severe IM in the gastric mucosa for 15 years after H. pylori eradication at five points of the stomach compared with original status', 'timeFrame': '15 years'}]","[{'measure': 'The proportion of more advanced stages for 15 years after H. pylori eradication by using operative link on gastritis assessment (OLGA) system compared with original status.', 'timeFrame': '15 years'}, {'measure': 'The proportion of more advanced stages for 15 years after H. pylori eradication by using operative link for gastritis intestinal metaplasia (OLGIM) system compared with original status.', 'timeFrame': '15 years'}]",5.0,18 Years,60 Years,ALL,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04766827,Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor,albumin-bound paclitaxel,"['Docetaxel', 'albumin-bound paclitaxel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Squamous Cell Carcinoma of Head and Neck,Tianjin Medical University Cancer Institute and Hospital,2025-09-01T16:18:20.963237,True,,,,NOT_FOUND,A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor,,['Squamous Cell Carcinoma of Head and Neck'],[],,2020-12-12,2021-12,"[{'measure': 'Objective response rate', 'description': 'ORR=CR+PR', 'timeFrame': '21 days'}]","[{'measure': 'Surgical resection rate', 'description': 'the rate of Surgical resection in all samples', 'timeFrame': '1 month'}, {'measure': 'pathological response rate', 'description': 'the rate of pathological response in all samples', 'timeFrame': '1 month'}, {'measure': 'PFS', 'description': 'progression-free survival', 'timeFrame': '5 year'}, {'measure': 'OS', 'description': 'overall survival', 'timeFrame': '5 year'}]",5.0,18 Years,,ALL,False,OTHER,0.0,116.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01611909,Citriodiol® and Impetigo,"p-menthane-3,8-diol oil","['p-menthane-3,8-diol oil']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Impetigo,Royal North Shore Hospital,2025-09-01T16:18:22.205279,True,,,,NOT_FOUND,"A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo.",,['Impetigo'],"['p-menthane-3,8-diol oil extract', 'topical therapy']",,2012-07,2013-03,"[{'measure': 'Improvement in severity score of impetigo', 'timeFrame': '2 weeks'}]",[],1.0,12 Months,12 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00622193,Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer,anamorelin HCl,"['ST-1291', 'anamorelin HCl', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Carcinoma, Non-Small-Cell Lung","Helsinn Therapeutics (U.S.), Inc",2025-09-01T16:18:22.207405,True,,,,CHEMBL2110579,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC",,"['Carcinoma, Non-Small-Cell Lung']",['NSCLC'],,2008-03,2009-12,"[{'measure': 'Hand grip strength and body weight', 'timeFrame': 'Twelve weeks'}]","[{'measure': 'Quality of Life and Biomarker', 'timeFrame': 'Twelve weeks'}]",2.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,228.0,ACTUAL,v2_robust,True,True,False,False,,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1,CHEMBL2110579,partial_match,True,546.72,2.72,3.0
NCT02805790,"Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study",Elamipretide,"['Bendavia', 'MTP-131', 'Elamipretide', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Primary Mitochondrial Disease,Stealth BioTherapeutics Inc.,2025-09-01T16:18:09.635793,True,,,,NOT_FOUND,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate Safety, Tolerability, and Efficacy of Subcutaneous Injections of MTP-131 in Subjects With Mitochondrial Myopathy Previously Treated in the SPIMM-201 Study",,['Primary Mitochondrial Disease'],"['Primary Mitochondrial Disease', 'Mitochondrial Myopathy', 'Elamipretide', 'MTP-131', 'Bendavia™']",,2016-08-22,2017-03-23,"[{'measure': 'Distance Walked on the 6-minute Walk Test (6MWT) by Visit', 'description': 'Distance in meters walked on the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of week 4 for Period 1 and end of week 12 for Period 2.', 'timeFrame': 'End of Week 4 and End of Week 12'}]","[{'measure': 'Wrist Accelerometer Counts by Day', 'description': 'Wrist Accelerometer Counts by the last 7 days prior to the date of the end of treatment visit; End of treatment being end of Week 4 for Treatment Period 1 and end of Week 12 for Treatment Period 2. Subjects wore an activity monitor, or wrist accelerometer, on their wrist daily (from the Screening Visit to the End-of-Study/Early Discontinuation Visit). As a measure of physical activity and mobility, subjects wore an activity monitor, or wrist accelerometer, which measured mean vector magnitude of accelerations per daywith higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data were used for the analysis of as the vector magnitude of the wrist data.', 'timeFrame': 'Last 7 days prior to the date of end of treatment visit'}, {'measure': 'Average Hip Accelerator Counts by Day', 'description': 'Average Hip Accelerator Counts by last 7 days predose, and prior to end of treatment; End of treatment being Week 4 for Treatment Period 1 and Week 12 for Treatment Period 2. As a measure of physical activity and mobility, subjects wore an activity monitor, or hip accelerometer, on their hip (or belt line) daily during waking hours (minimum of at least 7 consecutive days immediately prior to study drug administration in each Treatment Period \\[Predose; at Visit 2 for Treatment Period 1 and at Visit 4 for Treatment Period 2\\]), and at the end of each Treatment Period \\[at Visit 3 for Treatment Period 1 and Visit 5 for Treatment Period 2\\]), which measured average acceleration per day, with higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data was used for the analysis of mean vertical axis (Y) cou', 'timeFrame': 'Last 7 days prior to the date of end of treatment visit'}, {'measure': 'Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)', 'description': 'Participants respond to the following statements of the Quality of Life in Neurological Disorders Fatigue Assessment (Neuro-QOL Fatigue Item Bank at end of treatment: I felt exhausted;I felt that I had no energy; I felt fatigued; I was too tired to do my household chores;I was too tired to leave the house;I was frustrated by being too tired to do the things I wanted to do; I felt tired; I had to limit my social activity because I was tired.Individual response options range from a score of 1 to 5, where 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always for end of treatment, where end of treatment period is end of week 4 for period 1, and end of week 12 for period 2. Raw scores are calculated as simple summed scores to an Item Response Theory Metric referred to as the T-score metric. Higher T-score means more fatigue, which means a worse outcome, with possible scores ranging from 29.5 to 74.1. Mean population T-score and standard deviation was reported.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week', 'description': 'Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue score at end of treatment (sum of Q1 to Q4; tiredness/muscle weakness) is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Participants rate the following: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period, where end of treatment period is the weekly average of the last 7 days of week 4 for period 1 and the last 7 days of week 12 for period 2.', 'timeFrame': 'Last 7 days of Week 4 and Last 7 days of Week 12'}, {'measure': 'Triple Timed Up and Go (3TUG) Test by Visit', 'description': 'Participant performed 3TUG test after the 6MWT, and after at least 15 minutes rest prior to study drug administration in each Treatment Period (End of Week 4 for Period 1 and End of Week 12 for Period 2.) Participant was directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away,turn, walk back to the chair at normal pace, sit down again; activity was timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Patient Global Assessment [PGA] Score by Visit, Continuous', 'description': 'Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Patient Global Assessment by Visit, Categorical', 'description': 'Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Physician Global Assessment (PhGA) By Visit, Continuous', 'description': 'Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}, {'measure': 'Physician Global Assessment (PhGA) By Visit, Categorical', 'description': 'Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.', 'timeFrame': 'End of Week 4 and End of Week 12'}]",10.0,16 Years,,ALL,False,INDUSTRY,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00892840,Multiple-Ascending Dose Study,BMS-820836,"['Placebo', 'BMS-820836']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Depression,Bristol-Myers Squibb,2025-09-01T16:18:07.016148,True,,,,NOT_FOUND,"Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-820836 in Healthy Subjects",,['Depression'],[],,2009-05,2010-11,"[{'measure': 'To assess the safety and tolerability of BMS-820836 following multiple-dose administration', 'timeFrame': 'Within 27 days (+/- 2 days) of first dose'}]","[{'measure': 'To assess the pharmacodynamics of BMS-820836', 'timeFrame': 'Within 27 days of first dose'}]",2.0,21 Years,55 Years,ALL,True,INDUSTRY,0.0,57.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01096095,Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3,Placebo,"['Sodium Phenylbutyrate', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Spinocerebellar Ataxia Type 3,Hospital de Clinicas de Porto Alegre,2025-09-01T16:18:10.917613,True,,,,NOT_FOUND,"Phenylbutyrate in SCA3: a Double-blind, Placebo-controlled Study to Determine Safety and Efficacy of Sodium Phenylbutyrate in Patients With SCA3",,['Spinocerebellar Ataxia Type 3'],"['SCA', 'Spinocerebellar Ataxia', 'Sodium Phenylbutyrate', 'Machado-Joseph Disease', 'Treatment']",Regulatory authorities did not allow the entrance of the study drug in the country,2010-06,2011-07,"[{'measure': 'Safety and tolerability of phenylbutyrate in patients with SCA3', 'description': 'The number of adverse events, interruptions and dose reductions in the two groups (cases and controls).', 'timeFrame': '6 months - 12 months'}]","[{'measure': 'Efficacy of phenylbutyrate in SCA3 on neurological dysfunction and quality of life', 'description': 'Efficacy outcomes are the following scores in both groups: NESSCA, SARA, 9-hole peg board test, BDI, and WHOQol.', 'timeFrame': '6 months - 12 months'}]",2.0,16 Years,80 Years,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,True,Regulatory authorities did not allow the entrance of the study drug in the country,,,no_match,False,,,
NCT00895752,Riluzole in Fragile X Syndrome,Riluzole,['Riluzole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Fragile X Syndrome,Indiana University,2025-09-01T16:18:22.211651,True,,,,NOT_FOUND,Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay,,['Fragile X Syndrome'],[],,2009-04,2010-07,"[{'measure': 'Clinical Global Impression-Improvement (CGI-I)', 'description': ""The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse"", 'timeFrame': 'Obtained at Week 6'}, {'measure': ""Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)"", 'description': 'The CY-BOCS PDD has been utilized in a largescale clinical treatment study of repetitive behavior in idiopathic ASDs. CYBOCS-PDD scores range from 0 to 20 and measure repetitive/compulsive behavior and not obsessions. Higher score indicate worse outcome.', 'timeFrame': 'Obtained at Baseline and Week 6'}]","[{'measure': 'Aberrant Behavior Checklist', 'description': 'The Aberrant Behavior Checklist (ABC) is a 58-item measure of maladaptive behaviors and is used as a measure of drug effects. The ABC has 5 subscales: Social Withdrawal (16 items) ranging from 0 (not at all) to 48 (severe), Irritability (15 items) ranging from 0 (not at all) to 45 (severe), Inappropriate Speech (4 items) ranging from 0 (not at all) to 12 (severe), Hyperactivity (16 items) ranging from 0 (not at all) to 48 (severe), and Stereotypy (7 items) ranging from 0 (not at all) to 21 (severe). Items are rated from 0 (not at all) to 3 (severe).', 'timeFrame': 'Week 6'}, {'measure': 'The ADHD Rating Scale', 'description': 'The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity', 'timeFrame': 'Week 6'}, {'measure': 'The Clinical Global Impression - Severity Scale', 'description': ""The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill"", 'timeFrame': 'Week 6'}, {'measure': 'The Peabody Picture Vocabulary Test', 'description': 'The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank.', 'timeFrame': 'Week 6'}, {'measure': 'The Social Reciprocity Scale', 'description': 'The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment.', 'timeFrame': 'Week 6'}, {'measure': 'Extra-cellular Signal-relatedness Kinase (ERK)', 'description': 'ERK activations times, as defined as the time in minutes for ERK phosphorylation to reach the half maximal level.', 'timeFrame': 'Screen and Week 6'}]",8.0,18 Years,,ALL,False,OTHER,1.0,6.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06496100,"Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity",Triticum Aestivum,"['Placebo (calcined magnesia)', 'Calcined magnesia', 'Triticum Aestivum']",3,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Obesity,"Coordinación de Investigación en Salud, Mexico",2025-09-01T16:18:13.427525,True,,,,NOT_FOUND,"Effect of Triticum Aestivum on Appetite Regulation and the Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity",,"['Obesity', 'Leptin Deficiency', 'Ghrelin', 'Adiponectin']",[],,2024-01-03,2024-12-24,"[{'measure': 'To evaluate the effect of Triticum aestivum on leptin in patients with obesity.', 'description': 'To quantify the serum concentrations of leptin ( pg/mL) before and after of treatment with 1000 mg of Triticum aestivum or placebo.', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on ghrelin in patients with obesity.', 'description': 'To quantify the serum concentrations of ghrelin ( pg/mL) before and after of treatment with 1000 mg of Triticum aestivum or placebo.', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on adiponectin in patients with obesity.', 'description': 'To quantify the serum concentrations of adiponectin ( pg/mL) before and after of treatment with 1000 mg of Triticum aestivum or placebo.', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on satiety regulation', 'description': 'To evaluate the effect on satiety by the visual analog scale for satiety and appetite', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on appetite regulation', 'description': 'To evaluate the effect on satiety by the visual analog scale for satiety and appetite', 'timeFrame': '120 days'}]",[],5.0,30 Years,50 Years,ALL,True,OTHER_GOV,0.0,38.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03339349,Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma,Enoxaparin,['Enoxaparin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Venous Thromboembolism,University of Utah,2025-09-01T16:18:12.171423,True,,,,NOT_FOUND,Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma,,"['Venous Thromboembolism', 'Deep Vein Thrombosis', 'Pulmonary Embolus']",[],,2017-11-15,2019-10-29,"[{'measure': 'Number of Participants With Venous Thromboembolism Events', 'description': 'Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery', 'timeFrame': '90 days'}, {'measure': 'Number of Participants With Bleeding Events', 'description': 'Bleeding events requiring alteration in the course of care within 90 days of surgery', 'timeFrame': '90 days'}]",[],2.0,18 Years,,ALL,False,OTHER,0.0,80.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01289210,VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas,VTX-2337 plus radiotherapy,['VTX-2337 plus radiotherapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Low Grade B Cell Lymphoma,Celgene,2025-09-01T16:18:07.020486,True,,,,NOT_FOUND,A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas,,['Low Grade B Cell Lymphoma'],"['B cell', 'lymphoma']",The study was stopped due to slow rate of recruitment.,2011-07,2012-10,"[{'measure': 'Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation.', 'description': 'Tumor response was assessed via CT scans of the chest, abdomen, pelvis or other medically appropriate imaging modality to evaluate all areas of disease. Cheson Criteria were used for calculation of response.', 'timeFrame': 'Tumor assessment conducted at 12 weeks and every 3-6 months thereafter'}]","[{'measure': 'Assess the Safety and Feasibility of the Combination Regimen.', 'timeFrame': 'Safety assessed throughout study period.'}]",2.0,18 Years,,ALL,False,INDUSTRY,1.0,2.0,ACTUAL,v2_robust,True,False,True,True,The study was stopped due to slow rate of recruitment.,,,no_match,False,,,
NCT01120795,Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy,Pegylated interferon and ribavirin,"['Pegylated interferon and ribavirin', 'Pegasys and Copegus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Hepatitis C,Melbourne Health,2025-09-01T16:18:08.341257,True,,,,NOT_FOUND,Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes,,['Chronic Hepatitis C'],[],,2004-02,2006-07,"[{'measure': 'Sustained virological response', 'timeFrame': '24 weeks post cessation of HCV therapy'}]",[],1.0,18 Years,65 Years,ALL,False,OTHER,5.0,55.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05704049,A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma,Isatuximab,"['Dexamethasone IV', 'Diphenhydramine', 'Kyprolis', 'Acetaminophen', 'Montelukast', 'Isatuximab', 'Carfilzomib', 'Dexamethasone', 'Methylprednisolone']",9,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Relapsed/Refractory Multiple Myeloma,Sanofi,2025-09-01T16:18:19.673845,True,,,,NOT_FOUND,"A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)",,['Relapsed/Refractory Multiple Myeloma'],[],,2023-04-05,2028-05-12,"[{'measure': 'Overall response rate (ORR) - Cohorts 1 to 3', 'description': 'ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC).', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5', 'timeFrame': 'Cycle 1 (28 days)'}, {'measure': 'Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5', 'timeFrame': 'Cycle 1 (28 days)'}]","[{'measure': 'Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6', 'description': 'Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2).', 'timeFrame': '6 months from LPI i.e., approximately 16 months'}, {'measure': 'Incidence rate of infusion reactions (IRs)', 'timeFrame': 'From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months'}, {'measure': 'Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters', 'timeFrame': 'From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months'}, {'measure': 'Incidence rate of injection site reactions (ISRs)', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'PK concentration: trough plasma concentration (Ctrough)', 'description': 'Blood samples will be collected for measurement of isatuximab concentrations.', 'timeFrame': 'Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days)'}, {'measure': 'Overall response rate (ORR)', 'description': 'Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by investigator.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Duration of response (DOR)', 'description': 'DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first, for Cohorts 1 to 3. For Cohorts 4-5, the time from date of first investigator determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by investigator or death, whichever occurred first.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Time to first response (TT1R)', 'description': 'TT1R defined as time from first investigational medicinal product (IMP) administration or randomization to first IRC determined response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first investigator determined response (PR or better) that is subsequently confirmed.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Time to best response (TTBR)', 'description': 'TTBR defined as time from first IMP administration or randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first occurrence of investigator determined best response (PR or better) that is subsequently confirmed.', 'timeFrame': '6 months after the Last Participant In (LPI) i.e., approximately 16 months'}, {'measure': 'Progression free survival (PFS)', 'description': 'PFS defined as time from the date of first IMP administration or randomization to the date of first documentation of PD as determined by IRC for Cohorts 1 to 3 and by Investigator for all cohorts, or the date of death from any cause, whichever comes first.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Overall survival (OS)', 'description': 'OS defined as time from the date of first IMP administration or randomization to death from any cause.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Incidence of participants with anti-drug antibodies (ADA) against isatuximab', 'timeFrame': 'From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days)'}, {'measure': 'Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously', 'description': 'PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication).', 'timeFrame': 'Baseline'}, {'measure': 'Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously', 'description': 'PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method. This questionnaire has been developed using industry standard for instrument development and has been debriefed and adapted based on qualitative interviews with oncology patients. The more general treatment expectations instrument (v1) was further adapted and debriefed with patients to assess manual and OBDS subcutaneous delivery (v2). The PESQ v2 contains a total of 9 items. There are 6 items that are administered for the duration of treatment, and 3 preference items administered only after patient experience of both manual and OBDS.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ)', 'description': 'Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi for cohorts 1,2, 3, and 5. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'Health Related Quality of Life (HRQL)', 'description': 'HRQL is assessed for cohorts 1, 2, and 3 using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM.', 'timeFrame': '18 months after LPI i.e., approximately 28 months'}, {'measure': 'European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)', 'description': ""Health status is assessed for cohorts 1, 2, and 3, using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents."", 'timeFrame': '18 months after LPI i.e., approximately 28 months'}]",20.0,18 Years,,ALL,False,INDUSTRY,0.0,118.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04259359,Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure,Insect Venom,['Insect Venom'],1,OBSERVATIONAL,[],,RECRUITING,Bee Venom Allergy,Medical University of Graz,2025-09-01T16:18:12.185391,True,,,,NOT_FOUND,Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure,,['Bee Venom Allergy'],[],,2019-05-02,2026-03,"[{'measure': 'The primary objective of the study is to evaluate whether predominant sensitization to Api m 10 is a risk factor for treatment failure.', 'description': 'A sensitization is considered predominant if the proportion of specific IgE to a single venom allergen is at least 65% of the specific IgE to the venom preparations.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}]","[{'measure': 'To evaluate if predominant sensitization to either Api m 1, Api m 2, Api m 3 or Api m 5 is a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}, {'measure': 'To evaluate if low immunoglobulin G4 (IgG4) levels to bee venom or to Api m 1, Api m 2, Api m 3, Api m 5, or Api m 10 after VIT is a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}, {'measure': 'To evaluate if systemic side effects are a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}, {'measure': 'To evaluate if antihypertensive medication is a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}]",5.0,18 Years,70 Years,ALL,False,OTHER,0.0,266.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT04842552,Effect of Hydralazine on Alzheimer's Disease,Hydralazine hydrochloride 25mg tablets,"['Hydralazine hydrochloride 25mg tablets', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,2025-09-01T16:18:09.625821,True,,,,CHEMBL542541,The Effect of Hydralazine on the Early Stage of Alzheimer's Disease: A Randomized Clinical Trial,,['Alzheimer Disease'],"['Alzheimer Disease', 'Hydralazine', 'Early stage', 'Olfactory sense']",,2021-08-02,2023-12-20,"[{'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Three months after recruitment.'}, {'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Six months after recruitment.'}, {'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Nine months after recruitment.'}, {'measure': ""The progression of of Alzheimer's disease"", 'description': ""The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory"", 'timeFrame': 'Twelve months after recruitment.'}]","[{'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Function of patients with Alzheimer's disease"", 'description': ""Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Cognition of patients with Alzheimer's disease"", 'description': ""Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Behavior of patients with Alzheimer's disease"", 'description': ""Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Three months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Six months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Nine months after recruitment'}, {'measure': ""Caregiver's spent time"", 'description': ""Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Three months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Six months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Nine months after recruitment'}, {'measure': 'Olfactory sense', 'description': ""the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'"", 'timeFrame': 'Twelve months after recruitment'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported three month after recruitment. Urgent matter can be reported any time to the provided hotline.'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported six month after recruitment. Urgent matter can be reported any time to the provided hotline.'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported nine month after recruitment. Urgent matter can be reported any time to the provided hotline.'}, {'measure': 'Drug side effects', 'description': 'The side effects of hydralazine-treated group compare to placebo-treated', 'timeFrame': 'Daily records in the provided notebook and reported twelve month after recruitment. Urgent matter can be reported any time to the provided hotline.'}]",28.0,49 Years,,ALL,False,OTHER,2.0,424.0,ESTIMATED,v2_robust,True,False,False,False,,Cl.NNc1nncc2ccccc12,CHEMBL542541,partial_match,True,196.64,0.92,4.0
NCT02190279,18F-DCFBC PET/CT in Prostate Cancer,18F DCFBC,"['Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)', '18F DCFBC', 'Na 18F PET/CT']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Prostatic Neoplasms,National Cancer Institute (NCI),2025-09-01T16:18:12.186364,True,,,,NOT_FOUND,A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer,,"['Prostatic Neoplasms', 'Prostate Cancer']","['Prostate Specific Membrane Antigen', 'Radiolabeled PET Agent', 'Imaging', 'NaF']",,2014-07-12,2018-01-11,"[{'measure': 'Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) Imaging', 'description': 'Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered positive for prostate cancer, and each was classified as local recurrence, lymph node metastases or distant metastatic sites.', 'timeFrame': '1 hour and 2 hour timepoints at baseline'}, {'measure': 'Number of Lesions Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC)', 'description': 'Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered a positive lesion for prostate cancer.The measure would be compared with other imaging or pathology.', 'timeFrame': '1 hour and 2 hour timepoints at baseline'}]","[{'measure': 'Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)', 'description': 'Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 42 months and 21 days'}, {'measure': 'Number of Detectable Lesions in Bone With Respect to 18F-DCFBC Imaging and/or Na18F Positron Emission Tomography (PET)/Computed Tomography (CT) in Patients With Known Metastatic Disease', 'description': '18F-DFBC and conventional imaging was used to identify positive lesions in bone.', 'timeFrame': '3 months'}, {'measure': 'Average Standardized Uptake Value (SUVmax) for Primary Prostate Cancer Patients Compared to Benign Prostatic Hyperplasia (BPH)', 'description': 'Primary prostate cancer was compared to BPH nodules and normal prostate tissue using a one-way analysis of variance (Anova). Negative uptake is defined as tumor uptake less than adjacent background soft tissue, or blood pool for lymph nodes.', 'timeFrame': '1 hour and 2 hour post injection (p.i.)'}, {'measure': 'Median Tumor Foci Size in Suspected Localized Prostate Cancer Patients Undergoing Prostatectomy', 'description': 'Tissue was obtained and stained with hematoxylin-eosin. The resulting whole mount specimens were correlated with MRI and PET/CT imaging. For each dominant/index tumor (largest tumor with highest Gleason score) was determined.', 'timeFrame': '1 month'}, {'measure': 'Detectability of Suspicious Prostate Cancer Lesions in Suspected Localized Prostate Cancer Patients With Prostate Gland', 'description': 'Visualizing positive lesions with DCFBC and mpMRI.', 'timeFrame': '3 months'}, {'measure': 'Detectability of Suspicious Tumors Based on Prostate Specific-Antigen (PSA) Levels in the Biochemical Recurrence Group', 'description': 'Visualizing positive lesions as a function of PSA value. Undetectable PSA is normal in this population.', 'timeFrame': '3 months'}]",8.0,18 Years,99 Years,MALE,False,NIH,0.0,116.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01953341,Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines,AMG 333,"['Placebo', 'AMG 333']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Migraine,Amgen,2025-09-01T16:18:15.898869,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines.",,['Migraine'],['Migraine'],,2013-10,2014-11,"[{'measure': 'Primary', 'description': 'Treatment-emergent adverse events, including changes in vital signs, 12-lead ECGs, clinical laboratory safety tests, and physical and neurological assessments', 'timeFrame': 'Up to 29 days'}, {'measure': 'Primary', 'description': 'Headache assessment as measured by the occurrence of moderate-to-severe headache within 36 hours of treatment, as well as number of moderate-to-severe headaches within 4 days of dosing', 'timeFrame': 'Up to 29 days'}]","[{'measure': 'Secondary Outcome Measures', 'description': 'Time to maximum concentration \\[Tmax\\])', 'timeFrame': 'Up to 29 Days'}, {'measure': 'Secondary', 'description': 'Change in systolic and diastolic blood pressure in response to Cold Pressor Test (CPT)', 'timeFrame': 'Up to 29 days'}, {'measure': 'Secondary Outcome Measures', 'description': 'Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration \\[AUClast\\]', 'timeFrame': 'Up to 29 Days'}, {'measure': 'Secondary Outcome Measures', 'description': 'Area under the concentration-time curve from time 0 extrapolated to infinity \\[AUCinf\\], maximum observed concentration \\[Cmax\\], and T1/2)', 'timeFrame': 'Up to 29 Days'}]",6.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,74.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00290771,Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM),Imatinib tablets,"['Glivec®', 'Hydroxyurea capsules', 'Imatinib tablets']",3,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Recurrent Glioblastoma Multiforme (GBM),Novartis,2025-09-01T16:18:22.202706,True,,,,NOT_FOUND,"A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)",,['Recurrent Glioblastoma Multiforme (GBM)'],"['imatinib mesylate', 'hydroxyurea', 'protein tyrosine kinases', 'glioma', 'glioblastoma multiforme', 'recurrent glioblastoma multiforme', 'GBM', 'MacDonald criteria']",Lack of efficacy,2006-02,2008-08,"[{'measure': 'Percentage of Patients With an Objective Overall Response (OOR)', 'description': 'Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).', 'timeFrame': 'Baseline to end of study (Month 24)'}]","[{'measure': 'Duration of Objective Overall Response (OOR)', 'description': 'Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.', 'timeFrame': 'Baseline to end of study (Month 24)'}, {'measure': 'Percentage of Patients Who Had Clinical Benefit', 'description': 'Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.', 'timeFrame': 'Baseline to end of study (Month 24)'}, {'measure': 'Percentage of Patients With Progression-free Survival at Months 6 and 12', 'description': 'Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.', 'timeFrame': 'Months 6 and 12'}, {'measure': 'Percentage of Patients Surviving at Months 6, 12, and 24', 'description': 'Patients not known to have died were censored at the time of last survival follow-up.', 'timeFrame': 'Months 6, 12, and 24'}, {'measure': 'Number of Patients With at Least 1 Adverse Event', 'description': 'An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.', 'timeFrame': 'Baseline to end of study (Month 24)'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,231.0,ACTUAL,v2_robust,True,False,True,True,Lack of efficacy,,,no_match,False,,,
NCT04154488,A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders,Mavorixafor,"['X4P-001', 'Mavorixafor']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Neutropenia,X4 Pharmaceuticals,2025-09-01T16:18:20.962173,True,,,,NOT_FOUND,"A Phase 1b/2, Open-Label, Multicenter Study of Mavorixafor in Patients With Congenital Neutropenia and Chronic Neutropenia Disorders",,['Neutropenia'],"['Chronic congenital neutropenia', 'Chronic idiopathic neutropenia', 'SCN', 'CIN', 'CXCR4', 'Mavorixafor', 'Neutropenia glycogen storage disease type 1b', 'GSD1b', 'G6PC3', 'SLC37A4', 'GATA2']",,2021-10-16,2024-08-27,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of Mavorixafor', 'timeFrame': 'Baseline through Day 1 and 7 days follow-up'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Multiple Doses of Mavorixafor', 'timeFrame': 'Baseline through Month 6 and 30 days follow-up'}, {'measure': 'Change From Baseline in Absolute Neutrophil Count (ANC) to 8 hours Post-dose On Day 1', 'timeFrame': 'Baseline, 8 hours Post-dose On Day 1'}, {'measure': 'Change From Baseline in ANC to Month 6', 'timeFrame': 'Baseline, Month 6'}]","[{'measure': 'Serum Concentration of Mavorixafor in Relation to ANC and Area Under the Curve (AUC) for ANC (AUCANC)', 'timeFrame': '0 (pre-dose), 60 minutes and 2, 3, 4, 6, and 8 hours post-dose on Day 1'}, {'measure': 'Serum Concentrations of Mavorixafor', 'timeFrame': '0 (pre-dose) up to Month 6'}, {'measure': 'Change from Baseline in Absolute Lymphocyte Count (ALC)', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change from Baseline in Total White Blood Cells (WBC)', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change from Baseline in Absolute Monocyte (AMC)', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'AUC of ANC (AUCANC)', 'timeFrame': 'Baseline up to Month 6'}, {'measure': 'AUC of ALC (AUCALC)', 'timeFrame': 'Baseline up to Month 6'}, {'measure': 'AUC of AMC (AUCAMC)', 'timeFrame': 'Baseline up to Month 6'}, {'measure': 'AUC of WBC (AUCWBC)', 'timeFrame': 'Baseline up to Month 6'}]",13.0,12 Years,,ALL,False,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01924767,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets",BI 10773 Placebo,"['BI 10773', 'BI 10773 Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Diabetes Mellitus, Type 2",Boehringer Ingelheim,2025-09-01T16:18:10.922989,True,,,,NOT_FOUND,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients",,"['Diabetes Mellitus, Type 2']",[],,2007-07,2007-11,"[{'measure': 'Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests', 'description': 'Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).', 'timeFrame': 'day 1 to day 21'}, {'measure': 'Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results', 'description': 'Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results', 'timeFrame': 'day 1 to day 21'}, {'measure': 'Micturition Frequency', 'description': 'Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.', 'timeFrame': 'Baseline and Day 9'}, {'measure': 'Assessment of Tolerability by Investigator', 'description': 'Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.', 'timeFrame': 'day 21'}]","[{'measure': 'Concentration of the Analyte in Plasma', 'description': 'Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)', 'description': 'AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Time to Maximum Concentration of the Analyte in Plasma', 'description': 'Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Terminal Rate Constant in Plasma', 'description': 'Terminal rate constant in plasma after first dose and at steady-state', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Half-life and Mean Residence Time of the Analyte in Plasma', 'description': 'Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Apparent Volume of Distribution During the Terminal Phase', 'description': 'Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Amount of Analyte Eliminated in Urine', 'description': 'Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)', 'timeFrame': '0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9'}, {'measure': 'Fraction of Analyte Excreted Unchanged in Urine', 'description': 'Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100.\n\nFraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.', 'timeFrame': '0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9'}, {'measure': 'Apparent and Renal Clearance of the Analyte in Plasma', 'description': 'Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state.\n\nApparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state.\n\nRenal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Peak Trough Fluctuation', 'description': 'Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Linearity Index', 'description': 'The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Accumulation Ratios', 'description': 'Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state.\n\nAccumulation ratio for the respective doses were calculated using below mentioned equations:\n\nRA,Cmax = Cmax,ss/Cmax\n\nRA,AUC= AUCtau,ss/AUCtau', 'timeFrame': '-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.'}, {'measure': 'Change From Baseline to Day 8 in Urinary Glucose Excretion', 'description': 'Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.', 'timeFrame': '-2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8'}, {'measure': 'Mean Daily Glucose', 'description': 'Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.', 'timeFrame': '0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8'}, {'measure': 'Fasting Plasma Glucose', 'description': 'Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.', 'timeFrame': '-0:30 (Pre dose samples)'}, {'measure': 'Serum Insulin', 'description': 'Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5.\n\nAUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.', 'timeFrame': '0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8'}, {'measure': 'Serum Insulin', 'description': 'Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12.\n\nEmax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) \\& Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)', 'timeFrame': '0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8'}]",21.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04429542,Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors,BCA101,"['Pembrolizumab', 'Ficerafusp alfa', 'BCA101']",3,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Head and Neck Squamous Cell Carcinoma,Bicara Therapeutics,2025-09-01T16:18:23.462314,True,,,,NOT_FOUND,"First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",,"['Head and Neck Squamous Cell Carcinoma', 'Squamous Cell Carcinoma of Anal Canal', 'Colorectal Cancer', 'Squamous Cell Carcinoma of the Lung', 'EGFR Amplification', 'Epithelial Ovarian Cancer', 'Pancreas Cancer', 'Cutaneous Squamous Cell Carcinoma', 'Head and Neck Neoplasms', 'Carcinoma, Squamous Cell', 'Squamous Cell Carcinoma of Head and Neck']","['TGFβ', 'EGFR', 'pembrolizumab', 'ficerafusp alfa']",,2020-06-01,2027-06-01,"[{'measure': 'Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs', 'description': 'Incidence and severity of AEs and SAEs', 'timeFrame': '24 months'}, {'measure': 'Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs', 'description': 'Incidence and severity of AEs and SAEs', 'timeFrame': '24 months'}, {'measure': 'Incidence of Dose Limiting Toxicities (DLTs)', 'description': 'Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.', 'timeFrame': '21 days'}]","[{'measure': 'Objective Response Rate', 'description': 'Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Clinical Benefit Rate', 'description': 'Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Progression free survival', 'description': 'Determine PFS in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Duration of Response', 'description': 'Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Overall Survival', 'description': 'Determine survival rates in each part of the study.', 'timeFrame': '24 months'}, {'measure': 'AUC of BCA101 and pembrolizumab', 'description': 'AUC', 'timeFrame': '24 months'}, {'measure': 'Cmax of BCA101 and pembrolizumab', 'description': 'Cmax', 'timeFrame': '24 months'}, {'measure': 'Tmax of BCA101 and pembrolizumab', 'description': 'Tmax', 'timeFrame': '24 months'}, {'measure': 'Concentration vs time profile of BCA101 and pembrolizumab', 'description': 'Ctrough', 'timeFrame': '24 months'}, {'measure': 'Half-life of BCA101 and pembrolizumab', 'description': 'Half-life', 'timeFrame': '24 months'}, {'measure': 'Immunogenicity of BCA101 and pembrolizumab', 'description': 'Incidence and titer of anti-drug-antibodies', 'timeFrame': '24 months'}]",14.0,18 Years,,ALL,False,INDUSTRY,1.0,292.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02031939,Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer,"Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)","['Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)']",1,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Advanced Rectal Cancer,Sun Yat-sen University,2025-09-01T16:18:15.906470,True,,,,NOT_FOUND,Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer,,['Advanced Rectal Cancer'],"['Rectal cancer', 'neoadjuvant chemoradiotherapy', 'optimization']",,2014-01,2025-12,"[{'measure': 'overall survival', 'timeFrame': '5 years'}]","[{'measure': 'disease free survival', 'timeFrame': '3 years'}, {'measure': 'Disease free survival', 'timeFrame': '5 years'}, {'measure': 'Respond rate', 'timeFrame': 'One week after surgery'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,556.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01532882,Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs,Diosmin,"['Diosmin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Venous Disease of Lower Limbs,Laboratoire Innotech International,2025-09-01T16:18:07.022256,True,,,,NOT_FOUND,"Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups",,['Chronic Venous Disease of Lower Limbs'],[],,2012-01,2013-04,"[{'measure': 'Change of Visual analog Scale score for assessment of the painful venous symptomatology', 'timeFrame': 'baseline and after 28 days'}]","[{'measure': '- Painful symptom intensity (daily VAS score) Area Under the Curve', 'timeFrame': '28 days'}, {'measure': '- Daily VAS score for Response rate', 'timeFrame': '28 days'}, {'measure': '- Daily VAS score for Time to response', 'timeFrame': '28 days'}, {'measure': '- Score of Quality of life questionnaire (SQOR-V)', 'timeFrame': 'Between baseline and 28 days'}, {'measure': ""- Patient's and physician's global satisfaction score"", 'timeFrame': 'At 28 days'}, {'measure': 'Adverse Events (numbers and frequency)', 'timeFrame': '28 days'}, {'measure': '- Unusual intakes of analgesic treatments (rate of patients)', 'timeFrame': '28 days'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,378.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02236754,Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass,18 F-FP-DTBZ,['18 F-FP-DTBZ'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Healthy Volunteers,Columbia University,2025-09-01T16:18:10.911778,True,,,,NOT_FOUND,Scan Re-Scan Pancreatic Beta Cell Imaging Using PET Imaging and 18 F-FP-DTBZ,,"['Healthy Volunteers', 'Diabetes Mellitus, Type 1']","['dihydrotetrabenazine', 'beta cell mass', 'diabetes mellitus']",,2013-07-02,2014-04-23,"[{'measure': 'Mean VMAT2 Functional Binding Capacity in the β Cells to 18 F-FP-DTBZ', 'description': 'The VMAT2 functional binding capacity in the body and tail of the pancreas is calculated as BPND (VMAT2 binding potential) × PET ROI (region-of-interest) Volume. BPND is unitless, and ROI unit is mL. Higher values of the VMAT functional binding capacity indicates greater β cell mass.', 'timeFrame': 'Up to 2 months from enrollment'}]",[],1.0,18 Years,70 Years,ALL,True,OTHER,1.0,23.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00143312,Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants,voriconazole,['voriconazole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Prophylaxis Of Invasive Fungal Infections,Pfizer,2025-09-01T16:18:13.424212,True,,,,CHEMBL638,"Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).",,['Prophylaxis Of Invasive Fungal Infections'],"['Invasive Fungal Infection, Allogenic Stem Cell Transplant, prophylaxis, leukemia, voriconazole']",,2005-02,2008-04,"[{'measure': 'Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit', 'description': 'Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 12-month follow up', 'timeFrame': '12 months'}]","[{'measure': 'Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 6-month Follow-up Visit', 'description': 'Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 6-month follow up', 'timeFrame': '6 months'}, {'measure': 'Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Voriconazole Prophylaxis Until End of Prophylaxis Visit', 'description': 'Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until the End of Prophylaxis visit', 'timeFrame': '150 days'}, {'measure': 'Time to Occurrence of Proven or Probable Invasive Fungal Infection (IFI)', 'description': 'Time to occurrence of proven or probable IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI since the exact day on which the IFI began will not be known.', 'timeFrame': '12 months'}, {'measure': 'Time to Occurrence of Proven or Probable New (New Pathogen) Invasive Fungal Infection (IFI)', 'description': 'Time to occurrence of proven or probable new (new pathogen) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI.', 'timeFrame': '12 months'}, {'measure': 'Time to Occurrence of Proven or Probable Recurrent Invasive Fungal Infection (IFI) (Same Pathogen as Previous Baseline IFI)', 'description': 'Time to occurrence of proven or probable recurrent (same pathogen as baseline) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI. The pathogen identified as the positive culture recorded nearest to, but not after, the proven or probable IFI, was assumed to be responsible for the IFI.', 'timeFrame': '12 months'}, {'measure': 'Survival Without Proven or Probable Invasive Fungal Infection (IFI)', 'description': 'Number of participants who survive (ie., are alive) without proven or probable IFI at each of the 6 and 12 month follow-up visits', 'timeFrame': '6 months, 12 months'}]",7.0,18 Years,,ALL,False,INDUSTRY,1.0,45.0,ACTUAL,v2_robust,True,True,False,False,,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL638,exact_match,True,349.32,2.18,4.0
NCT00296049,Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy,daptomycin,"['vancomycin', 'daptomycin']",2,INTERVENTIONAL,['NA'],,WITHDRAWN,Infection,Wake Forest University Health Sciences,2025-09-01T16:18:22.212485,True,,,,NOT_FOUND,"An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients",,"['Infection', 'Neutropenia', 'Unspecified Adult Solid Tumor, Protocol Specific', 'Unspecified Childhood Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific', 'infection', 'neutropenia', 'unspecified childhood solid tumor, protocol specific']",,2005-07,2006-03,"[{'measure': 'determine the efficacy of daptomycin to treat gram positive infections', 'timeFrame': 'day 7'}, {'measure': 'determine the safety of daptomycin in neutropenic patients', 'timeFrame': 'day 7'}]",[],2.0,,120 Years,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,True,,,,no_match,False,,,
NCT02760797,A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,Emactuzumab,"['RO7009789', 'Emactuzumab', 'RO5509554']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Neoplasms,Hoffmann-La Roche,2025-09-01T16:18:07.020162,True,,,,NOT_FOUND,"An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors",,['Neoplasms'],[],,2016-05-09,2018-04-06,"[{'measure': 'Percentage of Participants with Dose-Limiting Toxicities (DLTs)', 'timeFrame': 'Up to 6 weeks from Day (D) 1 of Cycle (C) 1 (cycle = 3 weeks)'}]","[{'measure': 'Percentage of Participants with Anti-Drug Antibodies (ADAs) to Emactuzumab', 'timeFrame': 'Predose (PrD) (0 hours [H]) on D1 each cycle (cycle = 3 weeks) until progressive disease (PD) (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants with ADAs to RO7009789', 'timeFrame': 'PrD (0 H) on D1 each cycle (cycle = 3 weeks) until PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Serum Maximum Concentration (Cmax) of Emactuzumab', 'description': 'PrD (0 H), end of infusion (EOI) (infusion = 90 minutes \\[min\\]), postdose \\[5 H\\] D1 of C1/C4 (cycle = 3 weeks); on D2, 5, 8, 12, 15, 19 of C1/C4; on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Serum Trough Concentration (Ctrough) of Emactuzumab', 'timeFrame': 'PrD (0 H) on D1 of C2 onwards (cycle = 3 weeks) until PD (up to 2 years)'}, {'measure': 'Area Under the Concentration-Time Curve (AUC) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Total Clearance (CL) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Volume of Distribution at Steady State (Vss) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Accumulation Ratio of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Terminal Elimination Half-Life (T1/2) of Emactuzumab', 'description': 'PrD (0 H), EOI (infusion = 90 min), postdose \\[5 H\\] D1 of C1/C4; on D2, 5, 8, 12, 15, 19 of C1/C4 (cycle = 3 weeks); on D5, 8, 12, 17 of C2; on D2, 8, 15 of C3; PrD (0 H), EOI on D1 of C2, 3, 5 onwards until/at PD (up to 2 years); at 28, 44, 120 days after last dose (up to 2 years overall)', 'timeFrame': 'PrD (0 H) D1 of C1 up to 120 days after last dose (up to 2 years overall); see Outcome Measure Description for details'}, {'measure': 'Concentration at Time of Tumor Progression (Cprog) of Emactuzumab According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1', 'timeFrame': 'At time of PD (up to 2 years)'}, {'measure': 'Concentration of Emactuzumab at Time of Tumor Response (Complete or Partial Response) According to RECIST v1.1', 'timeFrame': 'At time of tumor response (up to 2 years)'}, {'measure': 'Concentration of Emactuzumab at Time of Infusion-Related Reaction (IRR) or Hypersensitivity Reaction', 'timeFrame': 'At time of IRR or hypersensitivity reaction (up to 2 years)'}, {'measure': 'Cmax of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Ctrough of RO7009789', 'timeFrame': 'PrD (0 H) on D1 of C2 onwards (cycle = 3 weeks) until PD (up to 2 years)'}, {'measure': 'AUC of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'CL of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Vss of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Accumulation Ratio of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'T1/2 of RO7009789', 'timeFrame': 'PrD (0 H), 15 min during infusion, EOI (infusion = 30 min), postdose (2, 4, 6 H) on D1 of C1 (cycle = 3 weeks); on D2, 3, 8 of C1; PrD (0 H), EOI on D1 of C2 onwards until/at PD (up to 2 years); at 120 days after last dose (up to 2 years overall)'}, {'measure': 'Total Tumor-Associated Macrophages (TAMs) in Paired-Tumor Biopsies', 'timeFrame': 'Baseline; on D1 of C2 (cycle = 3 weeks); and optionally at time of PD (up to 2 years)'}, {'measure': 'Total Dermal Macrophages in Paired-Skin Biopsies', 'timeFrame': 'Baseline; on D1 of C2 (cycle = 3 weeks); and optionally at time of PD (up to 2 years)'}, {'measure': 'Levels of Functional Tumor-Infiltrating Lymphocytes', 'timeFrame': 'Baseline; on D1 of C2 (cycle = 3 weeks); and optionally at time of PD (up to 2 years)'}, {'measure': 'Circulating Colony-Stimulating Factor (CSF)-1 Serum Levels', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1 (cycle = 3 weeks); on D2, 5, 15 of C3; PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Total Monocyte Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Total Dendritic Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Circulating Cluster of Differentiation (CD) 4 T Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Circulating CD8 T Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Circulating B Cell Count in Peripheral Blood', 'timeFrame': 'Baseline; on D2, 5, 8, 15 of C1/C3 (cycle = 3 weeks); PrD (+/- 1 day) on D1 of each cycle until/at PD (up to 2 years); at 44, 120 days after last dose (up to 2 years overall)'}, {'measure': 'Metabolic Response of Target Lesions Assessed as the Change in Maximum Standardized Uptake Value (SUVmax) on [18F]-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)', 'timeFrame': 'Baseline; on D15 of C1; PrD (+/- 4 days) on D1 of C3 (cycle = 3 weeks)'}, {'measure': 'Percentage of Participants by Best Overall Response as Assessed by RECIST v1.1', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Overall Response as Assessed by RECIST v1.1', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Progressive-Free Survival (PFS) as Assessed by RECIST v1.1', 'timeFrame': 'From Baseline until death or PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Duration of Response (DOR) as Assessed by RECIST v1.1', 'timeFrame': 'From OR until PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Clinical Benefit as Assessed by RECIST v1.1', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants by Best Overall Response as Assessed by Modified RECIST', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Overall Response as Assessed by Modified RECIST', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}, {'measure': 'Progressive-Free Survival (PFS) as Assessed by Modified RECIST', 'timeFrame': 'From Baseline until death or PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Duration of Response (DOR) as Assessed by Modified RECIST', 'timeFrame': 'From OR until PD; assessed every 6 weeks (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Clinical Benefit as Assessed by Modified RECIST', 'timeFrame': 'Baseline; every 6 weeks until PD (up to 2 years); at 28 days after last dose (up to 2 years overall)'}]",40.0,18 Years,,ALL,False,INDUSTRY,0.0,38.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02586623,Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension,Droxidopa capsules,"['Northera', 'Placebo capsules', 'Placebo', 'Droxidopa capsules']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Symptomatic Neurogenic Orthostatic Hypotension,H. Lundbeck A/S,2025-09-01T16:18:20.958738,True,,,,NOT_FOUND,RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy,,['Symptomatic Neurogenic Orthostatic Hypotension'],"[""Parkinson's Disease"", 'Multiple System Atrophy', 'Pure Autonomic Failure', 'Primary Autonomic Failure', 'Dopamine Beta Hydroxylase Deficiency']",,2016-02-11,2022-09-09,"[{'measure': 'Time To Intervention', 'description': 'Kaplan-Meier estimates are presented for time to treatment intervention. The estimates represent the quartiles of the survival time, where 50% corresponds to the median time to need for treatment intervention.\n\nNeed for intervention is defined as meeting ANY of the following criteria during the Double-Blind Treatment Period:\n\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) AND lack of efficacy as judged by the investigator; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at 2 consecutive visits; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at the visit before early discontinuation; OR\n* participant stops IMP or withdraws from study for patient-reported lack of efficacy.', 'timeFrame': 'Randomization (Day 0) up to Week 12'}]","[{'measure': 'Number of Participants Who Needed Intervention During the 12-week Double-Blind Treatment Period', 'description': 'Need for intervention is defined as meeting ANY of the following criteria during the Double-Blind Treatment Period:\n\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) AND lack of efficacy as judged by the investigator; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at 2 consecutive visits; OR\n* OHSA Item #1 ≥2 unit worsening from Randomization (Visit 6) at the visit before early discontinuation; OR\n* participant stops IMP or withdraws from study for patient-reported lack of efficacy.', 'timeFrame': 'Randomization (Day 0) up to Week 12'}, {'measure': 'Time To All-cause Discontinuation', 'description': 'Kaplan-Meier estimates are presented for time to all-cause discontinuation. The estimates represent the quartiles of the survival time, where 50% corresponds to the median time to discontinuation. Time to all-cause discontinuation was defined as the time from randomization to withdrawal or last contact date.', 'timeFrame': 'Randomization (Day 0) up to Week 12'}, {'measure': 'Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Symptom Assessment (OHSA) Item #1 Score', 'description': 'The OHSA scale was designed to rate symptoms occurring specifically as a result of low blood pressure (BP), on average, over the past week using an 11-point scale (0 to 10), with more severe symptoms scoring higher. A score of zero indicates that the symptom was not experienced, and 10 is the worst possible. The scale was used to assess six symptoms: 1) Dizziness, lightheadedness, feeling faint, or feeling like you might black out, 2) problems with vision, 3) weakness, 4) fatigue, 5) trouble concentrating, and 6) head/neck discomfort. Scores for each activity and a composite score for all six activities were tabulated. A mean negative change from baseline means that symptoms have improved. A mean positive change from baseline means that symptoms have gotten worse.', 'timeFrame': 'Randomization (Day 0); Weeks 2 to 12'}, {'measure': 'Change From Randomization To All Post-randomization Visits in Orthostatic Hypotension Questionnaire (OHQ) Composite Score', 'description': 'The OHQ composite score was a mean of the OHSA composite and the Orthostatic Hypotension Daily Activity Scale (OHDAS) composite scores. The OHDAS was designed as a measure of quality of life. It uses an 11-point scale to assess whether orthostatic hypotension (OH) ""interfered"" with four types of activities: 1) standing for a short time, 2) standing for a long time, 3) walking for a short time, and 4) walking for a long time. A zero rating means that over the preceding week the activity was performed with no interference and a 10 rating means that orthostatic hypotension completely interfered with the activity. Scores for each activity and a composite score for all four activities were tabulated. A mean negative change from baseline means that symptoms have improved. A mean positive change from baseline means that symptoms have gotten worse.', 'timeFrame': 'Randomization (Day 0); Weeks 2 to 12'}, {'measure': 'Clinician-rated Clinical Global Impressions - Severity (CGI-S)', 'description': ""The CGI-S was developed to provide global measures of the severity of a participant's clinical condition during clinical studies. The CGI-S was utilized by both the clinician and the participant to provide an impression of the participant's current state of OH. The severity of the participant's current illness was rated by the clinician on a 7-point scale ranging from 1 (normal, no OH) to 7 (among those patients most extremely ill with OH)."", 'timeFrame': 'Weeks 2 to 12'}, {'measure': 'Participant-rated CGI-S', 'description': ""The CGI-S was developed to provide global measures of the severity of a participant's clinical condition during clinical studies. The CGI-S was utilized by both the clinician and the participant to provide an impression of the participant's current state of OH. The severity of the participant's current illness was rated by the participant on a 7-point scale ranging from 1 (normal, no OH) to 7 (most extremely ill with OH)."", 'timeFrame': 'Weeks 2 to 12'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,453.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01016782,Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea,0444,['0444'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Inflammatory Rosacea,Fougera Pharmaceuticals Inc.,2025-09-01T16:18:18.419281,True,,,,CHEMBL10444,"Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0444 Gel",,['Inflammatory Rosacea'],"['Inflammatory Rosacea', 'Rosacea']",,2008-01,2009-07,"[{'measure': 'Reduction in the number of papules and pustules from Baseline to End of Treatment', 'timeFrame': '70 Days'}]","[{'measure': ""Reduction in the Investigator's Global Evaluation, Clear or Almost Clear"", 'timeFrame': '70 Days'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,867.0,ACTUAL,v2_robust,True,True,False,False,,O=C1O[C@H](c2ccc(F)cc2)[C@@](Cn2cncn2)(c2ccc(Cl)cc2Cl)O1,CHEMBL10444,partial_match,True,408.22,4.53,
NCT06363877,Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections,Povidone-Iodine,"['Povidone-Iodine', 'Normal Saline']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Surgical Site Infection,Loma Linda University,2025-09-01T16:18:15.907365,True,,,,NOT_FOUND,Wound Irrigation and Peritoneal Lavage With Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections,,['Surgical Site Infection'],"['Intraoperative Wound Irrigation', 'Intraoperative Peritoneal Lavage', 'Povidone-Iodine', 'Normal Saline', 'Exploratory Laparotomy', 'Clean Contaminated Wounds', 'Contaminated Wounds']",,2024-06-03,2025-11,"[{'measure': 'Surgical Site Infection', 'description': 'Subjects in each study arm will be assessed for presence of surgical site infection using a composite measurement based on the CDC/NHSN Guidelines for Surgical Site Infection (SSI) Event (January 2024).\n\nThe presence of one or more of the following will constitute a surgical site infection:\n\n1. purulent drainage from the superficial incision, deep incision or the drain in an organ/space\n2. organism(s) identified from an aseptically-obtained specimen from the superficial incision, subcutaneous tissue, deep soft tissues, or fluid or tissue in the organ space by a culture or nonculture based microbiologic testing method\n3. an incision that is deliberately opened by a provider AND patient has at least one of the following signs or symptoms: localized pain or tenderness; localized swelling; erythema; or heat\n4. an abscess or other evidence of infection involving the deep incision or organ/space detected on gross anatomical exam, histopathologic exam, or imaging test', 'timeFrame': 'Between date of initial operation and post-operative follow up visit (up to 30 days post-operatively)'}]","[{'measure': 'Readmission', 'description': 'Subjects in each study arm will be assessed for the number of times the subject has been readmitted into the hospital for any cause. This will be tracked by chart review and follow-up until 30 days after the initial operation.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}, {'measure': 'Return to the Operating Room', 'description': 'Subjects in each study arm will be assessed for the number of times the subject returns to the operating room for any cause. This will be tracked throughout the hospital stay and post-discharge by chart review and follow-up until 30 days after the initial operation.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}, {'measure': 'Ileus', 'description': 'Subjects in each study arm will be assessed for the development of an ileus. This will be diagnosed by lack of bowel function, physical examination (i.e. abdominal distention, tympany) and KUB x-ray to assess for distended loops of bowel with no transition point identified.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}, {'measure': 'Small Bowel Obstruction', 'description': 'Subjects in each study arm will be assessed for the development of a small bowel obstruction. This will be diagnosed by lack of bowel function, physical examination (i.e. abdominal distention, tympany) and KUB x-ray to assess for distended loops of bowel with a transition point identified. Additional testing including an upper gastrointestinal series (e.g. small bowel follow through) can be used in a case-by-case if medically necessary for diagnosis.', 'timeFrame': 'Between date of surgery and 30 days post-operatively'}]",5.0,18 Years,80 Years,ALL,False,OTHER,0.0,1100.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03165136,Hydroxychloroquine for Prevention of Recurrent Miscarriage.,Hydroxychloroquine,"['Placebo', 'Hydroxychloroquine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Recurrent Miscarriage,"University Hospital, Brest",2025-09-01T16:18:19.665163,True,,,,CHEMBL1690,"Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo",,"['Recurrent Miscarriage', 'First Trimester Abortion']","['Unexplained Recurrent Miscarriage', 'First trimester abortion', 'Hydroxychloroquine', 'Antiphospholipid antibody']",,2017-12-04,2026-02-01,"[{'measure': 'A live and viable birth', 'description': 'In case of preterm and/or low birth weight, we define the viability by the decision to transfer the newborn to a neonatal intensive care unit', 'timeFrame': 'At delivery'}]","[{'measure': 'a live and viable birth (for the subgroup analyses)', 'timeFrame': 'At delivery'}, {'measure': 'occurrence of pregnancy complications (Recurrent Miscarriage-any other premature termination of pregnancy-placental vascular disease)', 'timeFrame': 'Since the beginning of pregnancy up to delivery'}, {'measure': 'gestation time (in weeks of amenorrhea) at delivery,', 'timeFrame': 'At delivery up'}, {'measure': 'birth weight (in grams) at delivery', 'timeFrame': 'At delivery'}, {'measure': 'survival of the newborn', 'timeFrame': 'At 28 days of the newborn'}, {'measure': 'psychomotor development of the child (normal/abnormal)', 'timeFrame': 'at 6 months of age'}, {'measure': 'psychomotor development of the child (normal/abnormal)', 'timeFrame': 'at 12 months of age'}, {'measure': 'height (in centimeters)', 'timeFrame': 'at 6 months of age'}, {'measure': 'height (in centimeters)', 'timeFrame': 'at 12 months of age'}, {'measure': 'weight (in grams)', 'timeFrame': 'at 6 months of age'}, {'measure': 'weight (in grams)', 'timeFrame': 'at 12 months of age'}, {'measure': 'Cranial perimeter (in centimeters)', 'timeFrame': 'at 6 months of age'}, {'measure': 'Cranial perimeter (in centimeters)', 'timeFrame': 'at 12 months of age'}]",14.0,18 Years,38 Years,FEMALE,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,True,False,False,False,,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,CHEMBL1690,partial_match,True,433.96,3.78,4.0
NCT02694744,Patiromer With or Without Food for the Treatment of Hyperkalemia,patiromer,"['RLY5016 for Oral Suspension', 'patiromer', 'Veltassa']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Hyperkalemia,"Relypsa, Inc.",2025-09-01T16:18:10.926079,True,,,,NOT_FOUND,"The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)",,['Hyperkalemia'],"['Treatment of Hyperkalemia', 'Hyperkalemia', 'Potassium', 'Chronic Kidney Disease']",,2016-02,2016-08,"[{'measure': 'Percentage of Subjects With Serum Potassium in the Target Range (3.8 - 5.0 mEq/L) at Either Week 3 or Week 4', 'timeFrame': '21 to 28 Days'}]","[{'measure': 'Mean Change in Serum Potassium From Baseline to Week 4', 'description': 'An ANCOVA model was used to estimate the mean serum potassium change from Baseline to Week 4 with baseline serum potassium as a covariate and treatment group, race (white vs all others), and history of Type 1 or 2 diabetes mellitus (yes or no) as factors in the model.', 'timeFrame': 'Baseline to Day 28'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,114.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04971200,Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo,Tildrakizumab,['Tildrakizumab'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Skin and Connective Tissue Diseases,"Premier Specialists, Australia",2025-09-01T16:18:24.754265,True,,,,NOT_FOUND,Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo,,"['Skin and Connective Tissue Diseases', 'Skin Diseases', 'Pigmentation Disorder', 'Hypopigmentation', 'Biologic', 'Vitiligo']","['Tildrakizumab', 'non-segmental vitiligo', 'interleukin-23', 'IL-23', 'biological treatment', 'pilot study', 'Anti-Inflammatory Agents', 'Anti-Inflammatory Agents, Non-Steroidal', 'Vitiligo']",,2021-09-16,2024-11-10,"[{'measure': 'Percentage repigmentation: Vitiligo Area Scoring Index (VASI)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 24'}, {'measure': 'Percentage repigmentation: Vitiligo Extent Score (VES)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 24'}, {'measure': 'Percentage repigmentation: Photographs', 'description': 'Percentage repigmentation is assessed through comparison of photographs of vitiligo lesions from baseline.', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage repigmentation: Vitiligo Area Scoring Index (VASI)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 12'}, {'measure': 'Percentage repigmentation: Vitiligo Extent Score (VES)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 12'}, {'measure': 'Percentage repigmentation: Photographs', 'description': 'Percentage repigmentation is assessed through comparison of photographs of vitiligo lesions from baseline.', 'timeFrame': 'Week 12'}, {'measure': 'Time to repigmentation', 'timeFrame': 'through study treatment completion at 24-weeks'}, {'measure': 'Change in Quality of Life score from baseline: Dermatology Life Quality Index (DLQI)', 'description': ""Used to assess treatment response on subject's quality of life. Range 0-30. Higher score=larger effect on patient's life/worse"", 'timeFrame': 'Baseline through week 12 and through study treatment completion at 24-weeks'}, {'measure': 'Change in Quality of Life score from baseline: Patient Global Impression of Change (PGIC)', 'description': '1-tem questionnaire designed to assess a subject\'s impression of disease improvement. 7 point Likert scale ranging from ""Very much better"" to ""Very much worse"" with ""no change"" in the middle. Range\\[1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderately better, 6-better/a definite improvement, 7-a great deal better\\]. Higher score=better impression of change/better', 'timeFrame': 'Baseline through week 12 and through study treatment completion at 24-weeks'}, {'measure': 'Change in Quality of Life score from baseline: Self-Assessment Vitiligo Extent Score (SA-VES)', 'description': 'Validated patient reported outcome measurement to provide information about disease extent and repigmentation. Range 0-100. Higher score=greater depigmentation/worse.', 'timeFrame': 'Baseline through week 12 and through study treatment completion at 24-weeks'}, {'measure': 'Adverse events', 'description': 'incidence and nature of any adverse events', 'timeFrame': 'through study treatment completion at 24-weeks'}]",11.0,18 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04844814,Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation,Anakinra 100Mg/0.67Ml Inj Syringe,"['Prednisone', 'Anakinra 100Mg/0.67Ml Inj Syringe', 'Placebo of Prednisone', 'Placebo of Anakinra']",4,INTERVENTIONAL,['PHASE2'],PHASE2,SUSPENDED,Gout,Assistance Publique - Hôpitaux de Paris,2025-09-01T16:18:22.208945,True,,,,NOT_FOUND,"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation: a Randomized, Double Blinded, Multicenter Study",,"['Gout', 'Chronic Kidney Disease', 'Renal Transplantation']","['Gout', 'Flare', 'Urate crystals', 'Chronic kidney disease', 'Anakinra', 'IL-1b', 'Corticosteroid', 'Renal transplantation']","Peremption of treatments, difficulty of patients recrutment (28 patients in 3 years) and lack of funding to pursue the study.",2022-06-02,2026-03-12,"[{'measure': 'Pain difference between Day 3 and treatment initiation', 'description': 'Pain difference between day 3 and treatment initiation assessed by visual analogical scale (VAS) from 0 to 10 VAS = 0, no pain VAS =10, maximal pain', 'timeFrame': 'Day 3'}]","[{'measure': 'Percentage of responders (improvement ≥ 50%) at day 5', 'description': 'Percentage of responders (improvement ≥ 50%) at day 5', 'timeFrame': 'Day 5'}, {'measure': 'Percentage of flare resolution (improvement ≥ 80%) at day 5', 'description': 'Percentage of flare resolution (improvement ≥ 80%) at day 5', 'timeFrame': 'Day 5'}, {'measure': 'Time to treatment response', 'description': 'Time to treatment response', 'timeFrame': 'Day 3 or Day 5'}, {'measure': 'Time to flare resolution', 'description': 'Time to flare resolution', 'timeFrame': 'Day 3 or Day 5'}, {'measure': 'Treatment duration', 'description': 'Treatment duration', 'timeFrame': 'Day3 or Day 5'}, {'measure': 'Duration of hospitalization', 'description': 'Duration of hospitalization', 'timeFrame': 'Day 3 or Day 5'}, {'measure': 'Healthcare consumption at month 1 : number of consultations and hospitalizations related to gout flare', 'description': 'Healthcare consumption at month 1 assessed by number of consultations and hospitalizations related to gout flare', 'timeFrame': 'Month 1'}, {'measure': 'Healthcare consumption at month 1: total hospital stay', 'description': 'Healthcare consumption at month 1 assessed by total hospital stay', 'timeFrame': 'Month 1'}, {'measure': 'Healthcare consumption at month 1', 'description': 'Healthcare consumption at month 1 assessed by number and cumulative duration of sick leave related to gout', 'timeFrame': 'Month 1'}, {'measure': 'Side effects', 'description': 'Side effects', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1 : DT2 decompensation', 'description': 'Comorbidity decompensations at month 1 assessed by DT2 decompensation measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood pressure', 'description': 'Comorbidity decompensations at month 1 assessed by Blood pressure measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Hypertension', 'description': 'Comorbidity decompensations at month 1 assessed by hypertension measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Weight', 'description': 'Comorbidity decompensations at month 1 assessed by Weight measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: number of Cardiovascular events : coronary disease, heart attack, stroke', 'description': 'Comorbidity decompensations at month 1 assessed by number of Cardiovascular events : coronary disease, heart attack, stroke', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of serum creatinine level', 'description': 'Comorbidity decompensations at month 1 assessed by serum creatinine level measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of epidermal Growth Factor Receptor (eGFR)', 'description': 'Comorbidity decompensations at month 1 assessed by eGFR measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of C reactive protein (CRP)', 'description': 'Comorbidity decompensations at month 1 assessed by CRP measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of HbA1C', 'description': 'Comorbidity decompensations at month 1 assessed by HbA1C measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of total cholesterol', 'description': 'Comorbidity decompensations at month 1 assessed by total cholesterol measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of LDL cholesterol', 'description': 'Comorbidity decompensations at month 1 assessed by HDL cholesterol measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of HDL cholesterol', 'description': 'Comorbidity decompensations at month 1 assessed by HDL cholesterol measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of triglyceride', 'description': 'Comorbidity decompensations at month 1 assessed by triglyceride measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of glycaemia', 'description': 'Comorbidity decompensations at month 1 assessed by glycaemia measure', 'timeFrame': 'Month 1'}, {'measure': 'site injection reaction during day 0 to day 5: pain', 'description': 'site injection reaction during day 0 to day 5 assessed by pain (0-10 scale VAS) measure', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: inflammatory reaction', 'description': 'site injection reaction during day 0 to day 5 assessed by CRP level measure', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: swelling (yes/no)', 'description': 'site injection reaction during day 0 to day 5 assessed by swelling (yes/no)', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: itching (yes/no)', 'description': 'site injection reaction during day 0 to day 5 assessed by itching (yes/no)', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: redness (yes/no)', 'description': 'site injection reaction during day 0 to day 5 assessed by redness (yes/no)', 'timeFrame': 'Dat 3 or day 5'}]",30.0,18 Years,,ALL,False,OTHER,0.0,204.0,ESTIMATED,v2_robust,True,False,True,False,"Peremption of treatments, difficulty of patients recrutment (28 patients in 3 years) and lack of funding to pursue the study.",,,no_match,False,,,
NCT03748095,Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care,pipéracilline/tazobactam,['pipéracilline/tazobactam'],1,OBSERVATIONAL,[],,UNKNOWN,Resuscitation Patients With Sepsis,"University Hospital, Rouen",2025-09-01T16:18:18.434581,True,,,,CHEMBL404,Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care,,['Resuscitation Patients With Sepsis'],[],,2019-03-12,2024-06-15,"[{'measure': 'The objective is to develop a Bayesian estimator of the area under the blood concentration curves of the piperacillin / tazobactam combination in resuscitation patients with sepsis.', 'description': 'The primary endpoint of this study is the ability of the pharmacokinetic model developed to predict the AUC of the piperacillin / tazobactam combination at 24 hours after initiation of antibiotic therapy.', 'timeFrame': '24hours'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,90.0,ESTIMATED,v2_robust,False,False,False,False,,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,CHEMBL404,partial_match,True,300.3,-1.52,4.0
NCT01287754,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations,erlotinib [Tarceva],['erlotinib [Tarceva]'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Non-Small Cell Lung Cancer,Hoffmann-La Roche,2025-09-01T16:18:24.740782,True,,,,NOT_FOUND,A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor,,['Non-Small Cell Lung Cancer'],[],,2011-10,2013-11,"[{'measure': 'Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation', 'description': 'PFS was defined as the time from the first dose of erlotinib to the first documentation of disease progression or death, whichever occurred first. Tumor progression was determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), which defines progression as a 20 percent (%) or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeters (mm), or the appearance of one or more new lesions. PFS was calculated in months as \\[first event date minus first dose date plus 1\\] divided by 30.44.', 'timeFrame': 'Per standard of care (every 3 months) until discontinuation for up to approximately 2 years'}]","[{'measure': 'Number of Erlotinib-Treated Participants With the EGFR Mutation With an Objective Response Per RECIST v1.1', 'description': 'Objective tumor response was assessed by the investigator using RECIST v1.1 and recorded as complete response (CR), partial response (PR), or unmeasurable. RECIST v1.1 defines CR as disappearance of all target lesions, with short-axis reduction to less than (\\<) 10 mm for any pathological lymph nodes, and PR as a 30% or greater reduction from baseline in the sum of diameters of target lesions.', 'timeFrame': 'Per standard of care (every 3 months) until discontinuation for up to approximately 2 years'}, {'measure': 'Overall Survival (OS) Among Erlotinib-Treated and Untreated Participants', 'description': 'OS was defined as the time from recorded diagnosis to death from any cause or last patient last visit. OS was calculated in months as \\[death date or last-known alive date minus diagnosis date plus 1\\] divided by 30.44.', 'timeFrame': 'Per standard of care (every 3 months) until discontinuation for up to approximately 2 years'}, {'measure': 'Percentage of Participants Alive at 6 and 12 Months', 'description': 'Death from any cause was documented at 6 and 12 months from recorded diagnosis. The percentage of participants alive at each timepoint was calculated as \\[number of participants alive divided by number enrolled\\] multiplied by 100.', 'timeFrame': 'At 6 and 12 months'}, {'measure': 'Percentage of Participants With EGFR Mutation at Screening', 'description': 'Participants were tested at Screening for the presence of activating mutations in the tyrosine kinase domain of EGFR. The percentage of participants with mutation was calculated as \\[number of mutation-positive participants divided by number tested\\] multiplied by 100.', 'timeFrame': 'Screening'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,24.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06506032,Vancomycin and Negative Pressure Therapy for Post-sternotomy Deep Sternal Wound Infection,Intravenous Vancomycin administration,['Intravenous Vancomycin administration'],1,OBSERVATIONAL,[],,COMPLETED,Post-Sternotomy Deep Sternal Wound Infection,University Hospital Ostrava,2025-09-01T16:18:17.175938,True,,,,CHEMBL262777,Clinical Effect and Wound Penetration of Vancomycin in Open-heart Surgery Patients Receiving Negative Pressure Wound Therapy for Deep Sternal Wound Infection,,['Post-Sternotomy Deep Sternal Wound Infection'],"['Exudate', 'Deep Sternal Wound Infection', 'Negative Pressure Wound Therapy', 'Open-Heart Surgery', 'Vancomycin', 'Wound Penetration']",,2021-07-30,2023-12-31,"[{'measure': 'Vancomycin penetration into exudate', 'description': 'To determine the vancomycin penetration into the wound during NPWT, the investigators compared the vancomycin total (bound + unbound) average exudate concentration to the vancomycin total (bound + unbound) average serum concentration on the first study day. The same calculation was used to determine the penetration ratio for free (unbound) vancomycin concentrations on the first study day.\n\nFor samples from three consecutive days, the investigators compared the vancomycin total (bound + unbound) through exudate concentrations with the vancomycin total (bound + unbound) through serum concentrations. The same calculation was used to determine the penetration ratio for free (unbound) vancomycin concentrations on three consecutive days.', 'timeFrame': 'repeated measurements for the total of 72 hours'}]","[{'measure': 'Identification of pre-, intra-, and postoperative risk factors for deep sternal wound infection (DSWI) development', 'description': 'The investigators will identify independent risk factors for DSWI by comparing patients with and without DSWI after cardiac surgery.', 'timeFrame': '3 days'}, {'measure': 'Recurrence of DSWI', 'description': 'The investigators will assess the recurrence of DSWI in the study subjects.', 'timeFrame': '1- year follow-up'}, {'measure': 'Determination of mortality', 'description': 'The investigators will assess the in-hospital, 90-day, and all-cause mortality in the study subjects.', 'timeFrame': '1- year follow-up'}]",4.0,18 Years,,ALL,,OTHER,4.0,10.0,ACTUAL,v2_robust,False,True,False,False,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,CHEMBL262777,partial_match,True,1449.27,,4.0
NCT01288092,BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer,BEZ235,['BEZ235'],1,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Metastatic Breast Cancer,Novartis Pharmaceuticals,2025-09-01T16:18:17.171769,True,,,,NOT_FOUND,"A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer, With or Without PI3K Activated Pathway",,['Metastatic Breast Cancer'],"['Metastatic breast cancer', 'HER2 negative', 'HR positive', 'PI3K pathway', 'no more than 2 prior lines of chemotherapy', 'Metastatic Breast Cancer(MBC)']",,2012-03,,"[{'measure': 'Progression-free survival rate after 16 weeks of treatment', 'timeFrame': '16 weeks after the first BEZ235 administration'}]","[{'measure': 'determine the efficacy of BEZ235 (objective response rate)', 'timeFrame': 'about 6 months'}, {'measure': 'evaluate the clinical benefit rate of BEZ235', 'timeFrame': 'about 6 months'}, {'measure': 'evaluate the time to response', 'timeFrame': 'about 6 months'}, {'measure': 'evaluate the Progression Free Survival Rate at 16-week & 24-week using the Kaplan-Meier method', 'timeFrame': '16-week & 24-week after the first BEZ235 administration'}, {'measure': 'evaluate safety of BEZ235 (frequency and severity of Adverse Events, abnormal laboratory values, other safety data as appropriate)', 'timeFrame': '30-35 days after treatment discontinuation'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,,,,no_match,False,,,
NCT02828020,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine",Ubrogepant,"['Ubrogepant', 'Placebo-matching Ubrogepant']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Migraine, With or Without Aura",Allergan,2025-09-01T16:18:23.456761,True,,,,NOT_FOUND,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",,"['Migraine, With or Without Aura']",[],,2016-07-22,2017-12-14,"[{'measure': 'Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose', 'description': 'Pain freedom was defined as a reduction in headache severity from moderate/severe at baseline to no pain at 2 hours after the initial dose. Participants were provided with an electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.', 'timeFrame': 'Baseline (Predose) to 2 hours after initial dose'}, {'measure': 'Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose', 'description': ""The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms."", 'timeFrame': 'Baseline (Predose) to 2 hours after initial dose'}]","[{'measure': 'Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose', 'description': 'Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.', 'timeFrame': 'Baseline (Predose) to 2 hours after initial dose'}, {'measure': 'Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose', 'description': 'Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain relief from 2 to 24 hours after initial dose.', 'timeFrame': '2 to 24 hours after initial dose'}, {'measure': 'Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose', 'description': 'Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain freedom from 2 to 24 hours after initial dose.', 'timeFrame': '2 to 24 hours after initial dose'}, {'measure': 'Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose', 'description': 'Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.', 'timeFrame': '2 hours after initial dose'}, {'measure': 'Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose', 'description': 'Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.', 'timeFrame': '2 hours after initial dose'}, {'measure': 'Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose', 'description': 'Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.', 'timeFrame': '2 hours after initial dose'}]",8.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,1672.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03504410,Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML,CPI-613 + High Dose Cytarabine and Mitoxantrone,"['Fludarabine, Cytarabine, Filgrastim', 'CPI-613, CHAM', 'High Dose Cytarabine and Mitoxantrone', 'FLAG', 'HAM', 'Mitoxantrone, Etoposide and Cytarabine', 'MEC', 'CPI-613 + High Dose Cytarabine and Mitoxantrone']",8,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,Relapsed/Refractory Acute Myeloid Leukemia,Cornerstone Pharmaceuticals,2025-09-01T16:18:12.182071,True,,,,CHEMBL803,Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML,,['Relapsed/Refractory Acute Myeloid Leukemia'],[],Futile,2018-11-12,2022-01-19,"[{'measure': 'Complete Remission (CR)', 'description': 'Complete disappearance of all clinical evidence of disease', 'timeFrame': '12 months'}]",[],1.0,50 Years,,ALL,False,INDUSTRY,0.0,200.0,ACTUAL,v2_robust,True,False,True,False,Futile,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,CHEMBL803,partial_match,True,243.22,-2.56,4.0
NCT06961500,Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A,Obinutuzumab,"['Bendamustine', 'Obinutuzumab', 'CHOP']",3,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Follicular Lymphoma Grade 3A,Sun Yat-sen University,2025-09-01T16:18:17.170540,True,,,,NOT_FOUND,"A Multicenter, Phase 2, Randomized Trial of Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A (FL)",,['Follicular Lymphoma Grade 3A'],[],,2025-05-01,2030-11-01,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'From study entry to the first documented disease progression or death from any cause.', 'timeFrame': 'Assessed up to 5 years.'}]","[{'measure': 'Complete Response (CR)', 'description': 'Defined as the proportion of patients who achieve complete remission at the end of induction therapy.', 'timeFrame': 'Up to 6 cycles (up to 24 weeks).'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'The proportion of patients who achieve complete remission (CR) or partial remission (PR) at the end of induction therapy.', 'timeFrame': 'Up to 6 cycles (up to 24 weeks).'}, {'measure': 'Event-Free Survival (EFS)', 'description': 'From study entry to the first occurrence of any event, including disease progression, discontinuation of treatment, or death for any reason.', 'timeFrame': 'Assessed up to 5 years.'}, {'measure': 'Overall Survival (OS)', 'description': 'From study entry to death from any cause.', 'timeFrame': 'Assessed up to 5 years.'}, {'measure': 'Progression of Disease within 24 months (POD24)', 'description': 'The occurrence of disease progression or relapse within 24 months from the date of enrollment.', 'timeFrame': '24 months.'}]",6.0,18 Years,,ALL,False,OTHER,0.0,133.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03606837,68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging,68Ga-PSMA-617 PET/CT,"['68Ga-PSMA-617 PET/CT', '68Ga-RM2 PET/CT']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Prostate Cancer,"University Hospital, Bordeaux",2025-09-01T16:18:08.339959,True,,,,NOT_FOUND,"Exploratory, Single-institution Study, Comparing 68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Patients Diagnosed With Intermediate Risk Prostate Cancer Candidates for Radical Prostatectomy",,['Prostate Cancer'],"['Prostate Cancer', '68Ga-RM2', '68Ga-Prostate Specific Membrane Antigen', 'PET/CT', 'Prostate cancer imaging']",,2019-07-11,2023-07-11,"[{'measure': 'Median Standardized Uptake Value (SUV)', 'description': 'Uptake intensity of 68Ga-PSMA-617', 'timeFrame': 'Day 0 (inclusion) or Day 2 to 21 (Visit 2)'}]","[{'measure': 'Gleason score', 'timeFrame': 'Day 3 to 60 (Last visit)'}, {'measure': 'Receptor density Bmax', 'timeFrame': 'Day 0 (inclusion) or Day 2 to 21 (Visit 2)'}, {'measure': 'Local radioactive concentration (cpm)', 'timeFrame': 'Day 0 (inclusion) or Day 2 to 21 (Visit 2)'}, {'measure': 'Immunoreactive score (IRS)', 'timeFrame': 'Day 3 to 60 (Last visit)'}, {'measure': 'New World Health Organization 2016 classification', 'timeFrame': 'Day 3 to 60 (Last visit)'}]",6.0,18 Years,,MALE,False,OTHER,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01859234,89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma,89Zr-bevacizumab,"['Bevacizumab Roche registration limited eu/1/04/300/001', '89Zr-bevacizumab ATC code L01XC07', '89Zr-bevacizumab']",3,INTERVENTIONAL,['NA'],,UNKNOWN,Multiple Myeloma,University Medical Center Groningen,2025-09-01T16:18:08.349007,True,,,,NOT_FOUND,Evaluation of VEGF Expression With 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma; a Feasibility Study,,['Multiple Myeloma'],"['multiple myeloma', 'PET scan']",,2013-05,,"[{'measure': 'Focal lesion of 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma', 'description': 'We assume focal lesion will be feasible with 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma. For each 89Zr-bevacizumab PET scan the amount of focal lesion and the localisation will be reported. When there is diffuse bone marrow uptake this will also be reported. The focal lesion found on the 89Zr-bevacizumab PET scan will be compared with focal lesions found on the FDG-PET scan. Furthermore the amount of focal lesion will be compared with the expression of VEGF, MVD, HIF 1 alpha and 2 alpha and GLUT 1 and 3.', 'timeFrame': 'during scanning'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04373473,Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis,PRIM-DJ2727,"['Placebos', 'PRIM-DJ2727']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Adults With Ulcerative Colitis,"The University of Texas Health Science Center, Houston",2025-09-01T16:18:20.964915,True,,,,NOT_FOUND,"A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis",,['Adults With Ulcerative Colitis'],[],,2020-09-14,2025-12-31,"[{'measure': 'Patients in remission after administering 12 weeks of PRIM-DJ2727 capsules will be measured by partial Mayo score ≤ 3', 'timeFrame': '9 months'}]","[{'measure': 'Quality of life will be characterized by health-related quality of life score.', 'timeFrame': '9 months'}, {'measure': 'Subject-reported score in Hospital Anxiety and Depression Scale', 'description': 'After administering 12 weeks of PRIM-DJ2727', 'timeFrame': '9 months'}]",3.0,18 Years,,ALL,False,OTHER,0.0,58.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00750243,Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation,LT-NS001,"['Naprosyn®', 'LT-NS001']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Logical Therapeutics,2025-09-01T16:18:23.447565,True,,,,NOT_FOUND,"A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation",,['Healthy'],[],,2008-09,2009-04,"[{'measure': 'Assessment of GI mucosal injury by endoscopy', 'timeFrame': '7 days'}]","[{'measure': 'Comparison of naproxen PK at steady state', 'timeFrame': '7.5 days'}]",2.0,45 Years,70 Years,ALL,True,INDUSTRY,0.0,120.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01987219,The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia,Albuterol-sulphate,"['(Proventil ®)', 'Albuterol-sulphate', 'Ipratropium-bromide', '(Atrovent ®)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Familial Dysautonomia,NYU Langone Health,2025-09-01T16:18:13.425061,True,,,,NOT_FOUND,The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia,,['Familial Dysautonomia'],['familial dysautonomia'],,2013-03,2014-12,"[{'measure': 'Change From Baseline of Forced Vital Capacity', 'description': 'FVC is a measure of the amount of air exhaled, and is measured in liters of air per second. The percentage in the change in the amount of air exhaled from baseline, measured in liters of air per second. Increase in the percentage of air exhaled from baseline indicates improvement in respiratory function.', 'timeFrame': 'Pre and 30 minutes post study drug administration'}, {'measure': 'Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline', 'description': 'The percentage change in respiratory function from baseline is measured in percentage change in Resistance, kPa/(L/s).', 'timeFrame': 'Pre and 30 minutes post study drug administration'}]","[{'measure': 'Change in Forced Expiratory Volume (FEV) From Baseline', 'description': 'Forced expiratory volume is measured in liters of air per second. FEV was measured during the first second of exhalation.', 'timeFrame': 'Pre and 30 post study drug admistration'}, {'measure': 'Change in Forced Expiratory Flow Between 25-75% (FEF25-75)', 'description': 'FEF25-75 is measured in liters of air per second at 25-75%', 'timeFrame': 'pre and 30 minutes post intervention'}]",4.0,12 Years,80 Years,ALL,False,OTHER,0.0,15.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05239091,Comparison of the Efficacy of Prolotherapy Injection Therapy & Local Anesthetic Injection Therapy.,Dextrose solution,"['Dextrose solution', 'Lidocain', 'Local anesthetic', 'Dextrose prolotherapy']",4,INTERVENTIONAL,['NA'],,COMPLETED,Myofascial Pain Syndrome of Neck,Istanbul Physical Medicine Rehabilitation Training and Research Hospital,2025-09-01T16:18:20.954159,True,,,,NOT_FOUND,Comparison of the Efficacy of Prolotherapy Injection Therapy and Local Anesthetic (Lidocaine) Injection Therapy in Myofascial Pain Syndrome.,,['Myofascial Pain Syndrome of Neck'],"['Lidocaine', 'dextrose prolotherapy', 'pain']",,2022-08-01,2022-08-22,"[{'measure': 'Pressure pain threshold', 'description': 'It will be measured by algometer. Its unit is kg/cm2', 'timeFrame': 'Change from baseline pressure pain threshold at 2,4,6 and 8 weeks.'}]","[{'measure': 'Pain intensity', 'description': 'Pain intensity will be evaluated by using a visual analog scale (VAS).The maximum score is 10 points. A higher score indicates a worse pain level', 'timeFrame': 'Change from baseline pain intensity score at 2,4,6 and 8 weeks.'}, {'measure': 'Pain tolerance measurement', 'description': 'A pressure of 2.5 kg/cm2 will be applied to the trigger point using an algometer (WAGNER -FPK20) and patients will be asked to express their pain intensity according to the visual analog scale (VAS) scale. All patients will be informed that VAS is 0 (no pain) and 10 (worst pain imaginable), and will be asked to indicate the point between 0 and 10 that can represent the severity of their pain.', 'timeFrame': 'change from baseline pain tolerance at 2,4,6 and 8 weeks.'}, {'measure': 'SF-36 (Short Form-36) Survey', 'description': 'The scale consists of 36 items and these provide the measurement of 8 dimensions. Instead of giving only a single total score, the scale gives a total score for each subscale separately. Subscales evaluate health on a scale of 0 to 100, with 0 indicating poor health and 100 indicating good health.', 'timeFrame': 'Change from baseline SF-36 Short Form Survey score at 8 week.'}]",4.0,18 Years,65 Years,ALL,False,OTHER_GOV,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00117364,Effect of SACCHACHITIN on Healing of a Chronic Wound,SACCHACHITIN patch,['SACCHACHITIN patch'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Wounds,Min-Sheng General Hospital,2025-09-01T16:18:22.204602,True,,,,NOT_FOUND,Effect of SACCHACHITIN on Healing of Chronic Wound ---A Clinical Trial,,['Wounds'],"['chronic ulcer', 'poor healing', 'The patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study']",,2005-01,2005-06,[],[],0.0,16 Years,80 Years,ALL,False,OTHER,0.0,30.0,,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT06067425,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia",SAR442501,['SAR442501'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Osteochondrodysplasia,Sanofi,2025-09-01T16:18:12.177235,True,,,,NOT_FOUND,"A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia",,['Osteochondrodysplasia'],[],Sponsor decision. Not related to safety concern.,2023-10-10,2025-02-12,"[{'measure': 'Number of participants with adverse events (AE), serious adverse events (SAE), and adverse events of special interest (AESI) during the treatment-emergent period', 'timeFrame': 'Baseline to Week 52'}]","[{'measure': 'Change in annualized growth velocity (AGV) Zscore', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in AGV (cm/year)', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in height Z score', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper-to-lower body segment ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper to lower extremity ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in sitting to standing height ratio (crown-to-rump length to total length for infants)', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in arm span to height ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper arm to forearm length ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper leg to lower leg ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in head circumference to height ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in brainstem parameter', 'description': 'Change in surface area of the bony foramen magnum (cm2) as measured by head and neck Magnetic Resonance Imaging (MRI).', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in skull parameter', 'description': 'Change in dimensions of skull base parameters, and degree of synchondroses fusion as measured by head and neck MRI.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in spine morphometric parameter', 'description': 'Change in grading of cord compression and cord constriction as assessed by head and neck MRI.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in volumetric parameter', 'description': 'Change in brainstem and spinal cord volume as measured by head and neck MRI.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in overall health-related quality of life score in the PedsQL Inventory Generic Core Scale', 'description': 'PedsQL Generic Core Scales, global score ranging from 0-100, with higher scores representing better outcomes', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in fatigue score in the PedsQL Multidimensional Fatigue Scale', 'description': 'PedsQL Multidimensional Fatigue Scale, global score ranging from 0-100, with higher scores representing better outcomes', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in present pain and worst pain rating (PPQ) score', 'description': 'Pediatric Pain Questionnaire (PPQ) score value between 0-4. The lower the better.', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in mobility and symptom rating (STEMS) score', 'description': 'Screening Tool for Everyday Mobility and Symptoms (STEMS) score value between 1-5. The lower the better.', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in developmental score in the Achondroplasia Developmental Recording Form', 'description': 'Achondroplasia Developmental Recording Form to record the age at which participants achieve developmental milestones. The earlier the better.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Assessment of pharmacokinetic (PK) parameter: plasma concentration of SAR442501', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: maximum plasma concentration observed (Cmax)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: time to reach Cmax (Tmax)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: Area under the plasma concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: concentration observed before treatment administration during repeated dosing (Ctrough)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of pharmacodynamics (PD) parameter: change in collagen X biomarker (CXM) levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in osteocalcin levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in bone-specific alkaline phosphatase', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in procollagen type 1 N-terminal propeptide (P1NP) levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in collagen-type 1 C-Telopeptide (CTX) levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Number of participants with treatment-emergent anti-drug antibodies (ADA)', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Changes in neurological examination', 'description': 'Percentage of participants with changes (i.e. abnormal to normal or normal to abnormal) in neurological examination findings', 'timeFrame': 'Baseline through Week 26 and Week 52'}]",32.0,0 Days,12 Years,ALL,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,False,True,True,Sponsor decision. Not related to safety concern.,,,no_match,False,,,
NCT06453824,"SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants",MDI-2517,['MDI-2517'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Safety and Tolerability,"MDI Therapeutics, Inc.",2025-09-01T16:18:23.457577,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants",,['Safety and Tolerability'],[],,2024-05-17,2024-11-11,"[{'measure': 'To evaluate the incidence of treatment emergent adverse events [safety and tolerability] of a single-ascending oral dose of MDI-2517 in healthy participants', 'description': 'Adverse reactions to the study drug MDI-2517 will be measured', 'timeFrame': '5 days'}]","[{'measure': 'To evaluate the levels of MDI-2517 in blood plasma following a single oral dose of MDI-2517 in healthy participants', 'description': 'The levels of MDI-2517 in blood plasma following an oral single-dose of MDI-2517 tablets will be measured.', 'timeFrame': '5 days'}]",2.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,48.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02596776,Cold Induced Changes in White Adipose,Propranolol and fat biopsy,['Propranolol and fat biopsy'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Obese,Philip Kern,2025-09-01T16:18:07.015443,True,,,,CHEMBL27,Cold Induced Changes in Human Subcutaneous White Adipose,,"['Obese', 'Normal Body Weight', 'Prediabetes', 'Metabolic Syndrome']",[],,2016-03,2018-08-20,"[{'measure': 'WAT changes during repeated exposure to cold temperatures', 'description': 'Adipose biopsies will be performed', 'timeFrame': '28 Weeks (Summer and Winter Seasons)'}, {'measure': 'WAT changes following Propranolol dosing', 'description': 'Subjects will be prescribed propranolol and adipose biopsies will be obtained.', 'timeFrame': '17 days in the summer season'}, {'measure': 'In vivo measurement of adipose lipolysis and triglyceride (TG) turnover', 'description': 'The heavy water will be given to and adipose biopsies will be obtained.', 'timeFrame': '5 weeks per season (summer and winter)'}]",[],3.0,35 Years,60 Years,FEMALE,True,OTHER,1.0,26.0,ACTUAL,v2_robust,True,True,False,False,,CC(C)NCC(O)COc1cccc2ccccc12,CHEMBL27,partial_match,True,259.35,2.58,4.0
NCT00187928,Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder,Topiramate,['Topiramate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Obsessive-Compulsive Disorder,University of Florida,2025-09-01T16:18:13.426066,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder",,['Obsessive-Compulsive Disorder'],"['Obsessive-Compulsive Disorder', 'Obsessions', 'Compulsions', 'Adjunctive treatment']",,2003-01,2006-03,[],[],0.0,18 Years,65 Years,ALL,False,OTHER,1.0,96.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00446849,Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC),MMX Mesalamine,"['Lialda', 'MMX Mesalamine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Ulcerative Colitis,Shire,2025-09-01T16:18:19.674036,True,,,,CHEMBL704,"A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)",,['Ulcerative Colitis'],"['ulcerative colitis', 'compliance', 'mesalamine', 'clinical study', 'clinical trial', 'clinical research', 'maintenance', 'long term', 'uc study', 'uc trial', 'uc research', 'open label', 'once a day', 'once', 'daily', 'daily dosing', 'simple', 'oral']",,2007-05-01,2009-08-17,"[{'measure': 'Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding."", 'timeFrame': '6 months'}]","[{'measure': 'Clinical Recurrence of UC During the Maintenance Phase at 12 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding."", 'timeFrame': '12 Months'}, {'measure': 'Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: \\[(Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals)\\] x 100."", 'timeFrame': '6 Months'}, {'measure': 'Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months', 'description': ""Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: (Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals) x 100."", 'timeFrame': '12 months'}, {'measure': 'Quiescent UC During the Maintenance Phase at 12 Months', 'description': 'Quiescent UC is defined as scores of 0 for both rectal bleeding and bowel movements. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Bowel movements are assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day).', 'timeFrame': '12 Months'}, {'measure': 'Endoscopic Remission of UC During the Maintenance Phase at 12 Months', 'description': 'Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal \\[intact vascular pattern; no friability or granulation\\], 1 = mild \\[erythema; decreased vascular pattern; minimal granularity\\], 2 = moderate \\[marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations\\], 3 = severe \\[ulceration; spontaneous bleeding\\].', 'timeFrame': '12 Months'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,290.0,ACTUAL,v2_robust,True,True,False,False,,Nc1ccc(O)c(C(=O)O)c1,CHEMBL704,partial_match,True,153.14,0.67,4.0
NCT00872144,Sativex for Treatment of Chemotherapy Induced Neuropathic Pain,Sativex,['Sativex'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Neuropathic Pain,Mary Lynch,2025-09-01T16:18:13.430069,True,,,,NOT_FOUND,A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain,,['Neuropathic Pain'],[],,2010-06,2013-03,"[{'measure': 'Change in the NRS-PI from baseline to the final week of stable dose treatment)', 'timeFrame': 'Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)'}, {'measure': 'Participants gaining a 30% or greater reduction in the NRS-PI', 'timeFrame': 'Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)'}]","[{'measure': 'Secondary outcome measures will include measures in the remaining domains (suggested by IMMPACT). These include SF36, Quantitative sensory examination, Global Impression of Change, PGIC and Patient Satisfaction Scale, PSS', 'timeFrame': 'After stable dosing is achieved (week 3)'}]",3.0,18 Years,,ALL,False,OTHER,0.0,16.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00424268,Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128),Roflumilast,"['Roflumilast', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Obstructive Pulmonary Disease,AstraZeneca,2025-09-01T16:18:07.016561,True,,,,CHEMBL193240,"Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study",,['Chronic Obstructive Pulmonary Disease'],"['COPD', 'Roflumilast']",,2007-01,2008-07,"[{'measure': 'Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)', 'description': 'Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \\[L\\]', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}]","[{'measure': 'Post-bronchodilator FEV1', 'description': 'Mean change from baseline during the treatment period in post-bronchodilator FEV1 \\[L\\]', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}, {'measure': 'COPD Exacerbation Rate (Moderate or Severe)', 'description': ""Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \\[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\\]."", 'timeFrame': '24 weeks treatment period'}, {'measure': 'Transition Dyspnea Index (TDI) Focal Score', 'description': 'The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}, {'measure': 'Shortness of Breath Questionnaire (SOBQ) Total Score', 'description': 'Mean change from baseline during the treatment period in SOBQ. This is a 24-item measure that assesses self-reported shortness of breath while performing a variety of activities of daily living. The questions were administered at visits V0, V2, V3, V4, V5, V6 and Vend to assess the perceived shortness of breath of the patient. For each activity listed in the questionnaire the patient should rate his/her breathlessness on a scale between zero and five, where zero is ""not at all breathless"" and five is ""maximally breathless or too breathless to do the activity"".', 'timeFrame': 'Change from baseline over 24 weeks of treatment'}]",5.0,40 Years,,ALL,False,INDUSTRY,0.0,743.0,ACTUAL,v2_robust,True,True,False,False,,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,CHEMBL193240,exact_match,True,403.21,5.03,4.0
NCT05371249,Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy,Vonoprazan-based triple therapy,"['S-14', 'Extended sequential therapy', 'VAC-7', 'Vonoprazan-based triple therapy']",4,INTERVENTIONAL,['PHASE4'],PHASE4,ACTIVE_NOT_RECRUITING,Helicobacter Pylori,Fu Jen Catholic University Hospital,2025-09-01T16:18:25.983717,True,,,,NOT_FOUND,Seven-Day Vonoprazan-Based Triple Therapy With High-Dose Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial in Taiwan,,['Helicobacter Pylori'],['Proton Pump Inhibitors'],,2021-12-01,2024-02-28,"[{'measure': 'Eradication rate of helicobacter pylori', 'description': 'Assessed by urea breath test', 'timeFrame': 'Assessed at least 6 weeks after the therapy'}]","[{'measure': 'Adverse effects of the drugs', 'description': 'Self-reported adverse effects by patients through a questionnaire.', 'timeFrame': 'After patients completed the therapy (For VAC-7 group: 1 week after the therapy; For S-14 group: 2 weeks after the therapy)'}, {'measure': 'Compliance', 'description': 'Self-reported compliance by patients through a questionnaire.', 'timeFrame': 'After patients completed the therapy ((For VAC-7 group: 1 week after the therapy; For S-14 group: 2 weeks after the therapy)'}]",3.0,20 Years,,ALL,False,OTHER,0.0,628.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00753558,Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae,Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.,['Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.'],1,INTERVENTIONAL,['NA'],,COMPLETED,Carriage of Carbapemen-resistant Klebsialle Pneumoniae,Soroka University Medical Center,2025-09-01T16:18:25.985322,True,,,,NOT_FOUND,"A Randomized,Double-Blind,Placebo-Controled Trial of Selective Digestive Decontamination Using Oral Gentamicin and Oral Polymyxin E for Eradication of Carbapenem-Resistant Klebsiella Pneumoniae Carriage",,['Carriage of Carbapemen-resistant Klebsialle Pneumoniae'],[],,2008-11,2010-07,"[{'measure': 'Eradication of CRKP carriage measured by negative rectal swabs', 'timeFrame': 'Two days after treatment ends'}]","[{'measure': 'No new in-hospital acquisition of CRKP', 'timeFrame': 'Six weeks'}]",2.0,18 Years,,ALL,False,OTHER,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00681603,Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization,subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg),"['subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)', 'bevacizumab ( Avastin )']",2,INTERVENTIONAL,['NA'],,COMPLETED,Lipid Keratopathy,National Taiwan University Hospital,2025-09-01T16:18:15.896052,True,,,,NOT_FOUND,The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization,,"['Lipid Keratopathy', 'Penetrating Keratoplasty', 'Herpetic Keratopathy', 'Rosacea']","['corneal neovascularization', 'lipid keratopathy', 'penetrating keratopathy', 'bevacizumab', 'Avastin', 'subconjunctival injection']",,2007-08,2008-02,"[{'measure': 'Resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity', 'timeFrame': 'prospective'}]","[{'measure': 'major side effects', 'timeFrame': 'prospective'}]",2.0,10 Years,70 Years,,False,OTHER,0.0,13.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04955158,Dexmedetpmidine Versus Ketamine for Postoperative Sore Throat in Sinus Surgery,Dexmedetomidine,"['Ketamine', 'ketalar', 'Precedex', 'Dexmedetomidine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Sore Throat,Assiut University,2025-09-01T16:18:17.183910,True,,,,CHEMBL778,Impact of Dexmedetomidine Versus Ketamine Soaked Pharyngeal Packing on Postoperative Sore Throat in Functional Endoscopic Sinus Surgery: a Randomized Double Blind Trial,,['Sore Throat'],[],,2021-08-19,2023-02-15,"[{'measure': 'Incidence of postoperative sore throat (POST)', 'description': 'On arrival in the post anesthesia care unit, the patient was immediately evaluated for the presence of sore throat (time 0 hour) using a standardized scale. The severity of POST was graded on a 4-point scale ranging from 0 to 3; 0 being no sore throat, 1 being mild discomfort (complains only with questioning), 2 being moderate sore throat (complains on their own), and 3 being severe sore throat (change in voice, hoarseness, and throat pain). Evaluations occurred at 0, 1, 2, 4, 6, 12 and 24 hours postoperatively.', 'timeFrame': '24 hour after surgery'}]","[{'measure': 'Postoperative nausea and vomiting (PONV) score', 'description': 'PONV score was assessed and documented using a Verbal Descriptive Scale, which correlates to visual analog nausea scores, with an objective measure of severity: 0 = no PONV: patient reports no nausea and has had no emesis episodes; 1 = mild PONV: patient reports nausea but declines antiemetic treatment; 2 = moderate PONV: patient reports nausea and accepts antiemetic treatment; and 3 = severe PONV: nausea with any emesis episode (retching or vomiting). The score was obtained at 0, 30, 60, 90, and 120 minutes after PACU arrival; 4 mg IV ondansetron for occurred nausea \\& vomiting.', 'timeFrame': '2 hours postoperative'}]",2.0,18 Years,65 Years,ALL,False,OTHER,0.0,143.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CHEMBL778,exact_match,True,200.28,3.18,4.0
NCT02015819,"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas",flucytosine,"['CFR', 'leucovorin calcium', 'flucytosine', 'CF', 'Ro 2-9915', '5-fluorocytosine', 'LV', '5-FC']",8,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Adult Anaplastic Astrocytoma,City of Hope Medical Center,2025-09-01T16:18:13.425138,True,,,,NOT_FOUND,A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas,,"['Adult Anaplastic Astrocytoma', 'Adult Anaplastic Oligodendroglioma', 'Adult Giant Cell Glioblastoma', 'Adult Glioblastoma', 'Adult Gliosarcoma', 'Recurrent Adult Brain Tumor', 'Anaplastic Oligoastrocytoma']",[],,2014-10-07,2017-10-07,"[{'measure': 'Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)', 'description': 'Number of DLTs per dose level and the MTD/MFD.', 'timeFrame': 'Day 28 of course 1'}, {'measure': 'Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham', 'description': 'Number of participants with mechanical issues with repeat administrations of NSCs via Rickham.', 'timeFrame': '28 days after last infusion of NSCs, up to 6 months total'}]","[{'measure': 'Number of Participants Developing Antibodies Against NSCs', 'description': 'Development of a antibody response to the NSCs will be evaluated by flow cytometry. Data from assessing for possible development of NSC immunogenicity with repeat exposure will be presented in an exploratory fashion using descriptive statistics.', 'timeFrame': 'While receiving treatment, up to 6 months.'}, {'measure': 'Average Steady State Levels of 5-FC and 5-FU in the Brain', 'description': 'Pharmacokinetic (PK) data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics. All summaries will be exploratory in spirit.', 'timeFrame': 'Following the first dose of 5-FC, samples were collected every hour for 24 hours and then every 3 hours thereafter until the end of the 7-day course of 5-FC or until the microdialysis catheter stopped functioning.'}, {'measure': 'Average Steady State Levels of 5-FC Concentrations in Plasma', 'description': 'PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics.', 'timeFrame': 'Samples were obtained prior to the first dose of 5-FC then every 30 minutes for 3 hours, additional samples at 4 and 6 hours after the morning doses on days 4, 5. On days 6, 7, 8 blood samples were collected just before morning dose and 90 minutes later'}, {'measure': 'Comparison of 5-FC in the Brain to 5-FC in the Plasma', 'description': 'PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using the mean ratio of average brain interstitial 5-FC concentrations to the average steady-state plasma levels.', 'timeFrame': 'The ratio of average brain interstitial 5-FC and 5-FU concentrations to average plasma steady-state levels was calculated using all measured data.'}, {'measure': 'Summary of Tumor Response Using the Response Assessment in Neuro-Oncology (RANO) Criteria', 'description': 'Per RANO criteria:\n\nComplete Response (CR): Complete disappearance of all enhancing disease that is sustained for at least 4 weeks, stable or improved non-enhancing FLAIR/T2 lesions, no new lesions, off corticosteroids, and neurologically stable or improved.\n\nPartial Response (PR): \\>= 50% decrease of all measurable enhancing lesions, sustained or at least 4 weeks, no progression of non-measurable disease, stable or improved non-enhancing FLAIR/T2 lesions, non new lesions, corticosteroid dose stable or reduced, and neurologically stable or improved.\n\nStable Disease (SD): Dose not qualify for CR, PR, or PD, stable non-enhancing FLAIR/T2 lesions, stable or reduced corticosteroids, clinically stable.\n\nProgressive Disease (PD): \\>=25% increase in enhancing lesion despite stable or increasing steroid dose, increase (significant) in non-enhancing T2/FLAIR lesions that is not attributable to other non-tumor causes, any new lesions, clinical deterioration', 'timeFrame': 'Up to 3 years post NSC infusion'}]",7.0,18 Years,,ALL,False,OTHER,1.0,16.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00311753,Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients,Certoparin,"['Certoparin', 'Heparin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Embolism,Novartis Pharmaceuticals,2025-09-01T16:18:08.339154,True,,,,NOT_FOUND,An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients,,['Embolism'],"['heparin, thromboprophylaxis, medical patients, acutely ill', 'Acutely ill non surgical patients', 'Immobilization']",,2006-02,,"[{'measure': 'The occurrence of thromboembolic events (proximal or distal DVT, PE or VTE related death) during treatment', 'timeFrame': '10 ± 2 days'}]","[{'measure': 'Thromboembolic events during follow-up period of 3 months', 'timeFrame': '90 days (± 7 days) after the end of the treatment'}, {'measure': 'Safety endpoints occurring during the treatment period: Hemorrhage (major or minor), Thrombocytopenia, Symptomatic HIT type II, Induction of HIT-II specific antibodies', 'timeFrame': '10 ± 2 days'}]",3.0,40 Years,,ALL,,INDUSTRY,0.0,342.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00482001,Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults,donepezil,"['Aricept', 'Placebo (cornstarch)', 'donepezil']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Mental Health,Sunnybrook Health Sciences Centre,2025-09-01T16:18:13.423792,True,,,,CHEMBL502,The Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults: A Pilot Study,,"['Mental Health', 'Geriatrics']","['Donepezil', 'Driving', 'Cholinesterase Inhibitors', 'Geriatric Psychiatry', 'Psychopharmacology', 'Aricept']",,2007-06,2008-08,"[{'measure': 'Psychomotor Vigilance Test (PVT)', 'description': 'A measure of reaction time in milliseconds, using a handheld unit, in which participants respond to a visual simulus', 'timeFrame': 'Day 15'}, {'measure': 'Attention Network Test (ANT)', 'description': 'A measure of reaction time in milliseconds, based on the speed with which participants press a key in response to a visual stimulus', 'timeFrame': 'Day 15'}, {'measure': 'Speed Deviation', 'description': 'A measure of deviation from posted speed limit, measured in km/h', 'timeFrame': 'Day 15'}, {'measure': 'Deviation From Road Position', 'description': 'A measure of deviation from central road position, measured in cm', 'timeFrame': 'Day 15'}, {'measure': 'Reaction Time to Wind Gusts', 'description': 'Reaction time to wind gusts, measured in seconds', 'timeFrame': 'Day 15'}, {'measure': 'Percentage of Time in Safe Zone', 'description': 'Time spent in safe zone (within 10km/h of speed limit and within 0.838m of centre of driving lane), measured as %', 'timeFrame': 'Day 15'}, {'measure': 'Collisions', 'description': 'Number of collisions (on driving simulator)', 'timeFrame': 'Day 15'}]",[],7.0,65 Years,85 Years,ALL,True,OTHER,1.0,22.0,ACTUAL,v2_robust,True,True,False,False,,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,CHEMBL502,exact_match,True,379.5,4.36,4.0
NCT05022160,Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block,pudendal nerve block,['pudendal nerve block'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,Bladder Neoplasm,"Armed Forces Hospital, Pakistan",2025-09-01T16:18:14.677928,True,,,,NOT_FOUND,Preventing Catheter Related Bladder Discomfort (CRBD) in Male Patients Undergoing Lower Urinary Tract Surgery With Bilateral Pudendal Nerve Block: a Randomized Control Trial,,"['Bladder Neoplasm', 'Prostatic Neoplasms']","['Bupivacaine', 'pudendal nerve block', 'CRBD']",,2021-08-10,2021-11-10,"[{'measure': 'Catheter related bladder discomfort', 'description': 'Frequency of catheter related bladder discomfort at 3,8,12 and 24 hours after surgery', 'timeFrame': '24 hours post surgery'}]","[{'measure': 'average intensity of Catheter related bladder discomfort', 'description': 'average intensity of CRBD using numeric rating scale for pain at 3,8,12 and 24 hours after surgery', 'timeFrame': '24 hours post surgery'}]",2.0,18 Years,60 Years,MALE,True,OTHER,0.0,250.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05035381,PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer,Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen,"['Irinotecan', 'Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen', 'Fluorouracil', 'Leucovorin', 'Bevacizumab']",5,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,MSI-H Advanced Colorectal Cancer,Tianjin Medical University Cancer Institute and Hospital,2025-09-01T16:18:10.921127,True,,,,NOT_FOUND,Phase II Clinical Study on Efficacy and Safety of PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Unresectable Recurrent or Metastatic MSI-H Colorectal Cancer,,['MSI-H Advanced Colorectal Cancer'],[],,2019-01-01,2022-12-30,"[{'measure': 'Objective response rate', 'timeFrame': 'Up to one year'}]","[{'measure': 'Disease Control Rate', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall survival', 'timeFrame': 'up to 3 years'}, {'measure': 'Adverse Events', 'timeFrame': 'up to one year'}]",5.0,18 Years,75 Years,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02122146,A Study Of PF-06664178 In Patients With Advanced Solid Tumors,PF-06664178,['PF-06664178'],1,INTERVENTIONAL,['PHASE1'],PHASE1,TERMINATED,Neoplasms,Pfizer,2025-09-01T16:18:18.423148,True,,,,NOT_FOUND,"A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors",,['Neoplasms'],"['ADC', 'PF-06664178', 'solid tumors', 'tumors', 'neoplasm metastasis', 'NSCLC', 'non small cell lung cancer', 'OVCA', 'ovarian cancer', 'Phase 1', 'breast cancer']",The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.,2014-08,2016-06,"[{'measure': 'First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD)', 'description': 'Number of participants that experienced dose limiting toxicities(DLTs) at given dose level.', 'timeFrame': 'Day 1 up to Day 21'}, {'measure': 'Number of Patients With All-Causality Treatment-Emergent Adverse Events(TEAEs) [Part 2 & 3]', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. TEAEs were those AEs with initial onset or increasing in severity after the first dose of study drug.', 'timeFrame': 'Day 1 up to Day 21'}, {'measure': 'Number of Participants With Laboratory Abnormalities [Part 2 & 3]', 'description': 'Number of participants with a laboratory abnormality meeting specified criteria. The laboratory test included: hematology( hemoglobin, platelets, white blood cell count, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils), chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate), coagulation (prothrombin time or International normalized ratio, partial thromboplastin time), Urinalysis (urine protein, urine blood) and pregnancy test.', 'timeFrame': 'On Day1, Day4, Day8, Day15 of the first cycle; on Day1, Day8, Day15 of the second cycle; on Day 1 of the subsequent cycles; end of treatment visit(no longer than 1 week after the patient has been discontinued)'}]","[{'measure': 'Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs ) [Part 1]', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. TEAEs were those AEs with initial onset or increasing in severity after the first dose of study drug.', 'timeFrame': 'From screening up to 28 days after the last treatment administration in each cycle, and follow-up visits(At least 28 days and no more than 35 days after discontinuation of treatment)'}, {'measure': 'Number of Participants With Laboratory Abnormalities[Part 1]', 'description': 'Number of participants with a laboratory abnormality meeting specified criteria. The laboratory test included: hematology( hemoglobin, platelets, white blood cell count, absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils, absolute basophils), chemistry (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen or urea, creatinine, uric acid, glucose, albumin, phosphorous or phosphate), coagulation (prothrombin time or International normalized ratio, partial thromboplastin time), Urinalysis (urine protein, urine blood) and pregnancy test.', 'timeFrame': 'Screening; on Day1, Day4, Day8, Day15 of the first cycle; on Day1, Day8, Day15 of the second cycle; on Day 1 of the subsequent cycles; end of treatment visit(no longer than 1 week after the patient has been discontinued)'}, {'measure': 'Overall Incidence of Anti-PF-06664178-Antibodies[Part 1]', 'description': 'Number of participants with the presence of anti-PF-06664178 antibodies', 'timeFrame': 'Day 1, 15, 21, and every 21 days thereafter up to 24 months, and end of treatment'}, {'measure': 'Overall Incidence of Anti-PF-06664178-Antibodies [Part 2 & 3]', 'description': 'Number of participants with the presence of anti-PF-06664178 antibodies', 'timeFrame': 'Day 1, 15, 21, and every 21 days thereafter up to 24 months, and end of treatment'}, {'measure': 'Overall Number of Participants With Objective Tumor Response[Part 1]', 'description': 'Objective tumor response, was assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 by calculating the Overall Response Rate, and Prolonged Stable Disease. The criterion is defined as: Objective Progression(PD):20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5mm; Stable (SD): All target lesions must be assessed. Stable can follow PR only in the rare case that the sum increases by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds; symptomatic deterioration(Sym):Participants with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time; Indeterminate (In):Progression has not been determined and one, or more non-target sites were not assessed, or assessment methods were inconsistent with those used at baseline.', 'timeFrame': 'Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months'}, {'measure': 'Overall Number of Participants With Objective Tumor Response [Part 2 & 3]', 'description': 'Objective tumor response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 by calculating the Overall Response Rate (ORR), and Prolonged Stable Disease (SD).No Progression Free Survival (PFS) was completed. The criterion is as follow: Objective Progression(PD), Stable (SD), symptomatic deterioration(Sym), and Indeterminate (In)', 'timeFrame': 'Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for PF-06664178 [Part 1 ,2 & 3]', 'description': 'Cmax of PF-06664178 was observed directly from data', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'Cmax of total antibody PF-06479118 was observed directly from data', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Cmax of unconjugated payload PF-06380101 was observed directly from data', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Area Under the Concentration-Time Curve Over the Dosing Interval(AUCtau) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'AUCtau refers to area under the concentration-time profile from time zero to the time tau, the dosing interval', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Area Under the Concentration-Time Curve Over the Dosing Interval(AUCtau) of Total Antibody(PF-06479118) [Part 1 ,2 & 3]', 'description': 'AUCtau refers to area under the concentration-time profile from time zero to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Area Under the Concentration-Time Curve Over the Dosing Interval(AUCtau) of Unconjugated Payload(PF-06380101) [Part 1 ,2 & 3]', 'description': 'AUCtau refers to area under the concentration-time profile from time zero to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Systemic Clearance (CL) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Systemic Clearance (CL) of Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Systemic Clearance (CL) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Volume of Distribution (Vss) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Volume of Distribution (Vss) of Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Volume of Distribution (Vss) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Total Antibody (PF-06479118)[Part 1 ,2 & 3]', 'description': 'Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Trop-2 Expression Levels on Archived Tissue [Part 2 & 3]', 'description': 'Number of participents meeting the following criterion for Trop-2 expression assessment : low expression, medium expression and high expression', 'timeFrame': 'Day 1'}, {'measure': 'Accumulation Ratio (Rac) of PF-06664178 [Part 1 ,2 & 3]', 'description': 'Accumulation ratio refers to AUCtau for cycle 4/AUCtau for cycle 1, where AUCtau is defined as area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Accumulation Ratio (Rac) of Total Antibody (PF-06479118) [Part 1 ,2 & 3]', 'description': 'Accumulation ratio refers to AUCtau for cycle 4/AUCtau for cycle 1, where AUCtau is defined as area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}, {'measure': 'Accumulation Ratio (Rac) of Unconjugated Payload (PF-06380101) [Part 1 ,2 & 3]', 'description': 'Accumulation ratio refers to AUCtau for cycle 4/AUCtau for cycle 1, where AUCtau is defined as area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to the time tau, the dosing interval.', 'timeFrame': '0, 1, 4, 24 hours post-dose on Day 1, and on Day 4, Day 8 and Day 15 of cycles 1 and 4; 0, 1hour post-dose on Cycle 2, 3 and every cycle after cycle 4, end of treatment'}]",28.0,18 Years,,ALL,False,INDUSTRY,0.0,31.0,ACTUAL,v2_robust,True,False,True,True,The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.,,,no_match,False,,,
NCT03149419,Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments,Paroxetine,"['Placebo oral capsule', 'Paroxetine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Postmenopausal Flushing,Rio de Janeiro State University,2025-09-01T16:18:10.921305,True,,,,CHEMBL1708,"Endothelial, Autonomic and Pressure Effects of Paroxetine in Recent Postmenopause Women With Hot Flashes: a Randomized Placebo Controlled Clinical Trial",,"['Postmenopausal Flushing', 'Cardiovascular Risk Factor', 'Endothelial Dysfunction']","['postmenopause', 'paroxetine', 'endothelial dysfunction', 'blood pressure', 'heart rate variability', 'sleep quality', 'perceived stress', 'sleepiness']",,2016-03-01,2018-03-30,"[{'measure': 'Endothelial function in non invasive venous occlusion plethysmography', 'description': 'Forearm blood flow (ml/min per 100 ml)', 'timeFrame': '12 weeks'}]",[],1.0,45 Years,65 Years,FEMALE,True,OTHER,0.0,140.0,ACTUAL,v2_robust,True,True,False,False,,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,CHEMBL1708,partial_match,True,365.83,3.33,4.0
NCT05427162,A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist,Prostacyclin Receptor Agonist,['Prostacyclin Receptor Agonist'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pulmonary Arterial Hypertension,Actelion,2025-09-01T16:18:07.025042,True,,,,NOT_FOUND,"Open-Label, Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Different Formulations of an IP Receptor Agonist",,['Pulmonary Arterial Hypertension'],[],,2022-06-21,2023-12-05,"[{'measure': 'Number of Participants with Treatment-emergent Adverse Events (TEAEs)', 'description': 'An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants With Serious TEAEs', 'description': 'A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Serious TEAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants with TEAEs by Severity', 'description': 'Number of participants with TEAEs by severity will be evaluated. An assessment of severity grade will be made using the following general categorical descriptors, such as Mild (Awareness of symptoms that are easily tolerated, causing minimal discomfort, and not interfering with everyday activities), Moderate (Sufficient discomfort is present to cause interference with normal activity), and Severe (Extreme distress, causing significant impairment of functioning or incapacitation, and prevents normal everyday activities).', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants with TEAEs Leading to Discontinuation', 'description': 'Number of participants with TEAEs leading to discontinuation will be reported.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants With Change from Baseline in Clinical Laboratory Values', 'description': 'Number of participants with change from baseline in clinical laboratory values (chemistry, hematology, and urinalysis) will be evaluated.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Number of Participants With Injection Site Reactions', 'description': 'Number of participants with injection site reactions will be evaluated.', 'timeFrame': 'Up to 114 days'}]","[{'measure': 'Treatment Period 1: Maximum Observed Plasma Concentration of Prostacyclin Receptor Agonist at Steady State (Cmax[ss])', 'description': 'Cmax(ss) is the maximum observed plasma concentration of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 1: Time to Reach Maximum Observed Plasma Concentration of Prostacyclin Receptor Agonist at Steady State (Tmax[ss])', 'description': 'Tmax(ss) is the actual sampling time to reach maximum observed plasma concentration of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 1: Area Under the Curve From Time Zero to tau of Prostacyclin Receptor Agonist at Steady State (AUC[0-tau{ss}])', 'description': 'AUC(0-tau\\[ss\\]) is defined as area under the curve from time 0 to tau hours post dose of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 1: Plasma Concentration at the End of One Dose Interval of Prostacyclin Receptor Agonist at Steady State (Ctrough[ss])', 'description': 'Ctrough(ss) is the plasma concentration at the end of one dose interval of prostacyclin receptor agonist at steady state, during treatment period 1.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Maximum Observed Plasma Concentration (Cmax) of Prostacyclin Receptor Agonist', 'description': 'Cmax is the maximum observed plasma concentration of prostacyclin receptor agonist, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Prostacyclin Receptor Agonist', 'description': 'Tmax is the actual sampling time to reach maximum observed plasma concentration of prostacyclin receptor agonist, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve from time Zero to time t (AUC[0-t]) of Prostacyclin Receptor Agonist', 'description': 'Area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of concentration of prostacyclin receptor agonist, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time calculated as the sum of AUC (0-last) and C (0-last)/ lambda(z); wherein AUC (0-last) is area under the plasma concentration time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration of prostacyclin receptor agonist, and lambda (z) is elimination rate constant, during treatment period 2.', 'timeFrame': 'Up to 114 days'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve From Zero to Time 24 Hours (AUC [0-24h]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-24h) is the area under the plasma concentration-time curve from zero to time 24 hours, during treatment period 2.', 'timeFrame': 'Predose up to 24 hours post dose'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve From Zero to Day 14 (AUC [0-Day 14]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-Day 14) is the area under the plasma concentration-time curve from zero to Day 14, during treatment period 2.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Treatment Period 2: Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC [0-Day 28]) of Prostacyclin Receptor Agonist', 'description': 'AUC (0-Day 28) is the area under the plasma concentration-time curve from zero to Day 28, during treatment period 2.', 'timeFrame': 'Up to Day 28'}, {'measure': 'Treatment Period 2: Plasma Concentration of Prostacyclin Receptor Agonist at Day 14 (C[Day 14])', 'description': 'C(Day 14) is the plasma concentration of prostacyclin receptor agonist at Day 14, during treatment period 2', 'timeFrame': 'Up to Day 14'}, {'measure': 'Treatment Period 2: Plasma Concentration of Prostacyclin Receptor Agonist at Day 28 (C[Day 28])', 'description': 'C(Day 28) is the plasma concentration of prostacyclin receptor agonist at Day 28, during treatment period 2.', 'timeFrame': 'Up to Day 28'}]",19.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,88.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01981616,Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab,Vedolizumab,"['Vedolizumab', 'Placebo', 'MLN0002', 'MLN02', 'Entyvio', 'LDP-02']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Inflammatory Bowel Disease,"Millennium Pharmaceuticals, Inc.",2025-09-01T16:18:25.979791,True,,,,NOT_FOUND,"A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab",,['Inflammatory Bowel Disease'],['Drug therapy'],,2011-09,2012-07,"[{'measure': 'Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74', 'description': 'Immune response was defined as hepatitis B surface antibody (anti-HBs) ≥ 10 IU/L.', 'timeFrame': 'Day 74'}]","[{'measure': 'Percentage of Participants With an Immune Response to Oral Cholera Vaccine', 'description': 'A positive immune response was defined as an increase of greater than 4-fold over the Baseline immunoglobulin M (IgM), IgG, or IgA anticholera antibodies.', 'timeFrame': 'Baseline and Day 74'}, {'measure': 'Anti-Hepatitis B Surface Antibody Over Time', 'timeFrame': 'Baseline and Days 18, 32, 60 and 74'}, {'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment.\n\nSerious adverse event (SAE) meant any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. Relationship of each AE to study drug was determined by the Investigator.', 'timeFrame': 'From the first dose of study medication through Day 127'}]",4.0,18 Years,39 Years,ALL,True,INDUSTRY,0.0,127.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04398680,A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function,Belantamab mafodotin,['Belantamab mafodotin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Multiple Myeloma,GlaxoSmithKline,2025-09-01T16:18:15.893187,True,,,,NOT_FOUND,A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13),,['Multiple Myeloma'],"['DREAMM 13', 'Belantamab mafodotin monotherapy', 'Hepatic impairment', 'Normal hepatic function', 'Relapsed or refractory multiple myeloma']",,2021-04-20,2025-10-13,"[{'measure': 'Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Time to Cmax (Tmax) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Concentration at the end of infusion (C-EOI)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Predose plasma concentration (Ctrough) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Cmax of total monoclonal antibody (mAb)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Tmax of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: C-EOI of total mAB', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Ctrough of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Tlast of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Cmax of Cys Monomethyl Auristatin F (cys-mcMMAF)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Tmax of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: C-EOI of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: AUC(0-168 hours) of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: tlast of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}]","[{'measure': 'Part 1 and Part 2: Change from Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury [mmHg])', 'timeFrame': 'Baseline and up to 4 years'}, {'measure': 'Part 1 and Part 2: Change from Baseline in Vital Sign- Heart rate (beats per minute)', 'timeFrame': 'Baseline and up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'Up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with toxicity grading for hematology parameters', 'timeFrame': 'Up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with toxicity grading for clinical chemistry parameters', 'timeFrame': 'Up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with toxicity grading for urine parameters', 'timeFrame': 'Up to 4 years'}]",23.0,18 Years,,ALL,False,INDUSTRY,0.0,28.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00704223,Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes,biphasic insulin aspart,"['biphasic insulin aspart', 'NovoMix® 70']",2,OBSERVATIONAL,[],,COMPLETED,Diabetes,Novo Nordisk A/S,2025-09-01T16:18:15.891985,True,,,,NOT_FOUND,Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus,,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],,2008-05,2008-11,"[{'measure': 'number of major and minor hypoglycaemic events and adverse events', 'timeFrame': '3 months'}]","[{'measure': 'HbA1c', 'timeFrame': '3 months'}, {'measure': 'PPBG', 'timeFrame': '3 months'}, {'measure': 'FBG', 'timeFrame': '3 months'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,619.0,ACTUAL,v2_robust,False,True,False,True,,,,no_match,False,,,
NCT02083250,"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant",Busulfan,"['Busulfanum', 'GT 41', 'BUS', '1, 4-Bis[methanesulfonoxy]butane', 'Tetramethylene bis[methanesulfonate]', 'Mylecytan', 'Fludara', 'Zolinza', 'Busulphan', 'Suberoylanilide Hydroxamic Acid', 'Bussulfam', 'Myelosan', 'Methanesulfonic acid, tetramethylene ester', 'Vorinostat', 'SH T 586', 'Busulfan', 'Myleran', 'Clofarex', 'Misulban', 'Tetramethylene Bis(methanesulfonate)', 'Suberanilohydroxamic Acid', '2-F-ara-AMP', 'SAHA', 'CB-2041', 'Clofarabine', 'Beneflur', 'Myeloleukon', 'GT-41', 'MSK-390', 'Misulfan', 'Glyzophrol', 'Sulfabutin', 'Joacamine', 'Methanesulfonic Acid Tetramethylene Ester', 'L-001079038', 'Clolar', 'Mielucin', 'Fludarabine Phosphate', 'Busulfex', 'CB 2041', '9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-', 'WR-19508', 'Mitosan', 'Myeleukon']",44,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Acute Lymphoblastic Leukemia in Remission,M.D. Anderson Cancer Center,2025-09-01T16:18:18.414510,True,,,,CHEMBL820,Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia,,"['Acute Lymphoblastic Leukemia in Remission', 'Acute Myeloid Leukemia in Remission', 'Allogeneic Hematopoietic Stem Cell Transplantation Recipient', 'Myelodysplastic Syndrome', 'Previously Treated Myelodysplastic Syndrome', 'Recurrent Acute Lymphoblastic Leukemia', 'Recurrent Acute Myeloid Leukemia']",[],,2014-03-06,2021-11-12,"[{'measure': 'Maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using Common Terminology Criteria for Adverse Events version 4', 'description': 'The 2-stage time-to-event continual reassessment method will be used. Toxicity will be tabulated by dose, type, and grade. The probability of toxicity over 30 days as a function of dose will be estimated by fitting a Bayesian binary outcome regression model.', 'timeFrame': '30 days'}]","[{'measure': 'Recurrence-free survival', 'description': 'Will be estimated by the Kaplan and Meier method.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall survival', 'description': 'Will be estimated by the Kaplan and Meier method.', 'timeFrame': 'Up to 5 years'}]",3.0,,60 Years,ALL,False,OTHER,1.0,70.0,ACTUAL,v2_robust,True,True,False,True,,CS(=O)(=O)OCCCCOS(C)(=O)=O,CHEMBL820,exact_match,True,246.31,-0.28,4.0
NCT01684748,Angiotensin II Blockade and Inflammation in Obesity,Olmesartan medoxomil,"['Olmesartan medoxomil', 'Benicar']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Overweight,Virginia Polytechnic Institute and State University,2025-09-01T16:18:17.184306,True,,,,NOT_FOUND,Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity,,"['Overweight', 'Obese', 'Prehypertension', 'Hypertension']","['angiotensin II', 'obesity', 'diabetes']",,2009-02,2011-08,"[{'measure': 'Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time)', 'description': ""Data collected from the intravenous glucose tolerance tests included blood concentrations of glucose and insulin. Glucose was measured immediately on a YSI glucose analyzer and insulin was measured via ELISA colormetric kits once all study samples were collected. To analyze changes in insulin sensitivity, the MINMOD software was used. The MINMOD software uses Bergman's minimal model to determine insulin sensitivity during an intravenous glucose tolerance test. Both glucose and insulin values were inserted at each timepoint collected (33 in total over the 3-hour protocol) and the software was run to generate the insulin sensitivity value at baseline and post-test. This information was then used to calculate the change of insulin sensitivity from baseline to post-testing after each 8-week intervention."", 'timeFrame': 'Baseline testing to post-testing after 8-week intervention'}]",[],1.0,18 Years,75 Years,ALL,False,OTHER,1.0,20.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01908426,Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,Cabozantinib tablets,"['Placebo tablets', 'XL184', 'Cabozantinib tablets']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hepatocellular Carcinoma,Exelixis,2025-09-01T16:18:19.675979,True,,,,NOT_FOUND,"A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib",,['Hepatocellular Carcinoma'],"['cabozantinib', 'XL184', 'liver cancer', 'hepatocellular carcinoma', 'tyrosine kinase inhibitor', 'MET kinase', 'vascular endothelial growth factor receptor 2 (VEGFR2)']",,2013-09-26,2021-01-12,"[{'measure': 'Overall Survival (OS)', 'description': 'The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.', 'timeFrame': 'Up to 45 months'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.', 'timeFrame': 'Up to 45 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': 'ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)'}]",3.0,18 Years,,ALL,False,INDUSTRY,0.0,707.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00885651,Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines,Metoprolole (Selo-Zok ®),"['Metoprolole (Selo-Zok ®)', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Heart Failure,"Rigshospitalet, Denmark",2025-09-01T16:18:15.901752,True,,,,CHEMBL13,"A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.",,['Heart Failure'],"['SNP', 'catecholamines', 'metoprolole', 'healthy subjects', 'physiological stress']",,2008-09,2009-12,"[{'measure': 'Changes in stress-triggered response of catecholamines.', 'timeFrame': '2 weeks and 3 days'}]","[{'measure': 'Change in stress-triggered blood pressure response.', 'timeFrame': '2 weeks and 3 days'}, {'measure': 'Change in stress-triggered pulse response.', 'timeFrame': '2 weeks and 3 days'}]",3.0,18 Years,30 Years,MALE,True,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,False,,COCCc1ccc(OCC(O)CNC(C)C)cc1,CHEMBL13,partial_match,True,267.37,1.61,4.0
NCT03864627,"A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis",MOR106,"['MOR106', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Atopic Dermatitis,Galapagos NV,2025-09-01T16:18:20.963188,True,,,,NOT_FOUND,"A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis",,['Atopic Dermatitis'],[],MOR106 clinical development in atopic dermatitis was stopped for futility,2019-03-25,2020-02-27,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious Adverse Events (SAEs)', 'description': 'An Adverse Events (AE) was any untoward medical occurrence, new or worsening of any pre-existing condition, in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with the treatment. TEAEs: AES with an onset date on or after the start date of the IMP administration. AESIs: skin-related events (SRE) (except exacerbation and infective exacerbation of AD) or injection site reactions (ISRs) as per common terminology criteria for AEs (Grade 3: ulceration or necrosis; severe tissue damage; operative intervention indicated, Grade 4: life-threatening consequences; urgent intervention indicated, Grade 5: death ). An SAE: AE that resulted in any of the following outcomes: death; life threatening; results in persistent or significant disability/incapacity; requires in-patient hospitalization or prolongation of existing hospitalization; congenital anomaly/birth defect; is medically significant.', 'timeFrame': 'Day 1 up to Day 169/Early discontinuation(ED)'}]","[{'measure': 'Serum Concentrations of MOR106', 'timeFrame': 'Day 1, Day 4, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141, Day 155 and Day 169'}, {'measure': 'Number of Participants With Anti-drug Antibodies (ADAs)', 'timeFrame': 'Day 1 up to Day 169/ED'}]",3.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,33.0,ACTUAL,v2_robust,True,False,True,True,MOR106 clinical development in atopic dermatitis was stopped for futility,,,no_match,False,,,
NCT01617967,Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis,Patisiran,"['ALN-TTR02', 'Patisiran']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,TTR-mediated Amyloidosis,Alnylam Pharmaceuticals,2025-09-01T16:18:13.426883,True,,,,NOT_FOUND,"A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis",,['TTR-mediated Amyloidosis'],['RNAi therapeutic'],,2012-05,2014-01,"[{'measure': 'Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation', 'description': 'The number of participants experiencing at least one adverse event (AE), at least one serious adverse event (SAE) and study drug discontinuation (due to any reason).', 'timeFrame': 'Up to 56 days post first dose'}]","[{'measure': 'Percentage Change From Baseline in Serum Transthyretin (TTR) Protein', 'description': 'Percentage change of TTR relative to pretreatment/baseline levels is reported. For arms with a dosing regimen of Q4W TTR protein samples were measured on Days 28 and 56. For the arms with a dosing regimen of Q3W TTR protein samples were measured on Days 21 and 42.', 'timeFrame': 'Baseline to Day 21/28 and Day 42/56 depending on dosing regimen (Q3W/Q4W)'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Area Under the Concentration Curve From Time 0 to Last Measurable Time Point (AUC0-last)', 'description': 'Pharmacokinetic profiles for patisiran (ALN-TTR02) were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing regimen (Q3W/Q4W)'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Maximum Observed Plasma Concentration (Cmax)', 'description': 'Pharmacokinetic profiles for patisiran (ALN-TTR02) were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing regimen (Q3W/Q4W)'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Beta Elimination Half-life (t1/2 Beta)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing frequency'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Systemic Clearance (CL)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing frequency'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Apparent Volume of Distribution at Steady State (Vss)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing frequency'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Renal Clearance (CLR)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose (within 1 h of planned dosing start) and post-infusion at 0-6 h (pooled) on Day 0 and Day 21/28 depending on dosing frequency'}]",8.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,29.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00889486,Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus,TZP-102,"['TZP-102', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gastroparesis,"Tranzyme, Inc.",2025-09-01T16:18:15.896938,True,,,,NOT_FOUND,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus",,"['Gastroparesis', 'Diabetes Mellitus']","['gastroparesis', 'diabetes mellitus', 'delayed gastric emptying']",,2009-04,2010-04,"[{'measure': 'change from baseline in gastric half-emptying time', 'timeFrame': 'study days 1 and 28'}]","[{'measure': 'change from baseline in gastroparesis symptoms and health-related quality of life', 'timeFrame': 'study days 8, 15 and 28'}]",2.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,92.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01260922,10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.,Donepezil Hydrochloride,"['Donepezil Hydrochloride (generic name)', 'Aricept®', 'Donepezil Hydrochloride']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Teva Pharmaceuticals USA,2025-09-01T16:18:15.901566,True,,,,CHEMBL502,A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.,,['Healthy'],"['Bioequivalence', 'Healthy Subjects']",,2006-04,2006-05,"[{'measure': 'Cmax of Donepezil.', 'description': 'Bioequivalence based on Donepezil Cmax (maximum observed concentration of drug substance in plasma).', 'timeFrame': 'Blood samples collected over a 72 hour period.'}, {'measure': 'AUC0-t of Donepezil.', 'description': 'Bioequivalence based on Donepezil AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).', 'timeFrame': 'Blood samples collected over a 72 hour period.'}]",[],2.0,18 Years,,ALL,True,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,False,,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,CHEMBL502,partial_match,True,379.5,4.36,4.0
NCT01570244,Drug-drug Interaction of BI 201335 and Microgynon,levonorgestrel,"['BI 201335', 'Ethinylestradiol', 'levonorgestrel']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Hepatitis C, Chronic",Boehringer Ingelheim,2025-09-01T16:18:10.926096,True,,,,CHEMBL1389,"An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of 240 mg BI 201335 QD on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers",,"['Hepatitis C, Chronic']",[],,2012-04,2012-08,"[{'measure': 'AUCt,ss of Ethinylestradiol', 'description': 'Area under the curve over the dosing interval t under steady state conditions of ethinylestradiol', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 hours (h) after drug administration'}, {'measure': 'Cmax,ss of Ethinylestradiol', 'description': 'maximum measured concentration over the uniform dosing interval under steady state conditions of ethinylestradiol', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'C24,ss of Ethinylestradiol', 'description': 'measured concentration of the analyte at the end of dosing interval under steady state conditions of ethinylestradiol', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'AUCτ,ss of Levonorgestrel', 'description': 'Area under the curve over the dosing interval τ under steady state conditions of levonorgestrel', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'Cmax,ss of Levonorgestrel', 'description': 'maximum measured concentration over the uniform dosing interval under steady state conditions of levonorgestrel', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}, {'measure': 'C24,ss of Levonorgestrel', 'description': 'measured concentration of the analyte at the end of dosing interval under steady state conditions of levonorgestrel', 'timeFrame': 'on day 13 of first period and on day 8 of second period 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 h after drug administration'}]","[{'measure': 'Clinical Relevant Abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG.', 'description': 'Clinical relevant abnormalities for Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.', 'timeFrame': 'from drug administration up to 14 days'}, {'measure': 'Number of Participants With Drug Related Adverse Events', 'description': 'number of participants with investigator-defined drug related adverse events', 'timeFrame': 'from drug administration up to 14 days'}]",8.0,18 Years,35 Years,FEMALE,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,CHEMBL1389,exact_match,True,312.45,3.88,4.0
NCT00000138,Herpetic Eye Disease Study (HEDS) I,Prednisolone Phosphate,"['Acyclovir', 'Prednisolone Phosphate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,"Keratitis, Herpetic",National Eye Institute (NEI),2025-09-01T16:18:25.984458,True,,,,NOT_FOUND,,,"['Keratitis, Herpetic', 'Ocular Herpes Simplex']",['Herpes Simplex Stromal Keratitis'],,1989-05,,[],[],0.0,12 Years,,ALL,False,NIH,0.0,,,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00532194,An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer,cediranib,"['Recentin', 'cediranib', 'AZD2171']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Ovarian Cancer,Medical Research Council,2025-09-01T16:18:24.741764,True,,,,NOT_FOUND,"A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer",,['Ovarian Cancer'],"['ovarian cancer', 'fallopian tube cancer', 'primary serous peritoneal cancer', 'gynaecological carcinoma', 'randomised controlled trial', 'Cediranib', 'AZD2171', 'efficacy']",,2007-07,2016-12,"[{'measure': 'Progression-free survival', 'timeFrame': 'Apr 2013'}]","[{'measure': 'Overall survival', 'timeFrame': 'Q2 2016'}, {'measure': 'Toxicity', 'timeFrame': 'Q2 2015'}, {'measure': 'Quality of Life', 'timeFrame': 'Q2 2015'}]",4.0,18 Years,,FEMALE,False,OTHER_GOV,6.0,486.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04486157,Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects,IN-A012,"['IN-A012', 'Akynzeo 300Mg-0.5Mg Capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,HK inno.N Corporation,2025-09-01T16:18:10.919690,True,,,,NOT_FOUND,"A Phase 1, Open Label, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Crossover Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects",,['Healthy'],[],,2021-03-18,2021-05-10,"[{'measure': 'AUC0-t of netupitant', 'description': 'Area under the plasma concentration versus time curve of netupitant', 'timeFrame': 'pre-dose(0hour), 0.5, 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96 , 120, 144, 168, 192, 216, and 240 hours post-dose'}]","[{'measure': 'Cmax of fosnetupitant, netupitant, netupitant metabolites and palonosetron', 'description': 'Peak Plasma Concentration of fosnetupitant, netupitant metabolites and palonosetron', 'timeFrame': 'pre-dose(0hour), 0.5, 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96 , 120, 144, 168, 192, 216, and 240 hours post-dose'}, {'measure': 'tmax of fosnetupitant, netupitant, netupitant metabolites and palonosetron', 'description': 'Time to reach maximum (peak) plasma concentration of fosnetupitant, netupitant, netupitant metabolites and palonosetron', 'timeFrame': 'pre-dose(0hour), 0.5, 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 12, 24, 48, 72, 96 , 120, 144, 168, 192, 216, and 240 hours post-dose'}]",3.0,19 Years,45 Years,ALL,True,INDUSTRY,0.0,44.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05930847,Digital Respiratory Game in Asthma,Use of medication for asthma,['Use of medication for asthma'],1,INTERVENTIONAL,['NA'],,COMPLETED,Asthma in Children,Ege University,2025-09-01T16:18:25.983201,True,,,,NOT_FOUND,"Effect of Respiratory Training Digital Game on Respiratory Functions, and Psychological Status in Childhood Asthma",,['Asthma in Children'],"['Digital game', 'Pediatric asthma', 'Quality of life', 'Respiratory training', 'Psychological status']",,2022-02-20,2022-06-20,"[{'measure': 'Pulmonary Function Test (PFT)', 'description': 'The respiratory function of the children was evaluated with a portable spirometer (Spirobank MIR, Italy) according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) criteria. The test will be performed in a sitting position, with the patient asked to inhale deeply and then exhale rapidly through the spirometer.', 'timeFrame': '6 months'}]","[{'measure': 'The Pediatric Asthma Quality of Life Questionnaire (PAQLQ)', 'description': 'It is used to evaluate the quality of life of children aged 7-17 years by measuring the physical, mental, and social impairment specific to asthma. It is a 23-item quality-of-life scale developed to measure the physical, mental, and social disorders of children with asthma. The total score for all items is 23-161. Higher scores suggest a better quality of life.', 'timeFrame': '6 months'}, {'measure': 'Childhood Depression Inventory (CDI)', 'description': 'The depression status of the children was evaluated with the Child Depression Scale. In this 27-item scale, 1,2,3 items are specified for each question and the scoring is done on a maximum of 54 points, with 0 for 1, 1 for 2 and 2 for 3. The cut-off score is recommended as 19 and the severity of depression increases as the score increases.', 'timeFrame': '4 months'}]",3.0,8 Years,14 Years,ALL,False,OTHER,0.0,15.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00095355,Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease,Lithium,"['Lithium', 'Divalproex']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Huntington's Disease,National Institute of Neurological Disorders and Stroke (NINDS),2025-09-01T16:18:12.173451,True,,,,CHEMBL1200826,Stimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's Disease,,"[""Huntington's Disease""]","['BDNF', 'Lithium', 'Divalproex', 'Huntington Disease', 'HD']",,2004-10,2005-03,[],[],0.0,,,ALL,False,NIH,0.0,35.0,,v2_robust,True,True,False,False,,O=C([O-])[O-].[Li+].[Li+],CHEMBL1200826,partial_match,True,73.89,,4.0
NCT01760148,Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2),interferon alpha 2b,"['FDA Approval number:S20030032,H10940157', 'interferon alpha 2b', 'Generic: Recombinant Human Interferon alpha-2b,Ribavirin', 'Brand: Kaiyinyisheng,Weilake', 'Other Names:IFN+Ribavirin']",5,OBSERVATIONAL,[],,UNKNOWN,"Hepatitis C, Chronic",Junqi Niu,2025-09-01T16:18:17.184528,True,,,,NOT_FOUND,Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase),,"['Hepatitis C, Chronic', 'Liver Diseases', 'Interferon Deficiency']","['Hepatitis C Virus', 'HCV', 'Interferon', 'Prediction', 'SVR', 'Sustained Virus Response']",,2012-07,2014-03,"[{'measure': 'Absolute Blood HCV RNA Copies at designed time points', 'description': 'Blood HCV RNA copies were assayed with Roche - COBAS® AmpliPrep/COBAS® TaqMan® HCV Test.', 'timeFrame': '0hr,24hr,1wk,2wk,4wk,6wk,12wk,24wk,48wk,72wk'}]","[{'measure': 'IL-28B polymorphism', 'description': 'IL28 gene polymorphism,rs8099917,rs12979860,etc', 'timeFrame': 'Baseline'}, {'measure': 'HCV genotype', 'description': 'HCV NS5A is cloned into T vector and sequenced for evolutionary analysis.', 'timeFrame': 'Baseline'}, {'measure': 'Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)', 'description': 'ALT AST are assayed to detect the hepatic function.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Fibrosis stage', 'description': 'Fibrosis is analyzed with Fibroscan.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Regular blood test', 'description': 'The distribution and absolute count of the different types of blood cells are assayed.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Electrocardiography', 'description': 'Electrocardiography is taken to avoid severe side effects.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Alcohol ,smoking condition', 'description': 'Patients are asked whether they take alcohol or smoke cigarettes during the therapy period.', 'timeFrame': 'Baseline,4wk,12wk,24wk,48wk'}, {'measure': 'Drug abuse history', 'description': 'Patients will be asked about their drug usage history.', 'timeFrame': 'Baseline'}]",9.0,,,ALL,False,OTHER,1.0,300.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT00277030,Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams,Surfactant,['Surfactant'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Respiratory Distress Syndrome,Pontificia Universidad Catolica de Chile,2025-09-01T16:18:24.752145,True,,,,NOT_FOUND,Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams,,['Respiratory Distress Syndrome'],"['Respiratory Distress Syndrome', 'Surfactant', 'Nasal CPAP']",,2006-01,,[{'measure': 'The need of intubation and surfactant administration.'}],"[{'measure': 'Mechanical ventilation and CPAP duration.'}, {'measure': 'Oxygen therapy.'}, {'measure': 'BPD incidence.'}, {'measure': 'Length of stay.'}, {'measure': 'Enteral feeding tolerance.'}, {'measure': 'Air leak.'}, {'measure': 'NEC, gastric perforation.'}, {'measure': 'Death.'}]",9.0,5 Minutes,1 Day,ALL,False,OTHER,1.0,110.0,,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03314402,"The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers",Jaktinib Dihydrochloride Monohydrate,"['Jaktinib Dihydrochloride Monohydrate', 'PLA', 'Jaktinib', 'placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",2025-09-01T16:18:18.432801,True,,,,NOT_FOUND,"A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers",,['Healthy Volunteers'],"['JAK2 inhibitor', 'Tolerance', 'Pharmacokinetics', 'Dose-escalated']",,2017-09-28,2018-09-27,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'Evaluating Dose-Limiting Toxicities (DLTs) from the individuals taking orally dose-escalated jaktinib', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Maximum Plasma Concentration [Cmax]', 'description': 'The parameter to evaluating the plasma concentration of the oral jaktinib', 'timeFrame': 'up to 120 hours'}, {'measure': 'Area Under the Curve [AUC]', 'description': 'The parameter to evaluating the exposure of the oral jaktinib', 'timeFrame': 'up to 120 hours'}]",3.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,126.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06304805,TGRX-326 Pharmacokinetic Food Effect Bioavailability Study,cycle 1: treatment drug,"['cycle 1: reference drug', 'cycle 2: treatment drug', 'cycle 1: treatment drug', 'cycle 3: treatment drug', 'cycle 2: reference drug', 'cycle 3: reference drug']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Non Small Cell Lung Cancer,"Shenzhen TargetRx, Inc.",2025-09-01T16:18:13.416816,True,,,,NOT_FOUND,"A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human",,['Non Small Cell Lung Cancer'],[],,2023-12-13,2024-01-19,"[{'measure': 'Plasma Cmax', 'description': 'Maximum concentration of TGRX-326 measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma AUC(0-t)', 'description': 'Area Under drug concentration-time curve (AUC) from time 0 to last measureable timepoint for TGRX-326 as measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma AUC(0-inf)', 'description': 'Area Under drug concentration-time curve from time 0 to infinity for TGRX-326 as measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}]","[{'measure': 'Plasma Tmax', 'description': 'Time to maximum concentration of TGRX-326 measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'terminal elimination rate constant (lambda-z)', 'description': 'terminal elimination rate constant calculated from plasma TGRX-326 concentrations', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Elimination half-life (T1/2-Z)', 'description': 'Time for TGRX-326 to decrease from maximum plasma concentration to half of maximum plasma concentration', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'AUC(%Extrap)', 'description': 'Calculated percentage of Area under curve for AUC(0-inf) that is from last measurable timepoint ot infinity, calculated based on TGRX-326 plasma concentration over time curve.', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma volume of distribution (Vz/F)', 'description': 'Apparent volume of distribution of TGRX-326 in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma clearance (CL/F)', 'description': 'Apparent clearance of TGRX-326 in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Adverse events/serious adverse events', 'description': 'to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'through completion of the study, a total duration of 37 days'}]",10.0,18 Years,55 Years,ALL,True,INDUSTRY,1.0,24.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00271401,"A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab",Abxicimab,"['Abxicimab', 'Heparin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Angioplasty, Transluminal, Percutaneous Coronary","Centocor, Inc.",2025-09-01T16:18:08.343028,True,,,,NOT_FOUND,"A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention",,"['Angioplasty, Transluminal, Percutaneous Coronary']","['Stents', 'Angioplasty, Transluminal, Percutaneous Coronary']",,1996-07,1997-09,"[{'measure': 'Number of Participants With any one of these: Deaths, Myocardial Infarctions, or Urgent Repeat Revascularizations', 'timeFrame': 'Up to 30 days'}]","[{'measure': 'Number of Particpants with Angiographic Outcome, Death or Myocardial Infraction and Cardiovascular Functional Status', 'timeFrame': 'Up to 6 months'}]",2.0,21 Years,,ALL,False,INDUSTRY,0.0,2399.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03468062,The Effect of Dexmedetomidine on Postoperative Quality of Recovery,Dexmedetomidine,"['Dexmedetomidine', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,The Effect of Dexmedetomidine on Postoperative Quality of Recovery,Kyungmi Kim,2025-09-01T16:18:20.961278,True,,,,CHEMBL778,The Effect of Preoperative Intravenous Dexmedetomidine on Postoperative Quality of Recovery: Randomized Study,,['The Effect of Dexmedetomidine on Postoperative Quality of Recovery'],[],,2018-05-09,2019-08-31,"[{'measure': 'Quality of recovery questionnaire', 'description': 'The Quality of Recovery questionnaire (QoR-40) is a tool used to assess the quality of recovery after surgery through questions pertaining to 40 items related to 5 domains. It has been validated as a global and reliable measurement tool.', 'timeFrame': 'postoperative first day'}]",[],1.0,20 Years,75 Years,ALL,False,OTHER,0.0,90.0,ESTIMATED,v2_robust,True,False,False,False,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CHEMBL778,exact_match,True,200.28,3.18,4.0
NCT04710719,Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids,Triamcinolone Injection,"['TAC', 'Triamcinolone Injection and 5-fluorouracil injection', 'Triamcinolone Injection', 'TAC + 5FU']",4,INTERVENTIONAL,['NA'],,COMPLETED,Keloid,Our Lady of the Lake Hospital,2025-09-01T16:18:10.921404,True,,,,NOT_FOUND,Efficacy of Post-Surgical Intralesional Injection With Triamcinolone Versus Triamcinolone Plus Fluorouracil in the Treatment of Keloids,,"['Keloid', 'Keloid Scar Following Surgery']",[],,2021-02-01,2022-07-01,"[{'measure': 'Keloid Recurrence by visual assessment meaning either there is or is not a keloid physically present (determined by number of keloids observed and rate of recurrence after treatment)', 'description': 'Treatment effective if no keloid recurrence is visible by 12 months post treatment', 'timeFrame': '12 months'}]","[{'measure': 'Symptomatology-assessed by Patient and Observer Scar Assessment Scale', 'description': 'Effectiveness of treatment on symptoms (pruritus, pain, hyperpigmentation or other side effects) as determined by changes in the POSAS survey (1 being ""not observed"" to 10 being ""present always"" and also by visual assessment by the physician', 'timeFrame': '3 months'}]",2.0,,,ALL,True,OTHER,1.0,7.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02057874,3-Tesla MRI Response to TACE in HCC (Liver Cancer),Magnevist® (Intravenous (IV) administration of MRI contrast agent),"['Magnevist® (Intravenous (IV) administration of MRI contrast agent)', 'intravenous (IV) injection of Magnevist® (gadopentetate dimeglumine); IV contrast infusion; IV gadolinium (Gd)']",2,INTERVENTIONAL,['NA'],,TERMINATED,Adult Primary Hepatocellular Carcinoma,Vanderbilt-Ingram Cancer Center,2025-09-01T16:18:09.634862,True,,,,NOT_FOUND,Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC),,"['Adult Primary Hepatocellular Carcinoma', 'Advanced Adult Primary Liver Cancer', 'Localized Resectable Adult Primary Liver Cancer', 'Localized Unresectable Adult Primary Liver Cancer', 'Stage A Adult Primary Liver Cancer (BCLC)', 'Stage B Adult Primary Liver Cancer (BCLC)']",[],Funding unavailable,2014-02,2015-12-04,"[{'measure': 'Correlation of Changes in Imaging Biomarkers (Ktrans, ADC, MTR, and APTasym) as Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively, With Changes in Tumor Volume (mRECIST).', 'description': 'The following will be longitudinally measured using 3 Tesla (3T) magnetic resonance imaging (MRI) prior to transarterial chemoembolization (TACE) and 2-4, 4-8, and 12 weeks following TACE: 1) the volume transfer coefficient (Ktrans), measured by dynamic contrast-enhanced (DCE) MRI; 2) the apparent diffusion coefficient (ADC), measured by diffusion-weighted (DW) MRI; 3) the magnetization transfer ratio (MTR), measured by magnetization transfer (MT) MRI; and 4) the amide proton transfer asymmetry (APTasym), measured by chemical exchange saturation transfer (CEST) MRI. We will use a general linear model (GLM) approach to measure the association between changes in each of the above imaging metrics (relative to pretreatment baseline) and changes in tumor volume (according to standard-of-care modified RECIST) at 3 or 6 month follow-up, accounting for the effect of potential confounders, e.g., age and size of the tumor at baseline.', 'timeFrame': 'Baseline to up to 12 weeks post-TACE'}]","[{'measure': 'Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Time-to-progression (TTP).', 'description': 'Proportional hazard model will be employed to assess the ability of the longitudinal change (relative to pretreatment baseline) in each of the 3T MR imaging metrics (Ktrans, ADC, MTR, and APTasym) to predict patient survival outcomes, time-to-progression (TTP) and progression-free survival (PFS) as well as overall survival (OS). The calibration of prediction will be validated by computing the difference between predicted survival and Kaplan-Meier survival estimates at a fixed time, which estimates the over-optimism of the difference using bootstrapping.', 'timeFrame': 'Baseline to up to 6 months post-TACE'}, {'measure': 'Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Changes in the Ratio of Viable-to-necrotic Tumor Volume', 'description': 'Longitudinal changes in 3T MRI-derived measures and the change in the ratio of viable vs. necrotic tumor will be assessed by using a GLM approach in which the underlying temporal correlation can be modeled via an autoregressive order one (AR(1)) structure, validated by computing Akaike Information Criterion (AIC) against the other common structures, e.g., unstructured and constant correlation.', 'timeFrame': 'Baseline to up to 12 weeks post-TACE'}, {'measure': 'Correlation of Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Pathological Response Within Explanted Tissue Following Orthotopic Liver Transplant (OLT)', 'description': 'Histopathological features on explanted livers following OLT, including percentage necrosis and cellular density as determined by hematoxylin and eosin staining, as well as the extent of fibrosis as determined by collagen staining, will be assessed for correspondence with findings on ex vivo 3T MRI.', 'timeFrame': 'Subset of patients undergoing OLT: within 12 hours following surgery'}, {'measure': 'Correlation of Changes in Ktrans, ADC, MTR, and APTasym (Measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, Respectively) With Overall Survival (OS)', 'description': 'Proportional hazard model will be employed to assess the ability of the longitudinal change (relative to pretreatment baseline) in each of the 3T MR imaging metrics (Ktrans, ADC, MTR, and APTasym) to predict patient survival outcomes, time-to-progression (TTP) and progression-free survival (PFS) as well as overall survival (OS). The calibration of prediction will be validated by computing the difference between predicted survival and Kaplan-Meier survival estimates at a fixed time, which estimates the over-optimism of the difference using bootstrapping.', 'timeFrame': 'Baseline to up to 6 months post-TACE'}]",5.0,18 Years,,ALL,False,OTHER,1.0,2.0,ACTUAL,v2_robust,True,False,True,False,Funding unavailable,,,no_match,False,,,
NCT00344227,Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study),Lucentis (Ranibizumab),['Lucentis (Ranibizumab)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Neovascular Age-Related Macular Degeneration,University of Miami,2025-09-01T16:18:18.424557,True,,,,NOT_FOUND,Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular Age-Related Macular Degeneration (AMD) Treated With Intra-Ocular Lucentis™ (Ranibizumab): PrONTO Study,,['Neovascular Age-Related Macular Degeneration'],"['neovascularization', 'age-related macular degeneration', 'vascular endothelial growth factor (VEGF)', 'antigen-binding fragment (Fab)', 'antiangiogenesis', 'optical coherence tomography (OCT)']",,2004-08,2007-04,"[{'measure': 'Mean Visual Acuity'}, {'measure': 'Total number of treatments'}]","[{'measure': 'Time to decrease of OCT central retinal thickness'}, {'measure': 'Time to improved visual acuity'}, {'measure': 'Proportion gaining 3 lines of vision'}, {'measure': 'Proportion stable or improved'}, {'measure': 'Frequency of Retreatment'}]",7.0,50 Years,,ALL,False,OTHER,1.0,40.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06121830,Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD),DWP14012 20mg,"['DWP14012 40mg', 'DWP14012 20mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Non-erosive Reflux Disease,Daewoong Pharmaceutical Co. LTD.,2025-09-01T16:18:19.660805,True,,,,NOT_FOUND,"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-erosive Gastroesophageal Reflux Disease",,"['Non-erosive Reflux Disease', 'Non-Erosive Gastro-Esophageal Reflux Disease', 'Non-Erosive Esophageal Reflux Disease']",['NERD'],,2023-08-31,2025-03,"[{'measure': 'Percentage of heartburn-free days for 4 weeks (daytime/nighttime)', 'timeFrame': '4 Weeks'}]","[{'measure': 'Percentage of major symptom-free (heartburn, acid regurgitation, or heartburn/acid regurgitation) days for 2 and 4 weeks (daytime/nighttime, daytime and nighttime)', 'timeFrame': '4 Weeks'}]",2.0,19 Years,75 Years,ALL,False,INDUSTRY,0.0,324.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02614742,SFX-01 After Subarachnoid Haemorrhage,SFX-01,"['Cyclodextrin', 'Sulforadex', 'SFX-01', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Subarachnoid Hemorrhage, Spontaneous",Evgen Pharma,2025-09-01T16:18:20.963789,True,,,,NOT_FOUND,SFX-01 After Subarachnoid Haemorrhage,,"['Subarachnoid Hemorrhage, Spontaneous']",[],,2016-04,2019-11,"[{'measure': 'Number of participants with treatment-related adverse events as assessed by Common Toxicity Criteria', 'description': 'To evaluate the safety of up to 28 days of SFX-01 dosed at up to 96 mg Sulforaphane (SFN) per day', 'timeFrame': 'up to 28 days'}, {'measure': 'Maximum CSF Concentration [Cmax],', 'description': 'To detect the presence of SFN in Cerebrospinal Fluid (CSF)', 'timeFrame': 'up to 28 days'}, {'measure': 'Number of participants with treatment related reduction in middle cerebral artery (MCA) peak flow velocity following Subarachnoid Haemorrhage (SAH) measured by trans cranial doppler ultrasound', 'description': 'To determine if a minimum of 7 days treatment with SFX-01 reduces Middle Cerebral Artery (MCA) peak flow velocity following Subarachnoid Haemorrhage (SAH).', 'timeFrame': 'up to 28 days'}]","[{'measure': 'modified Rankin Scale', 'description': 'To determine if a minimum of 7 days treatment with SFX-01 improves clinical outcome following SAH as measured using the modified Rankin Scale assessed at 7 , 28, 90 and 180 days post ictus.', 'timeFrame': 'up to 180 days post ictus'}, {'measure': 'Plasma PK', 'description': 'To determine plasma SFN levels (and its metabolites) with treatment with SFX-01 (300mg bid).', 'timeFrame': 'up to 28 days'}, {'measure': 'CSF drug levels', 'description': 'To determine CSF drug levels following treatment with SFX-01 (300mg bid).', 'timeFrame': 'up to 14 days'}, {'measure': 'Serum Haptoglobin levels', 'description': 'To determine if up to 28 days treatment with SFX-01 increases serum haptoglobin (HP) levels following SAH', 'timeFrame': 'Up to 28 days'}, {'measure': 'Delayed Cerebral Ischaemia', 'description': 'To determine if up to 28 days treatment with SFX-01 can reduce the incidence of Delayed Cerebral Ischaemia (DCI) following SAH.', 'timeFrame': 'Up to 28 days'}]",8.0,18 Years,80 Years,ALL,False,INDUSTRY,0.0,90.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00777738,Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia,BORTEZOMIB,['BORTEZOMIB'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Waldenstrom Macroglobulinemia,Assistance Publique - Hôpitaux de Paris,2025-09-01T16:18:17.182881,True,,,,NOT_FOUND,A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia,,['Waldenstrom Macroglobulinemia'],"[""Advanced Waldenström's macroglobulinemia"", 'Bortezomib', 'Dexamethasone', 'Safety', 'Efficacy']",,2008-10,2012-08,"[{'measure': ""Complete and partial remission, defined by the 2nd Workshop on Waldenstrom's macroglobulinemia"", 'timeFrame': '3 months and 6 months'}]","[{'measure': 'Duration of the response', 'timeFrame': 'during the study'}, {'measure': 'Overall survival', 'timeFrame': 'during the study'}, {'measure': 'Quality of life', 'timeFrame': 'months 0, 3, 12, 24'}]",4.0,18 Years,,ALL,False,OTHER,0.0,34.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00920309,Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy,Rapamycin,"['sirolimus', 'Rapamycin']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,TERMINATED,Autosomal Dominant Polycystic Kidney Disease,Yale University,2025-09-01T16:18:14.657796,True,,,,NOT_FOUND,Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy,,['Autosomal Dominant Polycystic Kidney Disease'],"['Autosomal Dominant Polycystic Kidney Disease', 'rapamycin', 'ADPKD']",This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD,2009-06,2010-07,"[{'measure': 'Total Kidney Volume (mL)', 'timeFrame': '2 years'}]","[{'measure': 'Glomerular Filtration Rate (Kidney Function)', 'timeFrame': '2 years'}]",2.0,18 Years,70 Years,ALL,True,OTHER,0.0,21.0,ACTUAL,v2_robust,True,False,True,False,This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD,,,no_match,False,,,
NCT01854658,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",GFF MDI (PT003),"['(GFF MDI)', 'GP MDI (PT001)', 'glycopyrrolate/formoterol fumarate metered-dose inhaler', 'glycopyrrolate metered dose inhaler (GP MDI)', 'formoterol fumarate metered dose inhaler (FF MDI)', 'Placebo', 'FF MDI (PT005)', 'GFF MDI (PT003)']",8,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Chronic Obstructive Pulmonary Disease (COPD),"Pearl Therapeutics, Inc.",2025-09-01T16:18:09.627283,True,,,,NOT_FOUND,"A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo",,['Chronic Obstructive Pulmonary Disease (COPD)'],[],,2013-07,2015-03,"[{'measure': 'Change From Baseline in Morning Pre-dose Trough FEV1', 'description': 'Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24.', 'timeFrame': 'At Week 24'}]","[{'measure': 'Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks', 'description': 'Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.', 'timeFrame': 'Over 24 weeks'}, {'measure': 'Peak FEV1', 'description': 'Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24', 'timeFrame': 'At week 24'}, {'measure': 'St. George Respiratory Questionnaire (SGRQ) Score', 'description': 'Change from baseline in the SGRQ total score at Week 24. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.', 'timeFrame': '24 weeks'}, {'measure': 'Rescue Ventolin HFA Use', 'description': 'Change from baseline in average daily rescue Ventolin HFA use over 24 weeks', 'timeFrame': '24 weeks'}, {'measure': 'Onset of Action as Assessed by FEV1', 'description': 'Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant', 'timeFrame': 'Day 1'}]",6.0,40 Years,80 Years,ALL,False,INDUSTRY,0.0,1615.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06066112,Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body,"Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.","['Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.', 'Reference (R) Amisulpride tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Bioequivalence,The Affiliated Hospital of Qingdao University,2025-09-01T16:18:22.197932,True,,,,NOT_FOUND,"Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets (200 mg) in Chinese Healthy Subjects Under Single Dose, Randomized, Open, Two Formulation, Two Sequence, Two Cycle, Double Crossover, Fasting, and Postprandial Conditions",,"['Bioequivalence', 'Schizophrenia']",['amisulpride orally disintegrating tablets'],,2023-09-20,2024-03-31,"[{'measure': 'Cmax', 'description': 'Evaluation of Peak Plasma Concentration (Cmax)', 'timeFrame': '48 hours'}, {'measure': 'Area under the plasma concentration versus time curve (AUC0-t)', 'description': 'Area under the drug concentration-time curve from time 0 to the last accurately measurable concentration at sample collection time t', 'timeFrame': '48 hours'}, {'measure': 'Area under the plasma concentration versus time curve (AUC0-∞)', 'description': 'Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinite Time', 'timeFrame': '48 hours'}]",[],3.0,18 Years,,ALL,True,OTHER,0.0,100.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02321397,To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain,Oxycodone,"['Oxycodone', 'Naloxone']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Malignant Pain,Mundipharma Research GmbH & Co KG,2025-09-01T16:18:09.636107,True,,,,CHEMBL1200890,"Randomised, Double-blind, Double-dummy, Cross-over Multicenter Study to Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Taking Oxycodone Equivalents of 120 & 160 mg Per Day as Achieved With the Higher OXN PR Tablet Strengths (OXN60/30 mg PR, OXN80/40 mg PR) BID Compared to the Identical Daily Dose Taken as a Combination of Lower Tablet Strengths in Subjects With Non-malignant or Malignant Pain That Requires Around-the-clock Opioid Therapy.",,"['Malignant Pain', 'Non-malignant Pain']","['oxycodone naloxone combination', 'severe chronic and non-malignant pain', 'Malignant and non-malignant pain that requires around-the clock opioid therapy']",,2014-11,2016-09,"[{'measure': '(mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale.)', 'description': 'Pain scores based on the mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale. To demonstrate equivalence between multiple lower strength OXN PR tablets and a single higher strength OXN PR tablet taken at the same overall total daily dose', 'timeFrame': '24 hours at one day in week 2, 3 5 and 6 from date of randomisation.'}, {'measure': 'Equivalent bowel function as assessed by the Bowel Function Index (BFI).', 'timeFrame': 'Week 2, 3 5 and 6 from date of randomisation.'}]","[{'measure': 'Pain scores of subjects average pain over the last 24 hours and rescue medication use.', 'timeFrame': 'Week 1,2,3,4,5 and 6 from date of randomisation'}, {'measure': 'To assess bowel function (assess BFI and laxative use)', 'description': 'To assess BFI and laxative use', 'timeFrame': 'Week 1,2,3,4,5 and 6 from date of randomisation'}, {'measure': 'To assess quality of life based on the EuroQol EQ-5D.', 'description': 'EuroQol EQ-5D is a standardized instrument for use as a measure of health outcome.', 'timeFrame': 'Visit 3 and visit 6 from date of randomisation'}, {'measure': 'Number of participants with adverse events, high/low laboratory values and clinically significant ECG findings.', 'timeFrame': 'Up to 35 weeks'}, {'measure': 'Pain right now scores at intake of oxycodone/naloxone tablets.', 'timeFrame': 'Week 2,3,5 and 6 from date of randomisation'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,155.0,ACTUAL,v2_robust,True,True,False,True,,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,CHEMBL1200890,partial_match,True,351.83,1.05,4.0
NCT03239743,Effects of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in Children and Adolescents,Midazolam,"['Midazolam', 'Versed']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Tonsillectomy,Valley Anesthesiology Consultants,2025-09-01T16:18:09.629678,True,,,,NOT_FOUND,A Pilot Study to Evaluate the Efficacy of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in a Children's Hospital,,['Tonsillectomy'],"['virtual reality', 'adenoidectomy', 'induction of anesthesia', 'pre-operative anxiety']",,2017-07-20,2019-05,"[{'measure': 'Pre-Operative Anxiety measured by mYPAS anxiety scores', 'description': 'Determine if the use of a VR device will result in lower mYPAS anxiety scores during the preoperative period', 'timeFrame': 'Baseline'}]","[{'measure': 'Induction Compliance of Anesthesia measured by the induction compliance checklist', 'description': 'Determine if the use of a VR device will result in greater induction of anesthesia measured by the induction compliance checklist.', 'timeFrame': 'Baseline'}, {'measure': 'Post-Operative Emergence Delirium measured by the PAED scale', 'description': 'Determine if VR use will reduce incidence of post-operative emergence delirium measured by the PAED scale.', 'timeFrame': 'up to 3 hours post operative'}, {'measure': 'Post-Operative Pain', 'description': 'Measure if VR use will reduce post-operative pain scores compared to patients receiving standard of care.', 'timeFrame': 'up to 3 hours post operative'}, {'measure': 'Post-Operative Opioid Use', 'description': 'Measure VR use will reduce opioid use compared to patients receiving standard of care', 'timeFrame': 'up to 3 hours post operative'}]",5.0,5 Years,11 Years,ALL,True,OTHER,2.0,80.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04795583,Corticosteroids for COVID-19,Prednisone,['Prednisone'],1,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Covid19,University of Alberta,2025-09-01T16:18:20.965655,True,,,,CHEMBL635,A Randomized Clinical Trial Comparing 7 Days Treatment With Corticosteroids Versus Placebo for Early COVID-19,,['Covid19'],[],Funding Issues,2021-08-01,2022-08,"[{'measure': 'Hospital admission or death in the first 2 weeks after randomization', 'description': 'Need to be admitted to hospital or death during the first 2 weeks after randomization', 'timeFrame': '14 days'}]","[{'measure': 'Hospitalization at 30 days', 'description': 'Need of hospital admission in the first 30 days after randomization', 'timeFrame': '30 days'}, {'measure': 'Mortality at 30 days', 'description': 'Death in the first 30 days after randomization', 'timeFrame': '30 days'}, {'measure': 'Serious adverse events at 30 days', 'description': 'Occurrence of SAEs in the first 30 days after randomization', 'timeFrame': '30 days'}, {'measure': 'Death at week 12', 'description': 'Death in the first 12 weeks after randomization', 'timeFrame': 'Week 12'}, {'measure': 'Duration of symptoms', 'description': 'COVID-19 symptoms duration in days', 'timeFrame': 'Week 12'}]",6.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,True,Funding Issues,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,CHEMBL635,exact_match,True,358.43,1.77,4.0
NCT01162460,Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures,Eslicarbazepine acetate (BIA 2-093),['Eslicarbazepine acetate (BIA 2-093)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Epilepsy,Bial - Portela C S.A.,2025-09-01T16:18:07.020984,True,,,,CHEMBL1067,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study",,['Epilepsy'],[],,2010-12,2016-09,"[{'measure': 'The primary efficacy variable will be the proportion of subjects in the PP set who are seizure free for the entire 26-week Evaluation Period at the last received dose level.', 'timeFrame': '26 weeks'}]","[{'measure': 'Proportion of subjects in the ITT set without a seizure during the 26-week Evaluation Period at the last evaluated dose.', 'timeFrame': '26 weeks'}, {'measure': 'Proportion of subjects without a seizure during the 26-week Evaluation Period at the last evaluated dose.', 'timeFrame': '26 weeks'}, {'measure': 'Proportion of seizure-free subjects during 1 year of treatment at the last evaluated dose, where the end of the 1-year period is defined as the same start date as for the 26-week evaluation +365 days.', 'timeFrame': '52 weeks'}, {'measure': 'Time to first seizure at the last evaluated dose set.', 'timeFrame': 'up to 183 weeks'}, {'measure': 'QOLIE-31 and Bond-Lader VAS', 'description': 'Changes in quality of life assessed using the QOLIE-31 (Overall score, subscores covering emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects and assessment of overall health).', 'timeFrame': '26 weeks; up to 183 weeks'}, {'measure': 'Treatment retention time at the last evaluated dose', 'description': 'Treatment retention time at the last evaluated dose, where treatment retention time is defined as the time of the first occurrence of one of the following:\n\n* Withdrawal of IMP due to AEs.\n* Withdrawal of IMP due to lack of efficacy.', 'timeFrame': '26 weeks'}, {'measure': 'Time to treatment failure at the first evaluated dose', 'description': 'Time to treatment failure at the first evaluated dose, where time to treatment failure is defined as the time of the first occurrence of 1 of the following:\n\n* Seizure\n* Withdrawal of IMP due to AEs.\n* Withdrawal of IMP due to lack of efficacy.', 'timeFrame': '26 weeks'}, {'measure': 'seizure freedom', 'description': 'Dose level at which subjects reached 26-week seizure freedom.', 'timeFrame': '26 weeks'}, {'measure': 'Adverse Event monitoring', 'description': 'Incidence of AEs, SAEs, withdrawals, out-of-range laboratory values, abnormal 12-lead ECG and physical examination findings.', 'timeFrame': 'up to 183 weeks'}]",10.0,18 Years,,ALL,False,INDUSTRY,0.0,815.0,ACTUAL,v2_robust,True,True,False,True,,NC(=O)N1c2ccccc2CC(O)c2ccccc21,CHEMBL1067,partial_match,True,254.29,2.49,3.0
NCT01437735,Dose Finding Study for QAW039 in Asthma,QAW039,"['Montelukast', 'QAW039', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Asthma,Novartis Pharmaceuticals,2025-09-01T16:18:19.677741,True,,,,NOT_FOUND,"A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.",,['Asthma'],"['Asthma', 'QAW039']",,2011-08,2013-11,"[{'measure': 'Change in trough Forced Expiratory Volume in 1 second (FEV1) from baseline to week 12', 'description': 'Forced Expiratory Volume in 1 second (FEV1) (measured in litters), and the trough measurement is taken 24 hours after morning dose on the previous day.', 'timeFrame': 'Baseline and week 12'}]","[{'measure': 'Change in Asthma Control Questionnaire (ACQ) score from baseline to week 12', 'description': 'The Asthma Control Questionnaire (ACQ) is a validated questionnaire consisting of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 assessing the patients Forced Expiratory Volume in 1 second (FEV1) result against the predicted result for a person of similar age and stature. Each item is graded on a scale of 0-6, and a mean score of 1.5 or greater is considered to demonstrate inadequate asthma control in this trial. The minimal important difference that is considered clinically important is a change of 0.5 in the mean score.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change in Forced Expiratory Volume in 1 second (FEV1) from baseline to weeks 2, 4 and 8.', 'description': 'Forced Expiratory Volume in 1 second (FEV1) (measured in litters), and the measurement is taken 24 hours after the morning dose on the previous day.', 'timeFrame': 'Baseline, week 2, week 4 and week 8'}, {'measure': 'Change in the Asthma Control Questionnaire (ACQ) score from baseline to weeks 2, 4 and 8.', 'description': 'The Asthma Control Questionnaire (ACQ) is a validated questionnaire consisting of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 assessing the patients Forced Expiratory Volume in 1 second (FEV1) result against the predicted result for a person of similar age and stature. Each item is graded on a scale of 0-6, and a mean score of 1.5 or greater is considered to demonstrate inadequate asthma control in this trial. The minimal important difference that is considered clinically important is a change of 0.5 in the mean score.', 'timeFrame': 'Baseline, week 2, week 4 and week 8'}, {'measure': 'Change in the dose response relationship among QAW039 doses with respect to Forced Expiratory Volume in 1 second (FEV1) after 12 weeks treatment.', 'description': 'Forced Expiratory Volume in 1 second (FEV1) (measured in litters), and the measurement is taken 24 hours after the morning dose on the previous day.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Comparison of vital signs, ECG, laboratory tests and adverse events across QAW039 doses and placebo.', 'description': 'Comparisons of vital signs (i.e. systolic and diastolic blood pressure, pulse rate), ECG (e.g. quantitative assessments - heart rate, QTcF, PRS, PR intervals), laboratory tests (haematology, clinical chemistry and urinalysis) and adverse events across QAW039 doses and placebo.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Comparison of efficacy of QAW039 with that of active comparator as an add-on therapy to Inhaled Corticosteroids (ICS)', 'description': 'Forced Expiratory Volume in 1 second (FEV1) measurement taken 24 hours after the morning dose on the previous day. The Asthma Control Questionnaire (ACQ)consisting of 7 items: 5 on system assessment, 1 on rescue bronchodilator use and 1 assessing the patients for FEV1 result against the predicted result for a person of similar age and stature. Each item is graded on a scale of 0-6, and a mean score of 1.5 or greater is considered to demonstrate inadequate asthma control in this trial. The minimal important difference that is considered clinically important is a change of 0.5 in the mean score.', 'timeFrame': 'Baseline and week 12'}, {'measure': 'Assess the effect of QAW039 on asthma symptoms as measured by asthma control diary.', 'description': 'The asthma control diary mimics the Asthma Control Questionnaire (ACQ), but is recorded daily by the patient, rather than at each visit. As for the ACQ, the ACD consists of 7 questions.', 'timeFrame': 'Baseline and week 12'}]",8.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,1043.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02162160,Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women,Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Post Menopausal Dryness in the Intimate Area of Women,Karolinska Institutet,2025-09-01T16:18:14.677677,True,,,,NOT_FOUND,Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women,,['Post Menopausal Dryness in the Intimate Area of Women'],"['probiotic', 'post-menopausal', 'atrophic vaginitis']",,2013-09,2014-03,"[{'measure': 'Presence of at least one LN bacteria strain in the intimate area of women in the intervention group', 'description': 'Bacterial Culture of LN bacterial strains', 'timeFrame': 'the end of a 10 days crème-usage'}]","[{'measure': 'Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area', 'description': 'Measured by bacterial Culture and subtyping by PCR', 'timeFrame': 'at the end of creme usage and 10 days after finished crème-usage (9-11 days after).'}, {'measure': 'subjective feeling of dryness and freshness in the intimate of women', 'description': 'Assessed through self adminstered questionnair with grading of feeling of dryness and freshness on a scale from 0 (no dryness and feeling fresh) to 5 (max dryness and absolutely not feeling fresh)', 'timeFrame': 'the end of the 10 days crème-usage (Day 8-10) and 10 days after finished crème-usage (9-11 days after)'}]",3.0,45 Years,65 Years,FEMALE,False,OTHER,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02480764,Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension,Azilsartan medoxomil,"['Valsartan Placebo', 'Valsartan', 'Diovan®', 'Azilsartan medoxomil Placebo', 'Azilsartan medoxomil', 'Edarbi', 'TAK-491']",7,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Essential Hypertension,Takeda,2025-09-01T16:18:24.757851,True,,,,CHEMBL57242,"A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension",,['Essential Hypertension'],['Drug therapy'],,2015-08-27,2017-10-13,"[{'measure': 'Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP)', 'description': ""The change in trough clinic sitting SBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting SBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Baseline and Week 8'}]","[{'measure': 'Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure (DBP)', 'description': ""The change in trough clinic sitting DBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting DBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Percentage of Participants Who Achieved a Clinic SBP Response at Week 8', 'description': ""Clinic SBP response was defined as clinic SBP \\<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved a Clinic DBP Response at Week 8', 'description': ""Clinic DBP response was defined as clinic DBP \\<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved Both Clinic SBP and DBP Response at Week 8', 'description': ""Clinic SBP response was defined as clinic SBP \\<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline and clinic DBP response was defined as clinic DBP \\<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved Target Clinic SBP <140 mm Hg, Clinic DBP <90 mm Hg or Both at Week 8', 'description': ""Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved Target Clinic SBP <130 mm Hg, Target Clinic DBP <80 mm Hg or Both at Week 8', 'description': ""Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,612.0,ACTUAL,v2_robust,True,True,False,False,,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,CHEMBL57242,partial_match,True,456.46,4.19,3.0
NCT03053830,Open Label Ketamine Treatment for Major Depressive Disorder in Veterans,Ketamine,['Ketamine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Major Depressive Disorder,VA Connecticut Healthcare System,2025-09-01T16:18:10.921818,True,,,,CHEMBL1714,An Open Label Study of the Effects of Ketamine on a Veteran Clinical Population With Major Depressive Disorder (MDD),,['Major Depressive Disorder'],"['Ketamine', 'Major Depressive Disorder']",,2017-01-31,2018-09-26,"[{'measure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)', 'description': 'MADRS is a standardized instrument to ascertain depressed mood and neurovegetative signs and symptoms of a major depressive episode.', 'timeFrame': 'Baseline, 40 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Quick Inventory of Depressive Symptomatology-Self Report (QUIDS-SR)', 'description': 'A patient rated depression instrument', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Hamilton Anxiety Rating Scale (HAM-A)', 'description': 'Standardized instrument to evaluate anxiety severity', 'timeFrame': 'Frame: Baseline, 40 mins after infusion,140 mins after infusion, 240 mins after infusion'}, {'measure': 'Clinical Global Impression Scale', 'description': 'Widely used instrument which asses overall severity of illness on a 1-7 point scale, with 1 indicating, not at all ill and 7 indicating among the most extremely ill patients', 'timeFrame': 'Baseline'}, {'measure': 'Change in Brief Psychotic Rating Scale (BPRS)', 'description': 'The BPRS is a standardized instrument that contains scales assessing psychotic symptoms including positive and negative symptoms, activation and emotional distress.', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Clinician-Administered Dissociative States Scale (CADSS)', 'description': 'The CADSS has self and interviewer-administered items including 5 subscales, generated a priori, evaluating dissociation including altered environmental perception, time perception, spatial/body perception, derealization and memory impairment.', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Change in Visual Analog Scale (VAS) of Mood States', 'description': 'The VAS includes scales for anxiety, drowsiness, high irritability, anger and sadness. The scales are 100 mm lines marked by subjects at a point corresponding to the apparent intensity of the feeling state (0 = none, to 100 = most ever).', 'timeFrame': 'Baseline, 40 mins after infusion, 80 mins after infusion, 110 mins after infusion, 140 mins after infusion, 240 mins after infusion'}, {'measure': 'Time Line Follow Back (TLFB)', 'description': 'The TLFB is a standardized measure utilized for collecting information on daily alcohol use as well as other substance use.', 'timeFrame': 'Baseline'}, {'measure': 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS has both lifetime/recent and since last visit versions. The ""Lifetime/Recent"" version gathers information on lifetime history of suicidality and recent suicidal ideation/self-injurious behavior. The ""Since Last Visit"" version of the C-SSRS asks about any suicidal thoughts or behaviors the subject has exhibited since the last time administered the C-SSRS.', 'timeFrame': 'Baseline'}, {'measure': 'Quality of life enjoyment and satisfaction survey (Q-LES-Q)', 'description': 'The Q-LES-Q is a self-report measure of quality of life.', 'timeFrame': 'Baseline'}, {'measure': 'Cognition', 'description': 'A standard computerized battery will be done to assess cognitive ability post treatment of ketamine. The battery will include a wide range on cognitive tasks including but not\n\nlimited to attention, learning, and working memory. While it is know ketamine causes acute cognitive effects, the longer-term effects of ketamine are not known. When the cognitive battery is being conducted on test days it will be done at the end of the test day, to eliminate the confounding effects of acute treatment of ketamine..', 'timeFrame': '140 mins after infusion'}]",[],11.0,21 Years,75 Years,ALL,False,FED,0.0,11.0,ACTUAL,v2_robust,True,True,False,False,,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,CHEMBL1714,partial_match,True,274.19,2.9,4.0
NCT01207622,Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD,Atomoxetine,"['Atomoxetine', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,WITHDRAWN,Attention Deficit Hyperactivity Disorder,Massachusetts General Hospital,2025-09-01T16:18:24.743314,True,,,,CHEMBL1702,Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD),,"['Attention Deficit Hyperactivity Disorder', 'Substance Use Disorder']",[],Poor enrollment,,,[],[],0.0,15 Years,30 Years,ALL,False,OTHER,2.0,0.0,ACTUAL,v2_robust,True,False,True,False,Poor enrollment,CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl,CHEMBL1702,partial_match,True,291.82,3.72,4.0
NCT02762084,"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients",Patidegib,"['Study drug', 'Placebo', 'Patidegib', 'Vehicle gel']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Basal Cell Nevus Syndrome,"PellePharm, Inc.",2025-09-01T16:18:22.210606,True,,,,CHEMBL2105764,"Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients",,['Basal Cell Nevus Syndrome'],"['Gorlin Syndrome', 'Basal Cell', 'Nevus Syndrome', 'BCNS', 'nevoid basal cell carcinoma syndrome', 'Basal cell carcinoma', 'Hedgehog', 'Surgically Eligible Basal Cell Carcinomas']",,2016-06-06,2017-04-24,"[{'measure': 'Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline', 'description': 'SEBs were defined as clinically diagnosed basal cell carcinoma (BCC) 5 millimeters (mm) or greater in diameter on the face, excluding the nose and periorbital skin, and 9 mm or greater at sites other than the face. The percent change in greatest diameters of treatment-targeted surgically eligible basal cell carcinomas (SEBs) from Baseline to Week 26 was calculated as follows: (sum \\[Baseline\\] - sum \\[Week 26\\] / sum \\[Baseline\\] \\* 100), where sum = the greatest diameters of Baseline treatment-targeted SEBs and positive numbers represent decrease in tumor size and negative numbers to represent increase in tumor size. Missing values were imputed using Last-Observation Carried Forward (LOCF).', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Molecular Efficacy: Percent Change in the Hedgehog (HH) Signaling Pathway Target Gene Glioma-associated Oncogene Homolog 1 (GLI1) Messenger Ribonucleic Acid (mRNA) Levels From Baseline', 'description': 'SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin, and 9-mm or greater at sites other than the face. A single baseline SEB designated as a treatment targeted tumor at Baseline was biopsied first at Baseline and again following 6 weeks of treatment. This was used to assess percent change in GLI1 mRNA levels as follows: (Baseline - Week 6) / Baseline \\* 100, where positive numbers to represent decrease in GL1 mRNA level and negative numbers to represent increase in GL1 mRNA level. Any missing values were not imputed; all available data is summarized.', 'timeFrame': 'Baseline, Week 6'}, {'measure': 'Safety and Tolerability Assessment of Treatment With Patidegib Gel: Number of Participants With a Treatment-emergent Adverse Event Causally Related to Study Drug', 'description': 'All serious adverse events (SAEs) and all other non-serious adverse events (AEs) regardless of causality are located in the Reported AE Module. AEs considered as related where categorized by the Investigator as either definitely related, probably related, or possibly related. Treatment-emergent AEs are those with an onset after use of study drug.', 'timeFrame': 'Baseline through Week 26'}, {'measure': 'Safety and Tolerability Assessment of Treatment With Patidegib Gel: Number of Participants With Treatment-emergent Administrative Site Skin Condition AEs Causally Related to Study Drug', 'description': 'All SAEs and all other non-serious AEs, regardless of causality, are located in the Reported AE Module. The number of participants reporting administrative-site, skin condition treatment-emergent AEs considered related to study drug by the Investigator are presented below. Treatment-emergent AEs are those with an onset after use of study drug.', 'timeFrame': 'Baseline through Week 26'}]","[{'measure': 'The Number of Participants Reporting New SEBs on the Face From Baseline for the Combined Patidegib Treatment Groups', 'description': 'Facial SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin. A new facial SEB was defined as an SEB first noted on the face after Week 2 that developed at a site where there was no visible BCC of any size at Baseline or Week 2. New facial SEBs were investigated for participants on vehicle gel versus participants on patidegib 2% and 4% gel. Missing values were imputed using LOCF.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'The Mean Number of New SEBs on the Face for the Combined Patidegib Treatment Groups', 'description': 'Facial SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin. A new facial SEB was defined as an SEB first noted on the face after Week 2 that developed at a site where there was no visible BCC of any size at Baseline or Week 2. New facial SEBs were investigated for participants on vehicle gel versus participants on patidegib 2% and 4% gel. Missing values were imputed using LOCF. The mean number of new SEBs (number per participant) are presented. No measure of dispersion/precision was calculated.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'The Mean Number of New SEBs on the Face for the Combined Patidegib Treatment Groups by Tumor Population', 'description': 'Facial SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin. A new facial SEB was defined as an SEB first noted on the face after Week 2 that developed at a site where there was no visible BCC of any size at Baseline or Week 2. New facial SEBs were investigated for participants on vehicle gel versus participants on patidegib 2% and 4% gel. Missing values were imputed using LOCF. The mean number of new SEBs (number per participant) are presented. No measure of dispersion/precision was calculated.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Percent Change in Baseline Treatment-targeted SEBs Tumor Size From Baseline', 'description': 'SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin, and 9 mm or greater at sites other than the face. The percent change in greatest diameters of Baseline treatment-targeted SEBs from Baseline to Week x (Week 6, 10, 14, 18, or 22) was calculated as follows: (sum \\[Baseline\\] - sum \\[Week x\\] / sum \\[Baseline\\] \\* 100), where sum = the greatest diameters of Baseline treatment-targeted SEBs, and positive numbers to represent decrease in tumor size and negative numbers to represent increase in tumor size. Missing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, and 22'}, {'measure': 'Percent Change in Central Facial SEBs From Baseline', 'description': 'Central facial SEBs were defined as those located on the nose or periorbital area (eyelids) which were 3 mm or greater at Baseline. The percent change from Baseline to Week x (Week x = Weeks 6, 10, 14, 18, 22, or 26) in central facial SEBs was calculated as follows: \\[sum (Baseline) - sum (Week x)\\] / \\[sum (Baseline)\\] \\* 100 where sum = the greatest diameters of Baseline treatment-targeted SEBs where positive numbers to represent decrease in tumor size and negative numbers to represent increase in tumor size. Missing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, 22, and 26'}, {'measure': 'Proportion of Non-central Facial BCCs Increasing to ≥ 5 mm From Baseline', 'description': 'The proportion of non-central facial BCCs that at Baseline measured a greatest diameter of \\< 5 mm and increased to a diameter of ≥ 5 mm by Week x (Week x = Weeks 6, 10, 14, 18, 22, or 26) were calculated for each participant as follows: (Number of non-central facial BCCs with greatest diameter ≥ 5 mm at Week x) / (Number of non-central facial BCCs with greatest diameter \\< 5 mm at Baseline). Missing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, 22, and 26'}, {'measure': 'Proportion of Treatment-Targeted SEBs No Longer Classified as SEBs After 26 Weeks', 'description': 'SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin, and 9 mm or greater at sites other than the face. The proportion of Baseline treatment-targeted SEBs that at the end of 26 weeks of treatment were no longer large enough to be classified as SEBs (that is, the proportion of Baseline treatment targeted SEBs on the face that became \\< 5 mm in greatest diameter and non-facial Baseline treatment targeted SEBs that became \\< 9 mm in greatest diameter) were calculated for each participant as follows:\n\n(Number of Baseline treatment-targeted facial SEBs with greatest diameter \\< 5 mm) + (Baseline treatment targeted non-facial SEBs with greatest diameter \\< 9 mm) / Number of baseline treatment targeted SEBs.\n\nMissing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, 22, and 26'}]",11.0,18 Years,85 Years,ALL,False,INDUSTRY,0.0,17.0,ACTUAL,v2_robust,True,True,False,True,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C.Cl,CHEMBL2105764,partial_match,True,541.24,5.03,2.0
NCT01810575,Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction,WC3036-11F/Alprostadil in Vehicle 2.5%,"['12F', 'WC3036-11F/Alprostadil in Vehicle 2.5%', 'Vehicle', 'WC3036-12F/Alprostadil in Vehicle 0.5%', '11F', 'WC3036-13P/Vehicle Only 0.5%']",6,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Erectile Dysfunction,Warner Chilcott,2025-09-01T16:18:24.749394,True,,,,NOT_FOUND,A Study to Assess the Relative Efficacy and Safety of a Single Dose of Alprostadil Cream Combined With 2 Concentrations of WC3036 Compared to Vehicle in Subjects With Erectile Dysfunction,,['Erectile Dysfunction'],[],Re-assessment of study,2013-02,2013-04,"[{'measure': 'Penile rigidity', 'description': '≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 1 / Up to 5 days ± 3 days'}, {'measure': 'Penile rigidity', 'description': '≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 2 / Up to 9 days ± 3 days'}, {'measure': 'Penile rigidity', 'description': '≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 3 / Up to 14 Days'}]","[{'measure': 'Quality of erection', 'description': 'Subject description of quality of erection using non-validated questionnaire. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 1 / Up to 5 days ± 3 days'}, {'measure': 'Quality of erection', 'description': 'Subject description of quality of erection using non-validated questionnaire. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 2 / Up to 9 days ± 3 days'}, {'measure': 'Quality of erection', 'description': 'Subject description of quality of erection using non-validated questionnaire. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 3 / Up to 14 days'}]",6.0,40 Years,,MALE,False,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,False,True,False,Re-assessment of study,,,no_match,False,,,
NCT06090474,"Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers",NDC-002,['NDC-002'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Stroke Sequelae,Dr. Noah Biotech Inc.,2025-09-01T16:18:18.415669,True,,,,NOT_FOUND,"An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability Between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers",,"['Stroke Sequelae', 'Stroke']",[],,2023-01-12,2023-03-15,"[{'measure': 'Safety Evaluation: Adverse events', 'description': 'Subjective/objective symptoms', 'timeFrame': 'Up to 10 days post final dose'}, {'measure': 'Pharmacokinetic Evaluation: AUCss,τ of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}, {'measure': 'Pharmacokinetic Evaluation: Css,max of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}]","[{'measure': 'Pharmacokinetic Evaluation: AUCss,inf of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}, {'measure': 'Pharmacokinetic Evaluation: Tss,max of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}, {'measure': 'Pharmacokinetic Evaluation: Tss,1/2 of NDC-002B/C', 'description': 'after single and concomitant administration of NDC-002B/C', 'timeFrame': 'Day 1, Day 7, Day15, Day 29, Day 36'}]",6.0,19 Years,55 Years,ALL,True,INDUSTRY,0.0,33.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04535518,Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease,IVIG,"['Aspirin', 'IVIG', 'Intravenous Immunoglobulins, Human', 'Acetylsalicylic acid', 'Remicade', 'Infliximab']",6,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Kawasaki Disease,Children's Hospital of Fudan University,2025-09-01T16:18:18.416007,True,,,,NOT_FOUND,"Efficacy of Primary Treatment With Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease: a Multicenter, Open-label, Blinded-end Randomized Controlled Study.",,['Kawasaki Disease'],"['Kawasaki disease', 'infliximab', 'coronary artery lesion']",lack of funding,2020-10,2022-09,"[{'measure': 'Percentage of the regression of coronary artery lesion (CAL) at one month of illness', 'description': 'The regression of CAL is defined as z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.Two-dimensional echocardiography will be performed to evaluate CAL at 1 month of illness. The measurement of each patient included the diameter of the left main coronary artery (LMCA), the left anterior descending artery (LAD), the left circumflex coronary artery (LCX), and the proximal and middle segments of the right coronary artery (RCA). Z score of each coronary artery will be calculated (Journal of the American Society of Echocardiography, 2011, 24(1):60-74).', 'timeFrame': 'at one month of illness'}]","[{'measure': 'Percentage of the need for additional treatment', 'description': ""Participants who have recurrent or persistent fever (axillary temperature ≥37.5°C or rectal temperature ≥38°C) after 36 hours of completion of initial IVIG infusion will be given additional treatment, including a second dose of IVIG (2 g/kg), or a high dose of methylprednisolone (10 to 30 mg/kg per day), or other immunosuppressive agents such as ciclosporin and cyclophosphamide, or a combination with two or more drugs, or even more aggressive treatment such as plasmapheresis, depending on patients'condition and physicians' experience. Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization."", 'timeFrame': 'from admission to discharge (about 2 weeks of illness)'}, {'measure': 'z scores of LMCA throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LMCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of LAD throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LAD will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of LCX throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of LCX will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of the proximal segment of RCA throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of the proximal segment of RCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'z scores of the middle segment of RCA throughout the study period', 'description': 'This is a repeated measurement. Z score will be calculated based on the height, weight and coronary artery diameter (Journal of the American Society of Echocardiography, 2011, 24(1): 60-74.). The internal diameter of the middle segment of RCA will be measured by echocardiography at least seven time points: at enrollment, at 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of illness.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'Duration of fever (hours) after initiation of initial IVIG infusion', 'description': 'Participants with an axillary temperature \\<37.5℃ (or rectal temperature \\<38℃) for more than 24 hours are considered afebrile. Axillary temperature (or rectal temperature) will be measured every 6 hours a day during hospitalization. Record the time of the initiation of IVIG infusion and the time of the body temperature first becoming normal.', 'timeFrame': 'from initiation of initial IVIG infusion to the first record of being afebrile (defined as an axillary temperature <37.5 for more than 24 hours)'}, {'measure': 'Change in serum C-reactive protein (CRP) concentration', 'description': 'CRP level is measured before initial IVIG infusion and 72 hours after completion of initial IVIG infusion.Change would be described by difference.', 'timeFrame': 'from admission to 72 hours after completion of initial IVIG infusion'}, {'measure': 'Number of patients with serious adverse events', 'description': 'This is a composite outcome, including death, hypertension (defined as the blood pressure (BP) ≥90th percentile for age and height or ≥ 120/80 mmHg in the children younger than 13, and ≥ 120/80 mmHg in children ≥ 13 years), severe infection (such as septicopyemia, pulmonary infection and urinary system infection), allergic reactions, heart failure, thrombosis, etc.', 'timeFrame': 'from admission to 12 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 3 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 3 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 6 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 6 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 9 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 9 months of illness'}, {'measure': 'Percentage of the regression of coronary artery lesion (CAL) at 12 months of illness', 'description': 'The regression of CAL is defined as the z \\< 2 of all coronary arteries of LMCA, LAD, LCX, and the proximal and middle segment of the RCA.', 'timeFrame': 'at 12 months of illness'}]",14.0,1 Month,14 Years,ALL,False,OTHER,4.0,0.0,ACTUAL,v2_robust,True,False,True,True,lack of funding,,,no_match,False,,,
NCT00201669,A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma,Clofarabine,"['Clofarabine', 'Clolar']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-Hodgkin's Lymphoma,Ohio State University Comprehensive Cancer Center,2025-09-01T16:18:07.028875,True,,,,CHEMBL1750,A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma,,"[""Non-Hodgkin's Lymphoma""]","['Aggressive', 'Clofarabine']",,2004-10,2006-06,"[{'measure': 'Response rate', 'timeFrame': 'up to two years'}]","[{'measure': 'Determine the toxicity of clofarabine administered in conjunction with growth factor support in patients with relapsed/refractory aggressive NHL.', 'timeFrame': 'up to two years'}, {'measure': 'determine the effect of clofarabine on T-, B-, and natural killer (NK)-cell subsets and quantitative immunoglobulin levels after prolonged administration of clofarabine in patients with NHL.', 'timeFrame': 'up to two years'}, {'measure': 'Assess cytokine (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, and IL-10) release following clofarabine therapy.', 'timeFrame': 'up to two years'}, {'measure': 'Assess the effect of pre-treatment prognostic factors (p53 mutational status, DNA methylation, and apoptotic protein levels) in patient-derived tumor tissue on response to clofarabine.', 'timeFrame': 'up to two years'}]",5.0,18 Years,,ALL,False,OTHER,0.0,6.0,ACTUAL,v2_robust,True,True,False,False,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,CHEMBL1750,exact_match,True,303.68,-0.35,4.0
NCT05037591,Effect of Sea Grapes-antioxidants Extract in Obese Men : 4 Weeks Randomized-Double Blind Controlled Trial,Sea grapes extract 1.68 g/70kg BW,"['Sea grapes extract 1.68 g/70kg BW', 'Placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Obesity,State Islamic University of Sunan Kalijaga Yogyakarta,2025-09-01T16:18:14.675196,True,,,,NOT_FOUND,Effect of Sea Grapes-antioxidants Extract in Obese Men,,"['Obesity', 'Aging', 'Diabetes']","['Obesity', 'Aging', 'Functional Food', 'Diabetes', 'Dyslipidemia']",,2021-08-01,2021-09-15,"[{'measure': 'Peroxisome proliferator-activated receptor (PPAR)-γ coactivator 1 alpha (PGC-1α) Levels ""change"" is being assessed', 'description': 'Evaluate PGC-1α level in pg/dL', 'timeFrame': 'Change from Baseline PGC-1α Levels at 4th weeks of the intervention period'}, {'measure': 'Total Cholesterol ""change"" is being assessed', 'description': 'Evaluate total Cholesterol level in mg/dL', 'timeFrame': 'Change from Baseline Total Cholesterol at 4th weeks of the intervention period'}, {'measure': 'Blood Glucose ""change"" is being assessed', 'description': 'Evaluate total blood sugar level in mg/dL', 'timeFrame': 'Change from Baseline Blood Glucose at 4th weeks of the intervention period'}]","[{'measure': 'Body Mass Index (BMI)', 'description': 'Body Mass Index (BMI) weight and height will be combined to report BMI in kg/m\\^2', 'timeFrame': 'Change from Baseline Body Mass Index (BMI) at 4th weeks of the intervention period'}, {'measure': 'Triglycerides', 'description': 'Triglycerides in mg/dL', 'timeFrame': 'Change from Baseline Triglycerides Levels at 4th weeks of the intervention period'}, {'measure': 'high-density lipoprotein (HDL)', 'description': 'high-density lipoprotein (HDL) in mg/dL', 'timeFrame': 'Change from Baseline high-density lipoprotein (HDL) Levels at 4th weeks of the intervention period'}, {'measure': 'low-density lipoprotein (LDL)', 'description': 'low-density lipoprotein (LDL) in mg/dL', 'timeFrame': 'Change from Baseline low-density lipoprotein (LDL) Levels at 4th weeks of the intervention period'}, {'measure': 'Body Weight', 'description': 'Weight in kilograms (kg)', 'timeFrame': 'Change from Baseline Body Weight at 4th weeks of the intervention period'}, {'measure': 'Body Height', 'description': 'Height in meters (M)', 'timeFrame': 'Change from Baseline Body Height at 4th weeks of the intervention period'}, {'measure': 'waist-to-hip ratio (WHR)', 'description': 'This is calculated as waist measurement divided by hip measurement (W⁄H). For example, a person with a 30"" (76 cm) waist and 38"" (97 cm) hips has a waist-hip ratio of about 0.78.', 'timeFrame': 'Change from Baseline waist-to-hip ratio (WHR) at 4th weeks of the intervention period'}]",10.0,19 Years,60 Years,MALE,False,OTHER,0.0,70.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00425919,Study Evaluating PPM-204 In Subjects With Type 2 Diabetes,PPM-204,['PPM-204'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Diabetes Mellitus,Wyeth is now a wholly owned subsidiary of Pfizer,2025-09-01T16:18:24.751912,True,,,,NOT_FOUND,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes",,['Diabetes Mellitus'],"['Type 2 Diabetes', 'Diabetes']",Study terminated as a result of interim analysis not meeting predetermined criteria.,2007-01,2007-10,[{'measure': 'Fasting Plasma Glucose'}],"[{'measure': 'Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.'}]",2.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,500.0,,v2_robust,True,False,True,False,Study terminated as a result of interim analysis not meeting predetermined criteria.,,,no_match,False,,,
NCT03218657,"Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole",levamisole hydrochloride,"['levamisole hydrochloride', 'Cyclosporins', 'levamisole', 'Androgens']",4,INTERVENTIONAL,['NA'],,UNKNOWN,Aplastic Anemia,Shengyun Lin,2025-09-01T16:18:22.197031,True,,,,NOT_FOUND,"A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride",,['Aplastic Anemia'],"['Aplastic Anemia', 'levamisole hydrochloride', 'clinical study']",,2018-01-01,2022-07-01,"[{'measure': 'Routine blood test', 'description': 'hemoglobin；white blood cell；Platelet', 'timeFrame': 'up to 4 weeks'}]","[{'measure': 'Bone marrow', 'description': 'The proliferation of cells in bone marrow', 'timeFrame': '1 year'}, {'measure': 'biochemical test', 'description': 'Alanine aminotransferase；Aspartate aminotransferase', 'timeFrame': 'up to 4 weeks'}]",3.0,18 Years,70 Years,ALL,False,OTHER,0.0,248.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05972135,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,Teclistamab,"['(TECVAYLI™)', 'Actemra', 'Teclistamab', 'Tocilizumab', 'Talquetamab', 'TALVEY™']",6,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Multiple Myeloma,"SCRI Development Innovations, LLC",2025-09-01T16:18:09.630116,True,,,,NOT_FOUND,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,,['Multiple Myeloma'],"['Teclistamab (TECVAYLI™)', 'Humanized IgG-4 PAA bispecific antibody', 'CD3 receptor complex', 'RRMM-Relapsed or Refractory Multiple Myeloma', 'MM-Multiple Myeloma', 'Tocilizumab prophylaxis', 'CRS- Cytokine Release Syndrome', 'Neurologic toxicity', 'ICANS-Immune Effector Cell-associated Neurotoxicity Syndrome', 'Talquetamab (TALVEY™)', 'GPRC5D', 'BCMA']",,2023-10-23,2026-03,"[{'measure': 'Incidence of CRS of any grade during the first two cycles', 'description': 'Evaluate the overall incidence of CRS in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}]","[{'measure': 'Incidence of recurrent CRS of any grade', 'description': 'Evaluate the incidence of recurrent CRS after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of CRS of any grade', 'description': 'Evaluate the incidence of CRS after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of recurrent CRS of any grade', 'description': 'Evaluate the incidence of recurrent CRS after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of Recurrent Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab .', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles and throughout the study after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of Recurrent Grade ≥2 CRS', 'description': 'Evaluate the incidence of Grade ≥2 CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for CRS (Grade 1 to 5 with grade 5 defined as the worse outcome-Death) in the first 2 cycles and throughout the study after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of Grade ≥3 and any grade infections', 'description': 'Evaluate the risk of Grade ≥3 and any grade infections throughout the study based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of All grade and Grade ≥3 neurotoxicity', 'description': 'Evaluate neurotoxicity in the setting of prophylactic tocilizumab based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of All grade and Grade ≥3 ICANS', 'description': 'Evaluate neurotoxicity including ICANS in the setting of prophylactic tocilizumab based on the American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS (Grade 1 to 4 with grade 4 representing a worse outcome)', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Incidence of All grade neutropenia and Grade ≥3 neutropenia', 'description': 'Evaluate treatment-emergent neutropenia in the setting of teclistamab or talquetamab plus prophylactic tocilizumab based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Incidence of all grade febrile neutropenia and Grade ≥3 febrile neutropenia', 'description': 'Evaluate treatment-emergent febrile neutropenia in the setting of teclistamab or talquetamab plus prophylactic tocilizumab based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (Grade 1 to 5 with grade 5 representing a worse outcome)', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Total length of each hospital stay', 'description': 'Evaluate the length of each hospital stay in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Number of hospitalizations per participant', 'description': 'Evaluate the number of hospitalizations per participant, in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Healthcare resource utilization in the outpatient setting', 'description': 'Monitor the utilization of healthcare resources in the outpatient setting to mitigate the AEs associated with CRS/ICANS in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'From first dose of teclistamab or talquetamab, from Day 1 first step-up dose to the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Overall response rate (ORR)', 'description': 'Overall response rate (ORR) will be defined as the proportion of participants who achieve a PR or better response according to the IMWG response criteria', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Time to initial response (TTR)', 'description': 'Time to initial response (TTR) will be defined as the time between the date of the first dose of teclistamab or talquetamab and the first efficacy evaluation that the participants have met all criteria for PR or better response according to the IMWG response criteria', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Time to best response (TTBR)', 'description': 'Time to best response (TTBR) will be defined as the time between the date of the first dose of teclistamab or talquetamab and the first efficacy evaluation that the participants have the best response according to the IMWG response criteria', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Duration of response (DOR)', 'description': 'Duration of response (DOR) will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG response criteria', 'timeFrame': 'Day 1 of every 2 cycles From Cycle 1 Day 1 and up to approximately 12 months of teclistamab treatment or 6 months for talquetamab. (each cycle is 28 days)'}, {'measure': 'Time to next treatment (TTNT)', 'description': 'Time to next treatment (TTNT) is defined as the time from the date of the first dose of teclistamab or talquetamab to the date of next treatment, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as the time from the date of the first dose of teclistamab or talquetamab to the date of death, due to any cause.', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the time from the date of the first dose of teclistamab or talquetamab, to the date of first documented disease progression, as defined in the IMWG response criteria, or death due to any cause, whichever occurs first.', 'timeFrame': 'Day 1 of every 2 cycles From Cycle 1 Day 1 and up to approximately 12 months of teclistamab or 6 months for talquetamab treatment. (each cycle is 28 days)_'}, {'measure': 'Timing of each hospital stay', 'description': 'Evaluate the timing of each hospital stay in the setting of teclistamab or talquetamab plus prophylactic tocilizumab', 'timeFrame': 'Up to 12 months of teclistamab or 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Number of participants who have had a change in health-related quality of life parameters, from baseline to end of treatment', 'description': 'Talquetamab Arm only: Assess health-related quality of life parameters related to overall health as well as specific impact of taste changes, xerostomia, dysphagia, oral mucositis, and other aspects of oral toxicity using EORTC-QLQ and Epstein taste scale', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Number of participants with oral toxicities', 'description': 'Talquetamab Arm only: Assess health-related quality of life parameters related to overall health as well as specific impact of taste changes, xerostomia, dysphagia, oral mucositis, and other aspects of oral toxicity using Epstein taste scale, PRO-CTCAE, STTA and SXI', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Number of patients with overall side effects', 'description': 'Talquetamab Arm only: Assess health-related quality of life parameters related to overall health as well as specific impact of taste changes, xerostomia, dysphagia, oral mucositis, and other aspects of oral toxicity using PGI-S and EORTC Q168/EORTC-IL46', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Rate of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'description': 'Talquetamab Arm only: To assess rate of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'timeFrame': 'Up to 6 months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Time to first onset of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'description': 'Talquetamab Arm only: To assess time to first onset of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'timeFrame': 'Up 6 to months for talquetamab treatment'}, {'measure': 'Talquetamab Arm only: Duration of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'description': 'Talquetamab Arm only: To assess duration of treatment-emergent dysgeusia, oral mucositis, dysphagia, and xerostomia', 'timeFrame': 'Up 6 to months for talquetamab treatment'}]",30.0,18 Years,,ALL,False,OTHER,1.0,75.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05732506,Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria,Edoxaban,"['Edoxaban', 'Lixiana']",2,OBSERVATIONAL,[],,COMPLETED,Auricular Fibrillation,Galaxia Empírica,2025-09-01T16:18:17.178799,True,,,,CHEMBL1269025,Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria,,['Auricular Fibrillation'],[],,2023-02-01,2025-04-09,"[{'measure': 'Major bleeding.', 'description': 'Proportion of patients who had a major bleeding during the 12 months of follow-up.', 'timeFrame': '12 months'}]","[{'measure': 'Stroke or systemic embolism.', 'description': 'Proportion of patients who suffered stroke or systemic embolism during the 12 months of follow-up.', 'timeFrame': '12 months'}]",2.0,75 Years,,ALL,False,NETWORK,0.0,411.0,ACTUAL,v2_robust,False,True,False,False,,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,CHEMBL1269025,exact_match,True,548.07,1.29,4.0
NCT05333861,"An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA",hetrombopag,['hetrombopag'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Primary Immune Thrombocytopenia,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2025-09-01T16:18:18.425235,True,,,,NOT_FOUND,"An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA",,"['Primary Immune Thrombocytopenia', 'Aplastic Anemia']",['Hetrombopag'],,2022-05-01,2026-05-01,"[{'measure': 'Adverse events', 'description': ""Information will be collected via reports from the Investigators based on the patient's medical records and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0"", 'timeFrame': 'Data will be collected for all routine visits completed during the study period no more than 24 months.'}]","[{'measure': 'Number and proportion of patients achieving hematologic response after 3/6/12/24 months treatment', 'description': ""Laboratory measures of CBC will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts and other hematologic assessments will be based on local laboratory results."", 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'The maximum continuous duration and total duration of response', 'description': 'Hematologic assessments will be based on local laboratory results', 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Number and proportion of patients requiring rescue medication.', 'description': ""Information will be collected via the patient's medical records."", 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Change from enrollment in the 36-Item Short Form Survey (SF-36)', 'description': 'SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting.', 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Change from enrollment in the use of concomitant ITP/AA medications throughout the study', 'description': ""Information will be collected via the patient's medical records."", 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}, {'measure': 'Number and proportion of patients achieving a sustained remission off-treatment (SROT) after discontinuation of hetrombopag', 'description': 'The proportion of responders that were able to taper and discontinue hetrombopag maintaining the response during a period of observation of at least six months.', 'timeFrame': 'Data will be collected for all routine visits completed during the study period which is no more than 24 months.'}]",7.0,,,ALL,False,OTHER,1.0,1150.0,ESTIMATED,v2_robust,False,False,False,True,,,,no_match,False,,,
NCT05233124,Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia,Rivaroxaban 15 MG,"['Aspirin', 'Clopidogrel 75 Mg Oral Tablet', 'Acetylsalicylic acid 100mg', 'Clopidogrel 75mg', 'Rivaroxaban 15 MG', 'Plavix']",6,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Acute Coronary Syndrome,Instituto Nacional de Cardiologia Ignacio Chavez,2025-09-01T16:18:23.457594,True,,,,NOT_FOUND,A Randomized Controlled Trial of Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy and Oral Anticoagulation in Patients With Acute Coronary Syndrome and Coronary Artery Ectasia: OVER-TIME,,"['Acute Coronary Syndrome', 'Coronary Artery Ectasia']","['Coronary artery ectasia', 'Antithrombotic therapy', 'Acute coronary syndrome', 'Coronary dilatation']",,2021-09-01,2024-07-30,"[{'measure': 'Composite of cardiovascular death, recurrent MI and repeated revascularization', 'description': 'Main efficacy combined outcome of cardiovascular death, recurrent MI and repeated revascularization', 'timeFrame': '1 year.'}, {'measure': 'Composite of minor and major bleeding events.', 'description': 'Main safety combined outcome of minor and major events, measured by BARC scale.', 'timeFrame': '1 year'}]","[{'measure': 'Net clinical benefit composite endpoint, including cardiovascular death, recurrent MI, repeated revascularization and minor/major bleeding', 'description': 'Composite of cardiovascular death, recurrent MI, repeated revascularization and minor/major bleeding', 'timeFrame': '1 year'}, {'measure': 'Clot lysis time by turbidimetry', 'description': 'Time (in seconds) taken for turbidity to drop by 50% from maximum as a measure of lysis potential', 'timeFrame': '6 months'}]",4.0,18 Years,99 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06216340,Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes,Henagliflozin,"['diet-exercise therapy', 'Henagliflozin', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Obese,The First People's Hospital of Changzhou,2025-09-01T16:18:07.015927,True,,,,NOT_FOUND,"Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",,"['Obese', 'Weight Loss', 'Pre-diabetes']","['Henagliflozin', 'Obese', 'Weight loss', 'Glucose']",,2024-02-15,2026-10-01,"[{'measure': 'Weight change', 'description': 'Proportion of weight change from baseline', 'timeFrame': '3 months (12 weeks)'}]","[{'measure': 'Proportion of ≥5% weight loss', 'description': 'Proportion of patients who lost at least 5% of their body weight from baseline', 'timeFrame': '3 months (12 weeks)'}, {'measure': 'Incident diabetes', 'description': 'New-onset diabetes during follow up', 'timeFrame': '1 month (4 weeks), 2 months (8 weeks), 3 months (12 weeks), 6 months (24 weeks), 9 months (36 weeks), 12 months (48 weeks)'}]",3.0,18 Years,65 Years,ALL,False,OTHER,9.0,300.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05819918,Calcifediol in the Treatment of COVID 19,Calcifediol,"['Calcifediol', 'Best available therapy']",2,OBSERVATIONAL,[],,COMPLETED,COVID-19,Maimónides Biomedical Research Institute of Córdoba,2025-09-01T16:18:20.954855,True,,,,NOT_FOUND,Calcifediol in the Treatment of COVID 19. Modification of Therapeutic Response by Best Available Treatment or Other Treatment or Clinical Variables,,['COVID-19'],[],,2022-04-01,2023-04-17,"[{'measure': 'Need for ICU admission', 'description': 'Measure the need for ICU admission by differentiating the groups calcifediol yes/no; corticosteroids yes/no.', 'timeFrame': 'from hospitalization till discharge /death'}, {'measure': 'Mortality', 'description': 'Measure mortality by differentiating groups: calcifediol yes/no; corticosteroids yes/no.', 'timeFrame': 'from hospitalization till discharge /death'}, {'measure': 'Composite variable poor prognosis, (ICU&death)', 'description': 'Measure the composite variable poor prognosis, (ICU\\&death) by differentiating the groups calcifediol yes/no; corticosteroids yes/no.', 'timeFrame': 'from hospitalization till discharge /death'}]","[{'measure': 'clinical variables that calcifediol response', 'description': 'To detect clinical variables that may modify the response to calcifediol.', 'timeFrame': 'from hospitalization till discharge /death'}, {'measure': 'drug modifying calcifediol response', 'description': 'To detect clinical variables that may modify the response to calcifediol.', 'timeFrame': 'from hospitalization till discharge /death'}]",5.0,18 Years,,ALL,,OTHER,0.0,728.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT01302327,GLP Analogs for Diabetes in Wolfram Syndrome Patients,Exenatide,['Exenatide'],1,INTERVENTIONAL,['NA'],,WITHDRAWN,Diabetes Mellitus Associated With Genetic Syndrome,Hadassah Medical Organization,2025-09-01T16:18:18.424399,True,,,,NOT_FOUND,,,"['Diabetes Mellitus Associated With Genetic Syndrome', 'Wolfram Syndrome']","['Wolfram syndrome', 'Diabetes mellitus', 'Exenatide', 'GLP-1 analog', 'beta cell function']","Very rare disease, we were unable to recruit patients",2011-03-01,2013-03-01,"[{'measure': 'beta cell function', 'description': 'IVGTT test and meal test will be performed before starting treatment with Exenetide and after 3 months of treatment.', 'timeFrame': '3 months'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,"Very rare disease, we were unable to recruit patients",,,no_match,False,,,
NCT03433183,SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors,Selumetinib,"['AZD6244', 'Sirolimus', 'Rapamycin', 'Selumetinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Malignant Peripheral Nerve Sheath Tumors,Sarcoma Alliance for Research through Collaboration,2025-09-01T16:18:13.415791,True,,,,NOT_FOUND,SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors,,"['Malignant Peripheral Nerve Sheath Tumors', 'Neurofibromatosis 1']",[],,2019-10-02,2023-10-01,"[{'measure': 'Clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.', 'description': 'An evaluable patient will be classified as a responder if the patient achieves a partial response (PR), complete response (CR) or stable disease (SD) ≥ 4 cycles.', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Progression free and overall survival', 'description': 'Determined using the Kaplan-Meier method with PFS at important time points reported along with 95% two sided confidence intervals.', 'timeFrame': 'Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of objective progression or death. [Time Frame: Up to 4 years]'}, {'measure': 'Define and describe the toxicities of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.', 'description': 'This study will use CTEP Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for toxicity and adverse event reporting. The toxicities will be graded and summarized descriptively and tabulations on the type, severity and relationship to study treatment will be performed.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Assess the impact on pain interference', 'description': 'Pain interference metrics will be assessed using the Patient Reported Outcomes Measurements Information System (PROMIS) scale to assess the impact of pain on daily activities. This is a self-report measure that assesses the degree to which pain has interfered with the ability to complete daily activities over the past 7 days. Items are rated on a 5-point Likert scale and the measures yield standardized T-scores.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Assess the impact on pain severity', 'description': 'Pain metrics will be assessed using the Numerical Rating Scale-11 (NRS-11) scale to assess pain severity. The scale consists of a horizontal line with 0 representing ""no pain"" and 10 representing ""worst pain you can imagine."" Patients will circle one number from 0 to 10 that best describes how much their tumor pain hurt during the past week.', 'timeFrame': 'Up to 6 months'}]",5.0,12 Years,,ALL,False,OTHER,2.0,21.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00461006,A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.,Actos,"['aleglitazar', 'Actos']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Diabetes Mellitus Type 2,Hoffmann-La Roche,2025-09-01T16:18:12.169442,True,,,,CHEMBL3260567,"A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.",,['Diabetes Mellitus Type 2'],[],,2007-06,2008-09,"[{'measure': 'Relative change from baseline in glomerular filtration rate', 'timeFrame': '26 weeks'}]","[{'measure': 'Relative change from baseline in estimated renal plasma flow (ERPF) and urine albumin-creatinine ratio (UACR)', 'timeFrame': '26 weeks'}, {'measure': 'Absolute change in Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and fasting plasma insulin (FPI).', 'timeFrame': 'End of treatment'}, {'measure': 'Adverse events (AEs), laboratory parameters.', 'timeFrame': 'Throughout study'}]",4.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,176.0,ACTUAL,v2_robust,True,True,False,True,,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,CHEMBL3260567,partial_match,True,399.43,4.24,2.0
NCT03852459,Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS,S-Ibuprofen,"['Vehicle', 'S-Ibuprofen']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Pain, Acute","Aponia Laboratories, Inc.",2025-09-01T16:18:20.959684,True,,,,CHEMBL521,"A Randomized, Double-Blind,Vehicle-Controlled Study to Determine the Efficacy and Safety of AP0302 in the Treatment of Delayed Onset Muscle Soreness (DOMS)",,"['Pain, Acute']",[],,2018-01-12,2019-04-11,"[{'measure': 'Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero', 'description': 'The primary efficacy outcome is the sum of the time-weighted differences from baseline in muscle pain/soreness with movement over 0-24 hours post T0 (SPIDMOVE 0-24h), that is the area under the differences from baseline pain/soreness intensity difference curve. The pain intensity differences (PIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of investigational product (IP).', 'timeFrame': '0-24 hours.'}]","[{'measure': 'SPIDMOVE Over the Following Intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48 and 0-48 Hours Post-T0.', 'description': 'Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline pain/soreness intensity difference curve. The PIDs with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 pain score with movement from the pain score with movement at time point Ti. Positive and higher scores indicate greater reduction in pain. Measured by Pain Intensity Numerical Rating Scale (PI-NRS) where 0 = no pain and 10 = worst possible pain at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.', 'timeFrame': 'From 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28,36-48, and 0-48 hours post-T0. Time point i included 1, 2, 3, 4, 5, 6 (pre-dose), 7, 8, 9, 10, 11, 12 (pre-dose), 16, 18 (pre-dose), 20, and 24 (pre-dose) hours after the first dose.'}, {'measure': 'Sum of Time Weighted Differences From Baseline in Muscle Stiffness (SSID) With Movement Over the Interval', 'description': 'Sum of the time-weighted differences from baseline in muscle stiffness with movement (SSIDMOVE) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 24-36, 24-48, 0-36, 36-48, and 0-48 hours post-T0, that is the area under the differences from baseline stiffness difference curve. The muscle Stiffness Intensity Differences (SIDs) with movement from time point A to time point B was calculated using the trapezoid rule by subtracting each post-T0 stiffness score with movement from the stiffness score with movement at time point Ti. Positive and higher scores indicate greater reduction in stiffness. Measured by Muscle Stiffness Numerical Rating Scale (NRS) where 0 = No Stiffness and 10 = Worst Possible Stiffness at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24, 26, 28, 30, 32, 34, 36, 40, 44, and 48 hours post-initial IP dose and immediately prior to the subsequent doses of IP.', 'timeFrame': '0-6, 6-12, 0-12, 12-24, 24-36, 24-48, 0-36, 36-48, and 0-48 post T0'}, {'measure': 'Total Relief With Movement (TOTPAR) 0-6 Hours Post Time Zero', 'description': 'Total relief with movement (TOTPAR) 0-6 hours post time zero\n\nTOTPAR was calculated as the sum of pain relief at time point i (PR i) times the weight for each PR i, where i referred to each pain relief scheduled assessment time point between A and B (not including B). The higher the number the better pain relief.\n\nCategorical Relief Rating Scale: Subjects rated relief from starting pain with movement using a 5-point categorical relief scale ""0=no relief,"" ""1=a little relief,"" ""2=some relief,"" ""3=a lot of relief,"" or ""4=complete relief"" at 1, 2, 3, 4, 5, and 6 hours post-initial IP dose and immediately prior to a subsequent dose of IP if one occurred prior to 6 hours.', 'timeFrame': '0-6 hours'}, {'measure': 'Subject Global Assessment of Study Medication Assessed at Approximately 48 Hours Post Time Zero', 'description': 'Global assessment of efficacy will be assessed at approximately 48 hours post-T0 (or upon early termination if the subject withdraws prior to the 48-hour assessment).\n\nSubject Global Assessment Using Original 5 Categories as 0=poor, 1=fair, 2=good, 3=very good, 4=excellent. In addition, the 5 categories were dichotomized into 2 categories (good/very good/excellent versus poor/fair). The proportion of good, very good, and excellent ratings were calculated for each treatment.', 'timeFrame': '48 hours post time zero'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'description': 'TEAE was defined as an adverse event that was new or worsened in severity after the first dose of study drug. A treatment-related TEAE was defined as a TEAE that was at least possibly related to the administration of study drug or was missing the relationship assessment. If a TEAE was recorded on multiple occasions, only the highest severity was presented.', 'timeFrame': 'Up to Day 7'}]",6.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,251.0,ACTUAL,v2_robust,True,True,False,True,,CC(C)Cc1ccc(C(C)C(=O)O)cc1,CHEMBL521,partial_match,True,206.28,3.07,4.0
NCT03104413,A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment,placebo for risankizumab IV,"['risankizumab SC', 'placebo for risankizumab IV', 'SKYRIZI', 'ABBV-066 BI 655066', 'risankizumab IV']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Crohn's Disease,AbbVie,2025-09-01T16:18:18.417636,True,,,,NOT_FOUND,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment",,"[""Crohn's Disease""]","['ABBV-066', 'BI 655066']",,2017-12-18,2021-05-19,"[{'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission"", 'description': ""The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \\< 150."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Endoscopic Response', 'description': 'The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \\> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Clinical Remission', 'description': 'Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Endoscopic Response', 'description': 'The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \\> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).', 'timeFrame': 'Week 12'}]","[{'measure': 'US Specific: Percentage of Participants With Clinical Remission', 'description': 'Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.', 'timeFrame': 'Week 12'}, {'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 4'}, {'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue', 'description': ""The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement."", 'timeFrame': 'Week 12'}, {'measure': ""US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \\< 150."", 'timeFrame': 'Week 4'}, {'measure': 'US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response', 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.\n\nEndoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \\> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline)."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Stool Frequency (SF) Remission', 'description': 'Stool Frequency (SF) remission is defined as an average daily SF \\<= 2.8 and not worse than baseline.', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Abdominal Pain (AP) Remission', 'description': 'The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \\<= 1 and not worse than baseline.', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Endoscopic Remission', 'description': 'Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 4'}, {'measure': 'US Specific: Percentage of Participants With Ulcer-Free Endoscopy', 'description': 'Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline', 'description': ""Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver."", 'timeFrame': 'Week 12'}, {'measure': 'US Specific: Percentage of Participants With CD-Related Hospitalization', 'description': ""Participants with at least one admission to the hospital due to Crohn's Disease."", 'timeFrame': 'Up to Week 12'}, {'measure': 'US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline', 'description': 'Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.', 'timeFrame': 'Week 12'}, {'measure': ""Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission"", 'description': ""The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \\< 150."", 'timeFrame': 'Week 12'}, {'measure': ""Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 4'}, {'measure': 'Global Outside of US: Percentage of Participants With Clinical Remission', 'description': 'Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.', 'timeFrame': 'Week 4'}, {'measure': ""Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response"", 'description': ""Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue', 'description': ""The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score', 'description': 'The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response', 'description': ""Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \\> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline)."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US:: Percentage of Participants With Endoscopic Remission', 'description': 'Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 4'}, {'measure': 'Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy', 'description': 'Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Enhanced Clinical Response', 'description': 'Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission', 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline', 'description': ""Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants With CD-Related Hospitalization', 'description': ""Participants with at least one admission to the hospital due to Crohn's Disease."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline', 'description': 'Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.', 'timeFrame': 'Week 12'}, {'measure': ""Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment"", 'description': ""WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \\[OWI\\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity."", 'timeFrame': 'Week 12'}, {'measure': 'Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score', 'description': ""The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement."", 'timeFrame': 'Week 12'}]",35.0,16 Years,80 Years,ALL,False,INDUSTRY,0.0,618.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02099110,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)",Matching Placebo to Ertugliflozin 5 mg,"['Matching Placebo to Ertugliflozin 5 mg', 'AMARYL', 'JANUVIA®', 'Ertugliflozin 10 mg', 'Glimepiride Rescue Medication', 'Metformin >= 1500 mg/day', 'Ertugliflozin 5 mg', 'Matching Placebo to Ertugliflozin 10 mg', 'Sitagliptin 100 mg', 'Glucophage XR', 'Matching Placebo to sitagliptin 100 mg', 'MK-8835', 'Glucophage', 'PF-04971729']",14,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 2 Diabetes Mellitus,Merck Sharp & Dohme LLC,2025-09-01T16:18:09.636292,True,,,,NOT_FOUND,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy",,['Type 2 Diabetes Mellitus'],[],,2014-04-22,2016-05-26,"[{'measure': 'Change From Baseline in A1C at Week 26: Excluding Rescue Approach', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.', 'timeFrame': 'Up to 54 weeks'}, {'measure': 'Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.', 'timeFrame': 'Up to 52 weeks'}]","[{'measure': 'Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach', 'description': 'This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach', 'description': 'Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach', 'description': 'A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Week 26'}, {'measure': 'Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach', 'description': 'Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \\* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \\[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\\] and model-based \\[beta cell function and insulin secretion rate at 9 mM glucose\\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\\^-9 min\\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': '30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26'}, {'measure': 'Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach', 'description': 'This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.', 'timeFrame': 'Baseline and Week 26'}]",8.0,18 Years,,ALL,False,INDUSTRY,1.0,1233.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06233474,Study of Intra-articular Allocetra in Knee Osteoarthritis,Allocetra,['Allocetra'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,ACTIVE_NOT_RECRUITING,"Osteoarthritis, Knee",Enlivex Therapeutics Ltd.,2025-09-01T16:18:18.415429,True,,,,NOT_FOUND,"A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis",,"['Osteoarthritis, Knee']",[],,2024-01-26,2026-02-01,"[{'measure': 'Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection', 'description': 'Number and severity of adverse events (AEs), serious adverse events (SAEs) and treatment disruptions/ discontinuations throughout the study from Day 0 and up to 6 months following the last injection', 'timeFrame': '7 months following Day 0'}]","[{'measure': 'Weekly average of knee pain.', 'description': 'Evaluation of change from baseline in weekly average of knee pain as measured using NRS (Numeric Rating Scale ) assessed at 3 months and 6 months from last study treatment.\n\nScores range from 0-10 points, with higher scores indicating greater pain intensity', 'timeFrame': '4 months and 7 months following Day 0.'}, {'measure': 'Change from baseline in WOMAC total score.', 'description': 'Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) total score at 3 months, 6 months, and 12 months from last study treatment administration.\n\nHigher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.', 'timeFrame': '4 months, 7 months and 13 months following Day 0.'}, {'measure': 'Change in quality of life- Euro Quality of Life-5-dimension (EQ-5D) questionnaire', 'description': 'Change from baseline in QoL as measured by Euro Quality of Life-5-dimension (EQ-5D) questionnaire at 6 months and at 12 months from last study treatment administration.', 'timeFrame': '4 months, 7 months and 13 months following Day 0.'}]",4.0,45 Years,80 Years,ALL,False,INDUSTRY,1.0,160.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00961571,Sunitinib and Capecitabine for First Line Colon Cancer,sunitinib and capecitabine,"['Capecitabine, Xeloda', 'Sunitinib, NSC 736511, Sutent', 'sunitinib and capecitabine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Metastatic Colorectal Cancer,Georgetown University,2025-09-01T16:18:13.429370,True,,,,NOT_FOUND,"A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer",,['Metastatic Colorectal Cancer'],"['colorectal cancer', 'sunitinib', 'capecitabine']",Unanticipated side effects and futility,2009-08,2011-03,"[{'measure': 'Progression-free Survival', 'description': ""Progression-free survival (PFS) will be measured as the number of months between each patient's enrollment and his/her date of progression or date of death."", 'timeFrame': '36 months'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,50.0,ACTUAL,v2_robust,True,False,True,False,Unanticipated side effects and futility,,,no_match,False,,,
NCT04690036,PD-1 Antibody for Reactive EBV After BMT,toripalimab injection,"['EBV-DNA positive', 'toripalimab injection']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,UNKNOWN,PD-1,Beijing Friendship Hospital,2025-09-01T16:18:24.755654,True,,,,NOT_FOUND,Reactivation of EBV for Patients With CAEBV and EBV Associated HLH After Transplantation,,"['PD-1', 'EBV Infection', 'Transplant']",[],,2021-07-01,2023-01-01,"[{'measure': 'EBV-DNA turn negative', 'description': 'after treatment, the EBV-DNA copies can not be detected in peripheral blood', 'timeFrame': '4 weeks after PD-1 antibody was used'}]","[{'measure': 'treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'Adverse events including thyroid function，liver function damage, myelosuppression, infection, bleeding and so on', 'timeFrame': '4 weeks after PD-1 antibody was used'}]",2.0,18 Years,,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05212493,The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder,Cannabis oil,['Cannabis oil'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Autism Spectrum Disorder,Assaf-Harofeh Medical Center,2025-09-01T16:18:17.177430,True,,,,NOT_FOUND,The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder,,['Autism Spectrum Disorder'],"['Autism', 'Cannabis', 'co-morbid symptoms', 'ASD', 'Cannabidiol']",,2019-11-14,2023-12-31,"[{'measure': 'Cannabinoids levels change', 'description': 'To compare CBD, THC their and metabolites blood levels before and after intervention', 'timeFrame': '3 months'}, {'measure': 'Changes in attention span', 'description': 'To characterize the effect of medical cannabis treatment on the attention span using Conners teacher questionnaires. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in cognitive level', 'description': 'To examine the effect of cannabis treatment on cognitive level using part of Wechsler test. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Comparison of efficacy between two different cannabis oil products', 'description': 'To compare efficacy of medical cannabis products with the same CBD: THC ratio in terms of communication skills using ADOS test. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in adaptive behavior', 'description': 'To examine the effect of cannabis treatment on adaptive behavior as per ADOS test. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in violent behavior', 'description': 'To examine the effect of cannabis treatment on violent behavior as per specific trial-designed questionnaire. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}]","[{'measure': 'Side effects', 'description': 'To identify side effects as per parents report in a specific trial-designed questionnaire. Significant change is defined as a change of 10% in new side effects as examined by questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Therapeutic failure', 'description': 'To identify therapeutic failure reasons as per Professional expert opinion. Significant reason is defined as reason that will effect at least 20% of therapeutic failure cases.', 'timeFrame': '6 months'}, {'measure': 'Changes in sleep problems', 'description': 'To examine whether high concentration CBD cannabis oil is effective in improving sleep as per Sleep questionnaire. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in eating problems', 'description': 'To examine whether high concentration CBD cannabis oil is effective in improving eating as per eating questionnaire. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.', 'timeFrame': '6 months'}, {'measure': 'Changes in hormonal profile', 'description': 'To compare hormonal profile measured as per by Hospital Lab SOP before and during treatment. measured hormones are: TSH, FT4, 17OH-testosterone, LH, prolactine. Significant change is defined as a clinically significant diversion from lab defined normal ranges, according to age and sex, between baseline and 3 months.', 'timeFrame': '3 months'}, {'measure': 'Changes in biochemical parameters', 'description': 'To compare liver enzymes measured as per by Hospital Lab SOP before and during treatment. Measured enzymes are: ALT, AST, GGT, Bilirubin. Significant change is defined as a clinicaly significant diversion (more than twice the Upper Limit of Noraml for each enzyme) from lab defined normal ranges, between baseline and 3 months.', 'timeFrame': '3 months'}]",12.0,5 Years,25 Years,ALL,False,OTHER_GOV,2.0,128.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05102058,Magnesium and Dexmedetomidine in Pheochromocytoma,Magnesium-Dexmedetomidine,['Magnesium-Dexmedetomidine'],1,OBSERVATIONAL,[],,COMPLETED,Phaeochromocytoma Crisis,Istanbul University,2025-09-01T16:18:09.627045,True,,,,CHEMBL77921,Magnesium and Dexmedetomidine Combination Reduces Sodium Nitroprusside Requirement in Laparoscopic Pheochromocytoma,,"['Phaeochromocytoma Crisis', 'Hemodynamic Instability']","['Magnesium', 'Dexmedetomidine', 'Nitroprusside', 'Pheochromocytoma']",,2011-01-01,2020-03-01,"[{'measure': 'Sodium nitroprusside (SNP) requirement', 'description': 'intraoperative hypertensive episodes requiring SNP therapy', 'timeFrame': 'intraoperative period'}]","[{'measure': 'vasoactive therapy', 'description': 'hemodynamic fluctuations (hypotension, tachycardia, severe hypertensive crisis) which needed vasoactive therapy.', 'timeFrame': 'intraoperative period'}]",2.0,18 Years,75 Years,ALL,False,OTHER,0.0,108.0,ACTUAL,v2_robust,False,True,False,False,,Cc1cccc(C(C)c2c[nH]cn2)c1C,CHEMBL77921,partial_match,True,200.28,3.18,3.0
NCT03228628,Nitrous Oxide for Lumbar Puncture,Fixed 50:50 mixture of nitrous oxide and oxygen,['Fixed 50:50 mixture of nitrous oxide and oxygen'],1,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Pain,"University Hospital, Clermont-Ferrand",2025-09-01T16:18:24.752672,True,,,,NOT_FOUND,Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Multicenter Double-blind Randomized Controlled Trial,,"['Pain', 'Anxiety']","['Spinal puncture', 'Pain', 'Anxiety', 'Nitrous oxyde']",,2017-10-01,2019-09-01,"[{'measure': 'Proportion of patients with significant pain', 'description': 'maximal pain perceived during the lumbar puncture evaluated using a simple numeric 0-10 pain scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation'}]","[{'measure': 'Proportion of patients with significant anxiety', 'description': 'maximal anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation'}, {'measure': 'Analgesic efficacy measured with pain as a continuous variable', 'description': 'maximal pain perceived during the lumbar puncture evaluated using a simple numeric 0-10 pain scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation.'}, {'measure': 'Anxiolytic efficacy measured with anxiety as a continuous variable', 'description': 'maximal anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation'}, {'measure': 'Pain during the procedure evaluated one hour after the end of the lumbar puncture', 'description': 'maximal pain and anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '1 hour after the end of gaz inhalation'}, {'measure': 'Anxiety during the procedure evaluated one hour after the end of the lumbar puncture', 'description': 'maximal pain and anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '1 hour after the end of gaz inhalation'}, {'measure': 'Side effects', 'description': 'every side effects reported by the patients during the procedure up to 24 hours after the lumbar puncture, including post-puncture puncture headache', 'timeFrame': 'from the beginning of gaz inhalation to 24 hours later'}, {'measure': 'Impact of age on side effects', 'description': 'incidence and type of side effects according to patient age', 'timeFrame': 'during the procedure and the 24 hours after'}, {'measure': 'Induced cost', 'description': 'supplementary cost induced by the use of nitrous oxide inhalation for a total of 81 patients throughout the study', 'timeFrame': 'at day 1'}]",9.0,18 Years,,ALL,False,OTHER,4.0,162.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT06006169,"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",BL-B01D1,"['izalontamab brengitecan', 'iza-bren', 'BL-B01D1', 'SI-B003', 'BMS-986507']",5,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Head and Neck Squamous Cell Carcinoma,"Sichuan Baili Pharmaceutical Co., Ltd.",2025-09-01T16:18:18.427376,True,,,,NOT_FOUND,"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",,['Head and Neck Squamous Cell Carcinoma'],[],,2023-10-20,2025-10,"[{'measure': 'Objective response rate (ORR)', 'description': 'ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Recommended Phase II Dose (RP2D)', 'description': 'The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study.', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'Progression-free survival (PFS)', 'description': 'The PFS is defined as the time from the first dose of medication to disease progression or death, whichever occurred first.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\\]).', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Duration of response (DOR)', 'description': ""The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first."", 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Treatment-Emergent Adverse Event (TEAE)', 'description': 'TEAE is defined as any adverse and unexpected change in body structure, function, or chemistry or any exacerbation of an existing condition (i.e., any clinically significant adverse change in frequency and/or intensity) during treatment. The type, frequency, and severity of TEAE will be assessed during treatment.', 'timeFrame': 'Up to approximately 24 months'}]",6.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,186.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03277742,"Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz",Standard of care,['Standard of care'],1,INTERVENTIONAL,['NA'],,WITHDRAWN,Pulmonary Tuberculosis,"Instituto Nacional de Salud Publica, Mexico",2025-09-01T16:18:07.027170,True,,,,NOT_FOUND,"Evaluation of an Integral Strategy for Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz.",,"['Pulmonary Tuberculosis', 'Diabetes Mellitus, Type 2']",[],Due to safety reasons. The region was considered too dangerous.,2017-09-20,2020-12,"[{'measure': 'Treatment success', 'description': 'Bacteriological cure using sputum smear and culture', 'timeFrame': 'Up to 6 months'}, {'measure': 'Blood glucose control', 'description': 'mg/dl', 'timeFrame': 'Up to 6 months'}]",[],2.0,20 Years,,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Due to safety reasons. The region was considered too dangerous.,,,no_match,False,,,
NCT04547855,Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen,anlotinib combined with dose-dense temozolomide,"['Anlotinib hydrochloride capsule', 'anlotinib combined with dose-dense temozolomide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Glioblastoma,Yonggao Mou,2025-09-01T16:18:25.985826,True,,,,CHEMBL810,A Phase II Study of Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen,,['Glioblastoma'],[],,2020-09-11,2023-03-11,"[{'measure': '6 months Objective Response Rates', 'description': 'Percentage of Participants With Objective Response (Partial Response \\[PR\\] Plus Complete Response \\[CR\\]), as Assessed Using as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': '6 month'}, {'measure': '6 months Progression-Free Survival Rates', 'description': '6 months Progression-Free Survival Rates as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': '6 months'}]","[{'measure': 'Progress-free survival (PFS)', 'description': 'Progression-Free Survival (PFS) as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': 'Approximately 6 months'}, {'measure': 'overall survival', 'description': 'OS was defined as the time from the date of randomization to the date of death due to any cause.', 'timeFrame': 'Approximately 1 years'}, {'measure': 'Toxic side effects', 'description': 'Toxic side effects as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': 'Approximately 1 years'}]",5.0,18 Years,75 Years,ALL,False,OTHER,1.0,54.0,ESTIMATED,v2_robust,True,False,False,False,,Cn1nnc2c(C(N)=O)ncn2c1=O,CHEMBL810,partial_match,True,194.15,-2.08,4.0
NCT02099071,"Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949",ACT-389949 1 mg,"['ACT-389949 20 mg', 'ACT-389949 5 mg', 'ACT-389949 100 mg', 'ACT-389949 50 mg', 'ACT-389949 1 mg', 'Placebo', 'ACT-389949 200 mg', 'ACT-389949 500 mg', 'ACT-389949 1000 mg']",9,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Subjects,Idorsia Pharmaceuticals Ltd.,2025-09-01T16:18:22.203342,True,,,,NOT_FOUND,"Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Dose and Food Interaction Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Male Subjects",,['Healthy Subjects'],['ACT-389949'],,2011-11,2012-05,"[{'measure': 'Change from baseline up to 60 hours in supine systolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in standing systolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in supine diastolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in standing diastolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in pulse rate', 'description': 'Pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in body temperature', 'description': 'Body temperature will be measured in the sitting position using the same thermometer(s) for all the subjects and throughout the study.', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in body weight', 'description': 'Body weight will be measured using the same weighing scale for all subjects and throughout the study. The weighing scale should have a precision of at least 0.5 kg.', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in QTcB interval', 'description': ""A standard 12-lead electrocardiogram (ECG) is to be recorded at rest with the subject in the supine position for a 5-minute period. The QTcB interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Bazett's formula (QTcB = QT/RR\\^0.5 where RR is 60/heart rate)."", 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in QTcF interval', 'description': ""A standard 12-lead ECG is to be recorded at rest with the subject in the supine position for a 5-minute period. The QTcF interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Fridericia's formula (QTcF = QT/RR\\^0.33 where RR is 60/heart rate)."", 'timeFrame': '60 hours'}, {'measure': 'Treatment-emergent ECG abnormalities from baseline up to 60 hours', 'description': 'Treatment-emergent abnormalities will be determined from standard 12-lead ECGs recorded in the supine position, after a 5-minute period of resting. Treatment-emergent ECG abnormalities are defined as ECG abnormalities occurring up to 60 h after study drug administration in each treatment period.', 'timeFrame': '60 hours'}]","[{'measure': 'Maximum plasma concentration (Cmax) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. Cmax will be calculated on the basis of the blood sampling time points.', 'timeFrame': '60 hours'}, {'measure': 'Area under the plasma concentration-time curve (AUC(0-t)) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. AUC(0-t) will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification.', 'timeFrame': '60 hours'}, {'measure': 'Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. AUC(0-infinity) will be calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase.', 'timeFrame': '60 hours'}, {'measure': 'Time to maximum plasma concentration (tmax) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. tmax will be calculated on the basis of the blood sampling time points.', 'timeFrame': '60 hours'}, {'measure': 'Plasma half life (t1/2) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. t1/2 will be calculated on the basis of the blood sampling time points.', 'timeFrame': '60 hours'}]",15.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,65.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05076461,Ondansetron Versus Domperidone for Treating Vomiting in Acute Gastroenteritis in Children,Ondansetron,['Ondansetron'],1,INTERVENTIONAL,['NA'],,COMPLETED,Vomiting in Infants and/or Children,Tehsil Headquarter Hospital,2025-09-01T16:18:23.462046,True,,,,CHEMBL46,Comparison of Ondansetron Versus Domperidone for Treating Vomiting in Acute Gastroenteritis in Children At a Resource Limited Setting,,"['Vomiting in Infants and/or Children', 'Acute Gastroenteritis']",[],,2020-07-01,2021-06-30,"[{'measure': 'Cessation of vomiting', 'description': 'Children in ondansetron group received oral suspension of ondansetron as 0.15mg per body weight while in domperidone group, oral suspension of domperidone was given as 0.5 mg per kg body weight. Children in both study groups were administered designated drugs in the emergency department. Children were observed in the emergency department for 6-hours and discharged if they were vomiting free. All children were asked to follow up after 24 hours for the assessment of the effectiveness of the treatment for cessation of vomiting.', 'timeFrame': '24 hours'}]",[],1.0,1 Day,12 Years,ALL,True,OTHER_GOV,0.0,300.0,ACTUAL,v2_robust,True,True,False,False,,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,CHEMBL46,exact_match,True,293.37,3.13,4.0
NCT05854849,Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC,Camrelizumab,"['Gemcitabine', 'Apatinib', 'Cisplatin', 'Camrelizumab']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Nasopharyngeal Carcinoma,Sun Yat-sen University,2025-09-01T16:18:14.665800,True,,,,NOT_FOUND,"A Multicenter, Phase 3 Clinical Trial of Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma",,['Nasopharyngeal Carcinoma'],"['Nasopharyngeal Carcinoma', 'PD-1', 'metastatic']",,2023-05-01,2027-12-01,"[{'measure': 'Progression-free survival', 'description': 'the time from treatment initiation to disease progression or death from any cause.', 'timeFrame': '2 years'}]","[{'measure': 'Overall survival', 'description': 'the survival time until death from any cause', 'timeFrame': '2 years'}, {'measure': 'Objective response rate', 'description': 'the proportion of patients with complete response (CR) or partial response (PR) according to RECIST v1.1', 'timeFrame': '2 years'}, {'measure': 'Disease control rate', 'description': 'the proportion of patients who achieved CR, PR, or stable disease', 'timeFrame': '2 years'}, {'measure': 'Duration of response', 'description': 'the time from the first evidence of response to disease progression or death', 'timeFrame': '2 years'}, {'measure': 'Safety evaluation', 'description': 'incidence of adverse events', 'timeFrame': '2 years'}]",6.0,18 Years,75 Years,ALL,False,OTHER,0.0,244.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02947854,"Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant",Fimaporfin (Photosensitizer),['Fimaporfin (Photosensitizer)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteer,PCI Biotech AS,2025-09-01T16:18:15.899226,True,,,,NOT_FOUND,"An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects",,['Healthy Volunteer'],"['Vaccine', 'Photochemical Internalisation', 'Immune Response', 'Peptide vaccine', 'Anti cancer vaccine']",,2016-09,2018-03-26,"[{'measure': 'Incidence of Treatment Emergent Adverse Events', 'description': 'Safety', 'timeFrame': 'Up to 1 year'}, {'measure': 'Incidence of abnormal and clinical significant measures', 'description': 'Clinical Laboratory, ECG, Vital Signs and Physical Examinations', 'timeFrame': 'Up to 1 year'}, {'measure': 'Pain as measured by Visual Analogue Scale (VAS)', 'description': 'Tolerability', 'timeFrame': 'Up to 1 year'}, {'measure': 'Incidence and grading of local skin reactions as by CTCAE v. 4.03', 'description': 'Local Tolerability (pain, erythema, oedema, induration and ulceration)', 'timeFrame': 'Up to 1 year'}]","[{'measure': 'Induction of Immune Response', 'description': 'Blood samples will be collected prior, during and after treatment for assessment of Antibody Production and T-cell Responses (change from baseline)', 'timeFrame': 'Up to 1 year'}]",5.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,96.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04179019,Calcium Channel Blockade in Primary Aldosteronism,Amlodipine,['Amlodipine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Primary Aldosteronism,Brigham and Women's Hospital,2025-09-01T16:18:13.425363,True,,,,CHEMBL2111097,Calcium Channel Blockade in Primary Aldosteronism,,"['Primary Aldosteronism', 'Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)']","['primary aldosteronism', 'calcium channel blocker']",,2020-09-01,2023-12-30,"[{'measure': 'Change in 24-hour Urinary Aldosterone Excretion Rate', 'description': 'Change in 24h urinary aldosterone excretion rate in response to maximal amlodipine therapy', 'timeFrame': 'Baseline and 2 weeks of amlodipine therapy'}, {'measure': 'Change in Plasma Aldosterone Concentration', 'description': 'Change in plasma aldosterone concentration in response to maximal amlodipine therapy', 'timeFrame': 'Baseline and 2 weeks of amlodipine therapy'}]","[{'measure': 'Acute Change in Plasma Aldosterone Concentration', 'description': 'Change in plasma aldosterone concentration after a single dose of amlodipine, before and after 2 weeks of amlodipine therapy', 'timeFrame': 'Baseline plasma aldosterone concentration before amlodipine therapy and 6 hours post-amlodipine dose, compared to baseline plasma aldosterone after 2 weeks of amlodipine therapy and 6 hours post-amlodipine therapy.'}]",3.0,18 Years,80 Years,ALL,False,OTHER,1.0,15.0,ACTUAL,v2_robust,True,True,False,False,,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl,CHEMBL2111097,partial_match,True,408.88,2.27,4.0
NCT00641680,Rhinocort Aqua Versus Placebo and Fluticasone Propionate,Budesonide,"['Fluticasone propionate', 'Flonase®', 'Placebo', 'Budesonide', 'Rhinocort AQUA']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Seasonal Allergic Rhinitis,AstraZeneca,2025-09-01T16:18:18.421019,True,,,,CHEMBL1370,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb Study to Assess the Efficacy, Safety & Product Attributes of Rhinocort Aqua(Budesonide) Versus Placebo and FluticasonePropionate as an Active Comparator in Patients 12yrs Age &Older With SeasonalAllergicRhinitis",,['Seasonal Allergic Rhinitis'],"['Seasonal allergic rhinitis', 'Nasal symptoms', 'Congestion', 'Rhinorrhea', 'Sneeze', 'budesonide', 'Rhinocort AQUA', 'Fluticasone propionate', 'Flonase']",,2003-04,2003-07,"[{'measure': 'To compare once daily treatment with Rhinocort against placebo and at reliving the nasal symptoms of seasonal allergic rhinitis.', 'timeFrame': '2 weeks'}]","[{'measure': 'To compare once daily treatment with Rhinocort against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.', 'timeFrame': '2 weeks'}, {'measure': 'To compare once daily treatment with placebo against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.', 'timeFrame': '2 weeks'}, {'measure': 'Safety assessment via adverse events and clinical measurements.', 'timeFrame': '2 & 4 weeks'}]",4.0,12 Years,,ALL,False,INDUSTRY,0.0,750.0,ESTIMATED,v2_robust,True,True,False,True,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CHEMBL1370,exact_match,True,430.54,2.72,4.0
NCT03753204,Salt-Sensitivity and Immunity Cell Activation,Furosemide 40 mg,"['Lasix', 'Furosemide 40 mg']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,High Blood Pressure,Vanderbilt University Medical Center,2025-09-01T16:18:08.355249,True,,,,CHEMBL35,Salt-Sensitivity and Immunity Cell Activation,,"['High Blood Pressure', 'Salt; Excess', 'Inflammation']",[],,2021-09-01,2025-09-15,"[{'measure': 'The percent of participants with salt sensitive blood pressure', 'description': 'A reduction in systolic blood pressure \\>9 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive', 'timeFrame': 'Over 3 days'}]","[{'measure': 'Percent of participants with immune cell activation', 'description': 'We will collect blood before and after a salt-loading (Weinberger) protocol and assess immune cell activation.', 'timeFrame': 'Over 3 days'}]",2.0,18 Years,60 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,CHEMBL35,partial_match,True,330.75,1.89,4.0
NCT07044310,5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss,WBF-038,"['Synbiotic Formulation WBF-038 (SY)', 'WBF-038', 'WBF-038 (CN)', 'Akkermansia muciniphila/Anaerobutyricum hallii/Bifidobacterium infantis/Clostridium beijerinckii/Clostridium butyricum/Inulin WBF-038', 'WBF038 (CN)', 'WBF 038 (CN)', 'Pendulum WBF-038 (SY)', 'Probiotic/Prebiotic Formulation WBF-038 (SY)']",8,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Anatomic Stage 0 Breast Cancer AJCC v8,Mayo Clinic,2025-09-01T16:18:09.636429,True,,,,NOT_FOUND,Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss,,"['Anatomic Stage 0 Breast Cancer AJCC v8', 'Anatomic Stage I Breast Cancer AJCC v8', 'Anatomic Stage II Breast Cancer AJCC v8', 'Anatomic Stage III Breast Cancer AJCC v8', 'Hormone Receptor-Positive Breast Carcinoma']",[],,2025-07-25,2027-07-25,"[{'measure': 'Change in C-terminal telopeptide of type 1 collagen (CTx)', 'description': 'Assessed by standard lab tests at baseline (at study enrollment/eligibility assessment before any therapy) followed by 6 study visits. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.', 'timeFrame': 'Baseline; 90 days after start of AI therapy (before beginning WBF-038); 14 days after start of WBF-038; 90 days after start of WBF-038; 180 days after start of WBF-038; 365 days after start of WBF-038; 90 days after stopping WBF-038'}]","[{'measure': 'Change in lumbar spine mineral density', 'description': 'Will be measured by central dual energy x-ray absorptiometry. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.', 'timeFrame': 'Baseline; 365 days after start of WBF-038'}, {'measure': 'Change in hip bone mineral density', 'description': 'Will be measured by central dual energy x-ray absorptiometry. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.', 'timeFrame': 'Baseline; 365 days after start of WBF-038'}, {'measure': 'Incidence of adverse events', 'description': 'Will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': 'Baseline; 90 days after start of AI therapy (before beginning WBF-038); 90 days after start of WBF-038; 365 days after starting WBF-038; 90 days after stopping WBF-038;'}]",4.0,18 Years,,FEMALE,False,OTHER,0.0,38.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00799513,Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma,Lenalidomide,"['Lenalidomide', 'Revlimid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Diffuse Large B-cell Lymphoma,IRCCS San Raffaele,2025-09-01T16:18:23.455868,True,,,,CHEMBL848,"A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT (Autologous Stem-Cell Transplantation)",,['Diffuse Large B-cell Lymphoma'],"['Lenalidomide', 'revlimid', 'large B-cell lymphoma', 'relapse']",,2009-03,2021-08,"[{'measure': '1-year Progression-free Survival', 'description': 'It is defined as the number of participants alive after 1 year from enrolment to progression or relapse of lymphoma (if post-induction disease status was PR (Partial Response) or CR (Complete Response), respectively). Patients alive at last follow-up will be censored.', 'timeFrame': '1-year'}]","[{'measure': 'Progression Free Survival', 'description': 'Secondary measures to describe long term outcome of treatment\n\n-Progression free survival It is defined as the number of participants, on a 5 yrs follow up, free from disease progression', 'timeFrame': '5 years'}, {'measure': 'Progression', 'description': 'Progression It is defined as the number of participants with disease recurrence observed on a 5 yrs follow up.', 'timeFrame': '5 years'}, {'measure': 'Duration of Response', 'description': 'Secondary measures to describe long term outcome of treatment\n\n* Duration of response It is defined as the number of participants experiencing a PFS (Progression Free Survival) from study therapy longer than previous line of treatment', 'timeFrame': '5 years'}, {'measure': 'Overall Survival', 'description': 'Secondary measures to describe long term outcome of treatment\n\n-Overall survival It is defined as the number of participants alive at 5ys from enrolment (death for any cause). Patients alive at last follow-up will be censored.', 'timeFrame': '5 years'}]",5.0,18 Years,,ALL,False,OTHER,1.0,48.0,ACTUAL,v2_robust,True,True,False,False,,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,CHEMBL848,exact_match,True,259.26,0.03,4.0
NCT07007793,A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism,Baxdrostat,"['CIN-107', 'Baxdrostat', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,NOT_YET_RECRUITING,Primary Hyperaldosteronism,AstraZeneca,2025-09-01T16:18:14.661437,True,,,,NOT_FOUND,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism",,['Primary Hyperaldosteronism'],"['Primary hyperaldosteronism', 'Primary aldosteronism', 'PA', 'Baxdrostat', 'CIN-107', 'Aldosterone']",,2025-08-07,2028-02-18,"[{'measure': 'Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8', 'description': 'To assess the effect of baxdrostat versus placebo on seated Systolic Blood Pressure (SBP) at Week 8', 'timeFrame': 'At week 8'}, {'measure': 'Achieving normalization of the Renin Angiotensin Aldosterone system (RAAS) at week 8', 'description': 'To assess the effect of baxdrostat versus placebo on achieving normalization of the Renin Angiotensin Aldosterone system (RAAS) at week 8, in participants with dysregulated RAAS at baseline', 'timeFrame': 'At week 8'}]","[{'measure': 'Change from Randomised withdrawal (RWD) baseline (Week 44) in seated Systolic Blood Pressure (SBP) at Week 52', 'description': 'To assess the effect of baxdrostat versus placebo on seated Systolic Blood Pressure (SBP) 8 weeks after Randomised withdrawal (RWD)', 'timeFrame': 'At week 52'}, {'measure': 'Percent change from RWD baseline (Week 44) in Plasma Renin Activity (PRA) at Week 52', 'description': 'To assess the effect of baxdrostat versus placebo on the percent change in PRA 8 weeks after RWD', 'timeFrame': 'At week 52'}, {'measure': 'Achieving serum potassium ≥ 3.7 mmol/L without potassium supplementation at Week 8 in participants with serum potassium < 3.7 mmol/L or potassium supplementation at baseline', 'description': 'To assess the effect of baxdrostat versus placebo on achieving serum potassium ≥ 3.7 mmol/L without potassium supplementation at Week 8 in participants with serum potassium \\< 3.7 mmol/L or potassium supplementation at baseline', 'timeFrame': 'At week 8'}, {'measure': 'Percent change from baseline in PRA at Week 8', 'description': 'To assess the effect of baxdrostat versus placebo on the percent change from baseline in PRA at Week 8', 'timeFrame': 'At week 8'}, {'measure': 'Achieving 24-hour urine aldosterone < 10 μg at Week 8 in participants with 24-hour urine aldosterone ≥ 10 μg at baseline', 'description': 'To assess the effect of baxdrostat versus placebo on achieving 24-hour urine aldosterone \\< 10 μg at Week 8 in participants with 24-hour urine aldosterone\n\n≥ 10 μg at baseline', 'timeFrame': 'At week 8'}, {'measure': 'Change from baseline in 24-hour urine albumin at Week 8', 'description': 'To assess the effect of baxdrostat versus placebo on 24-hour urine albumin at Week 8', 'timeFrame': 'At week 8'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,180.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01343823,Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema,ecallantide 60 mg,"['placebo', 'ecallantide 60 mg', 'ecallantide 30 mg', 'placebo match for 10 mg ecallantide arm', 'placebo match for 30 mg ecallantide arm', 'ecallantide 10 mg']",6,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,ACE Inhibitor Induced Angioedema,Shire,2025-09-01T16:18:09.638533,True,,,,NOT_FOUND,Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema,,['ACE Inhibitor Induced Angioedema'],[],Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.,2011-06-01,2012-06-01,"[{'measure': 'Safety and Efficacy of Ecallantide', 'description': 'Compare the proportion of patients meeting prespecified discharge criteria in the group receiving ecallantide with conventional therapy to patients receiving placebo with conventional therapy. Patients were evaluated against 6 discharge eligibility criteria at 1,2,3,4,5, and 6 hours after study drug administration or until discharged from the ER. A responder was defined as a patient meeting all six discharge eligibility criteria as below: • Improvement of edema to ""a little better"" or ""a lot better"" as assessed by health care provider using a five point scale • Stable vital signs (within an acceptable range) • Absence of stridor • Absence of dyspnea or use of accessory muscles during respiration • Absence of drooling • Able to drink without difficulty', 'timeFrame': '6 hours'}]","[{'measure': 'Time to Symptom Resolution Based on the Visual Analog Scale (VAS)', 'description': 'Compare the time to onset of symptom resolution between the ecallantide-treated and placebo-treated groups. The patient assessed severity of the angioedema attack using a VAS at baseline and following study drug administration every 15 minutes for the first 2 hours and then every 30 minutes through 6 hours post dosing or until the time of discharge from the ER (whichever occurred first). The scale ranged from ""totally resolved"" to ""very severe"".', 'timeFrame': '6 hours'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,79.0,ACTUAL,v2_robust,True,False,True,True,Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.,,,no_match,False,,,
NCT03525678,A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody,Belantamab mafodotin frozen liquid,"['Belantamab mafodotin lyophilized powder', 'Belantamab mafodotin frozen liquid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Multiple Myeloma,GlaxoSmithKline,2025-09-01T16:18:17.185756,True,,,,NOT_FOUND,"A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)",,['Multiple Myeloma'],"['Relapsed Refractory multiple myeloma', 'Antibody-drug conjugate', 'Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events', 'Quality of Life Questionnaire 20-item Multiple Myeloma module', 'Multiple Myeloma', 'Quality of Life Questionnaire 30-item Core module']",,2018-06-18,2024-09-12,"[{'measure': 'Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population)', 'description': 'ORR was determined according to the 2016 international myeloma working group (IMWG) response criteria by IRC. ORR was calculated as the percentage of participants with a confirmed partial response (PR) or better (that is \\[i.e.\\], PR, very good partial response \\[VGPR\\], complete response \\[CR\\] and stringent complete response \\[sCR\\]). Confidence intervals were based on the exact method.', 'timeFrame': 'Up to 48 weeks'}, {'measure': 'Overall Response Rate by Independent Review Committee (Efficacy Population)', 'description': 'ORR was determined according to the 2016 IMWG response criteria by IRC. ORR was calculated as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Efficacy Population comprised of first 130 intent-to-treat participants whether or not randomized treatment (frozen solution) was administered. Intent-to-treat Population comprised of all randomized participants whether or not randomized treatment was administered.', 'timeFrame': 'Up to 48 weeks'}]","[{'measure': 'Overall Response Rate by Investigator Assessment (IA) (Full Analysis Population)', 'description': 'ORR was determined by the investigator according to the 2016 IMWG response criteria. ORR was calculated as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Overall Response Rate by Investigator Assessment (Efficacy Population)', 'description': 'ORR was determined by the investigator according to the 2016 IMWG response criteria. ORR was calculated as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate (CBR) by Investigator Assessment (Full Analysis Population)', 'description': 'CBR was determined by the investigator according to the 2016 IMWG response criteria. CBR was calculated as the percentage of participants with a confirmed minimal response (MR) or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate by Investigator Assessment (Efficacy Population)', 'description': 'CBR was determined by the investigator according to the 2016 IMWG response criteria. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate by Independent Review Committee (Full Analysis Population)', 'description': 'CBR was determined according to the 2016 IMWG response criteria by IRC. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Clinical Benefit Rate by Independent Review Committee (Efficacy Population)', 'description': 'CBR was determined according to the 2016 IMWG response criteria by IRC. CBR was calculated as the percentage of participants with a confirmed MR or better (i.e., MR, PR, VGPR, CR and sCR). Confidence intervals were based on the exact method. Percentage values are rounded off.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response (DoR) by Investigator Assessment (Full Analysis Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented disease progression (PD) per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response by Investigator Assessment (Efficacy Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response by Independent Review Committee (Full Analysis Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Duration of Response by Independent Review Committee (Efficacy Population)', 'description': 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of documented PD per IMWG response criteria; or death due to PD among participants who achieved an overall response, i.e., confirmed PR or better. DOR based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of DOR are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Investigator Assessment (Full Analysis Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Investigator Assessment (Efficacy Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Independent Review Committee (Full Analysis Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Response by Independent Review Committee (Efficacy Population)', 'description': 'Time to response is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better). Time to response based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of time to response are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Progression Free Survival by Investigator Assessment', 'description': 'Progression free survival is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to any cause. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Progression free survival based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of progression free survival are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Progression Free Survival by Independent Review Committee', 'description': 'Progression free survival is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to any cause. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Progression free survival based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of progression free survival are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Progression by Investigator Assessment', 'description': 'Time to progression is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to PD. Time to Progression based on responses assessed by investigator is presented. Median and inter-quartile range (first quartile and third quartile) of time to progression are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Time to Progression by Independent Review Committee', 'description': 'Time to progression is defined as the time from randomization until the earliest date of documented PD per IMWG, or death due to PD. Time to Progression based on responses assessed by IRC is presented. Median and inter-quartile range (first quartile and third quartile) of time to progression are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time from randomization until death due to any cause. Overall survival was analyzed using the Kaplan-Meier method by dose level. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal Range', 'description': 'Following parameters were assessed:basophils,eosinophils,hematocrit,mean corpuscular hemoglobin (MCH),MCH concentration,MC volume,monocyte,erythrocytes, reticulocytes.Baseline is latest pre-dose assessment(Day1)with a non-missing value, including unscheduled visits.Data was categorized as decrease to low(value below lower limit of normal range\\[LNR\\]),increase to high(value above upper LNR),change to normal/no change(NC).If values were unchanged(eg.high to high) or whose value became normal,were recorded in change to normal/NC category.Participants were counted twice if participant had both decreased to low/increased to high during post-Baseline(PB).Data for worst case PB is presented.Full Safety Population(FSP) comprised of all participants who received at least 1dose of study drug(frozen liquid or lyophilized powder). 3 out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Grade Change From Baseline in Hematology Parameters', 'description': 'Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocyte count (Lymph), neutrophil count (Neutro), platelet count (PC), and leukocyte count (leuko). The laboratory parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with increase to grade 3 and increase to grade 4 have been presented.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Clinical Chemistry Parameters With Respect to the Normal Range', 'description': 'Blood samples were collected for analysis of clinical chemistry parameters: bicarbonate, direct bilirubin(D.Bil), calcium, chloride, lactate dehydrogenase(LDH), total protein,Urea enzymatic colorimetry.Baseline is latest pre-dose assessment(Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case clinical chemistry change from Baseline with respect to normal range are presented. Data was categorized as decrease to low (value below the lower LNR), increase to high (value above the upper LNR) and change to normal or NC. If values were unchanged (example: high to high), or whose value became normal, were recorded in the change to normal or NC category. Participants were counted twice if the participant had both decreased to low and increased to high during post Baseline. 3 out of 221participants did not receive any study treatment, were excluded from FSP.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters', 'description': 'Blood samples were collected for analysis of:glucose(Gl), albumin, alkaline phosphatase (ALP), alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(T.Bil),creatinine kinase (CK),creatinine, gamma glutamyl transferase (GGT),potassium (Pot), magnesium (Mg),sodium (Sod), phosphate (Ph) urate \\& estimated glomerular filtration rate (eGFR). Values (Hyper and hypo) for Gl, Pot, Mg and Sod is presented. Grading was according to NCI-CTCAE version 4.03. Grade1: mild; Grade2: moderate; Grade3: severe or medically significant; Grade4: life-threatening consequences.Baseline is latest pre-dose assessment(Day 1) with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case PB is presented.Only those participants with increase to grade3 and increase to grade4 have been presented. 3 out of 221participants did not receive any study treatment, were excluded from FSP.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Abnormal Findings During Physical Examination', 'description': 'Physical examination included assessment of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. This analysis was planned, but data was not collected and captured in the database.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Pulse Rate', 'description': ""Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case change from Baseline in pulse rate is presented. Data is categorized as: pulse rate 'decrease to \\<60 beats per minute \\[bpm\\]', 'increase to \\>100 bpm' and 'change to normal or no change'. If values were unchanged (example: increase to \\>100 bpm to increase to \\>100 bpm), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to \\<60 bpm' and 'increased to \\>100 bpm' during post Baseline. Data for worst-case post Baseline is presented."", 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Body Temperature', 'description': ""Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with worst case change from Baseline in body temperature are presented. Data is categorized as: body temperature 'decrease to \\<=35 degrees celsius', 'increase to \\>=38 degrees celsius' and 'change to normal or no change'. If values were unchanged (example: increase to \\>=38 to increase to \\>=38 degrees celsius), or whose value became normal, were recorded in the 'change to normal or no change' category. Participants were counted twice if the participant had both 'decreased to \\<=35' and 'increased to \\>=38 degrees celsius' during post Baseline. Data for worst-case post Baseline is presented."", 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)', 'description': 'SBP and DBP were graded using NCI CTCAE version 4.03. For SBP: Grade 0: \\<120 millimeter mercury (mmHg); Grade 1: 120-139 mmHg; Grade 2: 140-159 mmHg; Grade 3: \\>=160 mmHg. For DBP: Grade 0: \\<80 mmHg; Grade 1: 80-89 mmHg; Grade 2: 90-99 mmHg; Grade 3: \\>=100 mmHg. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented. Only those participants with increase to grade 2 and increase to grade 3 have been presented.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs), Common (>=5%) Non-serious Adverse Events and Adverse Events of Special Interest (AESI)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events which were not Serious were considered as non-serious adverse events. Number of participants who had SAEs and common (\\>=5%) non-SAEs are presented. Number of participants with AESI (keratopathy, dry eye events, blurred vision, thrombocytopenia, infusion-related reactions, corneal events and neutropenia) are also presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Best Corrected Visual Acuity (BCVA) Test Scores', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. BCVA score was assessed individually for each eye. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from Baseline \\<0.12 Logarithm of the Minimum Angle of Resolution (logMAR) score; a possible worsened vision was defined as a change from Baseline \\>=0.12 to \\<0.3 logMAR score; a definite worsened vision was defined as a change from Baseline \\>=0.3 logMAR score. Data for worst-case change from Baseline is presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline (Day 1) and Up to 186 weeks'}, {'measure': 'Number of Participants With Intraocular Pressure (IOP) >=22 mmHg Anytime Post-Baseline', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. IOP was assessed individually for each eye. Number of participants with IOP \\>=22 mmHg anytime post-Baseline are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Pupillary Examination Findings From Normal (Baseline) to Abnormal (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with shift in pupillary examination findings from normal (Baseline) to abnormal (worst post-Baseline) are presented.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Extraocular Muscle Movement From Yes (Baseline) to no (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Extraocular muscle movement was assessed individually for each eye. Number of participants with shift in extraocular muscle movement from yes (Baseline) to no (worst post-Baseline) are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Corneal Epithelium Findings From Normal (Baseline) to Abnormal (Worst Post-Baseline) for Corneal Epithelium (CE) and Corneal Stroma (CS)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Corneal epithelium findings for CE and CS were assessed individually for each eye. Number of participants with shift in corneal epithelium findings from normal (Baseline) to abnormal (worst post-Baseline) for CE and CS are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Corneal epithelium findings like active edema, active opacity, corneal neovascularization (CN), corneal ulcer, epithelial microcystic edema (EME) and subepithelial were performed using a slit lamp. Number of participants with shift in corneal epithelium findings from no (Baseline) to yes (worst post-Baseline) are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Number of Participants With Shift in Tear Break-up Time From >10 Seconds (Baseline) to <=5 Seconds (Worst Post-Baseline)', 'description': 'Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Number of participants with shift in tear break-up time from \\>10 seconds (Baseline) to \\<=5 seconds (worst post-Baseline) are presented. 3 participants out of 221 participants did not receive any study treatment and thus, were excluded from the Full Safety Population.', 'timeFrame': 'Baseline and Up to 186 weeks'}, {'measure': 'Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. Full Pharmacokinetic (PK) Population comprised of all participants in the Full Safety Population who had atleast 1 non-missing PK assessment.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, end of infusion (EOI), 2 hours and 24 hours post start of infusion (SOI) on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-infinity) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tau) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tlast) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Cmax of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Tmax of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 't1/2 of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-infinity) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tau) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'AUC(0-tlast) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 't1/2 of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM', 'description': 'Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.', 'timeFrame': 'Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)'}, {'measure': 'Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody (ADA) Result', 'description': ""Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Confirmed positive ADA samples were further characterized in the titration assay to quasi-quantitate the amount of ADA in the sample. Additionally, confirmed positive ADA samples were also tested in a validated neutralizing antibody assay to determine the potential neutralizing activity of the ADA."", 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Titers of Anti-drug Antibodies Against GSK2857916', 'description': 'Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. Titers of anti-drug antibodies against GSK2857916 is presented. No participant was found with positive results for ADA test in arm GSK2857916 3.4 mg/kg (Lyophilized). Hence, titer values was not presented for the arm.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'description': 'The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. It included symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, heart palpitations, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting and watery eyes. Items were scored individually on a 0 to 4 scale for severity, frequency and interference. Number of participants with symptomatic AEs (those who had a maximum post-Baseline rating greater than 0, example; 1, 2, 3, or 4) measured by PRO-CTCAE are presented.', 'timeFrame': 'Up to 186 weeks'}, {'measure': 'Worst Change From Baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Score', 'description': 'The NEI-VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question to assess the impact of ocular toxicity on visual function. Items were coded to a 0 to 100 scale and averaged to calculate domains. Domain scores ranged from 0 to 100; higher scores are better. Therefore, increase in score means improvement. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for worst-case post Baseline is presented.', 'timeFrame': 'Baseline (Day 1) and up to Week 186'}, {'measure': 'Worst Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score', 'description': 'The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning. The total OSDI score was calculated as (sum of scores for all questions answered\\*100) divided by (total number of questions answered\\*4). Domain scores ranged from 0 to 100; lower scores are better. Therefore, decrease in score from Baseline means improvement. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for worst-case post Baseline is presented.', 'timeFrame': 'Baseline (Day 1) and up to Week 186'}, {'measure': 'Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score', 'description': 'The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \\[PF\\], role functioning \\[RF\\], cognitive functioning \\[CF\\], emotional functioning \\[EF\\] and social functioning \\[SF\\]), three symptom scales (fatigue, pain and nausea/vomiting \\[N/V\\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \\[AL\\] and financial difficulties \\[FD\\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.', 'timeFrame': 'Baseline (Day 1) and Week 07, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 61, Week 79, Week 97, Week 115, Week 133, Week 151, Week 169, and Week 186'}, {'measure': 'Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score', 'description': 'The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.', 'timeFrame': 'Baseline (Day 1) and Week 07, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 61, Week 79, Week 97, Week 115, Week 133, Week 151, Week 169, and Week 186'}]",62.0,18 Years,,ALL,False,INDUSTRY,0.0,221.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT01940523,Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical,Topical Tranexamic Acid,"['Topical Tranexamic Acid', 'Intravenous Tranexamic Acid']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Osteoarthritis,"Hospital for Special Surgery, New York",2025-09-01T16:18:12.185333,True,,,,NOT_FOUND,Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical,,['Osteoarthritis'],"['total knee arthroplasty', 'total knee replacement', 'tranexamic acid', 'osteoarthritis', 'degenerative joint disease']",,2013-05,2017-05-16,"[{'measure': 'Total Blood Loss', 'description': ""The amount of blood lost during surgery is the primary outcome measure. Blood loss is determineusing an equation that calculates the patient's blood volume based on their height and weight, then multiplies the patient's blood volume by the change in their hematocrit after surgery compared to before surgery."", 'timeFrame': 'during surgery'}]","[{'measure': 'Drain Output', 'description': 'The amount of blood collected by a drain attached to the knee is measured 24 hours after surgery.', 'timeFrame': 'from end of surgery to 24 hours postoperatively'}, {'measure': 'The Number Patients Requiring a Transfusion', 'description': ""TThe number Patients requiring a transfusion over the course of the patient's hospital stay."", 'timeFrame': 'over course of hospital stay (averaging three days)'}]",3.0,18 Years,100 Years,ALL,False,OTHER,1.0,640.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01701063,An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus,Telaprevir,"['Rebetol®', 'PegIntron®', 'Peginterferon alfa-2b', 'Telaprevir', 'Ribavirin']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Hepatitis C,Vertex Pharmaceuticals Incorporated,2025-09-01T16:18:22.206803,True,,,,NOT_FOUND,"A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus",,['Hepatitis C'],[],,2013-01,2015-04,"[{'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'AE: any adverse change from the participant\'s baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. ""Study drug"" includes all investigational agents administered during the course of the study.', 'timeFrame': 'Baseline up to Week 52'}]","[{'measure': 'Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)', 'description': 'SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (less than \\[\\<\\] lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/High Pure System (HPS) RNA assay version 2.0. The lower limit of quantification was 25 international units per milliliter (IU/mL).', 'timeFrame': '12 weeks after last planned dose of study drug (up to Week 60)'}, {'measure': 'Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)', 'description': 'SVR24 was defined as an undetectable HCV RNA Levels (\\< lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.', 'timeFrame': '24 weeks after last planned dose of study drug (up to Week 72)'}, {'measure': 'Percentage of Participants With Rapid Virologic Response (RVR)', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. RVR was defined as an undetectable HCV RNA (\\<lower limit of quantification) 4 weeks after the start of study treatment.', 'timeFrame': 'Week 4'}, {'measure': 'Percentage of Participants With Extended Rapid Virologic Response (eRVR)', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. eRVR was defined as an undetectable HCV RNA (\\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.', 'timeFrame': 'Week 4 and Week 12'}, {'measure': 'Percentage of Participants With Undetectable HCV RNA at Week 12', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With On-treatment Virologic Failure', 'description': 'On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Futility rules: 1) HCV RNA \\>1000 IU/mL at Week 4; 2) HCV RNA \\>1000 IU/mL at Week 12; 3) Detectable HCV RNA after Week 12 to end of treatment.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Percentage of Participants With Virologic Relapse', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Viral relapse was defined as having detectable HCV at follow-up in participants who had HCV RNA less than (\\<) lower limit of quantification (LLOQ) at planned EOT.', 'timeFrame': '12 weeks after planned EOT (up to Week 60)'}, {'measure': 'Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region', 'description': 'Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \\>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by age.', 'timeFrame': 'Baseline, On treatment (up to Week 48)'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Telaprevir', 'description': 'Cmax was measured for telaprevir only.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}, {'measure': 'Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir', 'description': 'Tmax was measured for telaprevir only.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir', 'description': 'AUC was measured for telaprevir only. AUC 0-t last was defined as the area under the concentration-time curve from the time of dosing to the last measurable concentration. AUC 0-12 hour (AUC 0-12h) was calculated by respecifying predose concentrations as 12 hour concentrations. AUC 0-24h was calculated as AUC 0-12h multiplied by 2. Dose adjusted AUC (AUC 0-24h\\_Adj) was calculated by multiplying AUC 0-24h by the dose adjustment factor to obtain projected exposures in participants who were misdosed. Data were presented for AUC 0-t last, AUC 0-12h, AUC 0-24h, AUC 0-24h\\_Adj.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}, {'measure': 'Elimination Half-Life (T1/2) of Telaprevir', 'description': 'T1/2 was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}]",13.0,3 Years,17 Years,ALL,False,INDUSTRY,1.0,42.0,ACTUAL,v2_robust,True,False,True,True,,,,no_match,False,,,
NCT05219812,A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain,BAY2395840,"['BAY2395840', 'Placebo for BAY2395840']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Neuropathic Pain Associated With Diabetic Peripheral Neuropathy,Bayer,2025-09-01T16:18:22.197593,True,,,,NOT_FOUND,"A Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Phase 2a Study to Assess the Safety and Signal in Efficacy of BAY 2395840 in Patients With Diabetic Neuropathic Pain",,"['Neuropathic Pain Associated With Diabetic Peripheral Neuropathy', 'Peripheral Neuropathic Pain', 'Diabetes Mellitus']",['Neuropathic Pain'],,2022-02-16,2022-11-21,"[{'measure': 'Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention', 'description': 'NRS is an one-item assessment of average neuropathic pain intensity which is presented as an 11-point Likert scale with 0 as ""no pain"" and 10 as ""worst imaginable pain"".', 'timeFrame': 'Baseline to end of intervention (in total up to 16 weeks)'}]","[{'measure': 'Change in Neuropathic Pain Symptom Inventory (NPSI) score from baseline to the end of intervention.', 'description': 'The Neuropathic Pain Symptom Inventory (NPSI) is a PRO developed to evaluate different symptoms of neuropathic pain.', 'timeFrame': 'At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).'}, {'measure': 'Change in Patient Global Impression of Severity (PGI-S) score from baseline to the end of intervention.', 'description': 'The PGI-S is a one-item self-reported instrument used to assess to assess patients\' impression of disease severity with a 6-point scale response options, scores ranging from 1 (""none"") to 6 (""very severe).', 'timeFrame': 'At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).'}, {'measure': 'The proportion of participants achieving a ≥30% and a ≥50% reduction in weekly mean 24-hour average pain intensity score (i.e. responder rates using NRS)', 'timeFrame': 'From baseline to end of intervention (in total up to 12 weeks)'}, {'measure': 'Number of participants with treatment emergent adverse events (TEAE)', 'timeFrame': 'From start of study intervention to 14 days after last dose.'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,80.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03589313,Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.,GLPG3067 single dose,['GLPG3067 single dose'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Cystic Fibrosis,Galapagos NV,2025-09-01T16:18:12.182860,True,,,,NOT_FOUND,"Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG3067 Administered as Solid Formulation in Male Subjects With Cystic Fibrosis.",,['Cystic Fibrosis'],[],,2018-02-12,2018-03-26,"[{'measure': 'Maximum observed plasma concentration (cmax) of GLPG3067 single dose.', 'description': 'To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.', 'timeFrame': 'Between Day 1 pre-dose and Day 4.'}, {'measure': 'Area under the plasma concentration-time curve from time zero until 24 hours post-dose ( (AUC0-24h) of GLPG3067 single dose.', 'description': 'To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.', 'timeFrame': 'Between Day 1 pre-dose and Day 4.'}, {'measure': 'Area under the plasma concentration-time curve from time zero until 72 hours post-dose (AUC0-72h) of GLPG3067 single dose.', 'description': 'To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.', 'timeFrame': 'Between Day 1 pre-dose and Day 4.'}]","[{'measure': 'The number of subjects with adverse events.', 'description': 'To evaluate the safety and tolerability of a single oral dose of GLPG3067 in adult male subjects with CF.', 'timeFrame': 'From screening to 19 days after the last dose.'}]",4.0,18 Years,,MALE,False,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03288441,Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia,Hold,"['Change antithrombotic Drug', 'Hold', 'Full dose antithrombotics', 'Intermediate dose antithrombotic', 'Prophylactic dose antithrombotic']",5,OBSERVATIONAL,[],,UNKNOWN,Hematologic Neoplasms,Maastricht University Medical Center,2025-09-01T16:18:07.029607,True,,,,NOT_FOUND,Management Patterns of AntiThrombotics and Outcomes in Patients With Hematological Malignancy and ThrombocytopEnia: a Prospective Registry (MATTER Study),,"['Hematologic Neoplasms', 'Thrombocytopenia', 'Anticoagulants', 'Platelet Aggregation Inhibitors']","['Hematologic Neoplasms', 'Thrombocytopenia', 'Anticoagulants', 'Platelet Aggregation Inhibitors']",,2018-03-20,2021-12-31,"[{'measure': 'Composite of major bleeding or thrombosis', 'description': '1\\) ISTH-defined Major bleeding events defined as: Fatal bleeding; bleeding into a critical organ; clinically overt bleeding associated with a decrease in hemoglobin level of more than 2 g/dL or leading to the transfusion of two or more units of blood OR: 2) Thrombosis defined as: Any symptomatic deep or superficial venous or arterial thromboembolism demonstrated on objective imaging/laboratory tests. Ischemic strokes with no immediate imaging signs will also be considered events, provided this was diagnosed by a neurologist and that the patient had objective neurological signs.', 'timeFrame': '30 days (from study index) or until death (whichever first)'}]","[{'measure': 'Platelet transfusion related adverse effects', 'description': 'Number of adverse effects (all types and individually grouped) related to platelet/plasma transfusion, occurring within 24 hours of transfusion', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Clinically Relevant non-Major Bleeding', 'description': 'Defined according to the ISTH criteria published in the journal of thrombosis and Hemostasis by Kaatz et al in 2015', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Number of platelet tranfusions', 'description': 'Number of platelet transfusions', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Number of RBC tranfusions', 'description': 'Number of red blood cell transfusions', 'timeFrame': '30 days (from study index) or until death (whichever first)'}, {'measure': 'Death', 'description': 'death from any cause', 'timeFrame': '30 days (from study index)'}, {'measure': 'Change in antithrombotic management', 'description': 'Change in dose/type of antiplatelet or anticoagulant medication OR change in platelet threshold, AFTER the initial intervention which was recorded at study index.', 'timeFrame': '30 days (from study index) or until death (whichever first)'}]",7.0,18 Years,,ALL,False,OTHER,0.0,300.0,ESTIMATED,v2_robust,False,False,False,True,,,,no_match,False,,,
NCT02652728,Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy,Enalapril Orodispersible Minitablet,"['Enalapril Orodispersible Minitablet', 'Enalapril ODMT']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Heart Failure,Ethicare GmbH,2025-09-01T16:18:19.661320,True,,,,NOT_FOUND,Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy,,"['Heart Failure', 'Dilated Cardiomyopathy']",[],,2016-01,2017-06,"[{'measure': 'Area under the Curve (AUC) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure', 'description': 'Area under the Curve (AUC) of enalapril and enalaprilat are measured at first dose or at any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Maximum Concentration (Cmax) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure', 'description': 'Maximum Concentration (Cmax) of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Time to Maximum Concentration (Tmax) of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure', 'description': 'Time to Maximum Concentration (Tmax) of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy (1 month to less than 12 years); descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}]","[{'measure': 'AUC of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets', 'description': 'AUC of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Cmax of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets', 'description': 'Cmax of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Tmax of enalapril and its active metabolite enalaprilat after administration of enalapril ODMTs in children with heart failure of two age-subsets', 'description': 'Tmax of enalapril and enalaprilat are measured at first dose or any time during steady state to assess bioavailability of enalapril ODMTs in children with heart failure due to dilated cardiomyopathy in the age subsets 1 month to less than 1 year and 1 year to less than 12 years; descriptive pharmacokinetic investigation', 'timeFrame': '0 hours to 12 hours'}, {'measure': 'Renin', 'description': 'Renin as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56)'}, {'measure': 'Angiotensin 1', 'description': 'Angiotensin 1 as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit after 8 (day 56)'}, {'measure': 'Aldosterone', 'description': 'Aldosterone as marker of the renin-angiotensin-aldosterone system at every study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56)'}, {'measure': 'Plasma Renin Activity', 'description': 'Plasma Renin Activity as marker of the renin-angiotensin-aldosterone system at each study visit up to the end of treatment at 8 weeks; exploratory pharmacodynamic investigation', 'timeFrame': 'Pre-dose, 4 h post first dose, pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42) up to Last Visit (day 56)'}, {'measure': 'Brain natriuretic peptides (BNP)', 'description': 'Brain natriuretic peptides measurement as indicator of disease severity measured at every visit up to the end of treatment at 8 weeks', 'timeFrame': 'At Screening Visit and then pre-dose at each Titration Visit and Study Control Visit (day 14, 28, 42), at Last Visit (day 56)'}, {'measure': 'Acceptability of the ODMTs', 'description': 'Acceptability assessment according to an age-appropriate scale', 'timeFrame': 'Assessment time points: at Initial Dose, at one Study Control Visit (at days 14, 28 or 42), at Last Visit (day 56)'}, {'measure': 'Palatability of the ODMTs', 'description': 'Palatability assessment according to an age-appropriate scale', 'timeFrame': 'Assessment time points: at Initial Dose, at one Study Control Visit (at days 14, 28 or 42), at Last Visit (day 56)'}, {'measure': 'Blood pressure', 'description': 'Safety monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit, over 8 hours at Initial Dose Visit, over 4 hours at First Titration Visit (day 3 to 7), over 2 hours after all other Titration Visits, pre-dose at all Study Control Visits (at days 14, 28 and 42), at Last Visit (day 56)'}, {'measure': 'Serum potassium', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Blood urea nitrogen (BUN)', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Creatinine', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Micro-albuminuria', 'description': 'Renal monitoring parameter to decide on next dose prescription level', 'timeFrame': 'Pre-dose at each Visit: Screening Visit, Initial Dose Visit, all Titration Visits, all Study Control Visits (day 14,28, 42) up to Last Visit (day 56)'}, {'measure': 'Shortening fraction', 'description': 'Shortening Fraction in echocardiography', 'timeFrame': 'Assessment time points: at Screening Visit and at Last Visit (day 56)'}, {'measure': 'Number of patients experiencing rehospitalisation due to heart failure', 'description': 'Number of patients experiencing rehospitalisation due to heart failure including the need for heart transplantation or the institution of mechanical circulatory support', 'timeFrame': 'During 8 weeks of treatment'}, {'measure': 'Death due to worsening of the underlying disease', 'description': 'Death due to worsening of the underlying disease', 'timeFrame': 'During 8 weeks of treatment'}]",21.0,1 Month,11 Years,ALL,False,INDUSTRY,0.0,50.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00365742,Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements,simvastatin,"['red yeast rice', 'simvastatin', 'pharmaceutical grade fish oil']",3,INTERVENTIONAL,['NA'],,COMPLETED,Hyperlipidemia,Chestnut Hill Health System,2025-09-01T16:18:20.963796,True,,,,NOT_FOUND,Simvastatin Vs Therapeutic Lifestyle Changes and Supplements: A Primary Prevention Randomized Trial,,['Hyperlipidemia'],"['red yeast rice', 'pharmaceutical grade fish oil', 'simvastatin', 'primary prevention']",,2006-04,2006-06,[{'measure': 'LDL-c cholesterol'}],"[{'measure': 'total cholesterol'}, {'measure': 'HDL'}, {'measure': 'Triglycerides'}, {'measure': 'cardiac CRP'}]",5.0,18 Years,75 Years,ALL,True,OTHER,0.0,80.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06164821,Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia,luspatercept,['luspatercept'],1,INTERVENTIONAL,['NA'],,RECRUITING,Effect of Drug,Hematology department of the 920th hospital,2025-09-01T16:18:08.353638,True,,,,NOT_FOUND,Efficary and Safety of Luspatercept for Treatment of Anaemia in Transfusion-dependent β-thalassaemia in Southwest China,,['Effect of Drug'],"['luspatercept', 'β-Thalassemia']",,2024-01-01,2024-11-30,"[{'measure': 'Number of units in cumulative transfusion volume', 'description': 'The decrease of cumulative blood transfusion volume in low transfusion burden group (\\<7.5 units /24 weeks) and high transfusion burden group (7.5-15 units /24 weeks) after 24 weeks of treatment;', 'timeFrame': 'Within 24 weeks'}, {'measure': 'Proportion of patients with a 33% reduction in transfusion burden', 'description': '33% reduction in blood transfusion burden at week 24 in low transfusion burden group (\\<7.5 units /24 weeks) and high transfusion burden group (7.5-15 units /24 weeks);', 'timeFrame': 'Within 24 weeks'}]","[{'measure': 'Blood transfusion burden reduction ratio', 'description': 'The proportion of RBC transfusion burden reduced by 50% at any 12 weeks;\n\n(2) transfusion independence (TI) rates at any 8-week and any 12-week in the whole study population;', 'timeFrame': 'Within 24 weeks'}, {'measure': 'Ratio of TI', 'description': 'Transfusion independence (TI) rates at any 8 weeks and at any 12 weeks in the entire study population；', 'timeFrame': 'Within 24 weeks'}]",4.0,18 Years,,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT07071246,Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis,Rituximab Injection,"['Rituximab Injection', 'RTX']",2,INTERVENTIONAL,['NA'],,ACTIVE_NOT_RECRUITING,Treatment,Tang-Du Hospital,2025-09-01T16:18:18.423178,True,,,,NOT_FOUND,Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis,,['Treatment'],"['myasthenia gravis', 'rituximab', 'efficacy', 'safety']",,2022-08-01,2027-07-31,"[{'measure': '70% enrolled patients reached the minimum state (MM) or better state of MGFA - post intervention state (PIs) at 1 year after administration of study drug', 'description': 'No functional impairment and some muscle weakness may be detected by a specialist neurologist', 'timeFrame': '12 months'}, {'measure': '80% enrolled patients reached the clinical complete remission (CSR) of MGFA - post intervention status (PIs) at 2 years after administration of study drug', 'description': 'No signs and symptoms of muscle weakness for at least 1 year, no medical treatment for MG during this period, no evidence of muscle weakness after examination by a professional neurologist, mild eyelid closure weakness is allowed', 'timeFrame': '24 months'}, {'measure': 'Safety: The incidence of treatment-related adverse reactions and withdrawal because of serious adverse reaction', 'description': 'Any adverse reaction, like fever, rash, dizziness and so on.', 'timeFrame': 'through study completion'}]","[{'measure': 'The proportion of patients with ocular myasthenia gravis (OMG) progressed to generalized myasthenia gravis (GMG).', 'description': 'OMG progressed to the GMG at 2 years after treatment of study drug.', 'timeFrame': 'After 2 years of follow-up'}]",4.0,18 Years,,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00146120,Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result,Idarubicin,"['Cytosin-Arabinosid', 'All-trans Retinoid acid', 'Etoposide', 'Idarubicin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Acute Myeloid Leukemia,University of Ulm,2025-09-01T16:18:09.637340,True,,,,NOT_FOUND,Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result,,['Acute Myeloid Leukemia'],[],,1998-05,2005-05,"[{'measure': 'relapse-free survival', 'timeFrame': 'two years'}]","[{'measure': 'overall survival', 'timeFrame': 'two years'}]",2.0,16 Years,60 Years,ALL,False,OTHER,0.0,400.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01950000,Treatment of Procedural Pain Associated With Turning in Patients With Mechanical Ventilation,Fentanyl,['Fentanyl'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Critical Illness,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,2025-09-01T16:18:24.754111,True,,,,CHEMBL688,Efficacy and Safety of Opioid Analgesics as a Preventive Treatment of Procedural Pain Associated With Turning Among Critically Ill Patients Under Mechanical Ventilation. A Controlled Clinical Trial Comparing Placebo and Fentanyl,,"['Critical Illness', 'Pain']",['Pain. Analgesia. Prevention'],,2011-03,2012-04,"[{'measure': 'Change in the incidence of pain at the beginning and end of rotation', 'description': 'Participants will be evaluated at the beginning and the end of rotation, an expected average of 5 minutes. The evaluation of the change in the incidence of pain will be done calculating the mean between the beginning and the end of rotation.', 'timeFrame': 'Expected average of 5 minutes'}]","[{'measure': 'Area under the curve (AUC) of incidence of pain (BPS) during mobilizations with spin', 'timeFrame': 'Since the end of the turn until 30 minutes after'}]",2.0,18 Years,85 Years,ALL,False,OTHER,0.0,75.0,ACTUAL,v2_robust,True,True,False,False,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,CHEMBL688,partial_match,True,528.6,4.14,4.0
NCT06712199,Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery,oxalidine,"['Less opioids for anesthesia', 'oxalidine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Morbid Obesity,Yongtao Sun,2025-09-01T16:18:14.658264,True,,,,NOT_FOUND,"Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery: a Prospective, Single-center, Randomized, Parallel Controlled Study",,['Morbid Obesity'],"['Oxeridine', 'Hypopiate anesthesia', 'Multimodal analgesia', 'Morbid obesity']",,2025-01-01,2026-12-31,"[{'measure': 'Oral morphine equivalent (OME) opioid consumption in the 24 hours prior to surgery', 'timeFrame': '24 hours after surgery'}]","[{'measure': 'Area under the NRS score curve at rest and exercise 72 hours after surgery (AUC)', 'description': 'Area under the NRS score curve at rest and exercise 72 hours after surgery (AUC)', 'timeFrame': 'Within 72 hours after surgery'}]",2.0,18 Years,,ALL,True,OTHER,1.0,124.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02160041,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,BGJ398,['BGJ398'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Solid Tumor,Novartis Pharmaceuticals,2025-09-01T16:18:15.899073,True,,,,NOT_FOUND,Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations,,"['Solid Tumor', 'Hematologic Malignancies']","['Solid tumor malignancy', 'hematologic malignancy', 'mutation', 'translocations', 'amplifications,', 'fusions', 'signature', 'FGFR', 'ligand', 'BGJ398']",,2014-07-24,2018-04-30,"[{'measure': 'Clinical Benefit Rate (CBR) Associated With BGJ398 Treatment', 'description': 'Tumor Response: Overall response rate (ORR) and clinical benefit rate (CBR) for solid tumor (non-lymphoma) which excludes 3 TIO and 1 Lymphoma patients (hence 80 patients and not 84)\n\nClinical benefit rate for patients with solid tumors were assessed using RECIST 1.1 and include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria may apply\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', 'timeFrame': '16 weeks'}]","[{'measure': 'Overall Response (OR) or Partial Response (PR) or Greater', 'description': 'The key secondary endpoint, OR, was determined by Investigator assessment for each tumor assessment and defined as responses of CR and PR per RECIST version 1.1.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', 'timeFrame': 'baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Kaplan-Meier estimates of PFS timing, months\n\nProgression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause', 'timeFrame': 'every 8 weeks until death, assessed up to 24 months'}, {'measure': 'Kaplan-Meier Estimates of PFS Rate, % (95% CI)', 'timeFrame': 'Months 1, 2, 3, 4, 5, 6, 12, 18, 24'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause', 'timeFrame': 'every 8 weeks until death, assessed up to 36 months'}, {'measure': 'Kaplan-Meier Estimates of Survival Rate, % (95% CI)', 'description': 'Overall survival (OS) is the time from the date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact.', 'timeFrame': 'months 3, 6, 9, 12, 24'}, {'measure': 'Number of Participants With 99 Day Minimum Duration of Response (DOR)', 'description': 'The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause', 'timeFrame': 'baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,84.0,ACTUAL,v2_robust,True,False,True,False,,,,no_match,False,,,
NCT03149679,The p53 Colorectal Cancer Trial,Cyclophosphamide,"['Cyclophosphamide', 'Sendoxan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Colorectal Cancer Metastatic,Haukeland University Hospital,2025-09-01T16:18:23.459188,True,,,,NOT_FOUND,Treatment of Patients With Metastatic Colorectal Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Colorectal Cancer Trial,,"['Colorectal Cancer Metastatic', 'Colorectal Cancer Stage IV', 'TP53 Gene Mutation']","['Cyclophosphamide', 'Colorectal Cancer Metastatic', 'TP53 Gene Mutation']",The study was discontinued after the first pre-planned interim analysis due to insufficient response rates.,2017-05-09,2020-08-07,"[{'measure': 'Objective response rate (ORR)', 'description': 'Partial response (PR) or complete response (CR) as defined by the RECIST criteria', 'timeFrame': '4 months'}]","[{'measure': 'Possible molecular markers of therapy response/resistance and survival outcome beyond TP53 mutations will be examined.', 'description': 'Tissue and blood sampling at baseline and whenever treatment is changed', 'timeFrame': '10 years'}, {'measure': 'Number of patients with treatment response among patients harboring TP53 mutations belonging to particular mutation subgroups', 'description': 'Tissue and blood sampling at baseline and whenever treatment is changed', 'timeFrame': '10 years'}, {'measure': 'Clinical benefit rate (CBR)', 'description': 'Stable disease (SD) \\>6 months, PR or CR', 'timeFrame': '5 years'}, {'measure': 'Recurrence-free and overall survival, compared to historical data', 'description': 'Survival analyses', 'timeFrame': 'All patients will be followed for 5 years or until death to record survival outcome'}, {'measure': 'Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Clinical examination and blood samples', 'timeFrame': 'Every second week during the treatment period from start of treatment, and thereafter every second month for 5 years or until death'}]",6.0,18 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,False,True,True,The study was discontinued after the first pre-planned interim analysis due to insufficient response rates.,,,no_match,False,,,
NCT00418002,Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.,AQW051,['AQW051'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Novartis,2025-09-01T16:18:24.745514,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051",,['Healthy'],"['Single-rising dose , multiple rising dose, elderly, cognitive, , pharmacokinetic, impairment.', 'Healthy elderly male and female subjects']",,2006-05,,[{'measure': 'Safety and tolerability.'}],"[{'measure': 'Pharmacokinetics at the end of the study.'}, {'measure': 'Effect of AQW051 on cognition as assessed by a computerized cognitive test battery.'}, {'measure': 'To assess a potential food effect on pharmacokinetics of AQW051.'}, {'measure': 'To explore the drug abuse liability potential of AQW051.'}]",5.0,60 Years,80 Years,ALL,True,INDUSTRY,0.0,72.0,ESTIMATED,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02957929,"Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally",APX001 single IV dose,"['APX001 single oral dose 3', 'APX001 single IV dose', 'APX001 multiple oral doses 2', 'Matching placebo control', 'APX001 single oral dose 1', 'APX001 multiple oral doses 1', 'Cytochrome P450 substrates', 'APX001 single oral dose 2', 'APX001 multiple oral doses 3', 'APX001 single oral dose fasted', 'APX001 single oral dose fed']",11,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Fungal Infection,Basilea Pharmaceutica,2025-09-01T16:18:18.431672,True,,,,NOT_FOUND,"A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001",,['Fungal Infection'],[],,2016-10-31,2017-04-20,"[{'measure': 'Safety and tolerability of single and multiple oral doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG).', 'timeFrame': '21 days'}]","[{'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple dose of APX001 as measured by area under the curve (AUC).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by terminal half life (t1/2).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel).', 'timeFrame': '21 days'}, {'measure': 'Pharmacokinetics of single and multiple doses of APX001 as measured by accumulation ratio.', 'timeFrame': '21 days'}]",7.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,46.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05968937,Vaginal Baclofen Suppositories in Chronic Pelvic Pain,20 mg baclofen vaginal suppository daily per vagina,"['20 mg baclofen vaginal suppository daily per vagina', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Chronic Pelvic Pain Syndrome,University of Louisville,2025-09-01T16:18:13.420950,True,,,,NOT_FOUND,"Baclofen in Chronic Pelvic Pain, a Randomized, Double-Blind, Placebo Controlled Trial",,['Chronic Pelvic Pain Syndrome'],"['Baclofen', 'vaginal suppository', 'pelvic floor muscle dysfunction']",,2024-01-01,2026-06-01,"[{'measure': 'Visual analogue Score (VAS) 1-100 for pain', 'description': 'VAS is a 1-100mm scale with lower scores indicating less pain', 'timeFrame': 'at 8 weeks of suppository use'}]","[{'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference score', 'description': 'Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference score is a 40-200 point scale with lower values indicating lower pain interference with quality of life', 'timeFrame': 'at baseline and at 4, 8 and 12 weeks'}, {'measure': 'Pelvic floor impact questionnaire', 'description': 'pelvic floor impact questionnaire is a 0-63 point composite scale consisting of questions concerning bladder/urinary, bowel/rectal, and vaginal/pelvic symptoms with higher values indicating higher symptoms', 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Pelvic floor disability index (PFDI) questionnaire', 'description': 'the pelvic floor disability index (PFDI) questionnaire is a composite questionnaire on a 0-80 point scale containing questions regarding pelvic organ prolapse, colorectal/anal distress, and urinary distress questions with higher scores indicating higher symptoms', 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Visual analogue Score (VAS) 1-100 for pain', 'description': 'VAS is a 1-100mm scale with lower scores indicating less pain', 'timeFrame': 'at baseline and at 4 and 12 week follow up'}, {'measure': ""O'Leary Sant questionnaire"", 'description': ""O'Leary Sant questionnaire is a 0 to 37 point score with higher points indicating increased symptoms"", 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) global health score', 'description': 'Patient-Reported Outcomes Measurement Information System (PROMIS) global health score is a 9-45 point scale with higher scores indicating better overall health and quality of life', 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Overall Satisfaction', 'description': 'Overall Satisfaction is a yes/no questionnaire with if ""yes"" is selected one selects choices from ""somewhat"" to ""quite a bit"" in satisfaction. ""quite a bit"" would indicate greater satisfaction.', 'timeFrame': 'at 4, 8, and 12 week follow up'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual function score', 'description': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual function score is a 9-36 point score with higher scores indicating higher bother related to sexual function', 'timeFrame': 'at 0, 4, 8, and 12 week follow up'}, {'measure': 'Number of other treatments for chronic pelvic pain during the trial period', 'description': 'Number of other treatments for chronic pelvic pain during the trial period to determine if results are clouded by other, appropriate, evidence based treatments received for chronic pelvic pain.', 'timeFrame': 'at 4, 8, and 12 week follow up'}, {'measure': 'Pill Count', 'description': 'Pill Count to determine how many doses of the study medication have been missed', 'timeFrame': 'at 4, 8, and 12 week follow up'}]",11.0,18 Years,65 Years,FEMALE,True,OTHER,0.0,44.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01181024,"A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1",Placebo,"['RO5303253', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Hepatitis C, Chronic, Healthy Volunteer",Hoffmann-La Roche,2025-09-01T16:18:20.958378,True,,,,NOT_FOUND,"A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration",,"['Hepatitis C, Chronic, Healthy Volunteer']",[],,2010-04,2010-10,"[{'measure': 'Safety and tolerability: Adverse events, laboratory parameters, ECG, blood pressure', 'timeFrame': 'approximately 6 months'}, {'measure': 'Pharmacokinetics: Plasma and urine concentrations of RO5303253 and its main metabolite RO1080713', 'timeFrame': 'approximately 6 months'}]","[{'measure': 'Effect of food intake on pharmacokinetics in healthy volunteers', 'timeFrame': 'Days 1-4'}, {'measure': 'Pharmacodynamics (viral responses) and drug resistance profiling in chronic hepatitis C patients', 'timeFrame': 'From baseline to Day 15'}]",4.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,82.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04544098,"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver",177Lu-DOTATATE,['177Lu-DOTATATE'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,ACTIVE_NOT_RECRUITING,Neuroendocrine Tumors,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:22.206580,True,,,,NOT_FOUND,"A Pilot Study Investigating Intrahepatic Arterial And Intravenous Infusion Of The Radiolabeled Somatostatin Agonist 177Lu-DOTATATE In Patients With Liver-Dominant Metastatic Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Well Differentiated Neuroendocrine Tumors",,"['Neuroendocrine Tumors', 'Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors']","['177Lu-DOTATATE', 'Pan-NETs', 'Intrahepatic Arterial', 'Intravenous Infusion', 'Gastroenteropancreatic (GEP),', 'Bronchial or Unknown Primary Well Differentiated Neuroendocrine Tumors']",,2020-09-02,2026-09,"[{'measure': 'number of patients who successfully complete 2 IA injections', 'description': 'Feasibility will be defined as at least 7 or more patients out of 10 patients who successfully complete 2 IA injections.', 'timeFrame': '2 years'}, {'measure': 'Objective response', 'description': 'classified according to RECIST 1.1 criteria', 'timeFrame': '1 year'}]",[],2.0,18 Years,,ALL,False,OTHER,0.0,10.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01652092,Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies,Alemtuzumab 0.3 mg,"['Fludara', 'MESNA', 'Mesnex', 'Myerlan', 'Alemtuzumab 0.3 mg', 'Fludarabine phosphate 40 mg', 'Campath-1H', 'mercaptoethane sulfonate Na (Na being the symbol for sodium)', 'Alkeran', 'Fludarabine phosphate 30 mg', 'Busulfan', 'Alemtuzumab 0.2 mg', 'Cyclophosphamide', 'Cytoxan', 'Campath 1-H', 'Melphalan']",16,INTERVENTIONAL,['NA'],,RECRUITING,SCID,"Masonic Cancer Center, University of Minnesota",2025-09-01T16:18:24.755424,True,,,,NOT_FOUND,Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies,,"['SCID', ""Omenn's Syndrome"", 'Reticular Dysgenesis', 'Wiskott-Aldrich Syndrome', 'Bare Lymphocyte Syndrome', 'Common Variable Immunodeficiency', 'Chronic Granulomatous Disease', 'CD40 Ligand Deficiency', 'Hyper IgM Syndrome', 'X-linked Lymphoproliferative Disease', 'Hemophagocytic Lymphohistiocytosis', 'Griscelli Syndrome', 'Chediak-Higashi Syndrome', ""Langerhan's Cell Histiocytosis""]","['immunodeficiency disorder', 'histiocytic disorder']",,2012-09-04,2026-12,"[{'measure': 'Neutrophil Engraftment', 'description': 'Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.', 'timeFrame': 'Day 42'}]","[{'measure': 'Incidence of Graft Failure', 'description': 'Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.', 'timeFrame': 'Day 100'}, {'measure': 'Incidence of Chimerism', 'description': 'a state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease.', 'timeFrame': 'Day 100, 6 Months, 1 Year'}, {'measure': 'Incidence of Acute Graft-Versus-Host Disease', 'description': 'Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.', 'timeFrame': 'Day 100'}, {'measure': 'Incidence of Chronic Graft-Versus-Host Disease', 'description': 'Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.', 'timeFrame': '6 Months and 1 Year'}, {'measure': 'Incidence of Transplant-Related Mortality', 'description': 'In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.', 'timeFrame': '6 Months'}, {'measure': 'Disease-Free Survival', 'description': 'the length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.', 'timeFrame': '6 Months'}, {'measure': 'Overall Survival', 'description': 'Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.', 'timeFrame': '6 Months'}]",8.0,,50 Years,ALL,False,OTHER,0.0,30.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03940053,Prevention of Cancer Development and Progression,Arginine hydrochloride,['Arginine hydrochloride'],1,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Cancer,Zujiang YU,2025-09-01T16:18:18.433024,True,,,,NOT_FOUND,"The Efficacy of Arginine in Preventing Cancers. A Single Center, Open, Prospective Study",,['Cancer'],[],,2019-05-10,2025-05-10,"[{'measure': 'Incidence', 'description': 'the percentage of patients with cancer from start of treatment to follow-up date of last participant cancers Incidence', 'timeFrame': '60 months'}]","[{'measure': 'tumor markers', 'description': 'the levels of tumor markers in every check point', 'timeFrame': '60 months'}, {'measure': 'Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score', 'description': 'The overall enjoyment of life', 'timeFrame': '60 months'}]",3.0,40 Years,70 Years,ALL,True,OTHER,0.0,300.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT05555329,Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study,Pomalidomide 4 mg every day in cycle 1,"['Cycle 2 (Group B)', 'Cycle 3 (Group B)', 'Cycle 3 (Group A)', 'Pomalidomide 2 mg every day in cycle 3', 'Cycle 2 (Group A)', 'Pomalidomide 4 mg every other day in cycle 3', 'Pomalidomide 4 mg every other day in cycle 2', 'Pomalidomide 4 mg every day in cycle 1', 'Cycle 1', 'Pomalidomide 2 mg every day in cycle 2']",10,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Multiple Myeloma in Relapse,"Amsterdam UMC, location VUmc",2025-09-01T16:18:24.744588,True,,,,CHEMBL43452,"Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day: Reduction in Costs, Same Efficacy? A PKPD Bioequivalence Pilot Study; the POMAlternative Study",,"['Multiple Myeloma in Relapse', 'Multiple Myeloma', 'Multiple Myeloma, Refractory']","['Multiple myeloma', 'Pomalidomide', 'Pharmacokinetics/dynamics', 'Cost-effectiveness']",,2022-12-01,2024-02-14,"[{'measure': 'The AUC/MIC ratio', 'description': 'The AUC/MIC ratio during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1-21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'The level of the Ctrough', 'description': 'The level of the Ctrough during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1-21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}]","[{'measure': 'Cmax', 'description': 'The Cmax during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1- 21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'Time above EC50', 'description': 'The time above the EC50 during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1- 21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'Toxicity and side effects', 'description': 'Toxicity and side effects during usage of pomalidomide 4 mg every day on day 1-21, pomalidomide 4 mg every other day on day 1-21, and pomalidomide 2 mg every day on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'Overall response rate (ORR)', 'description': 'Overall response rate (ORR), based on the IMWG criteria', 'timeFrame': 'During three cycles of 28 days'}]",6.0,18 Years,,ALL,False,OTHER,0.0,12.0,ACTUAL,v2_robust,True,True,False,False,,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,CHEMBL43452,partial_match,True,273.25,-0.33,4.0
NCT01445925,Substrate Ablation and Remodelling in Non-paroxysmal Atrial Fibrillation (AF),Pharmacological Substrate modification,['Pharmacological Substrate modification'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Atrial Fibrillation,Liverpool Heart and Chest Hospital NHS Foundation Trust,2025-09-01T16:18:25.989107,True,,,,NOT_FOUND,Substrate Modification With Ablation and Antiarrhythmic Drugs in Non-Paroxysmal Atrial Fibrillation,,['Atrial Fibrillation'],[],,2011-09,2014-11,"[{'measure': 'Freedom from atrial fibrillation/ atrial tachycardia at 6 months following a single procedure.', 'description': 'Defined as \\>30 sec of AF/ atrial tachycardia identified on ECG or ambulatory ECG monitoring following a 3 month blanking period.', 'timeFrame': '12 months'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,130.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04444193,Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma,Durvalumab,"['LENVIMA', 'Durvalumab', 'Durvalumab injection', 'Lenvatinib Oral Product']",4,INTERVENTIONAL,['NA'],,UNKNOWN,Endometrial Cancer,Shanghai First Maternity and Infant Hospital,2025-09-01T16:18:22.207558,True,,,,NOT_FOUND,Safety and Efficacy Study of Durvalumab in Combination With Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma--DULECT Trial,,['Endometrial Cancer'],['endometrial cancer'],,2020-08-31,2021-05-31,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'Defined as time from randomisation to first progression by investigator assessment using modified RECIST 1.1 or death (by any cause in the absence of progression)', 'timeFrame': 'Up to 3 years'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Objective response rate is defined as the proportion of patients with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR) as determined by the Investigator at local site', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from randomisation to death due to any cause', 'timeFrame': 'Up to 5 years'}, {'measure': 'Percentage of Participants who Experience an Adverse Event (AE)', 'description': 'An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.', 'timeFrame': 'Up to 1 years'}]",4.0,18 Years,80 Years,FEMALE,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00472966,Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma,Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels,"['Tri-Luma® Cream', 'Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels', 'NeoStrata® Glycolic Acid Skin Renewal Peel']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Melasma,Galderma R&D,2025-09-01T16:18:07.031577,True,,,,CHEMBL38,"Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma",,['Melasma'],[],,2006-11,2007-04,"[{'measure': ""Efficacy - Improvement in Investigator's global assessment of melasma"", 'timeFrame': '12 weeks'}]","[{'measure': 'Safety - Tolerability assessments and adverse event reporting', 'timeFrame': '12 weeks'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,CHEMBL38,partial_match,True,300.44,5.6,4.0
NCT05863260,Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer,Treatment Group,['Treatment Group'],1,OBSERVATIONAL,[],,UNKNOWN,Cervical Cancer,Fudan University,2025-09-01T16:18:23.456138,True,,,,NOT_FOUND,"Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial",,"['Cervical Cancer', 'Immune Checkpoint Inhibitor', 'Chemoradiotherapy']",[],,2020-11-09,2024-12-31,"[{'measure': 'ORR', 'description': 'Objective response rate', 'timeFrame': '1 year'}]","[{'measure': '1-year PFS', 'description': '1-year PFS', 'timeFrame': '1 year'}, {'measure': '1-year OS', 'description': '1-year OS', 'timeFrame': '1 year'}]",3.0,18 Years,70 Years,FEMALE,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT00404729,Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases,Citicoline,['Citicoline'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Glaucoma,"Fondazione G.B. Bietti, IRCCS",2025-09-01T16:18:24.744658,True,,,,NOT_FOUND,Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases,,"['Glaucoma', 'Optic Neuropathy, Ischemic', 'Visual Pathway Disorder', 'Optic Nerve', 'Neural Conduction']","['Glaucoma', 'Optic Neuropathy, Ischemic', 'Visual Pathways,', 'Optic nerve', 'Neural conduction']",,2005-02-28,2006-07-30,"[{'measure': 'VEPs responses', 'description': 'P100 Implicit time and N75-P100 Amplitude', 'timeFrame': '24 months'}]","[{'measure': 'Visual Field Defects', 'description': 'Humphrey 24/1: Mean Deviation and Corrected Pattern Standard Deviation', 'timeFrame': '24 months'}]",2.0,40 Years,70 Years,ALL,True,OTHER,0.0,60.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03043430,Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients,Ketamine 100 MG/ML,"['Ketamine 100 MG/ML', 'Midazolam 5 MG/ML']",2,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Anxiety,Brooke Army Medical Center,2025-09-01T16:18:08.344135,True,,,,NOT_FOUND,Anxiolysis for Emergency Department Procedures in Pediatric Patients Using Intranasal Ketamine Compared With Intranasal Midazolam: A Randomized Controlled Trial,,"['Anxiety', 'Pediatric ALL', 'Procedural Anxiety']",[],Research manpower shortage,2016-05,2023-04,"[{'measure': 'Change in mYPAS', 'description': 'Modified Yale preoperative anxiety scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre-procedure'}]","[{'measure': 'Change in sedation scale', 'description': 'University of Michigan sedation scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre procedure, 5 minutes post procedure, and 5 minutes pre-discharge'}, {'measure': 'Change in pain rating (Wong-Baker Pain Faces Rating Scale)', 'description': 'Wong-Baker Pain Faces Rating Scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre procedure, 5 minutes post procedure, and 5 minutes pre-discharge'}, {'measure': 'Change in anxiety score (Visual analogue scale)', 'description': 'Visual analogue scale', 'timeFrame': 'Change in score between initial measurement versus 5 minutes pre procedure, 5 minutes post procedure, and 5 minutes pre-discharge'}]",4.0,2 Years,12 Years,ALL,False,FED,0.0,10.0,ACTUAL,v2_robust,True,False,True,False,Research manpower shortage,,,no_match,False,,,
NCT01841112,"Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers",Placebo,"['BI-409306 25 milligram (mg) SD', 'BI-409306 100 mg SD', 'Placebo', 'BI-409306 100 mg MD', 'BI-409306 50 mg SD']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:24.750711,True,,,,NOT_FOUND,"Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)",,['Healthy'],[],,2013-04-22,2013-07-18,"[{'measure': 'Percentage (%) of Subjects With Drug-related Adverse Events (AEs)', 'description': 'Percentage (%) of subjects with drug-related adverse events (AEs).', 'timeFrame': 'From first drug administration until 11 days after last dose of study medication, up to 18 days.'}]","[{'measure': 'Maximum Measured Concentration of a Single Dose of BI 409306 in Plasma (Cmax)', 'description': 'Maximum measured concentration of a single dose of BI 409306 in plasma (Cmax).', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of a Single Dose of BI 409306 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)', 'description': 'Area under the concentration-time curve of a single dose of BI 409306 in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity).', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of a Single Dose of BI 409306 in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of a single dose of BI 409306 in plasma over the time interval 0 to the last quantifiable data point (AUC0-tz).', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Maximum Measured Concentration of the Metabolite CD 13896 in Plasma (Cmax)', 'description': 'Maximum measured concentration of the metabolite CD 13896 in plasma (Cmax) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Maximum Measured Concentration of the Metabolite CD 14084 in Plasma (Cmax)', 'description': 'Maximum measured concentration of the metabolite CD 14084 in plasma (Cmax) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 13896 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)', 'description': 'Area under the concentration-time curve of the metabolite CD 13896 in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 14084 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)', 'description': 'Area under the concentration-time curve of the metabolite CD 14084 in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 13896 in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).', 'description': 'Area under the concentration-time curve of the metabolite CD 13896 in plasma over the time interval 0 to the last quantifiable data point (AUC0-tz) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 14084 in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).', 'description': 'Area under the concentration-time curve of the metabolite CD 14084 in plasma over the time interval 0 to the last quantifiable data point (AUC0-tz) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}]",10.0,20 Years,45 Years,MALE,True,INDUSTRY,0.0,65.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05509127,Evaluation of Cervical Restorations Performance Using Modified Universal Adhesive,Modified universal adhesive,"['3M ESPE™ Single Bond Universal Adhesive', 'Conventional universal adhesive', 'Modified universal adhesive', '3M ESPE™ Scotchbond Universal Plus Adhesive']",4,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Clinical Performance,Cairo University,2025-09-01T16:18:20.962902,True,,,,NOT_FOUND,Evaluation of Cervical Restorations Performance Using Modified Universal Adhesive Compared to Conventional Universal Adhesive: A Randomized Clinical Trial,,['Clinical Performance'],"['Performance', 'Carious', 'Cervical', 'Universal adhesive', 'USPHS criteria']",,2023-01-01,2025-01-01,"[{'measure': 'Change in Marginal adaptation', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}]","[{'measure': 'Marginal discoloration', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}, {'measure': 'Post-operative sensitivity', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}, {'measure': 'Retention', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}, {'measure': 'Secondary caries', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}]",5.0,20 Years,40 Years,ALL,True,OTHER,0.0,50.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01591083,The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers,"esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)","['esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)', 'Nexium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Peptic Ulcer Bleeding,National Cheng-Kung University Hospital,2025-09-01T16:18:18.428179,True,,,,NOT_FOUND,The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses,,['Peptic Ulcer Bleeding'],"['Peptic ulcer rebleeding, double dose of esomeprazole']",,2011-08,2014-07,"[{'measure': 'recurrent bleeding', 'timeFrame': 'within 28 days after the first bleeding event'}]","[{'measure': 'the length of hospitalization', 'timeFrame': 'within 28 days after the first bleeidng event'}, {'measure': 'the amount of blood transfusion', 'timeFrame': 'within 28 days after the first bleeding event'}, {'measure': 'major events such as surgery or transarterial embolization', 'timeFrame': 'within 28 days after the first bleeding event'}, {'measure': 'the fading rate of major stigmata of recent hemorrhage', 'description': 'At the primary gastroscopy, the adherent clot is vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.\n\nSecond-look endoscopy is scheduled 48-72 hours after successful primary endoscopic hemostasis and intravenous high-dose proton pump inhibitor infusion. For each patient with either suspected or active recurrent bleeding, emergent endoscopy is conducted earlier before the schedule to confirm and treat peptic ulcer recurrent bleeding.\n\nMultiple logistic regression analysis is applied to assess the independent risk factors related to residual major stigmata or early recurrent bleeding of peptic ulcers.', 'timeFrame': 'within 3 days after the first bleeding event'}, {'measure': 'mortality', 'timeFrame': 'within 28 days and 120 days after the first bleeding event'}]",6.0,18 Years,95 Years,ALL,False,OTHER,1.0,474.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06970223,A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV,Cabotegravir long-acting,"['Lenacapavir long-acting', 'Cabotegravir', 'Cabotegravir long-acting']",3,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,HIV Infections,ViiV Healthcare,2025-09-01T16:18:07.022813,True,,,,NOT_FOUND,"Phase 1, Open-Label, Randomised Crossover Study Assessing the Tolerability and Acceptability of Long Acting Cabotegravir Intramuscular and Lenacapavir Subcutaneous Injections Over Time in Healthy Adults Without HIV",,['HIV Infections'],"['Long-acting', 'Tolerability', 'Acceptability', 'Injection site reactions', 'Cabotegravir', 'Lenacapavir', 'Healthy adults']",,2025-04-22,2026-07-10,"[{'measure': 'Percentage of participants reporting very acceptable or totally acceptable local reactions', 'description': 'The analysis is performed using the 21-item perception of injection (PIN) questionnaire which includes 21 items grouped into 4 multi-item domains: \'Acceptance of ISR\' scale score (2 items); \'Bother from ISR\' scale score (6 items); \'Leg movement\' scale score (4 items); \'Sleep\' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain.\n\n""Acceptance of ISR"" is reported in this outcome measure for 2 scores: ""very acceptable ISR: and ""totally acceptable ISR"".', 'timeFrame': '7 days after each injection (injections administered on Day 1 and Day 15)'}]","[{'measure': 'Percentage of participants reporting very acceptable or totally acceptable local reactions at days 43 and 190', 'description': 'The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: \'Acceptance of ISR\' scale score (2 items); \'Bother from ISR\' scale score (6 items); \'Leg movement\' scale score (4 items); \'Sleep\' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain.\n\n""Acceptance of ISR"" is reported in this outcome measure for 2 scores: ""very acceptable ISR: and ""totally acceptable ISR"".', 'timeFrame': 'At Day 43 (28 days after second injection) and Day 190 (26 weeks after second injection)'}, {'measure': 'Mean injection site reaction scores, over time, post-injection, at days 8 and 22', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 8 and Day 22 (7 days after each injection visit)'}, {'measure': 'Median injection site reaction scores, over time, post-injection, at days 8 and 22', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 8 and Day 22 (7 days after each injection visit)'}, {'measure': 'Mean injection site reaction scores, over time, post-injection, at days 43 and 190', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 43 (28 days after second injection) and Day 190 (26 weeks after second injection)'}, {'measure': 'Median injection site reaction scores, over time, post-injection, at days 43 and 190', 'description': ""The analysis is performed using the 21-item PIN questionnaire which includes 21 items grouped into 4 multi-item domains: 'Acceptance of ISR' scale score (2 items); 'Bother from ISR' scale score (6 items); 'Leg movement' scale score (4 items); 'Sleep' scale score (4 items); and 5 standalone items: pain during injection; anxiety before injection; anxiety after injection; willingness to be injected in the future; and overall satisfaction with mode of administration. Participant responses are scored on a 5-point Likert scale, where 1 represents the least favorable perception of injection and 5 the most favorable, with domain scores calculated as the mean of all items in that domain."", 'timeFrame': 'At Day 43 (28 days after second injection) and Day 190 (26 weeks after second injection)'}, {'measure': 'Change in the intensity of post-injection site pain assessed over time', 'description': 'The analysis is performed using the numerical rating scale (NRS), which is a visual analogue scale that assesses the maximum level of pain experienced with injections ranging from 0 (no pain) to 10 (extreme pain). An NRS related to each injection is self-administered electronically at the clinic visits at the same timepoints after each injection', 'timeFrame': 'At days 1, 2, 5 and 8 for the first injection and days 15, 16, 19, and 22 for the second injection'}, {'measure': 'Percentage of participants with ISRs overall and by severity', 'description': 'The ISRs severity is graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Percentage of participants with specific ISRs of interest', 'description': 'The ISRs of interest are nodules (maximum diameter and visibility over time), pigmentation changes (assessed surface area, distinction of hyperpigmentation vs hypopigmentation), and induration/ swelling (visibility over time).', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Mean duration of ISRs', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Median duration of ISRs', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Percentage of participants with adverse events (AEs) overall and by severity', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The AEs severity is graded using the DAIDS criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.', 'timeFrame': 'Up to 6 months post a single dose of CAB LA and LEN LA sequentially administered'}, {'measure': 'Number of participants with laboratory abnormalities', 'timeFrame': 'Up to 6 months post any injection'}, {'measure': 'Number of participants with change in laboratory parameters over time', 'timeFrame': 'Up to 6 months post any injection compared to Baseline (Day 1)'}, {'measure': 'Maximum change in toxicity grade from baseline in laboratory values', 'description': 'Toxicity is graded using the DAIDS criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.', 'timeFrame': 'Up to 6 months post any injection compared to Baseline (Day 1)'}]",15.0,18 Years,,ALL,True,INDUSTRY,0.0,57.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01130467,Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder,methylphenidate,"['Ritalin, Concerta', 'methylphenidate', 'Atomoxetine', 'Straterra']",4,OBSERVATIONAL,[],,UNKNOWN,Attention Deficit Disorders With Hyperactivity,Far Eastern Memorial Hospital,2025-09-01T16:18:10.922979,True,,,,CHEMBL827,,,"['Attention Deficit Disorders With Hyperactivity', 'Attention Deficit Disorder', 'Hyperkinetic Syndrome']","['Attention Deficit Disorders with Hyperactivity', 'Attention Deficit Disorder', 'Event related potential']",,2009-09,,"[{'measure': 'Chinese version of SNAP-IV Rating Scale', 'timeFrame': '8 weeks'}]","[{'measure': 'Event-related potential', 'timeFrame': '8 weeks'}]",2.0,6 Years,18 Years,ALL,True,OTHER,2.0,150.0,ESTIMATED,v2_robust,False,False,False,False,,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,CHEMBL827,partial_match,True,233.31,2.09,4.0
NCT04994483,Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease,Simufilam,"['Placebo', 'PTI-125', 'Simufilam']",3,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Alzheimer Disease,"Cassava Sciences, Inc.",2025-09-01T16:18:18.427888,True,,,,NOT_FOUND,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease",,['Alzheimer Disease'],[],,2021-11-03,2024-10-02,"[{'measure': ""Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)"", 'description': 'The change from baseline to Week 52 in the ADAS-Cog12, a psychometrician-administered battery comprised of several cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Scores range from 0 (best) to 80 (worst).', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': ""Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)"", 'description': 'The change from baseline to Week 52 in the ADCS-ADL, a 23-item study partner questionnaire that covers both basic activities of daily living (ADL) and more complex ADL or instrumental ADL. Scores range from 0 to 78, with a lower score indicating greater severity of functional loss.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}]","[{'measure': ""Change From Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS)"", 'description': 'The change from baseline to Week 52 in the iADRS, where scores range from 0 to 146 with lower scores indicating worse performance.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Neuropsychiatric Inventory (NPI)', 'description': 'The change from baseline to Week 52 in the NPI, a 12-item study partner interview, which records the frequency and severity of common neuropsychiatric symptoms in dementia, as well as the level of study partner distress due to each of the neuropsychiatric problems. Scores range from 0 to 144, with higher scores indicating more frequent and severe symptoms, and greater levels of partner distress.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Mini-Mental State Exam (MMSE)', 'description': 'The change from baseline to Week 52 in the MMSE, a set of standardized questions covering several target areas: orientation, registration, attention and calculation, short-term verbal recall, naming, repetition, 3-step command, reading, writing, and visuospatial cognitive assessment. Scores range from 0 to 30, lower scores indicate more severe impairment.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Clinical Dementia Rating Sum of Boxes (CDR-SB)', 'description': 'The change from baseline to Week 52 in the CDR-SB, which characterizes 6 domains of cognitive and functional performance applicable to AD and related dementias: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Scores for each domain have a minimum of 0 and a maximum of 3, and the 6 domain scores are summed to give the CDR-SB, which has a minimum score of 0 and a maximum score of 18. Higher scores indicate more severe impairment.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}, {'measure': 'Change From Baseline in the Zarit Burden Interview (ZBI)', 'description': 'The change from baseline to Week 52 in the ZBI, a 22-item study partner questionnaire designed to assess the stress or burden experienced by caregivers of people with dementia. Scores range from 0 to 88, with a higher score indicating greater stress or burden.', 'timeFrame': 'Baseline (Study Day 1) to Week 52'}]",7.0,50 Years,87 Years,ALL,False,INDUSTRY,1.0,804.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02205541,Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU,Eculizumab,"['Eculizumab', 'Soloris®', 'Solution with 5% glucose', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Hemolytic Uremic Syndrome of Childhood,"University Hospital, Toulouse",2025-09-01T16:18:15.898771,True,,,,NOT_FOUND,Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo,,['Hemolytic Uremic Syndrome of Childhood'],"['Eculizumab', 'Shiga-toxin', 'hemolytic and uremic syndrome', 'pediatric']",,2015-06,2018-06,"[{'measure': 'the duration in days of extrarenal epuration', 'description': 'Extrarenal epuration means peritoneal dialysis or hemodialysis, and is assessed at each visit.', 'timeFrame': 'From the inclusion date and assessed up to 13 months'}]","[{'measure': 'Number of adverse events as a measure of Safety and tolerance of treatment injections (ECZ or placebo)', 'timeFrame': 'At each injection (treatment visits 2, 3, 4, 5, 6 at respectively day 0, 7, 14, 21, 28) and at each follow-up visit (7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Adverse reactions related to the treatment (ECZ or placebo)', 'timeFrame': 'At each injection (treatment visits 2, 3, 4, 5, 6 at respectively day 0, 7, 14, 21, 28) and at each follow-up visit (7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Duration of Acute Renal Failure (ARF)', 'description': 'Duration of ARF will be evaluated as follow : urine output measurement, creatinin clearance estimated with the Schwartz 2009 assay (based on creatinin plasma levels), ionogram, proteinuria.', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1 ), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Renal sequels', 'description': 'Renal sequels will be evaluated as follow : blood pressure, creatinin clearance, ionogram, proteinuria and microalbuminuria.', 'timeFrame': 'At 1, 6 and 12 months after last injection of ECZ (follow-up visits 7, 8, 9)'}, {'measure': 'Hematological abnormalities', 'description': '* Duration (in days) of the thrombocytopenia\n* Duration (in days) of the hemolytic anemia', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Blood parameters of Complement Alternative Pathway (CAP)', 'description': 'Blood parameters of CAP will be evaluated with plasmatic dosages of the complement components C3 and CD46.', 'timeFrame': 'Inclusion visit (1 at day -3 to -1), Treatment visits (3, 4, 5, 6 at day 7, 14, 21, 28), follow-up visit (7 at month 2)'}, {'measure': 'Inhibition of the Terminal Complement Complex (TCC)', 'description': 'Inhibition of the TCC will be evaluated trough the CH50 assay and plasmatic free ECZ levels.', 'timeFrame': 'Inclusion visit (1 at day -3 to -1), Treatment visits (3, 4, 5, 6 at day 7, 14, 21, 28), follow-up visit (7 at month 2)'}, {'measure': 'Incidence of extrarenal manifestations', 'description': '* Neurological involvement (seizures, coma, focal deficit)\n* Cardiac involvement (cardiac failure, ischemic myocarditis, conduction or rhythm troubles)\n* Digestive involvement (pancreatitis, hepatitis, hemorrhagic colitis, bowel perforation, rectal prolapsus)', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28)'}, {'measure': 'Mortality', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)'}]",10.0,1 Month,18 Years,ALL,False,OTHER,0.0,100.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02599168,Effect of Dexmedetomidine on Propofol Requirement During Anesthesia,Propofol,"['Placebo (normal saline)', 'Propofol', 'Dexmedetomidine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Anesthesia,Dr Nitin Sethi,2025-09-01T16:18:20.952753,True,,,,NOT_FOUND,The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study,,['Anesthesia'],"['dexmedetomidine', 'propofol', 'BIS', 'CLADS']",,2015-12-05,2017-03-20,"[{'measure': 'Change in Propofol usage in milligrams', 'description': ""Comparison of 'dexmedetomidine' versus 'no dexmedetomidine' administration in decreasing quantitative propofol requirements (measured in milligrams) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based general anaesthesia."", 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}, {'measure': 'Assessment of change in anaesthesia depth using Bi-spectral index score', 'description': 'Comparison of anaesthesia depth adequacy in intervention (with dexmedetomidine) versus control (without dexmedetomidine) using Varvel criteria to assess Bi-spectral index (BIS) score consistency during closed loop anaesthesia delivery system empowered and BIS-controlled propofol-based general anaesthesia', 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}]","[{'measure': 'Change in Intraoperative heart Rate (beats per minute)', 'description': ""Comparison of intraoperative heart rate in the 'intervention' (with dexmedetomidine) versus 'control' (without dexmedetomidine) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based GA"", 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}, {'measure': 'Change in Intraoperative blood pressure - systolic , diastolic, and mean (mmHg)', 'description': ""Comparison of intraoperative blood pressure (systolic , diastolic, and mean) in the 'intervention' (with dexmedetomidine) versus 'control' (without dexmedetomidine) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based GA"", 'timeFrame': 'From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively'}, {'measure': 'Postoperative sedation', 'description': 'Will be assessed using Observer asssesment of Alertness/Sedation Scale (OAAS)', 'timeFrame': 'From the end of anaesthesia till 24-hours, postoperatively'}, {'measure': 'Intraoperative awareness', 'description': 'Will be assessed using modified brice questionnaire', 'timeFrame': 'From the end of anaesthesia till 48-hours, postoperatively'}, {'measure': 'Postoperative nausea and vomiting', 'description': 'Will be assessed using PONV scale', 'timeFrame': 'From the end of anaesthesia till 24-hours, postoperatively'}, {'measure': 'Postoperative Analgeisa', 'description': 'Will be assessed using Visual Analogue Scale (VAS) Score', 'timeFrame': 'From the end of anaesthesia till 24-hours, postoperatively'}]",8.0,20 Years,65 Years,ALL,False,OTHER,0.0,80.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01682161,A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate,Paliperidone palmitate,"['Paliperidone palmitate', 'INVEGA SUSTENNA']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Schizophrenia,"Janssen Korea, Ltd., Korea",2025-09-01T16:18:13.412900,True,,,,NOT_FOUND,"An Open-Label, Comparative Study of Immediate or Delayed Switch to Paliperidone Palmitate in Patients Unsatisfied With Current Oral Atypical Antipsychotics to Evaluate the Evolution of Medication Satisfaction and Adherence",,['Schizophrenia'],"['Schizophrenia', 'Paliperidone Palmitate', 'Invega Sustenna', 'Antipsychotics', 'Atypical antipsychotics', 'Medication Satisfaction and Adherence']",,2012-01,2013-09,"[{'measure': 'Change from baseline to Week 21 in scores of Medication Satisfaction Questionnaire (MSQ)', 'description': 'MSQ is designed to assess treatment satisfaction among patients with schizophrenia. The responses will be assessed on a 7-point Likert-type scale rated as follows: 1=extremely dissatisfied, 2=very dissatisfied, 3=somewhat dissatisfied, 4=neither satisfied nor dissatisfied, 5=somewhat satisfied, 6=very satisfied, and 7=extremely satisfied.', 'timeFrame': 'Screening (Week -2), baseline (Week 0), Week 1, Week 5, Week 8, Week 9, Week 13, Week 17, and Week 21'}]","[{'measure': 'Change from baseline to Week 21 in scores of Treatment Satisfaction Questionnaire for Medication (TSQM)', 'description': 'The TSQM is a 14-item subject assessed evaluation of treatment medication using a 7-point Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7= Extremely Satisfied.', 'timeFrame': 'Screening, baseline, Week 1, Week 5, Week 8, Week 9, Week 13, Week 17, and Week 21'}, {'measure': 'Change from baseline to Week 21 in scores of Positive and Negative Syndrome Scale (PANSS)', 'description': 'The PANSS is a medical scale used for measuring symptom severity of patients with schizophrenia. The neuropsychiatric symptoms of schizophrenia will be assessed using the 30-item PANSS scale. Each item is rated as follows: 1=absent, 2=Minimal, 3=Mild, 4=Moderate, 5=Moderate Severe, 6=Severe, and 7=Extreme.', 'timeFrame': 'Baseline, Week 8, and Week 21'}, {'measure': 'Change from baseline to Week 21 in scores of Clinical Global Impression - Severity (CGI-S) scale', 'description': ""The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale. It is rated as follows: 1=Normal, not at all ill, 2=Borderline mentally ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Among the most extremely ill."", 'timeFrame': 'Baseline, Week 1, Week 5, Week 8, Week 9, Week 13, Week 17, and Week 21'}, {'measure': 'Change from baseline to Week 21 in scores of Personal and Social Performance (PSP) scale', 'description': 'The PSP is a clinician rated instrument providing an overall rating of personal and social functioning in patients with schizophrenia on a scale of 1-100. The scale defines a continuum from grossly impaired functioning, in which total lack of autonomy in basic functioning and survival risk is evident, to excellent functioning. Four domains of functioning are considered in the rating: 1) socially useful activities, including work and study, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior.', 'timeFrame': 'Baseline, Week 8, and Week 21'}, {'measure': 'Score of Mediation Adherence Rating Scale (MARS)', 'description': 'The MARS is a 10-items self-rating scale to measure the adherence of the drug medication for psychosis. Each item is answered ""yes/no"" and the total score ranges from 0 points (Low medication adherence) to 10 points (High medication adherence).', 'timeFrame': 'Baseline'}]",6.0,20 Years,65 Years,ALL,False,INDUSTRY,0.0,154.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05774873,"IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",IBI334 D,"['IBI334 C', 'IBI334 A', 'IBI334 F', 'IBI334 D', 'IBI334 E', 'IBI334 B']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Solid Tumors,Innovent Biologics (Suzhou) Co. Ltd.,2025-09-01T16:18:23.463599,True,,,,NOT_FOUND,"A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",,['Solid Tumors'],[],,2023-08-09,2026-06-30,"[{'measure': 'Number of patients with treatment-related adverse events', 'description': 'Number of patients who experienced a treatment related AEs from the first dose until 60 days after the last dose', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Percentage of subjects woth Dose-Limitine toxicities(DLTs)', 'description': 'To evaluate the safety and tolerability of IBI334', 'timeFrame': 'Up to 28 days following first dose'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response(PR) assessed per RECIST v1.1 criteria .', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Duration of response (DoR)', 'description': 'For subjects with CR or PR, duration of response(DoR) is the time from the first documented CR or PR to disease progression or death assessed per RECIST V1.1 criteria.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Disease control rate (DCR)', 'description': 'Disease control rate (DCR) is the percentage of CR plus PR Plus stable disease (SD) assessed per RECIST v1.1 criteria.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Time to Response (TTR)', 'description': 'For subjects with CR or PR, time to response(TTR) is the time from first dose of study drugs to the first documented CR or PR assessed per RECIST v1.1 criteria.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Time from randomization to first documented disease progression (radiographic) assessed by investigator per RECIST v1.1 criteria or death due to any cause.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Overall survival (OS)', 'description': 'Time from randomization to death of the subject due to any cause.', 'timeFrame': 'Up to 60 days post last dose'}]",8.0,18 Years,,ALL,False,INDUSTRY,0.0,128.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06419777,Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes,Insulin,"['Lantus', 'Lispro', 'Levemir', 'Insulin', 'Humalog', 'NPH']",6,INTERVENTIONAL,['NA'],,RECRUITING,Gestational Diabetes,Thomas Jefferson University,2025-09-01T16:18:15.907549,True,,,,NOT_FOUND,Strict Versus Permissive Threshold for Initiation of Pharmacotherapy in Gestational Diabetes Mellitus (GDM) With Glucometer Use - A Randomized Control Trial (START1),,"['Gestational Diabetes', 'Pregnancy Related']","['gestational diabetes', 'pregnancy', 'insulin', 'Initiation of medication']",,2024-09-01,2026-05,"[{'measure': 'Neonatal Composite Outcome', 'description': 'neonatal composite including the following measures: large for gestational age (LGA) of neonate defined as birth weight \\>90th percentile for gestational age using the Fenton growth chart, hypoglycemia o defined as glucose \\<40 mg/dL \\<48 hours after birth or glucose, hyperbilirubinemia, stillbirth or neonatal death, birth trauma', 'timeFrame': 'First 28 days of birth'}]","[{'measure': 'Neonatal Outcome: Gestational Age of Birth', 'description': 'Gestational age at delivery in weeks and days', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: APGAR Score', 'description': 'Scoring system provided a standardized assessment for infants after delivery from 0-10', 'timeFrame': 'At 1 minute of life and at 5 min of life'}, {'measure': 'Neonatal Outcome: Birthweight', 'description': 'Birthweight in grams, Macrosomia (birthweight \\>4000g, Small for gestational age (\\<10th percentile based on Fenton Growth Charts)', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: Brachial Plexus Injury', 'description': 'Brachial plexus nerves in neonate are torn, stretched, or compressed at delivery', 'timeFrame': 'Delivery Time'}, {'measure': 'Neonatal Outcome: Respiratory distress', 'description': 'Breathing difficulties after birth requiring supplemental oxygen, mask, intubation, and/or surfactant', 'timeFrame': 'Within first 24 hours after delivery'}, {'measure': 'Neonatal Outcome: Admission to Neonatal intensive Care Unit', 'description': 'Admission to neonatal intensive care unit (NICU)', 'timeFrame': 'From delivery to discharge from NICU'}, {'measure': 'Maternal Outcomes: Maternal hypoglycemia', 'description': 'Maternal episode of hypoglycemia \\< 60 mg/dL throughout the pregnancy', 'timeFrame': 'Initiation of insulin to delivery'}, {'measure': 'Maternal Outcomes: Shoulder Dystocia', 'description': ""An obstetric emergency where the anterior fetal shoulder becomes stuck on the maternal pubic symphysis, delaying the birth of the baby's body."", 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Obstetric anal sphincter injury (OASIS)', 'description': '3rd degree and 4th degree perineal injuries', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Operative Delivery', 'description': 'Vacuum-assisted and Forcep-assisted vaginal Delivery', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Cesarean Delivery', 'description': 'Cesarean birth', 'timeFrame': 'At Delivery'}, {'measure': 'Maternal Outcomes: Postpartum hemorrhage', 'description': 'Defined as cumulative blood loss ≥1000 mL, or bleeding associated with signs/symptoms of hypovolemia within 24 hours of the birth process', 'timeFrame': 'Within 24 hours of delivery'}, {'measure': 'Maternal Outcomes: Hypertensive Disorders of Pregnancy', 'description': 'Hypertensive disorders of pregnancy: gestational hypertension, Preeclampsia without severe features, Pre-eclampsia with severe features, severe range blood pressures defined as (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg), symptoms of central nervous dysfunction, thrombocytopenia with Platelet count \\<100,000 platelets/microL, hepatic abnormalities, kidney impairment, and or pulmonary edema', 'timeFrame': 'From gestational age of 20 weeks during pregnancy to 6 weeks postpartum'}]",14.0,18 Years,,FEMALE,True,OTHER,1.0,430.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03219632,Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG,Fimasartan,['Fimasartan'],1,OBSERVATIONAL,[],,COMPLETED,Left Ventricular Hypertrophy,Seoul National University Bundang Hospital,2025-09-01T16:18:17.176074,True,,,,NOT_FOUND,"Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry",,"['Left Ventricular Hypertrophy', 'Hypertension']",[],,2012-06-05,2017-05-30,"[{'measure': 'The change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG (composite).', 'description': 'Measurements of changes in baseline at 12 months (change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG)', 'timeFrame': '1 year'}]",[],1.0,20 Years,80 Years,ALL,False,OTHER,0.0,72.0,ACTUAL,v2_robust,False,True,False,False,,,,no_match,False,,,
NCT00146731,A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania,SP,"['chlorproguanil-dapsone', 'AQ + artesunate', 'SP', 'SP + amodiaquine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Malaria,London School of Hygiene and Tropical Medicine,2025-09-01T16:18:10.915591,True,,,,NOT_FOUND,Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania,,['Malaria'],"['malaria', 'pregnancy', 'treatment', 'Africa', 'Tanzania']",,2004-01,2007-09,[{'measure': 'The primary end-point of the trial will be treatment failure. This is defined above.'}],"[{'measure': 'Incidence of foetal death during treatment, defined as absence of foetal heartbeat assessed by Doppler'}, {'measure': 'Hypoglycaemia requiring treatment'}, {'measure': 'Parasite recrudescence or re-infection on day 28'}, {'measure': 'Parasite clearance on day 3'}, {'measure': 'Level of recovery of haemoglobin on day 14'}, {'measure': 'Fever clearance time'}, {'measure': 'Incidence of perinatal and neonatal mortality, assessed 4-6 weeks after due date of delivery'}, {'measure': 'Clinically apparent neonatal abnormality, assessed 4-6 weeks after due date of delivery'}, {'measure': 'Placental malaria'}, {'measure': 'Preterm delivery'}, {'measure': 'Other adverse events during treatment'}]",12.0,15 Years,38 Years,FEMALE,False,OTHER,1.0,310.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,Docetaxel,"['Taxotere®', 'Doxorubicin', 'Cyclophosphamide', 'Docetaxel', '5-fluorouracil', '5-FU']",6,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Breast Cancer,Sanofi,2025-09-01T16:18:12.178200,True,,,,NOT_FOUND,A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.,,['Breast Cancer'],['adjuvant treatment'],,1997-06,2010-01,"[{'measure': 'Number of Participants With Disease-Free Survival Events', 'description': 'Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.', 'timeFrame': 'up to 10 year follow-up'}]","[{'measure': 'Number of Participants With Overall Survival Events', 'description': 'Overall Survival - time from the date of randomization up to the date of death of any cause.', 'timeFrame': 'up to 10 year follow-up'}, {'measure': 'Number of Participants With Second Primary Malignancies (Toxicity)', 'description': 'Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.', 'timeFrame': 'up to 10 year follow-up'}]",3.0,18 Years,70 Years,FEMALE,False,INDUSTRY,1.0,1491.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00418496,Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,Aldesleukin,"['Nexavar', 'Sorafenib', 'Proleukin', 'Aldesleukin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Renal Cancer,Ohio State University Comprehensive Cancer Center,2025-09-01T16:18:18.422223,True,,,,NOT_FOUND,A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,,"['Renal Cancer', 'Melanoma']","['Unresectable', 'Metastatic']",,2006-11-08,2013-10,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'Determine the MTD for high dose (HD) aldesleukin and sorafenib in patients with metastatic or unresectable clear cell renal cell carcinoma and metastatic melanoma', 'timeFrame': 'up to 1 year'}]","[{'measure': 'Determine the progression free survival.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Evaluate in a preliminary manner the response rate.', 'timeFrame': 'Up to 12 weeks'}]",3.0,18 Years,,ALL,False,OTHER,2.0,17.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02095886,Relative Bioavailability Study With BMS-955176,BMS-955176,['BMS-955176'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Infection, Human Immunodeficiency Virus",ViiV Healthcare,2025-09-01T16:18:18.426077,True,,,,NOT_FOUND,Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects,,"['Infection, Human Immunodeficiency Virus']",[],,2014-03-25,2014-07-07,"[{'measure': 'Maximum observed plasma concentration (Cmax) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}]","[{'measure': 'Time of maximum observed plasma concentration (Tmax) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Terminal plasma half-life (T-HALF) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Apparent total body clearance (CLT/F) of BMS-955176', 'timeFrame': 'Days 1-4 of Periods 1, 2, 3 and 4'}, {'measure': 'Safety and tolerability based on incidence of adverse events (AEs), serious AEs, AEs leading to discontinuation and deaths, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs and physical examinations', 'timeFrame': 'Up to Period 4/Day 4 (discharge)'}]",7.0,18 Years,50 Years,ALL,True,INDUSTRY,1.0,47.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00236639,A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity,topiramate,['topiramate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Obesity,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",2025-09-01T16:18:15.906818,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity",,['Obesity'],"['Obesity', 'Hypertension', 'Hyperlipidemia', 'Type 2 Diabetes Mellitus', 'Body Mass Index']",,2000-07,2002-06,[{'measure': 'The percent change in body weight from the baseline (randomization) to Week 60 (after one year of maintenance therapy).'}],"[{'measure': 'Changes from either baseline to Week 60 and/or Week 112, or enrollment to Week 60 and/or Week 112 in absolute body weight, Body Mass Index (BMI), body measurements, fasting lipid profile.'}]",2.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,1293.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04777396,A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE),Semagludtide,"['Semagludtide', 'Placebo (semaglutide)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Early Alzheimer's Disease,Novo Nordisk A/S,2025-09-01T16:18:12.186602,True,,,,NOT_FOUND,A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE),,"[""Early Alzheimer's Disease""]",[],,2021-05-18,2026-10-23,"[{'measure': 'Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score', 'description': 'Score on scale (0 to 18)\n\nMeasures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer\'s disease:\n\n* Cognitive domains: memory, orientation, and judgement and problem solving\n* Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents ""none"" to ""severe"" impairment for each of the six domains.\n\nThe CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}]","[{'measure': ""Main Phase: Change in the 24-item Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) score"", 'description': 'Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase:Change in the ADCS-ADL-MCI (Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment ) score"", 'description': 'Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥) 1.0 among patients with CDR global score equal to (=) 0.5 at baseline', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥) 1.0 among patients with CDR global score equal to (=) 0.5 at baseline', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': ""Main Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score"", 'description': 'Score on scale (0 to 85) ADAS-Cog-13 measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The ADAS-Cog-13 is composed of tasks in the original 11-item ADAS-Cog as well as delayed word recall and number cancellation items. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score"", 'description': 'Score on scale (0 to 85) ADAS-Cog-13 measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The ADAS-Cog-13 is composed of tasks in the original 11-item ADAS-Cog as well as delayed word recall and number cancellation items. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the Montreal Cognitive Assessment (MoCA) score', 'description': 'Score on scale (0 to 30) The MoCA is a brief assessment of cognitive abilities including orientation, short-term memory, clock-drawing test, executive function, language abilities, animal naming, attention and abstrac-tion. The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the Montreal Cognitive Assessment (MoCA) score', 'description': 'Score on scale (0 to 30) The MoCA is a brief assessment of cognitive abilities including orientation, short-term memory, clock-drawing test, executive function, language abilities, animal naming, attention and abstrac-tion. The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': ""Main Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)"", 'description': 'Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)"", 'description': 'Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the Mini-Mental State Examination (MMSE) score', 'description': 'Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the Mini-Mental State Examination (MMSE) score', 'description': 'Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to progression in disease stage based on global CDR score', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Time to progression in disease stage based on global CDR score', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Main Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13', 'description': 'Score', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13', 'description': 'Score', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score', 'description': 'Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score', 'description': 'Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in high sensitivity C-reactive protein level', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in high sensitivity C-reactive protein level', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Number of treatment emergent adverse events (TEAEs)', 'description': 'Number of events', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Number of treatment emergent adverse events (TEAEs)', 'description': 'Number of events', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Main Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to first occurrence of stroke', 'description': 'Week(s', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Time to first occurrence of stroke', 'description': 'Week(s', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the EQ-5D-5L (proxy version) index score', 'description': 'Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \\[the proxy\\] would rate the subject´s health) will be used in this trial.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the EQ-5D-5L (proxy version) index score', 'description': 'Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \\[the proxy\\] would rate the subject´s health) will be used in this trial.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Extension phase: Change in the CDR-SB score', 'description': 'Score on scale (0 to 18)\n\nMeasures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer\'s disease:\n\n* Cognitive domains: memory, orientation, and judgement and problem solving\n* Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents ""none"" to ""severe"" impairment for each of the six domains.\n\nThe CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}]",30.0,55 Years,85 Years,ALL,False,INDUSTRY,0.0,1840.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06147544,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.",PB-718,"['PB-718', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Obesity,"PegBio Co., Ltd.",2025-09-01T16:18:19.666422,True,,,,NOT_FOUND,"A Single Center, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.",,['Obesity'],[],,2023-07-06,2024-04-16,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events', 'timeFrame': 'From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit (20 weeks for cohort 1 and cohort 2 or 26 weeks for cohort 3)'}]","[{'measure': 'Pharmacokinetic profile', 'description': 'Cmax', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12 (for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 'Tmax', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 'Area under the concentration-time curve over dosing interval(AUC0-tau）', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 'Area under the concentration-time curve from time zero to the time of the last quantifiable concentration（AUC0-last）', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort2) or week 18(for cohort 3)'}, {'measure': 'Pharmacokinetic profile', 'description': 't1/2', 'timeFrame': 'From the first dose (Day 1 ) of study drug until week 12(for cohort 1 and cohort 2) or week 18(for cohort3)'}, {'measure': 'Proportion of participants with ≥5% weight loss', 'timeFrame': 'week 12 (for cohort 1 and cohort2) or week 18(for cohort 3)'}, {'measure': 'Change in body weight from baseline', 'timeFrame': 'Week12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}, {'measure': 'Change in Fasting Plasma Glucose(FPG) from baseline', 'timeFrame': 'week 12(for cohort 1 and cohort 2) or week 18(for cohort 3)'}]",9.0,18 Years,60 Years,ALL,True,OTHER,0.0,36.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00255424,Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients,ferumoxytol or oral iron,['ferumoxytol or oral iron'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Anemia,"AMAG Pharmaceuticals, Inc.",2025-09-01T16:18:18.419437,True,,,,NOT_FOUND,A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis,,['Anemia'],[],,2004-05,2006-08,[{'measure': 'The mean change in hemoglobin from baseline.'}],[{'measure': 'Change in iron indices.'}],2.0,18 Years,,ALL,False,INDUSTRY,0.0,304.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01004224,A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,BGJ398,['BGJ398'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3",Novartis Pharmaceuticals,2025-09-01T16:18:18.419425,True,,,,NOT_FOUND,"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies",,"['Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3', 'Squamous Lung Cancer With FGFR1 Amplification', 'Bladder Cancer With FGFR3 Mutation or Fusion', 'Advanced Solid Tumors With FGFR1 Amplication', 'Advanced Solid Tumors With FGFR2 Amplication', 'Advanced Solid Tumors With FGFR3 Mutation']","['advanced solid tumors', 'lung cancer', 'bladder cancer', 'BGJ398', 'FGFR', 'kinase inhibitor', 'advanced solid malignancies']",,2009-12-11,2018-10-08,"[{'measure': 'Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)', 'description': 'Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD). This will be calculated using an established statistical model, based on incidence of adverse events and serious adverse events, physical examinations, vital signs, electrocardiograms, and laboratory parameters', 'timeFrame': '23 months'}]","[{'measure': 'To assess preliminary anti-tumor activity of BGJ398 for patients in expansion Arm 4 (previously treated patients with advanced/metastatic UCC with FGFR3 gene alterations)', 'description': 'overall response rate (ORR), as assessed by investigator per RECIST v 1.0; overall survival (OS), duration of response (DOR) and disease control rate (DCR) will be assessed', 'timeFrame': '23 months'}, {'measure': 'To determine the pharmacokinetic (PK) profiles of oral BGJ398', 'description': 'Time vs. concentration profiles, PK parameters of BGJ398 and known active metabolite(s).', 'timeFrame': '23 months'}, {'measure': 'To evaluate the pharmacodynamic effect of the drug.', 'description': 'Pre- vs. post treatment serial changes in FGF23 plasma levels (not done for patients enrolled to expansion Arm 4)', 'timeFrame': '23 months'}, {'measure': 'Assess preliminary anti-tumor activity for patients not in Arm 4.', 'description': 'Overall tumor response rate (ORR) and PFS assessed by investigator per RECIST', 'timeFrame': '23 months'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,208.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02687594,"Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)",sucroferric oxyhydroxide,"['PA21 (Velphoro)', 'sucroferric oxyhydroxide']",2,OBSERVATIONAL,[],,COMPLETED,Hyperphosphatemia,Vifor Fresenius Medical Care Renal Pharma,2025-09-01T16:18:18.429254,True,,,,NOT_FOUND,"Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis or Peritoneal Dialysis",,['Hyperphosphatemia'],[],,2016-04-06,2019-04-06,"[{'measure': 'Incidence of Adverse Drug Reactions (ADRs)', 'timeFrame': 'through study completion, up to 42 months'}, {'measure': 'Proportion of Adverse Drug Reactions (ADRs)', 'timeFrame': 'through study completion, up to 42 months'}]","[{'measure': 'Patient Reported Outcome questionnaire - Adherence to Velphoro based on the standard Morisky questionnaire', 'description': 'Patient reported outcomes will be evaluated by descriptive statistics', 'timeFrame': 'through study completion, up to 42 months'}, {'measure': 'Patient Reported Outcome questionnaire - Perceived Pill based on the ACTG questionnaire', 'description': 'Patient reported outcomes will be evaluated by descriptive statistics', 'timeFrame': 'through study completion, up to 42 months'}, {'measure': 'Patient Reported Outcome questionnaire - Treatment satisfaction based on the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)', 'description': 'Patient reported outcomes will be evaluated by descriptive statistics', 'timeFrame': 'through study completion, up to 42 months'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,1400.0,ACTUAL,v2_robust,False,True,False,True,,,,no_match,False,,,
NCT05911724,Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.,CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study,"['HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study', 'Empa- CAD', 'CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study', 'Empa-HF']",4,OBSERVATIONAL,[],,COMPLETED,Stable Angina,Damanhour University,2025-09-01T16:18:23.457840,True,,,,CHEMBL2107830,Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.,,"['Stable Angina', 'Heart Failure']","['vaspin', 'visfatin', 'lipoprotein A', 'high-sensitivity C-reactive protein', 'sortilin', 'homocysteine', 'troponin I', 'fetuin A']",,2023-03-01,2024-09-30,"[{'measure': 'All Cause 30 day hosptial admission', 'description': 'Number of patients admited to hospital during 1 month.', 'timeFrame': '1 month'}, {'measure': 'All Cause 90 day hosptial admission', 'description': 'Number of patients admited to hospital during 3 month.', 'timeFrame': '3 months'}, {'measure': 'vaspin (ng/ml)', 'description': 'vaspin blood concentration', 'timeFrame': '1 month'}, {'measure': 'visfatin (ng/ml)', 'description': 'visfatin blood concentration', 'timeFrame': '1 month'}, {'measure': 'Sortillin (pg/ml)', 'description': 'Sortillin blood concentration', 'timeFrame': '1 month'}, {'measure': 'Homocystien(umol/L)', 'description': 'Homocystien blood concentration', 'timeFrame': '1 Month'}, {'measure': 'Troponin.I (ng/ml)', 'description': 'Troponin.I blood concentration', 'timeFrame': '1 Month'}]",[],7.0,18 Years,80 Years,ALL,False,OTHER,1.0,180.0,ACTUAL,v2_robust,False,True,False,False,,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,CHEMBL2107830,partial_match,True,450.92,1.61,4.0
NCT04018703,The Study of Different Sedative Medications in Monitored Anesthesia Care During Eye Surgery With Local Anesthesia,Dexmedetomidine,"['Midazolam', 'Dexmedetomidine']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Balanced Anesthesia,Eye & ENT Hospital of Fudan University,2025-09-01T16:18:18.424160,True,,,,CHEMBL778,Effective Dose of Dexmedetomidine or Midazolam in Monitored Anesthesia Care for Patients Undergoing Ophthalmologic Surgery With Retrobulbar Nerve Block,,"['Balanced Anesthesia', 'Adjuvants,Anesthesia']","['Monitored anesthesia care', 'Ophthalmic surgery', 'Dexmedetomidine', 'Midazolam']",,2019-11-01,2021-12-31,"[{'measure': ""Perioperative change of Observer's Assessment of Alertness/Sedation scale (OAA/S)"", 'description': 'Conventional subjective sedation scales with 1 to 5. Successful sedation was defined as an OAA/S scale score between 1 and 3, while failure was defined as an OAA/S score of more than 3.', 'timeFrame': 'OAA/S score will be recorded from patient arrival in the operating room to about 30 minutes after surgery at following time points: before sedative administration, before skin incision, every 5 minutes intraoperatively and every 10 minutes in PACU.'}, {'measure': 'Numerical rating scale (NRS)', 'description': 'The surgeons rated anesthesia management on a numerical rating scale (NRS), ranging from 0 to 10, with 10 defined as the best condition and 0 as the worst.', 'timeFrame': 'Immediately after surgery, the surgeons report NRS only once'}]","[{'measure': 'Intraocular pressure', 'description': 'Measured with Tono-Pen tonometer', 'timeFrame': 'Intraocular pressure will be measured at two time points: before sedative medication administration and before skin incision.'}, {'measure': 'Bispectral index (BIS)', 'description': 'Anesthesia depth index', 'timeFrame': 'Bis will be continuously recorded with BIS monitor from arrival in the operating room to discharge to ward (about 30 minutes after surgery).'}, {'measure': 'Visual analogue scale (VAS)', 'description': 'Patient self-report pain score ranging from 0 to 10, with 0 defined as no pain at all and 10 as the intolerable pain.', 'timeFrame': 'VAS will be recorded at the following time points until 1h postoperatively: before sedative medication administration, before skin incision, every 10 minutes intraoperatively and 1h postoperatively'}]",5.0,18 Years,80 Years,ALL,False,OTHER,0.0,150.0,ESTIMATED,v2_robust,True,False,False,False,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CHEMBL778,exact_match,True,200.28,3.18,4.0
NCT04270344,The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment,Pitavastatin 4mg,"['Pitavastatin 4mg', 'valsartan']",2,OBSERVATIONAL,[],,UNKNOWN,Hypercholesterolemia,JW Pharmaceutical,2025-09-01T16:18:08.348466,True,,,,NOT_FOUND,"A 12-month Open-label, Multicenter Observation Study on the Occurrence of Major Adverse Cardiac Events (MACE) in Patients With Acute Myocardial Infarction (AMI) Receiving Pitavastatin/Valsartan Treatment",,['Hypercholesterolemia'],[],,2018-07-01,2022-06-30,"[{'measure': 'all-cause mortality, non-fatal MI, repeat re-vascularization', 'description': 'MACE', 'timeFrame': '12 months'}]","[{'measure': 'The rate of mortality', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of cardiac death', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of nonfatal MI', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of hospitalization due to heart failure', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of Coronary artery bypass graft(CABG)', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of target lesion re-vascularization', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of target vessel re-vascularization', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The rate of cerebrovascular disease', 'description': 'MACE', 'timeFrame': '6 and 12 months'}, {'measure': 'The change of SBP, DBP', 'description': 'Hypertensive parameters', 'timeFrame': '6 and 12 months'}, {'measure': 'The change of TC, TG, HDL-C, LDL-C, hsCRP', 'description': 'Lipid parameters', 'timeFrame': '6 and 12 months'}, {'measure': 'The change of HbA1c, FBS', 'description': 'No Onset of Diabetes', 'timeFrame': '6 and 12 months'}]",12.0,19 Years,,ALL,True,INDUSTRY,0.0,905.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT00003487,Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus,Antineoplaston therapy (Atengenal + Astugenal),"['Antineoplaston therapy (Atengenal + Astugenal)', 'A10 (Atengenal); AS2-1 (Astugenal)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Adenocarcinoma of the Esophagus,Burzynski Research Institute,2025-09-01T16:18:17.177401,True,,,,NOT_FOUND,Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Esophagus,,['Adenocarcinoma of the Esophagus'],"['esophageal cancer', 'recurrent esophageal cancer', 'stage IV esophageal cancer']",Slow accrual,1996-05-30,2001-04-27,"[{'measure': 'Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable', 'description': 'Objective response rate per The International Working Group response criteria (1999): Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \\>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable lesions, sustained for at least four weeks. Stable Disease (SD), \\< 50% change in the sum of the products of of the greatest perpendicular diameters of all measurable lesions, sustained for at least twelve weeks.', 'timeFrame': '59 months'}]",[],1.0,18 Years,99 Years,ALL,False,OTHER,0.0,8.0,ACTUAL,v2_robust,True,False,True,False,Slow accrual,,,no_match,False,,,
NCT02750410,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes,Dulaglutide,"['Dulaglutide', 'Placebo', 'LY2189265']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Type 2 Diabetes,Eli Lilly and Company,2025-09-01T16:18:23.455244,True,,,,NOT_FOUND,A Phase 4 Study of Efficacy and Safety of Dulaglutide When Added to Insulin Treatment With or Without Oral Antidiabetic Medication in Patients With Type 2 Diabetes,,['Type 2 Diabetes'],[],,2016-08,2018-06-18,"[{'measure': 'Change From Baseline in Hemoglobin A1c (HbA1c)', 'description': 'HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline HbA1c, treatment, visit, and treatment-by-visit insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.', 'timeFrame': 'Baseline, Week 16'}]","[{'measure': 'Percentage of Participants With HbA1c <7.0% or ≤6.5%', 'description': 'Percentage of participants whose HbA1c was \\<7.0% or ≤6.5%. HbA1c \\<7.0% is presented.', 'timeFrame': 'Week 16'}, {'measure': 'Change From Baseline in Fasting Serum Glucose (FSG)', 'description': 'The LS mean change from baseline in FSG was calculated using a REML based MMRM and adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c Group (\\<8.5%, \\>=8.5%) + insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Plasma Glucose From 7-Point Self-Monitored Blood Glucose Profiles (SMBG)', 'description': 'The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: prebreakfast blood glucose (BG), breakfast 2-hour postprandial blood glucose (PPBG), prelunch BG, lunch 2-hour PPBG, predinner BG, dinner 2-hour PPBG, and bedtime BG. LS mean was calculated with fixed effect test of analysis of covariance (ANCOVA) model and adjusted by, baseline value, treatment, baseline HbA1c Group (\\<8.5%, ≥8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin).', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Body Weight', 'description': 'LS mean change from baseline in body weight was calculated using a REML based MMRM and was adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c group (\\<8.5%, \\>=8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Daily Total Insulin Dose', 'description': 'Mean change from baseline in total insulin dose was measured in each treatment groups.', 'timeFrame': 'Baseline, Week 16'}]",6.0,20 Years,,ALL,False,INDUSTRY,0.0,159.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06881290,Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus,Vunakizumab (IL-17A inhibitor),['Vunakizumab (IL-17A inhibitor)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,"Lupus Erythematosus, Systemic",Chinese SLE Treatment And Research Group,2025-09-01T16:18:07.019434,True,,,,NOT_FOUND,Pilot Study on the Treatment of Vunakizumab in Mild to Moderate Systemic Lupus Erythematosus,,"['Lupus Erythematosus, Systemic']","['Vunakizumab', 'Systemic lupus erythematosus']",,2025-05-19,2027-12-01,"[{'measure': 'the percentage of patients achieving an BICLA response at the end of 24 weeks', 'description': 'The BICLA response was defined as a reduction of all severe (BILAG-2004 A) or moderately severe (BILAG-2004 B) disease activity at baseline to lower levels (BILAG-2004 B, C, or D and C or D, respectively) and no worsening in other organ systems (with worsening defined as ≥1 new BILAG-2004 A item or ≥2 new BILAG-2004 B items); no worsening in disease activity, as determined by the SLEDAI-2K score (no increase from baseline) and by the PGA score (no increase of ≥0.3 points from baseline)', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}]","[{'measure': 'the percentage of patients achieving an BICLA response at the end of 12 weeks', 'description': 'The BICLA response was defined as a reduction of all severe (BILAG-2004 A) or moderately severe (BILAG-2004 B) disease activity at baseline to lower levels (BILAG-2004 B, C, or D and C or D, respectively) and no worsening in other organ systems (with worsening defined as ≥1 new BILAG-2004 A item or ≥2 new BILAG-2004 B items); no worsening in disease activity, as determined by the SLEDAI-2K score (no increase from baseline) and by the PGA score (no increase of ≥0.3 points from baseline)', 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'the percentage of patients achieving SRI-4 response at the end of 24 weeks.', 'description': ""The SRI-4 (SLE Responder Index-4) response was defined as a reduction of at least 4 points in SLEDAI score compared with the baseline level, no new British Isles Lupus Assessment Group (BILAG) A organ domain score or no more than one new BILAG B organ domain score, and no worsening in the Physician's Global Assessment (PGA) (\\<0.3 points worsening from the baseline level)."", 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'the percentage of patients achieving SRI-4 response at the end of 12 weeks.', 'description': ""The SRI-4（SLE Responder Index-4） response was defined as a reduction of at least 4 points in SLEDAI score compared with the baseline level, no new British Isles Lupus Assessment Group (BILAG) A organ domain score or no more than one new BILAG B organ domain score, and no worsening in the Physician's Global Assessment (PGA) (\\<0.3 points worsening from the baseline level)."", 'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}, {'measure': 'Changes from baseline in SLEDAI at 24 weeks', 'description': 'SLEDAI stands for Systemic Lupus Erythematosus Disease Activity Index, with a score of 0-6 representing mild disease activity, 7-12 representing moderate disease activity, and 12-16 representing severe disease activity', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'Changes from baseline in CLASI at 24 weeks.', 'description': 'CLASI stands for Cutaneous Lupus Erythematosus Disease Area and Severity Index. It is a measure of the severity of skin disease, with scores ranging from 0 to 70, with higher scores indicating more severe disease activity', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'Changes from baseline in PGA at 24 weeks', 'description': ""PGA stands for Physician's Global Assessment (PGA ) . It is used to assess the activity of systemic lupus erythematosus on a scale ranging from 0 to 3, where 0 indicates no disease activity and 3 indicates the most severe disease activity."", 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}, {'measure': 'Changes from baseline of the SJC and TJC at 24 weeks', 'description': 'Swollen Joint Count(SJC) and Tender Joint Count(TJC) indicate the number of swollen and tender joints in 28 joints, respectively. 28 joints refer to both shoulders, both elbows, both wrists, both knees, 10 metacarpophalangeal joints, and 10 proximal interphalangeal joints, which ranging from 0 to 28, the higher value means more serious disease activity.', 'timeFrame': 'From enrollment to the end of treatment at 24 weeks'}]",8.0,18 Years,65 Years,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00255606,Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer,docetaxel,"['prednisone', 'docetaxel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Prostate Cancer,Tampere University,2025-09-01T16:18:19.671509,True,,,,NOT_FOUND,A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial,,['Prostate Cancer'],"['adenocarcinoma of the prostate', 'stage IV prostate cancer', 'recurrent prostate cancer']",,2005-08,2010-08,[{'measure': 'Time to treatment failure (TTF)'}],"[{'measure': 'Quality of life every 6 weeks until TTF'}, {'measure': 'Safety'}, {'measure': 'Overall survival'}, {'measure': 'Response rate'}, {'measure': 'Use of epoetin beta'}]",6.0,18 Years,,MALE,False,OTHER,0.0,360.0,ESTIMATED,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02934828,Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer,Neoadjuvant Chemotherapy,"['postoperative chemotherapy', 'Neoadjuvant Chemotherapy', 'preoperative chemotherapy', 'Adjuvant Chemotherapy']",4,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Breast Cancer,Chinese Academy of Medical Sciences,2025-09-01T16:18:15.910484,True,,,,NOT_FOUND,A Randomized Study of Preoperative Chemotherapy or Postoperative Chemotherapy for Early Triple Negative or Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Operable Breast Cancer,,['Breast Cancer'],[],,2014-10,2018-12,"[{'measure': 'Recurrence-Free Survival (RFS) of neoadjuvant and adjuvant treatment in TNBC and her2 positive breast cancer', 'timeFrame': '5 years'}]",[],1.0,18 Years,70 Years,FEMALE,False,OTHER,0.0,230.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00966030,Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042),MK0974 tablet,"['MK0974 tablet', 'Comparator: MK0974 liquid filled capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Migraine,Merck Sharp & Dohme LLC,2025-09-01T16:18:22.199292,True,,,,NOT_FOUND,"An Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate Vs. a Single Dose of the Reference MK0974 Liquid Filled Capsule in Healthy Subjects",,['Migraine'],[],,2008-03,2008-05,"[{'measure': 'Area under the curve (AUC(0 to infinity)) following single dose administration of MK0974 tablet formulation and MK0974 liquid filled capsule formulation', 'timeFrame': 'Through 48 Hours Post Dose'}, {'measure': 'Peak plasma concentration (Cmax) following single dose administration of MK0974 tablet formulation and MK0974 liquid filled capsule formulation', 'timeFrame': 'Through 48 Hours Post Dose'}]",[],2.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03752905,A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB),PTR-01,"['Recombinant human collagen 7 (rC7)', 'PTR-01', 'Normal saline']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Recessive Dystrophic Epidermolysis Bullosa,"Phoenix Tissue Repair, Inc.",2025-09-01T16:18:18.429205,True,,,,NOT_FOUND,"A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)",,['Recessive Dystrophic Epidermolysis Bullosa'],['RDEB'],,2019-01-09,2020-11-30,"[{'measure': 'Incidence of treatment-emergent adverse events', 'description': 'The primary endpoint of this study is safety and tolerability, as assessed by treatment-emergent adverse events, infusion-associated reactions (IAR) and immunogenicity', 'timeFrame': 'Up to Day 127'}]","[{'measure': 'To measure the peak serum concentration (Cmax) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of Cmax', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the time to peak concentration (Tmax) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of Tmax', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the area under the curve (AUC) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of AUC', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the clearance of PTR-01', 'description': 'Pharmacokinetic parameter estimates of clearance', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'To measure the half-life (t1/2) of PTR-01', 'description': 'Pharmacokinetic parameter estimates of t1/2', 'timeFrame': 'Pre-dose, 15 minutes, 60 minutes, 2 hours, 4 hours, 8 hours and 24 hours post-dose'}, {'measure': 'Change from Baseline in rC7', 'description': 'Change in rC7 on skin biopsy by immunofluorescence (IF)', 'timeFrame': 'Screening and Day 127'}, {'measure': 'Change from Baseline in anchoring fibrils', 'description': 'Change in anchoring fibrils on skin biopsy by electron microscopy (EM)', 'timeFrame': 'Screening and Day 127'}, {'measure': 'Duration of rC7 residence in tissue', 'description': 'Duration of rC7 residence in tissue by skin biopsy', 'timeFrame': 'Screening and Day 127'}]",9.0,16 Years,,ALL,False,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00483405,"Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer",capecitabine,"['Eloxatin', 'Xeloda', 'capecitabine', 'oxaliplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Liver Cancer,UNC Lineberger Comprehensive Cancer Center,2025-09-01T16:18:15.899824,True,,,,NOT_FOUND,"Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma",,['Liver Cancer'],"['advanced adult primary liver cancer', 'localized unresectable adult primary liver cancer', 'recurrent adult primary liver cancer', 'adult primary hepatocellular carcinoma']",,2006-10,2010-12,"[{'measure': 'Disease Response Rate', 'description': 'Radiographic response will be measured every six weeks while subject is on treatment. Response will be measured using RECIST criteria.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions.', 'timeFrame': '42 days (2 cycles)'}]","[{'measure': 'Number of Subjects Experiencing Adverse Events', 'description': 'Adverse events will be assessed using CTCAE criteria.', 'timeFrame': 'every 3 weeks of treatment with an average of 15 weeks on treatment'}, {'measure': 'Overall Survival', 'description': 'Overall survival will be calculated from time of enrollment to death or last contact date.', 'timeFrame': 'Median 23 month follow-up'}, {'measure': 'Time to Progression', 'description': 'Time to progression will be calculated from the time of enrollment until confirmed disease progression. Defined by RECIST (Response Evaluation Criteria in Solid Tumors), Progressive Disease (PD) - at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.', 'timeFrame': 'Median 23 month follow-up'}]",4.0,18 Years,120 Years,ALL,False,OTHER,5.0,33.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05657015,Lepidium Sativum Extract Versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy,Lepidium Sativum,"['Garden cress', 'Lepidium Sativum', 'Simvastatin']",3,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Periodontitis,Ain Shams University,2025-09-01T16:18:09.629916,True,,,,NOT_FOUND,Lepidium Sativum Extract Versus Simvastatin as an Adjunctive Local Delivery Agents to Non-Surgical Periodontal Therapy: A Randomized Controlled Clinical Trial With Biochemical Analysis,,['Periodontitis'],"['In situ gel', 'High Performance Thic Layer Chromatography', 'Local Drug Delivery']",,2021-09-01,2022-07-01,"[{'measure': 'Assess clinically the plaque index (PI) in periodontitis patients', 'description': 'Percentage of tooth surfaces with bacterial deposits. Plaque index scores were recorded at six sites per tooth (mesiobuccal, buccal, disto-buccal, mesio-lingual, lingual, disto-lingual).The plaque index visually records the score such as 0,1,2, and 3 using the standard probe.', 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}, {'measure': 'Asses clinically the mean sulcus bleeding index (MSBI) in periodontitis patients', 'description': 'Percentage of tooth surfaces with bleeding point sites on probing. Bleeding index scores were recorded at six sites (mesiobuccal, buccal, disto-buccal, mesio-lingual, lingual, disto-lingual). The scores were recorded as 0,1,2,3,4, and 5.', 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}, {'measure': 'Assess clinically the probing depth (PD) in periodontitis patients', 'description': ""The distance between the margin of the gingiva and the base of the pocket was recorded at four points (mesio-facial, mid-facial, disto-facial, and mid-lingual) to the nearest millimeter using the University of Michigan O' probe with Williams' graduations in conjunction with an occlusal stent for the standardization of readings. The probe was inserted parallel to the long axis of the tooth."", 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}, {'measure': 'Assess clinically the clinical attachment level (CAL) in periodontitis patients', 'description': ""The CAL was measured in millimeters from the cemento-enamel junction (CEJ) to the base of the pocket using the University of Michigan O' probe with Williams' graduations in conjunction with an occlusal stent for the standardization of readings."", 'timeFrame': 'Change at baseline (after 1 week from the last debridement) and after 3 months follow-up period'}]","[{'measure': 'Detect biochemically the nuclear factor kappa B (NF-κB) level in the gingival crevicular fluid (GCF).', 'description': ""Levels of NF-κB (ng/ml) in GCF samples were determined by using a commercially available means of Enzyme Linked Immuno Sorbent Assay (ELISA) according to the manufacturer's recommendations. The GCF samples were collected using perio-paper strips (Oraflow Inc., Smithtown, New York, USA). Perio-paper strips visually contaminated with blood were discarded. The samples were immediately placed into a sterile, labeled Eppendorf tube and stored at -20 ºC for subsequent assays. Each perio-paper was soaked with 200ul of phosphate buffering saline (PBS), vortexed, and centrifuged. A supernatant was used for the detection of NF-κB. The kit was provided by Bioassay Technology Laboratory (China) Cat No E7121 Hu."", 'timeFrame': 'Change from baseline to 1 month, from 1 month to 3 months, and from baseline to 3 months'}]",5.0,25 Years,50 Years,ALL,True,OTHER,0.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05821517,METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX),Administration of METHOXYFLURANE,"['Administration of METHOXYFLURANE', 'Standard of care']",2,INTERVENTIONAL,['PHASE4'],PHASE4,RECRUITING,Anterior Shoulder Dislocation,Centre Hospitalier Universitaire de Nice,2025-09-01T16:18:12.177704,True,,,,CHEMBL1341,METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation,,['Anterior Shoulder Dislocation'],[],,2023-05-01,2025-02-01,"[{'measure': 'Decrease in the rate of procedural sedation of anterior shoulder dislocation', 'description': 'Rate of use of procedural sedation for anterior shoulder dislocation reduction in the interventional groups compared to the control group', 'timeFrame': 'Day 1 (day of reduction of anterior shoulder dislocation)'}]","[{'measure': 'The amount of co-antalgesics administered', 'description': 'Posology of co-analgesic medications administered', 'timeFrame': '3 months'}, {'measure': 'The duration of the procedure', 'description': 'Time lenght of the reduction procedure', 'timeFrame': 'Day 1 (day of change of anterior shoulder dislocation)'}, {'measure': 'The dosage of drugs used in procedural sedation', 'description': 'Posology of sedative drugs administered for a procedural sedation', 'timeFrame': 'Day 1 (day of reduction of anterior shoulder dislocation)'}, {'measure': 'The average length of stay in the emergency department', 'description': 'Average length of stay in the emergency department', 'timeFrame': '3 months'}, {'measure': 'Patient satisfaction', 'description': 'Patient satisfaction at the end of care evaluated with a questionnaire EVA', 'timeFrame': '3 months'}, {'measure': 'The rate of reduction-related complications', 'description': 'Complications related to the reduction', 'timeFrame': '3 months'}]",7.0,18 Years,,ALL,False,OTHER,0.0,150.0,ESTIMATED,v2_robust,True,False,False,False,,COC(F)(F)C(Cl)Cl,CHEMBL1341,partial_match,True,164.97,2.03,4.0
NCT02153723,Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone),Glatiramer Acetate,"['Glatiramer Acetate', 'Copaxone']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Rett Syndrome,Montefiore Medical Center,2025-09-01T16:18:09.638403,True,,,,NOT_FOUND,Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone),,['Rett Syndrome'],"['Treatment trial, Rett syndrome, Glatiramer acetate']",,2013-08,2016-01,"[{'measure': 'Gait Velocity as Measured by GAITRite System', 'description': 'To perform quantitative gait assessments a computerized walkway (457 × 90.2 × 0.64cm) with embedded pressure sensors (GAIT Rite system) was used. Subjects walked on the walkway for two trials, while wearing comfortable footwear.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}]","[{'measure': 'Breath Hold Index (Number of Breath Holds Per Hour; Assessed in the Sleep Monitoring Lab)', 'description': 'Breath hold index is defined as number of breath holds/hour. Respirations were monitored with sleep monitoring equipment during the daytime at the polysomnography laboratory with additional oronasal airflow, electromyography (EMG), EEG and video monitoring to confirm wakefulness during the period of study.', 'timeFrame': 'Baseline and during final week of treatment (week 32)'}, {'measure': 'Breath Hold Time (Assessed in the Sleep Monitoring Lab)', 'description': 'Breath Hold Time is defined as percentage of time spent holding the breath in a specific time unit. It is measured by a standard medical technique where belts are placed on the chest and abdomen to record movement and sensors are used to record nasal flow. Wake respiration was monitored with sleep monitoring equipment during the daytime at the polysomnography laboratory with additional oronasal airflow, EMG, EEG and video monitoring to confirm wakefulness during the period of study.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}, {'measure': 'Visual Memory Novelty Score as Assessed by TX300 Tobii Computer.', 'description': 'Eye-tracking is considered an indication of visual memory. Eye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 computer (Tobii Technology, Danderyd, Sweden). The actual data given by the computer represents the percentage of time spent looking at a novel visual target - this is called the novelty score. Visual memory, as indexed by the novelty score, is the percentage of time spent looking at a novel target during the test (""visual paired comparison paradigm""). Duration of testing was 2 minutes.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}, {'measure': 'Visual Attention (Number of Fixations) Assessed by Eye-tracking TX300 Tobii Computer.', 'description': 'Visual attention is indexed by duration and number of fixations on novel target on testing. The standard method of assessing visual attention in neuropsychology is by measuring:\n\nA)number of fixations (how many times the subject looks at each of the 2 visual targets). The higher number of fixations, the more attentive the subject to that visual target.\n\nB) duration of fixations in seconds (the longer the fixation the more attentive). Duration of fixations correlates with intelligence: the smarter the person is the shorter his fixations are.\n\nEye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 (Tobii Technology AB, Danderyd, Sweden). The measured index is called the Novelty Score which indicates the percentage of time spent looking at novel visual target. Duration of testing session was 2 minutes.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}, {'measure': 'Visual Attention (Fixation Length) Assessed by Eye-tracking TX300 Tobii Computer.', 'description': 'The standard method of assessing visual attention in neuropsychology is by measuring:\n\nA)number of fixations (how many times the subject looks at each of the 2 visual targets). The higher number of fixations, the more attentive the subject to that visual target.\n\nB) duration of fixations in seconds (the longer the fixation the more attentive). Duration of fixations correlates with intelligence: the smarter the person is the shorter his fixations are.\n\nEye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 (Tobii Technology AB, Danderyd, Sweden). The measured index is called the Novelty Score which indicates the percentage of time spent looking at novel visual target. Visual attention is indexed by number of fixations on novel target on test.\n\nDuration of testing session was 2 minutes.', 'timeFrame': 'Baseline and Final week of treatment (week 32)'}]",6.0,10 Years,,FEMALE,False,OTHER,1.0,10.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02053350,Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection,Alanyl-glutamine,"['alagln', 'Alanyl-glutamine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Clostridium Difficile Infection,University of Virginia,2025-09-01T16:18:18.414522,True,,,,NOT_FOUND,"Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled Trial",,['Clostridium Difficile Infection'],"['Clostridium difficile', 'glutamine', 'diarrhea', 'alanyl-glutamine']",Funding ended,2015-04,2017-04-05,"[{'measure': 'Number of Participants With Recurrent C. Difficile Infection', 'description': 'Day 40 clinical failure - clinical failure includes death or CDI recurrence assessed 40 days post randomization or lack of clinical cure', 'timeFrame': 'At day forty'}, {'measure': 'Mortality', 'description': 'Death from any cause at days 40, 70 and 190', 'timeFrame': 'Up to 6 months after end of treatment'}]",[],2.0,18 Years,,ALL,False,OTHER,0.0,7.0,ACTUAL,v2_robust,True,False,True,False,Funding ended,,,no_match,False,,,
NCT06886035,Effectiveness of Curcuminoids in Controlling Postoperative Pain Following Total Laparoscopic Hysterectomy,liposomal curcumin,['liposomal curcumin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Postoperative Care,Erzincan Military Hospital,2025-09-01T16:18:25.988244,True,,,,CHEMBL116438,Effectiveness of Curcuminoids in Controlling Postoperative Pain Following Total Laparoscopic Hysterectomy,,"['Postoperative Care', 'Pain Management']",[],,2025-03-21,2026-01-15,"[{'measure': 'the visual analogue scale (VAS)', 'description': 'The primary goal was to assess the variation in postoperative pain levels recorded on the VAS (scored from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable) 24 hours after surgery', 'timeFrame': '24 hours after surgery'}]",[],1.0,20 Years,80 Years,FEMALE,True,OTHER,0.0,126.0,ESTIMATED,v2_robust,True,False,False,False,,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,CHEMBL116438,partial_match,True,368.39,3.85,3.0
NCT03016234,IOP Changes With Different Anesthetic Agents During Laparoscopic Colorectal Surgery,Desflurane,"['Desflurane', 'Propofol', 'Fresofol medium-chain triglyceride (MCT) 2% inj. 50mL', 'Suprane soln. 240ml/Bottle']",4,INTERVENTIONAL,['NA'],,COMPLETED,Intraocular Pressure,"Saint Vincent's Hospital, Korea",2025-09-01T16:18:14.657149,True,,,,NOT_FOUND,Intraocular Pressure Changes During Laparoscopic Colorectal Surgery: Propofol Versus Desflurane Anesthesia,,['Intraocular Pressure'],"['intraocular pressure', 'trendelenburg position', 'pneumoperitoneum']",,2016-09-29,2017-03-08,"[{'measure': 'changes in intraocular pressure (IOP) in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T1 (baseline: initial IOP before anesthesia induction), T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 minutes after position change to head down and right tilt), T5 (10 minutes after position change to head up and right tilt), T6 (30 minutes after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'before anesthesia induction, immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}]","[{'measure': 'changes in mean arterial pressure (MAP) in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T1 (baseline: initial MAP before anesthesia induction), T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 minutes after position change to head down and right tilt), T5 (10 minutes after position change to head up and right tilt), T6 (30 minutes after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'before anesthesia induction, immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}, {'measure': 'changes in end tidal carbon dioxide in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 mins after position change to head down and right tilt), T5 (10 mins after position change to head up and right tilt), T6 (30 mins after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}, {'measure': 'changes in peak airway pressure in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 mins after position change to head down and right tilt), T5 (10 mins after position change to head up and right tilt), T6 (30 mins after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}]",4.0,30 Years,80 Years,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06695572,Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers,CKD-383,['CKD-383'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Type 2 Diabetes Mellitus (T2DM),Chong Kun Dang Pharmaceutical,2025-09-01T16:18:24.747364,True,,,,NOT_FOUND,"An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Effects of Food on Pharmacokinetics and the Safety of CKD-383 in Healthy Adult Volunteers",,['Type 2 Diabetes Mellitus (T2DM)'],[],,2024-11-06,2024-12-13,"[{'measure': 'AUCt of CKD-383', 'description': 'Area under the CKD-383 concentration in blood-time curve from 0 to t', 'timeFrame': '0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours'}, {'measure': 'Cmax of CKD-383', 'description': 'The maximum CKD-383 concentration in blood sampling time t', 'timeFrame': '0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours'}]",[],2.0,19 Years,55 Years,ALL,True,INDUSTRY,1.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02269540,A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A),Sertraline,"['Celexa', 'N-acetylcysteine (NAC)', 'Citalopram', 'Existing depression medication treatment', 'Sertraline', 'Zoloft']",6,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Major Depressive Disorder,Centre for Addiction and Mental Health,2025-09-01T16:18:14.672540,True,,,,CHEMBL809,A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A),,['Major Depressive Disorder'],[],,2014-10,2018-07,"[{'measure': 'MAO-A distribution volume with positron emission tomography', 'description': 'Treatment take 1 week for titration and 6 weeks at full dose=7weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}]","[{'measure': 'Hamilton Depression Rating Scale Score', 'description': 'Treatment takes 1 week for titration and 6 weeks at full dose=7 weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}, {'measure': 'Magnetic Resonance Spectroscopy (n-acetylaspartate and glutathione levels)', 'description': 'Treatment takes 1 week for titration and 6 weeks at full dose=7 weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}, {'measure': 'Blood markers of monoamine oxidase-A fragment level and glutathione level', 'description': 'Treatment takes 1 week for titration and 6 weeks at full dose=7 weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}]",4.0,18 Years,49 Years,ALL,False,OTHER,0.0,10.0,ACTUAL,v2_robust,True,True,False,False,,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,CHEMBL809,exact_match,True,306.24,5.18,4.0
NCT02753205,Dexmedetomidine on Optic Nerve Sheath Diameter,Dexmedetomidine,"['NS', 'dex', 'Dexmedetomidine', 'normal saline']",4,INTERVENTIONAL,['NA'],,WITHDRAWN,Intracranial Hypertension,Gachon University Gil Medical Center,2025-09-01T16:18:07.030693,True,,,,CHEMBL778,Effect of Dexmedetomidine on Optic Nerve Sheath Diameter During Laparoscopic Anterior Resection,,['Intracranial Hypertension'],[],,2016-04,2018-04,"[{'measure': 'Optic nerve sheath diameter', 'description': 'mm', 'timeFrame': 'Change from Baseline optic nerve sheath diameter at pneumoperitoneum 30 min'}]","[{'measure': 'Respiratory and mean arterial pressure', 'description': 'mmHg', 'timeFrame': 'Change from Baseline Respiratory and mean arterial pressure at pneumoperitoneum 30 min'}]",2.0,20 Years,65 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CHEMBL778,exact_match,True,200.28,3.18,4.0
NCT02427958,A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants,Leuprorelin,"['Enantone', 'Leuprorelin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Central Precocious Puberty,Takeda,2025-09-01T16:18:14.666962,True,,,,NOT_FOUND,"An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty",,['Central Precocious Puberty'],['Drug Therapy'],,2015-08-07,2018-11-23,"[{'measure': 'Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Day 1 up to Week 100'}]","[{'measure': 'Percentage of Participants With Regression or no Progression in Tanner Staging at Week 96', 'description': 'Tanner assessment score was used to document the stage of development of puberty through the assessment of secondary sexual characteristics. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Regression or no progression was defined as negative change (improvement) or no change in Tanner score at Week 96 compared to baseline.', 'timeFrame': 'Week 96'}]",2.0,1 Year,9 Years,ALL,False,INDUSTRY,0.0,307.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00869141,Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma,"glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)","['glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)', 'Timolol, Brimonidine, Dorzolamide, Brinzolamide']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Glaucoma,"University of California, Los Angeles",2025-09-01T16:18:07.029723,True,,,,CHEMBL844,Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma,,['Glaucoma'],['Glaucoma tube shunt procedure'],,2009-03,2013-03,"[{'measure': 'Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma', 'description': 'Intraocular pressure more than 21 mmHg during the first 6 months after Ahmed valve implantation after the pressure has been reduced to less than 22 mmHg in the first postoperative week', 'timeFrame': 'within 6 months after surgery'}, {'measure': 'Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma', 'description': 'intraocular pressure comparison between groups after the Ahmed valve implantation', 'timeFrame': '3 weeks after surgery'}, {'measure': 'Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase', 'description': 'intraocular pressure of eyes with hypertensive phase versus without hypertensive phase', 'timeFrame': '1 year after surgery'}]",[],3.0,18 Years,85 Years,ALL,False,OTHER,0.0,52.0,ACTUAL,v2_robust,True,True,False,False,,Brc1c(NC2=NCCN2)ccc2nccnc12,CHEMBL844,partial_match,True,292.14,1.76,4.0
NCT04825743,A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI,zalunfiban,"['zalunfiban', 'RUC-4', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,ST-elevation Myocardial Infarction (STEMI),CeleCor Therapeutics,2025-09-01T16:18:09.629501,True,,,,NOT_FOUND,"A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting",,['ST-elevation Myocardial Infarction (STEMI)'],[],,2021-04-24,2026-05-13,"[{'measure': 'primary efficacy -clinical outcome', 'description': 'As assessed by a 7-point scale. The 7 outcomes, ranking from worst to best are:\n\n1. Death (all cause) at 30 days follow-up\n2. Stroke at 30 days follow-up\n3. Recurrent MI (type 1 to 4 MI) at 30 days follow-up\n4. Acute stent thrombosis at 24 hours post-PCI/angiography\n5. New onset heart failure or rehospitalization for heart failure at 30 days follow-up\n6. MI with hs-cTnT levels ≥10x ULN at 24 hours post-PCI/angiography\n7. None of the above', 'timeFrame': 'at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo'}, {'measure': 'primary safety- bleeding events [BARC criteria]', 'description': '• To assess bleeding events (according to Global Use of Strategies to Open Occluded Coronary Arteries \\[GUSTO\\] severe or life threatening criterion for safety assessment and according to the Bleeding Academic Research Consortium \\[BARC\\] 3C and 5 criteria for information only)', 'timeFrame': 'after a single subcutaneous injection of zalunfiban versus placebo at 30 days post-PCI/angiography'}]","[{'measure': 'secondary efficacy-restoration of the coronary artery blood flow', 'description': 'To assess restoration of the culprit coronary artery blood flow (corrected Thrombolysis in Myocardial Infarction \\[TIMI\\] Frame Count) before intended PCI (or post coronary angiography in case no PCI is performed) after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'before PCI (or coronary angiography if no PCI is performed)'}, {'measure': 'efficacy-resolution of ST segment deviation', 'description': 'To assess resolution of ST segment deviation post-PCI/angiography after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': '1 hour post-PCI/angiography'}, {'measure': 'Efficacy-composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist', 'description': 'To assess a composite of all cause death, recurrent MI, acute stent thrombosis or blinded bail-out use of IV αIIbβ3 antagonists or IV P2Y12 antagonist', 'timeFrame': 'at 30 days follow-up after a single subcutaneous injection of zalunfiban versus placebo'}, {'measure': 'Efficacy-acute stent thrombosis', 'description': 'To assess incidence of definite, probable or possible acute stent thrombosis after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'up to 24 hours post-PCI'}, {'measure': 'Safety throughout the study by AE reporting', 'description': 'Recording of AEs and SAEs fibrillation up to 12-months follow-up', 'timeFrame': 'AEs up to 30 days follow-up; SAEs up to resolution/stabilization, the SAEs mortality, hospitalization for heart failure and atrial fibrillation up to 12-months follow-up'}, {'measure': 'Safety-platelet count', 'description': 'To assess platelet count after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'before PCI/angiography, at the end of the PCI/angiography, 6 and 24 hours post-PCI/angiography and at hospital discharge/72-hours post-PCI/angiography (whichever occurs first)'}, {'measure': 'Safety-bleeding events (ISTH and TIMI)', 'description': 'To assess bleeding events (according to International Society on Thrombosis and Haemostasis \\[ISTH\\] Major and TIMI Major for information only) after a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'at 30 days follow-up'}, {'measure': 'Safety-bleeding events (GUSTO mild and moderate, BARC type 2, 3 and 5, ISTH minor and/or major and TIMI minor and major)', 'description': 'To assess incidence of bleeding events according to GUSTO mild and moderate criteria, BARC type 2, 3 and 5 criteria, ISTH minor and or major bleeding, TIMI minor and major criteria', 'timeFrame': '30 days follow-up'}, {'measure': 'Safety-injection site reactions', 'description': 'To assess the injection site reactions of a single subcutaneous injection of zalunfiban versus placebo', 'timeFrame': 'baseline, 1-hour post-PCI/angiography, hospital discharge/72-hours post-PCI/angiography, and at 30 days follow-up'}]",11.0,18 Years,,ALL,False,INDUSTRY,0.0,2463.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02490878,Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,bevacizumab,"['bevacizumab', 'corticosteroids']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Radionecrosis,Alliance for Clinical Trials in Oncology,2025-09-01T16:18:17.185404,True,,,,NOT_FOUND,Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,,"['Radionecrosis', 'Brain Metastases']",[],Slow accrual,2016-04,2022-12-15,"[{'measure': 'Change in M. D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score', 'description': 'The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a 28-item multi-symptom patient-reported outcome measure assessing the severity of symptoms experienced by cancer patients and the interference with daily living caused by these symptoms, with 9 items specific to brain tumors. Each item ranges from 0 (best condition) to 10 (worst condition). A subscale score (Symptom Severity) is the average of the subscale items with 0 being ""not present"" and 10 being ""as bad as you can imagine."", given that a specified minimum numbers of items were completed. A negative change in score from baseline to given time point indicates a worsening score.', 'timeFrame': 'Baseline, 2, 4, 6 and 8 weeks'}]","[{'measure': 'Toxicity (CTCAE Version 4.0)', 'description': 'Toxicity associated with bevacizumab and corticosteroids in patients with radionecrosis using CTCAE Version 4.0. The number of patients reporting a grade 3 or higher, 4 or higher, or 5 at least possibly related to treatment are included in this table.', 'timeFrame': 'Up to 1.5 years post-treatment'}, {'measure': 'Quality of Life Measure Using the Single Item Linear Analogue Scale (LASA)', 'description': 'The Linear Analogue Scale used is a 5-question survey. Patients are asked to score the following questions on a 1(as bad as it can be) -10 (as good as it can be) scale: 1) your overall quality of life, 2) your overall (intellectual) well being, 3) your overall physical well being, 4) your overall emotional well being, and 5) your overall spiritual well being. The change in score was computed from baseline to 1.5 years post-treatment. A negative difference is thought of as a worsening score from baseline.', 'timeFrame': 'Up to 1.5 years post-treatment'}, {'measure': 'Quality of Life Measure Using the Dexamethasone Symptoms Questionnaire - Chronic (DSQ-C)', 'description': 'The DSQ-C was developed for use in the brain tumor patient population. It consists of 18 questions rated on a 4-point scale (1 to 4, with 4 indicating a worse symptom) to indicate the presence and severity of symptoms. For each patient, the sum across all 18 questions were computed(18-72, with 18 being a score of 1 for each of the 18 questions and 72 being a score of 4 for each of the questions, refering to the previous sentence, a score of 18(a score of 1, 18 times) indicates the best possible score. A score of 72(a score of 4, 18 times) indicates the worst possible. The mean for total score across each week (weeks 2, 4, 6, 8) is reported.', 'timeFrame': 'Baseline and weeks 2, 4, 6, 8 of treatment'}, {'measure': 'Quality of Life Measure Using the The M. D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Score.', 'description': 'The MDASI-BT was developed and validated for use in the brain tumor patient population, including those with brain metastases and typically requires less than 4 minutes to complete. It consists of 23 symptoms rated on a 0 to 10 numerical rating scale (NRS) to indicate the presence and severity of the symptom, with 0 being ""not present"" and 10 being ""as bad as you can imagine."" MDASI-BT Symptom Scoring: A global symptom score for the MDASI symptom severity scale is obtained by taking the average of the 23 items together. This puts the score on a 0-10 scalenumerical rating scale (NRS) to indicate the presence and severity of the symptom, with 0 being ""not present"" and 10 being ""as bad as you can imagine."" The mean global symptom at baseline and at weeks 2, 4, 6, 8 were used in this analysis.', 'timeFrame': 'Up to 1.5 years post-treatment'}, {'measure': 'Progression Free Survival', 'description': 'Progression free survival is defined as the time from start of treatment to the earliest of the date patient stops placebo or bevacizumab for either alternative therapy or crossover to bevacizumab (if initially on placebo). Result will be summarized by Kaplan-Meier method.', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Time to Maximum Radiographic Response', 'description': 'Time from start of treatment to maximum radiographic response', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Time to Stopping Corticosteroids', 'description': 'Time to stopping corticosteroids is defined as the time from start of protocol treatment to the last day corticosteroids were given. Time to stopping corticosteroid will be summarized by Kaplan-Meier curve with log-rank tests conducted to investigate differences between treatment arms.', 'timeFrame': 'Up to 16 weeks'}]",8.0,18 Years,,ALL,False,OTHER,2.0,19.0,ACTUAL,v2_robust,True,False,True,False,Slow accrual,,,no_match,False,,,
NCT02621606,[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001),[11C]MK-6884,['[11C]MK-6884'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Alzheimer's Disease,Merck Sharp & Dohme LLC,2025-09-01T16:18:22.209805,True,,,,NOT_FOUND,A Three-Part Trial to Qualify [11C]MK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 PAM Receptor Density Quantification in the Human Brain,,"[""Alzheimer's Disease""]",[],,2016-01-08,2017-12-28,"[{'measure': 'Number of Participants Experiencing an Adverse Event (AE)', 'description': ""The number of participants experiencing an adverse event (AE) was assessed. An AE is defined as any unfavorable and unintended medical occurrence, sign, symptom, or disease temporally associated with the use of a pharmaceutical product or protocol-specified procedure, whether or not considered related to the pharmaceutical product or protocol-specified procedure. Any worsening of a preexisting condition, temporally associated with the use of the Sponsor's product, is also an AE."", 'timeFrame': 'Up to 15 days'}, {'measure': 'Number of Participants Discontinuing the Study Due to an Adverse Event (AE)', 'description': ""The number of participants discontinuing the study due to an AE was assessed. An AE is defined as any unfavorable and unintended medical occurrence, sign, symptom, or disease temporally associated with the use of a pharmaceutical product or protocol-specified procedure, whether or not considered related to the pharmaceutical product or protocol-specified procedure. Any worsening of a preexisting condition, temporally associated with the use of the Sponsor's product, is also an AE."", 'timeFrame': 'Up to 15 days'}, {'measure': '[Part 1] Mean Effective Dose of [11C]MK-6884', 'description': 'Mean effective dose (ED) of \\[11C\\]MK-6884 was calculated as a measure of risk associated with exposure of the whole body (WB) to low levels of ionizing radiation. Following \\[11C\\]MK-6884 injection, WB positron emission tomography (PET) scans were collected to visually identify organs absorbing \\[11C\\]MK-6884 in significant amounts. Around identified organs, three-dimensional (3D) volumes were drawn to estimate the percentage of injected activity absorbed. These data were converted into time-activity curves (TACs) and retention of radioactivity in these regions was entered into a human biodistribution model to determine ED of \\[11C\\]MK-6884. ED is expressed in units millisieverts (mSv) / MBq.', 'timeFrame': 'Up to 2 hours post-dose'}, {'measure': '[Part 1] Mean Organ Effective Dose of [11C]MK-6884', 'description': 'Mean organ ED of \\[11C\\]MK-6884 was calculated as a measure of risk associated with exposure of individual organs to low levels of ionizing radiation. Following \\[11C\\]MK-6884 injection, WB PET scans were collected to visually identify organs absorbing \\[11C\\]MK-6884 in significant amounts. Around identified organs, 3D volumes were drawn to estimate the percentage of injected activity absorbed. These data were converted into TACs and retention of radioactivity in these regions was used to calculate organ-specific ED of \\[11C\\]MK-6884. For sex organs (testes/ovaries), organ EDs were derived for participants of the respective sex. However, organ ED for the uterus was estimable in all participants as the male radiologic phantom was sufficiently hermaphroditic.', 'timeFrame': 'Up to 2 hours post dose'}, {'measure': '[Part 2] Mean Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)', 'description': 'Mean BPND of \\[11C\\]MK-6884 in each brain ROI was assessed. BPND is the ratio at equilibrium of specifically bound \\[11C\\]MK-6884 to that of non-displaceable \\[11C\\]MK-6884 in tissue. At time ""0"", a single IV bolus of \\[11\\]MK-6884 is administered and PET scanning initiated, yielding brain regional TACs. These TACs are then used to determine peak standard uptake value (SUV) and area under the curve (AUC) in order to quantify brain regional \\[11C\\]MK-6884 uptake. The target region BPND is estimated using the cerebellum as the reference region with the transient equilibrium tissue ratio (TE-TR) method. Higher values indicate increased specific \\[11C\\]MK-6884 binding in the brain ROI.', 'timeFrame': 'Up to 90 minutes post dose'}, {'measure': '[Part 2] Intra-subject Test-Retest (T-RT) Variability of Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)', 'description': 'Intra-subject T-RT variability in BPND of \\[11C\\]MK-6884 in each brain ROI was assessed. For each healthy elderly participant receiving 2 doses of \\[11C\\]MK-6884 in study Part 2, the BPND calculated during the first dose (BPND-1) was compared to the BPND calculated during the second dose (BPND-2) to determine the percent T-RT variability of the BPND of \\[11C\\]MK-6884 for each brain ROI.\n\nPercent T-RT variability = \\[absolute value (BPND-1 - BPND-2) / (average BPND)\\] \\* 100. A percent T-RT variability = 0, indicates no variability between BPND-1 and BPND-2.', 'timeFrame': 'Up to 24 hours post dose'}, {'measure': '[Part 3] Mean Regional Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest', 'description': 'Mean BPND of \\[11C\\]MK-6884 in each brain ROI was assessed. BPND is the ratio at equilibrium of specifically bound \\[11C\\]MK-6884 to that of non-displaceable \\[11C\\]MK-6884 in tissue. At time ""0"", a single IV bolus of \\[11\\]MK-6884 is administered and PET scanning initiated, yielding brain regional TACs. These TACs are then used to determine SUV and AUC in order to quantify brain regional \\[11C\\]MK-6884 uptake. The target region BPND is estimated using the cerebellum as the reference region with the TE-TR method. Higher values indicate increased specific \\[11C\\]MK-6884 binding in the brain ROI.', 'timeFrame': 'Up to 90 minutes post dose'}]",[],7.0,18 Years,85 Years,ALL,True,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06301698,The Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction,Lidocaine Hydrochloride,"['Lidocaine Hydrochloride', 'Lidocaine']",2,INTERVENTIONAL,['NA'],,NOT_YET_RECRUITING,Bulbar Palsy,Ahmadu Bello University Teaching Hospital,2025-09-01T16:18:24.759081,True,,,,CHEMBL79,A Double-blind Randomized Controlled Study to Explore Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction,,['Bulbar Palsy'],[],,2024-03,2024-06,"[{'measure': 'Penetration-Aspiration Scale', 'description': 'Penetration-Aspiration Scale was used to assess dysphagia under Videofluoroscopic Swallowing Study, primarily evaluating the extent to which fluid food entered the airway and caused penetration or aspiration during the swallowing process. As the level increased, the severity of dysphagia also increased.', 'timeFrame': 'day 1 and day 10'}]","[{'measure': 'Functional Oral Intake Scale', 'description': ""During Dysphagia-Functional Oral Intake Scale assessment, evaluators engage in communication with the patient, conduct observations, and make records to assess the patient's oral intake ability. The Functional Oral Intake Scale assessment form includes seven levels of scoring, ranging from level 1 to level 7, indicating a progressive improvement in the patient's oral intake ability. In general, the result below level 6 indicates unsafe for oral intake while level 6 and above indicates that eating via mouth can be safely conducted."", 'timeFrame': 'day 1 and day 10'}, {'measure': 'Murray secretion severity scale', 'description': 'Murray secretion severity scale is used for assessment of Pharyngeal secretion. The result was divided into 0-3 levels (0, normal; 1, a small amount of secretion remained and not entering the laryngeal vestibule; 2: temporary accumulation in the laryngeal vestibule; 3: persistent accumulation in the laryngeal vestibule. A higher score indicates the worse dysphagia.', 'timeFrame': 'day 1 and day 10'}, {'measure': 'Yale pharyngeal residue severity rating scale', 'description': 'The Yale pharyngeal residue severity rating scale was recruited for assessment of Pharyngeal residue.The result would be divided into 5 levels (1, no residue; 2, the covered pharyngeal mucosa; 3, mild residue, less than 50%; 4, moderate residue, more than 50%; 5, severe residue, spillage from laryngeal vestibule observed). A higher score indicates the worse dysphagia.', 'timeFrame': 'day 1 and day 10'}]",4.0,18 Years,,ALL,False,OTHER,0.0,80.0,ESTIMATED,v2_robust,True,False,False,False,,CCN(CC)CC(=O)Nc1c(C)cccc1C,CHEMBL79,partial_match,True,234.34,2.58,4.0
NCT05514197,The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty,Ascorbic acid 5000mg,"['Ascorbic acid 5000mg', 'Control Rx']",2,INTERVENTIONAL,['NA'],,COMPLETED,Ascorbic Acid,Chimei Medical Center,2025-09-01T16:18:18.416790,True,,,,NOT_FOUND,The Impact of Intravenous Vitamin C Combined With Nerve Blocks on Postoperative Pain and Recovery After Total Knee Arthroplasty.,,"['Ascorbic Acid', 'Postoperative Pain']","['Ascorbic Acid', 'Total knee arthroplasty', 'Regional analgesia']",,2022-06-01,2023-12-07,"[{'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '15 minutes postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': 'first hour postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '6th hour postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '24th hour postoperatively'}, {'measure': 'Visual analogue scale for pain', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no pain to worst pain', 'timeFrame': '48th hour postoperatively'}]","[{'measure': 'Visual analogue scale for sngcetion', 'description': 'Marking on a continuous 10 centimeter line from 0 to 10, representing no sore to worst sore', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Morphine consumption', 'description': 'Amount of IM morphine consumption in the first 24 hours postoperatively', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Time to first rescue morphine requirement at post-anesthetic care unit', 'description': 'Duration from arriving post-anesthetic care unit to requiring first morphine injection', 'timeFrame': 'up to 2 hours'}, {'measure': 'Severity of postoperative nausea/ vomiting and dizziness', 'description': 'From 0 to 5, 0: non, 1: mild, 2: moderate, 3: severe, 4: unbearable', 'timeFrame': '48 hours postoperatively'}]",9.0,50 Years,80 Years,ALL,False,OTHER,0.0,73.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03704220,Anti-thrombotic Monotherapy With the HeartMate 3 LVAS,Warfarin,['Warfarin'],1,INTERVENTIONAL,['NA'],,UNKNOWN,Heart Failure,Institute for Clinical and Experimental Medicine,2025-09-01T16:18:20.957426,True,,,,CHEMBL1200879,Safety and Feasibility of Anti-thrombotic Monotherapy With the HeartMate 3 LVAS: A Single Center Prospective Controlled Study,,"['Heart Failure', 'Cardiovascular Diseases']","['Single anti-thrombotic therapy', 'Mechanical circulatory support']",,2018-08-16,2021-12,"[{'measure': 'survival free rate of thromboembolic events', 'description': 'Determination of survival free of thromboembolic events (i.e. pump thrombosis or any ischemic stroke) using only a single antithrombotic therapy with Acetylsalicylic Acid.', 'timeFrame': '90 days'}]","[{'measure': 'Adverse Events', 'description': 'Adverse events rates per INTERMACS definitions.', 'timeFrame': '90 days'}]",2.0,18 Years,,ALL,False,OTHER_GOV,1.0,10.0,ESTIMATED,v2_robust,True,False,False,True,,CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[Na+],CHEMBL1200879,partial_match,True,330.31,3.61,4.0
NCT01953900,iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma,Fludarabine,"['Fludara', 'Cyclophosphamide', 'Cytoxan', 'Fludarabine']",4,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Osteosarcoma,Baylor College of Medicine,2025-09-01T16:18:13.427440,True,,,,NOT_FOUND,"Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)",,"['Osteosarcoma', 'Neuroblastoma']","['Osteosarcoma', 'T-Cells', 'varicella zoster virus (VZV)', 'GD2', 'Neuroblastoma']",,2014-04,2034-10-31,"[{'measure': 'Number of patients with dose limiting toxicity', 'description': 'The primary objective is to evaluate the safety and feasibility of intravenous injections of autologous iC9-GD2-CAR-VZV-CTLs in combination with VZV vaccination in patients with advanced GD2-positive sarcomas or neuroblastoma.', 'timeFrame': '6-weeks'}]","[{'measure': 'Amount of T cells in the blood after the infusions', 'description': 'To assess the effects of VZV vaccination on the in vivo expansion and persistence of transgenic VZV-specific T cells\n\nTo assess the in vivo persistence of infused T cells using immunoassays and transgene detection', 'timeFrame': '15 years'}, {'measure': 'Number of patients with a response to the T cells', 'description': 'To assess the anti-tumor effects of the infused GD2-specific T cells\n\nTo assess the effect of of myeloid derived suppressor cells (MDSC) on expansion and persistence of infused T cells.\n\nEvaluations of tumor size will be performed within 4 weeks of beginning treatment and 6 weeks (before the vaccine) and 12 to 14 weeks after the iC9-GD2-CAR-VZV-CTL injection. All patients who receive the first infusion will be evaluable for response.', 'timeFrame': '14 weeks'}]",3.0,,,ALL,False,OTHER,3.0,26.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT00002803,Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma,cyclophosphamide,"['vincristine sulfate', 'doxorubicin hydrochloride', 'cyclophosphamide']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Neuroblastoma,"Children's Hospital Medical Center, Cincinnati",2025-09-01T16:18:13.411782,True,,,,NOT_FOUND,COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA,,['Neuroblastoma'],"['localized resectable neuroblastoma', 'regional neuroblastoma', 'stage 4S neuroblastoma', 'localized unresectable neuroblastoma']",,1995-07,2002-02,[],[],0.0,,1 Year,ALL,False,OTHER,0.0,44.0,ESTIMATED,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03256526,6-week Safety and PD Study in Adults With NAFLD,Placebo,"['PF-06835919 Low Dose', 'PF-06835919 High Dose', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Non-alcoholic Fatty Liver Disease,Pfizer,2025-09-01T16:18:09.628230,True,,,,NOT_FOUND,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE",,['Non-alcoholic Fatty Liver Disease'],[],,2017-09-27,2018-04-27,"[{'measure': 'Percent Change From Baseline in Whole Liver Fat at Week 6', 'description': 'The percent change from baseline in whole liver fat at Week 6 was assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF).\n\nMRI-PDFF generates measures of the fraction of mobile protons in the liver attributable to fat content and provides whole liver coverage so that fat content can be assessed across 8 Couinaud liver segments. Whole liver PDFF was calculated as follows:\n\nWhole Liver PDFF= PDFFs for (Segment I+Segment II+Segment III+Segment IVa+Segment IVb+Segment V+Segment VI+Segment+VII+Segment VIII) / (number of segments assessed).\n\nThe same segments were to be used at both baseline and post-baseline time points in the calculation of whole liver PDFF to derive the percent change from baseline.\n\nThe values of whole liver PDFF ranges from 0 to 100 and higher values represent higher liver fat.', 'timeFrame': 'Baseline and Week 6'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'All-causality adverse events (AEs) were any untoward medical occurrence in a study participant who administered a product or medical device, the event need not necessarily have a causal relationship with the treatment or usage. Treatment-related AEs were any untoward medical occurrence in a study participant who administered a product or medical device, the event needed to have a causal relationship with the treatment or usage.\n\nA TEAE was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.', 'timeFrame': 'Baseline up to Day 77 (28-35 days post last dose)'}, {'measure': 'Number of Participants With Post-dose Vital Signs Data Meeting Categorical Criteria', 'description': 'The vital sign categorical criteria included:\n\nSitting DBP (diastolic blood pressure) millimeter of mercury (mmHg) Change \\>= 20 mmHg increase Sitting SBP (systolic blood pressure) (mmHg) Change \\>= 30 mmHg increase Sitting DBP (mmHg) Change \\>= 20 mmHg decrease Sitting SBP (mmHg) Change \\>= 30 mmHg decrease Sitting DBP (mmHg) Value \\< 50 mmHg Sitting Pulse Rate (bpm) Value \\< 40 bpm or Value \\> 120 bpm Sitting SBP (mmHg) Value \\< 90 mmHg', 'timeFrame': 'Baseline up to Day 56 (Week 8)'}, {'measure': 'Number of Participants With Post-dose ECG Data Meeting Categorical Criteria', 'description': ""The ECG categorical criteria included:\n\nPR Interval (msec) percent (%)Change \\>= 25% increase when baseline \\>200 or \\>=50% increase when baseline \\<=200 QRS Interval (msec) %Change \\>= 50% increase QTcF Interval (Fridericia's Correction) (msec) increase 30 \\<= Change \\< 60 or Change \\>= 60 PR Interval (msec) Value \\>= 300 QRS Interval (msec) Value \\>= 140 QTcF Interval (Fridericia's Correction) (msec) 450 \\<= Value \\<480 or 480 \\<=Value \\<500 or Value \\>= 500"", 'timeFrame': 'Baseline up to Day 56 (Week 8)'}, {'measure': 'Number of Participants With Laboratory Abnormalities', 'description': 'Below parameters were evaluated for laboratory tests: Hemoglobin, Hematocrit, Erythrocytes, Ery. Mean Copuscular Volume, Ery. Mean Copuscular Hemoglobin, Ery. Mean Corpuscular HGB Concentration, Platelets, Leukocytes, Lymphocytes, Neuprophils, Basophils, Eosinophils, Monocytes, Bilirubin, Direct Biliirubin, Indirect Bilirubin, Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase, Protein, Albumin, Albumin, Blood Urea Nitrogen, Creatinine, Urate, Sodium, Potassium, Chloride, Calcium, Bicarbonate, Glucose-Fasting, pH, Urine Glucose, Ketone, Urine Protein, Urine Hemoglobin, Urobilinogen, Urine Bilirubin, Nitrite, Leukocyte Esterase, Urine Erythocytes, Urine leukocytes, Hyaline Casts, Urine Creatinine.', 'timeFrame': 'Baseline up to Day 56 (Week 8)'}]",5.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,53.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04062526,Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT,[18F]NOS,"['[18F]NOS', '[18F]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,ACTIVE_NOT_RECRUITING,Parkinson Disease,University of Pennsylvania,2025-09-01T16:18:25.986269,True,,,,NOT_FOUND,Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT),,"['Parkinson Disease', 'Healthy Volunteer']",[],,2019-08-14,2026-04,"[{'measure': 'Characterize the uptake of [18F]NOS', 'description': 'Characterize the uptake of \\[18F\\]NOS in the human brain for healthy controls and PD patients.', 'timeFrame': '3 years'}]","[{'measure': 'Compare patterns of uptake', 'description': 'Compare patterns of \\[18F\\]NOS brain uptake in patients with PD versus healthy controls.', 'timeFrame': '3 years'}, {'measure': 'Compare peripheral blood inflammatory biomarkers', 'description': 'Compare peripheral blood inflammatory biomarkers, including cytokines and mtDAMPs, in PD patients with healthy controls.', 'timeFrame': '3 years'}]",3.0,18 Years,75 Years,ALL,True,OTHER,0.0,11.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00182442,"Cognition, Functioning and Quality of Life",Olanzapine & Quetiapine,['Olanzapine & Quetiapine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Schizophrenia,Hamilton Health Sciences Corporation,2025-09-01T16:18:15.896673,True,,,,NOT_FOUND,"A One-Year Multi-Centre Randomized, Double Blind, Controlled Effectiveness Study of Quetiapine and Olanzapine, Comparing Their Relative Potential in Improving Neuro-Cognitive Deficits, Functional Outcomes and Quality of Life in Schizophrenia",,['Schizophrenia'],"['Cognitive deficits', 'Psychosocial functioning', 'Quality of Life']",,2003-10,2006-03,"[{'measure': 'Primary outcome measures include changes in neurocognitive test scores, changes in measures of community functioning and quality of life.'}]","[{'measure': 'Secondary outcomes include changes in treatment adherence, subjective satisfaction with antipsychotic drug therapy, clinical symptoms and side effects.'}]",2.0,18 Years,65 Years,ALL,False,OTHER,1.0,80.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02850250,Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery,Cefuroxime,"['Ceftin', 'Cefuroxime']",2,OBSERVATIONAL,[],,WITHDRAWN,Cardiac Event,Alder Hey Children's NHS Foundation Trust,2025-09-01T16:18:07.017496,True,,,,CHEMBL2146124,Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery,,['Cardiac Event'],"['Observational', 'pharmacokinetic', 'cardiac', 'Cefuroxime', 'Paediatric']",CI left the country so study has never opened,2018-07,2019-10,"[{'measure': 'Plasma concentrations', 'description': 'To measure plasma concentrations of Cefuroxime in this patient population', 'timeFrame': '12 months'}]",[],1.0,,3 Months,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,False,False,True,False,CI left the country so study has never opened,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@H]12)c1ccco1.[Na+],CHEMBL2146124,partial_match,True,446.37,-0.54,4.0
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,Combination of varlilumab and ipilimumab,"['Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC', 'Combination of varlilumab and ipilimumab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Unresectable Stage III or Stage IV Melanoma,Celldex Therapeutics,2025-09-01T16:18:20.963219,True,,,,NOT_FOUND,"A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma",,['Unresectable Stage III or Stage IV Melanoma'],"['Yervoy™, CDX-1401']",Feasibility concerns due to changes in standard of care,2015-04,2016-11-09,"[{'measure': 'Phase l: Safety and tolerability of varlilumab in combination with ipilimumab as measured by incidences of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities and laboratory test abnormalities.', 'timeFrame': 'Safety follow-up is 70 days from last study drug dose.'}, {'measure': 'Phase ll: The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the mWHO tumor response criteria.', 'timeFrame': 'Up to 24 weeks'}]",[],2.0,18 Years,,ALL,False,INDUSTRY,0.0,9.0,ACTUAL,v2_robust,True,False,True,True,Feasibility concerns due to changes in standard of care,,,no_match,False,,,
NCT01489592,Effect of Curcumin on Iron Metabolism in Healthy Volunteer,curcuma longa,['curcuma longa'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Healthy Volunteers,"Institut National de la Santé Et de la Recherche Médicale, France",2025-09-01T16:18:19.664395,True,,,,NOT_FOUND,Effect of Curcumin on Iron Metabolism in Healthy Volunteer,,['Healthy Volunteers'],[],,2011-10,2012-03,"[{'measure': 'Maximal variation of serum hepcidin level after oral administration of curcumin', 'timeFrame': 'within 48 hours after administration of curcumin'}]","[{'measure': 'Plasmatic iron bioavailability', 'description': 'Iron, ferritin, transferrin, transferrin saturation', 'timeFrame': '30min, 1H, 2H, 3H, 4H, 6H, 8H, 12H, 24H et 48H'}, {'measure': ""Evaluation of the inhibitory activity of volunteers's serum on hepcidin expression by hepatocytes"", 'description': 'In vitro:\n\n* the coculture model that we previously developed to analyze endogenous hepcidin expression, and\n* human hepatic cells line (HepG2) stimulated or not by IL-6 which governs the STAT3 pathway, transfected with gene reporter constructs containing hepcidin promoter.', 'timeFrame': '30min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h'}]",3.0,18 Years,35 Years,MALE,True,OTHER_GOV,0.0,18.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00193557,Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma,Bortezomib,['Bortezomib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Multiple Myeloma,"SCRI Development Innovations, LLC",2025-09-01T16:18:15.908370,True,,,,NOT_FOUND,Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma,,['Multiple Myeloma'],[],,2004-05,2009-01,[{'measure': 'objective response rate'}],"[{'measure': 'progression-free survival'}, {'measure': 'overall survival'}, {'measure': 'Safety'}]",4.0,18 Years,,ALL,False,OTHER,1.0,40.0,,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02011126,Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors,Imetelstat Sodium,"['GRN163L, Sodium Salt', 'GRN163L', 'Imetelstat Sodium']",3,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Hepatoblastoma,Children's Oncology Group,2025-09-01T16:18:14.668224,True,,,,NOT_FOUND,"A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors",,"['Hepatoblastoma', 'Previously Treated Childhood Rhabdomyosarcoma', 'Recurrent Childhood Liver Cancer', 'Recurrent Childhood Rhabdomyosarcoma', 'Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor', 'Recurrent Neuroblastoma', 'Recurrent Osteosarcoma', 'Rhabdomyosarcoma']",[],IND no longer available.,2014-06-30,,"[{'measure': 'Objective response (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or MIBG scoring criteria', 'description': 'Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed accounting for the two-stage design. Each disease stratum will be reported separately.', 'timeFrame': 'Up to 126 days (6 courses)'}, {'measure': 'Incidence of grade 3 or higher adverse events using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0', 'description': 'Toxicity tables will be constructed to summarize the observed incidence in each reporting period by type of toxicity and grade. The relative frequency of each type of toxicity will be quantified as the number of toxicity-evaluable cycles in which the adverse event (AE) was noted at grade 3 or higher considered by the treating physician to be possibly, probably or definitely related to one of the agents in the regimen divided by the number of toxicity-evaluable courses administered to patients enrolled on the trial.', 'timeFrame': 'Up to 126 days (6 courses)'}]","[{'measure': 'Progression-free survival', 'description': 'The probability of remaining progression-free as a function of days since enrollment will be calculated according to the method of Gray accounting for censoring and the competing events.', 'timeFrame': 'Date of enrollment until the end progression-free interval (PFI) date, calculated as the date of disease progression, date of death, date of removal of all tumor by surgery or last patient contact, whichever occurs first, assessed up to 3 years'}]",3.0,1 Year,30 Years,ALL,False,NETWORK,1.0,0.0,ACTUAL,v2_robust,True,False,True,True,IND no longer available.,,,no_match,False,,,
NCT01097616,Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028),Suvorexant High Dose (HD),"['Suvorexant High Dose (HD)', 'Suvorexant Low Dose (LD)', 'Comparator: Placebo', 'MK-4305']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Primary Insomnia,Merck Sharp & Dohme LLC,2025-09-01T16:18:22.209302,True,,,,NOT_FOUND,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study A",,['Primary Insomnia'],[],,2010-05-05,2011-12-07,"[{'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily electronic diary (e-diary). Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any polysomnography \\[PSG\\] nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in sTSTm at Month 3', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Wakefulness After Persistent Sleep Onset (WASO) at Month 1', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in WASO at Month 3', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Time to Sleep Onset (sTSOm) at Month 1', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in sTSOm at Month 3', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Latency to Onset of Persistent Sleep (LPS) at Month 1', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in LPS at Month 3', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Number of Participants With an Adverse Event (AE) During Initial 3-Month DB TRT Phase', 'description': 'An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Participants with an AE occurring during the initial 3-month DB TRT Phase are counted once in this summary.', 'timeFrame': 'Up to 3 months'}, {'measure': 'Number of Participants Who Discontinued Study Drug Due to an AE Occurring During Initial 3-Month DB TRT Phase', 'description': 'An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Participants who discontinued study drug treatment due to an AE occurring during the initial 3-month DB TRT Phase are counted once in this summary.', 'timeFrame': 'Up to 3 months'}]","[{'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in sTSTm at Week 1', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Week 1 range is Days 2-8 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Week 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSTm at Month 1', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSTm at Month 3', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in WASO at Night 1', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Night 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in WASO at Month 1', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in WASO at Month 3', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in sTSOm at Week 1', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Week 1 range is Days 2-8 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Week 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSOm at Month 1', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSOm at Month 3', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in LPS at Night 1', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Night 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in LPS at Month 1', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in LPS at Month 3', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}]",22.0,18 Years,,ALL,False,INDUSTRY,0.0,1023.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03827603,Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia,Ibrutinib,"['Ibrutinib', 'Imbruvica']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,AIHA - Warm Autoimmune Hemolytic Anemia,Eugene Nikitin,2025-09-01T16:18:23.461242,True,,,,CHEMBL226335,Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach,,['AIHA - Warm Autoimmune Hemolytic Anemia'],[],,2017-02-21,2022-03-31,"[{'measure': 'Response rate', 'description': 'Response rate defined by transfusion independence, hemoglobin level, DAT and duration of response of autoimmunity (DR-AI), defined as the interval between time point of best response and relapse of AIC. Relapses of CLL will be censored.', 'timeFrame': '3 month after treatment'}]",[],1.0,18 Years,,ALL,False,OTHER,0.0,50.0,ACTUAL,v2_robust,True,False,False,False,,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,CHEMBL226335,partial_match,True,610.52,-1.69,2.0
NCT00167115,Metabolic Effects of Alcohol,Alcohol,['Alcohol'],1,INTERVENTIONAL,['NA'],,COMPLETED,Type 2 Diabetes Mellitus,"Bantle, John P., MD",2025-09-01T16:18:17.186687,True,,,,CHEMBL236687,Metabolic Effects of Alcohol in the Form of Wine in Persons With Type 2 Diabetes Mellitus,,['Type 2 Diabetes Mellitus'],"['Alcohol', 'Type 2 diabetes mellitus', 'Plama glucose', 'HDL cholesterol']",,2004-12,2005-09,"[{'measure': 'Fasing plasma glucose'}, {'measure': 'Fasting plasma HDL cholesterol'}]",[{'measure': 'Episodes of hypoglycemia'}],3.0,40 Years,,ALL,False,INDIV,0.0,20.0,,v2_robust,True,True,False,False,,C=C(C)[C@@H]1CC=C(CO)CC1,CHEMBL236687,partial_match,True,152.24,2.28,2.0
NCT02315495,Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes,Saxagliptin,"['Saxagliptin', 'Onglyza', 'Acarbose', 'Glucobay']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 2 Diabetes,Zilin Sun,2025-09-01T16:18:15.906438,True,,,,NOT_FOUND,Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes,,['Type 2 Diabetes'],[],,2015-04-03,2016-08-26,"[{'measure': 'Blood glucose concentrations at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}]","[{'measure': 'Plasma concentrations of incretin hormones at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'Plasma concentrations of insulin at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'Plasma concentrations of C-peptide at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'Plasma concentrations of glucagon at pre-defined intervals', 'timeFrame': '-60,-10,0,30,60,90,120,180min'}, {'measure': 'half-emptying time (T50)', 'timeFrame': '0-180min'}]",6.0,18 Years,70 Years,ALL,False,OTHER,0.0,22.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04380181,Influence of Inotropic Choice on Morbidity and Mortality in Complex Pediatric Heart Surgery,dobu,"['milrinone-epinephrine', 'dobu']",2,OBSERVATIONAL,[],,COMPLETED,Pediatric Cardiac Surgery,Brugmann University Hospital,2025-09-01T16:18:15.909358,True,,,,CHEMBL2105572,Does the Choice of Perioperative Inotropes Has Influence on the Morbidity and Mortality of Infants Operated for Complex Heart Defects?,,['Pediatric Cardiac Surgery'],"['pediatric cardiopulmonary bypass', 'milrinone', 'dobutamine', 'epinephrine']",,2020-05-11,2020-06-10,"[{'measure': 'MODS2 score', 'description': ""Impact of the inotropic plan on the morbi-mortality. Use of the MODS2 score who is defined by death or 2 organ's failures: circulation, respiratory or renal"", 'timeFrame': 'Weaning from cardiopulmonary bypass in the operating room'}]",[],1.0,,1 Year,ALL,False,OTHER,1.0,250.0,ACTUAL,v2_robust,False,True,False,False,,CCCCOc1cc(N)c(Cl)cc1C(=O)NC1CCN(CC2OCCO2)CC1,CHEMBL2105572,partial_match,True,411.93,2.67,2.0
NCT05062486,A Study to Evaluate the Safety and Efficacy of RQC for AMD,"Resveratrol, Quercetin, Curcumin (RQC)","['Curcumin', 'Resveratrol, Quercetin, Curcumin (RQC)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Age-related Macular Degeneration,"Paul A Knepper, MD PhD",2025-09-01T16:18:13.414005,True,,,,CHEMBL165,"An Open-Label, Randomized, Double Arm, Phase 2 Study to Evaluate the Safety and Efficacy of C and RQC for Preventing Progression in Age-Related Macular Degeneration",,['Age-related Macular Degeneration'],"['Curcumin', 'Resveratrol', 'Quercetin', 'Macular Degeneration, Age-Related', 'Age-Related Maculopathy', 'Adult Macular Degeneration']",,2021-10-04,2024-11-07,"[{'measure': 'Change in Drusen Volume from Baseline', 'description': 'Macular drusen volume measured in µm3.', 'timeFrame': '24 months'}, {'measure': 'Geographic Atrophy (GA) Growth Rate', 'description': 'The annual growth rate of GA or nascent GA area measured in mm2.', 'timeFrame': '24 months'}, {'measure': 'Progression to Moderate Vision Loss', 'description': 'Progression defined as a decrease in ETDRS BCVA score of 15 or more letters.', 'timeFrame': '24 months'}, {'measure': 'Adverse Events', 'description': 'Safety outcomes include adverse and serious adverse events and vital sign/physical examination tests.', 'timeFrame': '24 months'}]","[{'measure': 'Progression to Advanced AMD', 'description': 'Progression defined as the development of geographic atrophy or choroidal neovascularization detected by OCT imaging using autofluorescence, infrared, and/or angiography modules.', 'timeFrame': '24 months'}]",5.0,50 Years,90 Years,ALL,False,OTHER,0.0,55.0,ACTUAL,v2_robust,True,True,False,True,,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,CHEMBL165,partial_match,True,228.25,2.97,3.0
NCT00732121,Bone Turnover in Type 2 Diabetes Patients,Sitagliptin,"['Sitagliptin', 'Januvia (brand name for sitagliptin)', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Type 2 Diabetes,University of Vermont,2025-09-01T16:18:22.207928,True,,,,NOT_FOUND,Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes,,['Type 2 Diabetes'],['Type 2 Diabetes'],,2008-08,2010-08,"[{'measure': 'Change from baseline in the integrated response to the mixed meal test of markers of bone turnover following 8 weeks of treatment with sitagliptin vs. placebo.', 'timeFrame': '8 weeks per subject'}]","[{'measure': 'Change in the active GIP in response to the mixed meal test', 'timeFrame': '8 weeks'}, {'measure': 'Change in the active GLP-1 in response to the mixed meal test.', 'timeFrame': '8 weeks'}, {'measure': 'Change in the active GLP-2 in response to the mixed meal test.', 'timeFrame': '8 weeks'}, {'measure': 'Change in glucose response during the mixed meal test.', 'timeFrame': '8 weeks'}, {'measure': 'Change in insulin secretion during the mixed meal test.', 'timeFrame': '8 weeks'}]",6.0,18 Years,80 Years,ALL,False,OTHER,1.0,20.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00004642,Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease,SDZ MSL-109,['SDZ MSL-109'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Cytomegalovirus Infections,National Center for Research Resources (NCRR),2025-09-01T16:18:13.413154,True,,,,NOT_FOUND,Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease,,['Cytomegalovirus Infections'],"['congenital cytomegalovirus infection', 'cytomegalovirus infection', 'herpesvirus infection', 'immunologic disorders and infectious disorders', 'neonatal disorders', 'rare disease', 'viral infection']",,1995-02,,[],[],0.0,0 Years,29 Days,ALL,False,NIH,1.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00081588,"An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.",TMC114,['TMC114'],1,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,HIV Infection,"Tibotec Pharmaceuticals, Ireland",2025-09-01T16:18:15.895532,True,,,,NOT_FOUND,"An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.",,['HIV Infection'],"['TMC114-C215', 'Ritonavir', 'HIV infections', 'TMC114-C202', 'TMC114-C213']",,2003-11,2008-12,"[{'measure': 'The primary parameter is the confirmed virologic response at Week 24 (a drop in viral load (copies/mL) of at least 1 log10 versus baseline.', 'timeFrame': '24 weeks'}]","[{'measure': 'Proportion of patients with a virologic response; with plasma HIV-1 RNA levels < 50 copies/mL; with plasma HIV-1 RNA levels < 400 copies/mL; Time to loss of virologic response over 144 week treatment period; Change in plasma viral load at all time points', 'timeFrame': '144 weeks'}]",2.0,18 Years,,ALL,False,INDUSTRY,0.0,555.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01013987,Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients,maraviroc,"['Celsentri', 'maraviroc', 'Darunavir/ritonavir', 'Raltegravir', 'Issentres']",5,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,HIV-1 Adults Patients,Fundación Huésped,2025-09-01T16:18:14.660525,True,,,,NOT_FOUND,"A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients.",,"['HIV-1 Adults Patients', 'AIDS', 'Triple Class Failure']","['HIV-1', 'triple class failure', 'Maraviroc', 'Raltegravir', 'Darunavir/ritonavir', 'Maraviroc with raltegravir and darunavir/ritonavir']",,2010-02,,"[{'measure': 'Proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at week 24', 'timeFrame': 'week 24'}]","[{'measure': 'Proportion of patients with HIV RNA levels of less than 50 copies/ml at week 24 and with HIV RNA levels of less than 400 copies/ ml at weeks 24 and 48.', 'timeFrame': 'week 24 and week 48'}]",2.0,21 Years,,ALL,False,OTHER,1.0,60.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00002949,Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis,paclitaxel,"['paclitaxel', 'vinorelbine tartrate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Bladder Cancer,University of Chicago,2025-09-01T16:18:14.666317,True,,,,NOT_FOUND,Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies,,"['Bladder Cancer', 'Cervical Cancer', 'Endometrial Cancer', 'Vaginal Cancer']","['stage II cervical cancer', 'stage III cervical cancer', 'stage IV cervical cancer', 'stage II vaginal cancer', 'stage III vaginal cancer', 'stage IVA vaginal cancer', 'stage IVB vaginal cancer', 'stage II endometrial carcinoma', 'stage III endometrial carcinoma', 'stage IV endometrial carcinoma', 'stage II bladder cancer', 'stage III bladder cancer', 'stage IV bladder cancer']",,1996-07,2001-05,"[{'measure': 'Maximum tolerated dose', 'timeFrame': '4 years'}]",[],1.0,18 Years,,ALL,False,OTHER,1.0,33.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04821310,Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years,Full dose Pantoprazole plus matching placebo,"['Half Dose Pantoprazole plus matching placebo', 'Full dose Pantoprazole plus matching placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Esophagitis,Pfizer,2025-09-01T16:18:09.636418,True,,,,NOT_FOUND,"AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE ESOPHAGITIS",,['Esophagitis'],"['Erosive', 'esophagitis']",,2022-01-13,2030-05-09,"[{'measure': 'Proportion of patients with endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24, considering patients with excessive use of rescue medication as treatment failures', 'description': 'Endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24.', 'timeFrame': 'Week 24'}]","[{'measure': 'Number of Participants With Change From Baseline in Physical Examinations and Vital Signs', 'description': 'Safety and tolerability will be assessed by physical examinations, blood pressure, and pulse rate.', 'timeFrame': 'Baseline up to 36 weeks'}, {'measure': 'Incidence of Adverse Events (AEs)', 'timeFrame': 'Baseline up to 36 weeks'}, {'measure': 'Number of Participants With Change From Baseline in Laboratory Tests Results', 'description': 'Safety and tolerability will be assessed by clinical laboratory measurements', 'timeFrame': 'Baseline up to 36 weeks'}]",4.0,1 Year,17 Years,ALL,False,INDUSTRY,0.0,110.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02510014,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,SUBOXONE sublingual film,"['SUBOXONE sublingual film', 'RBP-6000', 'SUBOXONE', 'Atrigel buprenorphine', 'buprenorphine']",5,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Opioid Use Disorder,Indivior Inc.,2025-09-01T16:18:17.178340,True,,,,NOT_FOUND,"An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder",,"['Opioid Use Disorder', 'Opioid-related Disorders']",[],,2015-07-27,2017-01-31,"[{'measure': 'Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period', 'description': 'TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent one of the outcomes listed in this definition.', 'timeFrame': 'Day 1 to Week 49 (De novo arm); Day 1 to Week 25 (Roll-over arm)'}, {'measure': 'Percentage Change From Baseline to End of Study (Weeks 25 and 49) in Vital Signs', 'description': 'Vital signs include\n\n* systolic blood pressure (mmHg)\n* diastolic blood pressure (mmHg)\n* respiratory rate (breaths/minute)\n* weight (kg)\n* body mass index (kg/m\\^2)\n* waist-to-hip ratio\n\nBaseline is defined as the last non-missing value prior to subcutaneous injection of RBP-6000 on Day 1.', 'timeFrame': 'Baseline (Day 1 predose) End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Shifts in Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Most Severe Assessment During the Treatment Period', 'description': ""The C-SSRS asks questions of study participants regarding whether they had suicidal ideation and/or suicidal behavior since the last visit using the electronic version of the scale. Only the most severe assessment is reported in this summary. Participants who experienced suicidal ideation and suicidal behavior are only summarized in the suicidal behavior since behavior is more severe than ideation.\n\nC-SSRS baseline version was completed during the screening visit. C-SSRS 'since-last-visit' version was completed weekly for the first month and at least every month until the end of the study.\n\nShift table category titles are structured as: baseline category/treatment category. The category 'No Suicidal Ideation or Behaviour' has been abbreviated as 'No Suicidal I or B'."", 'timeFrame': 'Baseline (Screening visit, days -21 to -15), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Worst Local Injection Site Pain From Injections as Measured by Participant-Reported Visual Analog Scale (VAS)', 'description': ""Injection site pain as measured by participant-reported VAS. The participant-reported VAS for injection site pain was measured on a 100 mm scale with 'no pain' at 0 mm and 'strongest pain ever' at 100 mm (total scale of 0-100). Participants marked where along the scale reflected their localized injection pain.\n\nThe injection site pain VAS scores were obtained (after the completion of the injection) within 1 minute and at 5, 10, 15, 30 and 60 minutes (+- 5 minutes). The timing of the injection site pain VAS should have been measured from the end of the injection.\n\nData represents the worst pain recorded for each participant across all injections and all VAS records. The mean value is presented.\n\nDe Novo subjects were given injections on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309.\n\nRoll-over subjects were given injections on Days 1, 29, 57, 85, 113, 141."", 'timeFrame': 'De Novo Subjects: Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309 Roll-over Subjects: Days 1, 29, 57, 85, 113, 141'}]","[{'measure': 'Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) at End of Study (Weeks 25 and 49)', 'description': 'COWS is an 11-item instrument used to assess signs and symptoms of opioid withdrawal. The score is the sum of the responses for a total range of 0-48. The COWS is commonly used by clinicians treating patients with buprenorphine to monitor the severity of withdrawal. COWS scores below 5 are considered not indicative of withdrawal. Scores from 5 to 12 are considered mild withdrawal; from 13 to 24 moderate withdrawal; 25 to 36 moderately severe withdrawal, and 37-48 severe withdrawal. Negative change from baseline values indicate a lessening of withdrawal symptoms.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.', 'timeFrame': 'Baseline (Day 1 predose), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) at End of Study (Weeks 25 and 49)', 'description': 'The Subjective Opiate Withdrawal Scale (SOWS) contains 16 symptoms whose intensity the participant rates on a scale of 0 (not at all) to 4 (extremely) for a full scale of 0 (no withdrawal symptoms) to 64 (extreme withdrawal symptoms). Negative change from baseline values indicate a lessening of withdrawal symptoms.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.', 'timeFrame': 'Baseline (Day 1 predose), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Change From Baseline in the Opioid Craving Visual Analog Scale (VAS) at End of Study (Weeks 25 and 49)', 'description': ""The opioid craving scale was a 100 mm scale with 'no craving' indicated by 0 mm and 'strongest craving ever' indicated by 100 mm. Participants marked where along the scale reflected their craving for opioids.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values."", 'timeFrame': 'Baseline (Day 1 predose), End of Study: Week 49 (De novo arm); Week 25 (Roll-over arm)'}, {'measure': 'Cumulative Distribution Function (CDF) of the Percentage Abstinence Collected From Week 1 Through End of Study (Weeks 25 and 49)', 'description': ""Participants' self-reported illicit opioid drug use from the timeline followback (TLFB) interview and results from the urine drug screens (UDS) for opioids were combined into a single endpoint. Opioids assessed included codeine, hydrocodone, hydromorphone, methadone, morphine, opiates, oxycodone, and oxymorphone (by UDS) and amphetamine/methadone, buprenorphine, methadone, and opioids in the TLFB.\n\nData represent the count of participants at various percentage abstinence levels. Abstinence was defined as urine samples being negative for opioids AND negative self-reports (obtained from Timeline Followback (TLFB) interviews) for illicit opioid use. The endpoint was based on visits in which paired urine samples and self-reports were expected for each subject as specified in the schedule of events. All missing reports for opioids were considered nonnegative."", 'timeFrame': 'Weekly during Month 1, Every other week from Month 2-6, Monthly from Month 7-12. De novo arm stopped at Week 49. Roll-over arm stopped at Week 25'}]",8.0,18 Years,65 Years,ALL,False,INDUSTRY,0.0,775.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02762383,Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT),Peginterferon Alfa-2,"['Pegasys', 'Peginterferon Alfa-2']",2,INTERVENTIONAL,['PHASE3'],PHASE3,TERMINATED,HIV/HCV Coinfection,Hoffmann-La Roche,2025-09-01T16:18:10.910927,True,,,,NOT_FOUND,"A Pilot, Open-Label, Multicentre Study Evaluating the Long-Term Safety and Tolerability of a Low-Dose Peginterferon Alfa-2a Maintenance Monotherapy in Chronic Hepatitis C Patients Co-Infected With Human Immunodeficiency Virus and Who Do Not Respond to a Standard Regimen of Peginterferon Alfa-2a Plus Ribavirin",,['HIV/HCV Coinfection'],[],Low recruitment,2005-03,2009-06,"[{'measure': 'Percentage of Participants with Adverse Events (AEs)', 'timeFrame': 'From Baseline to end of treatment (up to 18 months)'}]","[{'measure': 'Percentage of Participants with Histological Response According to Paired Biopsy', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'HIV RNA Viral Load in Copies per Milliliter (copies/mL)', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'Cluster of Differentiation (CD) 4 Cell Count in Cells per Microliter (cells/mcL)', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'Percentage of Participants with Virological Response According to HCV RNA Viral Load', 'timeFrame': 'At 6, 12, and 18 months during treatment, and at 24 weeks after end of treatment (up to 2 years overall)'}, {'measure': 'Percentage of Participants with Biochemical Response According to Alanine Aminotransferase (ALT) Level', 'timeFrame': 'At end of treatment (up to 18 months)'}, {'measure': 'Percentage of Participants with Sustained Biochemical Response According to ALT Level', 'timeFrame': 'At 24 weeks after end of treatment (up to 2 years overall)'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,19.0,ACTUAL,v2_robust,True,False,True,True,Low recruitment,,,no_match,False,,,
NCT03994380,Use of DNAse in Neutrophilic Asthma,RhDNAse Inhalation Solution,['RhDNAse Inhalation Solution'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,Neutrophilic Asthma,National Jewish Health,2025-09-01T16:18:15.893131,True,,,,NOT_FOUND,Use of DNAse in Neutrophilic Asthma,,['Neutrophilic Asthma'],[],,2020-02-12,2020-12,"[{'measure': 'Lung Function', 'description': 'FEV1', 'timeFrame': '4 weeks'}, {'measure': 'Symptom Control', 'description': 'Asthma Control Test', 'timeFrame': '4 weeks'}]",[],2.0,18 Years,,ALL,False,OTHER,0.0,10.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00334399,Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide,Miglitol,['Miglitol'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Type 2 Diabetes Mellitus,"Sanwa Kagaku Kenkyusho Co., Ltd.",2025-09-01T16:18:14.658391,True,,,,NOT_FOUND,,,['Type 2 Diabetes Mellitus'],"['alpa-glucosidase inhibitor,Biguanide']",,,,[],[],0.0,20 Years,69 Years,ALL,False,INDUSTRY,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03797729,Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.,Tirofiban,"['Normal saline', 'Sodium Chloride Injection', 'Tirofiban']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,ST Elevation Myocardial Infarction,Shanghai Zhongshan Hospital,2025-09-01T16:18:08.337741,True,,,,CHEMBL916,Early Initiation of Low Dose Tirofiban for Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction.,,['ST Elevation Myocardial Infarction'],"['ST Elevation Myocardial Infarction', 'Tirofiban', 'Percutaneous Coronary Intervention']",,2019-05-14,2021-12,"[{'measure': 'TFG(TIMI flow grades) grade III: complete myocardial perfusion immediately after primary percutaneous coronary intervention detected by DSA(Digital Substraction Angiography).', 'description': 'TIMI flow grades: grade III.', 'timeFrame': 'Immediately after primary percutaneous coronary intervention.'}, {'measure': 'TMP(TIMI myocardial perfusion grades) grade III: complete myocardial perfusion immediately after primary percutaneous coronary intervention detected by DSA(Digital Substraction Angiography).', 'description': 'TIMI myocardial perfusion grades: grade III.', 'timeFrame': 'Immediately after primary percutaneous coronary intervention.'}]","[{'measure': 'Remedial Tirofiban intravenous use during primary percutaneous coronary intervention procedure.', 'description': 'Remedial Tirofiban use during primary percutaneous coronary intervention.', 'timeFrame': 'During the process of primary percutaneous coronary intervention.'}, {'measure': 'ST segment', 'description': 'The sum of the initial ST segment elevation drops 70% or more.', 'timeFrame': '90 minutes after primary percutaneous coronary intervention.'}, {'measure': 'Myocardial microcirculation perfusion estimated by cardiac magnetic (CMR).', 'description': 'Myocardial microcirculation perfusion estimated by cardiac magnetic resonance imaging.', 'timeFrame': '7 days after primary percutaneous coronary intervention.'}, {'measure': 'Major adverse cardiovascular events(MACE), including a composite of all-cause death, nonfatal myocardial infarction, stroke, target vessel revascularization.', 'description': 'Major adverse cardiovascular events, including a composite of all-cause death, nonfatal myocardial infarction, stroke, target vessel revascularization.', 'timeFrame': '30 days after primary percutaneous coronary intervention.'}]",6.0,18 Years,85 Years,ALL,False,OTHER,0.0,500.0,ESTIMATED,v2_robust,True,False,False,True,,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,CHEMBL916,exact_match,True,440.61,2.95,4.0
NCT06003218,Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation,Dexmedetomidine-esketamine combination,"['Remifentanil', 'Dexmedetomidine-esketamine combination', 'Oxycodone']",3,INTERVENTIONAL,['NA'],,COMPLETED,Liver Cancer,Peking University First Hospital,2025-09-01T16:18:09.635299,True,,,,CHEMBL77921,Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study,,"['Liver Cancer', 'Radiofrequency Ablation', 'Esketamine', 'Dexmedetomidine']","['Liver cancer', 'Radiofrequency ablation', 'Esketamine', 'Dexmedetomidine']",,2023-10-16,2024-09-28,"[{'measure': 'Area under curve of Numerical Rating Scale of pain during and within 24 hours after surgery.', 'description': 'Numerical Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) of pain will be assessed after percutaneous liver puncture, start of radiofrequency-ablation, every 5±1 minutes during radiofrequency-ablation, end of radiofrequency-ablation, and 10 minutes after needle removal during surgery, as well as at 0.5, 1, 2, 3-8, \\>8-12h,and 24 hours after surgery.', 'timeFrame': 'During and within 24 hours after surgery.'}]","[{'measure': 'The highest Numerical Rating Scale of pain during surgery.', 'description': 'Numerical Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) of pain will be assessed after percutaneous liver puncture, start of radiofrequency-ablation, every 2 minutes during radiofrequency-ablation, end of radiofrequency-ablation, and 10 minutes after needle removal during surgery', 'timeFrame': 'During surgery.'}, {'measure': 'Number of intraoperative adjustment of study drug infusion rate.', 'description': 'Number of adjustment of study drug infusion rate during surgery.', 'timeFrame': 'During surgery.'}, {'measure': 'Number of additional oxycodone or other analgesics during and within 24 hours after surgery.', 'description': 'Number of additional oxycodone or other analgesics during and within 24 hours after surgery.', 'timeFrame': 'During and within 24 hours after surgery.'}, {'measure': 'Dose of analgesics during and within 24 hours after surgery.', 'description': 'Dose of opioids (excluding remifentanil administered as study drugs) will be converted to intravenous morphine equivalent.', 'timeFrame': 'During and within 24 hours after surgery.'}, {'measure': 'Pain intensity and opioid consumption (PIOC) index during and within 24 hours after surgery.', 'description': 'Pain intensity will be calculated as area under curve (AUC) of Numerical Rating Scale (NRS, an 11-point scale where 0=no pain and 10=the worst pain) of pain during and within 24 hours after surgery. Opioid consumption (OC) during and within 24 hours after surgery will be calculated after excluding remifentanil administered as study drugs. Pain intensity and opioid consumption (PIOC) index will be calculated as: PIOC=\\[(AUCmean rank - AUCrank)/AUCmean rank\\] + \\[(OCmean rank - OCrank)/OCmean rank\\]. The range of the sum is -200% to +200%. Values above 0 indicate increased summed AUC and OC compared to the all patients.', 'timeFrame': 'During and within 24 hours after surgery.'}, {'measure': 'Numeric Rating Scale of subjective sleep quality on the first and second nights after surgery.', 'description': 'Numerical Rating Scale (NRS, an 11-point scale where 0=the best sleep and 10=the worst sleep) of sleep quality on the first and second nights after surgery.', 'timeFrame': 'On the first and second nights after surgery.'}]",7.0,18 Years,85 Years,ALL,False,OTHER,0.0,88.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cccc(C(C)c2c[nH]cn2)c1C,CHEMBL77921,partial_match,True,200.28,3.18,3.0
NCT01904539,Hepatic Impairment Trial of Obeticholic Acid,obeticholic acid 10 mg,"['6α-ethyl chenodeoxycholic acid', 'obeticholic acid 10 mg', '6-ECDCA', 'INT-747']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hepatic Impairment,Intercept Pharmaceuticals,2025-09-01T16:18:10.918206,True,,,,CHEMBL566315,"An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)",,['Hepatic Impairment'],[],,2013-06,2013-10,"[{'measure': 'Peak plasma concentration (Cmax) of OCA and conjugates', 'description': 'maximum concentration', 'timeFrame': 'Up to 48 hours'}, {'measure': 'Area under the concentration versus time curve from time 0 to the last sampling time with measurable analyte concentration (AUCt) of OCA and conjugates', 'timeFrame': 'Post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 216 hours post-dose'}, {'measure': 'Time to Cmax (Tmax) of OCA and conjugates', 'timeFrame': 'Up to 48 hours'}, {'measure': 'Area under the concentration versus time curve from time 0-24 hours with measurable analyte concentration of OCA and conjugates. (AUC 0-24)', 'timeFrame': '24 hours'}]","[{'measure': 'Urine concentration of unchanged OCA and conjugates', 'timeFrame': '0, 6, 12, 24, 30 hours'}, {'measure': 'Amount of OCA and conjugates excretion in urine', 'timeFrame': '-6to 0, 0 to 6, 6 to 12, 12 to 24, and 24 to 30 hours'}, {'measure': 'Total amount of OCA and conjugates excreted in urine', 'timeFrame': '0 to 30 hours'}, {'measure': 'Protein Binding', 'timeFrame': '0, 0.75, 1.5, 6, and 24 hours'}]",8.0,18 Years,,ALL,True,INDUSTRY,0.0,32.0,ACTUAL,v2_robust,True,True,False,False,,CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12,CHEMBL566315,partial_match,True,420.63,5.11,4.0
NCT03851172,Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery,Ketorolac Ophthalmic,"['Nepafenac Ophthalmic', 'Ketorolac Ophthalmic', 'Cyclopentolate Ophthalmic']",3,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Cataract,Assiut University,2025-09-01T16:18:08.340886,True,,,,NOT_FOUND,Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery,,"['Cataract', 'Miosis']","['Cataract surgery', 'Intraoperative Miosis', 'Ketorolac eye drops', 'Nepafenac eye drops']",,2019-03-01,2020-03-30,"[{'measure': 'Prevention of miosis during cataract surgery', 'description': 'The prevention of intraoperative miosis during cataract surgery after preparation by the different eye drops and cyclopentolate', 'timeFrame': '30 minutes'}]",[],1.0,2 Days,80 Years,ALL,True,OTHER,0.0,75.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01781975,Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus,Imatinib Mesylate,"['GLEEVEC', 'Imatinib Mesylate', 'Glivec', 'Placebo (For imatinib mesylate)']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,"Diabetes Mellitus, Type I","University of California, San Francisco",2025-09-01T16:18:13.422912,True,,,,NOT_FOUND,Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus,,"['Diabetes Mellitus, Type I', 'Diabetes Mellitus, Insulin-Dependent, 1', 'Type 1 Diabetes Mellitus', 'Insulin-Dependent Diabetes Mellitus 1', 'IDDM']",[],,2014-01,2018-05,"[{'measure': 'Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit', 'description': 'The primary outcome of each participant is the area under the stimulated c-peptide curve (AUC) mean based on data collected at time 0 to 2 hours of a 4-hour mixed meal tolerance test (MMTT) conducted at the primary endpoint visit. The timed measurements are done at: 0, 15, 30, 60, 90, and 120 minutes. The term ""AUC mean"" comes from the mean value theorem in calculus. It is the value on the scale of the y-axis that is equal to the AUC divided by the range on the x-axis (in this case 120 minutes).', 'timeFrame': 'Visit 9 (Week 52) at 0, 15, 30, 60, 90, 120 minutes post-dose'}]","[{'measure': 'Area Under the Stimulated C-peptide Curve (AUC) Mean Over 4 Hours at 24 Months', 'description': 'Area under the MMTT-stimulated peak, 4 hour C-peptide AUC mean at week 104. The units are reported as nano-moles/Liter because this is AUC mean (the AUC is divided by the time internal so that the units return to the c-peptide units of measure).', 'timeFrame': 'Visit 13 (Week 104)'}, {'measure': 'Change in HbA1c Levels Over Time', 'description': 'Change in HbA1c levels from Week 52 to Week 104', 'timeFrame': 'Visit 9 (Week 52) and Visit 13 (Week 104)'}, {'measure': 'Change in Insulin Dose (Units/kg) Over Time', 'description': 'Assess insulin use in units per kilogram body weight per day at weeks 52 and 104.', 'timeFrame': 'Visit 9 (Week 52) and Visit 13 (Week 104)'}, {'measure': 'Number of Severe Hypoglycemic Events', 'description': 'Major hypoglycemic events occurring from randomization at weeks 0, 52 and 104.', 'timeFrame': 'Visit 0 (Week 0), Visit 9 (Week 52), and Visit 13 (Week 104)'}, {'measure': 'Number of Adverse Events', 'description': 'Number of adverse events that were reported throughout the study.', 'timeFrame': 'Adverse Events will be assessed at Visit 0 (week 0), Visit 1 (Week 2), Visit 2 (Week 4), and every month thereafter.'}]",6.0,18 Years,45 Years,ALL,True,OTHER,1.0,67.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05654831,FTIH of ECC5004 in Healthy and Diabetic Participants,Placebo,"['ECC5004', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Type 2 Diabetes Mellitus,Eccogene,2025-09-01T16:18:10.915411,True,,,,NOT_FOUND,"A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients With Type 2 Diabetes Mellitus",,['Type 2 Diabetes Mellitus'],[],,2022-12-01,2023-11-01,"[{'measure': 'Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations', 'description': 'Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.', 'timeFrame': 'SAD: Up to Day 8 and MAD: Up to Day 35'}]","[{'measure': 'Pharmacokinetic Parameters: AUC0-24', 'description': 'AUC from time 0 to 24 hour dosing interval', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: AUC0-tlast', 'description': 'AUC from time 0 to the time of last quantifiable non-zero concentration', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: AUC0-tau', 'description': 'AUC over a dosing interval from time 0 to time of last quantifiable concentration', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: AUC0-infinity', 'description': 'AUC from time 0 extrapolated to infinity', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: Cmax', 'description': 'Maximum observed plasma concentration', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: C24', 'description': 'Observed concentration at 24 hours post dose', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: Ctau', 'description': 'Observed concentration at the end of the dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: tmax', 'description': 'Time of the maximum observed plasma concentration', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: tlag', 'description': 'Lag time (time delay between dosing and first observed plasma concentration)', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: t1/2', 'description': 'Apparent terminal elimination half-life', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacokinetic Parameters: Clast', 'description': 'Last measurable non-zero concentration', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: tlast', 'description': 'Time of last measurable non-zero concentration', 'timeFrame': 'SAD: Up to Day 3'}, {'measure': 'Pharmacokinetic Parameters: CL/F', 'description': 'Apparent Clearance', 'timeFrame': 'SAD: Up to Day 3 and MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for glucose', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for insulin', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for glucagon', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: AUC0-4 for C-peptide', 'description': 'AUC from time 0 to 4 hour dosing interval', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Fasting plasma glucose', 'description': 'Change from baseline', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Mean daily glucose', 'description': 'Change from baseline', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Body Weight and Waist Circumference', 'description': 'Change from baseline', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Fasting plasma glucose homeostatic model assessment', 'description': 'Fasting plasma glucose homeostatic model assessment', 'timeFrame': 'MAD: Up to Day 30'}, {'measure': 'Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment', 'description': 'Fasting plasma insulin homeostatic model assessment', 'timeFrame': 'MAD: Up to Day 30'}]",23.0,18 Years,70 Years,ALL,True,INDUSTRY,0.0,69.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06982196,Sulodexide in Controlling the Recurrence of Psoriasis,Sulodexide,"['Sulodexide', 'Vessel Due F (international brand)', 'Matching placebo for sulodexide soft capsules', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,ENROLLING_BY_INVITATION,Psoriasis (PsO),Xijing Hospital,2025-09-01T16:18:15.894260,True,,,,NOT_FOUND,"Multicenter, Randomized, Double-blinded，Controlled Clinical Study to Evaluate the Efficacy and Safety of Sulodexide in Controlling the Recurrence of Psoriasis",,"['Psoriasis (PsO)', 'Randomised Controlled Trial']",['Randomized controlled trials'],,2025-04-20,2027-12-31,"[{'measure': 'Time of appearance of the first psoriatic skin lesion', 'description': 'This outcome measures the duration (in days) from the start of the study intervention (sulodexide or placebo) until the first identifiable recurrence of a characteristic psoriatic skin lesion in participants who had previously achieved complete clearance (PASI 100) with secukinumab therapy.', 'timeFrame': '1 year'}]","[{'measure': 'Psoriasis lesion size and severity index score[PASI]', 'description': 'Psoriasis lesion size and severity index score', 'timeFrame': '1 year'}, {'measure': 'Dermatological Quality of Life Index[DLQI]', 'description': 'Dermatological Quality of Life Index', 'timeFrame': '1 year'}, {'measure': 'Self-Rating Anxiety Scale', 'description': 'The Self-Rating Anxiety Scale (SAS) is a validated 20-item questionnaire used to assess the severity of anxiety symptoms in participants. Each item is scored on a 4-point Likert scale (1 = ""None or a little of the time"" to 4 = ""Most or all of the time""), with higher total scores indicating greater anxiety levels.', 'timeFrame': '1 year'}, {'measure': 'Self-Rating Depression Scale', 'description': 'The Self-Rating Depression Scale (SDS) is a widely used psychological assessment tool designed to measure the intensity and presence of depressive symptoms in individuals.', 'timeFrame': '1 year'}, {'measure': 'Adverse Events [AEs]', 'description': 'AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0', 'timeFrame': '1 year'}]",6.0,18 Years,65 Years,ALL,False,OTHER,0.0,160.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04815187,Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease,Montelukast,"['Montelukast', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,ACTIVE_NOT_RECRUITING,Meniere Disease,House Ear Institute,2025-09-01T16:18:24.760338,True,,,,NOT_FOUND,Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease,,"['Meniere Disease', 'Allergic Rhinitis', 'Vertigo']",[],,2021-06-07,2025-12-31,"[{'measure': 'Percentage of Patients with AAO-HNS Vertigo Control Class A or B', 'description': 'Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)', 'timeFrame': '1 month after treatment initiation'}, {'measure': 'Percentage of Patients with AAO-HNS Vertigo Control Class A or B', 'description': 'Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)', 'timeFrame': '3 months after treatment initiation'}, {'measure': 'Percentage of Patients with AAO-HNS Vertigo Control Class A or B', 'description': 'Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)', 'timeFrame': '6 months after treatment initiation'}, {'measure': 'Difference in Dizziness Between Treatment Arms', 'description': 'Difference for each group in AAO-HNS dizziness functional disability scale from pre-treatment to 3 months after treatment initiation. A score improvement of 1 point on this 6-point scale will be considered significant improvement.', 'timeFrame': '3 months after treatment initiation'}, {'measure': 'Percentage of Subjects Experiencing Significant Hearing Fluctuation', 'description': 'Percentage of subjects in each treatment arm demonstrating clinically significant change in air conduction thresholds at \\> 2 frequencies at 3 months (\\> 10 dB change from baseline) or WDS (\\> 15% change from baseline) compared to the worst audiogram and WDS in the 6 months prior to treatment initiation.', 'timeFrame': '3 months after treatment initiation'}]",[],5.0,18 Years,,ALL,False,OTHER,1.0,39.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT06173531,Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome,Carbetocin,"['Carbetocin', 'Placebo', 'ACP-101']",3,INTERVENTIONAL,['PHASE3'],PHASE3,ACTIVE_NOT_RECRUITING,Hyperphagia in Prader-Willi Syndrome,ACADIA Pharmaceuticals Inc.,2025-09-01T16:18:13.419716,True,,,,NOT_FOUND,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome",,['Hyperphagia in Prader-Willi Syndrome'],"['Randomized', 'Placebo-controlled']",,2023-11-27,2025-11,"[{'measure': 'Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score', 'description': ""The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat.\n\nThe HQ-CT should be completed by the same caregiver throughout the study. The HQ-CT will be administered to the caregiver by a rater using standardized prompts. The Food Safe Zone should be administered immediately before administration of the HQ-CT.\n\nA higher score on the HQ-CT indicates greater severity of hyperphagia."", 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Change from Baseline at Week 12 in caregiver-rated Clinical Global Impression-Severity (CGI-S) score for PWS', 'description': ""The CGI-S is a rating scale that records a clinician's global impression of the current severity of illness on a seven-point scale, using a range of responses from 1 (normal) to 7 (among the most severely ill subjects)."", 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Clinical Global Impression-Change (CGI-C) for PWS score at Week 12', 'description': ""The CGI-C is a rating scale that records a clinician's global impression of change in severity of illness, using a range of responses from 1 (very much improved) to 7 (very much worse)."", 'timeFrame': 'Score at Week 12'}]",3.0,5 Years,30 Years,ALL,False,INDUSTRY,0.0,170.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00505284,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Placebo,"['E2007 (8 mg)', 'Perampanel', 'E2007 (2 mg)', 'E2007 (4 mg)', 'Placebo', 'E2007 (6 mg)']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Diabetic Neuropathy,Eisai Inc.,2025-09-01T16:18:17.180309,True,,,,NOT_FOUND,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy",,['Diabetic Neuropathy'],['Diabetic neuropathy'],,2007-06,2008-07,"[{'measure': 'Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT)', 'description': 'Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified baseline observation carried forward (BOCF).', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score', 'description': 'Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 50% Reduction in Pain Score', 'description': 'Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Mean Change in Average Pain Scores From Baseline at Each Study Week', 'description': 'Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Last on-treatment value refers to last 7 days of available diary data while subject was on double-blind study drug.', 'timeFrame': 'Baseline, Week 1 to Week 17'}]","[{'measure': 'Change in Average Sleep Interference Scores From Baseline to Week 15/EOT', 'description': 'Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for sleep interference (0=pain did not interfere with sleep, to 10=pain completely interfered with sleep \\[unable to sleep\\]). Based on modified BOCF.', 'timeFrame': 'Baseline to Week 15/EOT'}, {'measure': 'Change in Short Form - McGill Pain Questionnaire (SF-MPQ) From Baseline to Week 15/EOT', 'description': 'SF-MPQ sensory score = sum of intensity scores for descriptors 1-11 (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting). Each descriptor scored as 0=none, 1=mild, 2=moderate, or 3=severe. Range of possible sensory scores, 0 to 33, with a score of 33 being the most severe intensity.', 'timeFrame': 'Baseline and Week 15/EOT'}, {'measure': 'Analysis of Patient Global Impression of Change (PGIC) at Week 15/EOT', 'description': 'At the EOT (Visit 7) or Early Withdrawal Visit (as appropriate), the subject assessed his/her status compared to how they felt before entering the study. This assessment included an evaluation of pain frequency and intensity, the occurrence of AEs, and overall functional status using a 7-point scale where 1=very much improved and 7=very much worse. Using Modified BOCF.', 'timeFrame': 'Week 15/EOT'}, {'measure': 'Change From Baseline to Week 15/EOT in SF-36 Physical and Mental Component Scores', 'description': 'Short Form 36 Health Survey Questionnaire (SF-36) measuring limitations in Physical Components including physical activities, usual role activities (due to physical problems), measuring bodily pain, general health perceptions, and Mental Components including social activities, usual role activities (due to emotional problems), vitality (energy and fatigue. Each of the 8 domains are described by a score ranging from 0 to 100, for a range of total possible scores of 0-400 for physical and 0-400 for mental. Higher scores reflect better subject status.', 'timeFrame': 'Baseline and Week 15/EOT'}, {'measure': 'Change From Baseline to Week 15/EOT in Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression Subscale Scores', 'description': 'HADS anxiety subscale score=sum of scores for 7 anxiety items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse anxiety. Range of possible HADS anxiety subscale scores, 0 to 21. HADS depression subscale score=sum of scores for 7 depression items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse depression. Range of possible HADS depression subscale scores, 0 to 21.', 'timeFrame': 'Baseline and Week 15/EOT'}, {'measure': 'Withdrawal Due to Treatment Failure During Double-Blind Dosing Period', 'description': ""Based on data reported on the End of Study case report form (CRF): If a subject terminated the study early during the Double-blind Dosing Period due to 'lack of therapeutic efficacy,' the subject was counted as a withdrawal due to treatment failure."", 'timeFrame': 'Baseline and Week 15'}, {'measure': 'Presence or Absence of Allodynia at Week 15/EOT', 'description': ""Investigators rated subjects' allodynia as mild, moderate, severe, or not present. The presence of allodynia (yes/no) at Week 15/EOT was analyzed."", 'timeFrame': 'Week 15/EOT'}, {'measure': 'Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period', 'description': 'If acetaminophen was not reported on the Pain Therapy CRF or on the Concomitant Medication CRF, it was assumed that the subject did not use rescue analgesic medication.', 'timeFrame': 'Baseline to Week 15'}]",12.0,18 Years,,ALL,False,INDUSTRY,1.0,352.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04366089,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Azithromycin,"['hydroxychloroquine', 'Azithromycin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,COVID,"Roberto Poscia MD, PhD",2025-09-01T16:18:20.952491,True,,,,CHEMBL1200502,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,,"['COVID', 'SARS-CoV 2', 'Pneumonia, Viral', 'Coronavirus Infection']","['Oxygen-ozone therapy', 'gut microbiota']",,2020-03-26,2020-12-31,"[{'measure': 'Delta in the number of patients requiring orotracheal intubation despite treatment', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}]","[{'measure': 'Delta of crude mortality', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'Delta of length of stay for patients in hospital', 'description': 'Comparison between the two groups', 'timeFrame': '90 days'}, {'measure': 'delta in the value of interleukin (IL)-1', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of IL-6', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of IL-10', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of Tumor Necrosis Factor (TNF)-alpha', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of CD8+ CD38/ HLA-DR', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of fecal calprotectin', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of lipopolysaccharide (LPS)', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of zonulin', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}, {'measure': 'delta in the value of alpha1-antitrypsin', 'description': 'Comparison between the two groups', 'timeFrame': '21 days'}]",13.0,18 Years,,ALL,False,OTHER,0.0,152.0,ESTIMATED,v2_robust,True,False,False,False,,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O.O,CHEMBL1200502,partial_match,True,767.01,1.9,2.0
NCT02556411,Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS),"LNG-IUS 13,5 mg Levonorgestrel","['LNG-IUS 13,5 mg Levonorgestrel', 'Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Adenomyosis,University of Cagliari,2025-09-01T16:18:13.428881,True,,,,CHEMBL1389,Comparison of E/P Therapy in Continuous Regimen Versus Combination of LNG-IUS Plus E/P,,"['Adenomyosis', 'Chronic Pelvic Pain']",[],,2021-06-01,2022-06-01,"[{'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 45 days of treatment'}]","[{'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 90 days of treatment'}, {'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 180 days of treatment'}, {'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 365 days of treatment'}, {'measure': 'Quality of sexual life', 'timeFrame': 'Cases were administered and fulfilled the questionnaires at the moment of diagnosis of adenomyosis up to 4weeks; Change from baseline were evaluated 45 days after begin of treatment'}]",5.0,18 Years,40 Years,FEMALE,True,OTHER,0.0,50.0,ESTIMATED,v2_robust,True,False,False,False,,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,CHEMBL1389,partial_match,True,312.45,3.88,4.0
NCT05599919,Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19,Nitric Oxide,"['Nitric Oxide', 'Nasal Spray']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,SARS-CoV-2 Infection,Sanotize Research and Development corp.,2025-09-01T16:18:19.660627,True,,,,NOT_FOUND,"A Randomized, Double-blind, Parallel Arm, Multicenter Study To Evaluate The Efficacy And Safety Of Nitric Oxide Nasal Spray Combined With Standard Supportive Care In Adult Non-hospitalized Patients With COVID-19.",,['SARS-CoV-2 Infection'],[],,2021-11-01,2022-02-02,"[{'measure': 'The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization', 'description': 'Change from baseline in log viral load', 'timeFrame': '8 days'}]","[{'measure': 'The secondary objective is to evaluate the safety and tolerability of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization.', 'description': 'Number of adverse events, pain, discomfort or discontinuations of treatment', 'timeFrame': '18 days'}]",2.0,18 Years,65 Years,ALL,True,INDUSTRY,1.0,306.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00509145,Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS),Laquinimod,"['Laquinimod', 'TV-5600']",2,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Multiple Sclerosis,"Teva Branded Pharmaceutical Products R&D, Inc.",2025-09-01T16:18:13.421394,True,,,,CHEMBL66092,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS",,['Multiple Sclerosis'],"['Relapsing', 'Remitting']",,2007-11-13,2010-11-08,"[{'measure': 'Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period', 'description': ""A relapse was defined as the appearance of at least one new neurological abnormality or the reappearance of at least one previously observed neurological abnormalities lasting greater than or equal to 48 hours and immediately preceded by an improving neurological state of greater than or equal to 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with one or more of the following: An increase of greater than or equal to 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation, an increase of one grade in the actual score of greater than or equal to 2 of the 7 functional systems (FS), as compared to previous evaluation, or an increase of 2 grades in the actual score of one FS as compared to the previous evaluation."", 'timeFrame': 'Up to Month 24'}]","[{'measure': 'Composite Endpoint: Sum of the Number of T1 Gadolinium (Gd)-Enhanced Lesions on T1-Weighted MRI Images', 'description': 'Composite score was calculated as the sum of the number of gadolinium (Gd)-enhanced lesions at Month 12 and the number of gadolinium (Gd)-enhanced lesions at Month 24 on T1-Weighted MRI scans.', 'timeFrame': 'Month 12, Month 24'}, {'measure': 'Composite Endpoint: Sum of the Number of New/Enlarging T2 Lesions', 'description': 'Composite score calculated as the sum of T2 lesions at Months 12 and 24 that are new or enlarged.', 'timeFrame': 'Month 12, Month 24'}, {'measure': 'Accumulation of Physical Disability Measured by the Time to Confirmed Progression of Expanded Disability Status Scale (EDSS)', 'description': 'EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \\[MS\\]). A confirmed progression of EDSS is defined as at least 1 point increase from baseline if baseline EDSS was between 0 and 5.0, or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later. Participants were assessed between baseline and month 24 visit. Participants that met these criteria for any 3 consecutive months were counted in the progression category. Progression could not be confirmed during an MS relapse. Data is presented as a distribution of confirmed disease progression (CDP) events (number of participants with CDP).', 'timeFrame': 'Baseline to Month 24'}, {'measure': 'Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score', 'description': ""The Multiple Sclerosis Functional Composite is an instrument assessing disability that consists of 3 clinical assessments. The 3 are Timed 25-Foot Walk, 9-Hole Peg Test which measures upper extremity (arm and hand) function, and PASAT (Paced Auditory Serial Addition Test) which is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. A Z-score is used to define a common metric from the 3 assessments that constitute the MSFC score. The study's population at baseline was used as reference population for the Z-score calculation. A Z-score of 0 represents the population mean at baseline. Higher Z-scores correspond to an improved outcome."", 'timeFrame': 'Baseline, Month 24'}]",5.0,18 Years,55 Years,ALL,False,INDUSTRY,0.0,1106.0,ACTUAL,v2_robust,True,True,False,False,,CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,CHEMBL66092,exact_match,True,356.81,3.56,3.0
NCT02980068,A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction,15N Nitrate,"['15N Nitrate', '14N Sodium Nitrate', '15N Sodium Nitrate', '14N Nitrate']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pulmonary; Hypertension,"Gladwin, Mark, MD",2025-09-01T16:18:20.953366,True,,,,NOT_FOUND,An Open Label Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction (PH-HFpEF) and Normal Healthy Adults,,"['Pulmonary; Hypertension', 'Heart Failure', 'Preserved Ejection Fraction']",[],,2017-08-28,2022-02-25,"[{'measure': 'Change in nitrate level in urine', 'description': 'The investigators will examine urine nitrate', 'timeFrame': 'Urine collected approx 0 & 6 hours after drug administration'}, {'measure': 'Change in nitrate level in plasma', 'description': 'The investigators will examine plasma nitrate', 'timeFrame': 'Approx 50cc of blood drawn approx 0, 2, & 6 hours after drug administration'}, {'measure': 'Bacterial content of gut microbiome', 'description': 'Stool will be analyzed for bacterial makeup', 'timeFrame': 'Stool collected before drug administration'}, {'measure': 'Bacterial content of the oral microbiome', 'description': 'Saliva and tongue scraping will be analyzed for bacterial makeup', 'timeFrame': 'Saliva and tongue scraping will occur preceding administration of drug'}, {'measure': 'Change in nitrite level in urine', 'description': 'The investigators will examine urine nitrite', 'timeFrame': 'Urine collected approx 0 & 6 hours after drug administration'}, {'measure': 'Change in nitrite level in plasma', 'description': 'The investigators will examine plasma nitrite', 'timeFrame': 'Approx 50cc of blood drawn approx 0, 2, & 6 hours after drug administration'}]","[{'measure': 'Change in blood pressure', 'timeFrame': 'Frequently over 6 hour study visit'}, {'measure': 'Change in heart rate', 'timeFrame': 'Continuous over 6 hour study visit'}, {'measure': 'Change in respiratory rate', 'timeFrame': 'Continuous over 6 hour study visit'}, {'measure': 'Change in hemoglobin concentration', 'timeFrame': 'Continuous over 6 hour study visit'}]",10.0,18 Years,,ALL,True,INDIV,1.0,77.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04508647,Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma,Ublituximab,"['Ublituximab', 'Umbralisib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Marginal Zone Lymphoma,"University of Colorado, Denver",2025-09-01T16:18:25.983256,True,,,,NOT_FOUND,Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response,,"['Marginal Zone Lymphoma', 'Follicular Lymphoma']",[],,2020-11-23,2022-07-14,"[{'measure': 'Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction', 'description': 'Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.\n\nComplete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.\n\nPatients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib.', 'timeFrame': '8 weeks post induction'}, {'measure': 'Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.', 'description': 'Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.\n\nComplete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.', 'timeFrame': 'up to 12 months post induction'}]","[{'measure': 'Overall Response Rates (ORR) for Number of Participants', 'description': 'Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.\n\nOverall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (\\> 50% improvement) and stable disease (less than 50 % response)', 'timeFrame': 'up to 12 months post induction'}]",3.0,18 Years,,ALL,False,OTHER,0.0,4.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01225887,Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer,Nintedanib,"['BIBF 1120', 'Multitargeted Tyrosine Kinase Inhibitor BIBF 1120', 'tyrosine kinase inhibitor BIBF 1120', 'Vargatef', 'Intedanib', 'BIBF-1120', 'Nintedanib']",7,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Endometrial Adenocarcinoma,Gynecologic Oncology Group,2025-09-01T16:18:17.177311,True,,,,CHEMBL502835,A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma,,"['Endometrial Adenocarcinoma', 'Endometrial Clear Cell Adenocarcinoma', 'Endometrial Mucinous Adenocarcinoma', 'Endometrial Serous Adenocarcinoma', 'Endometrial Squamous Cell Carcinoma', 'Endometrial Transitional Cell Carcinoma', 'Endometrial Undifferentiated Carcinoma', 'Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm', 'Recurrent Uterine Corpus Carcinoma']",[],,2011-10,2016-01,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'The incidence of adverse events (grade 3 or higher) as assessed by the National Cancer Institute CTCAE version 4.0', 'timeFrame': 'Up to 5 years'}, {'measure': 'Objective Tumor Response', 'description': 'Complete and Partial Tumor Response by RECIST 1.1', 'timeFrame': 'For disease that can be evaluated by physical exam,response was assessed prior to each cycle CT scan or MRI if used to follow lesion for measurable disease every other cycle up to 5 years.'}, {'measure': 'Progression-free Survival > 6 Months', 'description': 'Whether or not the patient survived progression-free for at least 6 months.', 'timeFrame': 'for disease that can be evaluated by physical exam, progression was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle up to 5 years.'}]","[{'measure': 'Overall Survival', 'description': 'The observed length of life from entry into the study to death or the date of last contact.', 'timeFrame': 'From study entry to death or last contact, up to 5 years'}, {'measure': 'Progression Free Survival', 'description': 'the period of progression free survival for patients with persistent or recurrent endometrial cancer treated with study drug.', 'timeFrame': 'The duration of time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years'}]",5.0,18 Years,,FEMALE,False,NETWORK,1.0,37.0,ACTUAL,v2_robust,True,True,False,True,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,CHEMBL502835,exact_match,True,539.64,3.62,4.0
NCT00920595,Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors,CEP-9722,['CEP-9722'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Solid Tumor,Cephalon,2025-09-01T16:18:10.917908,True,,,,NOT_FOUND,"An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors",,['Solid Tumor'],['Cancer'],,2009-06,2011-10,"[{'measure': 'Determination of Maximum Tolerated Dose (MTD) upon Dose Limiting Toxicities (DLT) data', 'timeFrame': 'Up to 42 days'}]","[{'measure': 'Pharmacokinetic parameters', 'timeFrame': 'Days 1 and 5 of Cycle 1 and on Day 5 of Cycle 2'}, {'measure': 'Pharmacodynamics assay', 'timeFrame': 'Days 1, 5, and 8 of both Cycle 1 and Cycle 2'}, {'measure': 'Efficacy - will be assessed by the proportion of patients who achieve tumor response during the study', 'timeFrame': 'A 14-day cycle and at least one 28-day cycle'}]",4.0,18 Years,,ALL,False,INDUSTRY,0.0,26.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03221764,Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients,Amiodarone with CoSeal,"['Amiodarone with CoSeal', 'Amiodarone with CoSealadministered with CO2 driver']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Atrial Fibrillation,University of Louisville,2025-09-01T16:18:14.657473,True,,,,CHEMBL633,The Intra-Operative Application of Amiodarone Releasing Hydrogel to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Lung Transplantation,,"['Atrial Fibrillation', 'Lung Transplant; Complications']",[],,2017-10-19,2019-04-01,"[{'measure': 'Post Operative Atrial Fibrillation', 'description': 'Patient that developed atrial fibrillation after undergoing lung transplantation', 'timeFrame': 'Patients will be monitored for up to one year following lung transplant'}]","[{'measure': 'Atrial Fibrillation Requiring Intervention', 'description': 'Patients that underwent cardioversion or ablation due to post operative atrial fibrillation', 'timeFrame': 'From transplant to discharge from hospital, up to 1 year'}, {'measure': 'Anti-Arrhythmic Medication at Discharge', 'description': 'Patients that required anti-arrhythmic medication at the time of discharge for post operative atrial fibrillation.', 'timeFrame': '1 year'}]",3.0,18 Years,,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,CHEMBL633,partial_match,True,645.32,6.94,4.0
NCT03057041,Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration,Fentanyl,"['Fentanyl', 'placebo']",2,INTERVENTIONAL,['NA'],,COMPLETED,Pain Uterus,University of Hawaii,2025-09-01T16:18:15.899024,True,,,,CHEMBL688,Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration: A Randomized Controlled Trial,,['Pain Uterus'],[],,2017-03-23,2018-05-30,"[{'measure': 'Pain during uterine aspiration', 'description': 'Self reported on 100 mm VAS', 'timeFrame': 'During uterine aspiration or immediately after uterine aspiration'}]","[{'measure': 'Patient satisfaction with procedural pain control', 'description': 'Self reported on 100 mm VAS', 'timeFrame': 'approximately 15 minutes after procedure ends'}, {'measure': 'Post-procedural pain', 'description': 'Self reported on 100 mm VAS', 'timeFrame': 'approximately 15 minutes after procedure end'}]",3.0,14 Years,,FEMALE,True,OTHER,1.0,107.0,ACTUAL,v2_robust,True,True,False,False,,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,CHEMBL688,partial_match,True,528.6,4.14,4.0
NCT01420523,Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy,Raltegravir-Maraviroc,"['Raltegravir-Maraviroc', 'Isentress and Celsentri']",2,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Human Immunodeficiency Virus,"ANRS, Emerging Infectious Diseases",2025-09-01T16:18:09.638602,True,,,,NOT_FOUND,Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).,,"['Human Immunodeficiency Virus', 'Lipohypertrophy']","['HIV', 'Lipohypertrophy']",,2011-12,2013-04,"[{'measure': 'Virological failure', 'description': 'Occurrence of virological failure, as verified by 2 consecutive plasma viral load measurements \\> 50 copies/mL, taken 2 to 4 weeks apart at most, during the first 24 weeks.', 'timeFrame': 'Week 24'}]","[{'measure': 'Viro-immunological efficacy', 'description': '* Proportion of patients with a HIV RNA viral load \\< 50 copies/mL.\n* Proportion of patients discontinuing the therapy:\n* Plasma genotypic resistance profile where the viral load is \\> 50 copies/mL.\n* Evaluation of DNA/RNA tropism in the event of failure.\n* Evaluation of plasma HIV RNA where the viral load is \\< 50 copies/mL, through ultrasensitive PCR testing.\n* Evolution of the CD4 and CD8 T-cell counts.\n* Blood concentration of raltegravir and maraviroc.', 'timeFrame': 'Between baseline and W48'}, {'measure': 'Tolerability criteria and metabolic impact', 'description': '* Changes in glucose and lipid balance.\n* Changes in anthropometric measurements.\n* Number and severity of clinical and biological adverse effects.\n* Changes in bone mineral density and body composition, as measured by DEXA scan.\n* Changes in inflammation and endothelial activation markers between baseline and W48\n* Measurement of fat cells differentiation markers in adipose tissue biopsy samples', 'timeFrame': 'Between baseline and W48'}, {'measure': 'Compliance', 'description': '• Assessment of compliance conducted at screening and at W24 and 48.', 'timeFrame': 'Between baseline and W48'}, {'measure': 'Quality of life', 'description': '• Assessment of health-related quality of life conducted at baseline and at W24 and 48.', 'timeFrame': 'Between baseline and W48'}]",5.0,18 Years,,ALL,False,OTHER_GOV,2.0,48.0,ACTUAL,v2_robust,True,False,True,True,,,,no_match,False,,,
NCT02014064,Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls,Atomoxetine,"['Strattera', 'Atomoxetine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Continuous Methamphetamine Dependence,"University of California, Los Angeles",2025-09-01T16:18:14.657350,True,,,,CHEMBL1702,"A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine",,"['Continuous Methamphetamine Dependence', 'Methamphetamine Dependence in Remission']","['Methamphetamine, Atomoxetine, Clinical Pharmacology']",,2009-08,2012-08,"[{'measure': 'Cardiovascular & Subjective Effects of Methamphetamine & Atomoxetine', 'description': 'Participants will be followed for the duration of the study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}]","[{'measure': 'The effects of administration of atomoxetine on the preference of MA-using subjects for MA (0 and 15mg, IV) versus escalating doses of money, from $0.25 to $64 in a Multiple-Choice Procedure.', 'description': 'Participants will be followed for the duration of study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'The effects of atomoxetine administration on cognitive function, as determined by measures of performance on cognitive tests, such as working memory tasks and reaction time tests', 'description': 'Participants will be followed for the duration of study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'The effects of administration of atomoxetine on BOLD fMRI signals in the brain in MA users and normal controls.', 'description': 'Participants will be followed for the duration of study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}]",4.0,18 Years,50 Years,ALL,True,OTHER,0.0,41.0,ACTUAL,v2_robust,True,True,False,False,,CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl,CHEMBL1702,partial_match,True,291.82,3.72,4.0
NCT04342936,Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma,Camrelizumab,"[""Investigator's choice of Chemotherapy"", 'SHR-1210', 'Camrelizumab']",3,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Classical Hodgkin Lymphoma,"Jiangsu HengRui Medicine Co., Ltd.",2025-09-01T16:18:19.664631,True,,,,NOT_FOUND,"A Randomized,Open-label Phase III Study of Camrelizumab (SHR-1210) vs. Investigator's Choice of Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)",,['Classical Hodgkin Lymphoma'],[],,2020-07-17,2023-12-01,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'Time from randomisation to radiologically confirmed progressive disease', 'timeFrame': 'anticipated 16 months'}]",[],1.0,18 Years,,ALL,False,INDUSTRY,0.0,56.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT03771053,The Effect of Simvastatin Combined With Ezetimibe in Patients With Stable Angina and Diabetes,Ezetimibe with simvastatin,"['Ezetimibe with simvastatin', 'Simvastatin']",2,INTERVENTIONAL,['NA'],,UNKNOWN,Coronary Heart Disease,Chinese PLA General Hospital,2025-09-01T16:18:18.432966,True,,,,NOT_FOUND,Intravascular Ultrasound Evaluation of the Intervention Effect of Simvastatin Combined With Ezetimibe on Coronary Borderline Lesion in Patients With Stable Angina Pectoris and Diabetes Mellitus Compared With Simvastatin Alone,,['Coronary Heart Disease'],"['Coronary heart disease', 'Atherosclerosis', 'Acute myocardial infarction', 'Coronary intervention']",,2018-01-01,2019-12-31,"[{'measure': 'Change from Baseline coronary plaque volume percentage(PAV) at 12 months', 'description': 'PAV=∑（(ESA CSA-lumen CSA)/(ESA CSA)）x100, EEM CSA：cross-sectional area of outer elastic membrane boundary; lumen CSA: cross-sectional area of tube boundary', 'timeFrame': '12 months after PCI'}]","[{'measure': 'Change from Baseline standardized coronary plaque volume(TAV) at 12 months', 'description': 'TAV= (median number of images in ∑ (ESA CSA-lumen CSA) / retracement) x number of images (standardized according to the length of IVUS retracement, To ensure that each individual patient has the same weight)', 'timeFrame': '12 months after PCI'}, {'measure': 'LDL-C', 'description': 'Low density lipoprotein cholesterol (LDL-C)', 'timeFrame': 'follow up in one year'}, {'measure': 'HDL-C', 'description': 'High density lipoprotein cholesterol (HDL-C)', 'timeFrame': 'follow up in one year'}, {'measure': 'TG', 'description': 'Total triglyceride(TG)', 'timeFrame': 'follow up in one year'}, {'measure': 'TC', 'description': 'Total cholesterol (TC)', 'timeFrame': 'follow up in one year'}, {'measure': 'Inflammation marker', 'description': 'hs-CRP', 'timeFrame': 'follow up in one year'}]",7.0,18 Years,75 Years,ALL,False,OTHER,0.0,240.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02501928,Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.,Fesoterodine PR 4 mg,"['Fesoterodine BIC 4 mg', 'Fesoterodine PR 4 mg', 'Fesoterodine BIC 2 mg', 'Fesoterodine PR 8 mg']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,"Urinary Bladder, Neurogenic",Pfizer,2025-09-01T16:18:10.922222,True,,,,NOT_FOUND,LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047,,"['Urinary Bladder, Neurogenic']","['neurogenic detrusor overactivity', 'fesoterodine', 'Japan']",,2015-06-05,2020-04-01,"[{'measure': 'Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109', 'description': 'An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. TEAEs were summarized for each cohort (Cohort 1 and Cohort 2, irrespective of treatment received), each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)'}, {'measure': 'Change From Baseline in Visual Acuity at Week 12: Study A0221109', 'description': 'Visual acuity (VA) was assessed for each eye using the Snellen method, where logarithm of minimum angle of resolution (logMAR) units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Visual Acuity at Week 28: Study A0221109', 'description': 'VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Visual Acuity at Final Visit: Study A0221109', 'description': 'VA was assessed for each eye using the Snellen method, where logMAR units were derived from the Snellen ratios. Participants had to read letters from the chart at a distance of 20 feet/6 meter or 4 meter. VA (Snellen ratio) = distance between the chart and participant, divided by distance at which participant was able to see/read chart without impairment; expressed as decimal. logMAR = log10 (1/decimal VA). In this outcome measure, data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Visual Accommodation at Week 12: Study A0221109', 'description': 'The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Visual Accommodation at Week 28: Study A0221109', 'description': 'The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Visual Accommodation at Final Visit: Study A0221109', 'description': 'The visual accommodation was the minimum focusing distance for each eye at which vision became blurred - the mean of triplicate measurements. The participants focused on a single letter of the 20/40 line of an eye chart and chart was moved slowly towards the participant until letter was blurred. At this point, the distance from eye to letter was measured for each eye. In this outcome measure data have been reported for right and left eye separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 12: Study A0221109', 'description': ""CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Week 28: Study A0221109', 'description': ""CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) T Score (Derived Score) at Final Visit: Study A0221109', 'description': ""CBCL: assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale: 0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were categorized in 8 domains: aggressive behavior, anxious/depressed, attention problems, rule-breaking behavior, social problems, somatic complaints, thought problems, withdrawn. Summary scores: Internalizing problems =anxious/depressed+withdrawn+somatic complaints; Externalizing problems =rule-breaking+aggressive behavior. Total problems =8 domains+other 17 items. Raw scores for each domain, summary and total problems =sum of scores of related items. Using ADM tool raw scores transformed/derived into standard T-scores, range: each domain=50-100, internalizing problems=34-100, externalizing problems=33-100, total problems=24-100. Lower T-score (8 domain,2 summary,total problems)=better outcomes. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 12: Study A0221109', 'description': ""CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Week 28: Study A0221109', 'description': ""CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Child Behavior Checklist (CBCL) Total Score (Raw Score) at Final Visit: Study A0221109', 'description': ""CBCL:assessed child's behavioral and emotional problems. Parent/caregiver of child answered 120 items, each on scale:0=not true, 1=somewhat/sometimes true, 2=very/often true. 103 items were classified in 8 domains: aggressive behavior, total score range (TSR) =0-36; anxious/depressed,TSR=0-26; attention problems,TSR=0-20; rule-breaking behavior, TSR=0-34; social problems, TSR=0-22; somatic complaints, TSR=0-22; thought problems, TSR=0-30; withdrawn, TSR=0-16. Summary scores: externalizing problems combined rule-breaking and aggressive behavior,TSR=0-70; internalizing problems combined anxious/depressed, withdrawn and somatic complaints, TSR=0-64. Total problems combined 8 domains and 17 remaining items,TSR=0-240. TSR for each domain, summary and total problems was sum of scores of related items respectively. Lower scores for each domain, summary, total problems = better outcomes.Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only."", 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Time to Completion: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Time taken to complete the test was inversely correlated to the cognitive ability. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of Study A0221109 only.', 'timeFrame': 'A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Dropped: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs dropped while putting in the holes were measured. Participants were assigned to either a 10- or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (10 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 10 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 10-peg assessment was done on participants below age of 9 years. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 12- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Week 28- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit (up to 300 seconds). The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Grooved Pegboard Test (25 Pegs Group) at Final Visit- Number of Pegs Placed Correctly: Study A0221109', 'description': 'The grooved pegboard test was a manipulative dexterity test that assessed psychomotor speed, fine motor control, and rapid-visual motor coordination. Participants were asked to insert 25 grooved pegs into the holes within the given time limit up to 300 seconds. The task needs to be completed once for each hand; firstly, using the dominant hand followed by the non-dominant hand. Number of pegs placed correctly in hole was measured. Participants were assigned to either a 10 or 25-peg assessment based on their age. 25-peg assessment was done on participants of age 9 years and above. In this outcome measure data for dominant and non-dominant hand have been reported separately. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Vital Sign (Blood Pressure) at Week 12: Study A0221109', 'description': 'Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Vital Sign (Blood Pressure) at Week 28: Study A0221109', 'description': 'Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Vital Sign (Blood Pressure) at Final Visit: Study A0221109', 'description': 'Systolic and diastolic blood pressure were evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Vital Sign (Pulse Rate) at Week 12: Study A0221109', 'description': 'Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Vital Sign (Pulse Rate) at Week 28: Study A0221109', 'description': 'Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Vital Sign (Pulse Rate) at Final Visit: Study A0221109', 'description': 'Pulse rate was evaluated for examination of vital signs. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Number of Participants With Adverse Event Urinary Tract Infections (UTI): Merged Data of Studies A0221047 and A0221109', 'description': 'UTI data were summarized for each cohort, each treatment group and the total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Up to a maximum of 56 weeks (24 weeks of treatment in A0221047 and 32 weeks [28 weeks treatment + 4 weeks follow up post last dose] in A0221109)'}, {'measure': 'Number of Participants With Clinical Laboratory Abnormalities', 'description': 'Hematology: hemoglobin, hematocrit, erythrocytes \\<0.8\\*lower limit of normal (LLN); platelets\\<0.5\\*LLN\\>1.75\\*upper limit of normal (ULN); leukocytes \\<0.6\\*LLN\\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN \\>1.2\\*UL; basophils, eosinophils, monocytes \\>1.2\\*ULN. Clinical chemistry: bilirubin, direct bilirubin \\>1.5\\*ULN; aspartate aminotransferase (AT), alanine AT, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase \\>3.0\\*ULN; protein, albumin \\<0.8\\*LLN \\>1.2\\*ULN; blood urea nitrogen, creatinine \\>1.3\\*ULN; urate \\>1.2\\*ULN, sodium\\<0.95\\*LLN\\>1.05\\*ULN; potassium, chloride, bicarbonate \\<0.9\\*LLN\\>1.1\\*ULN; glucose \\<0.6\\*LLN\\>1.5\\*ULN; creatine kinase \\>2.0\\*ULN. Urinalysis: specific gravity \\<1.003\\>1.030, pH \\<4.5\\>8, glucose, ketones, protein, hemoglobin, nitrite, leukocyte esterase \\>=1; erythrocytes, leukocytes \\>=20; epithelial cells \\>=6, bacteria \\>20, hyaline casts \\>1. Data for this outcome was planned to be analysed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline to 28 weeks'}, {'measure': 'Change From Baseline in Post-Void Residual (PVR) Volume at Week 12: Study A0221109', 'description': 'Post-void residual volume was assessed by an ultrasound. PVR volume was assessed only in participants who did not perform clean intermittent catheterization or in any participants who had \\>1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 12'}, {'measure': 'Change From Baseline in Post-Void Residual (PVR) Volume at Week 28: Study A0221109', 'description': 'Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had \\>1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, Week 28'}, {'measure': 'Change From Baseline in Post-Void Residual (PVR) Volume at Final Visit: Study A0221109', 'description': 'Post-void residual volume measurement was measured by an ultrasound. PVR volume was only assessed for participants who did not perform clean intermittent catheterization or in any participants who had \\>1 UTI during the study. Data for this outcome measure was planned to be analyzed for each treatment group of study A0221109 only.', 'timeFrame': 'A0221109: Baseline, final visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}]","[{'measure': 'Change From Baseline in Maximum Cystometric Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Maximum cystometric bladder capacity was defined as maximal tolerable cystometric capacity, until voiding or leaking begins or at a pressure of \\>=40 centimeter (cm) water (H2O). Maximum cystometric bladder capacity was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Detrusor Pressure at Maximum Bladder Capacity at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Detrusor pressure (cm H2O) at maximum urinary bladder capacity was measured using urodynamic testing. Detrusor pressure was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Number of Participants With Presence of Involuntary Detrusor Contraction (IDC) at Baseline and Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Participants with presence of IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Bladder Volume at First Involuntary Detrusor Contraction (IDC) at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Bladder volume at first IDC was measured using urodynamic testing. Bladder volume at first IDC was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Bladder Compliance at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'Bladder compliance was defined as change in bladder volume in milliliter (mL) divided by change in bladder pressure in cm H2O (during the same time when change in bladder volume was estimated). Bladder Compliance was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of micturitions per 24 hours were calculated as the total number of micturitions divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed on, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with \\>0 micturitions at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Catheterizations Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of catheterizations per 24 hours were calculated as the total number of catheterizations divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with \\>0 catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Micturitions or Catheterizations Combined Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of micturitions and catheterizations combined per 24 hours were calculated as the total number of micturitions and catheterizations combined divided by the total number of diary days collected at the assessment point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour (hr) period. This outcome measure was only calculated for participants with \\>0 micturitions or catheterizations at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean number of incontinence episodes per 24 hours were calculated as the total number of incontinence episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. This outcome measure was only calculated for participants with \\>0 incontinence episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': ""The mean number of urgency episodes per 24 hours were calculated as the total number of urgency episodes divided by the total number of diary days collected at the assessment time point. Number of diary days collected at the assessment time point = number of calendar days when the diary was completed, even if it was not a full 24 hour period. Urgency episodes were defined as urgency marked as 'yes' in the diary. This outcome measure was only calculated for sensate participants with \\>0 urgency episodes at Baseline. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned."", 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Volume Voided Per Micturition at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean voided volume per micturition was calculated as sum of voided volume divided by the total number of micturition episodes with a recorded voided volume \\>0. This outcome measure included only participants who actually had the records of volume voided per micturition. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Volume Voided Per Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean volume per catheterization was calculated as sum of voided volume divided by the total number of catheterization, with a recorded voided volume \\>0. This outcome measure included only participants who actually had the records of volume voided per catherization. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}, {'measure': 'Change From Baseline in Mean Volume Voided Per Micturition or Catheterization at Week 12 of Study A0221047 and at Week 28 and Final Visit of Study A0221109', 'description': 'The mean voided volume per micturition or catheterization was calculated as sum of voided volume divided by the total number of micturition or catheterization episodes with a recorded voided volume \\>0. Data was summarized for each cohort, each treatment group and total of treatment groups, using the merged data of studies A0221047 and A0221109 as planned.', 'timeFrame': 'Study A0221047: Baseline, Week 12; Study A0221109: Week 28, Final Visit (Week 28 for participants who completed the study or in case of early withdrawal the last assessment before Week 28 was considered to be the final visit)'}]",55.0,6 Years,17 Years,ALL,False,INDUSTRY,0.0,12.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03587142,Buspirone for Early Satiety and Symptoms of Gastroparesis,Buspirone,"['Buspirone', 'buspirone hydrochloride (HCl)', 'Buspar Dividose', 'Buspar', 'Placebo', 'Placebo (for buspirone)', 'Vanspar']",7,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Gastroparesis,Johns Hopkins Bloomberg School of Public Health,2025-09-01T16:18:13.413794,True,,,,NOT_FOUND,"Buspirone for Early Satiety and Symptoms of Gastroparesis: A Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial (BESST)",,['Gastroparesis'],"['gastroparesis', 'early satiety', 'stomach', 'buspirone', '5-HT 1a receptor agonist']",,2019-08-27,2022-04-30,"[{'measure': '4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity', 'description': 'The outcome is assessed using the self-reported early satiety/postprandial fullness subscore (ES/PPF), which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.', 'timeFrame': 'baseline and 4-weeks'}]","[{'measure': '4-Week Change in Stomach Fullness Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of stomach fullness severity in the prior 2-weeks using the Gastroparesis Cardinal Symptoms Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Excessive Fullness Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of feeling excessively full after meals severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Inability to Finish a Normal-sized Meal Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of inability to finish a normal-sized meal severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Loss of Appetite Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of loss of appetite severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Total Overall GCSI Symptom Severity', 'description': 'The outcome is assessed using the self-reported Gastroparesis Cardinal Symptom Index (GCSI) total score, which is computed as the average of the 3 subscores on the GCSI survey: 3-item early satiety/postprandial fullness subscore, the nausea/vomiting subscore (average of 3-items: nausea, retching, vomiting), and bloating subscore (average of 2-items: bloating, stomach visibly larger). Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the total score ranges from 0 to 5. The change is computed as the total score at 4-weeks minus the baseline total score. A negative change indicates improved symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Nausea, Vomiting and Retching Symptoms Severity', 'description': 'The outcome is assessed using the self-reported nausea/vomiting subscore, which is computed as the average of 3 scores for 3-items on the Gastrointestinal Cardinal Symptom Index (GCSI) survey: nausea, retching, vomiting. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks. The change is computed as the subscore at 4-weeks minus the baseline subscore. Negative change indicates improvement in symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Nausea Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of nausea severity item from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Vomiting Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of vomiting severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates improvement in vomiting severity.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Bloating and Stomach Distention Symptoms Severity', 'description': 'The outcome is assessed using the self-reported bloating subscore, which is computed as the average of 2 scores for 2-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: bloating, stomach visibly larger. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative value for change indicates improvement in symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Bloating Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of bloating severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Upper Abdominal Pain and Discomfort Symptoms Severity', 'description': 'The outcome is assessed using the self-reported upper abdominal pain subscore, which is computed as the average of 2 scores for 2-items on the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) survey: upper abdominal pain, upper abdominal discomfort. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Upper Abdominal Pain Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of upper abdominal pain severity in the prior 2-weeks using the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Gastroesophageal (GERD) Symptoms Severity', 'description': 'The outcome is assessed using the self-reported GERD subscore, which is computed as the average of 7 scores for 7-items on the Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey: heartburn during the day, heartburn when lying down, feeling of discomfort inside chest during the day, feeling of discomfort inside chest during sleep, regurgitation or reflux during the day, regurgitation when lying down, bitter, acid or sour taste in mouth. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Gastrointestinal Symptoms Rating Scale (GSRS) Global Score', 'description': 'The outcome is assessed using the self-reported GSRS total score which is computed as the mean of the 15 item scores on the Gastrointestinal Symptom Rating Scale (GSRS) survey. Each item is scored from 1 (no discomfort) to 7 (very severe discomfort) of the symptom in the past week. The change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': ""4-Week Change in Participant's Rating of Symptom Relief"", 'description': 'The outcome is assessed using the participant-rated Clinical Patient Grading Assessment Scale (CPGAS) score which is scored from -3 (very considerably worse) to 3 (completely better) in the past week compared to the way the participant usually feels. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates patient feeling better.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Severity of Somatic Symptoms', 'description': 'The outcome is assessed using the self-reported Patient Health Questionnaire 15 Somatic Symptom Severity Scale (PHQ-15) total somatization score (ranges from 0 -30, with 30 being most bothered by symptoms in prior 4-weeks), calculated as the sum of 15-items, each scored from 0 (not bothered at all) to 2 (bothered a lot) by somatic symptoms in the prior 4-weeks. The change is computed as the score at 4-weeks minus the baseline score. A negative change indicates being less bothered by the symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Depression', 'description': 'The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) depression subscore, calculated as the sum of 7 items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative change indicates reduced depression.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Anxiety', 'description': 'The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) anxiety subscore, calculated as the sum of 7-items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative change indicates reduced anxiety at 4-weeks.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change Overall Quality of Health Due to Gastroparesis Issues', 'description': ""The outcome is assessed using the self-reported Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) total score which comprises 30 items scored from 0 (none of the time) to 5 (all of the time) the participant's QOL has been affected by their gastrointestinal issues in the prior two weeks. The total score is the mean of the 5 subscale scores and ranges from 0 (lowest QOL) to 5 (highest QOL) in past 2-weeks. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved QOL."", 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Overall Mental Quality of Life (QOL)', 'description': 'The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) mental health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved mental QOL.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Overall Physical Quality of Life (QOL)', 'description': 'The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) physical health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved Physical QOL.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Gastric Retention', 'description': 'The outcome is assessed using the percent of gastric retention at 4-hours from the Gastric Emptying Scintigraphy (GES) test. The change is computed as the percent retention at 4-weeks minus the baseline percent retention. % retention is the amount of food remaining in the stomach at 4-hours of the GES test and ranges from 0% (no food) to 100% (all of the food).', 'timeFrame': 'baseline and 4-weeks'}, {'measure': 'Change at 4-weeks in the Intragastric Meal Distribution (IMD)', 'description': 'The Intragastric meal distribution (IMD) is assessed at baseline and 4-weeks during the Gastric Emptying Scintigraphy Test. The ratio of gastric counts of the meal in the proximal stomach to the distal stomach is used to compute the Intragastric meal distribution (IMD) which can be used as an indirect measure of Fundic Accommodation.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': 'Change From Baseline at 4-weeks in the Water Load Satiety Test (WLST)', 'description': 'The Water Load Satiety Test (WLST) is the amount of water a patient can consume until full in 5 minutes. The volume of water is recorded. The change is computed as the volume of water ingested at baseline subtracted from the amount of water ingested at 4-weeks. A positive change indicates that the patient can ingest more water at 4-weeks than at baseline.', 'timeFrame': 'baseline and 4-weeks'}]",25.0,18 Years,85 Years,ALL,False,OTHER,7.0,96.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00967538,Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments,etanercept 50 mg,"['etanercept 50 mg', 'Enbrel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Psoriasis,Innovaderm Research Inc.,2025-09-01T16:18:14.666475,True,,,,NOT_FOUND,Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab,,['Psoriasis'],"['psoriasis', 'etanercept', 'efficacy', 'response', 'anti-TNF alpha', 'treatment efficacy']",,2009-09,2014-07,"[{'measure': ""Proportion of patients who reach a Physician's Global Assessment (PGA) of clear or almost clear after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg every other week (EOW)."", 'timeFrame': '24 weeks'}]","[{'measure': 'Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}, {'measure': 'Mean Body Surface Area (BSA) after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}, {'measure': 'Mean BSA after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Mean BSA after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Mean Psoriasis Area and Severity Index (PASI) score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}, {'measure': 'Mean PASI score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Mean PASI score after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Safety of etanercept in patients who have shown an unsatisfactory response to adalimumab, who have lost their satisfactory response to adalimumab or who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}]",10.0,18 Years,80 Years,ALL,False,OTHER,1.0,89.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06832540,Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects,[14C]TJ0113,['[14C]TJ0113'],1,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Healthy Chinese Subjects,"Hangzhou PhecdaMed Co., Ltd.",2025-09-01T16:18:14.672776,True,,,,NOT_FOUND,Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects,,['Healthy Chinese Subjects'],[],,2025-02-19,2025-08-15,"[{'measure': 'The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and feces', 'description': 'The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and feces', 'timeFrame': 'Predose up to 240 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: Cmax', 'description': 'Maximum concentration', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: Tmax', 'description': 'Time to Maximum Concentration', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: t1/2', 'description': 'Half Life', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: MRT', 'description': 'Mean Residence Time', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: AUC', 'description': 'Area Under the Plasma Concentration-time Curve', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}]",[],6.0,18 Years,45 Years,MALE,True,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00231192,Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes,Repaglinide and Insulin,['Repaglinide and Insulin'],1,INTERVENTIONAL,['NA'],,WITHDRAWN,Diabetes,Children's Hospital of Philadelphia,2025-09-01T16:18:13.428246,True,,,,NOT_FOUND,Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes,,['Diabetes'],"['Diabetes', 'Adolescents', 'Cystic Fibrosis', 'Insulin', 'Repaglinide']",Unable to recruit any subjects,2005-10,2007-08,"[{'measure': 'blood glucose'}, {'measure': 'insulin excursion during oral glucose tolerance test'}, {'measure': 'fasting blood glucose'}, {'measure': '2-hour post-prandial blood glucose'}, {'measure': 'hemoglobin A1C'}, {'measure': 'serum fructosamine'}]","[{'measure': 'weight'}, {'measure': 'body mass index'}, {'measure': 'lean body mass'}, {'measure': 'pulmonary function'}, {'measure': 'quality of life'}]",11.0,12 Years,20 Years,ALL,True,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Unable to recruit any subjects,,,no_match,False,,,
NCT01337427,Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis,BIIB017,"['PEG IFN β-1a', 'BIIB017', 'PEGylated Interferon beta-1a']",3,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Relapsing Remitting Multiple Sclerosis,Johns Hopkins University,2025-09-01T16:18:09.643279,True,,,,NOT_FOUND,"Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis",,['Relapsing Remitting Multiple Sclerosis'],"['multiple sclerosis', 'relapsing', 'MS', 'injectable', 'subcutaneous', 'SC', 'PEGylated', 'interferon', 'PEG', 'OCT', 'Optical Coherence Tomography']",The study was not feasible to conduct in the US and abroad.,2010-08,2013-08,"[{'measure': 'To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 12 in the BIIB-17 vs. placebo arms.', 'timeFrame': '1 year'}, {'measure': 'To determine the proportion of patients with RNFL decrease of 5 microns or more from baseline to month 24 in the BIIB-17 vs. placebo arms.', 'timeFrame': '2 years'}]","[{'measure': 'Analysis of proportion of patients with a decrease of >10 percent of baseline value in any RNFL quadrant from baseline to month 12 in the BIIB-17 vs. placebo arms.', 'timeFrame': 'baseline and 1 year'}, {'measure': 'Analysis of decrease between baseline scans and 3 month scan (to examine for pseudoatrophy) in this study population.', 'timeFrame': 'baseline and 3 months'}, {'measure': 'Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (12 months) in this study population.', 'timeFrame': '3 months and 1 year'}, {'measure': 'Analysis of macular volume decreases from baseline or 3 months to follow up scans at 12 months in this study population.', 'timeFrame': 'baseline and 1 year'}, {'measure': 'Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 12 months in this study population.', 'timeFrame': 'baseline and 1 year'}, {'measure': 'Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.', 'timeFrame': '1 year'}, {'measure': 'Analysis of proportion of patients with a decrease of >10 percent of baseline value in any RNFL quadrant from baseline to month 24 in the BIIB-17 vs. placebo arms.', 'timeFrame': 'baseline and 2 years'}, {'measure': 'Analysis of decrease between 3 month scans (mean and/or quadrant) and follow up scans (24 months) in this study population.', 'timeFrame': '3 months and 2 years'}, {'measure': 'Analysis of macular volume decreases from baseline or 3 months to follow up scans at 24 months in this study population.', 'timeFrame': 'baseline and 2 years'}, {'measure': 'Analysis of retinal nuclear layer decreases from baseline or 3 months to follow up scan at 24 months in this study population.', 'timeFrame': 'baseline and 2 years'}, {'measure': 'Analysis of the above OCT parameters in patients with optic neuritis or history of optic neuritis.', 'timeFrame': '2 years'}]",13.0,18 Years,55 Years,ALL,False,OTHER,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,The study was not feasible to conduct in the US and abroad.,,,no_match,False,,,
NCT00001443,A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection,indinavir (MK-0639),['indinavir (MK-0639)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Acquired Immunodeficiency Syndrome,National Cancer Institute (NCI),2025-09-01T16:18:25.987769,True,,,,NOT_FOUND,A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection,,"['Acquired Immunodeficiency Syndrome', 'HIV Infections']","['AIDS', 'Bioavailability', 'Immunologic Evaluations', 'Pharmacokinetics', 'Toxicity']",,1995-07,2000-10,[],[],0.0,,,ALL,False,NIH,0.0,63.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00963027,Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil,Treprostinil diethanolamine,"['Oral treprostinil', 'Esomeprazole', 'UT-15C', 'Treprostinil diethanolamine', 'UT-15C SR', 'Nexium']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,"Hypertension, Pulmonary",United Therapeutics,2025-09-01T16:18:20.963284,True,,,,CHEMBL119604,An Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult Volunteers,,"['Hypertension, Pulmonary', 'Pulmonary Arterial Hypertension']","['Hypertension, Pulmonary', 'Treprostinil', 'Pharmacokinetics', 'Treprostinil Diethanolamine', 'Pulmonary Arterial Hypertension', 'Esomeprazole']",,2009-09,2009-10,"[{'measure': 'Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of a 1 mg treprostinil diethanolamine sustained release tablet before and after repeated dosing with esomeprazole.', 'timeFrame': 'Within 10 minutes prior to through 36 hours post treprostinil diethanolamine dosing'}, {'measure': 'Adverse event monitoring', 'timeFrame': 'Time Frame: From the first dose of treprostinil diethanolamine through study end (Study Day 9/10)'}]","[{'measure': 'Clinical laboratories', 'timeFrame': 'Study Days 0 and 9'}]",3.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,30.0,ESTIMATED,v2_robust,True,True,False,True,,OCCNCCO,CHEMBL119604,partial_match,True,105.14,-1.44,3.0
NCT02424396,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,IL2,"['IL2', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Relapsing Remitting Multiple Sclerosis,Assistance Publique - Hôpitaux de Paris,2025-09-01T16:18:15.894115,True,,,,NOT_FOUND,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study,,['Relapsing Remitting Multiple Sclerosis'],"['Interleukin 2, IL2', 'Relapsing Remitting Multiple Sclerosis', 'Autoimmune diseases', 'Regulatory T cells, Tregs']",,2016-06-13,2020-06-15,"[{'measure': 'Treg response to low dose IL2 induction course period, expressed as % of total CD4 cells', 'timeFrame': 'at day5'}]","[{'measure': 'Change in Treg percentage on D15 after induction (D1-D5) compared to baseline', 'timeFrame': 'at day15'}, {'measure': 'Change in Treg percentage from D15 to M6 compared to baseline', 'timeFrame': 'Day 15 to Day 169'}, {'measure': 'The cumulative number of new lesions enhanced by Gd+ (Sum of Gd + lesions on T1 MRI on M2, M4 and M6)', 'timeFrame': 'Day 57, Day 113 and Day 169'}, {'measure': 'Frequency of patients free of Gd+ lesions at M6', 'timeFrame': 'Day 169'}, {'measure': 'The cumulative number of new T2 lesions', 'timeFrame': 'Day 169'}, {'measure': 'Annual relapse rate (number of relapses observed over a 6 month period)', 'timeFrame': 'Day 169'}, {'measure': '% of patients with flare', 'timeFrame': 'Day 169'}, {'measure': '% of disease free patient i.e % of patient with no clinical symptoms and no activity on MRI', 'timeFrame': 'Day 169'}]",9.0,18 Years,65 Years,ALL,False,OTHER,1.0,30.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00484068,Chicken-Diet vs. Enalapril to Reduce Albuminuria,enalapril,['enalapril'],1,INTERVENTIONAL,['NA'],,COMPLETED,Microalbuminuria,Hospital de Clinicas de Porto Alegre,2025-09-01T16:18:07.016760,True,,,,NOT_FOUND,Effect of Chicken-Based Diet Versus Enalapril on Albuminuria in Patients With Type 2 Diabetes and Microalbuminuria: a One-Year Randomized Controlled Study,,"['Microalbuminuria', 'Diabetic Nephropathy']","['type 2 diabetes', 'microalbuminuria', 'chicken-based diet', 'ACE inhibitor']",,2003-01,2006-06,"[{'measure': 'urinary albumin excretion', 'timeFrame': 'during study'}, {'measure': 'serum lipids', 'timeFrame': 'during study'}, {'measure': 'nutritional status', 'timeFrame': 'during study'}]",[],3.0,18 Years,,ALL,False,OTHER,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00561301,Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma,GemDOx,['GemDOx'],1,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Lymphoma,Cooperative Study Group A for Hematology,2025-09-01T16:18:15.908550,True,,,,NOT_FOUND,Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma,,['Lymphoma'],[],,2006-11,2009-10,"[{'measure': 'objective response rate', 'timeFrame': '10/2009'}]","[{'measure': 'toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT', 'timeFrame': '10/2009'}]",2.0,15 Years,65 Years,ALL,False,NETWORK,0.0,43.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00630630,Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy,Levetiracetam,"['Levetiracetam', 'Keppra, ucbL059']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Epilepsy,UCB Pharma,2025-09-01T16:18:10.921925,True,,,,NOT_FOUND,"A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Adult Female Subjects (18 to 40 Years of Age) With C1 Catamenial Epilepsy",,['Epilepsy'],"['Levetiracetam', 'Keppra']",,2002-11,2003-11,[{'measure': 'Percent change in catamenial seizure frequency.'}],"[{'measure': 'Responder rate'}, {'measure': 'Number of days free from seizures per week'}, {'measure': 'Ratio of catamenial seizure frequency to non-catamenial seizure frequency'}, {'measure': 'Catamenial seizure frequency during each cycle'}, {'measure': 'Seizure frequency of catamenial and non-catamenial combined'}, {'measure': 'Non-catamenial seizure frequency'}, {'measure': 'Catamenial seizure frequency separately for ovulatory and anovulatory cycles'}, {'measure': 'Safety'}]",9.0,18 Years,45 Years,FEMALE,False,INDUSTRY,0.0,3.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05388760,Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1),Tralokinumab,['Tralokinumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Atopic Dermatitis,LEO Pharma,2025-09-01T16:18:23.456412,True,,,,NOT_FOUND,"A Single (Assessor) Blinded, Randomized, Parallel-group, Monotherapy Trial to Evaluate the Pharmacokinetics and Safety of Tralokinumab in Children (Age 6 to <12 Years) With Moderate-to-severe Atopic Dermatitis",,['Atopic Dermatitis'],[],,2022-09-07,2026-04-23,"[{'measure': 'Ctrough (trough concentration)', 'timeFrame': 'at Week 16'}, {'measure': 'Cmax (maximum serum concentration)', 'timeFrame': 'between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)'}, {'measure': 'AUC (area under the curve)', 'timeFrame': 'between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)'}, {'measure': 'Tmax (time to maximum serum concentration)', 'timeFrame': 'between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)'}]","[{'measure': 'Number of treatment-emergent adverse events in the initial treatment period', 'description': 'An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.', 'timeFrame': 'Week 0-Week 16'}, {'measure': 'Anti-drug antibodies (status) in the initial treatment period', 'timeFrame': 'Week 0-Week 16'}, {'measure': 'Number of treatment-emergent adverse events in the open-label treatment period', 'description': 'An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.', 'timeFrame': 'Week 16-Week 68'}, {'measure': 'Anti-drug antibodies (status) in the open-label treatment period', 'timeFrame': 'Week 16-Week 68'}, {'measure': 'Change in Scoring Atopic Dermatitis (SCORAD)', 'description': 'The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis (AD) lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.', 'timeFrame': 'from Week 0-Week 68'}, {'measure': 'Change in Patient-Oriented Eczema Measure (POEM)', 'description': ""The POEM is a validated questionnaire used to assess disease symptoms in atopic eczema patients in both clinical practice and clinical trials (30, 31). The tool consists of 7 items each addressing a specific symptom (itching, sleep, bleeding, weeping, cracking, flaking, and dryness). POEM for proxy completion is used, where the caregiver will report their perception of how often the subject has experienced each symptom over the previous week on a 5-point categorical response scale (0 = 'no days'; 1 = '1 to 2 days'; 2 = '3 to 4 days'; 3 = '5 to 6 days'; 4 = 'every day'). The total score is the sum of the 7 items (range 0 to 28) and reflects disease-related morbidity; a high score is indicative of a worse disease severity."", 'timeFrame': 'from Week 0-Week 68'}, {'measure': 'Change in Eczema Area and Severity Index (EASI)', 'description': 'The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition.', 'timeFrame': 'from Week 0-Week 68'}]",11.0,6 Years,11 Years,ALL,False,INDUSTRY,0.0,24.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05048589,Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,Standard-Dose Quadrivalent Influenza Vaccine,"['QIV-HD', 'QIV-SD', 'Standard-Dose Quadrivalent Influenza Vaccine', 'High-Dose Quadrivalent Influenza Vaccine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Influenza,Tor Biering-Sørensen,2025-09-01T16:18:09.632867,True,,,,NOT_FOUND,Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,,['Influenza'],"['Influenza', 'Vaccination', 'Pragmatic', 'Registry']",,2021-10-01,2022-05-31,"[{'measure': 'Number of persons contacted by recruitment letter', 'timeFrame': 'Up to 8 months'}, {'measure': 'Number of participants included and randomized to QIV-HD or QIV-SD', 'timeFrame': 'Up to 8 months'}, {'measure': 'Agreement between randomization assignment and actual received vaccine', 'timeFrame': 'Up to 8 months'}, {'measure': 'Balance between groups in terms of number of subjects in each arm and baseline characteristics', 'timeFrame': 'Up to 8 months'}, {'measure': 'Comparison of baseline characteristics for the QIV-HD and QIV-SD groups to the overall Danish general population aged 65-79 years', 'timeFrame': 'Up to 8 months'}, {'measure': 'Comparison of baseline characteristics for the QIV-HD and QIV-SD groups to the population aged 65-79 years in the DLVS database used for recruitment', 'timeFrame': 'Up to 8 months'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for influenza and/or pneumonia', 'description': 'First hospitalization with a primary (A) diagnosis code for influenza or pneumonia of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for respiratory disease', 'description': 'First hospitalization with a primary (A) diagnosis code for respiratory disease of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for cardio-respiratory disease', 'description': 'First hospitalization with a primary (A) diagnosis code for cardio-respiratory disease of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for cardiovascular disease', 'description': 'First hospitalization with a primary (A) diagnosis code for cardiovascular disease of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization from any cause', 'description': 'First hospitalization with any diagnosis code of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for all-cause mortality', 'description': 'Death from any cause', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}, {'measure': 'Description of event rates and calculation of relative vaccine effectiveness for hospitalization for COVID-19', 'description': 'First hospitalization with a primary (A) diagnosis code for COVID-19 of at least 1 night duration', 'timeFrame': '>= 14 days after vaccination up to 8 months post-vaccination'}]",[],13.0,65 Years,79 Years,ALL,True,OTHER,1.0,12551.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT02240693,Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,BI 409306,"['BI 409306', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Alzheimer Disease,Boehringer Ingelheim,2025-09-01T16:18:19.669986,True,,,,NOT_FOUND,"A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease",,['Alzheimer Disease'],[],,2015-01-15,2017-10-09,"[{'measure': 'Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.', 'description': 'Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline', 'timeFrame': 'Baseline and 12 weeks'}, {'measure': 'Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)', 'description': 'Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline', 'timeFrame': 'Baseline and 12 weeks'}]","[{'measure': ""Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment"", 'description': ""Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver.\n\nEach item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function.\n\nLeast Squares Mean is actually an adjusted mean change from baseline."", 'timeFrame': 'Baseline and 12 weeks'}, {'measure': 'Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment', 'description': 'The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.\n\nEach domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline.', 'timeFrame': 'Baseline and 12 weeks'}, {'measure': ""Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment"", 'description': ""Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline."", 'timeFrame': 'Baseline and 12 weeks'}]",5.0,55 Years,,ALL,False,INDUSTRY,0.0,128.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03598699,A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease,AXR-159,"['Vehicle', 'AXR-159']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Dry Eye,"AxeroVision, Inc.",2025-09-01T16:18:24.758541,True,,,,NOT_FOUND,"A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)",,['Dry Eye'],[],,2018-06-26,2019-01-09,"[{'measure': 'Inferior Corneal Staining Score', 'description': 'Change from Baseline in Ora Calibra® Corneal and Conjunctival Staining Scale with a range from 0 to 4 (0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe) in the study eye. Higher negative scores mean a better outcome.', 'timeFrame': 'Month 3'}, {'measure': 'Eye Dryness', 'description': 'Change from baseline in Eye Dryness score on a subject level across both eyes. Using the visual analogue scale (VAS) subjects rated eye dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort with a range of 0 to 100. 0% corresponds to ""no dryness"" (no discomfort) and 100% corresponds to ""maximal dryness"" indicating maximal discomfort. A greater negative change from baseline score means a better outcome.', 'timeFrame': 'Month 3'}]","[{'measure': 'Total Ocular Surface and Disease Index (OSDI) © for Dry Eye', 'description': 'Change from baseline in OSDI © score on a subject level. The 12-question OSDI © is assessed on a total scale from 0 to 100, where higher scores represent greater disability. A greater negative change from baseline indicates a better outcome.', 'timeFrame': 'Month 3'}, {'measure': ""Schirmer's Test"", 'description': ""Change from baseline in Schirmer's Test score in the study eye. Unanesthetized Schirmer's Test measures the length of the moistened area of a test strip, placed in the lower temporal lid margin of each eye, in mm following a 5-minute exposure period. Greater positive numbers indicate a better outcome."", 'timeFrame': 'Month 3'}, {'measure': 'Tear Film Break-up Time (TBUT)', 'description': 'Change from baseline in the study eye with a greater positive increase indicating a better outcome. Following the instillation of a sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye and several blinks over 30 seconds, the examiner monitored the integrity of the tear film with the aid of a slit lamp, noting the time it takes to form micelles from the time that the eye is opened. TBUT was measured in seconds using a stopwatch and a digital image recording system for the right eye followed by the left eye. Values reported are for the study eye.', 'timeFrame': 'Month 3'}, {'measure': 'Conjunctival Redness Score', 'description': 'Change from baseline of Ora Calibra® Conjunctival Redness Scale for Dry Eye. Scores range from 0 to 4 with 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; with higher numbers indicating more conjunctival redness. Greater negative numbers indicate a better outcome. Values reported are for the study eye.', 'timeFrame': 'Month 3'}, {'measure': 'Total Lissamine Green Conjunctival Staining', 'description': 'Change from baseline of Oxford Grading Scale measuring staining within a range from 0-5 (0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe, 5=Confluent) for each panel (temporal and nasal) and 0-10 as the sum of both panel scores for the total exposed inter-palpebral conjunctiva. Larger negative numbers indicate reduced staining and a better outcome. Values reported are for the study eye.', 'timeFrame': 'Month 3'}]",7.0,18 Years,,ALL,False,INDUSTRY,1.0,102.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06134492,Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL,Acyclovir,"['Acyclovir', 'Aciclovir']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,"Pneumonia, Viral",Jena University Hospital,2025-09-01T16:18:17.171577,True,,,,CHEMBL1349,Effect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage,,"['Pneumonia, Viral', 'Ventilator Associated Pneumonia', 'Community-acquired Pneumonia', 'Herpes Simplex', 'Hospital-acquired Pneumonia']","['Pneumonia', 'Herpes Simplex', 'Mechanical Ventilation', 'Aciclovir']",,2024-02-20,2026-12,"[{'measure': 'mortality (survival status)', 'description': 'survival status', 'timeFrame': 'day 30'}]","[{'measure': 'Ventilation-free days', 'description': 'days without mechanically ventilation via endotracheal tube, incl. tracheostoma', 'timeFrame': 'day 30'}, {'measure': 'Vasopressor-free days', 'description': 'days without continuous vasopressor administration \\> 1h/day', 'timeFrame': 'day 30'}, {'measure': 'Delta SOFA score (Sepsis-related Organ Failure Assessment Score)', 'description': 'Each of six organ systems receive a score ranging from 0 (normal) to 4 (most abnormal), with a minimum SOFA score of 0 and a maximum SOFA score of 24', 'timeFrame': 'Baseline - Day 10 or EOT if this event occurs earlier'}, {'measure': 'Delta SOFA sub-score kidney (Sepsis-related Organ Failure Assessment Score)', 'description': 'Sub-score for kidney function, the score ranges from 0 (normal) to 4 (most abnormal)', 'timeFrame': 'Baseline - Day 10 or EOT if this event occurs earlier'}, {'measure': 'Delta GFR value', 'description': 'GFR value', 'timeFrame': 'Baseline - Day 10 or EOT if this event occurs earlier'}, {'measure': 'Length of stay in ICU', 'description': 'days LOS in ICU', 'timeFrame': 'day 30'}, {'measure': 'Length of stay in Hospital', 'description': 'days LOS in hospital', 'timeFrame': 'day 30'}, {'measure': 'Cost of intervention', 'description': 'ICU and hospitalization days + acyclovir', 'timeFrame': 'up to day 90'}, {'measure': 'Days without delirium/coma', 'description': 'based on CAM-ICU / RASS', 'timeFrame': 'Until day 10 or until EOT if this event occurs earlier'}, {'measure': 'Microbiological cure (EOT)', 'description': 'Percent of participants with HSV eradication (PCR testing negative) in blood and respiratory tract', 'timeFrame': 'At day 10 or day of EOT if this event occurs earlier'}, {'measure': 'mortality (survival status)', 'description': 'survival status', 'timeFrame': '90 days'}, {'measure': 'mortality (survival status)', 'description': 'survival status', 'timeFrame': '180 days'}, {'measure': 'Quality of life (EQ-5D-5L)', 'description': 'EuroQuality of Life Five Dimensions (EQ-5D-5L), the descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), with five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems.', 'timeFrame': 'Measurement at day 10 or EOT if this event occurs earlier, day 30, day 90, and day 180'}, {'measure': 'Incidence SAEs', 'description': 'Incidence of serious adverse events', 'timeFrame': 'From time of randomization until day 10 or EOT if this event occurs earlier'}]",15.0,18 Years,,ALL,False,OTHER,0.0,616.0,ESTIMATED,v2_robust,True,False,False,True,,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,CHEMBL1349,partial_match,True,324.34,-0.8,4.0
NCT02436980,Premedication for ERCP With Midazolam or Tramadol,Tramadol,"['Midazolam', 'CONTRAMAL', 'Tramadol', 'DORMICUM']",4,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Chronic Disease,Karadeniz Technical University,2025-09-01T16:18:18.421086,True,,,,NOT_FOUND,Effects of Midazolam or Tramadol Premedication on Early Cognitive Function in ERCP: a Randomized Controlled Double-Blind Study,,['Chronic Disease'],"['premedication', 'ERCP', 'midazolam', 'tramadol', 'cognitive']",,2009-01,2009-12,"[{'measure': 'The early cognitive functions after ERCP', 'description': 'The early cognitive functions after ERCP assessed by mini-mental test (MMT)', 'timeFrame': 'Postprocedure in the first 60 minutes'}]","[{'measure': 'Number of Participants with Adverse Events', 'description': 'With any side effects', 'timeFrame': 'Postprocedure in first 60 minutes'}]",2.0,18 Years,70 Years,ALL,False,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT06630624,"Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM",IP-001,['IP-001'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,RECRUITING,Colorectal Cancer,M.R. Meijerink,2025-09-01T16:18:15.891425,True,,,,NOT_FOUND,"INJECTABL-II: Dose Finding, Efficacy and Immunological Response of a Novel Immuno-Adjuvant (IP-001) Following Microwave Ablation or Irreversible Electroporation for Colorectal Liver Metastases.",,"['Colorectal Cancer', 'Liver Metastases', 'Liver Metastasis Colon Cancer']","['Colorectal liver metastases', 'Colorectal hepatic metastases', 'irreversible electroporation', 'Microwave ablation', 'Immunotherapy']",,2024-07-10,2031-08-01,"[{'measure': 'Maximum Tolerated Dose (MTD) (Phase 1)', 'description': 'The highest dose of IP-001 that does not cause unacceptable side effects defined as the dose level below the dose level that caused 2 or more Dose Limiting Toxicites (DLTs).', 'timeFrame': 'During the 10-day DLT-monitoring period.'}, {'measure': '1-Year Distant Progression Free Survival (DPFS) (Phase 2 part 1)', 'description': 'Overall DPFS is defined as the time from inclusion to the time of disease progression (according to the RECIST 1.1 guideline) or death (events). Death related to other causes is considered a failure event for DPFS.', 'timeFrame': '1 year'}, {'measure': 'Disease Control Rate (DCR) (Phase 2 part 2)', 'description': 'DCR is calculated as the percentage of patients experiencing either iSD (Stable Disease), iPR (Partial Response) or iCR (Complete Response) as best response in target lesions at 16 weeks after treatment according to iRECIST.', 'timeFrame': '16 weeks'}]","[{'measure': 'Elimination half-life of the study drug IP-001 in the blood (t1/2 ) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as elimination half-life of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}, {'measure': 'Overall Survival (OS; per patient analysis) (All phases)', 'description': 'OS is defined as the time from focal therapy to the time of death due to any cause, assessed up to 5 years;', 'timeFrame': 'Up to 5 years'}, {'measure': '(Serious) Adverse Events ((S)AEs) (All phases)', 'description': '(Serious) adverse events according to CTCAE v5.0, assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Duration of best overall response (DoR, per patient analysis) (Phase 2 part 2)', 'description': 'DoR is defined from when the time measurement criteria are first met for CR/iCR or PR/iPR until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years;', 'timeFrame': 'Up to 3 years'}, {'measure': 'Local Tumor Progression Free Survival (LTPFS, per lesion analysis) (All phases)', 'description': 'LTPFS is defined as the time from focal therapy to the time of local tumor progression or death from any cause, whichever occurs first. Local tumor is defined as the treated tumor, assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Distant Progression Free Survival (DPFS; per patient analysis) (All phases)', 'description': 'DPFS is defined as the time from focal therapy to the time of distant disease progression or death from any cause, whichever occurs first, assessed up to 5 years. Distant disease is defined as extra-hepatic lesions and untreated, hepatic lesions;', 'timeFrame': 'Up to 5 years'}, {'measure': 'Hepatic progression free survival (HPFS; per patient analysis) (All phases)', 'description': 'HPFS is defined as the time from focal therapy to the time of progression of any tumor in the liver (treated or untreated) or death from any cause, whichever occurs first, assessed up to 5 years;', 'timeFrame': 'Up to 5 years'}, {'measure': 'Time to progression (TTP; per patient analysis) (All phases)', 'description': 'TTP is defined as the time from focal therapy to the time of unequivocal disease progression (events); the date of death from any cause or death without established RECIST progressive disease is considered to be a competing risk. TTP will be analysed with and without competing risks. Assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Progression-free survival (PFS; per patient analysis) (All phases)', 'description': 'The time until the date of unequivocal disease progression (local site recurrence or metastatic disease) or death from any cause, whichever occurs first, assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Disease-free survival (DFS; per patient analysis) (All phases)', 'description': 'DFS is defined as the time from focal therapy until the appearance or worsening of signs or symptoms of the disease or death from any cause, whichever occurs first, assesed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Pain assessment (Per procedure analysis)', 'description': 'Pain assessment using visual analogue scale questionnaires (VAS; per procedure analysis). Assessed prior to, directly after and every three months after local treatment, and up to 1 year.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Ablative Success (All phases)', 'description': 'Ablative success (or technical success rate) is defined as the primary efficacy rate; the percentage of successfully eradicated tumor tissue after the local treatment, assessed directly after the treatment.', 'timeFrame': 'Directly after treatment'}, {'measure': 'Quality of Life using EORCT QLQ-C30 questionnaireS (QoL; per patient analysis) (Phase 2)', 'description': 'The quality of life is assessed using EORCT QLQ-C30 questionnaires, prior to, and every three months after treatment during a total follow-up time of 1 year.', 'timeFrame': '1 year'}, {'measure': 'Quality of Life using EQ-5D questionnaires (QoL; per patient analysis) (Phase 2)', 'description': 'The quality of life is assessed using EQ-5D questionnaires, prior to, and every three months after treatment during a total follow-up time of 1 year.', 'timeFrame': '1 year'}, {'measure': 'Quality of Life using PRODISQ questionnaires(QoL; per patient analysis) (Phase 2)', 'description': 'The quality of life is assessed using PRODISQ questionnaires, prior to, and every three months after treatment during a total follow-up time of 1 year.', 'timeFrame': '1 year'}, {'measure': 'Time of maximum observed concentration of the study drug IP-001 in the blood (Tmax) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as time of maximum observed concentration of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}, {'measure': 'Maximum observed concentration of the study drug IP-001 in the blood (Cmax) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as maximum observed concentration of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}, {'measure': 'Area under the curve from time 0 to the time of the last measurable concentration of the study drug IP-001 in the blood (AUC 0-t) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as the area under the curve from time 0 to the time of the last measurable concentration of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}]",21.0,18 Years,,ALL,False,OTHER,2.0,120.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02524652,Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction,Ropivacaine 0.5% 20 mLs,"['Ropivacaine 0.5% 20 mLs', 'Naropine, Naropin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Rupture of Anterior Cruciate Ligament,Centre Hospitalier Universitaire Vaudois,2025-09-01T16:18:25.982950,True,,,,NOT_FOUND,Postoperative Analgesic Efficacy of Local Infiltration Analgesia Versus Adductor Canal Block After Anterior Cruciate Ligament Reconstruction: A Randomised Controlled Double-blinded Trial,,"['Rupture of Anterior Cruciate Ligament', 'Infiltration', 'Regional Anesthesia Morbidity']",[],,2015-09,2018-03,"[{'measure': 'Total morphine consumption (mg)', 'timeFrame': '24 h postoperatively'}]","[{'measure': 'Total morphine consumption (mg)', 'timeFrame': '2 h postoperatively'}, {'measure': 'Total morphine consumption (mg)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Total morphine consumption (mg)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '2 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '12 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '24 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '36 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '48 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '60 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '72 h postoperatively'}, {'measure': 'Postoperative nausea and vomiting (yes/no)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Postoperative nausea and vomiting (yes/no)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Postoperative nausea and vomiting (yes/no)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Pruritus (yes/no)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Pruritus (yes/no)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Pruritus (yes/no)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Active flexion', 'description': 'Flexion of the knee by the patient measured in degrees', 'timeFrame': '24 h postoperatively'}, {'measure': 'Active flexion', 'description': 'Flexion of the knee by the patient measured in degrees', 'timeFrame': '48 h postoperatively'}, {'measure': 'Active flexion', 'description': 'Flexion of the knee by the patient measured in degrees', 'timeFrame': '72 h postoperatively'}, {'measure': 'Quadriceps muscle strength (numeric scale, 1-5)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Quadriceps muscle strength (numeric scale, 1-5)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Quadriceps muscle strength (numeric scale, 1-5)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Distance walked (meters)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Distance walked (meters)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Distance walked (meters)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Anterior Cruciate Ligament - Return to Sport after Injury scale', 'timeFrame': '4 months postoperatively'}, {'measure': 'Anterior cruciate ligament -Return to Sport after Injury scale', 'timeFrame': '8 months postoperatively'}, {'measure': 'International Knee Documentation Committee score', 'timeFrame': '4 months postoperatively'}, {'measure': 'International Knee Documentation Committee score', 'timeFrame': '8 months postoperatively'}]",30.0,18 Years,50 Years,ALL,False,OTHER,0.0,104.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04734262,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",Sitravatinib,"['Nanoparticle albumin-bound paclitaxel', 'BGB-A317', 'Nab-paclitaxel', 'MGCD516', 'Tislelizumab', 'Sitravatinib']",6,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Metastatic Breast Cancer,Fudan University,2025-09-01T16:18:15.894832,True,,,,NOT_FOUND,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",,['Metastatic Breast Cancer'],['Triple Negative Breast Cancer'],,2021-04-01,2024-06-30,"[{'measure': 'Overall Response Rate (ORR) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'The number of people with tumor responses according to RECIST (V1.1): the proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR).', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of participants experiencing ≥ Grade 3 TRAEs in Cohort B', 'description': 'TRAE are adverse events that occur during or after the first administration of the study drug until 30 days after the study drug is discontinued or the new anticancer treatment is initiated.', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Duration of Response (DOR) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'The time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Disease Control Rate (DCR) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'The proportion of participants who achieves a best overall response of CR, PR or stable disease(SD).', 'timeFrame': 'Up to 12 months'}, {'measure': 'Progression-free Survival (PFS) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first.', 'timeFrame': 'Up to 12 months'}, {'measure': 'One-year overall survival (OS) rate in Cohort A, Cohort B and Cohort C', 'description': 'OS defined as the time from the date of randomization to the date of death due to any reason. One-year survival rate (percentage of subjects alive at 1 year) was estimated from OS data.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of participants experiencing Adverse Events (AEs), Treatment-Related Adverse Events (TRAEs) or Serious Adverse Events (SAEs) in Cohort A, Cohort B and Cohort C', 'description': 'Adverse Events (AEs) according to CTCAE v5.0', 'timeFrame': 'Up to 12 months'}, {'measure': 'Patient report outcomes (PROs) based on the EORTC QLQ-C30 (V.3) Quality of Life Questionnaire in Cohort B and Cohort C', 'description': 'Evaluating the Quality of Life of participants as assessed by EORTC QLQ-C30 Questionnaire', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Potential biomarkers associated with efficacy, drug resistance, and/or disease progression (PD) in tumor tissues in Cohort A, Cohort B and Cohort C', 'description': 'Potential biomarkers in tumor tissues associated with efficacy', 'timeFrame': 'Through study completion, an average of 1 year'}]",9.0,18 Years,,FEMALE,False,OTHER,0.0,98.0,ACTUAL,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03105505,"The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis",Permethrin 5%,"['Permethrin 5%', 'Synthomycine 5%', 'Fusidic Acid 1% M/R Eye Drops']",3,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Inflammation of the Eyelids,Barzilai Medical Center,2025-09-01T16:18:18.429177,True,,,,NOT_FOUND,"The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial.",,['Inflammation of the Eyelids'],[],,2017-04-28,2018-09,"[{'measure': 'Decrease in demodex infestation in group A (permethrin 5%).', 'description': 'significant decrease in demodex infestation in comparison to group B and C.', 'timeFrame': '2 months'}, {'measure': 'Improvement in symptoms and complaints in group A.', 'description': 'OSDI Questionnaires that describe the severity of the ocular surface disease condition are filled in each visit.', 'timeFrame': '2 months'}]",[],2.0,18 Years,,ALL,False,OTHER,0.0,75.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT04569994,A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes,NNC0363-0845,"['Insulin degludec', 'Placebo (NNC0363-0845)', 'NNC0363-0845']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy Volunteers,Novo Nordisk A/S,2025-09-01T16:18:07.031187,True,,,,NOT_FOUND,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Healthy Subjects and in Subjects With Type 1 Diabetes",,"['Healthy Volunteers', 'Diabetes Mellitus, Type 1']",[],,2020-09-30,2021-06-23,"[{'measure': 'Number of treatment-emergent adverse events (AEs)', 'description': 'Number of events', 'timeFrame': 'Part 1 and 2: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10'}, {'measure': 'Number of treatment-emergent adverse events (AEs)', 'description': 'Number of events', 'timeFrame': 'Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)'}]","[{'measure': 'Number of treatment-emergent hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'Part 1 and 2 From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10'}, {'measure': 'Number of treatment-emergent hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)'}, {'measure': 'Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose', 'description': 'pmol\\*h/L', 'timeFrame': 'Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)'}, {'measure': 'Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose', 'description': 'pmol\\*h/L', 'timeFrame': 'Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)'}, {'measure': 'Maximum observed serum NNC0363-0845 concentration after a single dose', 'description': 'pmol/L', 'timeFrame': 'Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)'}, {'measure': 'Maximum observed serum NNC0363-0845 concentration after a single dose', 'description': 'pmol/L', 'timeFrame': 'Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)'}]",8.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,68.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00219583,"Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation","UK-390,957","['UK-390,957']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,COMPLETED,Ejaculation,Pfizer,2025-09-01T16:18:13.416122,True,,,,NOT_FOUND,"A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation",,['Ejaculation'],[],,2004-08,2005-06,[{'measure': 'Assessment of efficacy and safety'}],[{'measure': 'Assessment of quality of sexual life'}],2.0,18 Years,,MALE,False,INDUSTRY,0.0,460.0,,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT03311412,"Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas",Sym021,"['Anti-LAG-3', 'Sym022', 'Sym023', 'Anti-TIM-3', 'Sym021', 'Anti-PD-1']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Metastatic Cancer,Symphogen A/S,2025-09-01T16:18:22.198239,True,,,,NOT_FOUND,"A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas",,"['Metastatic Cancer', 'Solid Tumor', 'Lymphoma']","['Locally advanced/unresectable', 'Metastatic solid tumor', 'Lymphoma', 'Anti-PD-1', 'PD-1', 'PD1', 'Anti-LAG-3', 'LAG-3', 'LAG3', 'Anti-TIM-3', 'TIM-3', 'TIM3']",,2017-11-20,2022-03-23,"[{'measure': 'Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.', 'description': 'Assess the safety and tolerability of Sym021 monotherapy on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.', 'timeFrame': '12 months'}, {'measure': 'Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.', 'description': 'Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 or Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.', 'timeFrame': '12 months'}, {'measure': 'Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.', 'description': 'Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 and Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.', 'timeFrame': '12 months'}]","[{'measure': 'Evaluation of the immunogenicity of Sym021 as a single agent and in combination with Sym022 and Sym023.', 'description': 'Serum sampling to assess the potential for anti-drug antibody (ADA) formation.', 'timeFrame': '24 months'}, {'measure': 'Evaluation of objective response (OR) or stable disease (SD).', 'description': 'Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type.', 'timeFrame': '24 months'}, {'measure': 'Time to progression (TTP) of disease.', 'description': 'Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type.', 'timeFrame': '24 months'}, {'measure': 'Area under the concentration-time curve in a dosing interval (AUC)', 'description': 'Will be estimated using non-compartmental methods and actual timepoints.', 'timeFrame': '24 months'}, {'measure': 'Maximum concentration (Cmax)', 'description': 'Will be derived from observed data.', 'timeFrame': '24 months'}, {'measure': 'Time to reach maximum concentration (Tmax)', 'description': 'Will be derived from observed data.', 'timeFrame': '24 months'}, {'measure': 'Trough concentration (Ctrough)', 'description': 'Will be derived from observed data.', 'timeFrame': '24 months'}, {'measure': 'Terminal elimination half-life (T½)', 'description': 'Will be estimated using non-compartmental methods and actual timepoints.', 'timeFrame': '24 months'}, {'measure': 'Clearance (CL)', 'description': 'Will be estimated using non-compartmental methods and actual timepoints.', 'timeFrame': '24 months'}]",12.0,18 Years,,ALL,False,INDUSTRY,0.0,89.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00374218,Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference,High Fructose Corn Syrup,"['High Fructose Corn Syrup', 'Sucromalt']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Abdominal Obesity,University of Toronto,2025-09-01T16:18:23.454089,True,,,,NOT_FOUND,"Effect of Replacing HFCS With Sucromalt on Glucose Tolerance, Blood Lipids and Inflammatory Markers in Subjects With Raised Waist Circumference",,['Abdominal Obesity'],"['Carbohydrate', 'Glycemic index', 'Randomized', 'Double-blind', 'Glucose', 'Insulin', 'C-reactive protein']",,2006-09,2007-04,"[{'measure': 'Fasting and 2h glucose after 75g oral glucose tolerance test', 'timeFrame': '4 weeks'}]","[{'measure': 'Fasting and 2h insulin after 75g oral glucose', 'timeFrame': '4 weeks'}, {'measure': 'Gut hormone responses (eg. GLP-1) after 75g oral glucose', 'timeFrame': '4 weeks'}, {'measure': 'Postprandial glucose and insulin elicited by control and test foods/drinks', 'timeFrame': 'Baseline'}, {'measure': 'Fasting blood lipids (total, HDL and LDL cholesterol and triglycerides)', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Fasting C-reactive protein', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Fasting apolipoproteins A1 and B100', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Body weight', 'timeFrame': 'Weekly for 4 weeks'}, {'measure': 'Waist circumference', 'timeFrame': '4 weeks'}, {'measure': 'Blood pressure', 'timeFrame': '4 weeks'}, {'measure': 'Symptoms', 'timeFrame': '4 weeks'}]",11.0,20 Years,50 Years,ALL,True,OTHER,0.0,28.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03662620,Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers,Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg,"['Study drug', 'Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg', 'Comparator drug']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Hypertension,Yuhan Corporation,2025-09-01T16:18:23.457008,True,,,,NOT_FOUND,"A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers",,['Hypertension'],[],,2018-10-05,2018-12-22,"[{'measure': 'AUClast of Telmisartan/amlodipine/chlorthalidone', 'description': 'AUClast', 'timeFrame': '0-168 hrs'}, {'measure': 'Cmax of Telmisartan/amlodipine/chlorthalidone', 'description': 'Cmax', 'timeFrame': '0-168 hrs'}]","[{'measure': 'AUCinf of Telmisartan/amlodipine/chlorthalidone', 'description': 'AUCinf', 'timeFrame': '0-168 hrs'}, {'measure': 'Tmax of Telmisartan/amlodipine/chlorthalidone', 'description': 'Tmax', 'timeFrame': '0-168 hrs'}, {'measure': 't1/2 of Telmisartan/amlodipine/chlorthalidone', 'description': 't1/2', 'timeFrame': '0-168 hrs'}]",5.0,19 Years,55 Years,MALE,True,INDUSTRY,0.0,67.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00528268,Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy,Sodium phenylbutyrate,"['NaPB', 'Sodium phenylbutyrate']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Spinal Muscular Atrophy,University of Utah,2025-09-01T16:18:20.952933,True,,,,CHEMBL1746,Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy,,['Spinal Muscular Atrophy'],"['Spinal Muscular Atrophy', 'SMA', 'Sodium Phenylbutyrate']",,2007-07,2013-12,"[{'measure': 'Safety and Tolerability of Sodium Phenylbutyrate in Neonates and Infants With SMA', 'description': 'The number of participants able to achieve specific developmental milestones, such as sitting unsupported or walking independently, during the study period.', 'timeFrame': '24 months'}]",[],1.0,1 Day,6 Months,ALL,False,OTHER,1.0,22.0,ACTUAL,v2_robust,True,True,False,True,,O=C([O-])CCCc1ccccc1.[Na+],CHEMBL1746,exact_match,True,186.19,2.09,4.0
NCT06601335,A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC),AK117 in combination with AK112,"['Placebo in combination with Pembrolizumab', 'AK117 in combination with AK112']",2,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Head and Neck Squamous Cell Carcinoma,Akeso,2025-09-01T16:18:12.176023,True,,,,NOT_FOUND,"A Randomized, Controlled, Multicenter Phase 3 Study of AK112 in Combination With AK117 Versus Pembrolizumab as First Line Treatment for a Programmed Cell Death-ligand 1 (PD-L1) Positive Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)",,['Head and Neck Squamous Cell Carcinoma'],[],,2024-10-30,2027-10,"[{'measure': 'Overall Survival (OS)', 'description': 'OS is the time from randomization to death due to any cause.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Cmax', 'description': 'Maximum plasma concentration of AK112 and AK117 after administration.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Cmin', 'description': 'Minimum plasma concentration of AK112 and AK117 after administration.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Anti-drug antibodies (ADA)', 'description': 'Number of subjects with detectable ADA.', 'timeFrame': 'Up to approximately 2 years'}]",7.0,18 Years,75 Years,ALL,False,INDUSTRY,0.0,510.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT05020483,FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients,FEIBA,"['activated prothrombin complex concentrate (aPCC) FEIBA', 'FEIBA', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,WITHDRAWN,Cardiac Disease,Mayo Clinic,2025-09-01T16:18:10.910791,True,,,,NOT_FOUND,Activated Prothrombin Complex Concentrate FEIBA to Optimize Postcardiopulomonary Bypass Hemostasis in Pediatric Cardiac Patients,,['Cardiac Disease'],['Cardiac Surgery'],Patient population changed and no subjects eligible for the study.,2021-10,2023-12,"[{'measure': 'Number of units of allogeneic blood products required early perioperatively in pediatric cardiac patients.', 'description': 'Number of units of transfused allogeneic blood products after cardiopulmonary bypass in the operating room (OR) and in the intensive care unit (ICU) on postoperative day (POD) 0 and 1.', 'timeFrame': 'approximately 1 day postoperatively'}]","[{'measure': 'Hospital length of stay', 'description': 'Number of days admitted to the hospital', 'timeFrame': 'Through hospital discharge, approximately 3 days'}, {'measure': 'Mortality', 'description': 'Total number of subject deaths', 'timeFrame': 'Through hospital discharge, approximately 3 days'}, {'measure': 'Intravascular and intracardiac thromboses', 'description': 'Number of subjects to experience intravascular and/or intracardiac thromboses up to POD 3', 'timeFrame': 'approximately 3 days postoperatively'}]",4.0,,5 Years,ALL,False,OTHER,0.0,0.0,ACTUAL,v2_robust,True,False,True,False,Patient population changed and no subjects eligible for the study.,,,no_match,False,,,
NCT04952012,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,LT4,['LT4'],1,OBSERVATIONAL,[],,UNKNOWN,"Thyroiditis, Autoimmune","Second Affiliated Hospital, School of Medicine, Zhejiang University",2025-09-01T16:18:19.660037,True,,,,NOT_FOUND,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,,"['Thyroiditis, Autoimmune']",[],,2020-11-30,2022-11-30,"[{'measure': 'Incidence rate of pregnancy complications in women with or without thyroid antibodies', 'timeFrame': '1 year'}]",[],1.0,18 Years,45 Years,FEMALE,True,OTHER,3.0,4000.0,ESTIMATED,v2_robust,False,False,False,False,,,,no_match,False,,,
NCT00502073,Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005),cyclosporine,['cyclosporine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Dry Eye Syndromes,"Sirion Therapeutics, Inc.",2025-09-01T16:18:18.427012,True,,,,NOT_FOUND,,,['Dry Eye Syndromes'],[],,,,[],[],0.0,18 Years,,ALL,,INDUSTRY,0.0,,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03914404,Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy,γ-linoleic acid and placebo(Thioctic Acid),"['γ-linoleic acid and placebo(Thioctic Acid)', 'Thioctic Acid and placebo(γ-linoleic acid)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Diabetic Neuropathy,Chonbuk National University Hospital,2025-09-01T16:18:25.980958,True,,,,CHEMBL8659,"A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy",,['Diabetic Neuropathy'],[],,2016-01-26,2018-07-25,"[{'measure': 'Changes of Visual Analog Scale(VAS)', 'description': 'The Visual Analog Scale(VAS) score is 0 point for no symptom, 10 points for the most severe symptom, and the patient is asked to mark the degree of subjective pain symptoms as an integer.', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Total Symptom Score(TSS)', 'description': 'Total Symptom Score(TSS) classifies diabetic neuropathy symptoms into four categories (pain, burning pain, paresthesia, numbness). The frequency (Occasional, Frequent, Continuous) and symptom intensity (Absent, Slight, Moderate, Severe) are calculated through each question and the score is obtained according to the visual analog scale. It is calculated from 0 point up to 14.64 points.', 'timeFrame': '12 weeks'}]","[{'measure': 'Changes of Michigan Neuropathy Screening Instrument(MNSIQ)', 'description': ""A 15-item questionnaire (MNSIQ) is used to assess deformation, infection, skin thickening of the skin's stratum corneum, and ulcers.\n\nMNSIQ was designed to screen for diabetic neuropathy through questionnaires on 15 questions that are related to neuropathic symptoms (pain, temperature, and sensation). Two of 15 (number 4 and 10) are vascular symptoms and are excluded from the total score regardless of the results. If you answered 'No' to questions 7 and 13, you will get 1 point. In the end, scores ranging from 0 to 13 indicate that the higher the score, the more severe the neuropathic symptoms."", 'timeFrame': '12 weeks'}, {'measure': 'Changes of Michigan Neuropathy Screening Instrument(MNSIE)', 'description': ""A foot test (MNSIE) is used to assess deformation, infection, skin thickening of the skin's stratum corneum, and ulcers.\n\nMNSIE evaluates foot shape, foot ulceration, ankle reflex, sense of vibration of big toe, monofilament right and left. The score ranges from point 0 to 10, and when the score is above 2, it is diagnosed as neuropathy."", 'timeFrame': '12 weeks'}, {'measure': 'Changes of Current perception Threshold(CPT)', 'description': 'Sensory nerve conduction threshold (SNCT) is a unique method for evaluating all three sensory neurons (small unmyelinated fibers, small myelinated fibers, and large myelinated fibers) that make up more than 90% of sensory nerves. It seems to be possible to objectively evaluate sensory nerve of small fiber which recovered early in diabetic neuropathy(Using neurometer).', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Modified Brief Pain Inventory-diabetic polyneuropathy(Modified BPI-DPN)', 'description': 'Modified Brief Pain Inventory-diabetic polyneuropathy(Modified BPI-DPN) displays the pain area on the human figure, the number of pain sites, treatment of pain, and pain medication.\n\nPain severity refers to the pain sensation- identification aspect (pain threshold). The worst pain, the least pain, the pain average, and the pain now for the last 24 hours are displayed on the 10-point scale (0 points: none, \\~ 10 Point: too big to imagine). Pain interference is the emotional-synchronous aspect of pain (pain tolerance). It classifies general activity, mood, walking, working, relationship, sleep and enjoyment of life, and use the 10-point scale (0 points: none to 10 points: completely disturbed).', 'timeFrame': '12 weeks'}, {'measure': 'Changes of EuroQol-5 Dimensions(EQ 5D)', 'description': ""EQ-5D index = 1 - (0.050 + 0.096 M2 + 0.418 x M3 + 0.046 x SC2 + 0.13 x SC3 + 0.051 x UA2 + 0.028 x UA3 + 0.037 x PD2 + 0.151 x PD3 + 0.043 x AD2 + 0.158 x AD3 + 0.050 × N3) - 1 if the variable is applicable, 0 if not (M: mobility, SC: self-care, UA: usual activity,, PD: pain / discomfort, AD: anxiety / depression)\n\n\\* Variable definition\n\n* M2: 1 if mobility is 'level 2', 0 if not\n* M3: 1 if mobility is 'level 3', 0 if not\n* SC2: 1 if self-care is 'level 2', 0 if not\n* SC3: 1 if self-care is 'level 3', 0 if not\n* UA2: 1 if usual activity is 'level 2', 0 if not\n* UA3: 1 if usual activity is 'level 3', 0 if not\n* PD2: 1 if pain / discomfort is 'level 2', 0 if not\n* PD3: 1 if pain / discomfort is 'level 3', 0 if not\n* AD2: 1 if anxiety / depression is 'level 2', 0 if not\n* AD3: 1 if anxiety / depression is 'level 3', 0 if not\n* N3: 1 if there is at least one level 3, others are 0"", 'timeFrame': '12 weeks'}]",7.0,20 Years,75 Years,ALL,False,OTHER,0.0,100.0,ACTUAL,v2_robust,True,True,False,False,,CCCCCCCC/C=C\CCCCCCCC(=O)O,CHEMBL8659,partial_match,True,282.47,6.11,2.0
NCT00057707,Effects of Modafinil on Brain Function in Patients With Schizophrenia,Modafinil,['Modafinil'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Schizophrenia,National Institute of Mental Health (NIMH),2025-09-01T16:18:17.170925,True,,,,CHEMBL1373,"Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype",,"['Schizophrenia', 'Schizoaffective Disorder']","['Catecholamines', 'Dopamine', 'fMRI', 'Working Memory', 'Clinical Trial', 'Stabilization', 'Inpatients', 'Placebo', 'Modafinil', 'Normal Volunteers', 'Schizophrenia', 'Schizoaffective Disorder', 'Healthy Volunteer', 'HV']",,2003-03-26,2017-06-16,[{'measure': 'Genetic differences in working memory testing or fMRI activation'}],"[{'measure': 'Panss, Ham-A, Blood draws for drug levels and liver enzymes'}]",2.0,18 Years,50 Years,ALL,True,NIH,0.0,176.0,ACTUAL,v2_robust,True,True,False,False,,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,CHEMBL1373,exact_match,True,273.36,2.01,4.0
NCT07132645,An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer,Gallium Ga 68-DOTA-FAPI-04,"['Gallium Ga 68-DOTA-FAPI-04', '68Ga-DOTA-FAPI-04', 'GALLIUM GA-68-DOTA-FAPI-04', '68Ga-FAPi-04', 'Gallium-68-FAPi-04']",5,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,NOT_YET_RECRUITING,Neuroendocrine Tumor,University of Michigan Rogel Cancer Center,2025-09-01T16:18:13.421098,True,,,,NOT_FOUND,An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms,,['Neuroendocrine Tumor'],[],,2025-09-01,2027-09-01,"[{'measure': 'Biodistribution of Gallium Ga 68-DOTA-FAPI-04 ([68Ga]Ga-FAPI-04)', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of [68Ga] Ga-FAPI-04', 'description': 'We will monitor/measure the amount of Ga-FAPI-04 seen within different tissue in patients that have neuroendocrine tumors. We will specifically measure the ratio of uptake in the tumors in comparison to reference tissues such as liver or muscle.', 'timeFrame': 'Day 1'}]","[{'measure': 'Tissue concentrations of [68Ga] Ga-FAPI-04 retention in tumors', 'timeFrame': 'Day 1'}, {'measure': 'Standardized uptake values (SUV) of [68Ga] Ga-FAPI-04 retention in tumors', 'description': 'Will compare the difference in SUVmax uptake within each subject using a two-side, one-sample t-test.', 'timeFrame': 'Day 1'}, {'measure': 'Clinical diagnostic performance of [68Ga] Ga-FAPI-04', 'description': 'When a comparison Ga-DOTATATE scan is available, we will look at the uptake in the tumor in the SOC image related to reference tissue and then compare the FAPI-04 uptake.', 'timeFrame': 'Day 1'}]",5.0,18 Years,,ALL,False,OTHER,1.0,30.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT01237678,A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer,IMGN901,"['BB-10901, Lorvotuzumab mertansine', 'IMGN901', 'Toposar®, VePesid®, Etopophos®', 'Carboplatin and Etoposide']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Small Cell Lung Cancer,"ImmunoGen, Inc.",2025-09-01T16:18:25.987005,True,,,,NOT_FOUND,A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer,,['Small Cell Lung Cancer'],"['Immunogen', 'Lung', 'Small Cell Lung Cancer', 'Carboplatin', 'ADC']",Study was stopped early due to lack of efficacy signal and safety concerns,2010-11,2015-05,"[{'measure': 'Occurrence of Dose Limiting Toxicities (DLT)', 'description': 'The primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) and characterize the dose limiting toxicities (DLT) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. For the purposes of dose escalation and determination of MTD, DLTs were defined as AEs or abnormal laboratory values related to study treatment which occurred in Cycle 1 of the Dose Escalation phase, including any AEs that resulted in failure to meet the criteria for re-treatment. The following events were considered DLTs (using the most current version of CTCAE): febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding; ≥ Grade 3 peripheral neuropathy; ≥ Grade 3 vomiting, nausea, or diarrhea that persisted despite the use of optimal therapy; other ≥ grade 3 non-hematologic toxicity (with the exception of brief fatigue i.e. ≤ 72 hours and alopecia)', 'timeFrame': '21 days (Cycle 1)'}, {'measure': 'Progression Free Survival (PFS) in Phase II', 'description': 'The primary outcome measure for Phase II was to determine the efficacy of IMGN901 in combination with carboplatin/etoposide chemotherapy as first-line treatment for patients with extensive stage small cell lung cancer. PFS was defined as the time from enrollment until objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. Only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented as the primary objective of this phase of the study was to compare PFS in the experimental arm (triplet combination) against historical PFS rates for carboplatin and etoposide. The control arm was planned primarily to reliably assess the safety of IMGN901 and to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed.', 'timeFrame': 'From randomization to objective tumor progression or death (up to post-treatment follow-up 28 days after last dose, up to 22 months)'}, {'measure': 'Maximum Tolerated Dose (MTD) of IMGN901', 'description': 'A primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. The MTD was determined based on DLTs that occurred during Cycle 1.', 'timeFrame': '21 days (Cycle 1)'}]","[{'measure': 'Overview of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'To assess the type and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs). An AE was defined as any noxious, pathologic, or unintended change un anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of the study, whether or not deemed study drug-related. An SAE was any AE resulting in death, life-threatening experience, initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, or congenital defect. All AEs were reported from the time of the first dose of study treatment until 28 days after the final dose of study drug. the severity of AEs were graded by the Investigator using National cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) version 4.0.', 'timeFrame': 'From the first dose of study drug on Cycle 1, Day 1 until 28 days after the last study treatment (up to 22 months)'}, {'measure': 'Progression Free Survival (PFS) Rate at 6 Months', 'description': 'The trial was not empowered to permit a statistically informative comparison of the randomized treatment groups with respect to PFS. The activity of IMGN901 was assessed by comparing the PFS rate at 6 months in the IMGN901 experimental arm against the historical 6-month PFS rate of 0.44 (equivalently a median PFS = 5 months). Only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented as the objective was to compare PFS at 6 months in the experimental arm (triplet combination) against the historical PFS rate of 0.44 (equivalently a median PFS = 5 months) for carboplatin and etoposide. The control arm was planned primarily to reliably assess the safety of IMGN901 and to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed.', 'timeFrame': '6 months'}, {'measure': 'Median Overall Survival (OS) in Phase II', 'description': 'A secondary outcome measure for Phase II was to determine the overall survival of patients treated with IMGN901 in combination with carboplatin/etoposide chemotherapy versus carboplatin/etoposide chemotherapy alone as first-line treatment for patients with extensive stage small cell lung cancer.', 'timeFrame': 'From the time of enrollment until death on study due to any cause (up to post-treatment follow-up 28 days after last dose, up to 22 months)'}, {'measure': 'Overall Survival (OS) Rate at 12 Months', 'description': 'OS was analyzed based on a binary definition of the number of patients dead or censored prior to 12 months and the number of patients alive at 12 months. The primary objective of this phase of the study was to compare PFS in the experimental arm (triplet combination) against historical PFS rates. The control arm was primarily planned to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed. Further, the trial was not empowered to permit a statistically informative comparison of the randomized treatment groups with respect to OS and no determination of the OS rate at 12 months for the control arm was performed; therefore only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented.', 'timeFrame': '12 months'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,181.0,ACTUAL,v2_robust,True,False,True,True,Study was stopped early due to lack of efficacy signal and safety concerns,,,no_match,False,,,
NCT04825197,Late Surfactant After a Recruitment Maneuver in Extremely Low Gestational Age Newborns - LATE-REC-SURF Trial,Poractant Alfa Intratracheal Suspension [Curosurf],"['Poractant Alfa Intratracheal Suspension [Curosurf]', 'Surfactant endotracheal administration following a recruitment HFOV manoeuvre']",2,INTERVENTIONAL,['PHASE2'],PHASE2,UNKNOWN,Bronchopulmonary Dysplasia,VENTO GIOVANNI,2025-09-01T16:18:23.455127,True,,,,NOT_FOUND,Effects of Late Surfactant Treatment Delivered After a Recruitment Maneuver on Respiratory Outcomes in Extremely Low Gestational Age Newborns: a Randomized Controlled Trial - LATE-REC-SURF Trial,,"['Bronchopulmonary Dysplasia', 'Chronic Pulmonary Insufficiency of Prematurity']","['surfactant', 'preterm', 'recruitment', 'bronchopulmonary dysplasia', 'hfov']",,2021-12-01,2025-02-01,"[{'measure': 'First successful extubation', 'description': 'The time to first successful extubation ( expressed as day of life).', 'timeFrame': 'From date of randomization until the date of first documented progression, assessed up to 40 weeks of post menstrual age'}]","[{'measure': 'Rate of Bronchopulmonary dysplasia', 'description': 'Oxygen-dependance at 36 weeks of post-menstrual age', 'timeFrame': 'At 36 weeks of post-menstrual age'}, {'measure': 'Rate of Interstitial emphysema', 'description': 'Xray-documented', 'timeFrame': 'In the 21 days following experimental treatment'}, {'measure': 'Rate of Pneumothorax', 'description': 'Ultrasound or Xray-documented', 'timeFrame': 'In the 21 days following experimental treatment'}, {'measure': 'Rate of Pulmonary haemorrhage', 'description': 'Clinically diagnosed', 'timeFrame': 'In the 21 days following experimental treatment'}, {'measure': 'Rate of Necrotising enterocolitis', 'description': ""Bell's Criteria"", 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Rate of intraventricular haemorrhage', 'description': ""Ultrasound documented intraventricular haemorrhage of any grade (Volpe's classification)"", 'timeFrame': 'From date of randomization - up to 40 weeks post-mestrual age'}, {'measure': 'Rate of Periventricular leukomalacia', 'description': ""Ultrasound documented periventricular leukomalacia (DeVries's classification)"", 'timeFrame': 'From date of randomization up to 40 weeks post-mestrual age'}, {'measure': 'Length of hospital stay', 'description': 'Number of days of hospital stay', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Length of invasive mechanical ventilation', 'description': 'Number of days of invasive mechanical ventilation', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Length of oxygen-therapy', 'description': 'Number of days of oxygen-therapy', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Length of respiratory support', 'description': 'Number of days of respiratory support', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Use of postnatal steroids', 'description': 'Use of postnatal steroids to prevent or treat bronchopulmonary dysplasia', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Rehospitalisation for respiratory problems in the first year of life', 'description': 'Number of rehospitalisation for respiratory problems in the first year of life', 'timeFrame': 'One year of life'}]",14.0,7 Days,10 Days,ALL,False,OTHER,0.0,20.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT02203578,Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease,romidepsin,"['romidepsin', 'Istodax', 'FR901228', 'FK228']",4,INTERVENTIONAL,['NA'],,TERMINATED,Graft Versus Host Disease,"Rutgers, The State University of New Jersey",2025-09-01T16:18:14.668607,True,,,,NOT_FOUND,A Pilot Study of Romidepsin for Therapy of Graft-versus-Host Disease,,['Graft Versus Host Disease'],[],slow accrual,2014-11,2016-06-14,"[{'measure': 'Incidence of aGVHD', 'timeFrame': 'At 28 days after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 1 month after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 3 months after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 6 months after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 9 months after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 12 months after initiation of romidepsin'}]","[{'measure': 'Total Duration of Immunosuppressive Therapy', 'timeFrame': 'Up to 12 months after initiation of romidepsin'}, {'measure': 'Rate of Documented Infection', 'timeFrame': 'Up to 12 months after initiation of romidepsin'}, {'measure': 'T Cell Kinetics - Reconstitution', 'timeFrame': 'Up to 12 months after initiation of romidepsin'}]",9.0,18 Years,,ALL,False,OTHER,2.0,1.0,ACTUAL,v2_robust,True,False,True,False,slow accrual,,,no_match,False,,,
NCT05159700,"A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors",PRJ1-3024,['PRJ1-3024'],1,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Advanced Solid Tumor,"Zhuhai Yufan Biotechnologies Co., Ltd",2025-09-01T16:18:10.923281,True,,,,NOT_FOUND,"A Phase I, First-In-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors",,"['Advanced Solid Tumor', 'Advanced Solid Malignancies']","['First in human', 'Maximum tolerated dose', 'Recommended Phase 2 dose', 'Dose Escalation', 'Hematopoietic progenitor kinase 1', 'PRJ1-3024']",,2022-03-31,2024-10-12,"[{'measure': 'Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period', 'description': 'Safety listings and pharmacokinetic listings will be used for evaluation', 'timeFrame': 'Day 1 to Day 21'}]","[{'measure': 'Incidence of adverse events (AEs)', 'description': 'Characterized by type, seriousness, relationship to study treatment, timing, and severity.', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetic parameter： Accumulation ratio', 'description': 'to estimate the accumulation of PRJ1-3024 from time 0 to the time of last quantifiable concentration after multiple administration', 'timeFrame': '24 months'}, {'measure': 'Objective response rate (ORR)', 'description': 'estimated by the proportion of subjects having a complete response (CR) or partial response (PR) with use of RECIST v1.1 criteria.', 'timeFrame': '24 months'}, {'measure': 'Duration of response (DOR)', 'description': 'defined as time from the first occurrence of a documented objective response to the time of relapse or death from any cause.', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetic parameter：AUC（0-last）', 'description': 'Area under the concentration-time curve AUC from time 0 to the time of the last quantifiable concentration', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetic parameter：Maximum observed concentration (Cmax)', 'description': 'assessed as time from time 0 to the time of the last quantifiable concentration', 'timeFrame': '24 months'}]",7.0,18 Years,,ALL,False,INDUSTRY,0.0,39.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00541073,"Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery",cisplatin,"['cisplatin', 'pemetrexed disodium']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Malignant Mesothelioma,Centre Oscar Lambret,2025-09-01T16:18:07.028538,True,,,,NOT_FOUND,Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma,,['Malignant Mesothelioma'],"['advanced malignant mesothelioma', 'recurrent malignant mesothelioma']",,2007-06,,[{'measure': 'Individual dosage-adapted protocol'}],"[{'measure': 'Relationship between pharmacokinetic and pharmacodynamic parameters'}, {'measure': 'Pharmacokinetics'}, {'measure': 'Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)'}]",4.0,18 Years,,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT05083208,PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma,Parsaclisib,"['PI3K inhibitor', 'Parsaclisib', 'IBI376', 'Chidamide']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,TERMINATED,Peripheral T-Cell Lymphoma,Henan Cancer Hospital,2025-09-01T16:18:12.177140,True,,,,NOT_FOUND,"A Single Arm, Multi-center, Phase Ib/II Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma",,['Peripheral T-Cell Lymphoma'],"['Relapsed/Refractory Peripheral T-cell Lymphoma', 'PI3Kδ inhibitor', 'Chidamide']",The clinical development of parsaclisib was stopped by it's manufacturer.,2022-02-20,2025-02-08,"[{'measure': 'objective response rate', 'description': 'the total proportion of patients with complete response (CR) and partial response (PR)', 'timeFrame': ""every 8 or 12 weeks from the day of the first cycle to 2 years after the last patient's enrollment (each cycle is 28 days).""}]","[{'measure': '2-year progression-free survival', 'description': 'the total proportion of patients with no progression from date of the first day of treatment to the date of confirmed progressive disease or death which one occurs first', 'timeFrame': ""from the day of the first cycle of treatment to the date of confirmed progressive disease or death, whichever occurs first, up to 2 years after last patient's enrollment (each cycle is 28 days).""}, {'measure': '2-year overall survival', 'description': 'from date of first day of treatment to the date of death by any cause', 'timeFrame': ""from date of the first cycle of treatment to the date of death from any cause, assessed up to 2 years after last patient's enrollment (each cycle is 28 days).""}, {'measure': 'incidence and relationship with study drugs of grade 3-4 adverse events', 'description': 'the incidence and relationship with study drugs of grade 3 or 4 adverse events (based on NCI CTC-AE v4.03', 'timeFrame': ""from the date of the first cycle of treatment to 2 years after last patient's enrollment (each cycle is 28 days).""}]",4.0,18 Years,75 Years,ALL,False,OTHER_GOV,0.0,12.0,ACTUAL,v2_robust,True,False,True,True,The clinical development of parsaclisib was stopped by it's manufacturer.,,,no_match,False,,,
NCT05130567,A Study of LP-128 Capsules in Healthy Subjects,LP-128 capsules,"['LP-128 capsules', 'NWP-1080']",2,INTERVENTIONAL,['PHASE1'],PHASE1,ACTIVE_NOT_RECRUITING,Chronic Hepatitis b,Guangzhou Lupeng Pharmaceutical Company LTD.,2025-09-01T16:18:19.662003,True,,,,NOT_FOUND,"A Randomized Study of LP-128 Capsules vs. Placebo to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects",,['Chronic Hepatitis b'],[],,2021-11-19,2026-12-30,"[{'measure': 'Area under the plasma concentration-time curve (AUC) of LP-128', 'description': 'Plasma samples were collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively'}, {'measure': 'Apparent terminal phase half-life (T1/2) of LP-128', 'description': 'Plasma samples were collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively'}, {'measure': 'Maximum observed plasma concentration (Cmax) of LP-128', 'description': 'Plasma samples were collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 and 17 days in Single-dose group and Multi-dose group, respectively'}, {'measure': 'Adverse events of LP-128', 'description': 'The incidence and severity of adverse events as assessed by NCI CTCAE v5.0.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Excretion of LP-128 in urine', 'description': 'Urine samples will be collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 days'}, {'measure': 'Excretion of LP-128 in feces', 'description': 'feces samples will be collected at different points for pharmacokinetic analysis', 'timeFrame': 'Up to 4 days'}]",6.0,18 Years,55 Years,ALL,True,INDUSTRY,0.0,104.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06430112,Liposomal Bupivacaine vs Ropivacaine for TAPBs,Liposomal Bupivacaine,"['Liposomal Bupivacaine', 'Bupivacaine liposome', 'Ropivacaine', 'Ropivacaine Hydrochloride Injection']",4,INTERVENTIONAL,['PHASE3'],PHASE3,RECRUITING,Abdominal Tumor,Sun Yat-sen University,2025-09-01T16:18:13.424357,True,,,,NOT_FOUND,Liposomal Bupivacaine vs Ropivacaine for Ultrasound-guided Transversus Abdominis Plane Blocks in Laparoscopic Lower Abdominal Tumor Resection: A Prospective Randomized Trial,,"['Abdominal Tumor', 'Postoperative Analgesia', 'Liposomal Bupivacaine', 'Ropivacaine']","['liposomal bupivacaine', 'ropivacaine', 'transversus abdominis plane block', 'laparoscopic lower abdominal tumor resection', 'opioid consumption']",,2023-11-01,2024-06,"[{'measure': 'Postoperative opioid use', 'description': 'The amount of drug used in the postoperative analgesia pump', 'timeFrame': '3 days postoperatively'}]","[{'measure': 'Postoperative pain score', 'description': 'Postoperative VAS score', 'timeFrame': '3 days postoperatively'}, {'measure': 'Postoperative adverse reactions', 'description': 'Postoperative adverse reactions were followed up', 'timeFrame': '3 days postoperatively'}]",3.0,18 Years,70 Years,ALL,False,OTHER,0.0,74.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01619332,"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763",Placebo,"['Sitagliptin', 'LEZ763', 'Placebo']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Type II Diabetes,Novartis Pharmaceuticals,2025-09-01T16:18:14.659115,True,,,,NOT_FOUND,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes",,['Type II Diabetes'],"['Healthy volunteers,', 'Diabetes', 'Glucose', 'Pharmacokinetics']",,2012-03,2013-09,"[{'measure': 'Number of Patients with adverse events, serious adverse events and death', 'description': 'An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations.', 'timeFrame': 'Day 28'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10'}, {'measure': 'Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10'}, {'measure': 'Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28'}, {'measure': 'Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28'}, {'measure': 'Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28'}, {'measure': 'Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test', 'timeFrame': '4 hour post-dose Day 27'}]","[{'measure': 'Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours)', 'description': 'GLP-1 Biomarker measures will be evaluated at pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose', 'timeFrame': 'Pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day -1, Day 1, Day 27, and Day 28'}, {'measure': '2-hour value of post-prandial glucose', 'timeFrame': 'Day 1 of Part I, Day 1 and day 10 of Part II'}, {'measure': 'Change from baseline in Fasting C-peptide at Day 27 (Part III)', 'timeFrame': 'Baseline, Day 27'}, {'measure': 'Change from baseline in Fasting Insulin at Day 27 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change from baseline in fasting plasma glucose at Day 27 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change From Baseline in peak glucose level following meal Test at Day 27 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Peak effect (Emax) on postprandial GLP-1 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change from baseline in Peptide YY (PYY) (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change from baseine in Gastric inhibit polypeptide (GIP) (Part III)', 'timeFrame': 'Baseline , Day 27'}]",27.0,18 Years,65 Years,ALL,True,INDUSTRY,0.0,220.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02323191,A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors,Atezolizumab,"['Emactuzumab', 'Atezolizumab', 'MPDL3280A, TECENTRIQ', 'RO5509554']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Solid Cancers,Hoffmann-La Roche,2025-09-01T16:18:12.179495,True,,,,NOT_FOUND,"Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors",,['Solid Cancers'],[],,2015-01-19,2020-08-21,"[{'measure': 'Percentage of Participants With Dose Limiting Toxicities (DLTs)', 'timeFrame': '21 days'}, {'measure': 'Maximum Tolerated Dose (MTD) of Emactuzumab', 'timeFrame': '21 days'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'timeFrame': 'Baseline up to 3 years'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of Emactuzumab', 'description': 'predose (-4 hours \\[h\\]) and 0.5h post end of infusion (90 minutes infusion) on Days (D) 1 of Cycle (C) 1, 2, 3, 4, 5, 6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Atezolizumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, then every 8 cycles (Cycle Length=21 days); 0.5h post end of infusion (60 minutes infusion) on D1 of C1; 120 days post last infusion (up to approximately 3 years)'}, {'measure': 'Minimum Observed Plasma Trough Concentration (Cmin) of Emactuzumab', 'timeFrame': 'predose (-4 h) on D1 of C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years)'}, {'measure': 'Minimum Observed Plasma Trough Concentration (Cmin) of Atezolizumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, then every 8 cycles (Cycle Length=21 days)'}, {'measure': 'Area under the Concentration-Time Curve (AUC) of Emactuzumab', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Total Clearance (CL) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Volume of Distribution at Steady State (Vss) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Accumulation Ratio (Rac) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Terminal Elimination Half-life (t1/2) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Emactuzumab Concentration at the time of Tumor Progression (Cprog)', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Emactuzumab Concentration at the Time of Tumor Response (Complete Response/Partial Response)', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Emactuzumab Concentration at the Time of Infusion-related Reaction (IRR) or Hypersensitivity Reaction', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Change From Baseline in Tumor-Associated Macrophages (TAMs) Levels in Paired-Tumor Biopsies at Specified Timepoints', 'timeFrame': 'Baseline (predose [-4 h] on D1 of C2; Cycle Length=21 days), at disease progression (up to approximately 3 years)'}, {'measure': 'Change From Baseline in Dermal Macrophages Levels in Paired Skin Biopsies at Specified Timepoints', 'timeFrame': 'Baseline, D15 of C1 (Cycle Length=21 days)'}, {'measure': 'Change From Baseline in Circulating Cluster of Differentiation (CD) 14DimCD16high Monocytes Levels in Peripheral Blood at Specified Timepoints', 'description': 'Baseline (predose \\[-4 h\\] on D1 of C1), predose \\[-4 h\\] on D1 of C2, C3, C5, then every other cycle (Cycle Length=21 days) until disease progression (up to approximately 3 years); postdose on D2, D8, D15 of C1, C2; D4 or D5 of C1; 44 days post last infusion (up to approximately 3 years)', 'timeFrame': 'Baseline up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Percentage of Participants With Anti-therapeutic Antibodies to Emactuzumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years), 44 and 120 days post last infusion, 28 day follow-up visit (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Anti-therapeutic Antibodies to Atezolizumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, then every 8 cycles (Cycle Length=21 days; up to approximately 3 years), 120 days post last infusion (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Best Overall Response as Determined Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Best Overall Response as Determined Using Modified RECIST', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Objective Response as Determined Using RECIST v1.1', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Objective Response as Determined Using Modified RECIST', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}]",24.0,18 Years,,ALL,False,INDUSTRY,0.0,221.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT02283788,Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization,BIA 2-093,"['ESL, Eslicarbazepine acetate', 'BIA 2-093', 'Moxifloxacin', 'avalox', 'Placebo', 'PLC']",6,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Epilepsy,Bial - Portela C S.A.,2025-09-01T16:18:07.025875,True,,,,NOT_FOUND,"A Randomized, Double-blind, Placebo-controlled and Open Label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization in Healthy Adult Men and Women",,['Epilepsy'],[],,2007-03,2007-06,"[{'measure': 'QTcI - QT Interval Individually Corrected for Heart Rate - Day 5', 'timeFrame': '-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose'}]","[{'measure': ""QTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula"", 'timeFrame': '-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose'}, {'measure': ""QTcF - QT Interval Corrected Using Fridericia's Formula"", 'timeFrame': '-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose'}]",3.0,18 Years,45 Years,ALL,True,INDUSTRY,0.0,67.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06785662,Budesonide Irrigation in Allergic Rhinitis,The budesonide nasal irrigation,"['The budesonide nasal irrigation', 'The budesonide nasal spray']",2,INTERVENTIONAL,['PHASE4'],PHASE4,NOT_YET_RECRUITING,Allergic Rhinitis,Siriraj Hospital,2025-09-01T16:18:23.459979,True,,,,CHEMBL1370,"The Efficacy of Budesonide Nasal Irrigation in Allergic Rhinitis Patients: A Randomized, Controlled Trial.",,['Allergic Rhinitis'],"['intranasal corticosteroid', 'budesonide nasal irrigation', 'Budesonide nasal spray', 'Allergic rhinitis']",,2025-02-12,2026-06-01,"[{'measure': 'Total Nasal Symptom Score (TNSS)', 'description': 'Full Name: Total Nasal Symptom Score Scale Range: 0 to 12 Scoring Interpretation: Higher scores indicate a worse outcome\n\nEach symptom is rated by the participant on a scale (0 to 3), based on severity:\n\n0: No symptoms\n\n1. Mild symptoms (present but not bothersome)\n2. Moderate symptoms (noticeable and somewhat bothersome)\n3. Severe symptoms (very bothersome and interfering with daily activities)', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}]","[{'measure': 'Postnasal Drip Symptom Score (PND)', 'description': 'Postnasal Drip Symptom Score (PND) determines the severity of post nasal drip sensation\n\nFull Name: Postnasal Drip Symptom Score Scale Range: 0 to 3 Scoring Interpretation: Higher scores indicate a worse outcome. The PND focuses specifically on the severity of postnasal drip symptoms, with scores representing none (0), mild (1), moderate (2), or severe (3) symptoms.', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}, {'measure': 'Rhinoconjunctivitis Quality of Life Questionnaire (RCQ-36)', 'description': 'Rhinoconjunctivitis Quality of Life Questionnaire (RCQ-36) determine disease-specific quality of life\n\nFull Name: Rhinoconjunctivitis Quality of Life Questionnaire - 36 Items Scale Range: 0 to 6 for each item, summing up to a total score. Scoring Interpretation: Higher scores indicate a worse outcome. This questionnaire assesses the impact of rhinoconjunctivitis symptoms on quality of life, covering domains such as sleep, activities, emotional well-being, and social functioning.', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}, {'measure': 'Peak Nasal Inspiratory Flow (PNIF)', 'description': 'Peak Nasal Inspiratory Flow (PNIF) is an objective measurement to determine nasal patency\n\nFull Name: Peak Nasal Inspiratory Flow Scale Range: Measured in liters per minute (L/min); there is no fixed maximum value, as it depends on individual physiology.\n\nScoring Interpretation: Higher values indicate a better outcome. PNIF measures the maximum airflow through the nasal passages during inspiration and is used as an objective measure of nasal patency (openness).', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}, {'measure': 'Adverse events', 'description': 'All adverse events occurred during the usage of budesonide nasal irrigation were reported.', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}]",5.0,18 Years,60 Years,ALL,False,OTHER,0.0,78.0,ESTIMATED,v2_robust,True,False,False,True,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,CHEMBL1370,partial_match,True,430.54,2.72,4.0
NCT00042575,"Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",Duloxetine,['Duloxetine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Major Depressive Disorder,Eli Lilly and Company,2025-09-01T16:18:13.423155,True,,,,NOT_FOUND,"Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",,['Major Depressive Disorder'],"['Sad, blue, lack of energy, depressed, hopelessness, guilt']",,2002-06,2002-08,[],[],0.0,18 Years,,ALL,True,INDUSTRY,0.0,120.0,,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03498391,A Study of Human Multi-Sensory Integration,Propofol,"['Propofol', 'Ketalar', 'Ketamine Injectable Product', 'Diprivan']",4,INTERVENTIONAL,['PHASE2'],PHASE2,SUSPENDED,Anesthesia Awareness,University of Pennsylvania,2025-09-01T16:18:09.634020,True,,,,NOT_FOUND,A Study of Human Multi-Sensory Integration: A Neurophysiologic Correlate of Conscious Perception,,['Anesthesia Awareness'],[],Due to the impact of COVID-19,2018-07-30,2023-05,"[{'measure': 'Multi-sensory Evoked Responses Measured using Electroencephalography', 'description': 'The primary study endpoint is multi-sensory evoked responses measured using EEG in units of millivolts squared per hertz at Richmond Agitation and Sedation Scale scores of 0, -1, -2, -3 and -4. Multisensory evoked responses will be compared to those evoked by each uni-sensory modality (auditory and visual) individually. Evoked responses will be assessed in the frequency domain using spectral analysis techniques which quantify power of each neuronal oscillation (e.g. alpha, delta, theta and gamma) in terms of mV\\^2/Hz. Analysis will be performed separately during the period before drug administration and at different levels of sedation quantified with RASS scores. The investigators will test the hypothesis that with increasing doses of intravenous anesthetics, audiovisual (multisensory) responses will approximate algebraic sum of neuronal responses elicited by visual and auditory stimuli presented separately.', 'timeFrame': '2-6 hours per subject'}]","[{'measure': 'Single Modality Evoked Potentials', 'description': 'The secondary endpoint is to use EEG recordings to demonstrate changes in the characteristics of evoked potentials under anesthesia using single sensory modality (visual, auditory) and across sensory modalities. Conventional evoked potentials will be computed as average waveforms aligned with respect to stimulus onset on a channel-by-channel basis.', 'timeFrame': '2-6 hours per subject'}]",2.0,18 Years,65 Years,ALL,True,OTHER,0.0,40.0,ESTIMATED,v2_robust,True,False,True,False,Due to the impact of COVID-19,,,no_match,False,,,
NCT01840592,Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,Sorafenib,"['Sorafenib', 'Doxorubicin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,ACTIVE_NOT_RECRUITING,Hepatocellular Carcinoma,Memorial Sloan Kettering Cancer Center,2025-09-01T16:18:19.663800,True,,,,CHEMBL1336,Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,,['Hepatocellular Carcinoma'],"['Liver', 'Sorafenib', 'Doxorubicin', '12-259']",,2013-04,2026-04,"[{'measure': 'overall survival', 'timeFrame': '6 months'}]","[{'measure': 'median time to progression', 'timeFrame': '2 years'}, {'measure': 'median progression free survival', 'timeFrame': '2 years'}, {'measure': 'median overall survival', 'timeFrame': '2 years'}, {'measure': 'toxicity', 'description': 'Toxicity rate will be reported by type and severity according to the NCI common toxicity criteria version 4 and descriptive statistics will be provided.', 'timeFrame': '2 years'}]",5.0,18 Years,,ALL,False,OTHER,2.0,30.0,ACTUAL,v2_robust,True,False,False,False,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,CHEMBL1336,exact_match,True,464.83,5.55,4.0
NCT06751277,QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer,"QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706","[""QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706""]",1,INTERVENTIONAL,['PHASE2'],PHASE2,NOT_YET_RECRUITING,Recurrent or Metastatic Endometrial Cancer,xiang yang,2025-09-01T16:18:13.422656,True,,,,NOT_FOUND,"A Single-arm, Open-label, Multi-center Clinical Trial of Iparomlimab and Tuvonralimab (QL1706, Anti-PD-1 /CTLA-4 Combination Antibody) Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer",,['Recurrent or Metastatic Endometrial Cancer'],"['immunotherapy', 'anti-PD-1 antibody', 'anti-CTLA-4 antibody.', 'endometrial cancer']",,2025-02-01,2027-07-30,"[{'measure': 'ORR', 'description': 'The best overall response (BOR) was defined as the proportion of subjects who achieved a confirmed CR or PR (according to RECIST v1.1).', 'timeFrame': 'up to 5 months'}]","[{'measure': 'PFS', 'description': 'It was defined as the time from the first use of a study drug to documentation of disease progression (according to RECIST v1.1) or death from any cause, whichever occurred first. Subjects who were alive without disease progression at the time of data cutoff for analysis were censored at the last tumor assessment. Subjects who did not undergo postbaseline assessments were censored at the date of the first dose.', 'timeFrame': 'up to 13months'}, {'measure': 'DoR', 'description': 'It was defined as the time from the first documentation of an objective response (CR or PR) to the first documentation of objective disease progression (according to RECIST v1.1 criteria) or death from any cause, whichever occurred first. Subjects who were alive without disease progression at the time of data cutoff for analysis were censored at the date of the last tumor measurement. DoR was evaluated only in subjects who achieved CR or PR in response.', 'timeFrame': 'up to 5 months'}, {'measure': 'OS', 'description': 'time from first use of a study drug until death from any cause. For those subjects who were alive at the time of data cutoff, censoring will be performed at the last known date of survival. Subjects who did not provide any follow-up information were censored at the date of enrollment.', 'timeFrame': 'up to 45 months'}]",4.0,18 Years,75 Years,FEMALE,False,OTHER,1.0,26.0,ESTIMATED,v2_robust,True,False,False,False,,,,no_match,False,,,
NCT00740961,Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer,systemic chemotherapy,['systemic chemotherapy'],1,OBSERVATIONAL,[],,TERMINATED,Breast Cancer,Case Comprehensive Cancer Center,2025-09-01T16:18:20.963518,True,,,,NOT_FOUND,The Vulnerable Elders Survey Study of Older Cancer Patients,,"['Breast Cancer', 'Cognitive/Functional Effects', 'Colorectal Cancer', 'Psychosocial Effects of Cancer and Its Treatment']","['psychosocial effects of cancer and its treatment', 'cognitive/functional effects', 'breast cancer', 'colon cancer']",low accrual,2008-03,2011-09,"[{'measure': 'Number of impaired domains on Comprehensive Geriatric Assessment (CGA)', 'timeFrame': 'at baseline and 12 months later.'}, {'measure': 'Chemotherapy adherence as measured by dose reduction, dose delay, and grade 3-5 toxicities', 'timeFrame': 'Patients are followed for 1 year for chemotherapy adherence and survival.'}, {'measure': 'Vulnerable Elders Survey scores', 'timeFrame': 'at baseline and 12 months later.'}, {'measure': 'Functional decline', 'timeFrame': 'at baseline and 12 months later.'}, {'measure': 'Time to death', 'timeFrame': 'Patients are followed for 1 year for chemotherapy adherence and survival.'}]","[{'measure': 'Scores of individual battery of tools included in the CGA', 'timeFrame': 'at baseline and 12 months later'}]",6.0,65 Years,,ALL,False,OTHER,0.0,63.0,ACTUAL,v2_robust,False,False,True,False,low accrual,,,no_match,False,,,
NCT01251354,Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy,BN83495,['BN83495'],1,INTERVENTIONAL,['PHASE2'],PHASE2,TERMINATED,Endometrial Cancer,Ipsen,2025-09-01T16:18:13.416616,True,,,,NOT_FOUND,"A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.",,['Endometrial Cancer'],[],The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.,2010-11,2011-07,"[{'measure': 'Determination of Clinical Benefit (CB), Defined as Sum of Patients Who Present Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ≥12 Weeks (CB=CR+PR+SD≥12 Weeks) Using Response Evaluation Criteria in Solid Tumors (RECIST Version1.1)', 'description': 'CR defined as: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.\n\nPR defined as: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.\n\nSD defined as: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study.\n\nPD defined as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).', 'timeFrame': '12 weeks'}]","[{'measure': 'Number of Participants With Adverse Events', 'timeFrame': 'Up to 28 days after last dose'}, {'measure': 'Determination of Time to Progression (TTP) in This Patient Population', 'description': 'Time to Progression (TTP): Time from first study treatment to first documentation of objective tumour progression.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Progression Free Survival (PFS) in This Patient Population', 'description': 'Progression Free Survival (PFS): Time from first study treatment until objective tumour progression or death from any cause.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Overall Response Rate (ORR) in This Patient Population', 'description': 'Overall Response Rate (ORR): Defined as the sum of CR and PR.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Duration of Response in This Patient Population', 'description': 'Duration of Response (DR): Time from the first documentation of objective tumour response (defined as CR or PR) to the first documentation of objective tumour progression or death on study due to any cause.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Overall Survival in This Patient Population', 'description': 'Overall Survival (OS): Defined as the time from first study treatment to death due to any cause.', 'timeFrame': '2 years after the last patient enrolled'}]",7.0,18 Years,,FEMALE,False,INDUSTRY,0.0,6.0,ACTUAL,v2_robust,True,False,True,True,The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.,,,no_match,False,,,
NCT02397603,Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy,dexmedetomidine bupivacaine,"['dexmedetomidine bupivacaine', 'Bupivacaine saline']",2,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Acute Post-thoracotomy Pain,Cairo University,2025-09-01T16:18:13.411610,True,,,,CHEMBL77921,Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Paravertebral Block in Patients Undergoing Thoracotomy,,['Acute Post-thoracotomy Pain'],[],,2015-02,2015-12,"[{'measure': 'Duration of first loading preoperative dose of paravertebral injectate', 'description': 'Time interval between initiation of the paravertebral block and the time to first rescue analgesia', 'timeFrame': 'One day'}]","[{'measure': 'Duration of surgery and anesthesia', 'description': 'Times from start of anesthesia and surgery to the conclusion of surgical intervention', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'End tidal isoflurane', 'description': 'Average End-tidal isoflurane concentration required to maintain stable hemodynamics', 'timeFrame': 'Duration of anesthesia, up to 3-4 hours'}, {'measure': 'Total intraoperative fentanyl requirements', 'description': 'The total dose of fentanyl required during the surgical procedure to maintain hemodynamic stability', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'Total intraoperative ephedrine and atropine requirements', 'description': 'The total amounts of ephidrine and atropine required for the treatment of possible reduction of arterial blood pressure or heart rate', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'Total intraoperative crystalloid requirements', 'description': 'The total volume of intraoperative fluids in ml required to maintain hemodynamic stability', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'Recovery time', 'description': 'the time interval between discontinuation of isoflurane and the patient first response to verbal commands', 'timeFrame': 'Immediate postoperative period, up to 2 hour'}, {'measure': 'Pain intensities at rest and during coughing as assessed by 0-10 VAS score', 'description': 'Pain scores will be assessed using the 11-points visual analogue pain score (VAS) where 0 indicates no pain and 10 indicates the worst pain.', 'timeFrame': 'Over 48 hours postoperatively'}, {'measure': 'Total doses of bupivacaine, dexmedetomidine, and morphine', 'description': 'The total doses of three medications will be recorded and compared in the intervention and control groups', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Number of paravertebral to-up injections', 'description': 'The number of to-up doses of bupivacaine required to maintain adequate postoperative analgesia over 48 hours postoperatively', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Side effects', 'description': 'Patients will be monitored for the possible reductions in arterial blood pressure and heart rate', 'timeFrame': '48 hours postoperatively'}]",11.0,18 Years,60 Years,ALL,False,OTHER,0.0,40.0,ACTUAL,v2_robust,True,True,False,False,,Cc1cccc(C(C)c2c[nH]cn2)c1C,CHEMBL77921,partial_match,True,200.28,3.18,3.0
NCT04976478,Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma,Nimotuzumab,['Nimotuzumab'],1,OBSERVATIONAL,[],,NOT_YET_RECRUITING,Cervical Squamous Cell Carcinoma,Peking University Third Hospital,2025-09-01T16:18:12.174478,True,,,,NOT_FOUND,"A Perspective, Multi-center, Single Arm Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma",,['Cervical Squamous Cell Carcinoma'],[],,2021-07,2026-12,"[{'measure': '3-year disease-free survival(DFS)', 'description': 'The rate of patient without disease in 3 years after treatment', 'timeFrame': 'up to 3 years'}]","[{'measure': 'Complete response rate(CRR)', 'description': 'The percentage of subjects who achieve complete response by imaging assessment from the end of the treatment to disease progression', 'timeFrame': '3 months later after treatment'}, {'measure': 'Objective response rate(ORR)', 'description': 'The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment', 'timeFrame': '3 months later treatment'}, {'measure': '3-year overall survival(OS)', 'description': 'The rate of patient alive in 3 years after treatment', 'timeFrame': 'up to 3 years'}, {'measure': 'The change of tumor related markers', 'description': 'the correlation of the value of SCC，Cyfra 21-1 and therapeutic effect \\[The changes of serum tumor markers (such as SCC-Ag and CYFRA21-1) were observed before and after treatment\\]', 'timeFrame': 'up to 3 years'}, {'measure': 'The change of cervical tumor', 'description': 'the change of the volume of the cervical tumor at diagnosis and before brachytherapy', 'timeFrame': 'At diagnosis and before brachytherapy'}, {'measure': 'QUALITY OF LIFE(QoL)', 'description': 'Quality of life assessed by EORTC QLQ-CX 24 \\[EORTC QLQ-CX 24 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 24 items\\]', 'timeFrame': 'up to 3 years'}, {'measure': 'SAFETY', 'description': 'Including severity of adverse events, the incidence of adverse events and serious adverse events. Adverse events should be reported and graded according to CTCAE version 5.0', 'timeFrame': 'up to 3 years'}]",8.0,65 Years,,FEMALE,False,OTHER,0.0,125.0,ESTIMATED,v2_robust,False,False,False,True,,,,no_match,False,,,
NCT05620901,DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia,Dextenza 0.4Mg Ophthalmic Insert,"['Pred Forte', 'Dextenza 0.4Mg Ophthalmic Insert']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,COMPLETED,Vitreoretinopathy,"Lejla Vajzovic, MD, FASRS",2025-09-01T16:18:22.197420,True,,,,NOT_FOUND,The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (TENDER),,"['Vitreoretinopathy', ""Coats' Disease"", 'Exudative Retinopathy', 'Lattice Degeneration', 'Retinal Hole', ""Sickler's Syndrome"", 'Retinal Detachment Rhegmatogenous', 'Retinal Detachment Exudative', 'Retinal Detachment Traction']",[],,2023-02-01,2025-02-24,"[{'measure': 'Pain as measured by the FLACC pain scale', 'description': 'The Face, Legs, Activity, Cry and Consolability (FLACC) scale is an observational scale. comprised five behavioural indicators that are scored from zero to two. The pain score is the sum of the item scores and ranges from zero to 10. A lower score indicates minimal to no pain while high scores indicate moderate to severe discomfort.', 'timeFrame': 'up to Day 45 post-op'}]","[{'measure': 'Incidence of adverse events', 'description': 'Adverse events are addressed/ assessed at each visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Severity of Adverse Events', 'description': 'Adverse events are addressed/ assessed at each visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Degree of inflammation (AC cell count)', 'description': 'Inflammation is evaluated at each visit during the slit lamp and fundus exam as measured by the ocular inflammation grading scale', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Resolution of inflammation or less cell on follow up post op exams', 'description': 'Inflammation is evaluated during slit lamp and fundus exams during each post-op visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Resolution of pain', 'description': 'This will be measured by using the FLACC Pain Rating Scale. The Face, Legs, Activity, Cry and Consolability (FLACC) scale is an observational scale comprised five behavioural indicators that are scored from zero to two. The pain score is the sum of the item scores and ranges from zero to 10', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Ratio of Intraocular pressure increase with insert', 'description': 'Intraocular pressure is assessed at each visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Percentage of patients with rebound inflammation from baseline through post-op care', 'description': 'Level of inflammation is evaluated at each post-op visit during slip lamp and fundus exams', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Percentage of patients that were given supplementary prednisolone drops', 'description': 'Supplemental treatment and additional drops needed will be documented at each subsequent visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'The number of drops needed in these patients', 'description': 'Supplemental treatment and additional drops needed will be documented at each subsequent visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Mean change in Best Corrected Visual Assessment (BCVA)', 'description': 'Determined by using either ETDRS or HOTV chart testing depending on age.', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Caregivers Treatment Adherence', 'description': ""Documented at each subsequent visits and with the primary caregiver satisfaction survey at Day 45. This is a subjective survey for each participants' family."", 'timeFrame': 'up to Day 45 post-op'}]",12.0,3 Years,17 Years,ALL,True,OTHER,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00862524,A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer,"ARRY-334543, EGFR/ErbB2 inhibitor; oral","['Gemcitabine, nucleoside analogue; intravenous', 'ARRY-334543, EGFR/ErbB2 inhibitor; oral']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,COMPLETED,Advanced Cancer,Array BioPharma,2025-09-01T16:18:23.457877,True,,,,NOT_FOUND,,,"['Advanced Cancer', 'Pancreatic Cancer']",[],,2009-03,2011-02,"[{'measure': 'Establish the maximum tolerated dose (MTD) of study drug in combination with gemcitabine.', 'timeFrame': 'Part 1'}, {'measure': 'Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.', 'timeFrame': 'Part 1'}, {'measure': 'Characterize the pharmacokinetics (PK) of study drug, gemcitabine and a gemcitabine metabolite.', 'timeFrame': 'Part 1'}, {'measure': 'Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.', 'timeFrame': 'Part 2'}]","[{'measure': 'Assess the efficacy of the study drug in combination with gemcitabine in terms of tumor response.', 'timeFrame': 'Part 1'}, {'measure': 'Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.', 'timeFrame': 'Part 2'}]",6.0,18 Years,,ALL,False,INDUSTRY,0.0,20.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT00577304,A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon,Nitroglycerin,"['Topical AmphiMatrix', 'Nitroglycerin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,UNKNOWN,Raynaud's Disease,MediQuest Therapeutics,2025-09-01T16:18:22.210376,True,,,,NOT_FOUND,"A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon",,"[""Raynaud's Disease"", ""Raynaud's Disease Secondary to Scleroderma"", ""Raynaud's Disease Secondary to Other Autoimmune Disease""]","[""Raynaud's"", 'Nitroglycerin', 'Scleroderma']",,2007-12,2008-03,"[{'measure': ""Reduction in Raynaud's Condition Score"", 'timeFrame': 'three months'}]","[{'measure': 'Frequency and severity of adverse events.', 'timeFrame': 'three months'}]",2.0,15 Years,70 Years,ALL,False,INDUSTRY,0.0,200.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT06204003,Cannabinoids for Pain Management and Neuroprotection From Concussion,Cannabis/Hemp Isolate Extract,"['Cannabis/Hemp Isolate Extract', 'Herbal Extract with a high CBD']",2,INTERVENTIONAL,['PHASE1'],PHASE1,RECRUITING,Healthy,University of Regina,2025-09-01T16:18:20.962729,True,,,,NOT_FOUND,Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Dose Escalation,,['Healthy'],[],,2024-02-15,2026-12,"[{'measure': 'Change in cerebrovascular and cardiovascular physiology', 'description': ""Monitor the participant's cerebrovascular and cardiovascular physiology before and after the dosage regimen"", 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Incidence of potential harmful side effects', 'description': 'Follow the participants enrolled in these studies at set intervals to monitor for potential harmful side effects of the high CBD cannabis/hemp extract. This will include bloodwork to assess for possible hematopoietic, renal or hepatic dysfunction, and pharmacokinetic and pharmacodynamic analysis of the dose escalation protocol', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}]","[{'measure': 'Assessment of GABAergic activity', 'description': 'Assess the inhibitory neurotransmitter δ-aminobutyric acid (GABAergic activity)', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Change in pain intensity', 'description': 'Pain Behaviour Measurement system (PBM) scale', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Cerebral blood flow (transcranial Doppler)', 'description': 'Assessment of cerebral hemodynamic activity', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Cerebral oxygenation (near infrared spectroscopy)', 'description': 'Assessment of cerebral hemodynamic activity', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Change in QoL', 'description': 'Assess quality of life (QOL) in study participants by scores on health questionnaires and medication use', 'timeFrame': 'up to day 104'}, {'measure': 'Incidence of AEs', 'description': 'Assess adverse events (AEs) in study participants by looking at sleepiness/lethargy, irritability, nausea/vomiting and diarrhea', 'timeFrame': 'Through study completion, From Day 0 to Day 104'}]",8.0,18 Years,35 Years,MALE,True,OTHER,2.0,35.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04194814,Skin bioMARkers for Atopic Eczema Therapy Evaluation,crisaborole (2%) ointment,"['Eucrisa', 'betamethasone valerate 0.1% cream', 'Betnovate cream', 'crisaborole (2%) ointment']",4,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Atopic Eczema/Dermatitis (Non-Specific),Sheffield Teaching Hospitals NHS Foundation Trust,2025-09-01T16:18:22.209110,True,,,,CHEMBL484785,Validation of a Novel Composite of Skin Biomarkers as a Primary Outcome Measure for Evaluating the Safety of Treatments for Atopic Dermatitis: a Randomized Controlled Trial (Phase 2) Comparing the Effects of Crisaborole 2% Ointment to Betamethasone Valerate 0.1% Cream on Skin Structure and Function in Participants With Atopic Dermatitis.,,['Atopic Eczema/Dermatitis (Non-Specific)'],[],,2020-11-20,2021-09-30,"[{'measure': 'Change in Epidermal Thickness', 'description': 'The difference in the change in epidermal thickness, measured by structural OCT, between the sites treated with crisaborole (2%) ointment and betamethasone valerate (0.1%) cream.', 'timeFrame': 'Day 1 - Day 57'}]","[{'measure': 'Analysis of Change in Objective Erythema', 'description': 'Analysis of the difference in the change in skin redness/erythema (relating to tolerability) during and after 28 days treatment determined by Mexameter measured on day 1, day 15, day 29 and day 57.\n\nThe Mexameter device has a range of 0-999AU (arbitrary units) and the lower the value, the better the condition of the skin. Objective redness can be classified using the following scale: 0-170AU - No erythema; 170-330AU - Minimal erythema; 330-450AU - Diffuse erythema; 450-570AU - High erythema; over 570AU - Extreme erythema', 'timeFrame': 'Day 1, Day 15, Day 29 and Day 57'}, {'measure': 'TEWL - Skin Barrier Function', 'description': 'Analysis of the change in Trans-Epidermal Water Loss (TEWL, relates to skin barrier function) during and after treatment. TEWL measurements on day 1, day 15, day 29 and day 57.', 'timeFrame': 'Day 1, Day 15, Day 29 and Day 57'}, {'measure': 'TEWL - After Tape-stripping', 'description': 'The difference in skin barrier integrity (TEWLts20) after 28 days treatment. TEWL measurements after tape-stripping (TEWLts20) on day 29', 'timeFrame': 'on Day 29, after 28 days treatment'}, {'measure': 'Comparison of TEWL - After Tape-stripping', 'description': 'The difference in skin barrier integrity (TEWLts20) after 28 days treatment. TEWL measurements after tape-stripping (TEWLts20) on day 29', 'timeFrame': 'on Day 29, after 28 days treatment'}, {'measure': 'Skin Dryness', 'description': 'The difference in the change in visual skin dryness during and after treatment. Visual skin dryness scored on day 1, day 15, day 29 and day 57. Visual skin dryness was scored using the following: 0 - Absent; 1 - Faint scaling, faint roughness and dull appearance; 2 - Small scales in combination with a few larger scales, slight roughness, whitish appearance; 3 - Small and larger scales uniformly distributed, definite roughness, possibly slight redness and possibly a few superficial cracks; 4 - Dominated by large scales, advanced roughness, redness present, eczematous changes and cracks. The lower the visual dryness score, the better the condition of the skin.', 'timeFrame': 'Visual skin dryness scored on day 1, day 15, day 29 and day 57'}, {'measure': 'Natural Moisturising Factor (NMF)', 'description': 'The difference in Natural Moisturising Factor (NMF, filaggrin breakdown products) levels at the end of treatment.\n\n3 NMF components were measured: Urocanic acid (UCA), Pyrrolidone carboxylic acid (PCA) and Free amino acids (FAA) and are expressed together as total NMF (tNMF).', 'timeFrame': 'Day 29'}, {'measure': 'Comparison of Natural Moisturising Factor (NMF) Between Treatments', 'description': 'The difference in Natural Moisturising Factor (NMF, filaggrin breakdown products) levels at the end of treatment.\n\n3 NMF components were measured: Urocanic acid (UCA), Pyrrolidone carboxylic acid (PCA) and Free amino acids (FAA) and are expressed together as total NMF (tNMF).', 'timeFrame': 'Day 29'}, {'measure': 'Change in Visual Redness/Erythema During and After 28 Days Treatment', 'description': 'The difference in the change in visual skin redness during and after treatment. Visual skin redness scored on day 1, day 15, day 29 and day 57 by an experienced grader. Visual skin redness was scored using the following: 0 - No redness; 0.5/+ - Slight patchy erythema, barely perceptible; 1 - Slight uniform erythema, mild erythema; 2 - Moderate uniform erythema, moderate erythema; 3 - Strong erythema, marked erythema. The higher the visual redness score, the more inflamed the skin looks to the naked eye.', 'timeFrame': 'Visual skin redness scored on day 1, day 15, day 29 and day 57'}]",9.0,18 Years,65 Years,ALL,False,OTHER,1.0,37.0,ACTUAL,v2_robust,True,True,False,False,,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,CHEMBL484785,partial_match,True,251.05,,4.0
NCT01665079,Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response,Propofol,['Propofol'],1,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Obesity,Universidad del Desarrollo,2025-09-01T16:18:07.024450,True,,,,NOT_FOUND,Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response.,,['Obesity'],"['anaesthetics iv', 'propofol', 'pharmacokinetics', 'pharmacodynamic']",,2011-04,2011-11,"[{'measure': 'Profile of Pharmacokinetic and Pharmacodynamic of an induction bolus dose of propofol in obese patients.', 'description': 'Pharmacokinetic parameters (V1, V2, V3, CL, Q)\n\nPharmacodynamic parameters (E0, Emax, C50, Gamma, t1/2Ke0, T peak )', 'timeFrame': '1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75'}]",[],1.0,20 Years,60 Years,ALL,True,OTHER,0.0,14.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01029704,Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus,EGT0001442,"['EGT0001442', 'Placebo capsules to match EGT0001442', 'Human SGLT2 inhibitor']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Diabetes Mellitus Type 2,Theracos,2025-09-01T16:18:08.355266,True,,,,NOT_FOUND,"A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Subjects With Type 2 Diabetes Mellitus With an Ascending Dose Safety and Pharmacokinetic Evaluation Period",,['Diabetes Mellitus Type 2'],['Diabetes Mellitus Type 2'],,2009-12,2010-07,"[{'measure': 'Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study', 'description': 'Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.', 'timeFrame': 'Baseline; Day -2 and Day 1. End of Treatment: Day 27 and Day 29'}, {'measure': 'Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4', 'description': 'Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.', 'timeFrame': 'Pre-dose to 48 h post-dose'}, {'measure': 'Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4', 'description': 'Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.', 'timeFrame': 'Pre-dose to 48 h post-dose'}]","[{'measure': 'Change in the Body Weight From Baseline at Week 4', 'description': 'Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.', 'timeFrame': 'Baseline and Day 29'}, {'measure': 'Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4', 'description': 'HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)', 'timeFrame': 'Baseline and Day 29'}, {'measure': 'Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28', 'description': 'Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).', 'timeFrame': 'Baseline, Day 1 and Day 28'}, {'measure': 'Change in FPG Following Cessation of Treatment', 'description': 'The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).', 'timeFrame': 'Days 27/29 to Days 41/43'}]",7.0,18 Years,70 Years,ALL,False,INDUSTRY,0.0,151.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT01188369,Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy,levosimendan,"['Simdax', 'levosimendan', 'Placebo', 'placebo drug']",4,INTERVENTIONAL,['PHASE4'],PHASE4,TERMINATED,Diastolic Dysfunction,University of Aarhus,2025-09-01T16:18:23.464568,True,,,,NOT_FOUND,Effects of Levosimendan on Systolic Deformation and Diastolic Function in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy,,"['Diastolic Dysfunction', 'Left Ventricular Hypertrophy']","['levosimendan', 'heart failure', 'inotropics', 'diastolic dysfunction', 'left ventricular hypertrophy', 'aortic valve stenosis']",Terminated prematurely due to high incidence of postoperative atrial fibrillation.,2010-09,2013-03,"[{'measure': ""E/E'(Unitless)"", 'description': ""Ration between early transmitral flow (E) and mitral annular tissue velocity(E'). This ratio is an echocardiographic index of diastolic function"", 'timeFrame': '4 hours before operation until 21 hour after operation'}]","[{'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '4 hours before surgery until 1 hour before operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'Transeosophageal echocardiography: Measure of systolic function', 'timeFrame': 'At start of operation until end of operation, approximately 3 hours'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': '4 hours before operation until 1 hours before operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml)', 'description': 'blood sample reflecting stretch of the atrium/ventricle', 'timeFrame': '4 hours before operation until 4 hours after operation'}, {'measure': 'Troponin T (ug/l)', 'description': 'Blood sample expressing damage to the myocytes', 'timeFrame': '4 hours before operation until 4 hours after operation'}, {'measure': 'Lactate (mmol/l)', 'description': 'Arterial sampling of blood lactate', 'timeFrame': '4 hours before operation until 4 hour after operation'}, {'measure': 'Mixed Venous Oxygenation (Per Cent)', 'description': 'Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery', 'timeFrame': '4 hours before operation until 4 hour after operation'}, {'measure': 'E/A Ratio (Unitless)', 'description': 'TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus', 'timeFrame': 'At the start of operation until the end of operationon, approximately 3 hours'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function.', 'timeFrame': 'At the start of operation until the end of operation, approximately 3 hours'}, {'measure': 'Need for Conventional Inotropical Agents', 'description': 'Conventional inotropics are comprised of all inotropics acting primarily through alfa- or beta- stimulation.', 'timeFrame': 'From start of operation until 5 days after operation'}, {'measure': 'Intravenous Fluid Requirement (l)', 'description': 'Total volume of intravenous fluid required including blood products.', 'timeFrame': 'Within 24 hours from start of operation'}, {'measure': 'Operation Time (Minutes)', 'timeFrame': 'From ""knife start"" until ""knife end"", approximately 3 hours'}, {'measure': 'Time on Heart-lung Machine (Minutes)', 'timeFrame': 'From time of cardioplegia until selfsufficient cardiac action, approximately 1 hour'}, {'measure': 'Intubation Time (Minutes)', 'description': 'Total time intubated including time of operation and in the intensive care ward', 'timeFrame': 'From intubation until extubation, approximately 6 hours'}, {'measure': 'Postoperative Admission Time at Intensive Care Unit (Hours)', 'description': 'Total admission time in the intensive care after operation', 'timeFrame': 'From admission to the intensive care unit until discharge from intensive care unit, approximately 24 hours'}, {'measure': 'No. of Patients With Adverse Events', 'description': 'Development of Ventricular tachycardia', 'timeFrame': '-4 hours until + 96 hours with respect to start of operation'}, {'measure': 'No. of Patients With Adverse Event', 'description': 'Development of atrial flutter/fibrillation', 'timeFrame': '-4 hours until + 96 hours with respect to start of operation'}, {'measure': 'No. of Patients With Adverse Event', 'description': 'Need for norepinephrine as an antagonist to the vasodilatatory effect of levosimendan', 'timeFrame': '4 hours before operaton until 1 hour before operaton'}, {'measure': 'No. of Patients With Adverse Event.', 'description': 'Occurence of nausea', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'No. of Patients With Adverse Event', 'description': 'Occurence of headache', 'timeFrame': '4 hours before operation until approximately 1 hour before operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '4 hours before until 1 hour before start of operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'TTE: Index of systolic function', 'timeFrame': '1 hour before until 21 hour after start of operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'TTE: Index of systolic function', 'timeFrame': '21 hours after operation until 96 hours after start of operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'TTE: Index of systolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function.', 'timeFrame': 'Froml the end of operation until approx 4 hours after operation'}, {'measure': 'E/A Ratio (Unitless)', 'description': 'TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus', 'timeFrame': 'At the end of operationon until approx 4 hours after operation'}, {'measure': 'Left Ventricular Rotation (Degrees)', 'description': 'TTE: Index of both systolic and diastolic function', 'timeFrame': '96 hour after operation until 6 months after operation'}, {'measure': 'Mixed Venous Oxygenation (Per Cent)', 'description': 'Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Lactate (mmol/l)', 'description': 'Arterial sampling of blood lactate', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Troponin T (ug/l)', 'description': 'Blood sample expressing damage to the myocytes', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Troponin T (ug/l)', 'description': 'Blood sample expressing damage to the myocytes', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml)', 'description': 'blood sample reflecting stretch of the atrium/ventricle', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml)', 'description': 'blood sample reflecting stretch of the atrium/ventricle', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': 'Start of operation until the end of operation, approximately 3 hours'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': 'End of operation until approx 4 hours after operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': 'Start of operation until end of operation, approximately 3 hours'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': 'End of operation until approx 4 hours after operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '1 hour before start of operation until 21 hours after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': 'Start of operation until end of operation, approximately 3 hours'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': 'End of operation until approx 4 hours after operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Peak Systolic Velocity (m/s)', 'description': 'Tissue Doppler measure of systolic function', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'Peak Systolic Velocity (m/s)', 'description': 'Tissue Doppler measure of systolic function', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Peak Systolic Velocity (m/s)', 'description': 'Tissue Doppler measure of systolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)', 'description': 'Transthoracic echocardiographic measure of systolic function', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)', 'description': 'Transthoracic echocardiographic measure of systolic function', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)', 'description': 'Transthoracic echocardiographic measure of systolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'E/A-ratio (Unitless)', 'description': 'Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function.', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'E/A-ratio (Unitless)', 'description': 'Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function.', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'E/A-ratio (Unitless)', 'description': 'Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function.', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': ""E'/A'-Ratio (Unitless)"", 'description': 'Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function.', 'timeFrame': '1 hour before operation until 21 hours after roperation'}, {'measure': ""E'/A'-Ratio (Unitless)"", 'description': 'Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function.', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': ""E'/A'-Ratio (Unitless)"", 'description': 'Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function.', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'Transeosophageal echocardiography: Measure of systolic function', 'timeFrame': 'End of operation until approx. 4 hours after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transeosophageal echocardiography: Time from closure of aortic valve to opening of mitral valve. Measure of diastolic function.', 'timeFrame': 'End of operation until approx. 4 hours after operation'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': 'Start of operation until end of operation, approximately 3 hours'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': 'End of operation operation until approx. 4 hours after operation'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Inflammatory Parameters', 'description': 'Blood sample values of pro- and antiinflammatory mediators', 'timeFrame': '4 hours before operation until 21 hours after operation'}, {'measure': 'Inflammatory Parameters', 'description': 'Blood sample values of pro- and antiinflammatory mediators', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'E/A-ratio (Transoesophageal)', 'description': 'Transoesophageal echocardiographic measure of diastolic heart function', 'timeFrame': 'from start of operation until end of operation, approximately 3 hours'}, {'measure': 'E/A-ratio (Transoesophageal)', 'description': 'Transoesophageal echocardiographic measure of diastolic heart function', 'timeFrame': 'from end of operation until approximately 4 hours after operation'}, {'measure': 'Urine Clearance', 'description': 'Urine analysis. Measure of kidney function.', 'timeFrame': 'from start of operation until 24 hours after operation'}]",78.0,30 Years,90 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,False,True,True,Terminated prematurely due to high incidence of postoperative atrial fibrillation.,,,no_match,False,,,
NCT03619005,Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study,Placebo Vaginal Insert,"['Placebo Vaginal Insert', 'Prasterone 6.5 mg (0.50%) Vaginal Insert']",2,INTERVENTIONAL,['PHASE3'],PHASE3,WITHDRAWN,Hypoactive Sexual Desire Disorder (HSDD),EndoCeutics Inc.,2025-09-01T16:18:10.912102,True,,,,NOT_FOUND,"Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)",,['Hypoactive Sexual Desire Disorder (HSDD)'],"['Prasterone', 'DHEA', 'Menopause', 'Sexual Disorder', 'HSDD']",Business decision to not continue this study (only few subjects were screened).,2018-11-13,2019-12-06,"[{'measure': 'Sexual desire', 'description': 'Change from Baseline in sexual desire as evaluated by Questions 1 \\& 2 of the 19-items questionnaire titled Female Sexual Function Index (FSFI). For this outcome, Question 1 and Question 2 (corresponding to the desire domain) will be graded from 1 to 5 (score range) and then be multiplied by 0.6 (domain factor). The desire domain (sum of scores from Questions 1 \\& 2) has a minimum score of 1.2 and a maximum score of 6. Higher values represent a better outcome.', 'timeFrame': '28 weeks'}, {'measure': 'Distress from low sexual desire', 'description': 'Change from Baseline in distress from low sexual desire as evaluated by Question 13 of the 15-items questionnaire titled Female Sexual Distress Scale - Desire Arousal Orgasm (FSDS-DAO). For this outcome, Question 13 is graded from 0 to 4 and a lower value represents a better outcome.', 'timeFrame': '28 weeks'}]","[{'measure': 'Satisfying sexual events (SSEs)', 'description': 'Change from Baseline in the number of SSEs from a daily log of sexual activity.', 'timeFrame': '28 weeks'}]",3.0,40 Years,80 Years,FEMALE,False,INDUSTRY,1.0,0.0,ACTUAL,v2_robust,True,False,True,False,Business decision to not continue this study (only few subjects were screened).,,,no_match,False,,,
NCT01485822,A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution,Travoprost 0.004% ophthalmic solution,"['Travoprost 0.004% ophthalmic solution', 'TRAVATAN', 'TRAVATAN Z']",3,OBSERVATIONAL,[],,TERMINATED,Open-angle Glaucoma,Alcon Research,2025-09-01T16:18:15.901577,True,,,,NOT_FOUND,A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution,,['Open-angle Glaucoma'],"['Glaucoma', 'Travatan', 'Trabeculectomy']",Study objectives met,2004-07,2012-02,"[{'measure': 'Melanin Granule Count', 'description': 'A trabecular meshwork tissue sample was collected by the investigator. The number of pigment granules was counted for three separate microscopic fields of view. Mean melanin granule count was calculated.', 'timeFrame': 'Day 1'}]",[],1.0,50 Years,,ALL,False,INDUSTRY,0.0,88.0,ACTUAL,v2_robust,False,False,True,False,Study objectives met,,,no_match,False,,,
NCT03791125,Phase I Single-dose Escalation Clinical Trial of Salvianolic Acid A Tablets,Salvianolic Acid A,"['Placebo Oral Tablet', 'Salvianolic Acid A']",2,INTERVENTIONAL,['PHASE1'],PHASE1,UNKNOWN,Neuropathy of Diabetes,Peking University First Hospital,2025-09-01T16:18:09.631183,True,,,,NOT_FOUND,"Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Evaluation of Safety, Tolerability, and Pharmacokinetic Properties of Salvianolic Acid A Tablets in Healthy Volunteers",,['Neuropathy of Diabetes'],[],,2018-11-20,2019-05-20,"[{'measure': 'Subject incidence of treatment-emergent adverse events', 'timeFrame': '7 days'}, {'measure': 'Percentage of participants with change from baseline in vital signs', 'description': 'Heart rate, Blood Pressure，auxillary temperature', 'timeFrame': '7 days'}, {'measure': 'Change from baseline in electrocardiograms (ECGs)', 'description': 'PR interval, QT interval, QTc interval, QTcF, and rhythm abnormalities', 'timeFrame': '7 days'}, {'measure': 'Percentage of participants with change from baseline in clinical laboratory parameters', 'description': 'blood routine, urine routine, biochemical parameters of blood and urine，coagulation tests', 'timeFrame': '7 days'}, {'measure': 'PK profile of Salvianolic acid A following administration of multiple doses assessed by area under the curve [AUC]', 'timeFrame': '2 days'}, {'measure': 'PK profile of Salvianolic acid A following administration of multiple doses assessed by maximum observed concentration [Cmax]', 'timeFrame': '2 days'}, {'measure': 'PK profile of Salvianolic acid A following administration of multiple doses assessed by time of occurrence of Cmax [tmax]', 'timeFrame': '2 days'}]",[],7.0,18 Years,45 Years,ALL,True,OTHER,2.0,40.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT04328441,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,BCG Vaccine,"['NaCl 0,9%', 'Danish strain 1331', 'BCG Vaccine', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,COVID-19,UMC Utrecht,2025-09-01T16:18:20.966204,True,,,,NOT_FOUND,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial.",,['COVID-19'],['Health care workers'],,2020-03-25,2021-03-31,"[{'measure': 'Health Care Workers absenteeism', 'description': 'Number of days of unplanned absenteeism for any reason', 'timeFrame': 'Maximum of 365 days'}]","[{'measure': 'the cumulative incidence of documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Hospital Admission due to documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of unplanned absenteeism, because of documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of self-reported acute respiratory symptoms or fever', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of death due to documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Intensive Care Admission due to documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of self-reported fever (≥38 gr C)', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of self-reported fever (≥38 gr C)', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of self-reported acute respiratory symptoms', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of self-reported acute respiratory symptoms', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of death for any reason', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Intensive Care Admission for any reason', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Hospital Admission for any reason', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period', 'description': 'Exploratory', 'timeFrame': '3-6 months after inclusion'}]",19.0,18 Years,,ALL,True,OTHER,1.0,1511.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT00235820,Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,adalimumab,"['ABT-D2E7', 'MTX', 'Humira', 'placebo', 'adalimumab', 'placebo adalimumab, placebo MTX']",6,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Psoriasis,Abbott,2025-09-01T16:18:15.890627,True,,,,NOT_FOUND,"A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis",,['Psoriasis'],"['Psoriasis', 'adalimumab']",,2005-07,,"[{'measure': 'Proportion of subjects achieving clinical response at Week 16 relative to the Baseline (Week 0) PASI score.', 'timeFrame': 'Week 16'}, {'measure': 'Safety parameters', 'timeFrame': 'Every Study Visit'}]","[{'measure': 'Physician Global Assessment', 'timeFrame': 'Baseline - Week 16'}, {'measure': 'PASI 50/90/100', 'timeFrame': 'Baseline - Week 16'}, {'measure': 'DLQI', 'timeFrame': 'Baseline - Week 16'}]",5.0,18 Years,,ALL,False,INDUSTRY,0.0,271.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT05311930,Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients,2.5mg/d Hetrombopag,"['2.5mg/d Hetrombopag', 'no use']",2,INTERVENTIONAL,['PHASE4'],PHASE4,UNKNOWN,Primary Immune Thrombocytopenia,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2025-09-01T16:18:15.910082,True,,,,NOT_FOUND,Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study,,['Primary Immune Thrombocytopenia'],"['hetrombopag', 'Primary Immune Thrombocytopenia', 'platelets']",,2022-05-01,2024-12-30,"[{'measure': 'Treatment response', 'description': 'Proportion of subjects with platelet counts ≥50×10\\^9/L after 28 days of treatment', 'timeFrame': '28 days'}]","[{'measure': 'Remission rate', 'description': 'Complete response, effective, ineffective proportion of testers after 28 days of treatment', 'timeFrame': '28 days'}, {'measure': 'Drug efficacy', 'description': 'During treatment, the proportion of subjects, which the platelet count at least once reached ≥50×109/L.', 'timeFrame': '28 days'}, {'measure': 'Evaluation of effectiveness', 'description': 'During treatment, the proportion of subjects, which the platelet count increased at least 2 times compared with baseline.', 'timeFrame': '28 days'}, {'measure': 'Adverse events', 'description': 'Evaluate the incidence and severity of bleeding based on the ITP-BAT bleeding score', 'timeFrame': '6 months from treatment'}, {'measure': 'Adverse events', 'description': 'During treatment, the proportion of subjects, which received at least once rescue', 'timeFrame': '6 months from treatment'}, {'measure': 'Side effects of drugs', 'description': 'Assessing safety through the adverse events,such as liver damage, etc.', 'timeFrame': '1 month from treatment'}]",7.0,60 Years,100 Years,ALL,False,OTHER,1.0,69.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT01528618,Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma,gemcitabine and cisplatin,"['FP', '5-Fluorouracil and cisplatin', 'GP', 'gemcitabine and cisplatin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,COMPLETED,Nasopharyngeal Neoplasms,Sun Yat-sen University,2025-09-01T16:18:07.019049,True,,,,NOT_FOUND,"A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)",,['Nasopharyngeal Neoplasms'],"['Advanced Nasopharyngeal Carcinoma', 'treatment']",,2012-02-21,2020-12-20,"[{'measure': 'Progression free survival (PFS) assessed by independent image committee and the investigators', 'timeFrame': '36 months'}]","[{'measure': 'Overall survival (OS)', 'timeFrame': '36 months'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': '36 months'}, {'measure': 'Number of Participants with Adverse Events', 'timeFrame': '36 months'}]",4.0,18 Years,,ALL,False,OTHER,0.0,362.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04765098,Tamoxifen Versus Etoposide After First Recurrence in GBM Patients,Tamoxifen,"['Etoposide', 'Tamoxifen']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Glioblastoma Multiforme,AHS Cancer Control Alberta,2025-09-01T16:18:08.351298,True,,,,CHEMBL37130,A Randomized Controlled Trial of Tamoxifen Versus Etoposide for Patients With First Recurrence of Glioblastoma Multiforme,,['Glioblastoma Multiforme'],[],,2022-01-28,2027-07,"[{'measure': '3 month progression-free survival', 'description': 'Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.', 'timeFrame': '3 months'}]","[{'measure': 'One-year progression-free survival', 'description': 'Time between randomization and radiographic or clinical progression leading to change in therapy for recurrent disease or death due to any cause.', 'timeFrame': '12 months'}, {'measure': 'Overall survival', 'description': 'Time between randomization and death due to any cause. Patients without an event will be censored the last time they were known to be alive.', 'timeFrame': 'Median, 6-month, 1-year, and 2-year OS rates will be measured'}, {'measure': 'Health-related quality-of-life status', 'description': 'Health-related quality-of-life will be assessed using the EORTC QLQ-BN20 brain tumor module questionnaire. This is a self-report questionnaire consisting of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit in brain tumor patients', 'timeFrame': 'Throughout study completion, up to 5 years.'}, {'measure': 'Adverse events', 'description': 'This includes fatigue, hematologic toxicities (neutropenia, thrombocytopenia, leukopenia, anemia), liver toxicities, hypertension, diarrhea, seizures and thrombosis and will all be recorded.', 'timeFrame': 'Throughout the whole duration of the trial, up to 5 years'}]",5.0,18 Years,65 Years,ALL,False,OTHER,0.0,60.0,ESTIMATED,v2_robust,True,False,False,True,,CC/C(=C(/c1ccc(OCCN(C)C)cc1)c1cccc(F)c1)c1ccccc1,CHEMBL37130,partial_match,True,389.51,6.14,
NCT03535935,"Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease",Astragalus Powder,['Astragalus Powder'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,UNKNOWN,Diabetic Nephropathies,The University of Hong Kong,2025-09-01T16:18:07.013324,True,,,,NOT_FOUND,"Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease (READY) - An Open-label Randomised Controlled Trial With Responder Regression Analysis",,"['Diabetic Nephropathies', 'Diabetic Kidney Disease']","['Chinese medicine', 'Astragalus', 'Pragmatic trial']",,2018-07-01,2022-12-31,"[{'measure': 'Change in estimated GFR', 'description': 'Efficacy and safety', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in spot urine albumin-to-creatinine ratio', 'description': 'Efficacy and safety', 'timeFrame': 'From baseline to 48 weeks after treatment'}]","[{'measure': 'Change in glycated haemoglobin (HbA1c)', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in urinary monocyte chemotactic protein 1 (MCP-1)', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in urinary Cystatin C', 'timeFrame': 'From baseline to 48 weeks after treatment'}, {'measure': 'Change in lipids', 'timeFrame': 'From baseline to 48 weeks after treatment'}]",6.0,35 Years,80 Years,ALL,False,OTHER,1.0,118.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT03915496,Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis,PF-04965842 200 mg,"['PF-04965842 200 mg', 'Placebo', 'PF-04965842 100 mg']",3,INTERVENTIONAL,['PHASE2'],PHASE2,COMPLETED,Atopic Dermatitis,Pfizer,2025-09-01T16:18:20.960860,True,,,,NOT_FOUND,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE MECHANISM OF ACTION OF ABROCITINIB MONOTHERAPY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",,['Atopic Dermatitis'],"['atopic dermatitis', 'atopic eczema', 'eczema', 'JAK', 'janus kinase']",,2020-06-18,2021-11-16,"[{'measure': 'Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12', 'description': 'Mean fold-changes from baseline at Week 12 in the biomarkers for general inflammation (Matrix Metallopeptidase \\[MMP\\]12), hyperplasia (Keratin \\[KRT\\]16), Th2 immune response (C-C motif chemokine ligand \\[CCL\\]17, CCL18, CCL26), and Th22 immune response (S100 calcium binding protein A \\[S100A\\]8, S100A9, S100A12), in lesional (LS) and non-lesional (NL) skin tissues, respectively. Expression levels from RT-PCR are normalized to the housekeeping gene RPLP0 by negatively transforming the Ct values to -dCt.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Fold-Change From Baseline in Cellular (T-cell and Dendritic Cell) Inflammation Markers at Week 12', 'description': 'Mean fold-changes from baseline in immunohistochemistry analysis in lesional skin endpoints at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Fold-Change From Baseline in Epidermal Hyperplasia Markers in Skin Biopsies and Skin Thickness at Week 12', 'description': 'Mean fold-changes from baseline in hyperplasia markers in skin biopsies at Week 12 are presented. Fold-changes are computed by obtaining the antilog of log2 fold-changes, retaining the sign for log2 fold-change.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Fold-Change From Baseline in Blood Biomarkers for Inflammation and Immune Response at Week 12', 'description': 'OLINK Proteomics Microassay was used to analyze biomarkers in serum to assess the effect of abrocitinib on the blood biomarkers. Mean fold-changes at Week 12 from baseline are listed. Baseline is defined as the last observation on or prior to day of first dose (Day 1).', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percent-Change From Baseline in T-cell Lymphocyte Subset Populations at Week 12', 'description': 'Mean percent changes from baseline at Week 12 in T-cell lymphocyte subset populations (CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, B cells) are presented. Baseline is defined as the last observation on or prior to day of first dose (Day 1).', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Response Based on at Least 4 Points Improvement in the Severity of Peak Pruritus Numerical Rating Scale (NRS) From Baseline and Changes From Baseline in Immunohistochemistry (IHC) and Gene Expression Biomarkers in Lesional Skin', 'description': 'PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms ""no itch"" (0) and ""worst itch imaginable"" (10). Participants who withdrew from the study were counted as non-responder. Spearman correlation coefficient was calculated to assess the relationship between PP-NRS CFB and fold CFB of IHC and gene expression biomarkers.', 'timeFrame': 'Baseline, Week 12'}, {'measure': ""Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline at Week 2, 4, 8 and 12"", 'description': 'The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, and 12'}, {'measure': 'Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline Week 2, 4, 8 and 12', 'description': 'The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline, Week 2, 4, 8, and 12'}, {'measure': 'Percentage of Participants With >=4 Points at Baseline and Achieving >=4 Points Improvement From Baseline in Numeric Rating Scale for Severity of Pruritus (PP-NRS) at Weeks 2, 4, 8 and 12', 'description': 'PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms ""no itch"" (0) and ""worst itch imaginable"" (10). Higher scores indicated worse itch. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline, Week 2, 4, 8, 12'}, {'measure': 'Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline at Week 2, 4, 8 and 12', 'description': 'The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline to Week 2, 4, 8 and 12'}, {'measure': 'Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline at Week 2, 4, 8 and 12', 'description': 'The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.', 'timeFrame': 'Baseline to Week 2, 4, 8 and 12'}, {'measure': 'Percent Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8 and 12', 'description': 'BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.', 'timeFrame': 'Baseline and Week 2, 4, 8 and 12'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs)', 'description': 'A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Number of Participants Who Discontinued From the Study Due to TEAEs', 'description': 'An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)', 'description': 'Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.', 'timeFrame': 'Baseline to 16 weeks'}]",16.0,18 Years,,ALL,False,INDUSTRY,0.0,46.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
NCT04762745,The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma,Pomalidomide,"['Pomalidomide', 'Bendamustine( Leweixin®, Chia Tai TIANQING, China)', 'Pomalidomide( Anyue®, Chia Tai TIANQING, China)', 'Dexamethasone', 'Bendamustine']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,UNKNOWN,"Relapsed, Refractory, Multiple Myeloma",Sun Yat-sen University,2025-09-01T16:18:08.340483,True,,,,CHEMBL43452,"Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China",,"['Relapsed, Refractory, Multiple Myeloma']","['pomalidomide, bendamustine, multiple myeloma']",,2021-02,2023-02,"[{'measure': 'Overall response rate', 'description': 'The number of patients achieving partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) after 8 cycles in phase II.\n\nsCR = CR as defined in Primary Outcome measure 2 plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.\n\nCR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow.\n\nVGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\> 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg/24 h.\n\nPR- \\> 50% reduction of serum M-protein and urine M-protein by \\>90% or to \\< 200 mg/24 h In addition, if present at baseline, a \\> 50% reduction in the size of soft tissue plasmacytomas is also required.', 'timeFrame': 'At the end of Cycle 8 in Phase II (each cycle is 28 days)'}]","[{'measure': 'Complete response(CR) and stringent complete response(sCR) rate', 'description': 'The CR and sCR rate after 8 cycles in phase II.\n\nCR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow.\n\nsCR = CR as defined in Primary Outcome measure 2 plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.', 'timeFrame': 'At the end of Cycle 8 in Phase II (each cycle is 28 days)'}, {'measure': 'Progression free survival(PFS)', 'description': 'The time relapsed for patients between initiation of study therapy and either disease progression or death', 'timeFrame': 'Through study completion, up to 2 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Number of participants with treatment-related adverse events during the study period as assessed by CTCAE v4.0', 'timeFrame': 'Through study completion, up to 2 years'}]",4.0,18 Years,75 Years,ALL,False,OTHER,0.0,56.0,ESTIMATED,v2_robust,True,False,False,True,,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,CHEMBL43452,exact_match,True,273.25,-0.33,4.0
NCT02121535,Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use,T80/A5 mg FDC tablet,"['T80/A5/H12.5 mg FDC tablet', 'H12.5 mg tablet', 'H12.5 mf tablet', 'T80/A5/H12.5 ng FDC tablet', 'T80/A5 mg FDC tablet']",5,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Boehringer Ingelheim,2025-09-01T16:18:07.013511,True,,,,NOT_FOUND,"Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Hydrochlorothiazide 12.5 mg Tablet in Healthy Male Subjects : an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study",,['Healthy'],[],,2014-04,2014-08,"[{'measure': 'Area Under the Concentration-time Curve of the Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of the telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h after drug administration'}, {'measure': 'Cmax for Telmisartan', 'description': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h after drug administration'}, {'measure': 'AUC0-tz for Amlodipine', 'description': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': '3hours(h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h, 144h after drug administration'}, {'measure': 'Cmax for Amlodipine', 'description': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': '3hours(h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h, 144h after drug administration'}, {'measure': 'Cmax for Hydrochlorothiazide', 'description': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h after drug administration'}, {'measure': 'AUC0-tz for Hydrochlorothiazide', 'description': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h after drug administration'}]","[{'measure': 'AUC0-∞ for Telmisartan', 'description': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h after drug administration'}, {'measure': 'AUC0-∞ for Amlodipine', 'description': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': '3hours(h) before drug administration and 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 72h, 96h, 120h, 144h after drug administration'}, {'measure': 'AUC0-∞ for Hydrochlorothiazide', 'description': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': '3hours(h) before drug administration and 15minutes (m), 30m, 45m, 1h, 1h30m, 2h, 2h30m, 3h, 4h, 6h, 8h, 12h, 24h, 32h, 48h after drug administration'}]",9.0,20 Years,35 Years,MALE,True,INDUSTRY,0.0,72.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT04102618,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,Letrozole,"['Trastuzumab', 'Atezolizumab', 'Letrozole']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,TERMINATED,Breast Cancer,Oncolytics Biotech,2025-09-01T16:18:09.635248,True,,,,NOT_FOUND,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1),,['Breast Cancer'],"['Breast', 'Breast Cancer', 'Primary Breast', 'Primary Breast Cancer', 'Pelareorep', 'Atezolizumab', 'Reovirus', 'Oncolytic virus', 'Letrozole', 'Early Breast Cancer', 'Triple-negative breast cancer', 'HR+ breast cancer', 'HER2+ breast cancer']",Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.,2019-03-29,2022-04-20,"[{'measure': 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.', 'description': 'CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:\n\nCelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.', 'timeFrame': 'The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days).'}]","[{'measure': 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HR+/HER2-negative breast cancer.', 'timeFrame': 'The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days).'}, {'measure': 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HER2-positive breast cancer.', 'timeFrame': 'The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days).'}, {'measure': 'To identify biological changes, as defined by gene expression between posttreatment and pretreatment samples following pelareorep in combination with different therapies.', 'timeFrame': 'throughout'}, {'measure': 'To describe the safety profile of the combination therapies', 'timeFrame': 'throughout'}]",5.0,18 Years,,FEMALE,False,INDUSTRY,1.0,26.0,ACTUAL,v2_robust,True,False,True,True,Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.,,,no_match,False,,,
NCT03044080,Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot,IncobotulinumtoxinA,"['IncobotulinumtoxinA', 'OnabotulinumtoxinA']",2,INTERVENTIONAL,['PHASE4'],PHASE4,COMPLETED,Stroke Rehabilitation,Parc de Salut Mar,2025-09-01T16:18:15.892987,True,,,,NOT_FOUND,Effects of Repeated Use of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot in Stroke Patients: A Randomized Clinical Trial,,"['Stroke Rehabilitation', 'Stroke Rehabilitation Spasticity Management']","['Walking Disorder', 'Stroke', 'Botulinum Toxin', 'Spasticity']",,2015-01-01,2017-09-30,"[{'measure': 'Change in walking speed', 'description': 'Walking speed, expressed in m/s, is assessed in a 10-m corridor', 'timeFrame': 'Baseline and monthly during 18 months'}]","[{'measure': 'Change in spasticity assessed with the Modified Ashworth Scale', 'description': 'Spasticity assessed with the Modified Ashworth Scale (range 0-5)', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in walking disability assessed with the Scandinavian Stroke Scale', 'description': 'Walking disability is assessed with the Scandinavian Stroke Scale', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in functional ambulation ability assessed with the Modified Walking Categories', 'description': 'Functional ambulation ability is assessed with the Modified Walking Categories', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in step time', 'description': 'Step time (Temporal gait parameter) is expressed in seconds and assessed with instrumented gait analysis', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in step length', 'description': 'Step length (Spatial gait parameter) is expressed in meters and assessed with instrumented gait analysis', 'timeFrame': 'Baseline and monthly during 18 months'}]",6.0,18 Years,80 Years,ALL,False,OTHER,0.0,20.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT06227156,"Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer",Disitamab Vedotin Injection,"['DV,RC48', 'Disitamab Vedotin Injection']",2,INTERVENTIONAL,['PHASE2'],PHASE2,RECRUITING,Castration-resistant Prostate Cancer,"RemeGen Co., Ltd.",2025-09-01T16:18:20.968345,True,,,,NOT_FOUND,"A Multicenter Open Phase II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer",,['Castration-resistant Prostate Cancer'],"['Metastatic Castration-resistant prostate cancer.', 'HER2- expression']",,2024-04-08,2026-06,"[{'measure': 'Radiographic progression free survival，rPFS', 'description': 'Define imaging disease progression according to RECIST v1.1 (for all lesions except bone lesions) or PCWG3 (for bone lesions) as the time from the first dose of the drug to the time when the imaging shows disease progression or death.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Objective remission rate (ORR)', 'description': 'ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1)', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Percentage of patients with complete response, partial response, or stable disease for a certain period of time according to RECIST v1.1.', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Time to PSA progression(TTPP)', 'description': 'Defined as time from date of first dose to first PSA progression', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Duration of response (DoR)', 'description': 'Defined as the time from the date of first documented response (CR/PR) until the first progression or death in the absence of disease progression by Investigators assessment according to RECIST 1.1', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'PSA response rate', 'description': 'Percent of subjects with different degree of decrease in PSA compared to baseline', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Time to first symptomatic bone-related event (SSE)', 'description': 'Defined as the time from the first dose to the first occurrence of SSE.', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS was defined as the time from the date of randomization to the date of death from any cause.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Cmax of RC48', 'description': 'Peak Plasma Concentration of RC48', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'AUC of RC48', 'description': 'Area under the plasma concentration versus time curve of RC48', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'AUC of MMAE', 'description': 'Area under the plasma concentration versus time curve of MMAE', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Immunogenicity of RC48', 'description': 'Anti-drug antibody (ADA) of RC48 positive samples, etc.', 'timeFrame': 'up to approximately 2 years'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'description': 'Number of participants with adverse effects of treatment. Frequency and severity of adverse effects of treatment as assessed by NCI CTCAE v5.0', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Incidence of laboratory tests abnormalities', 'description': 'To be summarized using descriptive statistics', 'timeFrame': 'Up to follow-up period, approximately 2 years'}, {'measure': 'Incidence of ECG abnormalities', 'description': 'To be summarized using descriptive statistics', 'timeFrame': 'Up to follow-up period, approximately 2 years'}]",15.0,18 Years,,MALE,False,INDUSTRY,0.0,40.0,ESTIMATED,v2_robust,True,False,False,True,,,,no_match,False,,,
NCT02125227,Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers,"Rosuvastatin, Metformin, YH14755","['YH14755', 'Crestor, GlucodaunOR, YH14755', 'Rosuvastatin, Metformin, YH14755']",3,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Healthy,Yuhan Corporation,2025-09-01T16:18:09.643214,True,,,,NOT_FOUND,"A Randomized, Open-label, Single-dose, 2-Way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755",,['Healthy'],[],,2014-04,2014-09,"[{'measure': 'AUClast of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': 'Cmax of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}]","[{'measure': 'Tmax of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': 't1/2 of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': '%AUC of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}, {'measure': 'AUCinf of rosuvastatin and metformin', 'timeFrame': '0~48hr, totally 17 points'}]",6.0,19 Years,55 Years,ALL,True,INDUSTRY,0.0,56.0,ACTUAL,v2_robust,True,True,False,False,,,,no_match,False,,,
NCT03138759,Effect of Probenecid on Pexidartinib Pharmacokinetics,Pexidartinib,"['Treatment B', 'Treatment A', 'Probenecid', 'Pexidartinib']",4,INTERVENTIONAL,['PHASE1'],PHASE1,COMPLETED,Pharmacokinetics in Healthy Volunteers,Daiichi Sankyo,2025-09-01T16:18:15.892780,True,,,,NOT_FOUND,"An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects",,['Pharmacokinetics in Healthy Volunteers'],[],,2017-02-27,2017-03-30,"[{'measure': 'Maximum Plasma Concentration (Cmax)', 'description': 'Maximum concentration of the drug and its metabolite in plasma', 'timeFrame': 'predose to 312 hours post dose'}, {'measure': 'Time to Maximum Concentration (Tmax)', 'description': 'Time at which the maximum concentration is reached', 'timeFrame': 'within 312 hours post dose'}, {'measure': 'Area under the curve to the last quantifiable measurement (AUClast)', 'description': 'Area under the drug concentration time curve from the first measurement to the last', 'timeFrame': 'within 312 hours post dose'}]","[{'measure': 'Number of participants experiencing an adverse event', 'description': 'Total number of participants experiencing any adverse event', 'timeFrame': 'within 312 hours post dose'}]",4.0,18 Years,60 Years,ALL,True,INDUSTRY,0.0,16.0,ACTUAL,v2_robust,True,True,False,True,,,,no_match,False,,,
